

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
26 June 2003 (26.06.2003)

PCT

(10) International Publication Number
WO 03/051366 A2(51) International Patent Classification⁷: A61K 31/4439,
31/444, C07D 401/12, 401/14, 401/04, 475/02, 213/63

(21) International Application Number: PCT/US02/39915

(22) International Filing Date:
12 December 2002 (12.12.2002)


(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
10/023,363 13 December 2001 (13.12.2001) US
10/295,833 18 November 2002 (18.11.2002) US(71) Applicant: ABBOTT LABORATORIES [US/US];
Dept. 377/AP6D-2, 100 Abbott Park Road, Abbott Park,
IL 60064-6050 (US).(72) Inventors: LI, Qun; 1417 Castleton Road, Libertyville,
IL 60048 (US). WOODS, Keith, W.; 200 Red Top Drive,
#303, Libertyville, IL 60048 (US). ZHU, Gui-Dong;
1395 Almaden Lane, Gurnee, IL 60031 (US). FISCHER,
John, P.; 2424-9 Avenue, #7306, Longmont, CO 80503
(US). GONG, Jianchun; 130 Ferndale Road, Deerfield,
IL 60015 (US). LI, Tongmei; 990 South Darla Court,
Waukegan, IL 60085 (US). GANDHI, Viraj; 4123
Greenleaf Court, Park City, IL 60085 (US). THOMAS,
Sheela, A.; 1525 Eric Lane, Libertyville, IL 60048 (US).
PACKARD, Garrick; 4550 Towne Centre Court, San
Diego, CA 92121 (US). SONG, Xiaohong; 4107 Green-
leaf Court, #203, Park City, IL 60085 (US). ABRAMS,
Jason, N.; 724 W. Algonquin Road, Des Plaines, IL 60016
(US). DIEBOLD, Robert; 2065 W. Skyhawk Avenue,#203, Waukegan, IL 60087 (US). DINGES, Jurgen; 1357
Mayfair Lane, Grayslake, IL 60030 (US). HUTCHINS,
Charles; 31005 Prairie Ridge Road, Green Oaks, IL 60048
(US). STOLL, Vincent, S.; 218 E. Winchester Road,
Libertyville, IL 60048 (US). ROSENBERG, Saul, H.; 15
Lighthouse Lane, Grayslake, IL 60030 (US). GIRANDA,
Vincent, L.; 272 South Fork Drive, Gurnee, IL 60031
(US).(74) Agents: STEELE, Gregory, W. et al.; Dept 377/AP6D-2,
100 Abbott Park Road, Abbott Park, IL 60064-6050 (US).(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE,
SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC,
VN, YU, ZA, ZM, ZW.(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK,
TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).**Published:**— without international search report and to be republished
upon receipt of that reportFor two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

WO 03/051366 A2

(54) Title: KINASE INHIBITORS



(57) Abstract: Compounds having the formula (I), are useful for inhibiting protein kinases. Also disclosed are compositions which inhibit protein kinases and methods of inhibiting protein kinases in a patient.

KINASE INHIBITORS

5

Technical Field


10 The present invention relates to compounds which are useful for inhibiting protein kinases, methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.

Background of the Invention

15 Protein kinases have been clearly shown to be important in the progression of many disease states that are induced by the inappropriate proliferation of cells. These kinases are often found to be up-regulated in many hyperproliferative states such as cancer. These kinases may be important in cell signaling, where their inappropriate activation induces cells to proliferate (e.g. EGFR, ERBB2, VEGFR, FGFR, PDGFR, c-Met, IGF-1R, RET, TIE2). Alternatively, they may be involved in signal transduction within cells (e.g. c-Src, PKC, Akt, 20 PKA, c-Abl, PDK-1). Often these signal transduction genes are recognized proto-oncogenes. Many of these kinases control cell cycle progression near the G1-S transition (e.g. Cdk2, Cdk4), at the G2-M transition (e.g. Wee1, Myt1, Chk1, Cdc2) or at the spindle checkpoint (Plk, Aurora1 or 2, Bub1 or 3). Furthermore, kinases are intimately linked to the DNA 25 damage response (e.g. ATM, ATR, Chk1, Chk2). Disregulation of these cellular functions; cell signaling, signal transduction, cell cycle control, and DNA repair, are all hallmarks of hyperproliferative diseases, particularly cancer. It is therefore likely that pharmacological modulation of one or more kinases would be useful in slowing or stopping disease progression in these diseases.

30 Summary of the Invention

In its principle embodiment the present invention provides a compound of formula (I)



or a therapeutically acceptable salt thereof, wherein

X is selected from the group consisting of C(R⁸) and N; wherein R⁸ is selected from the group consisting of hydrogen, alkyl, amino, carboxy, cyano, halo, hydroxy, and amido;

X' is selected from the group consisting of C and N;

Y is selected from the group consisting of C and N;

5 Y' is selected from the group consisting of C(R⁹) and N; wherein R⁹ is selected from the group consisting of hydrogen and -L²-L³(R³)(R⁶);

Z is selected from the group consisting of C and N;

provided that 0, 1, or 2 of X, X', Y, Y', and Z are N;

10 L¹ is selected from the group consisting of a bond, -O-, -NR⁵-, alkenyl, alkynyl,

-C(O)-, -S-, -S(O)-, -S(O)₂-, -S(O)₂N(R⁵)-, -N(R⁵)S(O)₂-, -C(R¹²)₂-, -C(R¹²)₂N(R⁵)-, -N(R⁵)C(O)-, and -C(O)N(R⁵)-; wherein each group is drawn with its left end attached to R¹ and its right end attached to the aromatic ring;

15 L² is selected from the group consisting of a bond, -O-, -C(R¹²)₂-, -S-, -N(R⁵)-, -N(R⁵)C(O)-, and -C(O)N(R⁵)-;

15 L³ is selected from the group consisting of a bond, alkylidene and alkylene, wherein the alkylidene and the alkylene are optionally substituted with one or two substituents independently selected from the group consisting of alkoxy, amino, cyano, and hydroxy;

15 R¹ is selected from the group consisting of aryl, heteroaryl, and heterocycle;

20 R² and R⁴ are independently absent or selected from the group consisting of hydrogen, alkenyl, alkyl, alkynyl, amino, aryl, arylalkynyl, cyano, cyanoalkenyl, halo, heteroaryl, heterocycle, hydroxyalkyl, and nitro; or

25 R² and L¹, together with the carbon atoms to which they are attached, form a ring selected from the group consisting of aryl, heteroaryl, and heterocycle; or

25 R⁴ and L², together with the carbon atoms to which they are attached, form a ring selected from the group consisting of aryl, heteroaryl, and heterocycle; provided that when L³ is alkylidene, R⁴ and L², together with the carbon atoms to which they are attached, form a ring selected from the group consisting of aryl, heteroaryl, and heterocycle;

30 R³ is absent or selected from the group consisting of hydrogen, aryl, arylalkoxy, arylalkylamino, arylalkylthio, aryloxy, arylthio, cycloalkyl, heteroaryl, heteroarylalkoxy, heteroaryloxy, and heterocycle;

35 R⁶ is selected from the group consisting of hydrogen, aryl, arylalkoxy, arylalkylamino, arylalkylthio, aryloxy, arylthio, cycloalkyl, heteroaryl, heteroarylalkoxy, heteroaryloxy, and heterocycle;

provided that when L¹ and L² are bonds, at least one of R³ and R⁶ is other than hydrogen;


R⁵ is selected from the group consisting of hydrogen, alkyl, alkylcarbonyl, alkylsulfonyl, arylcarbonyl, arylsulfonyl, and heteroarylsulfonyl;

R⁷ is absent or selected from the group consisting of hydrogen, alkyl, cyanoalkenyl, and -L²-L³(R³)(R⁶); or

5 R⁷ and L¹, together with the carbon atoms to which they are attached, form a ring selected from the group consisting of aryl, heteroaryl, and heterocycle; and

each R¹² is selected from the group consisting of hydrogen, alkenyl, alkyl, alkynyl, amino, aryl, cyano, halo, heteroaryl, heterocycle, and nitro.

In another embodiment the present invention provides a compound of formula (II)



10

or a therapeutically acceptable salt thereof, wherein

L¹ is selected from the group consisting of a bond, -O-, -N(R⁵)-, alkenyl, alkynyl, -N(R⁵)C(O)-, and -C(O)N(R⁵)-;

15

L² is selected from the group consisting of a bond, -O-, -N(R⁵)-, -N(R⁵)C(O)-, and -C(O)N(R⁵)-;

L³ is selected from the group consisting of a bond, alkylidene; and alkylene, wherein the alkylidene and the alkylene are optionally substituted with one or two substituents independently selected from the group consisting of amino, cyano, and hydroxy;

20

R¹ is selected from the group consisting of aryl, heteroaryl, and heterocycle;

R² and R⁴ are independently selected from the group consisting of hydrogen, alkenyl, alkynyl, arylalkynyl, amino, cyano, cyanoalkenyl, halo, hydroxyalkyl, and heteroaryl; wherein the heteroaryl is selected from the group consisting of furyl, pyrazinyl, thiazolyl, and thienyl; or

25

R² and L¹, together with the carbon atoms to which they are attached, form a ring selected from the group consisting of dihydropyrrolyl, pyrazolyl, and phenyl; or

R⁴ and L², together with the carbon atoms to which they are attached, form a ring selected from the group consisting of dihydropyrrolyl, phenyl, pyridinyl, and pyrrolyl; wherein the ring can be optionally substituted with oxo;

30

provided that when L³ is alkylidene, R⁴ and L², together with the carbon atoms to which they are attached, form a ring selected from the group consisting of dihydropyrrolyl, phenyl, pyridinyl, and pyrrolyl; wherein the ring can be optionally substituted with oxo;

35

R³ is absent or selected from the group consisting of hydrogen, aryl, arylalkoxy, arylalkylthio, aryloxy, arylthio, cycloalkyl, heteroaryl, heteroarylalkoxy, heteroaryloxy, and heterocycle;


R^6 are independently selected from the group consisting of hydrogen, aryl, arylalkoxy, arylalkylthio, aryloxy, arylthio, cycloalkyl, heteroaryl, and heteroarylalkoxy, heteroaryloxy, and heterocycle;

provided that when L^1 and L^2 are bonds, at least one of R^3 and R^6 is other than hydrogen;

R^5 is selected from the group consisting of hydrogen, alkyl, alkylcarbonyl, alkylsulfonyl, arylcarbonyl, arylsulfonyl, and heteroarylsulfonyl; and

X is selected from the group consisting of $C(R^8)$ and N ; wherein R^8 is selected from the group consisting of hydrogen, amino, carboxy, cyano, and halo.

10 In another embodiment the present invention provides a compound of formula (III)



or a therapeutically acceptable salt thereof, wherein

15 L^1 is selected from the group consisting of a bond, $-O-$, $-N(R^5)-$, alkenyl, alkynyl, and $-N(R^5)C(O)-$;

L^2 is selected from the group consisting of a bond, $-O-$, $-N(R^5)-$, $-N(R^5)C(O)-$, and $-C(O)N(R^5)-$;

20 L^3 is alkylene, wherein the alkylene is substituted with one or two substituents independently selected from the group consisting of amino and hydroxy;

R^1 is selected from the group consisting of aryl, heteroaryl, and heterocycle;

R^2 and R^4 are independently selected from the group consisting of hydrogen and halo;

25 R^3 and R^6 are independently selected from the group consisting of hydrogen, aryl, arylalkoxy, and heteroaryl; provided that when L^1 and L^2 are bonds, at least one of R^3 and R^6 is other than hydrogen; and

R^5 is selected from the group consisting of hydrogen and alkyl.

In another embodiment, the present invention provides a compound of formula (I) wherein X is selected from the group consisting of $C(R^8)$ and N , wherein R^8 is selected from the group consisting of hydrogen, alkyl, amino, carboxy, cyano, halo, hydroxy, and amido; X' is selected from the group consisting of C and N ; Y is C ; Y' is $C(R^9)$, wherein R^9 is $-L^2-L^3(R^3)(R^6)$; Z is C ; L^1 is alkenyl; L^2 is selected from the group consisting of a bond, $-O-$, $-C(R^{12})_2-$, $-S-$, $-N(R^5)-$, $-N(R^5)C(O)-$, and $-C(O)N(R^5)-$; L^3 is a bond or selected from the group consisting of alkylidene and alkylene, wherein the alkylidene and the alkylene are optionally substituted with one or two substituents independently selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R^1 is selected from the group consisting of aryl, heteroaryl, and heterocycle; R^2 and R^4 are independently absent or selected from the

group consisting of hydrogen, alkenyl, alkyl, alkynyl, amino, aryl, arylalkynyl, cyano, cyanoalkenyl, halo, heteroaryl, heterocycle, hydroxyalkyl, and nitro; R³ is absent or selected from the group consisting of hydrogen, aryl, arylalkoxy, arylalkylamino, arylalkylthio, aryloxy, arylthio, cycloalkyl, heteroaryl, heteroarylalkoxy, heteroaryloxy, and heterocycle; R⁶ is selected from the group consisting of hydrogen, aryl, arylalkoxy, arylalkylamino, arylalkylthio, aryloxy, arylthio, cycloalkyl, heteroaryl, heteroarylalkoxy, heteroaryloxy, and heterocycle; R⁵ is selected from the group consisting of hydrogen, alkyl, alkylcarbonyl, alkylsulfonyl, arylcarbonyl, arylsulfonyl, and heteroarylsulfonyl; R⁷ is absent or selected from the group consisting of hydrogen, alkyl, and cyanoalkenyl; and each R¹² is selected from the group consisting of hydrogen, alkenyl, alkyl, alkynyl, amino, aryl, cyano, halo, heteroaryl, heterocycle, and nitro.

In another embodiment, the present invention provides a compound of formula (I) wherein X is selected from the group consisting of C(R⁸) and N, wherein R⁸ is selected from the group consisting of hydrogen, alkyl, amino, carboxy, cyano, halo, hydroxy, and amido; X' is selected from the group consisting of C and N; Y is C; Y' is C(R⁹), wherein R⁹ is -L²-L³(R³)(R⁶); Z is C; L¹ is alkenyl; L² is -O-; L³ is alkylene, wherein the alkylene is optionally substituted with one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R¹ is selected from the group consisting of aryl, heterocycle, and heteroaryl; R² and R⁴ are independently selected from the group consisting of hydrogen, alkenyl, alkynyl, arylalkynyl, amino, cyano, cyanoalkenyl, halo, hydroxyalkyl, and heteroaryl, wherein the heteroaryl is selected from the group consisting of furyl, pyrazinyl, thiazolyl, and thieryl; R³ is hydrogen; R⁶ is selected from the group consisting of hydrogen, aryl, arylalkoxy, arylalkylamino, arylalkylthio, aryloxy, arylthio, cycloalkyl, heteroaryl, heteroarylalkoxy, heteroaryloxy, and heterocycle; and R⁷ is absent or selected from the group consisting of hydrogen, alkyl, and cyanoalkenyl.

In another embodiment, the present invention provides a compound of formula (I) wherein X is selected from the group consisting of C(R⁸) and N, wherein R⁸ is selected from the group consisting of hydrogen, alkyl, amino, carboxy, cyano, halo, hydroxy, and amido; X' is selected from the group consisting of C and N; Y is C; Y' is C(R⁹), wherein R⁹ is -L²-L³(R³)(R⁶); Z is C; L¹ is alkenyl; L² is -O-; L¹ is alkenyl; L² is -O-; L³ is alkylene, wherein the alkylene is optionally substituted with one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R¹ is heteroaryl; R² and R⁴ are independently selected from the group consisting of hydrogen, alkenyl, alkynyl, arylalkynyl, amino, cyano, cyanoalkenyl, halo, hydroxyalkyl, and heteroaryl, wherein the heteroaryl is selected from the group consisting of furyl, pyrazinyl, thiazolyl, and thieryl; R³ is hydrogen; R⁶ is selected from the group consisting of hydrogen, aryl, arylalkoxy, arylalkylamino, arylalkylthio,

aryloxy, arylthio, cycloalkyl, heteroaryl, heteroarylalkoxy, heteroaryloxy, and heterocycle; and R⁷ is absent or selected from the group consisting of hydrogen, alkyl, and cyanoalkenyl.

In another embodiment, the present invention provides a compound of formula (I) wherein X is N; X' is C; Y is C; Y' is C(R⁹), wherein R⁹ is -L²-L³(R³)(R⁶); Z is C; L¹ is 5 alkenyl; L² is -O-; L³ is alkylene, wherein the alkylene is optionally substituted with one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R¹ is heteroaryl; R² and R⁴ are independently selected from the group consisting of hydrogen, alkenyl, alkynyl, arylalkynyl, amino, cyano, cyanoalkenyl, halo, hydroxyalkyl, and 10 heteroaryl, wherein the heteroaryl is selected from the group consisting of furyl, pyrazinyl, thiazolyl, and thienyl; R³ is hydrogen; R⁶ is heteroaryl; and R⁷ is hydrogen.

In another embodiment, the present invention provides a compound of formula (I) wherein X is N; and X' is C; Y is C; Y' is C(R⁹), wherein R⁹ is -L²-L³(R³)(R⁶); Z is C; L¹ is 15 alkenyl; L² is -O-; L³ is alkylene, wherein the alkylene is optionally substituted with one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R¹ is heteroaryl; R² and R⁴ are independently selected from the group consisting of hydrogen, alkenyl, alkynyl, arylalkynyl, amino, cyano, cyanoalkenyl, halo, hydroxyalkyl, and 20 heteroaryl, wherein the heteroaryl is selected from the group consisting of furyl, pyrazinyl, thiazolyl, and thienyl; R³ is hydrogen; R⁶ is aryl; and R⁷ is hydrogen.

In another embodiment, the present invention provides a compound of formula (I) 25 wherein X is selected from the group consisting of C(R⁸) and N, wherein R⁸ is selected from the group consisting of hydrogen, alkyl, amino, carboxy, cyano, halo, hydroxy, and amido; and X' is selected from the group consisting of C and N; Y is C; Y' is C(R⁹), wherein R⁹ is -L²-L³(R³)(R⁶); Z is C; L¹ is alkenyl; L² is -O-; L³ is a bond; R¹ is heteroaryl; R² and R⁴ are independently selected from the group consisting of hydrogen, alkenyl, alkynyl, arylalkynyl, 25 amino, cyano, cyanoalkenyl, halo, hydroxyalkyl, and heteroaryl, wherein the heteroaryl is selected from the group consisting of furyl, pyrazinyl, thiazolyl, and thienyl; R³ is absent; R⁶ is heterocycle; and R⁷ is absent or selected from the group consisting of hydrogen, alkyl, and 30 cyanoalkenyl.

In another embodiment, the present invention provides a compound of formula (I) 30 wherein X is N; X' is C; Y is C; Y' is C(R⁹), wherein R⁹ is -L²-L³(R³)(R⁶); Z is C; L¹ is alkenyl; L² is -O-; L³ is a bond; R¹ is heteroaryl; R² and R⁴ are hydrogen; R³ is absent; R⁶ is heterocycle; and R⁷ is hydrogen.

In another embodiment, the present invention provides a compound of formula (I) 35 wherein X is selected from the group consisting of C(R⁸) and N, wherein R⁸ is selected from the group consisting of hydrogen, alkyl, amino, carboxy, cyano, halo, hydroxy, and amido; X' is selected from the group consisting of C and N; Y is C; Y' is C(R⁹), wherein R⁹ is -L²-L³(R³)(R⁶); Z is C; L¹ is alkenyl; L² is -N(R⁵)C(O)-; L³ is alkylene, wherein the alkylene

is optionally substituted with one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R¹ is selected from the group consisting of aryl, heterocycle, and heteroaryl; R² and R⁴ are independently selected from the group consisting of hydrogen, alkenyl, alkynyl, arylalkynyl, amino, cyano, cyanoalkenyl, halo, hydroxyalkyl, and heteroaryl, wherein the heteroaryl is selected from the group consisting of furyl, pyrazinyl, thiazolyl, and thienyl; R³ is hydrogen; R⁶ is selected from the group consisting of hydrogen, aryl, arylalkoxy, arylalkylamino, arylalkylthio, aryloxy, arylthio, cycloalkyl, heteroaryl, heteroarylalkoxy, heteroaryloxy, and heterocycle; and R⁷ is absent or selected from the group consisting of hydrogen, alkyl, and cyanoalkenyl.

10 In another embodiment, the present invention provides a compound of formula (I) wherein X is N; and X' is C; Y is C; Y' is C(R⁹), wherein R⁹ is -L²-L³(R³)(R⁶); Z is C; L¹ is alkenyl; L² is -N(R⁵)C(O)-; L³ is alkylene, wherein the alkylene is optionally substituted with one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R¹ is heteroaryl; R² and R⁴ are independently selected from the group consisting of hydrogen, 15 alkenyl, alkynyl, arylalkynyl, amino, cyano, cyanoalkenyl, halo, hydroxyalkyl, and heteroaryl, wherein the heteroaryl is selected from the group consisting of furyl, pyrazinyl, thiazolyl, and thienyl; R³ is hydrogen; R⁶ is heteroaryl; and R⁷ is hydrogen.

15 In another embodiment, the present invention provides a compound of formula (I) wherein X is N; X' is C; Y is C; Y' is C(R⁹), wherein R⁹ is -L²-L³(R³)(R⁶); Z is C; L¹ is alkenyl; L² is -N(R⁵)C(O)-; L³ is alkylene, wherein the alkylene is optionally substituted with one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R¹ is heteroaryl; R² and R⁴ are independently selected from the group consisting of hydrogen, alkenyl, alkynyl, arylalkynyl, amino, cyano, cyanoalkenyl, halo, hydroxyalkyl, and heteroaryl, wherein the heteroaryl is selected from the group consisting of furyl, pyrazinyl, thiazolyl, and thienyl; R³ is hydrogen; R⁶ is aryl; and R⁷ is hydrogen.

20 In another embodiment, the present invention provides a compound of formula (I) wherein X is selected from the group consisting of C(R⁸) and N, wherein R⁸ is selected from the group consisting of hydrogen, alkyl, amino, carboxy, cyano, halo, hydroxy, and amido; X' is selected from the group consisting of C and N; Y is C; Y' is C(R⁹), wherein R⁹ is -L²-
25 L³(R³)(R⁶); Z is C; L¹ is alkynyl; L² is selected from the group consisting of a bond, -O-, -C(R¹²)₂-, -S-, -N(R⁵)-, -N(R⁵)C(O)-, and -C(O)N(R⁵)-; L³ is a bond or selected from the group consisting of alkylidene and alkylene, wherein the alkylidene and the alkylene are optionally substituted with one or two substituents independently selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R¹ is selected from the group consisting of aryl, heteroaryl, and heterocycle; R² and R⁴ are independently selected from the group consisting of hydrogen, alkenyl, alkyl, alkynyl, amino, aryl, arylalkynyl, cyano, cyanoalkenyl, halo, heteroaryl, heterocycle, hydroxyalkyl, and nitro; R³ is absent or selected from the group

consisting of hydrogen, aryl, arylalkoxy, arylalkylamino, arylalkylthio, aryloxy, arylthio, cycloalkyl, heteroaryl, heteroarylalkoxy, heteroaryloxy, and heterocycle; R⁶ is selected from the group consisting of hydrogen, aryl, arylalkoxy, arylalkylamino, arylalkylthio, aryloxy, arylthio, cycloalkyl, heteroaryl, heteroarylalkoxy, heteroaryloxy, and heterocycle; R⁵ is

5 selected from the group consisting of hydrogen, alkyl, alkylcarbonyl, alkylsulfonyl, arylcarbonyl, arylsulfonyl, and heteroarylsulfonyl; R⁷ is absent or selected from the group consisting of hydrogen, alkyl, and cyanoalkenyl; and each R¹² is selected from the group consisting of hydrogen, alkenyl, alkyl, alkynyl, amino, aryl, cyano, halo, heteroaryl, heterocycle, and nitro.

10 In another embodiment, the present invention provides a compound of formula (I) wherein X is selected from the group consisting of C(R⁸) and N, wherein R⁸ is selected from the group consisting of hydrogen, alkyl, amino, carboxy, cyano, halo, hydroxy, and amido; X' is selected from the group consisting of C and N; Y is C; Y' is C(R⁹), wherein R⁹ is -L²-L³(R³)(R⁶); Z is C; L¹ is alkynyl; L² is -O-; L³ is alkylene, wherein the alkylene is optionally 15 substituted with one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R¹ is selected from the group consisting of aryl, heterocycle, and heteroaryl; R² and R⁴ are independently selected from the group consisting of hydrogen, alkenyl, alkynyl, arylalkynyl, amino, cyano, cyanoalkenyl, halo, hydroxyalkyl, and heteroaryl, wherein the heteroaryl is selected from the group consisting of furyl, pyrazinyl, thiazolyl, and thienyl; R³ is hydrogen; R⁶ is selected from the group consisting of hydrogen, aryl, arylalkoxy, arylalkylamino, arylalkylthio, aryloxy, arylthio, cycloalkyl, heteroaryl, heteroarylalkoxy, heteroaryloxy, and heterocycle; and R⁷ is absent or selected from the group consisting of 20 hydrogen, alkyl, and cyanoalkenyl.

25 In another embodiment, the present invention provides a compound of formula (I) wherein X is selected from the group consisting of C(R⁸) and N, wherein R⁸ is selected from the group consisting of hydrogen, alkyl, amino, carboxy, cyano, halo, hydroxy, and amido; X' is selected from the group consisting of C and N; Y is C; Y' is C(R⁹), wherein R⁹ is -L²-L³(R³)(R⁶); Z is C; L¹ is a bond; L² is selected from the group consisting of a bond, -O-, -C(R¹²)₂-, -S-, -N(R⁵)-, -N(R⁵)C(O)-, and -C(O)N(R⁵)-; L³ is a bond or selected from the group 30 consisting of alkylidene and alkylene, wherein the alkylidene and the alkylene are optionally substituted with one or two substituents independently selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R¹ is selected from the group consisting of aryl, heteroaryl, and heterocycle; R² and R⁴ are independently selected from the group consisting of hydrogen, alkenyl, alkyl, alkynyl, amino, aryl, arylalkynyl, cyano, cyanoalkenyl, halo, heteroaryl, heterocycle, hydroxyalkyl, and nitro; R³ is absent or selected from the group 35 consisting of hydrogen, aryl, arylalkoxy, arylalkylamino, arylalkylthio, aryloxy, arylthio, cycloalkyl, heteroaryl, heteroarylalkoxy, heteroaryloxy, and heterocycle; R⁶ is selected from

the group consisting of hydrogen, aryl, arylalkoxy, arylalkylamino, arylalkylthio, aryloxy, arylthio, cycloalkyl, heteroaryl, heteroarylalkoxy, heteroaryloxy, and heterocycle; R⁵ is selected from the group consisting of hydrogen, alkyl, alkylcarbonyl, alkylsulfonyl, arylcarbonyl, arylsulfonyl, and heteroarylsulfonyl; R⁷ is absent or selected from the group consisting of hydrogen, alkyl, and cyanoalkenyl; and each R¹² is selected from the group consisting of hydrogen, alkenyl, alkyl, alkynyl, amino, aryl, cyano, halo, heteroaryl, heterocycle, and nitro.

In another embodiment, the present invention provides a compound of formula (I) wherein X is selected from the group consisting of C(R⁸) and N, wherein R⁸ is selected from the group consisting of hydrogen, alkyl, amino, carboxy, cyano, halo, hydroxy, and amido; and X' is selected from the group consisting of C and N; Y is C; Y' is C(R³), wherein R⁹ is -L²-L³(R³)(R⁶); Z is C; L¹ is a bond; L² is -O-; L³ is alkylene, wherein the alkylene is optionally substituted with one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R¹ is selected from the group consisting of aryl, heterocycle, and heteroaryl; R² and R⁴ are independently selected from the group consisting of hydrogen, alkenyl, alkynyl, arylalkynyl, amino, cyano, cyanoalkenyl, halo, hydroxyalkyl, and heteroaryl, wherein the heteroaryl is selected from the group consisting of furyl, pyrazinyl, thiazolyl, and thienyl; R³ is hydrogen; R⁶ is selected from the group consisting of hydrogen, aryl, arylalkoxy, arylalkylamino, arylalkylthio, aryloxy, arylthio, cycloalkyl, heteroaryl, heteroarylalkoxy, heteroaryloxy, and heterocycle; and R⁷ is absent or selected from the group consisting of hydrogen, alkyl, and cyanoalkenyl.

In another embodiment, the present invention provides a compound of formula (I) wherein X is N; X' is C; Y is C; Y' is C(R³), wherein R⁹ is -L²-L³(R³)(R⁶); Z is C; L¹ is a bond; L² is -O-; L³ is alkylene, wherein the alkylene is optionally substituted with one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R¹ is heteroaryl; R² and R⁴ are independently selected from the group consisting of hydrogen, alkenyl, alkynyl, arylalkynyl, amino, cyano, cyanoalkenyl, halo, hydroxyalkyl, and heteroaryl, wherein the heteroaryl is selected from the group consisting of furyl, pyrazinyl, thiazolyl, and thienyl; R³ is hydrogen; R⁶ is aryl; and R⁷ is hydrogen.

In another embodiment, the present invention provides a compound of formula (I) wherein X is N; X' is C; Y is C; Y' is C(R³), wherein R⁹ is -L²-L³(R³)(R⁶); Z is C; L¹ is a bond; L² is -O-; L³ is alkylene, wherein the alkylene is optionally substituted with one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R¹ is heteroaryl; R² and R⁴ are independently selected from the group consisting of hydrogen, alkenyl, alkynyl, arylalkynyl, amino, cyano, cyanoalkenyl, halo, hydroxyalkyl, and heteroaryl, wherein the heteroaryl is selected from the group consisting of furyl, pyrazinyl, thiazolyl, and thienyl; R³ is hydrogen; R⁶ is heteroaryl; and R⁷ is hydrogen.

In another embodiment, the present invention provides a compound of formula (I) wherein X is selected from the group consisting of C(R⁸) and N, wherein R⁸ is hydrogen; X' is N; Y is C; Y' is C(R⁹), wherein R⁹ is -L²-L³(R³)(R⁶); Z is C; L¹ is a bond; L² is -O-; L³ is alkylene, wherein the alkylene is optionally substituted with one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R¹ is heteroaryl; R² and R⁴ are independently selected from the group consisting of hydrogen, alkenyl, alkynyl, arylalkynyl, amino, cyano, cyanoalkenyl, halo, hydroxyalkyl, and heteroaryl, wherein the heteroaryl is selected from the group consisting of furyl, pyrazinyl, thiazolyl, and thieryl; R³ is hydrogen; R⁶ is heteroaryl; and R⁷ is absent.

10 In another embodiment, the present invention provides a compound of formula (I) wherein X is N; X' is C; Y is N; Y' is C(R⁹), wherein R⁹ is -L²-L³(R³)(R⁶); Z is C; L¹ is a bond; L² is -O-; L³ is alkylene, wherein the alkylene is optionally substituted with one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R¹ is heteroaryl; R² is absent; R⁴ is selected from the group consisting of hydrogen, alkenyl, 15 alkynyl, arylalkynyl, amino, cyano, cyanoalkenyl, halo, hydroxyalkyl, and heteroaryl, wherein the heteroaryl is selected from the group consisting of furyl, pyrazinyl, thiazolyl, and thieryl; R³ is hydrogen; R⁶ is aryl; and R⁷ is hydrogen.

20 In another embodiment, the present invention provides a compound of formula (I) wherein X is N; X' is C; Y is N; Y' is C(R⁹), wherein R⁹ is -L²-L³(R³)(R⁶); Z is C; L¹ is a bond; L² is -O-; L³ is alkylene, wherein the alkylene is optionally substituted with one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R¹ is heteroaryl; R² is absent; R⁴ is selected from the group consisting of hydrogen, alkenyl, 25 alkynyl, arylalkynyl, amino, cyano, cyanoalkenyl, halo, hydroxyalkyl, and heteroaryl, wherein the heteroaryl is selected from the group consisting of furyl, pyrazinyl, thiazolyl, and thieryl; R³ is hydrogen; R⁶ is heteroaryl; and R⁷ is hydrogen.

30 In another embodiment, the present invention provides a compound of formula (I) wherein X is C(R⁸), wherein R⁸ is hydrogen; X' is C; Y is N; Y' is C(R⁹), wherein R⁹ is -L²-L³(R³)(R⁶); Z is C; L¹ is a bond; L² is -O-; L³ is alkylene, wherein the alkylene is optionally substituted with one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R¹ is heteroaryl; R² is absent; R⁴ is selected from the group consisting of hydrogen, alkenyl, alkynyl, arylalkynyl, amino, cyano, cyanoalkenyl, halo, hydroxyalkyl, and heteroaryl, 35 wherein the heteroaryl is selected from the group consisting of furyl, pyrazinyl, thiazolyl, and thieryl; R³ is hydrogen; R⁶ is aryl; and R⁷ is hydrogen.

35 In another embodiment, the present invention provides a compound of formula (I) wherein X is C(R⁸), wherein R⁸ is hydrogen; X' is C; Y is N; Y' is C(R⁹), wherein R⁹ is -L²-L³(R³)(R⁶); Z is C; L¹ is a bond; L² is -O-; L³ is alkylene, wherein the alkylene is optionally substituted with one substituent selected from the group consisting of alkoxy, amino, cyano,

and hydroxy; R¹ is heteroaryl; R² is absent; R⁴ is selected from the group consisting of hydrogen, alkenyl, alkynyl, arylalkynyl, amino, cyano, cyanoalkenyl, halo, hydroxyalkyl, and heteroaryl, wherein the heteroaryl is selected from the group consisting of furyl, pyrazinyl, thiazolyl, and thienyl; R³ is hydrogen; R⁶ is heteroaryl; and R⁷ is hydrogen.

5 In another embodiment, the present invention provides a compound of formula (I) wherein X is C(R⁸), wherein R⁸ is hydrogen; X' is C; Y is N; Y' is C(R⁹), wherein R⁹ is -L²-L³(R³)(R⁶); Z is N; L¹ is a bond; L² is -O-; L³ is alkylene, wherein the alkylene is optionally substituted with one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R¹ is heteroaryl; R⁴ is absent; R² is selected from the group consisting of 10 hydrogen, alkenyl, alkynyl, arylalkynyl, amino, cyano, cyanoalkenyl, halo, hydroxyalkyl, and heteroaryl, wherein the heteroaryl is selected from the group consisting of furyl, pyrazinyl, thiazolyl, and thienyl; R³ is hydrogen; R⁶ is aryl; and R⁷ is hydrogen.

15 In another embodiment, the present invention provides a compound of formula (I) wherein X is C(R⁸), wherein R⁸ is hydrogen; X' is C; Y is N; Y' is C(R⁹), wherein R⁹ is -L²-L³(R³)(R⁶); Z is N; L¹ is a bond; L² is -O-; L³ is alkylene, wherein the alkylene is optionally substituted with one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R¹ is heteroaryl; R⁴ is absent; R² is selected from the group consisting of 20 hydrogen, alkenyl, alkynyl, arylalkynyl, amino, cyano, cyanoalkenyl, halo, hydroxyalkyl, and heteroaryl, wherein the heteroaryl is selected from the group consisting of furyl, pyrazinyl, thiazolyl, and thienyl; R³ is hydrogen; R⁶ is heteroaryl; and R⁷ is hydrogen.

25 In another embodiment, the present invention provides a compound of formula (I) wherein X is N; X' is C; Y is N; Y' is C(R⁹), wherein R⁹ is -L²-L³(R³)(R⁶); Z is N; L¹ is a bond; L² is -O-; L³ is alkylene, wherein the alkylene is optionally substituted with one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R¹ is heteroaryl; R⁴ is absent; R² is selected from the group consisting of hydrogen, alkenyl, alkynyl, arylalkynyl, amino, cyano, cyanoalkenyl, halo, hydroxyalkyl, and heteroaryl, wherein the heteroaryl is selected from the group consisting of furyl, pyrazinyl, thiazolyl, and thienyl; R³ is hydrogen; R⁶ is aryl; and R⁷ is hydrogen.

30 In another embodiment, the present invention provides a compound of formula (I) wherein X is N; X' is C; Y is N; Y' is C(R⁹), wherein R⁹ is -L²-L³(R³)(R⁶); Z is N; L¹ is a bond; L² is -O-; L³ is alkylene, wherein the alkylene is optionally substituted with one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R¹ is heteroaryl; R⁴ is absent; R² is selected from the group consisting of hydrogen, alkenyl, alkynyl, arylalkynyl, amino, cyano, cyanoalkenyl, halo, hydroxyalkyl, and heteroaryl, 35 wherein the heteroaryl is selected from the group consisting of furyl, pyrazinyl, thiazolyl, and thienyl; R³ is hydrogen; R⁶ is heteroaryl; and R⁷ is hydrogen.

In another embodiment, the present invention provides a compound of formula (I) wherein X is selected from the group consisting of C(R⁸) and N, wherein R⁸ is selected from the group consisting of hydrogen, alkyl, amino, carboxy, cyano, halo, hydroxy, and amido; X' is selected from the group consisting of C and N; Y is C; Y' is C(R⁹), wherein R⁹ is -L²-L³(R³)(R⁶); Z is -C-; L¹ is a bond; L² is -N(R⁵)-; L³ is alkylene, wherein the alkylene is optionally substituted with one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R¹ is selected from the group consisting of aryl, heterocycle, and heteroaryl; R² and R⁴ are independently selected from the group consisting of hydrogen, alkenyl, alkynyl, arylalkynyl, amino, cyano, cyanoalkenyl, halo, hydroxyalkyl, and heteroaryl, wherein the heteroaryl is selected from the group consisting of furyl, pyrazinyl, thiazolyl, and thienyl; R³ is hydrogen; R⁵ is selected from the group consisting of hydrogen, alkyl, alkylcarbonyl, alkylsulfonyl, arylcarbonyl, arylsulfonyl, and heteroarylsulfonyl; R⁶ is selected from the group consisting of hydrogen, aryl, arylalkoxy, arylalkylamino, arylalkylthio, aryloxy, arylthio, cycloalkyl, heteroaryl, heteroarylalkoxy, heteroaryloxy, and heterocycle; and R⁷ is absent or selected from the group consisting of hydrogen, alkyl, and cyanoalkenyl.

In another embodiment, the present invention provides a compound of formula (I) wherein X is N; X' is C; Y is C; Y' is C(R⁹), wherein R⁹ is -L²-L³(R³)(R⁶); Z is C; L¹ is a bond; L² is -N(R⁵)-; L³ is alkylene, wherein the alkylene is optionally substituted with one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R¹ is heteroaryl; R² and R⁴ are independently selected from the group consisting of hydrogen, alkenyl, alkynyl, arylalkynyl, amino, cyano, cyanoalkenyl, halo, hydroxyalkyl, and heteroaryl, wherein the heteroaryl is selected from the group consisting of furyl, pyrazinyl, thiazolyl, and thienyl; R³ is hydrogen; R⁵ is selected from the group consisting of hydrogen, alkyl, alkylcarbonyl, alkylsulfonyl, arylcarbonyl, arylsulfonyl, and heteroarylsulfonyl; R⁶ is heteroaryl; and R⁷ is hydrogen.

In another embodiment, the present invention provides a compound of formula (I) wherein X is N; X' is C; Y is C; Y' is C(R⁹), wherein R⁹ is -L²-L³(R³)(R⁶); Z is C; L¹ is a bond; L² is -N(R⁵)-; L³ is alkylene, wherein the alkylene is optionally substituted with one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R¹ is heteroaryl; R² and R⁴ are independently selected from the group consisting of hydrogen, alkenyl, alkynyl, arylalkynyl, amino, cyano, cyanoalkenyl, halo, hydroxyalkyl, and heteroaryl, wherein the heteroaryl is selected from the group consisting of furyl, pyrazinyl, thiazolyl, and thienyl; R³ is hydrogen; R⁵ is selected from the group consisting of hydrogen, alkyl, alkylcarbonyl, alkylsulfonyl, arylcarbonyl, arylsulfonyl, and heteroarylsulfonyl; R⁶ is aryl; and R⁷ is hydrogen.

In another embodiment, the present invention provides a compound of formula (I) wherein X is selected from the group consisting of C(R⁸) and N, wherein R⁸ is selected from the group consisting of hydrogen, alkyl, amino, carboxy, cyano, halo, hydroxy, and amido; X' is selected from the group consisting of C and N; Y is C; Y' is C(R⁹), wherein R⁹ is 5 -L²-L³(R³)(R⁶); Z is C; L¹ is a bond; L² is -N(R⁵)C(O)-; L³ is alkylene, wherein the alkylene is optionally substituted with one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R¹ is selected from the group consisting of aryl, heterocycle, and heteroaryl; R² and R⁴ are independently selected from the group consisting of hydrogen, alkenyl, alkynyl, arylalkynyl, amino, cyano, cyanoalkenyl, halo, hydroxyalkyl, and 10 heteroaryl, wherein the heteroaryl is selected from the group consisting of furyl, pyrazinyl, thiazolyl, and thienyl; R³ is hydrogen; R⁶ is selected from the group consisting of hydrogen, aryl, arylalkoxy, arylalkylamino, arylalkylthio, aryloxy, arylthio, cycloalkyl, heteroaryl, heteroarylalkoxy, heteroaryloxy, and heterocycle; and R⁷ is absent or selected from the group 15 consisting of hydrogen, alkyl, and cyanoalkenyl.

15 In another embodiment, the present invention provides a compound of formula (I) wherein X is N; X' is C; Y is C; Y' is C(R⁹), wherein R⁹ is -L²-L³(R³)(R⁶); Z is C; L¹ is a bond; L² is -N(R⁵)C(O)-; L³ is alkylene, wherein the alkylene is optionally substituted with 20 one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R¹ is heteroaryl; R² and R⁴ are independently selected from the group consisting of hydrogen, alkenyl, alkynyl, arylalkynyl, amino, cyano, cyanoalkenyl, halo, hydroxyalkyl, and heteroaryl, wherein the heteroaryl is selected from the group consisting of furyl, pyrazinyl, thiazolyl, and thienyl; R³ is hydrogen; R⁶ is heteroaryl; and R⁷ is hydrogen.

25 In another embodiment, the present invention provides a compound of formula (I) wherein X is N; X' is C; Y is C; Y' is C(R⁹), wherein R⁹ is -L²-L³(R³)(R⁶); Z is C; L¹ is a bond; L² is -N(R⁵)C(O)-; L³ is alkylene, wherein the alkylene is optionally substituted with 30 one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R¹ is heteroaryl; R² and R⁴ are independently selected from the group consisting of hydrogen, alkenyl, alkynyl, arylalkynyl, amino, cyano, cyanoalkenyl, halo, hydroxyalkyl, and heteroaryl, wherein the heteroaryl is selected from the group consisting of furyl, pyrazinyl, thiazolyl, and thienyl; R³ is hydrogen; R⁶ is aryl; and R⁷ is hydrogen.

35 In another embodiment, the present invention provides a compound of formula (I) wherein X is selected from the group consisting of C(R⁸) and N, wherein R⁸ is selected from the group consisting of hydrogen, alkyl, amino, carboxy, cyano, halo, hydroxy, and amido; X' is selected from the group consisting of C and N; Y is C; Y' is C(R⁹), wherein R⁹ is -L²-L³(R³)(R⁶); Z is C; L¹ is -N(R⁵)-; L² is selected from the group consisting of a bond, -O-, -C(R¹²)₂-, -S-, -N(R⁵)-, -N(R⁵)C(O)-, and -C(O)N(R⁵)-; L³ is a bond or selected from the group 40 consisting of alkylidene and alkylene, wherein the alkylidene and the alkylene are optionally

substituted with one or two substituents independently selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R¹ is selected from the group consisting of aryl, heteroaryl, and heterocycle; R² and R⁴ are independently selected from the group consisting of hydrogen, alkenyl, alkyl, alkynyl, amino, aryl, arylalkynyl, cyano, cyanoalkenyl, halo, heteroaryl, heterocycle, hydroxyalkyl, and nitro; R³ is absent or selected from the group consisting of hydrogen, aryl, arylalkoxy, arylalkylamino, arylalkylthio, aryloxy, arylthio, cycloalkyl, heteroaryl, heteroarylalkoxy, heteroaryloxy, and heterocycle; R⁶ is selected from the group consisting of hydrogen, aryl, arylalkoxy, arylalkylamino, arylalkylthio, aryloxy, arylthio, cycloalkyl, heteroaryl, heteroarylalkoxy, heteroaryloxy, and heterocycle; R⁵ is selected from the group consisting of hydrogen, alkyl, alkylcarbonyl, alkylsulfonyl, arylcarbonyl, arylsulfonyl, and heteroarylsulfonyl; R⁷ is absent or selected from the group consisting of hydrogen, alkyl, and cyanoalkenyl; and each R¹² is selected from the group consisting of hydrogen, alkenyl, alkyl, alkynyl, amino, aryl, cyano, halo, heteroaryl, heterocycle, and nitro.

In another embodiment, the present invention provides a compound of formula (I) wherein X is selected from the group consisting of C(R⁸) and N, wherein R⁸ is selected from the group consisting of hydrogen, alkyl, amino, carboxy, cyano, halo, hydroxy, and amido; X' is selected from the group consisting of C and N; Y is C; Y' is C(R⁹), wherein R⁹ is -L²-L³(R³)(R⁶); Z is C; L¹ is -N(R⁵)-; L² is -O-; L³ is alkylene, wherein the alkylene is optionally substituted with one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R¹ is selected from the group consisting of aryl, heterocycle, and heteroaryl; R² and R⁴ are independently selected from the group consisting of hydrogen, alkenyl, alkynyl, arylalkynyl, amino, cyano, cyanoalkenyl, halo, hydroxyalkyl, and heteroaryl, wherein the heteroaryl is selected from the group consisting of furyl, pyrazinyl, thiazolyl, and thienyl; R³ is hydrogen; R⁵ is selected from the group consisting of hydrogen, alkyl, alkylcarbonyl, alkylsulfonyl, arylcarbonyl, arylsulfonyl, and heteroarylsulfonyl; R⁶ is selected from the group consisting of hydrogen, aryl, arylalkoxy, arylalkylamino, arylalkylthio, aryloxy, arylthio, cycloalkyl, heteroaryl, heteroarylalkoxy, heteroaryloxy, and heterocycle; and R⁷ is absent or selected from the group consisting of hydrogen, alkyl, and cyanoalkenyl.

In another embodiment, the present invention provides a compound of formula (I) wherein X is N; X' is C; Y is C; Y' is C(R⁹), wherein R⁹ is -L²-L³(R³)(R⁶); Z is C; L¹ is -N(R⁵)-; L² is -O-; L³ is alkylene, wherein the alkylene is optionally substituted with one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R¹ is selected from the group consisting of aryl, heterocycle, and heteroaryl; R² and R⁴ are independently selected from the group consisting of hydrogen, alkenyl, alkynyl, arylalkynyl, amino, cyano, cyanoalkenyl, halo, hydroxyalkyl, and heteroaryl, wherein the heteroaryl is

selected from the group consisting of furyl, pyrazinyl, thiazolyl, and thienyl; R³ is hydrogen; R⁵ is selected from the group consisting of hydrogen, alkyl, alkylcarbonyl, alkylsulfonyl, arylcarbonyl, arylsulfonyl, and heteroarylsulfonyl; R⁶ is heteroaryl; and R⁷ is hydrogen.

In another embodiment, the present invention provides a compound of formula (I) wherein X is N; X' is C; Y is C; Y' is C(R⁹), wherein R⁹ is -L²-L³(R³)(R⁶); Z is C; L¹ is -N(R⁵)-; L² is -O-; L³ is alkylene, wherein the alkylene is optionally substituted with one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R¹ is selected from the group consisting of aryl, heterocycle, and heteroaryl; R² and R⁴ are independently selected from the group consisting of hydrogen, alkenyl, alkynyl, arylalkynyl, amino, cyano, cyanoalkenyl, halo, hydroxyalkyl, and heteroaryl, wherein the heteroaryl is selected from the group consisting of furyl, pyrazinyl, thiazolyl, and thienyl; R³ is hydrogen; R⁵ is selected from the group consisting of hydrogen, alkyl, alkylcarbonyl, alkylsulfonyl, arylcarbonyl, arylsulfonyl, and heteroarylsulfonyl; R⁶ is aryl; and R⁷ is hydrogen.

In another embodiment, the present invention provides a compound of formula (I) wherein X is selected from the group consisting of C(R⁸) and N, wherein R⁸ is selected from the group consisting of hydrogen, alkyl, amino, carboxy, cyano, halo, hydroxy, and amido; X' is selected from the group consisting of C and N; Y is C; Y' is C(R⁹), wherein R⁹ is -L²-L³(R³)(R⁶); Z is C; L¹ is a bond; L² is a bond; L³ is a bond; R² and R⁴ are independently selected from the group consisting of hydrogen, alkenyl, alkynyl, arylalkynyl, amino, cyano, cyanoalkenyl, halo, hydroxyalkyl, and heteroaryl, wherein the heteroaryl is selected from the group consisting of furyl, pyrazinyl, thiazolyl, and thienyl; R³ is absent; R⁶ is heterocycle; and R⁷ is absent or selected from the group consisting of hydrogen, alkyl, and cyanoalkenyl.

In another embodiment, the present invention provides a compound of formula (I) wherein X is selected from the group consisting of C(R⁸) and N; wherein R⁸ is selected from the group consisting of hydrogen, alkyl, amino, carboxy, cyano, halo, hydroxy, and amido; X' is selected from the group consisting of C and N; Y is C; Y' is C(R⁹), wherein R⁹ is -L²-L³(R³)(R⁶); Z is C; L¹ is selected from the group consisting of a bond, -O-, -N(R⁵)-, alkenyl, alkynyl, -C(O)-, -S-, -S(O)-, -S(O)₂-, -S(O)₂N(R⁵)-, -N(R⁵)S(O)₂-, -C(R¹²)₂-, -C(R¹²)₂N(R⁵)-, -N(R⁵)C(O)-, and -C(O)N(R⁵)-, wherein each group is drawn with its left end attached to R¹ and its right end attached to the aromatic ring; L³ is alkylidene, wherein the alkylidene is optionally substituted with one or two substituents independently selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R¹ is selected from the group consisting of aryl, heteroaryl, and heterocycle; R⁴ and L², together with the carbon atoms to which they are attached, form a ring selected from the group consisting of aryl, heteroaryl, and heterocycle; R³ is absent or selected from the group consisting of hydrogen, aryl, arylalkoxy, arylalkylamino, arylalkylthio, aryloxy, arylthio, cycloalkyl, heteroaryl, heteroarylalkoxy, heteroaryloxy, and heterocycle; R⁶ is selected from the group consisting of

hydrogen, aryl, arylalkoxy, arylalkylamino, arylalkylthio, aryloxy, arylthio, cycloalkyl, heteroaryl, heteroarylalkoxy, heteroaryloxy, and heterocycle; R⁵ is selected from the group consisting of hydrogen, alkyl, alkylcarbonyl, alkylsulfonyl, arylcarbonyl, arylsulfonyl, and heteroarylsulfonyl; R⁷ is absent or selected from the group consisting of hydrogen, alkyl, and 5 cyanoalkenyl; and each R¹² is selected from the group consisting of hydrogen, alkenyl, alkyl, alkynyl, amino, aryl, cyano, halo, heteroaryl, heterocycle, and nitro.

In another embodiment, the present invention provides a compound of formula (I) wherein X is selected from the group consisting of C(R⁸) and N, wherein R⁸ is hydrogen; X' is C; Y is C; Y' is C(R⁹), wherein R⁹ is -L²-L³(R³)(R⁶); Z is C; L¹ is a bond; L³ is alkylidene, 10 wherein the alkylidene is substituted with one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R¹ is heteroaryl wherein the heteroaryl is isoquinolinyl; R⁴ and L², together with the carbon atoms to which they are attached, form a heterocycle wherein the heterocycle is pyrrolidinyl substituted with oxo; R³ is hydrogen; R⁶ is heteroaryl, wherein the heteroaryl is indolyl; and R⁷ is hydrogen.

15 In another embodiment, the present invention provides a compound of formula (I) wherein X is selected from the group consisting of C(R⁸) and N; wherein R⁸ is selected from the group consisting of hydrogen, alkyl, amino, carboxy, cyano, halo, hydroxy, and amido; and X' is selected from the group consisting of C and N; Y is C; Y' is C(R⁹), wherein R⁹ is -L²-L³(R³)(R⁶); Z is C; R² and L¹, together with the carbon atoms to which they are attached, 20 form a ring that is aryl wherein the aryl ring is phenyl; L² is -O-; L³ is alkylene, wherein the alkylene is optionally substituted with one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R¹ is heteroaryl; R³ is absent; R⁶ is heteroaryl; and R⁷ is absent or selected from the group consisting of hydrogen, alkyl, and cyanoalkenyl.

25 In another embodiment, the present invention provides a compound of formula (I) wherein X is N; X' is C; Y is C; Y' is C(R⁹), wherein R⁹ is -L²-L³(R³)(R⁶); Z is C; R² and L¹, together with the carbon atoms to which they are attached, form a ring that is aryl wherein the aryl ring is phenyl; L² is -O-; L³ is alkylene, wherein the alkylene is optionally substituted with one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R¹ is heteroaryl; R³ is absent; R⁶ is heteroaryl; and R⁷ is hydrogen.

30 In another embodiment, the present invention provides a compound of formula (I) wherein X is N; X' is C; Y is C; Y' is C(R⁹), wherein R⁹ is -L²-L³(R³)(R⁶); Z is C; R² and L¹, together with the carbon atoms to which they are attached, form a ring that is aryl wherein the aryl ring is phenyl; L² is -O-; L³ is alkylene, wherein the alkylene is optionally substituted with one substituent selected from the group consisting of alkoxy, amino, cyano, and 35 hydroxy; R¹ is heteroaryl; R³ is absent; R⁶ is aryl; and R⁷ is hydrogen.

In another embodiment, the present invention provides a compound of formula (I) wherein X is selected from the group consisting of C(R⁸) and N; wherein R⁸ is selected from

the group consisting of hydrogen, alkyl, amino, carboxy, cyano, halo, hydroxy, and amido; X' is selected from the group consisting of C and N; Y is C; Y' is C(R⁹), wherein R⁹ is -L²-L³(R³)(R⁶); Z is C; R² and L¹, together with the carbon atoms to which they are attached, form a ring that is heteroaryl wherein the heteroaryl is pyrazolyl; L² is a bond; L³ is alkylene, 5 wherein the alkylene is optionally substituted with one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R¹ is selected from the group consisting of aryl, heterocycle, and heteroaryl; R³ is hydrogen; R⁶ is selected from the group consisting of aryl, heterocycle, and heteroaryl; and R⁷ is absent or selected from the group consisting of hydrogen, alkyl, and cyanoalkenyl.

10 In another embodiment, the present invention provides a compound of formula (I) wherein X is C(R⁸), wherein R⁸ is hydrogen; X' is N; Y is C; Y' is C(R⁹), wherein R⁹ is -L²-L³(R³)(R⁶); Z is C; R² and L¹, together with the carbon atoms to which they are attached, form a ring that is heteroaryl wherein the heteroaryl is pyrazolyl; L² is a bond; L³ is alkylene, 15 wherein the alkylene is optionally substituted with one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R¹ is heteroaryl; R³ is hydrogen; R⁶ is aryl; and R⁷ is absent.

20 In another embodiment, the present invention provides a compound of formula (I) wherein X is C(R⁸), wherein R⁸ is hydrogen; X' is N; Y is C; Y' is C(R⁹), wherein R⁹ is -L²-L³(R³)(R⁶); Z is C; R² and L¹, together with the carbon atoms to which they are attached, 25 form a ring that is heteroaryl wherein the heteroaryl is pyrazolyl; L² is a bond; L³ is alkylene, wherein the alkylene is optionally substituted with one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R¹ is aryl; R³ is hydrogen; R⁶ is aryl; and R⁷ is absent.

30 In another embodiment, the present invention provides a compound of formula (I) wherein X is selected from the group consisting of C(R⁸) and N; wherein R⁸ is selected from the group consisting of hydrogen, alkyl, amino, carboxy, cyano, halo, hydroxy, and amido; X is C; Y is C; Y' is C(R⁹), wherein R⁹ is -L²-L³(R³)(R⁶); Z is C; R⁷ and L¹, together with the carbon atoms to which they are attached, form a ring selected from the group consisting aryl, heteroaryl and heterocycle; L² is -O-; L³ is alkylene, wherein the alkylene is optionally substituted with one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R¹ is selected from the group consisting of aryl, heterocycle, and heteroaryl; R³ is hydrogen; and R⁶ is selected from the group consisting of aryl, heterocycle, and heteroaryl.

35 In another embodiment, the present invention provides a compound of formula (I) wherein X is N; and X' is C; Y is C; Y' is C(R⁹), wherein R⁹ is -L²-L³(R³)(R⁶); Z is C; R⁷ and L¹, together with the carbon atoms to which they are attached, form a ring that is a heteroaryl wherein the heteroaryl is pyridinyl; L² is -O-; L³ is alkylene, wherein the alkylene is

optionally substituted with one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R¹ is heteroaryl; R³ is hydrogen; and R⁶ is heteroaryl.

In another embodiment, the present invention provides a compound of formula (I) wherein X is N; and X' is C; Y is C; Y' is C(R⁹), wherein R⁹ is -L²-L³(R³)(R⁶); Z is C; R⁷ and L¹, together with the carbon atoms to which they are attached, form a ring that is a heteroaryl wherein the heteroaryl is pyridinyl; L² is -O-; L³ is alkylene, wherein the alkylene is optionally substituted with one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R¹ is heteroaryl; R³ is hydrogen; and R⁶ is aryl.

In another embodiment the invention provides a pharmaceutical composition comprising a compound of formula (I), or a therapeutically acceptable salt thereof, in combination with a pharmaceutically acceptable carrier.

In another embodiment the invention provides a method of inhibiting protein kinases in a patient in recognized need of such treatment comprising administering to the patient a therapeutically acceptable amount of a compound of formula (I), or a therapeutically acceptable salt thereof.

Detailed Description of the Invention

As used in the present specification the following terms have the meanings indicated:

The term "alkenyl," as used herein, refers to a group derived from a straight or branched chain hydrocarbon of up to six atoms containing at least one double bond.

The term "alkoxy," as used herein, refers to an alkyl group attached to the parent molecular moiety through an oxygen atom.

The term "alkoxyalkyl," as used herein, refers to an alkoxy group attached to the parent molecular moiety through an alkyl group.

The term "alkoxycarbonyl," as used herein, refers to an alkoxy group attached to the parent molecular moiety through an alkyl group.

The term "alkyl," as used herein, refers to a group derived from a straight or branched chain saturated hydrocarbon of one to six atoms.

The term "alkylene," as used herein, refers to a divalent group derived from a straight or branched chain saturated hydrocarbon of one to six atoms.

The term "alkylcarbonyl," as used herein, refers to an alkyl group attached to the parent molecular moiety through a carbonyl group.

The term "alkylidene," as used herein, refers to an alkenyl group in which one carbon atom of the carbon-carbon double bond belongs to the moiety to which the alkenyl group is attached.

The term "alkylsulfonyl," as used herein, refers to an alkyl group attached to the parent molecular moiety through a sulfonyl group.

The term "alkynyl," as used herein, refers to a group derived from a straight or branched chain hydrocarbon of two to six atoms containing at least one triple bond.

The term "amido," as used herein, refers to an amino group attached to the parent molecular moiety through a carbonyl group.

5 The term "amino," as used herein, refers to -NR^aR^b, wherein R^a and R^b are independently selected from the group consisting of hydrogen, alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkyl, alkylcarbonyl, aryl, arylalkenyl, arylalkyl, cycloalkyl, haloalkylcarbonyl, (NR^cR^d)alkylcarbonyl, heteroaryl, heteroarylalkenyl, heteroarylalkyl, heterocycle, (heterocycle)alkenyl, and (heterocycle)alkyl, wherein the aryl, the aryl part of 10 the arylalkenyl, the arylalkyl, the heteroaryl, the heteroaryl part of the heteroarylalkenyl and the heteroarylalkyl, the heterocycle, and the heterocycle part of the (heterocycle)alkenyl and the (heterocycle)alkyl can be optionally substituted with one, two, three, four, or five substituents independently selected from the group consisting of alkenyl, alkoxy, alkoxyalkyl, alkyl, cyano, halo, haloalkoxy, haloalkyl, hydroxy, hydroxyalkyl, nitro, and oxo.

15 The term "aminoalkyl," as used herein, refers to an amino group attached to the parent molecular moiety through an alkyl group.

The term "aryl," as used herein, refers to a phenyl group, or a bicyclic or tricyclic fused ring system wherein one or more of the fused rings is a phenyl group. Bicyclic fused ring systems are exemplified by a phenyl group fused to a cycloalkyl group, as defined 20 herein, or another phenyl group. Tricyclic fused ring systems are exemplified by a bicyclic fused ring system fused to a cycloalkyl group, as defined herein, or another phenyl group. Representative examples of aryl include, but are not limited to, anthracenyl, azulenyl, fluorenyl, indanyl, indenyl, naphthyl, phenyl, and tetrahydronaphthyl. The aryl groups of the present invention can be optionally substituted with one, two, three, four, or five substituents 25 independently selected from the group consisting of alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkyl, alkylcarbonyl, alkylthio, amino, aminoalkyl, a second aryl group, arylalkoxy, arylalkyl, arylcarbonyl, carboxy, cyano, cycloalkyl, halo, haloalkoxy, haloalkyl, heteroaryl, heteroarylalkoxy, heteroarylalkyl, heterocycle, (heterocycle)alkoxy, (heterocycle)alkyl, hydroxy, hydroxyalkyl, nitro, oxo, -C(=NOH)NH₂, -C(=NH)NH₂; wherein 30 the second aryl group, the aryl part of the arylalkoxy, the arylalkyl, and the arylcarbonyl, the heteroaryl, the heteroaryl part of the heteroarylalkoxy and the heteroarylalkyl, the heterocycle, and the heterocycle part of the (heterocycle)alkoxy and the (heterocycle)alkyl can be further optionally substituted with one, two, three, four, or five substituents 35 independently selected from the group consisting of alkenyl, alkoxy, alkyl, hal, haloalkoxy, haloalkyl, hydroxy, hydroxyalkyl, and nitro.

The term "arylalkenyl," as used herein, refers to an aryl group attached to the parent molecular moiety through an alkenyl group.

The term "arylalkoxy," as used herein, refers to an aryl group attached to the parent molecular moiety through an alkoxy group.

The term "arylalkyl," as used herein, refers to an aryl group attached to the parent molecular moiety through an alkyl group.

5 The term "arylalkylamino," as used herein, refers to an arylalkyl group attached to the parent molecular moiety through a nitrogen atom, wherein the nitrogen atom is substituted with hydrogen.

The term "arylalkylidene," as used herein, refers to an aryl group attached to the parent molecular moiety through an alkylidene group

10 The term "arylalkylthio," as used herein, refers to an arylalkyl group attached to the parent molecular moiety through a sulfur atom.

The term "arylalkynyl," as used herein, refers to an aryl group attached to the parent molecular moiety through an alkynyl group.

15 The term "arylcarbonyl," as used herein, refers to an aryl group attached to the parent molecular moiety through a carbonyl group.

The term "aryloxy," as used herein, refers to an aryl group attached to the parent molecular moiety through an oxygen atom.

The term "arylsulfonyl," as used herein, refers to an aryl group attached to the parent molecular moiety through an sulfonyl group.

20 The term "arylthio," as used herein, refers to an aryl group attached to the parent molecular moiety through a sulfur atom.

The term "carbonyl," as used herein, refers to a -C(O)- group.

The term "carboxy," as used herein, refers to -C(O)OH.

The term "cyano," as used herein, refers to -CN.

25 The term "cyanoalkenyl," as used herein, refers to a cyano group attached to the parent molecular moiety through an alkenyl group

The term "cycloalkyl," as used herein, refers to a saturated monocyclic, bicyclic, or tricyclic hydrocarbon ring system having three to twelve carbon atoms. Examples of cycloalkyl groups include cyclopropyl, cyclopentyl, bicyclo[3.1.1]heptyl, adamantyl, and the like.

30 The term "(cycloalkyl)alkylidene," as used herein, refers to a cycloalkyl group attached to the parent molecular moiety through an alkylidene group.

The term "halo," or "halogen," as used herein, refers to F, Cl, Br, or I.

35 The term "haloalkoxy," as used herein, refers to a haloalkyl group attached to the parent molecular moiety through an oxygen atom.

The term "haloalkyl," as used herein, refers to an alkyl group substituted by one, two, three, or four halogen atoms.

The term "haloalkylcarbonyl," as used herein, refers to an haloalkyl group attached to the parent molecular moiety through a carbonyl group.

The term "heteroaryl," as used herein, refers to an aromatic five- or six-membered ring where at least one atom is selected from the group consisting of N, O, and S, and the remaining atoms are carbon. The five-membered rings have two double bonds, and the six-membered rings have three double bonds. The heteroaryl groups are connected to the parent molecular group through a substitutable carbon or nitrogen atom in the ring. The term "heteroaryl" also includes systems where a heteroaryl ring is fused to an aryl group, as defined herein, a heterocycle group, as defined herein, or an additional heteroaryl group.

10 Heteroaryls are exemplified by benzothienyl, benzoxadiazolyl, benzofuranyl, benzimidazolyl, benzotriazolyl, cinnolinyl, furyl, imidazolyl, indazolyl, indolyl, isoxazolyl, isoquinolinyl, isothiazolyl, naphthyridinyl, oxadiazolyl, oxadiazolyl, oxazolyl, purinyl, thiazolyl, thienopyridinyl, thienyl, triazolyl, thiadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyrazolyl, pyrrolyl, pyrido[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyridinyl, quinazolinyl, 15 quinolinyl, thieno[2,3-c]pyridinyl, tetrazolyl, triazinyl, and the like. The heteroaryl groups of the present invention can be optionally substituted with one, two, three, four, or five substituents independently selected from the group consisting of alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkyl, alkynyl, alkylcarbonyl, amino, aminoalkyl, aryl, arylalkoxy, arylalkyl, arylalkylthio, arylalkynyl, aryloxy, carboxy, cyano, cycloalkyl, halo, 20 haloalkoxy, haloalkyl, a second heteroaryl group, heteroarylalkoxy, heteroarylalkyl, heterocycle, (heterocycle)alkoxy, (heterocycle)alkyl, hydroxy, hydroxyalkyl, nitro, and oxo, wherein the aryl, the aryl part of the arylalkoxy, the arylalkyl, the arylalkylthio, the arylalkynyl, and the aryloxy, the second heteroaryl group, the heteroaryl part of the heteroarylalkoxy and the heteroarylalkyl, the heterocycle, and the heterocycle part of the 25 (heterocycle)alkoxy and the (heterocycle)alkyl can be further optionally substituted with one, two, three, four, or five substituents independently selected from the group consisting of alkenyl, alkoxy, alkoxyalkyl, alkyl, cyano, halo, haloalkoxy, haloalkyl, hydroxy, hydroxyalkyl, nitro, and oxo.

30 The term "heteroarylalkenyl," as used herein, refers to a heteroaryl group attached to the parent molecular moiety through an alkenyl group.

The term "heteroarylalkoxy," as used herein, refers to a heteroaryl group attached to the parent molecular moiety through an alkoxy group.

The term "heteroarylalkyl," as used herein, refers to a heteroaryl group attached to the parent molecular moiety through an alkyl group.

35 The term "heteroarylalkylidene," as used herein, refers to a heteroaryl group attached to the parent molecular moiety through an alkylidene group.

The term "heteroaryloxy," as used herein, refers to a heteroaryl group attached to the

parent molecular moiety through an oxygen atom.

The term "heteroarylsulfonyl," as used herein, refers to a heteroaryl group attached to the parent molecular moiety through a sulfonyl group.

The term "heterocycle," as used herein, refers to cyclic, non-aromatic, three-, four-, 5 five-, six-, or seven-membered rings containing at least one atom selected from the group consisting of oxygen, nitrogen, and sulfur. The five-membered rings have zero or one double bonds and the six- and seven-membered rings have zero, one, or two double bonds. The heterocycle groups of the invention are connected to the parent molecular group through a substitutable carbon or nitrogen atom in the ring. The term "heterocycle" also includes 10 systems where a heterocycle ring is fused to an aryl group, as defined herein, or an additional heterocycle group. Heterocycle groups of the invention are exemplified by aziridinyl, azetidinyl, 1,3-benzodioxolyl, dihydroisoindolyl, dihydroisoquinolinyl, dihydrocinnolinyl, dihydrobenzodioxinyl, dihydro[1,3]oxazolo[4,5-b]pyridinyl, benzothiazolyl, dihydroindolyl, dihydropyridinyl, 1,3-dioxanyl, 1,4-dioxanyl, 1,3-dioxolanyl, isoindolinyl, morpholinyl, 15 piperazinyl, pyrrolidinyl, tetrahydropyridinyl, piperidinyl, thiomorpholinyl, and the like. The heterocycle groups of the present invention can be optionally substituted with one, two, three, four, or five substituents independently selected from the group consisting of alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkyl, alkylcarbonyl, alkylidene, amino, aminoalkyl, aryl, arylalkoxy, arylalkyl, arylalkylidene, cyano, (cycloalkyl)alkylidene, halo, haloalkoxy, 20 haloalkyl, heteroaryl, heteroarylalkoxy, heteroarylalkyl, heteroarylalkylidene, iminohydroxy, a second heterocycle, (heterocycle)alkoxy, (heterocycle)alkyl, (heterocycle)alkylidene, hydroxy, hydroxyalkyl, nitro, and oxo, wherein the aryl, the aryl part of the arylalkoxy and the arylalkyl, the heteroaryl, the heteroaryl part of the heteroarylalkoxy, the heteroarylalkyl, and the heteroarylalkylidene, the second heterocycle, and the heterocycle part of the 25 (heterocycle)alkoxy, the (heterocycle)alkyl, and the (heterocycle)alkylidene can be further optionally substituted with one, two, three, four, or five substituents independently selected from the group consisting of alkenyl, alkoxy, alkoxyalkyl, alkyl, cyano, halo, haloalkoxy, haloalkyl, hydroxy, hydroxyalkyl, nitro, and oxo.

The term "(heterocycle)alkenyl," as used herein, refers to a heterocycle group attached 30 to the parent molecular moiety through an alkenyl group.

The term "(heterocycle)alkoxy," as used herein, refers to a heterocycle group attached to the parent molecular group through an oxygen atom.

The term "(heterocycle)alkyl," as used herein, refers to a heterocycle group attached to the parent molecular moiety through an alkyl group.

35 The term "(heterocycle)alkylidene," as used herein, refers to a heterocycle group attached to the parent molecular moiety through an alkylidene group.

The term "hydroxy," as used herein, refers to -OH.

The term "hydroxyalkyl," as used herein, refers to a hydroxy group attached to the parent molecular moiety through an alkyl group.

The term "iminohydroxy," as used herein, refers to =N(OH).

5 The term "-NR^cR^d," as used herein, refers to two groups, R^c and R^d, which are attached to the parent molecular moiety through a nitrogen atom. R^c and R^d are each independently selected from hydrogen and alkyl.

The term "(NR^cR^d)alkyl," as used herein, refers to a -NR^cR^d group attached to the parent molecular moiety through an alkyl group.

10 The term "(NR^cR^d)alkylcarbonyl," as used herein, refers to a (NR^cR^d)alkyl group attached to the parent molecular moiety through a carbonyl group.

The term "nitro," as used herein, refers to -NO₂.

The term "oxo," as used herein, refers to =O.

The term "sulfonyl," as used herein, refers to -S(O)₂-.

The compounds of the present invention can exist as therapeutically acceptable salts.

15 The term "therapeutically acceptable salt," as used herein, represents salts or zwitterionic forms of the compounds of the present invention which are water or oil-soluble or dispersible, which are suitable for treatment of diseases without undue toxicity, irritation, and allergic response; which are commensurate with a reasonable benefit/risk ratio, and which are effective for their intended use. The salts can be prepared during the final isolation and purification of the compounds or separately by reacting an amino group with a suitable acid. Representative acid addition salts include acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, glycerophosphate, hemisulfate, heptanoate, hexanoate, formate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethansulfonate (isethionate), lactate, maleate, mesitylenesulfonate, methanesulfonate, naphthylenesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, pamoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, trichloroacetate, trifluoroacetate, phosphate, glutamate, bicarbonate, para-toluenesulfonate, and undecanoate. Also, amino groups in the compounds of the present invention can be quaternized with methyl, ethyl, propyl, and butyl chlorides, bromides, and iodides; dimethyl, diethyl, dibutyl, and diamyl sulfates; decyl, lauryl, myristyl, and steryl chlorides, bromides, and iodides; and benzyl and phenethyl bromides. Examples of acids which can be employed to form therapeutically acceptable addition salts include inorganic acids such as hydrochloric, hydrobromic, sulfuric, and phosphoric, and organic acids such as oxalic, maleic, succinic, and citric.

35 Basic addition salts can be prepared during the final isolation and purification of the compounds by reacting a carboxy group with a suitable base such as the hydroxide, carbonate, or bicarbonate of a metal cation or with ammonia or an organic primary,

secondary, or tertiary amine. The cations of therapeutically acceptable salts include lithium, sodium, potassium, calcium, magnesium, and aluminum, as well as nontoxic quaternary amine cations such as ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, diethylamine, ethylamine, tributylamine, pyridine, N,N-dimethylaniline, N-methylpiperidine, N-methylmorpholine, dicyclohexylamine, procaine, dibenzylamine, N,N-dibenzylphenethylamine, 1-phenamine, and N,N'-dibenzylethylenediamine. Other representative organic amines useful for the formation of base addition salts include ethylenediamine, ethanolamine, diethanolamine, piperidine, and piperazine.

The present compounds can also exist as therapeutically acceptable prodrugs. The term "therapeutically acceptable prodrug," refers to those prodrugs or zwitterions which are suitable for use in contact with the tissues of patients without undue toxicity, irritation, and allergic response, are commensurate with a reasonable benefit/risk ratio, and are effective for their intended use. The term "prodrug," refers to compounds which are transformed in vivo to parent compounds of formula (I) for example, by hydrolysis in blood.

When any variable, substituent, or term (e.g. aryl, heterocycle, R¹², etc.) occurs more than one time in a formula or generic structure, its definition at each occurrence is independent of the definition at every other occurrence. Also, combinations of substituents and/or variables are permissible only if such combinations result in stable combinations.

Because carbon-carbon double bonds exist in the present compounds, the invention contemplates various geometric isomers and mixtures thereof resulting from the arrangement of substituents around these carbon-carbon double bonds. It should be understood that the invention encompasses both isomeric forms, or mixtures thereof, which possess the ability to inhibit protein kinases. These substituents are designated as being in the E or Z configuration wherein the term "E" represents higher order substituents on opposite sides of the carbon-carbon double bond, and the term "Z" represents higher order substituents on the same side of the carbon-carbon double bond.

Asymmetric centers exist in the compounds of the present invention. These centers are designated by the symbols "R" or "S," depending on the configuration of substituents around the chiral carbon atom. It should be understood that the invention encompasses all stereochemical isomeric forms, or mixtures thereof, which possess the ability to inhibit protein kinases. Individual stereoisomers of compounds can be prepared synthetically from commercially available starting materials which contain chiral centers or by preparation of mixtures of enantiomeric products followed by separation such as conversion to a mixture of diastereomers followed by separation or recrystallization, chromatographic techniques, or direct separation of enantiomers on chiral chromatographic columns. Starting compounds of particular stereochemistry are either commercially available or can be made and resolved by

techniques known in the art.

In accordance with methods of treatment and pharmaceutical compositions of the invention, the compounds can be administered alone or in combination with other anticancer agents. When using the compounds, the specific therapeutically effective dose level for any particular patient will depend upon factors such as the disorder being treated and the severity of the disorder; the activity of the particular compound used; the specific composition employed; the age, body weight, general health, sex, and diet of the patient; the time of administration; the route of administration; the rate of excretion of the compound employed; the duration of treatment; and drugs used in combination with or coincidently with the compound used. The compounds can be administered orally, parenterally, osmotically (nasal sprays), rectally, vaginally, or topically in unit dosage formulations containing carriers, adjuvants, diluents, vehicles, or combinations thereof. The term "parenteral" includes infusion as well as subcutaneous, intravenous, intramuscular, and intrasternal injection.

Parenterally administered aqueous or oleaginous suspensions of the compounds can be formulated with dispersing, wetting, or suspending agents. The injectable preparation can also be an injectable solution or suspension in a diluent or solvent. Among the acceptable diluents or solvents employed are water, saline, Ringer's solution, buffers, monoglycerides, diglycerides, fatty acids such as oleic acid, and fixed oils such as monoglycerides or diglycerides.

The anticancer effect of parenterally administered compounds can be prolonged by slowing their absorption. One way to slow the absorption of a particular compound is administering injectable depot forms comprising suspensions of crystalline, amorphous, or otherwise water-insoluble forms of the compound. The rate of absorption of the compound is dependent on its rate of dissolution which is, in turn, dependent on its physical state. Another way to slow absorption of a particular compound is administering injectable depot forms comprising the compound as an oleaginous solution or suspension. Yet another way to slow absorption of a particular compound is administering injectable depot forms comprising microcapsule matrices of the compound trapped within liposomes, microemulsions, or biodegradable polymers such as polylactide-polyglycolide, polyorthoesters or polyanhydrides. Depending on the ratio of drug to polymer and the composition of the polymer, the rate of drug release can be controlled.

Transdermal patches can also provide controlled delivery of the compounds. The rate of absorption can be slowed by using rate controlling membranes or by trapping the compound within a polymer matrix or gel. Conversely, absorption enhancers can be used to increase absorption.

Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In these solid dosage forms, the active compound can optionally comprise

diluents such as sucrose, lactose, starch, talc, silicic acid, aluminum hydroxide, calcium silicates, polyamide powder, tableting lubricants, and tableting aids such as magnesium stearate or microcrystalline cellulose. Capsules, tablets and pills can also comprise buffering agents, and tablets and pills can be prepared with enteric coatings or other release-controlling 5 coatings. Powders and sprays can also contain excipients such as talc, silicic acid, aluminum hydroxide, calcium silicate, polyamide powder, or mixtures thereof. Sprays can additionally contain customary propellants such as chlorofluorohydrocarbons or substitutes therefore.

Liquid dosage forms for oral administration include emulsions, microemulsions, 10 solutions, suspensions, syrups, and elixirs comprising inert diluents such as water. These compositions can also comprise adjuvants such as wetting, emulsifying, suspending, sweetening, flavoring, and perfuming agents.

Topical dosage forms include ointments, pastes, creams, lotions, gels, powders, 15 solutions, sprays, inhalants, and transdermal patches. The compound is mixed under sterile conditions with a carrier and any needed preservatives or buffers. These dosage forms can also include excipients such as animal and vegetable fats, oils, waxes, paraffins, starch, 20 tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof. Suppositories for rectal or vaginal administration can be prepared by mixing the compounds with a suitable non-irritating excipient such as cocoa butter or polyethylene glycol, each of which is solid at ordinary temperature but fluid in the rectum or vagina. Ophthalmic formulations comprising eye drops, eye ointments, powders, and solutions are also contemplated as being within the scope of this invention.

The total daily dose of the compounds administered to a host in single or divided doses can be in amounts from about 0.1 to about 200 mg/kg body weight or preferably from 25 about 0.25 to about 100 mg/kg body weight. Single dose compositions can contain these amounts or submultiples thereof to make up the daily dose.

Determination of Biological Activity

Enzymatic assays:

The Akt1 assay uses His-Akt1-S36, a truncated Akt1 containing a His tag at the N-terminus, amino acid 139-460 of Akt1 and the following point mutations: S378A, S381A, 30 T450D and S473D. The His-Akt1-S36 assay is run in 96 well plates by incubating 1nM His-Akt1-S36, 5 μ M Biotin-BAD-peptide (Biotin) and 5 μ M 33 P-ATP in 50 μ L of reaction buffer (20 mM HEPES, pH 7.5, 10 mM MgCl₂, 0.009% Triton X-100) for 30 minutes at room temperature. The reactions are stopped by adding 25 μ L of stopping buffer (4M NaCl and 0.1M EDTA). The samples are transferred to a Flash plate coated with streptavidin. The 35 phosphorylation of BAD-peptide in the reactions is measured by counting the plate with the TopCount. Other kinase assays (Akt2, Akt3, PKA, PKC, Erk2, Chk1, Cdc2, Src, CK2, MAPK AP kinase 2, and SGK) are carried out similarly using their specific biotinylated

peptide substrates and buffer conditions. Compounds of the invention inhibited Akt by 0-100% at a concentration of 1 μ M. Preferred compounds had percent inhibitions of between 77 and 100 at 1 μ M and more preferred compounds had percent inhibitions of between 92 and 100 at 1 μ M. Thus, the compounds of the invention are useful in treating disorders which are caused or exacerbated by increased protein kinase levels.


Synthetic Methods

Abbreviations which have been used in the descriptions of the scheme and the examples that follow are: DEAD for diethyl azodicarboxylate; THF for tetrahydrofuran; MTBE for methyl tert-butyl ether, PPh₃ for triphenylphosphine; OAc for acetate; P(o-tol)₃ for tri-o-tolylphosphine; dba for dibenzylideneacetone; DME for 1,2-dimethoxyethane; BINAP for 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl; DMAP for 4-dimethylaminopyridine; dppf for diphenylphosphinoferrocene; dppe for diphenylphosphinoethane; EDC for 1-ethyl-3-[3-(dimethylamino)propyl]carbodiimide hydrochloride; HOBt for 1-hydroxybenzotriazole; DCC for 1,3-dicyclohexylcarbodiimide; DMF for dimethylformamide; NMP for N-methylpyrrolidinone; DMSO for dimethylsulfoxide; Boc for tert-butoxycarbonyl; TFA for trifluoroacetic acid; DIBAL for diisobutylaluminum hydride; n-BuLi for n-butyllithium; 9-BBN for 9-borabicyclo[3.3.1]nonane; OiPr for isopropoxide; DMA for dimethylacetamide; AIBN for 2,2'-azobisisobutyronitrile; TEA for triethylamine; and NBS for N-bromosuccinimide.

The compounds and processes of the present invention will be better understood in connection with the following synthetic schemes which illustrate the methods by which the compounds of the invention may be prepared. The groups L¹, L², L³, R¹, R², R³, R⁴, R⁶, and R⁷ are as defined above unless otherwise noted below.

This invention is intended to encompass compounds having formula (I) when prepared by synthetic processes or by metabolic processes. Preparation of the compounds of the invention by metabolic processes include those occurring in the human or animal body (in vivo) or processes occurring in vitro.

Scheme 1




As shown in Scheme 1, compounds of formula (2) (Z is Cl, Br, I, or OTf) can be converted to compounds of formula (4) by treatment with compounds of formula (3) in the presence of triphenylphosphine and an activating agent such as DEAD. The reaction can be carried out neat or in the presence of a solvent such as THF, diethyl ether, and MTBE. The

reaction temperature is typically about -10 °C to about 35 °C and reaction times are typically about 8 to about 24 hours.

Compounds of formula (4) can be converted to compounds of formula (Ia) by treatment with compounds of formula (5) (M is selected from $B(OH)_2$; $Sn(R^a)_3$, where R^a is an alkyl or aryl group; and hydrogen) in the presence of a palladium catalyst and an optional additive such as triethylamine. Examples of palladium catalysts include $Pd(PPh_3)_4$, and $Pd(OAc)_2$ and $P(o-tol)_3$. Representative solvents include toluene, acetonitrile, and DME. The reaction is typically conducted at temperatures between about 60 °C and about 110 °C and reaction times are typically about 4 to about 12 hours.

10

Scheme 2




Scheme 2 shows that compounds of formula (6) (Z^1 and Z^2 are independently Cl, Br, I, or OTf) can be converted to compounds of formula (8) by treatment with compounds of formula (7) according to the procedure described in Scheme 1. These compounds can be converted to compounds of formula (9) by treatment with benzophenone imine, a palladium catalyst, and a base. Examples of palladium catalysts include Pd_2dba_3 and a ligand such as BINAP, dppf, or dppe. Representative bases include sodium tert-butoxide and potassium tert-butoxide. Typically, the reaction is conducted in a solvent such as toluene, acetonitrile, or DME; at temperatures from about 60 °C to about 90 °C; and at times from about 8 to about 24 hours.

20

Compounds of formula (9) can be treated with compounds of formula (10) in the presence of an acid such as acetic acid and then treated with sodium cyanoborohydride to provide compounds of formula (Ib). Representative solvents include methanol and ethanol. The reaction is typically conducted at about 20 °C to about 70 °C and reaction times are typically about 1 to about 4 hours.

25

Scheme 3




30

Scheme 3 shows the preparation of compounds of formula (Ic). Compounds of formula (11) (Z is Br) can be treated with a palladium catalyst under CO atmosphere to provide compounds of formula (12). Examples of palladium catalysts include $PdCl_2\cdot dppf$, $PdCl_2$ and BINAP, and $PdCl_2\cdot dppe$. Representative solvents include THF, water, DME, and

mixtures thereof. The reaction is typically conducted at about 80 °C to about 100 °C and reaction times are typically between 12 and 24 hours.


Compounds of formula (12) can be converted to compounds of formula (Ic) by treatment with a substituted amine in the presence of a coupling agent. Representative coupling agents include EDC, HOBr, DCC, DMAP, and mixtures thereof. Examples of solvents used include dichloromethane, DMF, and DME. The reaction is typically conducted at about 0 °C to about 35 °C and reaction times are typically about 12 to about 24 hours.

Scheme 4



As shown in Scheme 4, compounds of formula (13) can be hydrolyzed to provide compounds of formula (14) using methods known to those of ordinary skill in the art. Compounds of formula (14) can be converted to compounds of formula (Id) using the conditions described in Scheme 3.


Scheme 5



Scheme 5 shows the synthesis of compounds of formula (Ie). Compounds of formula (15) can be converted to compounds of formula (16) by treatment with a reducing agent. Examples of reducing agents include Pd/C and ammonium formate, Pd/C and hydrogen, and PtO₂ and hydrogen. Representative solvents include methanol and ethanol. The reaction is typically conducted at about 50 °C to about 70 °C for about 15 minutes to about 2 hours.

Compounds of formula (16) can be converted to compounds of formula (Ie) by treatment with an electrophile such as a halo-substituted heteroaryl group. Examples of solvents used in these reactions include ethanol and methanol. The reaction is typically conducted at about 50 °C to about 70 °C for about 6 to about 18 hours.


Scheme 6



As shown in Scheme 6, compounds of formula (8) can be converted to compounds of formula (If) (where L² is a bond) by treatment with compounds of formula (17) (M is

$B(OR^2)_2$, wherein R^2 is hydrogen or alkyl) in the presence of a palladium catalyst and a base such as cesium carbonate or sodium carbonate. Representative palladium catalysts include $PdCl_2\cdot dppf$, $Pd(PPh_3)_4$, and $PdCl_2(PPh_3)_2$. Examples of solvents used in these reactions include DMF, DME, and NMP. The reaction is typically conducted at about 30 °C to about 5 100 °C for about 4 to about 12 hours.

Scheme 7



As shown in Scheme 7, compounds of formula (9) can be reacted with compounds of formula (18) using the conditions described in Scheme 3 to provide compounds of formula 10 (Ig).

The present invention will now be described in connection with certain preferred embodiments which are not intended to limit its scope. On the contrary, the present invention covers all alternatives, modifications, and equivalents as can be included within the scope of the claims. Thus, the following examples, which include preferred embodiments, 15 will illustrate the preferred practice of the present invention, it being understood that the examples are for the purposes of illustration of certain preferred embodiments and are presented to provide what is believed to be the most useful and readily understood description of its procedures and conceptual aspects.

Example 1

20 N,N-dimethyl-N-[2-({5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-yl}oxy)ethyl]amine

Example 1A

N-[2-[(5-bromopyridin-3-yl)oxy]ethyl]-N,N-dimethylamine

A solution of N,N-dimethylethanolamine(0.5 mL) in DMF (10 mL) at room 25 temperature was treated with sodium hydride (0.2 g, 8.4 mmol), stirred for 30 minutes, and treated with 3,5-dibromopyridine (1.0 g, 4.2 mmol). The mixture was stirred at 90°C for 8 hours, and partitioned between ethyl acetate and water. The organic layer was washed with brine, dried (Na_2SO_4), filtered, and concentrated under vacuum. Purification by flash column chromatography on silica gel with 50% ethyl acetate/hexane provided the desired product (0.8 g, 78%). MS (DCI/NH₃) m/e 246 ($M+H$)⁺.

Example 1B

N,N-dimethyl-N-[2-({5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-yl}oxy)ethyl]amine

A mixture of Example 1A (0.8 g, 3.27 mmol), 4-vinylpyridine (0.69 g, 5.53 mmol), tri-o-tolylphosphine (0.6 g, 1.96 mmol), palladium acetate (0.16 g, 0.65 mmol) and triethylamine (0.66 g, 6.53 mmol) in acetonitrile (15 mL) was stirred for 8 hours at 80°C.

The reaction solution was partitioned between ethyl acetate and water. The organic layer was washed with brine, dried (Na_2SO_4), filtered, and concentrated under vacuum. Purification by flash column chromatography on silica gel with 10% methanol/dichloromethane provided the desired product (0.64g, 73%). MS (DCI/ NH_3) m/e 270 ($\text{M}+\text{H}$)⁺; ^1H NMR (DMSO-d_6) δ 8.58 (d, $J=6.0$ Hz, 2H), 8.39 (s, 1H), 8.24 (s, 1H), 7.73 (s, 1H), 7.56 (d, $J=6.0$ Hz, 1H), 7.56 (m, 2H), 7.45 (d, $J=16.5$ Hz, 2H), 4.19 (t, $J=6.0$ Hz, 2H), 2.67 (t, $J=6.0$ Hz, 2H), 2.23 (s, 6H).

Example 2

(1S)-2-(1H-indol-3-yl)-1-[({5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-yl}oxy)methyl]ethylamine

Example 2A

10 tert-butyl (1S)-2-[({5-hydroxypyridin-3-yl}oxy)-1-(1H-indol-3-ylmethyl)ethyl]carbamate

A solution of 3-bromo-5-hydroxypyridine (2.0 g, 11.5 mmol), L-Boc-tryptophanol (3.67 g, 12.6 mmol), and triphenylphosphine (4.53 g, 17.3 mmol) at 0°C was treated dropwise with DEAD (3.01 g, 17.3 mmol), warmed to room temperature, stirred overnight, and concentrated. The concentrate was purified by flash column chromatography on silica gel with hexane/ethyl acetate (4:1) to provide the desired product (4.55 g, 88.7%). MS (DCI/ NH_3): m/e 446, 448 ($\text{M}+\text{H}$)⁺.

Example 2B

tert-butyl (1S)-2-(1H-indol-3-yl)-1-[({5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-yl}oxy)methyl]ethyl]carbamate

20 The desired product was prepared by substituting Example 2A for Example 1A in Example 1B. MS (DCI/ NH_3) m/e 471 ($\text{M}+\text{H}$)⁺.

Example 2C

(1S)-2-(1H-indol-3-yl)-1-[({5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-yl}oxy)methyl]ethylamine

A solution of Example 2B (603 mg, 1.28 mmol) in dichloromethane (20 mL) at room 25 temperature was treated with 4N HCl in dioxane (5 mL), stirred for 2 hours, and concentrated. The residue was dissolved in water (1.5 mL) and freeze-dried to provide the desired product as the hydrochloride salt (610 mg, 99%). MS (DCI/ NH_3) m/e 371 ($\text{M}+\text{H}$)⁺, ^1H NMR (CD_3OD) δ 8.76 (d, $J=6.8$ Hz, 2H), 8.52 (d, $J=1.4$ Hz, 1H), 8.38 (d, $J=2.4$ Hz, 1H), 8.16 (d, $J=7.1$ Hz, 2H), 7.86 (d, $J=16.6$ Hz, 1H), 7.77 (m, 1H), 7.60 (d, $J=8.1$ Hz, 1H), 7.52 (d, $J=8.1$ Hz, 1H), 7.50 (d, $J=16.6$ Hz, 1H), 7.39 (d, $J=8.1$ Hz, 1H), 7.28 (s, 1H), 7.13 (m, 1H), 7.03 (m, 1H), 4.39 (dd, $J=3.4, 10.5$ Hz, 1H), 4.25 (dd, $J=5.4, 10.5$ Hz, 1H), 4.00 (m, 1H), 3.30 (m, 2H).

Example 2D

(1S)-2-(1H-indol-3-yl)-1-[({5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-yl}oxy)methyl]ethylamine

35 A solution of Example 2B (500 mg, 1.06 mmol) in dichloromethane (5 mL) at room temperature was treated with trifluoroacetic acid (5 mL), stirred for 2 hours, and concentrated. The residue was dissolved in water (1.5 mL) and freeze-dried to provide the

desired product as the trifluoroacetate salt (643 mg, 85%). MS (DCI/NH₃) m/e 371 (M+H)⁺; ¹HNMR (CD₃OD) δ 8.83 (d, J=7 Hz, 2H), 8.77 (br s, 1H), 8.58 (br s, 1H), 8.39 (br s, 1H), 8.29 (d, J=7 Hz, 2H), 7.98 (d, J=17 Hz, 1H), 7.82 (d, J=17 Hz, 1H), 7.61 (d, J=7 Hz, 1H), 7.48 (d, J=7 Hz, 1H), 7.28 (s, 1H), 7.09-7.14 (m, 1H), 6.99-7.04 (m, 1H), 4.504.57 (m, 1H), 4.39-4.45 (m, 1H), 4.02-4.08 (m, 1H), 3.30-3.38 (m, 2H).

5 Example 3

(1R)-2-(1H-indol-3-yl)-1-[{5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-yl}oxy)methyl]ethylamine

The desired product was prepared as the hydrochloride salt by substituting D-Boc-tryptophanol for L-Boc-tryptophanol in Example 2A then proceeding as described for Examples 2B and 2C. MS (DCI/NH₃) m/e 371 (M+H)⁺; ¹HNMR (CD₃OD) δ 8.76 (d, J=6.1 Hz, 2H), 8.52 (m, 1H), 8.37 (m, 1H), 8.17 (d, J=6.1 Hz, 2H), 7.86 (d, J=16.6 Hz, 1H), 7.79 (m, 1H), 7.59 (d, J=7.8 Hz, 1H), 7.53 (d, J=16.6 Hz, 1H), 7.50 (d, J=16.6 Hz, 1H), 7.38 (d, J=8.1 Hz, 1H), 7.23 (s, 1H), 7.12 (m, 1H), 7.02 (m, 1H), 4.38 (dd, J=3.1, 10.5 Hz, 1H), 4.25 (dd, J=5.4, 10.5 Hz, 1H), 3.99, (m, 1H), 3.26 (m, 2H).

10 Example 4

1-(1H-indol-3-yl)-3-{5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-yl}oxy)propan-2-ol

A solution of Example 2C (150 mg, 0.400 mmol) in acetic acid (2.4 mL) at room temperature was treated portionwise with NaNO₂ (117 mg, 1.70 mmol), stirred for 18 hours, quenched with water (40 μL), stirred for an additional hour, poured into 2N NaOH, and extracted with isopropanol/dichloromethane. The combined extracts were concentrated. The residue was treated with LiOH·H₂O (25 mg) in THF/water (1 mL/0.5 mL), heated to 55 °C overnight, diluted with dichloromethane, washed with water, dried (MgSO₄), filtered, and concentrated. The residue was purified by HPLC on a C18 column with 0-100% CH₃CN/H₂O/ 0.1% TFA to provide the desired product as the trifluoroacetate salt (9.7 mg, 5%). MS (DCI/NH₃) m/e 372 (M+H)⁺; ¹H NMR (DMSO-d₆) δ 10.82 (s, 1H), 8.85 (d, J=6.6 Hz, 2H), 8.49 (s, 1H), 8.37 (s, 1H), 8.08 (d, J=6.6 Hz, 2H), 7.90 (d, J=16.5 Hz, 1H), 7.79 (m, 1H), 7.65 (d, J=16.6 Hz, 1H), 7.56 (d, J=7.8 Hz, 1H), 7.32 (d, J=8.1 Hz, 1H), 7.18 (d, J=2.2 Hz, 1H), 7.04 (m, 1H), 6.95 (m, 1H), 4.06 (m, 2H), 3.83 (m, 1H), 3.03 (dd, J=6.2, 14.5 Hz, 1H), 2.91 (dd, J=6.2, 14.5 Hz, 1H).

20 Example 5

(1S)-2-(1-benzothien-3-yl)-1-[{5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-yl}oxy)methyl]ethylamine

The desired product was prepared as the trifluoroacetate salt by substituting 2-tert-butoxycarbonylamino-3-benzo[b]thiophen-3-yl-propan-1-ol for L-Boc-tryptophanol in Example 2A then proceeding as described for Examples 2B and 2D. MS (DCI/NH₃) m/e 388 (M+H)⁺; ¹H NMR (DMSO-d₆) δ 8.87 (d, J=6.3 Hz, 2H), 8.55 (s, 1H), 8.49 (br.s, 2H), 8.40 (d, J=7.2 Hz, 1H), 8.10 (d, J=6.3 Hz, 2H), 8.02 (d, J=7.2 Hz, 1H), 7.96 (d, J=7.2 Hz, 1H), 7.90

(d, $J=16.2$ Hz, 1H), 7.80 (m, 1H), 7.68 (s, 1H), 7.63 (d, $J=16.2$ Hz, 1H), 7.42 (m, 2H), 4.36 (dd, $J=3.1, 10.6$ Hz, 1H), 4.20 (dd, $J=5.3, 10.6$ Hz, 1H), 3.99 (m, 1H), 3.36 (m, 2H).

Example 6

(1S)-2,2-diphenyl-1-[({5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-yl}oxy)methyl]ethylamine

The desired product was prepared as the hydrochloride salt by substituting L-Boc-diphenylalaninol for L-Boc-tryptophanol in Example 2A then proceeding as described for Examples 2B and 2C. MS (DCI/NH₃) m/e 408 (M+H)⁺; ¹H NMR (DMSO-d₆) δ 8.89 (d, $J=6.8$ Hz, 2H), 8.57 (s, 1H), 8.45 (br s, 2H), 8.42 (d, $J=2.4$ Hz, 1H), 8.16 (d, $J=6.8$ Hz, 2H), 7.99 (d, $J=16.6$ Hz, 1H), 7.84 (s, 1H), 7.73 (d, $J=16.6$ Hz, 1H), 7.62 (m, 2H), 7.49 (m, 2H), 7.39 (m, 2H), 7.28 (m, 3H), 7.18 (m, 1H), 4.77 (m, 1H), 4.46 (m, 2H), 4.03 (m, 1H).

Example 7

(1S)-1-{4-[(2,6-dichlorobenzyl)oxy]benzyl}-2-({5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-yl}oxy)ethylamine

The desired product was prepared as the hydrochloride salt by substituitng L-Boc-(4-(2,6-dichlorobenzyl)oxy)phenyl)alaninol for L-Boc-tryptophanol in Example 2A then proceeding as described for Examples 2B and 2C. MS (DCI/NH₃) m/e 506, 508, 510 (M+H)⁺; ¹H NMR (CD₃OD) δ 8.81 (d, $J=7.1$ Hz, 2H), 8.71 (d, $J=1.0$ Hz, 1H), 8.55 (d, $J=2.7$ Hz, 1H), 8.28 (d, $J=7.1$ Hz, 2H), 8.25 (m, 1H), 7.99 (d, $J=16.3$ Hz, 1H), 7.79 (d, $J=16.3$ Hz, 1H), 7.46 (d, $J=1.7$ Hz, 1H), 7.43 (s, 1H), 7.36 (m, 1H), 7.30 (m, 2H), 7.05 (m, 2H), 5.28 (s, 2H), 4.45(dd, $J=3.1, 10.5$ Hz, 1H), 4.31 (dd, $J=5.8, 10.5$ Hz, 1H), 3.95 (m, 1H), 3.21 (m, 2H).

Example 8

(1S)-2-(benzyloxy)-1-[({5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-yl}oxy)methyl]ethylamine

The desired product was prepared as the hydrochloride salt by substituting L-Boc-3-benzyloxyalaninol for L-Boc-tryptophanol in Example 2A then proceeding as described for Examples 2B and 2C. MS (DCI/NH₃) m/e 362 (M+H)⁺; ¹H NMR (CD₃OD) δ 8.80-8.89 (m, 4H), 8.53-8.62 (m, 3H), 8.28-8.34 (m, 3H), 8.00-8.06 (m, 1H), 7.98 (d, $J=16.3$ Hz, 1H), 7.87 (d, $J=16.3$ Hz, 1H), 7.28-7.43 (m, 3H), 4.66 (s, 2H), 4.56-4.64 (m, 2H), 3.94-3.99 (m, 1H), 3.83-3.87 (m, 2H).

Example 9

30 N,N-dimethyl-N-[(1S,2S)-1-methyl-2-phenyl-2-({5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-yl}oxy)ethyl]amine

Example 9A

5-bromopyridin-3-yl acetate

A mixture of 3-bromo-5-hydroxypyridine (9.00 g, 51.7 mmol), acetic anhydride (6.0 mL) and triethylamine (12.0 mL) in THF (50 mL) was heated to reflux overnight, cooled to room temperature, diluted with diethyl ether, washed with water, 5% NaHCO₃, water, and brine, dried (MgSO₄), filtered, and concentrated to provide the desired product (9.37 g, 84%).

Example 9B5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-ol

A mixture of Example 9A (9.37 g, 43.3 mmol), 4-vinylpyridine (14.0 mL, 130 mmol), tri-*o*-tolylphosphine (13.5 g, 44.4 mmol), palladium acetate (2.65 g, 11.8 mmol) and triethylamine (120 mL, 0.861 mol) in acetonitrile (40 mL) was heated to reflux overnight and partitioned between ethyl acetate and water. The organic layer was washed with brine, dried (Na_2SO_4), filtered, and concentrated under vacuum. Purification by flash column chromatography on silica gel with 5% methanol/dichloromethane containing 0.5% ammonia provided the acetate (8.53 g). This was stirred with $\text{LiOH}\cdot\text{H}_2\text{O}$ (6.00g, 143 mmol) in THF/water (40mL/20mL) at room temperature for 4 hours, concentrated, adjusted to pH 7 with 1N HCl (aq.), and filtered. The filter cake was washed with water and dried under vacuum at 60 °C to provide the desired product (7.23 g, 84%). MS (DCI/ NH_3) m/e 199 ($\text{M}+\text{H}$)⁺; ¹H NMR (CD_3OD) δ 8.51 (m, 2H), 8.24 (d, $J=1.4$ Hz, 1H), 8.04 (d, $J=2.4$ Hz, 1H), 7.61 (m, 2H), 7.50 (m, 1H), 7.49 (d, $J=16.6$ Hz, 1H), 7.27 (d, $J=16.6$ Hz, 1H).

Example 9CN,N-dimethyl-N-[(1S,2S)-1-methyl-2-phenyl-2-(5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-yl)oxy]ethyl]amine

The desired product was prepared as the trifluoracetate salt by substituting Example 9B and (1S,2S)-2-(dimethylamino)-1-phenylpropan-1-ol for 3-bromo-5-hydroxypyridine and L-Boc-tryptophanol, respectively, in Example 2A then proceeding as described for Examples 2B and 2D. MS (DCI/ NH_3) m/e 360 ($\text{M}+\text{H}$)⁺; ¹H NMR (DMSO- d_6) δ 8.78 (d, 2H), 8.44 (s, 1H), 8.33 (d, 1H), 7.94 (d, 1H), 7.80 (s, 1H), 7.75 (d, 1H), 7.59 (d, 2H), 7.46-7.34 (m, 5H), 5.84 (d, 1H), 3.55-3.45 (m, 1H), 2.95 (s, 3H), 2.84 (s, 3H), 1.02 (d, 3H).

Example 10(1S)-2-(2-naphthyl)-1-[(5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-yl)oxy]methyl]ethylamine

The desired product was prepared as the trifluoracetate salt by substituting L-Boc-(2-naphthyl)alaninol for L-Boc-tryptophanol in Example 9 2A then proceeding as described for Examples 2B and 2D. MS (DCI/ NH_3) m/e 382 ($\text{M}+\text{H}$)⁺; ¹H NMR (DMSO- d_6) δ 8.88 (d, $J=6.8$ Hz, 2H), 8.57 (d, $J=1.0$ Hz, 1H), 8.43 (d, $J=2.4$ Hz, 1H), 8.15 (d, $J=6.8$ Hz, 2H), 7.99 (d, $J=16.6$ Hz, 1H), 7.90 (m, 5H), 7.73 (d, $J=16.6$ Hz, 1H), 7.50 (m, 3H), 4.35 (dd, $J=3.4, 10.5$ Hz, 1H), 4.21 (dd, $J=5.4, 10.5$ Hz, 1H), 3.97 (m, 1H), 3.32 (dd, $J=5.8, 13.6$ Hz, 1H), 3.21 (dd, $J=9.2, 13.6$ Hz, 1H).

Example 11N-[(2S)-2-amino-3-(1H-indol-3-yl)propyl]-N-[(5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-yl)amineExample 11A3-bromo-5-[(E)-2-pyridin-4-ylvinyl]pyridine

A solution of 3,5-dibromopyridine (5.56 g, 23.4 mmol), 4-vinylpyridine (5.1 mL), palladium acetate (1.05g), tri-o-tolylphosphine (5.00g) and triethylamine (33 mL) in acetonitrile (100 mL) was heated overnight at 80 °C and concentrated. The residue was partitioned between 5% NaHCO₃ and dichloromethane and filtered. The filtrate was 5 separated and the organic layer was washed with water, dried (MgSO₄), filtered, and concentrated. The concentrate was purified by flash column chromatography on silica gel with 4% methanol/dichloromethane to provide the desired product (2.18 g, 36%). (DCI/NH₃) m/e 261, 263 (M+H)⁺.

Example 11B

5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-amine

A mixture of Example 11A (1.88 g, 7.2 mmol), benzophenone imine (1.22 mL), Pd₂(dba)₃ (66 mg), BINAP (125 mg), sodium tert-butoxide (0.97 g), and toluene (19 mL) was heated to 80 °C overnight and concentrated. The residue was purified by flash column chromatography on silica gel with ethyl acetate to provide a solid (2.44 g). This was stirred 15 with 2N HCl (aq.) (5.0 mL) in THF (50 mL) at room temperature for 2 hours and concentrated. The residue was dissolved in 0.5N HCl (aq.) (100 mL) and washed three times with ethyl acetate. The aqueous layer was adjusted to pH 11 with 1N NaOH and extracted with dichloromethane. The combined extracts were washed with water, dried (MgSO₄), 20 filtered, and concentrated to provide the desired product (1.23 g, 87%). MS (DCI/NH₃) m/e 198 (M+H)⁺; ¹H NMR (DMSO-d₆) δ 8.55 (m; 2H), 8.00 (d, J=1.7 Hz, 1H), 7.89 (d, J=2.4 Hz, 1H), 7.56 (m, 2H), 7.42 (d, J=16.6 Hz, 1H), 7.17 (d, J=16.6 Hz, 1H), 7.15 (m, 1H).

Example 11C

tert-butyl (1S)-2-(1H-indol-3-yl)-1-[(5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-yl}amino)methyl]ethylcarbamate

A mixture of Example 11B (52 mg, 0.264 mmol), L-Boc-tryptophanal (J. Med. Chem., 1985, 28(12), 1874.) (80 mg, 0.277 mmol) and acetic acid (80 μL) in methanol (4 mL) was stirred at room temperature for 3 hours, refluxed for 2 hours, cooled to room temperature, treated with sodium cyanoborohydride (35 mg) stirred for 1 hour, and filtered. The filtrate was concentrated and the residue was purified by HPLC on a C18 column with 0-30 100% CH₃CN/H₂O/0.1% TFA to provide the designed product (43 mg, 35%). MS (DCI/NH₃) m/e 470 (M+H)⁺.

Example 11D

N-[(2S)-2-amino-3-(1H-indol-3-yl)propyl]-N-{5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-yl}amine

A solution of Example 11C (40 mg, 0.085 mmol) in dichloromethane (3.0 mL) at 35 room temperature was treated with 4N HCl in dioxane (0.5 mL), stirred for 1 hour, and concentrated to provide the desired product as the hydrochloride salt (30 mg, 74%). MS (DCI/NH₃) m/e 370 (M+H)⁺; ¹H NMR (DMSO-d₆) δ 11.09 (br s, 1H), 8.90 (d, J=5.8 Hz, 2H),

8.47 (br s, 2H), 8.33 (s, 1H), 8.22 (d, $J=1.8$ Hz, 1H), 8.14 (d, $J=5.8$ Hz, 2H), 7.98 (s, 1H), 7.94 (d, $J=16.5$ Hz, 1H), 7.86 (d, $J=16.5$ Hz, 1H), 7.62 (d, $J=7.9$ Hz, 1H), 7.37 (d, $J=4.5$ Hz, 1H), 7.36 (s, 1H), 7.08 (m, 1H), 6.98 (m, 1H), 3.71 (m, 1H), 3.67 (m, 1H), 3.54 (m, 1H), 3.15 (m, 2H).

5

Example 12

(1S)-2-({2-chloro-5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-yl}oxy)-1-(1H-indol-3-ylmethyl)ethylamine

Example 12A

3-(benzyloxy)-5-bromo-2-chloropyridine

10 A solution of 3-(benzyloxy)-5-bromopyridine N-oxide (2.0 g, 7.1 mmol) in POCl_3 (20 mL) was stirred at 100 °C for 7 hours, cooled to room temperature, concentrated, treated with ethyl acetate (50 mL), washed with brine, dried (MgSO_4), filtered, and concentrated. The concentrate was purified by flash column chromatography on silica gel with 10% ethyl acetate/hexane to provide the desired product (1.0g, 40%). MS (DCI/ NH_3) m/e 299 ($\text{M}+\text{H}$)⁺.

15

Example 12B

5-bromo-2-chloro-3-hydroxypyridine

15 A mixture of Example 12A in HBr/HOAc (30%, 50 mL) was stirred at 100 °C for 8 hours, cooled to room temperature and concentrated. The concentrate was partitioned between ethyl acetate and saturated Na_2CO_3 (aq.). The organic layer was washed with brine, dried (Na_2SO_4), filtered, and concentrated under vacuum. Purification by flash column chromatography on silica gel with 30% ethyl acetate/hexane provided the desired product (0.51 g, 72%). MS (DCI/ NH_3) m/e 209 ($\text{M}+\text{H}$)⁺.

20

Example 12C

tert-butyl (1S)-2-[(5-bromo-2-chloropyridin-3-yl)oxy]-1-(1H-indol-3-ylmethyl)ethylcarbamate

25

The desired product was prepared by substituting Example 12B for 3-bromo-5-hydroxypyridine in Example 2A (0.78 g, 66%). MS (DCI/ NH_3) m/e 481 ($\text{M}+\text{H}$)⁺.

Example 12D

(1S)-2-({2-chloro-5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-yl}oxy)-1-(1H-indol-3-ylmethyl)ethylamine

30

The desired product was prepared as the trifluoroacetate salt by substituting Example 12C for Example 2A in Examples 2B and 2D. MS (DCI/ NH_3) m/e 405, 407 ($\text{M}+\text{H}$)⁺; ¹H NMR (DMSO-d₆) δ 11.04 (s, 1H), 8.72 (d, $J=6.0$ Hz, 2H), 8.30 (s, 1H), 8.23 (br s, 2H), 7.84 (s, 1H), 7.78 (d, $J=6.0$ Hz, 2H), 7.70 (d, $J=16.8$ Hz, 1H), 7.62 (d, $J=8.1$ Hz, 1H), 7.50 (d, $J=16.8$ Hz, 1H), 7.38 (d, $J=8.1$ Hz, 1H), 7.28 (s, 1H), 7.10 (t, $J=7.2$ Hz, 1H), 7.00 (t, $J=7.2$ Hz, 1H), 4.38 (m, 1H), 4.18 (m, 1H), 3.91 (m, 1H), 3.20 (m, 2H).

35

Example 13

(1S)-2-({6-chloro-5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-yl}oxy)-1-(1H-indol-3-ylmethyl)ethylamine

Example 13A

tert-butyl (1S)-2-[(5-bromo-6-chloropyridin-3-yl)oxy]-1-(1H-indol-3-ylmethyl)ethylcarbamate

5 A solution of 5-bromo-6-chloro-3-hydroxypyridine (2.50 g, 12 mmol) N- α -(tert-butoxycarbonyl)-L-tryptophanol (3.77 g, 18 mmol) and triphenylphosphine (4.72 g, 18 mmol) in THF (100 mL) was stirred at 0 °C for 20 minutes, treated with DEAD (2.83 mL, 18 mmol), stirred for 1 hour, warmed to room temperature, stirred for 15 hours, treated with 10 ethyl acetate (300 mL), washed with brine, dried ($MgSO_4$), filtered, and concentrated. The concentrate was purified by flash column chromatography on silica gel with 25% ethyl acetate/hexane to provide the desired product (4.58 g, 80%). MS (APCI) m/e 480, 482 (M+H)⁺.

Example 13B

15 tert-butyl (1S)-2-({6-chloro-5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-yl}oxy)-1-(1H-indol-3-ylmethyl)ethylcarbamate

A solution Example 13A (1.50 g, 3.125 mmol), $Pd_2(dbu)_3$ (71 mg, 0.078 mmol) and tri-*o*-tolylphosphine (71 mg, 0.23 mmol) in DMF (30 mL) was treated with 4-vinylpyridine (492 mg, 4.68 mmol) and triethylamine (1.30 mL, 9.4 mmol), purged with nitrogen, and 20 heated to 100 °C for 4 hours. The mixture was cooled to room temperature, treated with ethyl acetate (200 mL), washed with brine, dried ($MgSO_4$), filtered, and concentrated. The concentrate was purified by flash column chromatography on silica gel with 75% ethyl acetate/hexanes to provide the desired product (1.37 g, 87%). MS (APCI) m/e 505, 507 (M+H)⁺.

25 Example 13C

(1S)-2-({6-chloro-5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-yl}oxy)-1-(1H-indol-3-ylmethyl)ethylamine

The desired product was prepared as the trifluoroacetate salt by substituting Example 30 13B for Example 2B in Example 2D. MS (APCI) m/e 405, 407 (M+H)⁺; ¹H NMR (300 MHz, CD_3OD) δ 8.76 (d, J = 6.7 Hz, 2H), 8.18 (d, J = 2.7 Hz, 1H), 8.15 (d, J = 6.5 Hz, 2H), 7.95 (d, J = 16.2 Hz, 1H), 7.86 (d, J = 3.0 Hz, 1H), 7.58 (d, J = 7.8 Hz, 1H), 7.43 (d, J = 16.3 Hz, 1H), 7.38 (d, J = 8.1 Hz, 1H), 7.23 (s, 1H), 7.13 (t, J = 7.1 Hz, 1H), 7.03 (t, J = 7.8 Hz, 1H), 4.38 (dd, J = 10.5, 3.0 Hz, 1H), 4.25 (dd, J = 10.6, 5.8 Hz, 1H), 3.97 (m, 1H), 3.31 (m, 2H); Anal. Calcd for $C_{23}H_{21}ClN_4O\cdot 2.3TFA$: C, 49.69; H, 3.52; N, 8.40. Found: C, 49.82; H, 35 3.48; N, 8.32.

Example 14

(1S)-2-(1H-indol-3-yl)-1-({[5-(pyridin-4-ylethynyl)pyridin-3-yl]oxy}methyl)ethylamine

Example 14Atert-butyl (1S)-2-(1H-indol-3-yl)-1-[({5-[{(trimethylsilyl)ethynyl]pyridin-3-yl}oxy)methyl]ethylcarbamate

A mixture of Example 2A (500 mg, 1.12 mmol), $Pd_2Cl_2(PPh_3)_2$ (77 mg, 0.112 mmol), 5 and CuI (52 mg, 0.27 mmol) was purged with nitrogen, treated with DMF (7 mL), trimethylsilylacetylene (475 μ L, 3.36 mmol) and triethylamine (468 μ L, 3.36 mmol) stirred at 50 °C for 15 hours, cooled to room temperature, treated with ethyl acetate (50 mL), washed with brine, dried ($MgSO_4$), filtered, and concentrated. The residual oil was purified by flash column chromatography on silica gel with 1:2 ethyl acetate/hexanes to provide the desired 10 product (417 mg, 80%). MS (APCI) m/e 464 ($M+H$)⁺.

Example 14Btert-butyl (1S)-2-[{(5-ethynylpyridin-3-yl)oxy]-1-(1H-indol-3-ylmethyl)ethylcarbamate

A solution of Example 14A (400 mg, 0.86 mmol) in THF (6 mL) at room temperature was treated with tetrabutylammonium fluoride (1.0 M solution in THF, 1.12 mL, 1.12 mmol), 15 stirred for 1 hour, treated with ethyl acetate (50 mL), washed with brine, dried ($MgSO_4$), filtered, and concentrated. The residual oil was purified by flash column chromatography on silica gel with 40% ethyl acetate/hexanes to provide the desired product (290 mg, 86%). MS (APCI) m/e 392 ($M+H$)⁺.

Example 14Ctert-butyl (1S)-2-(1H-indol-3-yl)-1-[{[5-(pyridin-4-ylethynyl)pyridin-3-yl]oxy}methyl]ethylcarbamate

A mixture of Example 14B (150 mg, 0.384 mmol), 4-bromopyridine hydrochloride (75 mg, 0.34 mmol), $Pd_2Cl_2(PPh_3)_2$ (27 mg, 0.0384 mmol), and CuI (18 mg, 0.093 mmol), was purged with nitrogen, treated with DMF (4 mL) and triethylamine (214 μ L, 1.54 mmol), 25 stirred at 50 °C for 20 hours, cooled to room temperature, treated with ethyl acetate (50 mL), washed with brine, dried ($MgSO_4$), filtered, and concentrated. The residual oil was purified by flash column chromatography on silica gel with 2:1 ethyl acetate/hexanes to provide the desired product (122 mg, 68%). MS (APCI) m/e 469 ($M+H$)⁺.

Example 14D(1S)-2-(1H-indol-3-yl)-1-[{[5-(pyridin-4-ylethynyl)pyridin-3-yl]oxy}methyl]ethylamine

The desired product was prepared as the trifluoroacetate salt by substituting Example 14C for Example 2B in Example 2D. MS (APCI) m/e 369 ($M+H$)⁺; ¹H NMR (300 MHz, CD_3OD) δ 8.76 (d, J = 6.5 Hz, 2H), 8.47 (d, J = 1.7 Hz, 1H), 8.42 (d, J = 2.7 Hz, 1H), 7.92 (d, J = 6.5 Hz, 2H), 7.66 (dd, J = 2.7, 1.7 Hz, 1H), 7.58 (d, J = 7.8 Hz, 1H), 7.38 (d, J = 8.2 Hz, 35 1H), 7.23 (s, 1H), 7.13 (td, J = 7.1, 1.0 Hz, 1H), 7.03 (td, J = 7.8, 1.1 Hz, 1H), 4.34 (dd, J = 10.1, 3.0 Hz, 1H), 4.19 (dd, J = 10.5, 5.8 Hz, 1H), 3.98 (m, 1H), 3.28 (m, 2H); Anal. Calcd for $C_{23}H_{20}N_4O \cdot 3.3$ TFA: C, 47.74; H, 3.15; N, 7.52. Found: C, 47.53; H, 3.18; N, 7.48.

Example 15(1S)-2-(1H-indol-3-yl)-1-[(5-[(Z)-2-pyridin-4-ylvinyl]pyridin-3-yl]oxy)methyl]ethylamine

A mixture of Example 14D (40 mg, 0.11 mmol), 5% Pd/BaSO₄ (8.1 mg) and quinoline (8.1 μ L) in methanol (3 mL) was stirred under hydrogen (20 psi) at room temperature for 12 minutes and filtered. The filtrate was concentrated and the residual oil was purified by HPLC on a C18 column with 0-100% CH₃CN/H₂O/0.1% TFA to provide the desired product (30 mg, 75%). MS (APCI) m/e 369 (M-H)⁺; ¹H NMR (300 MHz, CD₃OD) δ 8.57 (d, J = 6.8 Hz, 2H), 8.29 (d, J = 2.4 Hz, 1H), 8.04 (s, 1H), 7.69 (d, J = 6.4 Hz, 2H), 7.57 (d, J = 7.8 Hz, 1H), 7.53 (d, J = 7.8 Hz, 1H), 7.40 (d, J = 8.1 Hz, 1H), 7.33 (t, J = 1.7 Hz, 1H), 7.21 (s, 1H), 7.14 (m, 2H), 7.02 (td, J = 8.1, 1.0 Hz, 1H), 6.95 (d, J = 12.2 Hz, 1H), 4.24 (dd, J = 10.5, 3.0 Hz, 1H), 4.08 (dd, J = 10.5, 5.6 Hz, 1H), 3.92 (m, 1H), 3.26 (m, 2H); Anal. Calcd for C₂₃H₂₂N₄O·3.6 TFA: C, 46.45; H, 3.30; N, 7.17. Found: C, 46.56; H, 3.35; N, 7.34.

Example 16(2S)-2-amino-4-phenyl-N-{5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-yl}butanamideExample 16Atert-butyl (1S)-3-phenyl-1-[(5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-yl]amino)carbonyl]propylcarbamate

A mixture of Example 11B (200 mg, 1.0 mmol), HOBt (210 mg), EDC (290 mg), DMAP (25 mg) and Boc-homophenylalanine was stirred at room temperature overnight and concentrated. The residue was dissolved in ethyl acetate, washed sequentially with water, 5% NaHCO₃, and water, dried (MgSO₄), filtered, and concentrated. The residue was purified by flash column chromatography on silica gel with 3% methanol/dichloromethane to provide the desired product (192 mg, 41%). MS (DCI/NH₃) m/e 459 (M+H)⁺.

Example 16B(2S)-2-amino-4-phenyl-N-{5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-yl}butanamide

The desired product was prepared as the hydrochloride salt by substituting Example 16A for Example 2B in Example 2C (173 mg, 89%). MS (DCI/NH₃) m/e 359 (M+H)⁺; ¹H NMR (DMSO-d₆) δ 12.03 (s, 1H), 8.97 (s, 1H), 8.91 (d, J=6.6 Hz, 2H), 8.85 (s, 1H), 8.70 (d, J=4.1 Hz, 2H), 8.60 (s, 1H), 8.28 (d, J=6.6 Hz, 2H), 8.09 (d, J=16.5 Hz, 1H), 7.68 (d, J=16.5 Hz, 1H), 7.24 (m, 5H), 4.33 (m, 1H), 2.78 (m, 2H), 2.25 (m, 2H).

Example 175-[(2S)-2-amino-3-(1H-indol-3-yl)propyl]oxy-N-pyridin-4-ylnicotinamideExample 17A5-[(2S)-2-[(tert-butoxycarbonyl)amino]-3-(1H-indol-3-yl)propyl]oxy}nicotinic acid

A solution of Example 2A (1.30 g, 3.02 mmol) and PdCl₂.dppf (123 mg) in THF/water (6.3 mL/6.3 mL) was heated to 100 °C under CO (800 psi) for 19 hours, cooled to room temperature, and diluted with water. The mixture was extracted with dichloromethane

and the combined extracts were washed with water, dried (MgSO_4), filtered, and concentrated to provide the desired product (912 mg, 76%). MS (DCI/ NH_3) m/e 396 ($\text{M}+\text{H}$)⁺.

Example 17B

tert-butyl (1S)-2-(1H-indol-3-yl)-1-[({5-[pyridin-4-ylamino]carbonyl}pyridin-3-yl}oxy)methyl]ethylcarbamate

5 A solution of Example 17A (410 mg, 1.0 mmol), 4-aminopyridine (100 mg, 1.0 mmol), EDC (960 mg), and HOBr (680 mg) in DMF (10 mL) was stirred at room temperature overnight, diluted with dichloromethane, washed with water, dried (MgSO_4), filtered, and concentrated. The residue was purified by flash column chromatography on 10 silica gel with ethyl acetate/methanol (8:1) to provide the desired product (87 mg, 18%). MS (DCI/ NH_3) m/e 488 ($\text{M}+\text{H}$)⁺.

Example 17C

5-[(2S)-2-amino-3-(1H-indol-3-yl)propyl]oxy}-N-pyridin-4-ylnicotinamide

15 The desired product was prepared as the hydrochloride salt by substituting Example 17B for Example 2B in Example 2C (27 mg, 31%). MS (DCI/ NH_3) m/e 388 ($\text{M}+\text{H}$)⁺; ¹H NMR (DMSO-d₆) δ 11.32 (br s, 1H), 11.04 (br s, 1H), 8.83 (d, J=1.4 Hz, 1H), 8.69 (apparent d, J=6.8 Hz, 2H), 8.59 (d, J=2.7 Hz, 1H), 8.15 (br s, 2H), 8.08 (apparent d, J=6.8 Hz, 2H), 7.85 (dd, J=1.4, 2.7 Hz, 1H), 7.61 (d, J=7.8 Hz, 1H), 7.38 (d, J=8.12 Hz, 1H), 7.29 (d, J=2.7 Hz, 1H), 7.10 (m, 1H), 7.01 (m, 1H), 4.33 (m, 1H), 4.16 (m, 1H), 3.87 (m, 1H), 3.16 (m, 2H).

20 Example 18

N-(aminoethyl)-5-[(E)-2-pyridin-4-ylvinyl]nicotinamide

Example 18A

ethyl 5-[(E)-2-pyridin-4-ylvinyl]nicotinate

25 The desired product was prepared by substituting 3-bromo-5-ethoxycarbonylpyridine for Example 1A in Example 1B. MS (DCI/ NH_3) m/e 355 ($\text{M}+\text{H}$)⁺.

Example 18B

5-[(E)-2-pyridin-4-ylvinyl]nicotinic acid

30 A mixture of Example 18A (1.60 g, 6.3 mmol) and LiOH·H₂O (2.64 g) in THF/water (50 mL/50 mL) was stirred at room temperature for 2 hours. The THF was removed under vacuum and the aqueous layer was acidified with 1N HCl (aq.). The solid was collected by filtration and dried to provide the desired product. MS (DCI/ NH_3) m/e 227 ($\text{M}+\text{H}$)⁺.

Example 18C

N-(aminoethyl)-5-[(E)-2-pyridin-4-ylvinyl]nicotinamide

35 The desired product was prepared as the hydrochloride salt by substituting Example 18B and N-tert-butoxycarbonylaminoethylamine for Example 17A and 4-aminopyridine, respectively, in Examples 17B and 17C. MS (DCI/ NH_3) m/e 384 ($\text{M}+\text{H}$)⁺; ¹HNMR (DMSO-d₆) δ 9.19 (t, J=5.4 Hz, 1H), 9.09 (d, J=1.7 Hz, 1H), 9.01 (d, J=2.0 Hz, 1H), 8.89 (d, J=6.5 Hz,

2H), 8.82 (dd, J=1.7, 2.0 Hz, 1H), 8.18 (d, J=6.5 Hz, 2H), 8.07 (d, J=16.6 Hz, 1H), 7.87 (d, J=16.6 Hz, 1H), 3.72 (br s, 2H), 3.59 (m, 2H), 3.05 (m, 2H).

Example 19

N-[(2E)-3-(4-bromophenyl)prop-2-enyl]-N-[2-(5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-yl}oxy)ethyl]amine

5

Example 19A

(2E)-3-(4-bromophenyl)prop-2-en-1-ol

A solution of ethyl 4-bromocinnamate (5.430 g, 22.07 mmol) in toluene (20 mL) at –78 °C was treated over 10 minutes with DIBAL (1.5 M in toluene, 37.0 mL, 55.5 mmol), 10 stirred for 30 minutes at –78 °C, warmed to room temperature, stirred for 1 hour, quenched with 10% HCl (aq.), and extracted twice with diethyl ether. The combined extracts were washed with water and brine, dried (MgSO_4), filtered, and concentrated to provide the desired product (4.463g, 95%). MS (DCI/ NH_3) m/e 212, 214 ($\text{M}+\text{H}$)⁺, 228, 230 ($\text{M}+18$)⁺.

Example 19B

15 1-bromo-4-[(1E)-3-chloroprop-1-enyl]benzene

A mixture of Example 19A (2.0 g, 9.387 mmol) and SOCl_2 (3.5 mL, 47.9 mmol) in benzene (10 mL) was stirred at room temperature for 24 hours and concentrated to provide the desired product (2.167g, 99%). (DCI/ NH_3) m/e 231, 233, 235 ($\text{M}+\text{H}$)⁺.

Example 19C

20 2-(5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-yl}oxy)ethanamine

The desired product was prepared as the hydrochloride salt by substituting Example 9B and N-tert-butoxycarbonylaminoethanol (200 mg, 1.00 mmol) for 3-bromo-5-hydroxypyridine and L-Boc-tryptophanol, respectively, in Examples 2A and 2C. MS (DCI/ NH_3) m/e 242 ($\text{M}+\text{H}$)⁺; ¹H NMR (CD_3OD) δ 8.88 (d, J=6.1 Hz, 2H), 8.59 (s, 1H), 8.43 (s, 1H), 8.19 (d, J=6.1 Hz, 2H), 8.03 (d, J=16.3 Hz, 1H), 8.01 (s, 1H), 7.82 (d, J=16.3 Hz, 1H), 4.42 (t, J=4.9 Hz, 2H), 3.28 (m, 2H).

Example 19D

N-[(2E)-3-(4-bromophenyl)prop-2-enyl]-N-[2-(5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-yl}oxy)ethyl]amine

30 A solution of Example 19C (100 mg, 0.285 mmol), Example 19B (66.0 mg, 0.285 mmol), and triethylamine (250 μL , 1.79 mmol) in DMF (5 mL) at room temperature was stirred for 3 days, and poured into water. The aqueous layer was extracted three times with dichloromethane and the combined extracts were washed with water, dried (MgSO_4), filtered, and concentrated. The residue was chromatographed on silica gel with 35 dichloromethane/methanol/ NH_4OH (100:5:0.5) to provide the free base. The material was treated with 2M HCl/ Et_2O to provide the hydrochloride salt (34.0 mg, 22%). MS (DCI/ NH_3) m/e 436, 438 ($\text{M}+\text{H}$)⁺; ¹H NMR (CDCl_3) δ 8.61 (m, 2H), 8.37 (d, J=1.7 Hz, 1H), 8.27 (d,

J=2.7 Hz, 1H), 7.37 (m, 4H), 7.26 (m, 5H), 7.25 (d, J=16.3 Hz, 1H), 7.05 (d, J=16.3 Hz, 1H), 6.53 (d, J=15.9 Hz, 1H), 6.31 (dt, J=6.1, 15.9 Hz, 1H), 4.23 (t, J=5.1 Hz, 2H), 3.53 (dd, J=1.1, 6.1 Hz, 1H), 3.13 (t, J=5.1 Hz, 1H).

Example 20

5 N⁴-(3-[(2S)-2-amino-3-(1H-indol-3-yl)propyl]oxy}phenyl)pyrimidine-2,4-diamine

Example 20A

tert-butyl (1S)-2-(1H-indol-3-yl)-1-[(3-nitrophenoxy)methyl]ethylcarbamate

The desired product was prepared by substituting 3-nitrophenol for 3-bromo-5-hydroxypyridine in Example 2A (257 mg, 61%). MS (DCI/NH₃) m/e 412 (M+H)⁺, 419 (M+18)⁺.

Example 20B

tert-butyl (1S)-2-(3-aminophenoxy)-1-(1H-indol-3-ylmethyl)ethylcarbamate

A solution of Example 20A (247 mg, 0.600 mmol), ammonium formate (400 mg, 6.34 mmol) and 10% Pd/C (25 mg) in methanol (10 mL) was heated to reflux for 30 minutes, 15 cooled to room temperature, filtered through diatomaceous earth (Celite[®]), and concentrated. The concentrate was purified by flash column chromatography on silica gel with ethyl acetate/hexanes (1:1) to provide the desired product (200 mg, 87%). MS (DCI/NH₃) m/e 382 (M+H)⁺.

Example 20C

20 tert-butyl (1S)-2-{3-[(2-aminopyrimidin-4-yl)amino]phenoxy}-1-(1H-indol-3-ylmethyl)ethylcarbamate

A solution of Example 20B (41.2 mg, 0.108 mmol) and 2-amino-4-chloropyrimidine (14.0 mg, 0.108 mmol) in ethanol (0.5 mL) was heated to 80°C for 13 hours and purified by flash column chromatography on silica gel with dichloromethane/methanol/NH₄OH (100:5:0.5) to provide the desired product (50 mg, 98%). MS (DCI/NH₃) m/e 475(M+H)⁺.

Example 20D

N⁴-(3-[(2S)-2-amino-3-(1H-indol-3-yl)propyl]oxy}phenyl)pyrimidine-2,4-diamine

The desired product was prepared as the hydrochloride salt by substituting Example 20C for Example 2B in Example 2C (33 mg, 81%). MS (DCI/NH₃) m/e 375 (M+H)⁺; ¹H NMR (DMSO-d₆) δ 12.3 (br s, 1H), 10.8 (br s, 1H), 8.35 (br s, 4H), 7.85 (d, J=7.1 Hz, 1H), 7.61 (d, J=7.8 Hz, 1H), 7.45 (br s, 2H), 7.37 (d, J=7.8 Hz, 1H), 7.30 (m, 2H), 7.09 (m, 1H), 6.99 (m, 1H), 6.75 (m, 1H), 6.35 (m, 1H), 4.17 (dd, J=3.4, 10.5 Hz, 1H), 4.03 (dd, J=5.8, 10.5 Hz, 1H), 3.77 (m, 1H), 3.18 (d, J=7.5 Hz, 2H).

Example 21

35 (1R)-3-{6-chloro-5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-yl}-1-(1H-indol-3-ylmethyl)propylamine

Example 21A

6-chloro-5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-amine

A solution of 3-amino-5-bromo-6-chloropyridine (2.0 g, 9.64 mmol), $\text{Pd}_2(\text{dba})_3$ (440 mg, 0.48 mmol), tri-*o*-tolylphosphine (438 mg, 1.44 mmol), 4-vinylpyridine (2.08 mL, 19.28 mmol), and triethylamine (4.03 mL, 29 mmol) in DMF (30 mL) was stirred at 100 °C for 15 hours, cooled to room temperature, treated with ethyl acetate (200 mL), washed twice with brine, dried (MgSO_4), filtered and concentrated. The residual solid recrystallized from hexanes/dichloromethane to provide desired product (1.86 g, 84%). MS (APCI) m/e 232 ($\text{M}+\text{H})^+$.

Example 21B2-chloro-5-iodo-3-[(E)-2-pyridin-4-ylvinyl]pyridine

A solution of Example 21A (1.0 g, 4.3 mmol) in 30% H_2SO_4 (10 mL) at 0 °C was treated with NaNO_2 (386 mg, 5.6 mmol), stirred for 5 hours, treated with a solution of NaI (2.1 g, 14 mmol) in H_2O (2 mL), stirred for 2 hours, treated with additional NaI (2.1 g, 14 mmol), stirred for 2 hours, poured into 30% NaOH (aq.) (200 mL) at 0 °C and extracted three times with 10% methanol/ethyl acetate. The combined organic phases were dried (MgSO_4), filtered, and concentrated. The residual solid was purified by flash column chromatography on silica gel with 70% ethyl acetate/hexanes to provide the desired product (1.03 g, 70%). MS (DCI) m/e 343 ($\text{M}+\text{H})^+$.

Example 21Ctert-butyl (1*S*)-1-(1*H*-indol-3-ylmethyl)prop-2-enylcarbamate

A suspension of methyltrifluoromethylphosphonium bromide (5.65 g, 15.81 mmol) in THF (50 mL) at 0 °C was treated with *n*-BuLi (2.5 M solution in hexane, 6.33 mL, 15.81 mmol), stirred for 10 minutes, warmed to room temperature, stirred for 30 minutes, cooled to 0 °C, treated with a solution of L-Boc-tryptophanal (3.80 g, 13.2 mmol) in THF (10 mL), stirred for 2 hours, treated with diethyl ether (200 mL), washed with brine, dried (MgSO_4), filtered, and concentrated. The residual oil was purified by flash column chromatography on silica gel with 20% ethyl acetate/hexanes to provide the desired product (700 mg, 18%). MS (DCI) m/e 287 ($\text{M}+\text{H})^+$.

Example 21Dtert-butyl (1*R*)-3-{6-chloro-5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-yl}-1-(1*H*-indol-3-ylmethyl)propylcarbamate

A solution of Example 21C (100 mg, 0.35 mmol) in THF (3 mL) at 0 °C was treated with 9-BBN (0.5 M solution in THF, 0.70 mL, 0.35 mmol), stirred overnight while gradually warming to room temperature, cannulated into a mixture of Example 21B (108 mg, 0.32 mmol), $\text{PdCl}_2(\text{dppf})$ (26 mg, 0.032 mmol) and Cs_2CO_3 (228 mg, 0.7 mmol) in DMF, purged with nitrogen, and stirred at 50 °C for 8 hours. The mixture was treated with ethyl acetate (50 mL), washed with brine, dried (MgSO_4), filtered, and concentrated. The residual oil was

purified by flash column chromatography on silica gel with 80% ethyl acetate/hexanes to provide the desired product (69 mg, 40%).

Example 21E

(1R)-3-{6-chloro-5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-yl}-1-(1H-indol-3-ylmethyl)propylamine

5 The desired product was prepared as the trifluoroacetate salt by substituting Example 21D for Example 2B in Example 2D. MS (APCI) m/e 403, 405 (M+H)⁺; ¹H NMR (300 MHz, CD₃OD) δ 8.78 (d, J = 6.8 Hz, 2H), 8.19 (d, J = 1.7 Hz, 1H), 8.18 (d, J = 6.8 Hz, 2H), 7.97 (d, J = 2.4 Hz, 1H), 7.93 (d, J = 16.3 Hz, 1H), 7.48 (d, J = 7.8 Hz, 1H), 7.34 (d, J = 9.5 Hz, 1H), 7.33 (d, J = 16.0 Hz, 1H), 7.20 (s, 1H), 7.11 (td, J = 7.1, 1.0 Hz, 1H), 7.00 (td, J = 6.8, 1.0 Hz, 1H), 3.55 (p, J = 6.4 Hz, 1H), 3.16 (m, 2H), 2.82 (m, 2H), 2.06 (m, 2H); Anal. Calcd for C₂₄H₂₃ClN₄·2.8 TFA: C, 49.23; H, 3.60; N, 7.76. Found: C, 49.11; H, 3.64; N, 7.66.

Example 22

4-(5-[(2S)-2-amino-3-(1H-indol-3-yl)propyl]oxy)pyridin-3-yl)benzonitrile

Example 22A

tert-butyl (1S)-2-[(5-(4-cyanophenyl)pyridin-3-yl)oxy]-1-(1H-indol-3-ylmethyl)ethylcarbamate

20 A solution of Example 2A (250 mg, 0.56 mmol) in ethylene glycol dimethyl ether (20.0 mL) at room temperature was treated with tetrakis(triphenylphosphine)palladium(0) (32 mg, 0.03 mmol), stirred for 10 minutes, treated with a solution of (4-cyanophenyl)boronic acid (123 mg, 0.84 mmol) in ethanol (5.0 mL), stirred for 15 minutes, treated with 2M Na₂CO₃ (aq.) (1.4 mL), heated to reflux for 4 hours, cooled to room temperature and concentrated. The concentrate was purified by flash column chromatography on silica gel with hexanes/ethyl acetate (1:1) to provide the desired product (230 mg, 88%). MS (DCI/NH₃) m/e 469 (M+H)⁺.

Example 22B

4-(5-[(2S)-2-amino-3-(1H-indol-3-yl)propyl]oxy)pyridin-3-yl)benzonitrile

25 A solution of Example 22A (20 mg, 0.043 mmol) in dichloromethane (2.0 mL) at 0 °C was treated dropwise with trifluoroacetic acid (0.5 mL) and stirred for 2 hours while warming to room temperature. The reaction mixture was concentrated to provide the desired product as the trifluoroacetate salt (27 mg, 88%). MS (DCI/NH₃) m/e 369 (M+H)⁺; ¹H NMR (DMSO-d₆) δ 11.02 (s, 1H), 8.63 (d, J=1.9 Hz, 1H), 8.42 (d, J=2.8 Hz, 1H), 8.21 (br s, 2H), 7.99-7.92 (m, 4H), 7.73 (t, J=1.9 Hz, 1H), 7.61 (d, J=8.1 Hz, 1H), 7.38 (d, J=8.1 Hz, 1H), 7.29 (d, J=2.5 Hz, 1H), 7.10 (m, 1H), 7.01 (m, 1H), 4.36 (dd, J=10.6, 3.1 Hz, 1H), 4.19 (dd, J=10.9, 5.9 Hz, 1H), 3.89-3.82 (m, 1H), 3.16 (d, J=7.2 Hz, 2H).

Example 23

N-[(2S)-2-amino-3-(1H-indol-3-yl)propyl]-N'-isoquinolin-5-ylpyridine-3,5-diamineExample 23Aisoquinolin-5-yl trifluoromethanesulfonate

A mixture of 5-hydroxyisoquinoline (1.6 g; 11.0 mmol) and triethylamine (1.38 g; 13.6 mmol) in dichloromethane (25 mL) at 0 °C was treated slowly with triflic anhydride (3.35 g; 12.1 mmol), stirred overnight while warming to room temperature, diluted with dichloromethane, washed twice with water and saturated NH₄Cl (aq.), once with water and brine, dried (Na₂SO₄), filtered, and concentrated. The concentrate was purified by flash column chromatography on silica gel with 7% ethyl acetate/dichloromethane to provide the desired product (1.54 g; 50%).

Example 23B3-amino-5-bromopyridine

A solution of 3M NaOH (250 mL) at room temperature was treated with bromine (25.9 g, 162 mmol), stirred for 15 minutes, treated with 5-bromonicotinamide (25 g, 124 mmol), stirred for 45 minutes, heated to 85-100 °C for 3 hours, cooled to room temperature, adjusted to pH 1 with 10% HCl (aq.) washed twice with diethyl ether. The aqueous layer was adjusted to pH~10-11 with solid NaOH, and extracted four times with diethyl ether and twice with dichloromethane. The combined extracts were dried (MgSO₄), filtered, and concentrated to provide the desired product (13.3 g, 62%).

Example 23CN-(5-bromopyridin-3-yl)isoquinolin-5-amine

A mixture Example 23A (500 mg, 1.8 mmol), Example 23B (600 mg, 3.5 mmol), Pd₂(dba)₃ (42 mg; 0.045 mmol), BINAP (56 mg; 0.09 mmol), and sodium tert-butoxide (350 mg; 3.6 mmol) in 10 mL toluene was heated to reflux for 2 hours, diluted with water, and extracted three times with ethyl acetate. The combined extracts were washed successively with saturated NaHCO₃, water, and brine, dried (Na₂SO₄), and concentrated. The concentrate was purified by flash column chromatography on silica gel with 3% methanol/dichloromethane to provide the desired product (97 mg, 18%).

Example 23DN-(diphenylmethylene)-N'-isoquinolin-5-ylpyridine-3,5-diamine

A mixture of Example 23C (175 mg, 0.58 mmol), benzophenone imine (150 mg, 0.83 mmol), Pd₂(dba)₃ (54 mg, 0.06 mmol), BINAP (55 mg, 0.09 mmol), and sodium tert-butoxide (80 mg, 0.82 mmol) in 3 mL toluene was heated to 75-80 °C for 4 hours and concentrated. The concentrate was purified by flash column chromatography on silica gel with 3% methanol/dichloromethane to provide the desired product (150 mg, 64%).

Example 23EN-isoquinolin-5-ylpyridine-3,5-diamine

A mixture of Example 23D (145 mg; 0.36 mmol) in 3 mL THF at room temperature was treated with 10 drops of water and 3 drops of conc. HCl, stirred for 2 hours, and concentrated. The residue was partitioned between ethyl acetate and concentrated NaHCO₃ (aq). The aqueous layer was extracted three times with ethyl acetate. The combined extracts were washed with brine, dried (MgSO₄), filtered, and concentrated. The concentrate was purified by flash column chromatography on silica gel with 10% methanol/dichloromethane to provide the desired product (59 mg, 68%).

Example 23F

tert-butyl (1S)-2-(1H-indol-3-yl)-1-({[5-(isoquinolin-5-ylamino)pyridin-3-yl]amino}methyl)ethylcarbamate

A mixture of Example 23E (55 mg, 0.23 mmol) and L-Boc-tryptophanal (84 mg, 0.29 mmol) in 2 mL dichloromethane at room temperature was treated with Ti(iPrO)₄ (1 mL), stirred for 2 hours, and concentrated. The residue was dissolved in 2 mL ethanol, treated with NaBH₃CN (30 mg; 0.46 mmol), stirred for 2 hours, diluted with water, and filtered. The filter cake was washed with methanol and the filtrate was concentrated. The residue was suspended in methanol/dichloromethane and filtered. The filtrate was concentrated and the concentrate was purified by flash column chromatography on silica gel with 5% methanol/dichloromethane to provide the desired product (28 mg, 24%).

Example 23G

N-[(2S)-2-amino-3-(1H-indol-3-yl)propyl]-N'-isoquinolin-5-ylpyridine-3,5-diamine

A solution of Example 23F (26 mg, 0.05 mmol) in 2 mL dichloromethane at room temperature was treated with 0.5 mL TFA, stirred for 3 hours, and concentrated. The concentrate was purified by reverse phase HPLC on a C18 column with 0-100% CH₃CN/H₂O/0.1% TFA and the residue was dissolved in water and lyophilized to provide the desired product as the trifluoroacetate salt (27 mg, 70%). MS (ESI(+)) m/e 409 (M+H)⁺; ¹H NMR (DMSO-d₆, 500 MHz) δ 11.02 (s, 1H), 9.44 (s, 1H), 9.07 (s, 1H), 8.57 (d, J=9 Hz, 1H), 7.95-8.01 (m, 2H), 7.88-7.93 (m, 2H), 7.68-7.73 (m, 3H), 7.57-7.59 (m, 1H), 7.53 (d, J=8 Hz, 1H), 7.38 (d, J=8 Hz, 1H), 7.24-7.27 (m, 1H), 7.09 (t, J=9 Hz, 1H), 6.89 (t, J=9 Hz, 1H), 6.92 (s, 1H), 6.83 (br s, 1H), 3.33-3.40 (m, 1H), 3.00-3.14 (m, 4H); Anal. Calcd for C₂₅H₂₄N₆·3TFA·3H₂O: C, 46.28; H, 4.13; N, 10.44; F, 21.25. Found: C, 46.32; H, 3.54; N, 10.02; F, 21.58.

Example 24

N-[(2S)-2-amino-3-(1H-indol-3-yl)propyl]-N-[5-(isoquinolin-5-yloxy)pyridin-3-yl]amine

Example 24A

5-[5-bromopyridin-3-yl]oxy]isoquinoline

A sealed tube was charged with 5-hydroxyisoquinoline (0.15 g, 1.03 mmol), 3,5-dibromopyridine (0.24 g, 1.03 mmol), potassium carbonate (0.27 g, 2.0 mmol) and DMF (4

mL). The reaction was heated to 240 °C for 10 minutes in a personal chemistry microwave. The reaction was partitioned between water and ethyl acetate. The aqueous layer was extracted twice with ethyl acetate. The combined extracts were concentrated and the residue was purified by flash column chromatography on silica gel with 2:1 ethyl acetate/hexanes to 5 provide the desired product (0.071 g, 23%).

Example 24B

N-[(2S)-2-amino-3-(1H-indol-3-yl)propyl]-N-[5-(isoquinolin-5-yloxy)pyridin-3-yl]amine

The desired product was prepared by substituting Example 24A for Example 23C in Examples 23D then proceeding as described for Examples 23E, 23F, and 23G. MS (ESI) m/e 10 410 (M+H)⁺; ¹H NMR (DMSO-d₆, 300 MHz) δ 11.00 (br s, 1H), 9.47 (br s, 1H), 8.58 (d, J=8 Hz, 1H), 7.97-8.03 (m, 1H), 7.92-7.94 (m, 1H), 7.85-7.87 (m, 1H), 7.79-7.82 (m, 2H), 7.66-7.72 (m, 2H), 7.51-7.54 (m, 1H), 7.26-7.36 (m, 3H), 7.02-7.08 (m, 1H), 6.94-6.98 (m, 1H), 6.68-6.71 (m, 1H), 6.39 (br s, 1H), 3.73-3.80 (m, 1H), 3.43-3.52 (m, 2H), 3.16-3.19 (m, 2H); Anal. Calcd for C₂₅H₂₃N₅O·3TFA: C, 49.53; H, 3.46; N, 9.30; F, 22.76. Found: C, 49.44; H, 15 3.58; N, 9.14; F, 22.30.

Example 25

(2S)-2-amino-3-(1H-indol-3-yl)-N-[5-(1,6-naphthyridin-2-yl)pyridin-3-yl]propanamide

Example 25A

2,2-dimethyl-N-pyridin-4-ylpropanamide

20 A mixture of 4-aminopyridine (10 g, 106 mmol) and pivaloyl chloride (12.9 g, 107 mmol) in 200 mL dichloromethane was cooled to 0 °C and treated slowly with triethylamine (10.9 g, 108 mmol), warmed to room temperature, stirred overnight, and diluted with water. The aqueous layer was extracted three times with dichloromethane and the combined extracts were washed with brine, dried (Na₂SO₄), filtered, and concentrated. The product was 25 recrystallized from toluene to provide the desired product (14 g, 74%).

Example 25B

N-(3-formylpyridin-4-yl)-2,2-dimethylpropanamide

30 A mixture of Example 25A (11.4 g, 64 mmol) in 200 mL THF was cooled to -78 °C, treated with 1.6 M nBuLi in hexanes (100 mL, 160 mmol), warmed to 0 °C, stirred for 1 hour, treated with a solution of DMF (22 g, 215 mmol) in 100 mL THF, warmed to room temperature, stirred for 1 hour, diluted with brine, and extracted three times with ethyl acetate. The combined extracts were washed with water, washed twice with brine, dried (MgSO₄), filtered, and concentrated. The concentrate was purified by flash column chromatography on silica gel with 3% methanol/dichloromethane to provide the desired 35 product (9.1 g, 69%).

Example 25C

4-aminonicotinaldehyde

A solution of Example 25B (870 mg, 4.2 mmol) in 3N HCl (aq.) (10 mL) was heated to reflux overnight, and extracted three times with diethyl ether. The aqueous layer was adjusted to pH >7 with solid K₂CO₃ and extracted six times with 20% isopropanol/chloroform. The combined extracts were dried (Na₂SO₄), filtered, and concentrated to provide the desired product (450 mg; 87%).

5

Example 25D

5-acetylnicotinamide

A mixture of 5-bromonicotinamide (2.5 g, 12.4 mmol), tributyl(1-ethoxyvinyl)tin (5.0 g, 13.8 mmol) and dichlorobis(triphenylphosphine)palladium(II) (800 mg, 1.1 mmol) in 25 mL toluene was heated to reflux for 3 hours. The mixture was cooled to room temperature, treated with 25 mL 2N HCl (aq.), and stirred for 1 hour. The aqueous layer was washed with ethyl acetate, adjusted to pH >7 with solid K₂CO₃, and extracted six times into 20% isopropanol/chloroform. The combined extracts were dried (Na₂SO₄), filtered, and concentrated to provide the desired product (1.6 g, 78%).

15

Example 25E

5-(1,6-naphthyridin-2-yl)nicotinamide

A mixture of Example 25C (450 mg, 3.68 mmol) and Example 25D (605 mg, 3.68 mmol) in 20 mL ethanol and 1.2 mL of 10% NaOH (aq) was heated to reflux for 3 hours and concentrated. The solid was collected and rinsed with ethyl acetate to provide the desired product (740 mg, 80%).

20

Example 25F

5-(1,6-naphthyridin-2-yl)pyridin-3-amine

The desired product was prepared by substituting Example 25E for 5-bromonicotinamide in Example 23B.

25

Example 25G

tert-butyl (1S)-1-(1H-indol-3-ylmethyl)-2-{{[5-(1,6-naphthyridin-2-yl)pyridin-3-yl]amino}-2-oxoethylcarbamate}

The desired product was prepared by substituting Example 25F (100 mg, 0.45 mmol) and L-Boc-tryptophan (150 mg, 0.49 mmol) for Example 11B and Boc-homophenylalanine, respectively, in Example 16A.

30

Example 25H

(2S)-2-amino-3-(1H-indol-3-yl)-N-[5-(1,6-naphthyridin-2-yl)pyridin-3-yl]propanamide

The desired product was prepared as the trifluoroacetate salt by substituting Example 25G for Example 2B in Example 2D. MS (ESI) m/e 409 (M+H)⁺; ¹H NMR (DMSO-d₆, 500 MHz) δ 11.04 (br s, 1H), 10.91 (s, 1H), 9.50 (s, 1H), 9.23 (d, J=3 Hz, 1H), 8.95 (d, J=3 Hz, 1H), 8.77-8.83 (m, 3H), 8.42 (d, J=8 Hz, 1H), 8.28-8.32 (m, 2H), 7.97-8.00 (m, 1H), 7.65-7.69 (m, 1H), 7.37 (d, J=8 Hz, 1H), 7.26-7.28 (m, 1H), 7.06-7.11 (m, 1H), 6.96-7.01 (m, 1H),

4.18-4.25 (m, 1H), 3.25-3.45 (m, 2H); Anal. Calcd for $C_{24}H_{20}N_6O \cdot 3TFA \cdot 1H_2O$: C, 46.88; H, 3.28; N, 10.93; F, 22.25. Found: C, 47.19; H, 3.39; N, 11.14; F, 21.81.

Example 26

N-[(2S)-2-amino-3-(1H-indol-3-yl)propyl]-N-[5-(1,6-naphthyridin-2-yl)pyridin-3-yl]amine

5 The desired product was prepared as the trifluoroacetate salt by substituting Example 25F for Example 23E in Examples 23F and 23G. MS (ESI) m/e 395 ($M+H$)⁺; ¹H NMR (DMSO-d₆, 500 MHz) δ 11.07 (br s, 1H), 9.51 (s, 1H), 8.74-8.83 (m, 3H), 8.27 (d, J=9 Hz, 1H), 8.18 (d, J=4 Hz, 1H), 7.93-7.97 (m, 4H), 7.60-7.64 (m, 1H), 7.39 (d, J=9 Hz, 1H), 7.34 (d, J=4 Hz, 1H), 7.06-7.12 (m, 1H), 6.96-7.02 (m, 1H), 6.78 (br s, 1H), 3.40-3.67 (m, 3H), 10 3.11-3.16 (m, 2H); Anal. Calcd for $C_{24}H_{22}N_6 \cdot 3.25TFA$: C, 47.88; H, 3.33; N, 10.98; F, 24.21. Found: C, 47.51; H, 3.29; N, 10.94; F, 24.16.

Example 27

(1S)-2-(1H-indol-3-yl)-1-{{[(5-isoquinolin-6-ylpyridin-3-yl)oxy]methyl}ethylamine

Example 27A

6-(trimethylstannyl)isoquinoline

15 A solution of 6-bromoisoquinoline (0.35 g, 1.7 mmol) in DMA (6 mL) was treated with hexamethylditin (0.55 mL, 1.9 mmol) and Pd(PPh₃)₄ (0.23 g, 0.2 mmol), stirred at 100 °C for 1 hour, diluted with water, and extracted three times with ethyl acetate. The combined extracts were concentrated and the residue was purified by flash column chromatography on 20 silica gel with 1:1 hexanes/ethyl acetate to provide the desired product (0.247 g, 50%).

Example 27B

tert-butyl (1S)-2-(1H-indol-3-yl)-1-{{[(5-isoquinolin-6-ylpyridin-3-yl)oxy]methyl}ethylcarbamate

25 A solution of Example 27A (0.25 g, 0.86 mmol) and Example 2A (0.444 g, 1.00 mmol) in 6 mL of DMF was treated with Pd₂(dba)₃ (0.08 g, 0.086 mmol), tri-o-tolylphosphine (0.02 g, 0.04 mmol), and triethylamine (0.15 mL, 1.0 mmol), heated to 75 °C in a sealed tube for 8 hours, and concentrated. The residue was purified by flash column chromatography on silica gel with 2.5% methanol/dichloromethane to provide the desired product (0.125 g, 30%).

Example 27C

(1S)-2-(1H-indol-3-yl)-1-{{[(5-isoquinolin-6-ylpyridin-3-yl)oxy]methyl}ethylamine

30 A solution of Example 27B (0.125 g, 0.25 mmol) in dichloromethane (3 mL) at room temperature was treated with TFA (400 μL), stirred for 1 hour, and concentrated. The concentrate was azeotropically distilled with diethyl ether two times and the residue was 35 purified by reverse phase HPLC on a C18 column with 0-100% CH₃CN/H₂O/0.1 % TFA to provide the desired product as the di-trifluoroacetate salt (0.110 g, 70%). MS (ESI) m/e 395 ($M+H$)⁺; ¹H NMR (DMSO-d₆, 300 MHz) δ 11.02 (br s, 1H), 9.52 (s, 1H), 8.76 (d, J=3 Hz,

1H), 8.62 (d, J=8 Hz, 1H), 8.44-8.46 (m, 2H), 8.38 (d, J=9 Hz, 1H), 8.11-8.20 (m, 3H), 8.04-8.08 (m, 1H), 7.83-7.86 (m, 1H), 7.62 (d, J=9 Hz, 1H), 7.37-7.40 (m, 1H), 7.31 (d, J=3 Hz, 1H), 7.08-7.12 (m, 1H), 6.99-7.03 (m, 1H), 4.37-4.41 (m, 1H), 4.18-4.23 (m, 1H), 3.86-3.91 (m, 1H), 3.16-3.20 (m, 2H); Anal. Calcd for $C_{25}H_{22}N_4O \cdot 2TFA \cdot H_2O$: C, 49.35; H, 3.61; N, 7.43; F, 22.67. Found: C, 49.04; H, 3.55; N, 7.42; F, 22.28.

Example 28

(1R)-2-(1H-indol-3-yl)-1-[(5-quinolin-6-ylpyridin-3-yl)oxy]methyl}ethylamine

Example 28A

10 tert-butyl (1R)-2-[(5-hydroxypyridin-3-yl)oxy]-1-(1H-indol-3-ylmethyl)ethylcarbamate

The desired product was prepared by substituting D-Boc-tryptophanol for L-Boc tryptophanol in Example 2A.

Example 28B

(1R)-2-(1H-indol-3-yl)-1-[(5-quinolin-6-ylpyridin-3-yl)oxy]methyl}ethylamine

15 The desired product was prepared as the trifluoroacetate salt by substituting 28A for 2A in Example 27B then removing the Boc group as in Example 27C. MS (ESI) m/e 395 (M+H)⁺; ¹H NMR (DMSO-d₆, 500 MHz) δ 11.02 (s, 1H), 8.97-9.00 (m, 1H), 8.74 (d, J=3Hz, 1H), 8.50-8.54 (m, 1H), 8.39-8.42 (m, 2H), 8.18-8.23 (m, 3H), 8.13-8.17 (m, 1H), 7.81-7.83 (m, 1H), 7.61-7.66 (m, 2H), 7.39 (d, J=8 Hz, 1H), 7.31 (d, J=3 Hz, 1H), 7.07-7.10 (m, 1H), 20 6.99-7.02 (m, 1H), 4.38-4.41 (m, 1H), 4.21-4.24 (m, 1H), 3.79-3.83 (m, 1H), 3.16-3.19 (m, 2H).

Example 29

(1S)-2-[(6-chloro-5-isoquinolin-6-ylpyridin-3-yl)oxy]-1-(1H-indol-3-ylmethyl)ethylamine

The desired product was prepared as the trifluoroacetate salt by substituting Example 25 13A for Example 2A in Example 27. MS (APCI) m/e 429, 431 (M+H)⁺; ¹H NMR (300 MHz, CD₃OD) δ 9.77 (s, 1H), 8.63 (d, J = 6.4 Hz, 1H), 8.54 (d, J = 88 Hz, 1H), 8.43 (d, J = 6.4 Hz, 1H), 8.30 (s, 1H), 8.27 (d, J = 3.1 Hz, 1H), 8.06 (dd, J = 8.4, 1.7 Hz, 1H), 7.58 (s, 1H), 7.56 (d, J = 5.4 Hz, 1H), 7.35 (d, J = 8.1 Hz, 1H), 7.22 (s, 1H), 7.10 (td, J = 7.1, 1.4 Hz, 1H), 7.00 (td, J = 7.8, 1.0 Hz, 1H), 4.37 (dd, J = 10.5, 3.4 Hz, 1H), 4.24 (dd, J = 10.5, 5.8 Hz, 1H), 3.98 (m, 1H), 3.27 (m, 2H); Anal. Calcd for $C_{25}H_{21}ClN_4O \cdot 2.25TFA$: C, 51.69; H, 3.42; N, 8.17. Found: C, 51.75; H, 3.39; N, 8.13.

Example 30

(1S)-2-[(2-chloro-5-isoquinolin-6-ylpyridin-3-yl)oxy]-1-(1H-indol-3-ylmethyl)ethylamine

The desired product was prepared as the trifluoracetate salt by substituting Example 35 12C for Example 2A in Example 27 (0.02 g, 80%). MS (DCI/NH₃) m/e 429, 431 (M+H)⁺; ¹H NMR (DMSO-d₆) δ 11.04 (s, 1H), 9.50 (s, 1H), 8.62 (d, J=6.0 Hz, 1H), 8.57 (s, 1H), 8.44 (s, 1H), 8.35 (d, J=9.0 Hz, 1H), 8.22 (s, 2H), 8.13 (d, J=9.0 Hz, 1H), 8.00 (d, J=6.0 Hz, 1H), 7.98

(s, 1H), 7.64 (d, J=7.5 Hz, 1H), 7.38 (d, J=7.5 Hz, 1H), 7.30 (s, 1H), 7.10 (t, J=7.2 Hz, 1H), 7.00 (t, J=7.2 Hz, 1H), 4.46 (m, 1H), 4.30 (m, 1H), 3.92 (m, 1H), 3.21 (m, 2H).

Example 31

(1R)-1-(1H-indol-3-ylmethyl)-3-(5-isoquinolin-6-ylpyridin-3-yl)propylamine

Example 31A

6-(5-bromopyridin-3-yl)isoquinoline

A solution of 3,5-dibromopyridine (284 mg, 1.2 mmol), $Pd_2(dba)_3$ (110 mg, 0.12 mmol) and tri-*o*-tolylphosphine (110 mg, 0.36 mmol) in DMF (15 mL) was treated with Example 27A (500 mg, 1.2 mmol) and triethylamine (500 μ L, 3.6 mmol), purged with nitrogen, heated to 70 °C for 6 hours, cooled to room temperature, treated with ethyl acetate (100 mL), washed with brine, dried ($MgSO_4$), filtered, and concentrated. The residual oil was purified by flash column chromatography on silica gel with ethyl acetate to provide the desired product (110 mg, 32%). MS (APCI) m/e 285, 287 ($M+H$)⁺.

Example 31B

(1R)-1-(1H-indol-3-ylmethyl)-3-(5-isoquinolin-6-ylpyridin-3-yl)propylamine

The desired product was prepared as the trifluoroacetate salt by substituting Example 31A for Example 21B in Example 21D then removing the Boc protecting group as described for Example 21E. MS (DCI/NH₃) m/e 458 ($M+H$)⁺; ¹H NMR (CD₃OD) δ 9.78 (s, 1H), 8.97 (d, J=1.1 Hz, 1H), 8.64 (d, J=6.4 Hz, 1H), 8.61 (d, J=8.9 Hz, 1H), 8.55 (s, 1H), 8.53 (s, 1H), 8.47 (d, J=6.5 Hz, 1H), 8.25 (dd, J=8.4, 1.7 Hz, 1H), 8.23 (s, 1H), 7.49 (d, J=7.9 Hz, 1H), 7.30 (d, J=8.2 Hz, 1H), 7.22 (s, 1H), 7.06 (td, J=7.1, 1.0 Hz, 1H), 6.97 (td, J=7.1, 1.0 Hz, 1H), 3.59 (p, J=6.5 Hz, 1H), 3.18 (dd, J=7.1, 3.4 Hz, 2H), 2.99 (m, 2H), 2.15 (m, 2H).

Example 32

5-(5-{{(2S)-2-amino-3-(1H-indol-3-yl)propyl}oxy}pyridin-3-yl)-1H-isoindole-1,3(2H)-dione

Example 32A

tert-butyl (1S)-2-(1H-indol-3-yl)-1-{{[5-(trimethylstannyl)pyridin-3-yl]oxy}methyl}ethylcarbamate

A solution of Example 2A (1 g, 2.23 mmol) in DMA (15 mL) was treated with hexamethylditin (1.8 mL, 5.6 mmol) and $Pd(PPh_3)_4$ (0.4 g, 0.2 mmol), heated to 75 °C for 1.5 days, added to water, and extracted three times with ethyl acetate. The combined extracts were concentrated and the residue was purified by flash column chromatography on silica gel with 1:1 hexanes/ethyl acetate to provide the desired product (0.4 g, 34 %).

Example 32B

tert-butyl (1S)-2-{{[5-(1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl)pyridin-3-yl]oxy}-1-(1H-indol-3-ylmethyl)ethylcarbamate

A solution of Example 32A (0.2 g, 0.31 mmol) and 6-bromophthalimide (0.084 g, 0.4 mmol) in DMF (2 mL) was treated with $Pd_2(dba)_3$ (0.04 g, 0.02 mmol), tri-*o*-tolylphosphine

(0.02 g, 0.01 mmol), and triethylamine (0.06 mL, 0.4 mmol). The reaction was heated to 75 °C for 6 hours in a sealed tube and concentrated. The residue was purified by flash column chromatography on silica gel with 1:1 hexanes/ethyl acetate to provide the desired product (0.116 g, 55%).

5

Example 32C

5-(5-[(2S)-2-amino-3-(1H-indol-3-yl)propyl]oxy}pyridin-3-yl)-1H-isoindole-1,3(2H)-dione

The desired product was prepared as the trifluoroacetate salt by substituting Example 32B for Example 27B in Example 27C. MS (ESI) m/e 413 (M+H)⁺; ¹H NMR (DMSO-d₆, 300 MHz) δ 11.43 (s, 1H), 11.02 (br s, 1H), 8.67 (d, J=3 Hz, 1H), 8.42 (d, J=6 Hz, 1H), 8.14-8.18 (m, 4H), 7.92-7.96 (m, 1H), 7.79-7.81 (m, 1H), 7.61 (d, J=9 Hz, 1H), 7.38 (d, J=9 Hz, 1H), 7.30 (d, J=3 Hz, 1H), 7.08-7.12 (m, 1H), 6.98-7.03 (m, 1H), 4.35-4.40 (m, 1H), 4.17-4.22 (m, 1H), 3.83-3.88 (m, 1H), 3.13-3.17 (m, 2H). Anal. Calcd for C₂₄H₂₀N₄O₃·2.1TFA: C, 51.96; H, 3.42; N, 8.59; F, 18.30. Found: C, 51.45; H, 3.46; N, 8.56; F, 17.47.

10

Example 33

15

5-(5-[(2S)-2-amino-3-(1H-indol-3-yl)propyl]oxy}pyridin-3-yl)isoindolin-1-one

Example 33A

methyl 4-bromo-2-methylbenzoate

20

A solution of 4-bromo-2-methyl benzoic acid (1.0 g, 4.7 mmol) in methanol (24 mL) was treated with 20 drops of HCl, heated at reflux for 6 hours, and concentrated to provide the desired product (1.07 g, 100%).

20

Example 33B

methyl 4-bromo-2-(bromomethyl)benzoate

25

A solution of Example 33A (1.02 g, 4.47 mmol) in CCl₄ (22 mL) was treated with AIBN (0.065 g, 0.4 mmol) and NBS (0.955 g, 5.4 mmol), heated to reflux for 4 hours, washed with water, dried (Na₂SO₄), filtered, and concentrated to provide the desired product (1.1 g, 79%).

Example 33C

5-bromoisoindolin-1-one

30

A solution of Example 33B (1.1 g, 3.57 mmol) in THF (20 mL) at room temperature was treated with 1N NH₃ in methanol (7.14 mL, 7.14 mmol), stirred for 24 hours, and filtered. The filter cake was washed with diethyl ether (100 mL) to provide the desired product (0.4 g, 52%).

30

Example 33D

5-(5-[(2S)-2-amino-3-(1H-indol-3-yl)propyl]oxy}pyridin-3-yl)isoindolin-1-one

35

The desired product was prepared as the trifluoroacetate salt by substituting Example 33C for 6-bromophthalimide in Example 32. MS (ESI) m/e 399 (M+H)⁺; ¹H NMR (DMSO-d₆, 300 MHz) δ 11.03 (br s, 1H), 8.63 (s, 1H), 8.57 (s, 1H), 8.35 (br s, 3H), 7.90 (s, 1H), 7.78

(s, 2H), 7.67 (s, 1H), 7.61 (d, J=8 Hz, 1H), 7.37 (d, J=8 Hz, 1H), 7.79 (d, J=2 Hz, 1H), 7.03-7.10 (m, 1H), 6.96-7.01 (m, 1H), 4.32-4.36 (m, 1H), 4.17-4.22 (m, 1H), 3.80-3.83 (m, 1H), 3.18 (d, J=8 Hz, 2H), 2.50 (s, 2H).

Example 34

5 (1S)-2-[(5-cinnolin-6-ylpyridin-3-yl)oxy]-1-(1H-indol-3-ylmethyl)ethylamine

Example 34A

N-(2-acetylphenyl)acetamide

A solution of 2'-aminoacetophenone (5.0 g, 37 mmol) in dichloromethane (150 mL) at room temperature was treated with triethylamine (5.3 mL, 40 mmol) and acetyl chloride (3.2 mL, 45 mmol), stirred for 3 hours, then washed with water. The aqueous layer was extracted with ethyl acetate (2 x 20 mL) and the combined extracts were concentrated to provide the desired product (6.5 g, 100%).

Example 34B

N-(2-acetyl-4-bromophenyl)acetamide

15 A solution Example 34A (6.5 g, 37 mmol) in acetic acid (100mL) at room temperature was treated with Br₂ (4 mL, 84 mmol), stirred for 1 hour and 15 minutes, poured into water (200 mL), and filtered. The solid was washed with water (2 x 100 mL), and hexanes (2 x 100mL), dissolved in diethyl ether, washed with brine (50 mL), and concentrated to provide the desired product (8.5 g, 89 %).

20 Example 34C

6-bromocinnolin-4(1H)-one

A solution of Example 34B (6.28 g, 24.4 mmol) in THF (75 mL) was treated with concentrated HCl (aq.) (15 mL) and water (15 mL), heated to reflux for 1 hour, and concentrated to remove the THF. The aqueous solution was treated with additional water (5mL) and concentrated HCl (5 mL), cooled to 0 °C, treated with a solution of NaNO₂ (1.85 g, 26.84 mmol) in water (10 mL) in 5 portions, warmed to room temperature gradually over a 2-hour period, and stirred overnight at room temperature. The reaction was heated to reflux for 6 hours, and filtered. The solid was washed with water (50 mL) and diethyl ether (50 mL) and dried under vacuum to provide the desired product (3.0 g, 54%).

30 Example 34D

6-bromo-4-chlorocinnoline

A solution of Example 34C (0.4 g, 1.8 mmol) in POCl₃ (2.5 mL) was heated to 100 °C for 2 hours, and poured slowly onto ice. The aqueous layer was cooled to 0 °C and adjusted to pH 5-7 with 50% NaOH. The aqueous layer was extracted with ethyl acetate (2 x 50 mL), and the combined organic layers were concentrated. The residue was purified by flash column chromatography on silica gel with 4:1 hexanes/ethyl acetate to provide the desired product (0.190 g, 43%).

Example 34E6-bromo-4-hydrazinocinnoline

5 A solution of Example 34D (2.6 g, 10.6 mmol) in ethanol (70 mL) was treated with hydrazine monohydrate (3 mL, 90% solution), stirred at room temperature for 3 days, and filtered. The solid washed with water (50 mL) and diethyl ether (50 mL) and dried under vacuum to provide the desired product (2.5 g, 100%).

Example 34F6-bromocinnoline

10 A solution of Example 34E (3.5 g, 14 mmol) in water (50 mL) was heated to reflux, treated dropwise with a solution of CuSO₄ (2.8 g, 17.5 mmol) in water (20 mL), refluxed for 2 hours, cooled to room temperature, adjusted to pH 7 with saturated NaHCO₃ (aq), and extracted with ethyl acetate (2 x 25 mL). The combined extracts were concentrated and the residue was purified by flash column chromatography on silica gel with 1:1 hexanes/ethyl acetate to provide the desired product (0.7 g, 24%).

Example 34G(1S)-2-[(5-cinnolin-6-ylpyridin-3-yl)oxy]-1-(1H-indol-3-ylmethyl)ethylamine

15 The desired product was prepared as the trifluoroacetate salt by substituting Example 34F for 6-bromophthalimide in Example 32. MS (ESI) m/e 396 (M+H)⁺; ¹H NMR (DMSO-d₆, 300 MHz) δ 11.04 (s, 1H), 9.43 (d, J=6 Hz, 1H), 8.78 (d, J=2 Hz, 1H), 8.60 (d, J=8 Hz, 1H), 8.45-8.49 (m, 2H), 8.30-8.34 (m, 1H), 8.26 (d, J=6 Hz, 1H), 8.21-8.25 (m, 2H), 7.89 (t, J=2 Hz, 1H), 7.63 (d, J=8 Hz, 1H), 7.39 (d, J=8 Hz, 1H), 7.31 (d, J=2 Hz, 1H), 7.08-7.12 (m, 1H), 7.01-7.04 (m, 1H), 4.38-4.42 (m, 1H), 4.22-4.26 (m, 1H), 3.83-3.88 (m, 1H), 3.17-3.20 (m, 2H).

Example 35(1S)-2-{{5-(1H-indazol-5-yl)pyridin-3-yl}oxy}-1-(1H-indol-3-ylmethyl)ethylamineExample 35A5-bromo-1H-indazole

25 A mixture of 5-bromo-2-fluorobenzaldehyde (10 g, 49.2 mmol) and 98% hydrazine (20 mL) was heated to reflux for 5 hours, poured over ice, and filtered. The solid was 30 recrystallized from H₂O/methanol to provide the desired product (3.7 g, 38%).

Example 35B(1S)-2-{{5-(1H-indazol-5-yl)pyridin-3-yl}oxy}-1-(1H-indol-3-ylmethyl)ethylamine

35 The desired product was prepared as the trifluoroacetate salt by substituting Example 35A for 6-bromophthalimide in Example 32. MS (ESI) m/e 384 (M+H)⁺; ¹H NMR (DMSO-d₆, 300 MHz) δ 13.22 (br s, 1H), 11.04 (br s, 1H), 8.62 (d, J=2 Hz, 1H), 8.33 (d, J=3 Hz, 1H), 8.13-8.21 (m, 3H), 8.12 (s, 1H), 7.67-7.72 (m, 3H), 7.64 (d, J=8 Hz, 1H), 7.39 (d, J=8 Hz, 1H), 7.30 (d, J=2 Hz, 1H), 7.06-7.13 (m, 1H), 6.98-7.04 (m, 1H), 4.14-4.39 (m, 2H), 3.33-

3.38 (m, 1H), 3.13-3.16 (m, 2H); Anal. Calcd for $C_{23}H_{21}N_5O \cdot 2TFA \cdot H_2O$: C, 51.52; H, 4.00; N, 11.13. Found: C, 51.80; H, 3.61; N, 11.03.

Example 36

5-(5-[(2S)-2-amino-3-(1H-indol-3-yl)propyl]oxy}pyridin-3-yl)-1,3-dihydro-2H-indol-2-one

5 The desired product was prepared as the trifluoroacetate salt by substituting 5-bromooxindole for 6-bromophthalimide in Example 32. MS (APCI) m/e 399 ($M+H$)⁺; ¹H NMR (300 MHz, CD₃OD) δ 8.59 (s, 1H), 8.35 (s, 1H), 7.92 (s, 1H), 7.60 (d, J = 6.9 Hz, 1H), 7.58 (s, 1H), 7.55 (d, J = 10.1 Hz, 1H), 7.38 (d, J = 8.1 Hz, 1H), 7.24 (s, 1H), 7.13 (t, J = 7.6 Hz, 1H), 7.03 (d, J = 8.0 Hz, 1H), 7.03 (t, J = 7.5 Hz, 1H), 4.45 (dd, J = 10.5, 3.2 Hz, 1H), 4.31 (dd, J = 10.5, 5.8 Hz, 1H), 4.01 (m, 1H), 3.62 (s, 2H), 3.32 (m, 1H), 3.29 (m, 1H); Anal. Calcd for $C_{24}H_{22}N_4O_2 \cdot 2.5 TFA$: C, 50.96; H, 3.61; N, 8.20. Found: C, 50.96; H, 3.62; N, 8.12.

Example 37

(1S)-2-{[5-(2,1,3-benzoxadiazol-5-yl)pyridin-3-yl]oxy}-1-(1H-indol-3-ylmethyl)ethylamine

15 The desired product was prepared as the trifluoroacetate salt by substituting 5-chloro-2,1,3-benzoxadiazole for 6-bromophthalimide in Example 32. MS (APCI) m/e 386 ($M+H$)⁺; ¹H NMR (300 MHz, CD₃OD) δ 8.64 (s, 1H), 8.44 (s, 1H), 8.18 (s, 1H), 8.05 (d, J = 10.4 Hz, 1H), 7.81 (d, J = 10.9 Hz, 1H), 7.78 (s, 1H), 7.59 (d, J = 6.7 Hz, 1H), 7.37 (d, J = 7.1 Hz, 1H), 7.24 (s, 1H), 7.12 (t, J = 8.1 Hz, 1H), 7.03 (t, J = 6.9 Hz, 1H), 4.44 (dd, J = 10.5, 3.1 Hz, 1H), 4.29 (dd, J = 10.6, 5.8 Hz, 1H), 3.99 (m, 1H), 3.32 (s, 1H), 3.30 (s, 1H); Anal. Calcd for $C_{22}H_{19}N_5O_2 \cdot 2.45 TFA$: C, 48.60; H, 3.25; N, 10.53. Found: C, 48.68; H, 3.48; N, 10.58.

Example 38

(1S)-2-(1H-indol-3-yl)-1-{[(5-thieno[2,3-c]pyridin-2-yl)pyridin-3-yl]oxy}methyl}ethylamine

Example 38A

2-(trimethylstannyl)thieno[2,3-c]pyridine

25 A solution of thieno[2,3-c]pyridine (J. Wikel, et al., J. Heterocycl. Chem., 1993, 30, 289) (2.0 g, 14.8 mmol) in THF (50 mL) at -78 °C was treated with n-butyllithium (2.5 M solution in hexane, 7.1 mL, 17.8 mmol), warmed to 0 °C, stirred for 15 minutes, cooled to -78 °C, treated slowly with trimethyltin chloride (3.54 g, 17.8 mmol) in THF (10 mL), 30 warmed to room temperature for 2 hours, and partitioned between ethyl acetate and brine. The ethyl acetate solution was washed with water, and concentrated. The residue was purified by flash chromatography (10-35% ethyl acetate in hexane) to provide the desired product (3.15 g, 71%). MS (APCI) m/e 298 ($M+H$)⁺.

Example 38B

(1S)-2-(1H-indol-3-yl)-1-{[(5-thieno[2,3-c]pyridin-2-yl)pyridin-3-yl]oxy}methyl}ethylamine

The desired product was prepared as the trifluoroacetate by substituting Example 38A for Example 27A in Examples 27B and 27C. MS (APCI) m/e 402 (M+H)⁺; ¹H NMR (300 MHz, CD₃OD) δ 9.58 (s, 1H), 8.78 (s, 1H), 8.63 (d, J = 6.4 Hz, 1H), 8.49 (s, 1H), 8.36 (d, J = 6.4 Hz, 1H), 8.20 (s, 1H), 7.86 (s, 1H), 7.60 (d, J = 8.6 Hz, 1H), 7.38 (d, J = 8.1 Hz, 1H), 7.25 (s, 1H), 7.12 (t, J = 8.1 Hz, 1H), 7.03 (t, J = 7.5 Hz, 1H), 4.45 (dd, J = 10.6, 3.2 Hz, 1H), 4.30 (dd, J = 10.5, 5.7 Hz, 1H), 4.02 (m, 1H), 3.32 (s, 1H), 3.30 (s, 1H); Anal. Calcd for C₂₃H₂₀N₄OS·3.6 TFA: C, 44.73; H, 2.93; N, 6.91. Found: C, 44.74; H, 2.91; N, 6.77.

Example 39

(3Z)-5-{[(2S)-2-amino-3-(1H-indol-3-yl)propyl]oxy}pyridin-3-yl)-3-(1H-pyrrol-2-ylmethylene)-1,3-dihydro-2H-indol-2-one

The desired product was prepared by as the trifluoroacetate salt substituting 5-bromo-3-(1H-pyrrol-2-ylmethylene)-1,3-dihydro-indol-2-one for 6-bromophthalimide (L. Sun, et al., J. Med. Chem., 1998, 41, 2588.) in Example 32. MS (APCI) m/e 476 (M+H)⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 13.33 (br s, 1H), 11.05 (s, 1H), 11.04 (d, J = 6.5 Hz, 1H), 8.64 (s, 1H), 8.34 (s, 1H), 8.22 (br s, 2H), 8.09 (s, 1H), 7.91 (s, 1H), 7.74 (br s, 1H), 7.62 (d, J = 7.7 Hz, 1H), 7.51 (dd, J = 8.3 Hz, 1H), 7.40 (s, 1H), 7.38 (d, J = 8.3 Hz, 1H), 7.30 (d, J = 2.2 Hz, 1H), 7.1 (dd, J = 7.9 Hz, 1H), 7.01 (d, J = 7.7 Hz, 1H), 7.00 (d, J = 8.0 Hz, 1H), 6.85 (br s, 1H), 6.39 (s, 1H), 4.37 (dd, J = 12.00, 3.1 Hz, 1H), 4.20 (dd, J = 8.00, 6.0 Hz, 1H), 3.15–3.21 (m, 1H); Anal. Calcd for C₂₉H₂₅N₅O₂·2.6TFA: C, 53.21; H, 3.60; N, 9.07. Found: C, 53.36; H, 3.67; N, 8.92.

Example 40

6-(5-{[(2R)-2-amino-3-(1H-indol-3-yl)propyl]oxy}pyridin-3-yl)-1,3-benzothiazol-2(3H)-one

The desired product was prepared by substituting 6-bromo-2-benzothiazolinone for 6-bromophthalimide in Example 32. MS (APCI) m/e 417 (M+H)⁺; ¹H NMR (300 MHz, CD₃OD) δ 8.52 (s, 1H), 8.31 (d, J = 2.4 Hz, 1H), 7.77 (d, J = 1.7 Hz, 1H), 7.71 (t, J = 1.7 Hz, 1H), 7.59 (d, J = 7.8 Hz, 1H), 7.56 (dd, J = 6.0, 1.7 Hz, 1H), 7.39 (d, J = 8.2 Hz, 1H), 7.25 (d, J = 8.2 Hz, 1H), 7.23 (s, 1H), 7.14 (t, J = 7.2 Hz, 1H), 7.03 (t, J = 7.2 Hz, 1H), 4.41 (dd, J = 12.0, 3.4 Hz, 1H), 4.26 (dd, J = 9.0, 5.7 Hz, 1H), 3.97–4.02 (m, 1H); Anal. Calcd for C₂₃H₂₀N₄O₂·1.9 TFA: C, 50.84; H, 3.49; N, 8.85. Found: C, 51.22; H, 3.67; N, 8.49.

Example 41

2-(1H-indol-3-yl)-2-(5-isoquinolin-6-ylpyridin-3-yl)ethanamine

Example 41A

tert-butyl 3-(cyanomethyl)-1H-indole-1-carboxylate

A solution of 3-cyanomethylindole (7.50 g, 48 mmol), di-tert-butyl dicarbonate (11.5 g, 52.8 mmol), and DMAP (300 mg) in dichloromethane (200 mL) was stirred at room temperature overnight. The mixture was concentrated and the residue was purified by flash

column chromatography on silica gel with dichloromethane to provide the desired product (11.44 g, 93%). MS (DCI/NH₃) m/e 257 (M+H)⁺.

Example 41B

tert-butyl 3-[(5-bromopyridin-3-yl)(cyano)methyl]-1H-indole-1-carboxylate

5 A solution of Example 41A (5.46 g, 21.3 mmol) and 3,5-dibromopyridine (5.03 g, 21.3 mmol) in DMF (25 mL) at room temperature was treated with NaH (60% in mineral oil, 1.08 g, 25.6 mmol) in several portions. The reaction was stirred at room temperature for 20 minutes, heated to 60 °C for 2 hours, and poured into water. The aqueous layer was extracted with diethyl ether and the combined extracts were washed with water, dried (MgSO₄), 10 filtered, and concentrated. The residue was purified by flash column chromatography on silica gel with ethyl acetate/hexanes (1:7) to provide the desired product (336 mg, 4%). MS (DCI/NH₃) m/e 413 (M+H)⁺.

Example 41C

tert-butyl 3-[cyano(5-isoquinolin-6-ylpyridin-3-yl)methyl]-1H-indole-1-carboxylate

15 The desired product was prepared by substituting Example 41B for Example 2A in Example 27B. MS (DCI/NH₃) m/e 461 (M+H)⁺.

Example 41D

2-(1H-indol-3-yl)-2-(5-isoquinolin-6-ylpyridin-3-yl)ethanamine

20 A mixture of Example 41C (159 mg, 0.345 mmol), RaNi 2800 (525 mg), ammonia (2 mL), and triethylamine (2 mL) in methanol (20 mL) was stirred under hydrogen (60 psi) at room temperature for 73 hours and concentrated. The residue was triturated with ethyl acetate and methanol. The resulting solid was dissolved in trifluoroacetic acid (1 mL), stirred for 5 minutes at room temperature, and concentrated. The residue was purified by HPLC on a C18 column with 0-100% CH₃CN/H₂O/0.1 % TFA to provide the desired product as the trifluoroacetate salt (64 mg, 26%). MS (DCI/NH₃) m/e 365 (M+H)⁺; ¹H NMR (CD₃OD) δ 9.80 (s, 1H), 9.12 (br s, 1H), 8.87 (br s, 1H), 8.68 (s, 1H), 8.64 (m, 3H), 8.51 (d, J=6.6 Hz, 1H), 8.35 (dd, J=1.6, 8.4 Hz, 1H), 7.52 (d, J=8.1 Hz, 1H), 7.50 (s, 1H), 7.42 (d, J=8.4 Hz, 1H), 7.15 (m, 1H), 7.03 (m, 1H), 4.95 (t, J=7.8 Hz, 1H), 3.91 (m, 2H).

Example 42

2-(1H-indol-3-yl)-3-(5-isoquinolin-6-ylpyridin-3-yl)propan-1-amine

Example 42A

(2Z)-3-(5-bromopyridin-3-yl)-2-(1H-indol-3-yl)acrylonitrile

30 A solution of 3-cyanomethylindole (156 mg, 1.0 mmol) in anhydrous ethanol (1.5 mL) at room temperature was treated with 21% sodium ethoxide in ethanol (450 µL), stirred for 1 hour, treated with 3-bromopyridine-5-carboxaldehyde (J. Heterocycl. Chem., 1995, 32, 35 1801.) (187 mg, 1.0 mmol), stirred overnight, and concentrated. The residue was purified by

flash column chromatography on silica gel with 2% methanol/dichloromethane to provide the desired product (52 mg, 16%). MS (DCI/NH₃) m/e 325 (M+H)⁺.

Example 42B

2-(1H-indol-3-yl)-3-(5-isoquinolin-6-ylpyridin-3-yl)propan-1-amine

5 The desired product was prepared as the trifluoroacetate salt by substituting Example 42A for Example 41B in Examples 41C and 41D. MS (DCI/NH₃) m/e 379 (M+H)⁺; ¹H NMR (CD₃OD) δ 9.70 (s, 1H), 8.88 (s, 1H), 8.61 (d, J=6.6 Hz, 1H), 8.47 (m, 2H), 8.86 (d, J=6.6 Hz, 1H), 8.03 (s, 1H), 7.86 (s, 1H), 7.83 (dd, J=1.6, 8.4 Hz, 1H), 7.54 (d, J=7.8 Hz, 1H), 7.45 (d, J=8.1 Hz, 1H), 7.21 (s, 1H), 7.17 (m, 1H), 7.04 (m, 1H), 8.82 (m 1H), 3.61 (m, 2H), 3.36 (dd, J=4.1, 13.4 Hz, 1H), 3.30 (m, 1H).

10

Example 43

(1S)-2-(1H-indol-3-yl)-1-[(6-pyridin-4-ylquinolin-3-yl)oxy]methyl}ethylamine

Example 43A

6-bromo-3-hydroxyquinoline-4-carboxylic acid

15 A solution of 5-bromoisoatatin (2.26 g, 10 mmol) and potassium hydroxide (4.48 g, 80 mmol) in water (10 mL) was warmed until the materials were dissolved then cooled to room temperature, treated with bromopyruvic acid (2.3 g, 14 mmol), stirred for 6 days, adjusted to pH <7 with concentrated HCl, and filtered. The solid was washed with water and ethanol and dried to provide the desired product (1.5 g, 58%). MS (DCI/NH₃) m/e 269 (M+H)⁺.

20

Example 43B

6-bromo3-hydroxyquinoline

25

A solution of Example 43A (1.5 g, 5.6 mmol) in nitrobenzene (10 mL) was refluxed for 5 minutes, filtered, cooled to room temperature and filtered again. The solid was washed with hexanes and dried to provide the desired product (0.68g, 55%). MS (DCI/NH₃) m/e 225 (M+H)⁺.

Example 43C

tert-butyl (1S)-2-[(6-bromoquinolin-3-yl)oxy]-1-(1H-indol-3-ylmethyl)ethylcarbamate

30

The desired product was prepared by substituting Example 43B for 3-bromo-5-hydroxypyridine in Example 2A. Purification by flash column chromatography on silica gel with 100% ethyl acetate provided the desired product (0.89 g, 72%). MS (DCI/NH₃) m/e 497 (M+H)⁺.

Example 43D

tert-butyl (1S)-2-(1H-indol-3-yl)-1-[(6-pyridin-4-ylquinolin-3-yl)oxy]methyl}ethylcarbamate

35

A mixture of Example 43C (0.33 g, 0.67 mmol), pyridine-4-boronic acid (0.13 g, 0.99 mmol), cesium fluoride (0.2 g, 1.34 mmol) and tetrakis(triphenylphosphine) palladium (0.038 g, 0.034 mmol) in DMF (10 mL) was stirred at 100 °C for 8 hours, treated with ethyl acetate (10

mL), washed with brine, dried (MgSO_4), filtered, and concentrated. The concentrate was purified by flash column chromatography on silica gel with 10% methanol/dichloromethane to provide the desired product (0.25g, 76%). MS (DCI/ NH_3) m/e 495 ($\text{M}+\text{H}$)⁺.

Example 43E

5 (1S)-2-(1H-indol-3-yl)-1-{{[(6-pyridin-4-ylquinolin-3-yl)oxy]methyl}ethylamine

The desired product was prepared as the trifluoroacetate salt by substituting Example 43D for Example 27B in Example 27C. MS (DCI/ NH_3) m/e 395 ($\text{M}+\text{H}$)⁺; ^1H NMR (DMSO- d_6) δ 10.89 (s, 1H), 8.74 (d, $J=3.0$ Hz, 1H), 8.71 (d, $J=5.0$ Hz, 2H), 8.25 (s, 1H), 8.07 (d, $J=9.0$ Hz, 1H), 7.99 (d, $J=9.0$ Hz, 1H), 7.83 (d, $J=5.0$ Hz, 2H), 7.72 (d, $J=3.0$ Hz, 1H), 7.58 10 (d; $J=7.5$ Hz, 1H), 7.35 (d, $J=8.4$ Hz, 1H), 7.23 (s, 1H), 7.06 (t, $J=7.5$ Hz, 1H), 6.95 (t, $J=8.4$ Hz, 1H), 4.05 (m, 2H), 3.53 (m, 1H), 3.01 (dd, $J=6.3, 14.9$ Hz, 1H), 2.87 (dd, $J=6.9, 14.9$ Hz, 1H).

Example 44

15 (3Z)-3-[(2S)-2-amino-3-(1H-indol-3-yl)propylidene]-5-isoquinolin-6-yl-1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one

Example 44A

tert-butyl (1S,2Z)-2-(5-bromo-2-oxo-1,2-dihydro-3H-pyrrolo[2,3-b]pyridin-3-ylidene)-1-(1H-indol-3-ylmethyl)ethylcarbamate

A mixture of 5-bromo-7-aza-oxindole (D. Mazeas, et al., Heterocycles 1999, 50, 20 1065.) (213 mg, 1.0 mmol), L-BOC-tryptophanal (290 mg, 1.0 mmol) and piperidine (40 μL) in ethanol was refluxed for 2.5 hours and concentrated. The residue was triturated with dichloromethane (1 mL) and hexane (6 mL) and dried to provide the desired product (512 mg). MS (DCI/ NH_3) m/e 483, 485 ($\text{M}+\text{H}$)⁺.

Example 44B

25 (3Z)-3-[(2S)-2-amino-3-(1H-indol-3-yl)propylidene]-5-isoquinolin-6-yl-1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one

The desired product was prepared by substituting Example 44A (260 mg) for Example 2A in Example 27. MS (DCI/ NH_3) m/e 432 ($\text{M}+\text{H}$)⁺; ^1H NMR (CD₃OD) δ 9.57 (s, 1H), 8.64 (d, $J=2.5$ Hz, 1H), 8.52 (d, $J=7.6$ Hz, 1H), 8.26 (s, 1H), 8.24 (s, 1H), 8.08 (d, $J=6.4$ Hz, 1H), 7.64 (s, 1H), 7.60 (dd, $J=8.7, 1.7$ Hz, 1H), 7.55 (d, $J=6.6$ Hz, 1H); 7.54 (d, $J=7.1$ Hz, 1H), 7.33 (dd, $J=7.0, 1.1$ Hz, 1H), 7.29 (dd, $J=3.3, 1.3$ Hz, 1H), 7.26 (dd, $J=7.1, 0$ Hz, 1H), 6.26 (d, $J=2.2$ Hz, 1H), 4.20 (s, 1H), 3.94 (d, $J=6.8$ Hz, 1H), 3.61 (s, 1H), 2.78 (d, $J=14.7$ Hz, 1H), 2.68 (dd, $J=16.3, 6.9$ Hz, 1H). New Examples

35 Following the procedures described in Example 1, using the appropriate alcohols, the following compounds were made.

Example 453-Butoxyl-5-[2-(4-pyridinyl)vinyl]pyridine

MS (DCI/NH₃) m/e 255 (M+1). ¹H NMR (DMSO-d6): δ 8.58 (d; *J*=6.0 Hz, 1H), 8.39 (s; 1H), 8.22 (s; 1H), 7.70 (s; 1H), 7.56 (d; *J*=6.0 Hz, 1H), 7.56 (d, *J*=16.5 Hz, 1H), 7.45 (d; *J*=16.5 Hz, 2H), 4.12 (t; *J*=8.6 Hz, 3H), 1.74 (m; 2H), 1.47 (m; 2H), 0.96 (t; *J*=8.6 Hz, 2H).

Example 463-Methoxyl-5-[2-(4-pyridinyl)vinyl]pyridine

10 MS (DCI/NH₃) m/e 213 (M+1). ¹H NMR (DMSO-d6): δ ppm 8.58 (m, 2 H), 8.41 (d, *J*=1.7 Hz, 1 H), 8.24 (d, *J*=2.7 Hz, 1 H), 7.71 (m, 1 H) 7.57 (m, 3 H), 7.47 (d, *J*=16.5 Hz, 1H), 3.89 (s, 3 H).

Example 47S-3-[2-Amino-3-phenyl-propyloxy]-5-[2-(4-pyridinyl)vinyl]pyridine hydrochloride

15 MS (DCI/NH₃) m/e 332 (M+1). ¹H NMR (DMSO-d6): δ 8.58 (d; *J*=6.0 Hz, 2H), 8.40 (s; 1H), 8.25 (s; 1H), 7.69 (s; 1H), 7.56 (d; *J*=6.0 Hz, 1H), 7.56 (d; *J*=16.5 Hz, 1H), 7.43 (d; *J*=16.5 Hz, 1H), 7.26 (m; 5H), 3.94 (m; 2H), 3.28 (m; 1H), 2.87 (dd; *J*=6.0 Hz and 13.5 Hz, 1H), 2.65 (dd; *J*=9 Hz, 13.5 Hz, 1H).

Example 483-[2-(1H-3-Indolyl)-ethoxy]-5-[2-(4-pyridinyl)vinyl]pyridine hydrochloride

25 MS (DCI/NH₃): m/z 342 (M+1). ¹H NMR (DMSO-d6): δ 10.39 (br s, 1H), 8.60 (d, *J*=6.6 Hz, 2H), 8.38 (d, *J*=2.5 Hz, 1H), 8.25 (d, *J*=3.3 Hz, 1H), 7.72 (dd, *J*=2.5, 3.3 Hz, 1H), 7.62 (d, *J*=8.5 Hz, 1H), 7.55 (d, *J*=17.4 Hz, 1H), 7.36 (d, *J*=8.1 Hz, 1H), 7.54 (d, *J*=6.6 Hz, 2H), 7.28 (d, *J*=3.3 Hz, 1H), 4.36 (t, *J*=7.5 Hz, 2H), 3.11 (t, *J*=3.11 Hz, 2H).

Example 493-[2-(1H-3-Indolyl)-propyloxy]-5-[2-(4-pyridinyl)vinyl]pyridine

30 MS (DCI/NH₃): m/z 356 (M+1). ¹H NMR (DMSO-d6): δ 10.79 (br s, 1H), 8.57 (m, 2H), 8.39 (d, *J*=1.7 Hz, 1H), 8.25 (d, *J*=3.1 Hz, 1H), 7.69 (t, *J*=2.0 Hz, 1H), 7.56 (m, 2H), 7.55 (d, *J*=16.6 Hz, 1H), 7.52 (m, 1H), 7.43 (d, *J*=16.6 Hz, 1H), 7.33 (d, *J*=8.1 Hz, 1H), 7.15 (d, *J*=2.4 Hz, 1H), 7.06 (m, 1H), 6.96 (m, 1H), 4.16 (t, *J*=6.5 Hz, 2H), 2.89 (t, *J*=8.1 Hz, 2H), 2.14 (m, 2H).

Example 50S-3-[2-Amino-3-(4-benzyloxyphenyl)-propyloxy]-5-[2-(4-pyridinyl)vinyl]pyridine hydrochloride

5 MS (DCI/NH₃): m/z 438 (M+1). ¹H NMR (DMSO-d6): δ 10.04 (br s, 3H), 8.86 (d, *J*=7.5 Hz, 2H), 8.54 (s, 1H), 8.39 (d, *J*=3.3 Hz, 1H), 8.13 (d, *J*=7.5 Hz, 2H), 7.98 (d, *J*=17.4 Hz, 1H), 7.88 (m, 1H), 7.73 (d, *J*=17.4 Hz, 1H), 7.39 (m, 5 H), 7.24 (d, *J*=9.0 Hz, 2H), 6.99 (d, *J*=9.0 Hz, 2H), 4.28 (dd, *J*=3.9, 11.5 Hz, 1H), 5.07 (s, 2H), 4.12 (dd, *J*=6.5, 11.5 Hz, 1H), 3.29 (m, 1H), 3.05 (m, 2H).

10

Example 513-(Piperidin-4-yl)-5-[2-(4-pyridinyl)vinyl]pyridine

15 MS (DCI/NH₃): m/z 282 (M+1). ¹H NMR (DMSO-d6): δ 8.55 (m, 2H), 8.34 (d, *J*=1.7 Hz, 1H), 8.18 (d, *J*=2.7 Hz, 1H), 7.72 (m, 1H), 7.62 (m, 2H), 7.52 (d, *J*=16.3 Hz, 1H), 7.35 (d, *J*=16.3 Hz, 1H), 4.66 (m, 1H), 3.10 (m, 2H), 2.78 (m, 2H), 2.06 (m, 2H), 1.70 (m, 2H).

20

Example 52R-3-{2-Amino-3-benzyloxypropyloxy}-5-[2-(4-pyridinyl)vinyl]pyridine hydrochloride

25 MS (DCI/NH₃): m/z 362 (M+1). ¹H NMR (CD₃CD): δ 8.84 (m, 2H), 8.81 (m, 1H), 8.58 (m, 1H), 8.53 (m, 1H), 8.32 (m, 2H), 7.98 (d, *J*=16.3 Hz, 1H), 7.87 (d, *J*=16.3 Hz, 1H), 7.35 (m, 5H), 4.66 (s, 2H), 3.95 (m, 2H), 3.85 (m, 1H).

30

Example 533-(1-Methyl-imidazole-4-methoxyl)-5-[2-(4-pyridinyl)vinyl]pyridine

MS (DCI/NH₃): m/z 393 (M+1). ¹H NMR (CD₃OD): δ 8.52 (m, 2H), 8.39 (d, *J*=1.6 Hz, 1H), 8.27 (d, *J*=2.5 Hz, 1H), 7.84 (m, 1H), 7.69 (s, 1H), 7.62 (m, 2H), 7.53 (d, *J*=16.5 Hz, 1H), 7.88 (d, *J*=16.5 Hz, 1H), 7.15 (s, 1H), 5.29 (s, 2H), 3.78 (s, 3H).

35

Example 54S-3-{2-Amino-3-[3-hydroxylphenyl]-propyloxy}-5-[2-(4-pyridinyl)vinyl]pyridine trifluoroacetic acid salt

MS (DCI/NH₃): m/z 348 (M+1). ¹H NMR (DMSO-d6): δ 8.84 (d, *J*=6.8 Hz, 2H), 8.54 (m, 1H), 8.37 (d, *J*=2.7 Hz, 1H), 8.06 (d, *J*=6.8 Hz, 2H), 7.91 (m, *J*=16.6 Hz, 1H), 7.62 (d, *J*=16.6 Hz, 1H), 7.09 (d, *J*=8.5 Hz, 2H), 6.73 (d, *J*=8.5 Hz, 2H), 4.22 (dd, *J*=3.1, 10.5 Hz, 1H), 4.06 (dd, *J*=5.4, 10.5 Hz, 1H), 3.77 (m, 1H), 2.93 (m, 2H).

Example 55S-3-[2-Amino-3-[3-cyanophenyl]-propyloxy]-5-[2-(4-pyridinyl)vinyl]pyridine hydrochloride salt

5 MS (DCI/NH₃): m/z 357 (M+1). ¹H NMR (DMSO-d6): δ 8.92 (d, J=6.4 Hz, 2H), 8.66 (s, 1H), 8.49 (d, J=1.8 Hz, 1H), 8.21 (d, J=6.4 Hz, 2H), 8.13 (s, 1H), 8.06 (d, J=16.5 Hz, 1H), 7.90 (d, J=16.5 Hz, 1H), 7.83 (d, J=8.2 Hz, 2H), 7.59 (d, J=8.2 Hz, 2H), 4.40 (dd, J=3.4, 10.7 Hz, 1H), 4.24 (dd, J=5.8, 10.7 Hz, 1H), 3.91 (m, 1H), 3.29 (dd, J=6.1, 13.7 Hz, 1H), 3.16 (dd, J=8.5, 13.7 Hz, 1H).

10

Example 563-[1-(4-Cyanobenzyl)-imidazole-4-methoxy]-5-[2-(4-pyridinyl)vinyl]pyridine

15 MS (DCI/NH₃): m/z 394 (M+1). ¹HNMR (CD₃OD) δ 8.51 (d, J=6.1 Hz, 2H), 8.33 (d, J=1.5 Hz, 1H), 7.94 (d, J=2.5 Hz, 1H), 7.93 (s, 1H), 7.67 (d, J=8.2 Hz, 2H), 7.62 (d, J=6.1 Hz, 2H), 7.48 (m, 1H), 7.47 (d, J=16.5 Hz, 1H), 7.30 (d, J=16.5 Hz, 1H), 7.27 (s, 1H), 7.25 (d, J=8.2 Hz, 2H), 5.47 (s, 2H), 5.26 (s, 2H).

20

Example 57S-3-[2-Amino-3-(1-methyl-1H-3-indolyl)-propyloxy]-5-[2-(4-pyridinyl)vinyl]pyridine hydrochloride salt

25 MS (DCI/NH₃): m/z 385 (M+1). ¹HNMR (CD₃OD) δ 8.87 (d, J=6.8 Hz, 2H), 8.55 (s, 1H), 8.41 (d, J=2.7 Hz, 1H), 8.13 (d, J=6.8 Hz, 2H), 7.96 (d, J=6.8 Hz, 2H), 7.96 (d, J=16.6 Hz, 1H), 7.86 (m, 1H), 7.71 (d, J=16.6 Hz, 1H), 7.65 (d, J=8.1 Hz, 1H), 7.42 (d, J=8.1 Hz, 1H), 7.29 (s, 1H), 7.17 (m, 1H), 7.04 (m, 1H), 4.84 (dd, J=3.4, 10.5 Hz, 1H), 4.21 (dd, J=5.8, 10.5 Hz, 1H), 3.90 (m, 1H), 3.19 (m, 2H), 3.17 (s, 3H).

30

Example 58S-3-[2-Dimethylamino-3-(1H-3-indolyl)-propyloxy]-5-[2-(4-pyridinyl)vinyl]pyridine hydrochloride salt

35 MS (DCI/NH₃): m/z 399 (M+1). ¹HNMR (DMSO-d6) δ 8.88 (d, J=6.6 Hz, 2H), 8.58 (s, 1H), 8.45 (s, 1H), 8.16 (d, J=6.6 Hz, 2H), 7.96 (d, J=16.5 Hz, 1H), 7.95 (s, 1H), 7.76 (d, J=16.5 Hz, 1H), 7.74 (d, J=7.8 Hz, 1H), 7.35 (d, J=8.1 Hz, 1H), 7.29 (d, J=2.2 Hz, 1H), 7.07 (m, 1H), 6.97 (m, 1H), 4.54 (dd, J=1.6, 11.9 Hz), 4.35 (dd, J=5.0, 11.9 Hz, 1H), 3.95 (m, 1H), 3.51 (dd, J=3.1, 13.7 Hz, 1H), 3.29 (dd, J=11.5, 13.7 Hz, 1H), 2.96 (s, 6H).

Example 59S-3-[2-Amino-3-(1-naphthyl)-propyloxy]-5-[2-(4-pyridinyl)vinyl]pyridine hydrochloride saltMS (DCI/NH₃): m/z 382 (M+1). ¹H NMR (DMSO-d₆) δ 8.66 (d; J=6.1 Hz, 2H), 8.48 (d,

5 J=1.4 Hz, 1H), 8.32 (d, J=2.7 Hz, 1H), 8.20 (m, 1H), 7.98 (m, 1H), 7.90 (m, 1H), 7.69 (m, 3H), 7.60 (m, 3H), 7.46 m, 3H), 4.25 (dd, J=2.7, 10.5 Hz, 1H), 4.09 (dd, J=5.1, 10.5 Hz, 1H), 3.92 (m, 1H), 3.53 (m, 2H).

10

Example 603-(2-Aminoethoxy)-5-[2-(4-pyridinyl)vinyl]pyridine hydrochloride saltMS (DCI/NH₃) m/e 242 (M+1). ¹H NMR (CD₃OD): δ 8.88 (d, J=6.1 Hz, 2H), 8.59 (s, 1H), 8.43 (s, 1H), 8.19 (d, J=6.1 Hz, 2H), 8.03 (d, J=16.3 Hz, 1H), 8.01 (s, 1H), 7.82 (d, J=16.3 Hz, 1H), 4.42 (t, J=4.9 Hz, 2H), 3.28 (m, 2H).

15

Example 613-(3-Aminopropoxy)-5-[2-(4-pyridinyl)vinyl]pyridine hydrochloride saltMS (DCI/NH₃) m/e 256 (M+1). ¹H NMR (DMSO-d₆): δ 8.88 (d; J=6.4 Hz, 2H), 8.53 (d; J=1.4 Hz, 1H), 8.40 (d, J=2.7 Hz, 1H), 8.15 (d, J=6.4 Hz, 2H), 8.00 (d, J=16.6 Hz, 1H), 7.93 (m, 1H), 7.78 (d, J=16.6 Hz, 1H), 4.27 (t, J=6.1 Hz, 2H), 2.99 (m, 2H), 2.10 m(m, 2H).

25

Example 62S-3-(2-Amino3-methylbutyloxy)-5-[2-(4-pyridinyl)vinyl]pyridine hydrochloride saltMS (DCI/NH₃) m/e 284 (M+1). ¹H NMR (DMSO-d₆): δ 8.85 (d; J=6.5 Hz, 2H), 8.54 (d; J=1.4 Hz, 1H), 8.40 (d, J=3.1 Hz, 1H), 8.09 (d, J=6.5 Hz, 2H), 7.95 (d, J=16.3 Hz, 1H), 7.90 (m, 1H), 7.71 (d, J=16.3 Hz, 1H), 4.39 (m, 1H), 4.24 (m, 1H), 3.08 (m, 1H), 2.10 (m, 1H), 1.06 (d, J=8.1 Hz, 3H), 1.03 (d, J=7.8 Hz, 3H).

30

Example 633-(1-Methyl-3-piperidinyloxy)-5-[2-(4-pyridinyl)vinyl]pyridine trifluoroacetic acid saltMS (DCI/NH₃) m/z 296 (M+H). ¹H NMR (DMSO-d₆): δ 8.82 (d, 2H), 8.53 (s, 1H), 8.41 (d, 1H), 8.00 (t, 2H), 7.88 (dd, 2H), 7.59 (dd, 2H), 4.53 (dd, 1H), 4.37 (dd, 1H), 3.89 (bs, 1H), 3.64 (bs, 1H), 3.24-3.13 (m, 1H), 3.01 (s, 3H), 2.35-2.28 (m, 1H), 2.13-2.07 (m, 1H), 2.02-1.93 (m, 1H), 1.90-1.83 (m, 1H).

Example 643-(2-Chlorobenzyl)-5-[2-(4-pyridinyl)vinyl]pyridine trifluoroacetic acid salt

5 MS (DCI/NH₃) m/z 323 (M+H). ¹H NMR (DMSO-d₆): δ 8.84 (d, 2H), 8.53 (s, 1H), 8.44 (d, 1H), 8.07 (d, 2H), 7.96-7.92 (m, 2H), 7.70-7.67 (m, 2H), 7.57-7.55 (m, 1H), 7.46-7.43 (m, 2H), 5.33 (s, 2H).

6

Example 653-(N-Benzyl-N-methylaminoethoxy)-5-[2-(4-pyridinyl)vinyl]pyridine trifluoroacetic acid salt

10 MS (DCI/NH₃) m/z 346 (M+H). ¹H NMR (DMSO-d₆): δ 8.80 (d, 2H), 8.53 (s, 1H), 8.37 (d, 1H), 7.98 (d, 2H), 7.87 (d, 1H), 7.81 (s, 1H), 7.60 (d, 1H), 7.58-7.47 (m, 5H), 4.58-4.50 (m, 15 2H), 3.59-3.56 (m, 2H), 2.85 (s, 3H), 2.79 (t, 2H).

Example 663-(6-(N,N-Dimethylamino)hexyloxy)-5-[2-(4-pyridinyl)vinyl]pyridine trifluoroacetic acid salt

20 MS (DCI/NH₃) m/z 326 (M+H). ¹H NMR (DMSO-d₆): δ 8.82 (d, 2H), 8.49 (d, 1H), 8.33 (d, 1H), 8.04 (d, 2H), 7.89 (d, 1H), 7.80 (t, 1H), 7.66 (d, 1H), 4.14 (t, 2H), 3.06-3.02 (m, 2H), 2.78 (s, 3H), 2.77 (s, 3H), 1.82-1.76 (m, 2H), 1.68-1.62 (m, 2H), 1.51-1.45 (m, 2H), 1.40-1.34 (m, 2H).

Example 673-(2-Thiophenoxy-ethoxy)-5-[2-(4-pyridinyl)vinyl]pyridine trifluoroacetic acid salt

25 MS (DCI/NH₃) m/z 335 (M+H). ¹H NMR (DMSO-d₆): δ 8.76 (d, 2H), 8.46 (s, 1H), 8.27 (d, 1H), 7.93 (d, 1H), 7.80 (d, 1H), 7.77-7.74 (m, 2H), 7.59 (d, 1H), 7.43-7.42 (m, 1H), 7.36-7.31 (m, 3H), 7.24-7.16 (m, 1H), 4.33 (t, 2H), 3.43 (t, 2H).

30

Example 683-(1-Methyl-3-pyrrolidinylloxy)-5-[2-(4-pyridinyl)vinyl]pyridine trifluoroacetic acid salt

35 MS (DCI/NH₃) m/z 282 (M+H). ¹H NMR (DMSO-d₆): δ 8.75 (d, 2H), 8.52 (s, 1H), 8.31 (d, 1H), 7.88 (d, 2H), 7.80-7.77 (m, 2H), 7.57 (d, 1H), 5.36-5.30 (m, 1H), 3.46-3.39 (m, 1H), 3.23-3.15 (m, 1H), 2.97-2.95 (m, 1H), 2.91 (s, 3H), 2.73-2.63 (m, 1H), 2.36-2.25 (m, 1H), 2.17-2.09 (m, 1H).

Example 693-[(1-Methyl-2-piperidinyl)methoxyl]-5-[2-(4-pyridinyl)vinyl]pyridine trifluoroacetic acid salt

5

MS (DCI/NH₃) m/z 310 (M+H). ¹H NMR (DMSO-d₆): δ 8.81 (d, 2H), 8.54-8.53 (m, 1H), 8.40-8.38 (m, 1H), 8.01-7.99 (m, 2H), 7.91-7.85 (m, 2H), 7.64-7.59 (m, 1H), 4.55-4.52 (m, 1H), 4.38-4.31 (m, 1H), 3.71-3.62 (m, 1H), 3.55-3.45 (m, 1H), 3.35-3.23 (m, 1H), 2.91 (s, 10 3H), 2.88 (dt, 1H), 2.10-1.52 (m, 5H).

Example 703-(1-Pyridinyl-ethoxyl)-5-[2-(4-pyridinyl)vinyl]pyridine trifluoroacetic acid salt

15 MS (DCI/NH₃) m/z 304 (M+H). ¹H NMR (DMSO-d₆) δ 8.81 (d, 2H), 8.73 (d, 2H), 8.48 (s, 1H), 8.34 (d, 1H), 8.01 (d, 1H), 7.85-7.81 (m, 2H), 7.74 (d, 2H), 7.57 (d, 1H), 5.89 (q, 1H), 1.65 (d, 3H).

Example 714-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxyl]pyridin-3-yl}-N-hydroxyl-benzamidine trifluoroacetic acid saltExample 71A

25 4-{5-[(2S)-2-BOCamino-3-(1H-indol-3-yl)-propoxyl]pyridin-3-yl}-N-hydroxyl-benzamidine
To a solution of Example 22 (200 mg, 0.43 mmol) in toluene (7.0 ml) and methanol (0.5 ml) were added hydroxylamine hydrochloride (33 mg, 0.48 mmol) and potassium tert-butoxide (54 mg, 0.48 mmol) and the mixture was stirred for 8 h at room temperature under a nitrogen atmosphere. Another portion of hydroxylamine hydrochloride (33 mg, 0.48 mmol) and 30 potassium tert-butoxide (54 mg, 0.48 mmol) was added and the mixture was heated to 80 °C for 16 h. The mixture was concentrated and purified by column chromatography on silica gel using dichloromethane/methanol (15:1) as solvent system. Obtained were 130 mg (61 %) of the product as a white powder.

MS (DCI/NH₃) m/z 487 (M-OH+2H).

35

Example 71B.

4-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-N-hydroxyl-benzamidine trifluoroacetic acid salt

The desired product was prepared by substituting Example 71A for Example 22A in example 22B. MS (DCI/NH₃) m/z 369 (M-NHOH). ¹H NMR (DMSO-d₆) δ 11.02 (s, 1H), 8.63 (d, 1H), 8.40 (d, 1H), 8.23 (bs, 2H), 8.01-7.91 (m, 2H), 7.85-7.79 (m, 2H), 7.71 (t, 1H), 7.62 (d, 1H), 7.38 (d, 1H), 7.29 (d, 1H), 7.10 (t, 1H), 7.01 (q, 1H), 4.35 (dd, 1H), 4.19 (dd, 1H), 3.85-3.82 (m, 1H), 3.16 (m, 2H).

10

Example 72

4-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-benzamidine trifluoroacetic acid salt

Example 72 A

4-[(2S)-2-BOC-amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-benzamidine

To a solution of the product of Example 71 (110 mg, 0.22 mmol) in glacial acetic acid (5.0 ml) was added acetic anhydride (0.15 ml, 1.6 mmol) and the mixture was stirred for 2 h at ambient temperature. The acetic anhydride was hydrolyzed by addition of water (0.1 ml), 10 % palladium on charcoal (25 mg) was added and the mixture was stirred vigorously under a hydrogen atmosphere (1 atm.) for 4 h. The mixture was filtered through a pad of diatomaceous earth (Celite[®]) and the filtercake was washed with acetic acid. The combined filtrates were evaporated in high vacuum and the residue was triturated with ethyl acetate to give 80 mg (39 %) of the product as a beige powder.

MS (DCI/NH₃) m/z 486 (M+H). ¹H NMR (DMSO-d₆): δ 10.93 (s, 1H), 8.56 (s, 1H), 8.32 (d, 1H), 7.93-7.88 (m, 4H), 7.66 (s, 1H), 7.57 (d, 1H), 7.34 (d, 1H), 7.17 (s, 1H), 7.07-7.05 (m, 2H), 6.96 (t, 1H), 4.17-4.11 (m, 2H), 4.09-4.05 (m, 1H), 3.00 (dd, 1H), 2.92 (dd, 1H), 1.36 (s, 9H).

Example 72B

4-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-benzamidine trifluoroacetic acid salt

The desired product was prepared by substituting Example 72A for Example 22A in Example 22B. MS (DCI/NH₃) m/z 386 (M+H). ¹H NMR (DMSO-d₆): δ 11.03 (s, 1H), 9.38 (s, 2H), 9.24 (s, 2H), 8.65 (d, 1H), 8.42 (d, 1H), 8.25 (bs, 2H), 8.00-7.94 (m, 4H), 7.74 (t, 1H), 7.62 (d, 1H), 7.38 (d, 1H), 7.29 (d, 1H), 7.10 (t, 1H), 7.01 (t, 1H), 4.36 (dd, 1H), 4.20 (dd, 1H), 3.90-3.82 (m, 1H), 3.17 (m, 2H).

Example 733-[(2S)-2-Amino-3-(1H-3-indolyl)-propyloxy]-6-(3-pyridinyl)-quinoline

The desired product was prepared by substituting pyridine-3-boronic acid for pyridine-4-boronic acid in Example 43. MS (DCI/NH₃) m/e 395 (M+1). ¹H NMR (DMSO-d6): δ 10.89 (s; 1H), 9.02 (s; 1H), 8.72 (d; J =3.0 Hz, 1H), 8.62 (d; J =5.0 Hz, 1H), 8.20 (d; J =7.5 Hz, 1H), 8.15 (s; 1H), 8.06 (d; J =9.0 Hz, 1H), 7.95 (d; J =9.0 Hz, 1H), 7.70 (s; 1H), 7.59 (d; J =6.0 Hz, 1H), 7.57 (m; 1H), 7.35 (d; J =8.4 Hz, 1H), 7.22 (s; 1H), 7.06 (t; J =7.5 Hz, 1H), 6.95 (t; J =7.5 Hz, 1H), 4.05 (m; 2H), 3.53 (m; 1H), 3.01 (dd; J =6.3, 14.9 Hz, 1H), 2.87 (dd; J =6.9, 14.9 Hz, 1H).

Example 743-[(2S)-2-Amino-3-(1H-3-indolyl)-propyloxy]-6-(3-quinolinyl)-quinoline

The desired product was prepared by substituting quinoline-3-boronic acid for pyridine-4-boronic acid in Example 43. MS (DCI/NH₃) m/e 445 (M+1). ¹H NMR (DMSO-d6): δ 0.89 (s; 1H), 9.49 (s; 1H), 8.80 (s; 1H), 8.74 (s; 1H), 8.31 (s; 1H), 8.10 (m; 4H), 7.82 (t; J =6.6 Hz, 1H), 7.73 (s; 1H), 7.69 (t; J =6.6 Hz, 1H), 7.49 (d; J =8.4 Hz, 1H), 7.35 (d; J =8.4 Hz, 1H), 7.23 (s; 1H), 7.06 (t; J =7.5 Hz, 1H), 6.95 (t; J =7.5 Hz, 1H), 4.05 (m; 2H), 3.52 (m; 1H), 3.01 (dd; J =6.3, 14.9 Hz, 1H), 2.87 (dd; J =6.9, 14.9 Hz, 1H).

Example 753-[(2S)-2-Amino-3-(1H-3-indolyl)-propyloxy]-5-[2-(2-amino-4-pyridinyl)vinyl]pyridine trifluoroacetic acid saltExample 75A2-Amino-4-iodopyridine

A mixture of 2-fluoro-4-iodopyridine (3.0 g, 13.5 mmol), acetyl amide (15.8 g, 269 mmol) and potassium carbonate (9.2 g, 67 mmol) was stirred at 180 °C for 7 hours, poured into ice (100 g), extracted with ethyl acetate, washed with brine, dried (MgSO₄), filtered, and concentrated. The concentrate was purified by flash column chromatography on silica gel with 50% ethyl acetate/hexane to provide the title compound (1.1 g, 37%). MS (DCI/NH₃) m/e 221 (M+H).

Example 75BN,N-Bis(tert-butyloxycarbonyl)amino-4-iodopyridine

A solution of the product from Example 75A above (1.0 g, 4.5mmol) in THF (25 mL) was treated dropwise with 1.0M LiHMDS (9.0 mL, 9.0 mmol), stirred for 30 minutes, treated with di-*t*-butyl dicarbonate(1.96 g, 9.0 mmol) and stirred for 1 hour. The mixture was quenched with water (10 mL), warmed to room temperature and extracted with ethyl acetate. The 5 combined extracts were washed with brine, dried (MgSO_4), filtered, and concentrated. The concentrate was triturated with 1:1 hexanes/ethyl acetate to provide the desired product (1.0 g, 53%). MS (DCI/ NH_3) m/z 421 (M+H).

Example 75C

N,N-Bis(*tert*-butyloxycarbonyl)amino-4-vinylpyridine

10 A mixture of the product from Example 75B above (0.7 g, 1.67 mmol), vinyltributyltin (0.83 g, 2.6 mmol) and tetrakis-(triphenylphosphine)-palladium(0) (0.12 g, 0.11 mmol) was heated at 100 °C for 6 hours, cooled to room temperature, treated with ethyl acetate (10 mL), washed with brine, dried (MgSO_4), filtered, and concentrated. The concentrate was purified by flash 15 column chromatography on silica gel with 20% ethyl acetate/hexane to provide the title compound (0.4g, 75%). MS (DCI/ NH_3) m/e 321 (M+H).

Example 75D

3-[(2*S*)-2-(*N*-*tert*-Butoxycarbonyl)amino-3-(1*H*-3-indolyl)-propyloxy]-5-{2-[2-(*N,N*-bis(*tert*-butoxycarbonyl)amino]-4-pyridinyl}vinyl}pyridine

20 The desired product was prepared by substituting Example 75C for 4-vinylpyridine in Example 2B. Purification on silica gel eluting with 100% ethyl acetate provided the title compound (0.15 g, 49%). MS (DCI/ NH_3) m/e 685 (M+H).

Example 75E

4-(2-{5-[(2*S*)-2-Amino-3-(1*H*-indol-3-yl)-propoxy]-pyridin-3-yl}-vinyl)-pyridin-2-ylamine

The desired product was prepared by substituting Example 75D for Example 2B in Example 2C. Purification on HPLC provided the title compound (0.06g, 70%).

MS (DCI/ NH_3) m/e 386 (M+1). ^1H NMR (DMSO-d6): δ 11.05 (s; 1H), 8.50 (s; 1H), 8.35 (s; 1H), 8.23 (bs; 2H), 8.13 (bs; 2H), 7.95 (d; J =6.3 Hz, 1H), 7.72 (s; 1H), 7.65 (d; J =15.9 Hz, 1H), 7.61 (d; J =6.3 Hz), 7.42 (d; J =15.9 Hz, 1H), 7.38 (d; J =6.9 Hz, 1H), 7.28 (s; 1H), 7.18 (d; J =6.9 Hz, 1H), 7.10 (t; J =6.9 Hz, 1H), 7.00 (t; J =6.9 Hz, 1H), 6.93 (s; 1H), 4.29 (m; 1H), 4.14 (m; 1H), 3.87 (m; 1H), 3.17 (m; 2H).

Example 765-[(2S)-2-(Amino-3-(1H-3-indolyl)-propyloxy]-3-[2-(2-amino-4-pyridinyl)vinyl]-2-chloro-pyridine trifluoroacetic acid salt

The desired product was prepared by substituting 3-bromo-2-chloro-5-hydroxypyridine for 5-bromo-5-hydroxypyridine in Example 75. MS (DCI/NH₃) m/e 420 (M+1). ¹H NMR (DMSO-d6): δ 11.05 (s; 1H), 8.21 (s; 1H), 8.21 (bs; 2H), 8.04 (bs; 2H), 7.95 (d; J =6.3 Hz, 1H), 7.93 (s; 1H), 7.61 (d; J =6.3 Hz, 1H), 7.58 (d; J =15.9 Hz, 1H), 7.39 (d; J =15.9 Hz, 1H), 7.39 (d; J =6.9 Hz, 1H), 7.28 (s; 1H), 7.18 (d; J =6.9 Hz, 1H), 7.10 (t; J =6.9 Hz, 1H), 7.00 (t; J =6.9 Hz, 1H), 6.99 (s; 1H), 4.32 (m; 1H), 4.16 (m; 1H), 3.87 (m; 1H), 3.17 (m; 2H).

10

Example 77(1S)-1-(1H-Indol-3-ylmethyl)-2-(5-naphthalen-2-yl-pyridin-3-yloxy)-ethylamine

The desired product was prepared by substituting 2-bromonaphthalene for 6-

15 bromoisooquinoline in Example 27. ¹H NMR (d₆-DMSO, 500 MHz) δ : 11.02 (s, 1H), 8.74 (s, 1H), 8.38 (s, 1H), 8.30 (s, 1H), 8.18-8.21 (m, 2H), 8.04 (d, J =8 Hz, 1H), 7.97-8.01 (m, 2H), 8.85 (d, J =8 Hz, 1H), 7.81 (s, 1H), 7.62 (d, J =8 Hz, 1H), 7.50-7.58 (m, 1H), 7.35-7.39 (m, 1H), 7.23-7.31 (m, 1H), 7.08-7.12 (m, 1H), 6.96-7.03 (m, 2H), 4.18-4.41 (m, 2H), 3.82-3.87 (m, 1H), 3.17-3.21 (m, 2H).

20 MS: (ESI) (M + H)⁺ m/z = 394Example 78(1S)-1-(1H-Indol-3-ylmethyl)-2-(5-isoquinolin-5-yl-pyridin-3-yloxy)-ethylamine

25

Example 78A5-Bromoisoquinoline

To a solution of 5-aminoisoquinoline (2.0 g, 13.8 mmol) and 48% HBr (6 mL) in 20 mL water cooled to 0 °C was added a solution of sodium nitrite (0.95 g, 13.8 mmol) in 6 mL water. The solution was stirred at 0 °C for 20 minutes. The solution, while kept at 0 °C, was 30 added to a solution of CuBr (2.11 g, 15.9 mmol) in 48% HBr (4.77 mL) and water (10 mL). The reaction was stirred at room temperature for an additional 1 hr. The reaction was neutralized with NaOH (50%) and extracted with ethyl acetate (3X). The combined organic layer was concentrated *in vacuo* and chromatographed using 1:1 hexanes/ethyl acetate to yield 1.4 g product (50%).

35

Example 78B(1S)-1-(1H-Indol-3-ylmethyl)-2-(5-isoquinolin-5-yl-pyridin-3-yloxy)-ethylamine

The desired product was prepared by substituting Example 78A for 6-bromoisoquinoline in Example 27. MS (ESI) m/z 395 (M + H)⁺; ¹H NMR (d₆-DMSO, 300 MHz) δ 11.02 (bs, 1H), 9.53 (s, 1H), 8.52 (d, J=8 Hz, 1H), 8.49 (d, J=4 Hz, 1H), 8.37 (d, J=3 Hz, 1H), 8.30-8.34 (m, 1H), 8.15-8.19 (m, 2H), 7.84-7.88 (m, 2H), 7.68 (d, J=8 Hz, 1H), 7.56-7.60 (m, 2H), 7.47 (d, J=8 Hz, 1H), 7.28 (d, J=4 Hz, 1H), 7.60-7.12 (m, 1H), 6.94-6.99 (m, 1H), 4.12-4.32 (m, 2H), 3.82-3.87 (m, 1H), 3.13-3.17 (m, 2H).

Example 79

6-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-2H-isoquinolin-1-one

The desired product was prepared by substituting 2-hydroxylisoquinoline for 6-bromoisoquinoline in Example 27. MS (ESI) m/z 411 (M + H)⁺; ¹H NMR (DMSO-d₆, 300 MHz) δ 11.30 (bs, 1H), 11.04 (bs, 1H), 8.66-8.68 (m, 1H), 8.41 (d, J=3 Hz, 1H), 8.27 (d, J=8 Hz, 1H), 8.17-8.20 (m, 2H), 8.02-8.03 (m, 1H), 7.76-7.81 (m, 2H), 7.62 (d, J=8 Hz, 1H), 7.38 (d, J=8 Hz, 1H), 7.29-7.31 (m, 1H), 7.20-7.26 (m, 1H), 7.07-7.12 (m, 1H), 6.987.04 (m, 1H), 6.60 (d, J=8 Hz, 1H), 4.14-4.39 (m, 2H), 3.33-3.38 (m, 1H), 3.13-3.16 (m, 2H).
Anal. Calcd for C₂₅H₂₂N₄O•2TFA: C, 54.54; H, 3.78; N, 8.78; F, 17.86. Found: C, 54.54; H, 4.00; N, 8.56; F, 17.10.

Example 80

(1S)-2-[5-(3-Chloro-isoquinolin-6-yl)-pyridin-3-yloxy]-1-(1H-indol-3-ylmethyl)-ethylamine

Example 80A

6-Bromo-indan-1,2-dione 1-oxime

A solution of 5-bromo-1-indanone (1.8 g, 8.5 mmol) in ethanol (150 ml) was cooled to 0 °C, treated with t-butylnitrite (2.1 ml), stirred at room temperature for 2 hours, filtrated and washed the desired product with ether. The yield is 76%. MS (DCI/NH₃) m/e 242 (M+1)⁺.

Example 80B

6-Bromo-1,3-dichloro-isoquinoline

A suspension solution of Example 80A (1.5 g, 6.2 mmol) in POCl₃(40 ml) was treated with PCl₅ (1.55 g, 7.4 mmol) and introduced HCl gas until solution was saturated. The reaction was stirred at 60 °C for 6 hours and concentrated under vacuum. The residue was slowly hydrolysed by adding water, treated with ethyl acetate (200 mL), washed with brine, dried (MgSO₄), filtered, and concentrated. The concentrate was purified by flash column chromatography on silica gel with 10% ethyl acetate/hexane to provide the title compound (1.7g, 100%). MS (DCI/NH₃) m/e 278 (M+H)⁺.

Example 80C6-Bromo-3-chloro-isoquinoline

A mixture of Example 80B (1.8 g, 6.5 mmol), P (0.48g, 15.5 mmol) and HI (3ml, 48%) in acetic acid (20 ml) was refluxed for 8 hours, filtrated under hot condition and concentrated 5 under vacuum. The residue was basified by adding sodium hydroxide solution, treated with ethyl acetate (200 mL), washed with brine, dried (MgSO_4), filtered, and concentrated. The concentrate was purified by flash column chromatography on silica gel with 30% ethyl acetate/hexane to provide the title compound (0.81g, 50%). MS (DCI/NH₃) m/e 244 (M+H)⁺.

10

Example 80D3-Chloro-6-trimethylstannanyl-isoquinoline

The desired product was prepared by substituting Example 80C for 6-bromoisoquinoline in Example 27A. MS (DCI/NH₃) m/e 327 (M+H)⁺.

15

Example 80E(1*S*)-[2-[5-(3-Chloro-isoquinolin-6-yl)-pyridin-3-yloxy]-1-(1*H*-indol-3-ylmethyl)-ethyl]-carbamic acid *tert*-butyl ester

The desired product was prepared by substituting Example 80D for Example 27A in Example 27B. MS (DCI/NH₃) m/e 530 (M+H)⁺.

20

Example 80F(1*S*)-2-[5-(3-Chloro-isoquinolin-6-yl)-pyridin-3-yloxy]-1-(1*H*-indol-3-ylmethyl)-ethylamine

The desired product was prepared by substituting Example 80E for Example 27B in Example 27C. MS (DCI/NH₃) m/e 429 (M+1)⁺; ¹H NMR (DMSO-d₆, 300 MHz) δ 11.04 (s; 1H), 9.28 (s; 1H), 8.72 (s; 1H), 8.44 (s; 1H), 8.33 (s; 1H), 8.32 (d; 1H; J=8.4 Hz), 8.17 (s; 2H), 8.07 (s; 1H), 8.05 (d; 1H; J=8.4 Hz), 7.80 (s; 1H), 7.63 (d; 1H; J=7.5 Hz), 7.48 (d; 1H; J=7.5 Hz), 7.30 (s; 1H), 7.10 (t; 1H; J=7.2 Hz), 7.00 (t; 1H; J=7.2 Hz), 4.38 (m; 1H), 4.20 (m; 1H), 3.88 (m; 1H), 3.18 (m; 2H).

30

Example 81(1*S*)-2-([3,4']Bipyridinyl-5-yloxy)-1-(1*H*-indol-3-ylmethyl)-ethylamine trifluoroacetic acid

The desired product was prepared by substituting 4-tributylstannylpyridine for Example 27A in Example 27. MS (APCI) m/z 345 (M+1)⁺; ¹H NMR (CD₃OD, 300 MHz) δ 8.85 (d, J = 6.8 Hz, 2H), 8.73 (d, J = 1.7 Hz, 1H), 8.53 (d, J = 2.7 Hz, 1H), 8.20 (d, J = 6.8 Hz, 2H), 7.84 (t, J = 1.7 Hz, 1H), 7.59 (d, J = 7.8 Hz, 1H), 7.38 (d, J = 8.2 Hz, 1H), 7.24 (s, 1H), 7.12 (t, J = 6.8 Hz, 1H), 7.01 (t, J = 8.1 Hz, 1H), 4.44 (dd, J = 10.8, 3.4 Hz, 1H), 4.30 (dd, J = 10.5, 5.8 Hz, 1H),

4.01 (m, 1H), 3.33 (m, 2H); Anal. Calcd for $C_{21}H_{20}N_4O$ •2.7 TFA: C, 48.61; H, 3.51; N, 8.59. Found: C, 48.69; H, 3.50; N, 8.46.

5

Example 82(1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(2-pyridin-2-yl-vinyl)-pyridin-3-yloxy]-ethylamine

The desired product was prepared by substituting 2-vinylpyridine for 4-vinylpyridine in Example 2. MS (APCI) m/z 371 (M+1)⁺; ¹H NMR (CD₃OD, 300 MHz) δ 8.72 (d, J = 5.5 Hz, 1H), 8.55 (s, 1H), 8.39 (d, J = 2.4 Hz, 1H), 8.34 (td, J = 7.8, 1.7 Hz, 1H), 8.12 (d, J = 8.2 Hz, 1H), 7.88 (t, J = 1.7 Hz, 1H), 7.82 (d, J = 16.3 Hz, 1H), 7.74 (t, J = 6.7 Hz, 1H), 7.59 (d, J = 7.8 Hz, 1H), 7.53 (d, J = 16.3 Hz, 1H), 7.38 (d, J = 8.1 Hz, 1H), 7.24 (s, 1H), 7.12 (td, J = 7.1, 1.0 Hz, 1H), 7.03 (td, J = 7.1, 1.0 Hz, 1H), 4.41 (tt, J = 10.5, 3.4 Hz, 1H), 4.27 (dd, J = 10.5, 5.5 Hz, 1H), 4.00 (m, 1H), 3.33 (m, 2H); Anal. Calcd for $C_{23}H_{22}N_4O$ •3.8 TFA: C, 45.73; H, 3.24; N, 6.97. Found: C, 45.60; H, 3.34; N, 6.86.

15

Example 83(1S)-1-(1H-Indol-3-ylmethyl)-2-(5-pyridin-3-ylethynyl-pyridin-3-yloxy)-ethylamine trifluoroacetic acid salt

The desired product was prepared by substituting 3-bromopyridine for 4-bromopyridine in Example 14. MS (APCI) m/z 367 (M-1)⁺; ¹H NMR (CD₃OD, 300 MHz) δ 8.80 (s, 1H), 8.62 (br d, J = 4.7 Hz, 1H), 8.42 (s, 1H), 8.36 (d, J = 2.7 Hz, 1H), 8.12 (dt, J = 8.2, 1.7 Hz, 1H), 7.60 (m, 3H), 7.39 (d, J = 8.1 Hz, 1H), 7.22 (s, 1H), 7.14 (td, J = 7.1, 1.4 Hz, 1H), 7.04 (td, J = 8.2, 1.1 Hz, 1H), 4.33 (dd, J = 10.5, 3.0 Hz, 1H), 4.19 (dd, J = 10.5, 5.4 Hz, 1H), 3.97 (m, 1H), 3.29 (m, 2H); Anal. Calcd for $C_{23}H_{20}N_4O$ •3.0 TFA: C, 49.02; H, 3.26; N, 7.89. Found: C, 48.86; H, 3.14; N, 8.01.

Example 84(1S)-2-[5-(2-Fluoro-pyridin-4-ylethynyl)-pyridin-3-yloxy]-1-(1H-indol-3-ylmethyl)-ethylamine trifluoroacetic acid salt

The desired product was prepared by substituting 4-iodo-2-fluoropyridine for 4-bromopyridine in Example 14. MS (APCI) m/z 385 (M-1)⁺; ¹H NMR (CD₃OD, 300 MHz) δ 8.42 (d, J = 1.4 Hz, 1H), 8.38 (d, J = 2.7 Hz, 1H), 8.26 (d, J = 5.1 Hz, 1H), 7.61 (dd, J = 2.7, 1.7 Hz, 1H), 7.58 (d, J = 7.8 Hz, 1H), 7.43 (dt, J = 5.1, 1.7 Hz, 1H), 7.38 (d, J = 8.1 Hz, 1H), 7.23 (m, 2H), 7.13 (td, J = 7.1, 1.3 Hz, 1H), 7.04 (td, J = 7.8, 1.3 Hz, 1H), 4.33 (dd, J = 10.5,

3.4 Hz, 1H), 4.18 (dd, J = 10.5, 5.8 Hz, 1H), 3.97 (m, 1H), 3.30 (m, 2H); Anal. Calcd for $C_{23}H_{19}FN_4O$ •2.3 TFA: C, 51.10; H, 3.31; N, 8.64. Found: C, 51.06; H, 3.32; N, 8.69.

5

Example 85

(1S)-4-{5-[2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-ylethynyl}-pyridin-2-ol trifluoroacetic acid salt

A solution of *N*-BOC protected Example 84 (45 mg, 0.093 mmol) in acetic acid (5 mL) was heated at 80 °C for 15 h and at 100 °C for 5h. The solution was concentrated and the residual oil was dissolved in CH_2Cl_2 (5 mL). Trifluoroacetic acid (1.25 mL) was added at 0 °C. The solution was stirred at 0 °C for 10 min and at rt for 30 min, and was concentrated. The residual material was purified on HPLC (Zorbax, C-18) to provide the title compound (15 mg, 33%). MS (APCI) m/z 383 (M-1); 1H NMR (CD_3OD , 300 MHz) δ 8.40 (s, 1H), 8.36 (d, J = 2.3 Hz, 1H), 7.58 (m, 2H), 7.46 (d, J = 6.8 Hz, 1H), 7.39 (d, J = 8.2 Hz, 1H), 7.22 (s, 1H), 7.14 (td, J = 7.1, 1.0 Hz, 1H), 7.03 (td, J = 8.2, 1.1 Hz, 1H), 6.69 (brs, 1H), 6.46 (dd, J = 6.8, 1.7 Hz, 1H), 4.32 (dd, J = 10.5, 3.4 Hz, 1H), 4.18 (dd, J = 10.5, 5.8 Hz, 1H), 3.98 (m, 1H), 3.34 (m, 2H).

20

Example 86

(1S)-2-[6-Chloro-5-(1-chloro-isoquinolin-6-yl)-pyridin-3-yloxy]-1-(1H-indol-3-ylmethyl)-ethylamine trifluoroacetic acid salt

The title compound was prepared by substituting Example 13A for Example 2A and Example 80D for Example 27A in Example 27. MS (APCI) m/z 464 (M+1) $^+$; 1H NMR (CD_3OD , 300 MHz) δ 8.44 (d, J = 8.8 Hz, 1H), 8.31 (d, J = 5.8 Hz, 1H), 8.22 (d, J = 3.1 Hz, 1H), 8.03 (d, J = 1.7 Hz, 1H), 7.84 (m, 2H), 7.57 (dt, J = 7.8, 1.0 Hz, 1H), 7.53 (d, J = 3.0 Hz, 1H), 7.34 (d, J = 7.2 Hz, 1H), 7.22 (s, 1H), 7.10 (td, J = 7.2, 1.4 Hz, 1H), 7.01 (td, J = 7.7, 1.0 Hz, 1H), 4.36 (dd, J = 10.5, 3.0 Hz, 1H), 4.22 (dd, J = 10.5, 5.7 Hz, 1H), 3.97 (m, 1H), 3.27 (m, 2H); Anal. Calcd for $C_{25}H_{20}Cl_2N_4O$ •2.05 TFA: C, 50.14; H, 3.19; N, 8.04. Found: C, 50.16; H, 3.03; N, 7.88.

30

Example 87

Bis-[3-(4-Bromo-phenyl)-allyl]-{2-[5-(2-pyridin-4-yl-vinyl)-pyridin-3-yloxy]-ethyl}-amine hydrochloride

35

The title compound was obtained from the less polar product in Example 19D (5.3 mg, 3%). MS (DCI/NH₃) m/z 630, 632, 634 (M+H) $^+$; 1H NMR ($CDCl_3$, 300 MHz) δ 8.62 (m, 2H), 8.36

(s, 1H), 8.26 (d, J=2.7 Hz, 1H), 7.0-7.5 (m, 13H), 6.52 (m, 2H), 6.35 (m, 2H), 4.25 (m, 2H), 3.49 (m, 4H), 3.08 (m, 2H).

5

Example 88*N*⁴-[3-(2-Amino-ethoxy)-phenyl]-pyrimidine-2,4-diamine hydrochloride

The title compound was prepared by substituting *N*-Boc-aminoethanol for BOC-tryptophanol in Example 20. MS (DCI/NH₃) m/z 246(M+1)⁺; ¹H NMR (DMSO-d6, 300 mHz) δ 12.4 (br s, 1H), 11.0 (br s, 1H), 8.26 (br, 5H), 7.86 (d, J=7.1 Hz, 1H), 7.55 (m, 1H), 7.44 (m, 1H), 7.31 10 9t, J=8.1 Hz, 1h0, 6.79 (d, J=8.1 Hz, 1H), 6.46 (d, J=7.1 Ha, 1H), 4.22 (t, J=5.1 Hz, 2H), 3.22 (m, 2H).

10

Example 89

15 *trans*-[4-(2-{5-[(2*S*)-2-Amino-3-(1*H*-indol-3-yl)-propylamino]-pyridin-3-yl}-vinyl)-pyrimidin-2-yl]-carbamic acid ethyl ester trifluoroacetic acid salt

20

Example 89A*trans*-4-[(5-Bromo-pyridin-3-yl)-vinyl]-2-amino-pyrimidine

A solution of 5-bromo-pyridine-3-carbaldehyde (436 mg, 2.34 mmol) and 2-amino-4-methylpyrimidine (246 mg, 2.35 mmol) in formic acid (96%, 3 mL) was heated for 18 h. After cooling to rt, it was then diluted with water and basified to pH ~13 with 1 N NaOH. The mixture was then extracted with methylene chloride. The combined extracts was washed with water (1X), dried over MgSO₄ and concentrated. The residue was chromatographed on 25 silica gel eluting with CH₂Cl₂:MeOH:NH₄OH (100:5:0.5) to give the title compound (463 mg, 71%). MS (DCI/NH₃) m/z 277, 279(M+1)⁺.

25

Example 89B*trans*-4-[(5-Bromo-pyridin-3-yl)-vinyl]-2-[bis(*tert*-butoxycarbonyl)amino]-pyrimidine

30

A suspension of Example 89A (439 mg, 1.58 mmol), (BOC)₂O (1.040g, 4.77 mmol), DMAP (50 mg, 0.41 mmol), and triethylamine (670 μ L, 4.81 mmol) in THF (10 mL) was stirred at rt overnight. Reaction was concentrated and chromatographed on silica gel eluting with AcOEt:hexane (1:1) to give the title compound (511 mg, 68%). MS (DCI/NH₃) m/z 477, 479(M+1).

35

Example 89C*trans*-4-[(5-amino-pyridin-3-yl)-vinyl]-2-(*tert*-butoxycarbonyl)amino-pyrimidine

Example 89B was converted to the title compound according to the procedures described for Example 51, Steps 4 and 5. MS (DCI/NH₃) m/z 314(M+1)⁺.

Example 89D

5 trans-[4-(2-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propylamino]-pyridin-3-yl}-vinyl)-
pyrimidin-2-yl]-carbamic acid ethyl ester trifluoroacetic acid salt

The title compound was prepared by substituting Example 89C for Example 11B in Example 11. (DCI/NH₃) m/z 458(M+1)⁺; NMR (DMSO-d6): δ 8.58 (d, J=5.3 Hz, 1H), 8.17 (s, 1H), 7.91 (d, J=2.2 Hz, 1H), 7.75 (d, J=15.9 Hz, 1H), 7.58 (m, 1H), 7.35 (m, 2H), 7.32 (s, 1H), 10 7.22 (d, J=5.3 Hz, 1H), 7.15 (d, J=15.9 Hz, 1H), 7.11 (m, 1H), 7.04 (m, 1H), 4.28 (q, J=7.2 Hz, 2H), 3.80 (m, 1H), 3.62 (dd, J=4.4, 14.7 Hz, 1H), 3.50 (dd, J=8.1, 14.7 Hz, 1H), 3.20 (m, 2H), 1.35 (t, J=7.2 Hz, 3H).

15 Example 90

1-Amino-6-{5-[(2S)-2-amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-isoquinoline
trifluoroacetic acid salt

Example 90A

20 6-Bromo-1-chloroisooquinoline

A solution of 6-bromo-1-hydroxyisoquinoline (9.205 g, 41.0 mmol) in POCl₃ (100 mL) was heated to 100 °C for 4h. The reaction was concentrated to dryness. The residue was dissolved in ethyl acetate and the organic layer was washed with 5% NaHCO₃, water, brine, dried over MgSO₄ and concentrated. The residue was chromatographed on silica gel 25 eluting with CH₂Cl₂:hexane (3:7) to give the title compound (6.176 g, 62%). MS (DCI/NH₃) m/z 241, 243 (M+1)⁺.

Example 90B

1-Amino-6-bromoisoquinoline

30 A mixture of the chloride from Example 90A (264 mg, 1.09 mmol), acetamide (1.3 g) and K₂CO₃ (0.45 g) was heated to 180 °C for 5 h. After cooling to rt, the mixture was dissolved in ethyl acetate, which was washed with water, brine, dried over MgSO₄ and concentrated. The residue was chromatographed on silica gel eluting with CH₂Cl₂:MeOH:NH₄OH (100:5:0.5) to give the title compound (159 mg, 65%). MS (DCI/NH₃) m/z 223, 225 (M+1)⁺.

35

Example 90C

1-[(Bis(tert-butoxycarbonyl)]amino-6-bromoisoquinoline

A solution of Example 90B (616 mg, 2.76 mmol), BOC₂O (1.81 g), DMAP (67 mg), and triethylamine (1.15 mL) in acetonitrile (15 mL) was stirred at rt for 2h. The reaction was concentrated and the residue was chromatographed on silica gel eluting with AcOEt : hexane (3:7) to give the title compound (1.18 g, 71%). MS (DCI/NH₃) m/z 423 (M+1)⁺.

5

Example 90D1-Amino-6-{5-[(2S)-2-amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-isoquinoline trifluoroacetic acid salt

The title compound was prepared by substituting Example 90C for 6-bromophthalimide in Example 32. MS (DCI/NH₃) m/z 410(M+1)⁺; ¹H NMR (DMSO-d6, 300 MHz) δ 8.77 (s, 1H), 8.55 (d, J=8.6 Hz, 1H), 8.45 (d, J=2.5 Hz, 1H), 8.20 (d, J=1.5 Hz, 1H), 8.05 (dd, J=1.8, 8.6 Hz, 1H), 7.83 (dd, J=1.8, 2.5 Hz, 1H), 7.61 (m, 2H), 7.38 (d, J=7.1 Hz, 1H), 7.24 (s, 1H), 7.12 (m, 1H), 7.02 (m, 1H), 4.44 (dd, J=3.1, 10.4 Hz, 1H), 4.30 (dd, J=5.8, 10.4 Hz, 1 H), 4.01 (m, 1H), 3.32 (m, 2H).

15

Example 916-{5-[(2S)-2-amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-1-chloro-isoquinoline trifluoroacetic acid salt

The title compound was prepared by substituting Example 90A for 6-bromophthalimide in Example 32. MS (ESI) m/z 429, 431(M+1)⁺; ¹H NMR (DMSO-d6, 300 MHz) δ 11.03 (br s, 1H), 8.75 (d, J=1.6 Hz, 1H), 8.47 (d, J=1.6 Hz, 1H), 8.45 (d, J=5.6 Hz, 1H), 7.84 (m, 1H), 7.62 (d, J=8.1 Hz, 1H), 7.39 (d, J=8.1 Hz, 1H), 7.31 (d, J=2.2 Hz, 1H), 7.10 (m, 1H), 7.01 (m, 1H), 4.38 (dd, J=3.1, 10.6 Hz, 1H), 4.22 (dd, J=6.2, 10.4 Hz, 1 H), 3.88 (m, 1H), 3.18 (m, 2H).

25

Example 92(2S)-2-Amino-3-(1H-indol-3-yl)-N-[5-(2-pyridin-4-yl-vinyl)-pyridin-3-yl]-propionamide

The title compound was prepared by substituting Boc-tryptophane for Boc-homnophenylalanine in Example 16. MS (DCI/NH₃) m/z 384 (M+1)⁺; ¹H NMR (DMSO-d6, 300 MHz) δ 11.37 (s, 1 H), 11.05 (s, 1 H), 8.88 (d, J=6.44 Hz, 2 H), 8.74 (m, 2 H), 8.42 (m, 1H), 8.35 (s, 1 H), 8.22 (d, J=6.10 Hz, 2 H), 8.02 (d, J=16.61 Hz, 1 H), 7.71 (d, J=7.80 Hz, 1 H), 7.56 (d, J=16.27 Hz, 1 H), 7.36 (d, J=7.80 Hz, 1 H), 7.30 (m, 1 H), 7.07(m, 1 H), 6.95 (m, 1 H), 4.31 (m, 1 H), 3.36 (m, 2H).

Example 93(2S)-2-Amino-3-(naphtha-1-yl)-N-[5-(2-pyridin-4-yl-vinyl)-pyridin-3-yl]-propionamide hydrochloride

The title compound was prepared by substituting Boc-3-(1-naphthyl)alanine for Boc-homnophenylalanine in Example 16. MS (DCI/NH₃) m/z 395 (M+1)⁺. 1H NMR (DMSO-d₆, 500 MHz) δ 11.86 (s, 1 H), 8.90 (d, J=6.86 Hz, 2 H), 8.78 (m, 1 H), 8.85 (m, 1 H), 8.58 (m, 1 H), 8.45 (m, 1 H), 8.26 (d, J=6.86 Hz, 2 H), 8.04 (d, J=16.53 Hz, 1 H), 7.89 (m, 2 H) 7.84 (m, 1 H), 7.60 (d, J=16.53 Hz, 1 H), 7.58 (m, 1H), 7.49 (m, 2 H), 4.53 (m, 1H), 3.49 (m, 1H), 3.36 (m, 1H).

10

Example 94(2S)-2-Amino-3-phenyl-N-[5-(2-pyridin-4-yl-vinyl)-pyridin-3-yl]-propionamide hydrochloride

15 The title compound was prepared by substituting Boc-phenylalanine for Boc-homnophenylalanine in Example 16. MS (DCI/NH₃) m/z 345 (M+1)⁺; 1H NMR (DMSO-d₆, 500 MHz) δ 11.85 (s, 1 H), 8.93 (m, 2 H) 8.53 (m, 2 H), 8.49 (m, 1H), 8.29 (m, 2 H), 8.07 (d, J=16.22 Hz, 1 H), 7.63 (d, J=16.53 Hz, 1 H,) 7.32 (m, 5 H), 4.44 (m, 1H), 3.24 (m, 2 H)

20

Example 95S-2-Amino-3-(imidazol-4-yl)-N-[5-(2-pyridin-4-yl-vinyl)-pyridin-3-yl]-propionamide hydrochloride

25 The title compound was prepared by substituting bis(Boc)-histidine for Boc-homnophenylalanine in Example 16. MS (DCI/NH₃) m/z 335 (M+1)⁺, 1H NMR (DMSO-d₆, 300 MHz) δ 10.95 (s, 1 H), 9.04 (s, 1 H), 8.74 (m, 1 H), 8.70 (m, 1 H), 8.52 (m, 2 H) 8.32 (m, 1 H) 8.08 (m, 2 H), 7.93 (d, J=16.61 Hz, 1 H), 7.50 (m, 2 H), 4.50 (m, 1H), 3.33 (m, 2H).

30

Example 96(1R)-2-(1H-indol-3-yl)-1-[(5-isoquinolin-6-ylpyridin-3-yl)oxy]methyl}ethylamine

35 The title compound was prepared as the trifluoroacetate salt by substituting R-Boc-tryptophanol for L-Boc-tryptophanol in Example 27. MS (ESI) m/e 395 (M+H)⁺; ¹H NMR (DMSO-d₆, 300 MHz) δ 11.02 (br s, 1H), 9.52 (s, 1H), 8.76 (d, J=3 Hz, 1H), 8.62 (d, J=8 Hz, 1H), 8.44-8.46 (m, 2H), 8.38 (d, J=9 Hz, 1H), 8.11-8.20 (m, 3H), 8.04-8.08 (m, 1H), 7.83-7.86 (m, 1H), 7.62 (d, J=9 Hz, 1H), 7.37-7.40 (m, 1H), 7.31 (d, J=3 Hz, 1H), 7.08-7.12 (m, 1H),

6.99-7.03 (m, 1H), 4.37-4.41 (m, 1H), 4.18-4.23 (m, 1H), 3.86-3.91 (m, 1H), 3.16-3.20 (m, 2H); Anal. Calcd for $C_{25}H_{22}N_4O \cdot 2.65$ TFA: C, 52.24; H, 3.57; N, 8.04;. Found: C, 52.26; H, 3.70; N, 7.42.

5

Example 97(1S)-5-{5-[2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-1H-indazol-3-ylamineExample 97A2-Fluoro-5-(trimethylstannyl)benzonitrile

The desired product was prepared by substituting 5-bromo-2-fluorobenzonitrile for 6-bromoisoquinoline in Example 27A.

Example 97B(1S)-[2-[5-(3-Cyano-4-fluoro-phenyl)-pyridin-3-yloxy]-1-(1H-indol-3-ylmethyl)-ethyl]-carbamic acid *tert*-butyl ester

The desired product was prepared by substituting Example 97A for in Example 27A in Example 27B.

Example 97C(1S)-[2-[5-(3-Amino-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(1H-indol-3-ylmethyl)-ethyl]-carbamic acid *tert*-butyl ester

A mixture of Example 97B (120 mg, 0.25 mmol) and 98% hydrazine (5 mL) was heated to reflux for 5 hours, poured over ice, diluted with brine, extracted with ethyl acetate, dried over $MgSO_4$, and concentrated. Purification by flash chromatography (7% MeOH/CH₂Cl₂) provided the desired product (103 mg, 84%).

Example 97D(1S)-5-{5-[2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-1H-indazol-3-ylamine

The desired product was prepared as the trifluoroacetate salt by substituting Example 97C for Example 27B in Example 27C. MS (ESI) m/e 399 (M+H)⁺; ¹H NMR (DMSO-d₆ 300 MHz) δ 3.17 (d, *J*=7.12 Hz, 2 H) 3.84 (m, 1 H) 4.18 (dd, *J*=10.51, 5.76 Hz, 1 H) 4.36 (m, 1 H) 7.12 (m, 4 H) 7.30 (d, *J*=2.37 Hz, 1 H) 7.38 (m, 1 H) 7.42 (s, 1 H) 7.63 (d, *J*=7.46 Hz, 1 H) 7.66 (s, 1 H) 8.18 (m, 4 H) 8.32 (d, *J*=2.71 Hz, 1 H) 8.57 (d, *J*=1.70 Hz, 1 H) 11.04 (s, 1 H) 11.92 (bs, 1H); Anal. Calcd for $C_{23}H_{22}N_6O \cdot 2.9$ TFA: C, 47.44; H, 3.44; N, 11.53;. Found: C, 47.87; H, 3.49; N, 11.19.

Example 98(1S)-6-{5-[2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-1H-indazol-3-ylamine

The desired product was prepared as the trifluoroacetate salt by substituting 4-bromo-2-fluorobenzonitrile for 5-bromo-2-fluorobenzonitrile in Example 97. MS (ESI) m/e 399 (M+H)⁺; ¹H NMR (DMSO-d₆, 300 MHz) δ 3.16 (d, J=5.42 Hz, 2 H) 3.91 (d, J=30.85 Hz, 1 H) 4.19 (s, 1 H) 4.35 (m, 1 H) 7.07 (m, 2 H) 7.34 (m, 3 H) 7.63 (m, 2 H) 7.71 (s, 1 H) 7.88 (d, J=8.14 Hz, 1 H) 8.17 (s, 4 H) 8.37 (d, J=2.37 Hz, 1 H) 8.60 (d, J=1.36 Hz, 1 H) 11.03 (s, 1 H) 11.93 (bs, 1 H); Anal. Calcd for C₂₃H₂₂N₆O·3.5 TFA: C, 45.18; H, 3.22; N, 10.54, F, 25.01; Found: C, 44.83; H, 3.19; N, 10.40, F, 25.01.

Example 992-Amino-N-[(1S)-1-(1H-indol-3-ylmethyl)-2-(5-isoquinolin-6-yl-pyridin-3-yloxy)-ethyl]-acetamide

15

Example 99A{[(1S)-1-(1H-Indol-3-ylmethyl)-2-(5-isoquinolin-6-yl-pyridin-3-yloxy)-ethylcarbamoyl]-methyl}-carbamic acid *tert*-butyl ester

20 A solution of Example 27C (175 mg, 0.35 mmol), *N*-Boc-glycine (91 mg, 0.52 mmol), EDC (100 mg), iPr₂EtN (0.30 mL) and DMAP (10 mg) in CH₂Cl₂ (7 mL) was stirred at room temperature overnight, diluted with EtOAc, washed with water and brine, dried (MgSO₄), filtered, and concentrated. The residue was purified by flash column chromatography on silica gel with 3% methanol/CH₂Cl₂ to provide the desired product (112 mg, 58%).

25

Example 99B2-Amino-N-[(1S)-1-(1H-indol-3-ylmethyl)-2-(5-isoquinolin-6-yl-pyridin-3-yloxy)-ethyl]-acetamide

The desired product was prepared as the trifluoroacetate salt by substituting Example 99A for Example 27B in Example 27C. MS (ESI) m/e 452 (M+H)⁺; ¹H NMR (DMSO-d₆, 300 MHz) δ ppm 3.07 (m, 2 H) 3.58 (m, 2 H) 4.22 (m, 2 H) 4.48 (m, 1 H) 6.97 (t, J=6.95 Hz, 1 H) 7.06 (t, J=6.95 Hz, 1 H) 7.21 (d, J=2.37 Hz, 1 H) 7.34 (d, J=8.14 Hz, 1 H) 7.64 (d, J=7.46 Hz, 1 H) 7.86 (m, 1 H) 7.99 (bs, 2 H) 8.13 (d, J=6.10 Hz, 1 H) 8.19 (dd, J=8.82, 1.70 Hz, 1 H) 8.42 (m, 2 H) 8.51 (s, 1 H) 8.64 (d, J=6.10 Hz, 1 H) 8.67 (d, J=7.80 Hz, 1 H) 8.74 (d, J=1.70 Hz, 1 H) 9.60 (s, 1 H) 10.88 (s, 1 H); Anal. Calcd for C₂₇H₂₅N₅O₂·2.9 TFA: C, 50.37; H, 3.60; N, 8.95; Found: C, 50.59; H, 3.43; N, 8.83.

Example 100(2S)-2-Amino-N-[(1S)-1-(1H-indol-3-ylmethyl)-2-(5-isoquinolin-6-yl-pyridin-3-yloxy)-ethyl]-propionamide

5 The desired product was prepared by substituting *L*-Boc-alanine for *N*-Boc-glycine in Example 99. MS (ESI) m/e 466 (M+H)⁺; ¹H NMR (DMSO-d₆, 500 MHz) δ 1.36 (d, *J*=6.86 Hz, 3 H) 3.09 (m, 2 H) 3.88 (m, 1 H) 4.35 (m, 2 H) 4.46 (m, 1 H) 6.97 (t, *J*=7.33 Hz, 1 H) 7.05 (t, *J*=7.33 Hz, 1 H) 7.29 (d, *J*=1.87 Hz, 1 H) 7.35 (d, *J*=8.11 Hz, 1 H) 7.66 (d, *J*=7.80 Hz, 1 H) 8.30 (s, 1 H) 8.34 (bs, 2 H) 8.47 (dd, *J*=8.74, 1.56 Hz, 1 H) 8.53 (d, *J*=6.55 Hz, 1 H) 8.62 (d, *J*=1.87 Hz, 1 H) 8.70 (d, *J*=6.74, 1 H) 8.75 (d, *J*=6.24, 1 H) 8.89 (s, 1 H) 8.93 (s, 1 H) 9.01 (d, *J*=8.11 Hz, 1 H) 9.99 (s, 1 H) 10.98 (s, 1 H)

Example 1012-Dimethylamino-N-[(1S)-1-(1H-indol-3-ylmethyl)-2-(5-isoquinolin-6-yl-pyridin-3-yloxy)-ethyl]-acetamide

15 The desired product was prepared by substituting *N,N*-dimethylglycine for *N*-Boc-glycine in Example 99A. MS (ESI) m/e 480 (M+H)⁺; ¹H NMR (DMSO-d₆, 500 MHz) δ 2.71 (s, 3 H) 2.77 (s, 3 H) 3.10 (m, 2 H) 3.95 (m, 2 H) 4.40 (m, 2 H) 4.52 (m, 1 H) 6.97 (t, *J*=7.33 Hz, 1 H) 7.05 (t, *J*=7.49 Hz, 1 H) 7.28 (s, 1 H) 7.34 (d, *J*=8.11 Hz, 1 H) 7.67 (d, *J*=7.80 Hz, 1 H) 8.38 (s, 1 H) 8.50 (d, *J*=8.73 Hz, 1 H) 8.55 (d, *J*=6.24 Hz, 1 H) 8.67 (d, *J*=1.87 Hz, 1 H) 8.71 (d, *J*=8.73 Hz, 1 H) 8.75 (d, *J*=6.55 Hz, 1 H) 8.92 (s, 1 H) 8.98 (s, 1 H) 9.34 (d, *J*=8.42 Hz, 1 H) 10.00 (s, 1 H) 11.02 (s, 1 H).

25

Example 102(1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamineExample 102A

30 A solution of 5-bromo-2-fluorobenzaldehyde (24.75 g; 122 mmol) in Et₂O (125mL) at 0 °C was treated with 3.0 M MeMgBr in Et₂O (43 mL, 129 mmol), stirred for 30 min., carefully diluted with water then acidified with 10% HCl (aq). The aqueous was extracted with Et₂O, rinsed successively with 10% HCl (aq), water, and brine, dried (MgSO₄), and evaporated to give the desired product (26.6 g; 99%) of sufficient purity to carry on to the next step.

35

Example 102B1-(5-Bromo-2-fluoro-phenyl)-ethanone

A solution of Example 102A (26.6 g; 121 mmol) and manganese(IV) oxide (53 g; 610 mmol) in *p*-dioxane (500 mL) was heated at reflux for 4 hrs., cooled, filtered through Celite®, evaporated, and purified by flash chromatography (5-10% Et₂O/hexane) to yield the desired product as a nearly colorless oil that solidified upon standing (20.5 g; 78%).

5

Example 102C5-Bromo-3-methyl-1*H*-indazole

A mixture of 102B (10 g, 46 mmol) and 98% hydrazine (25 mL) was heated to reflux for 9 hours, and poured over ice. The precipitate was collected and purified by flash chromatography (1:1 Et₂O:hexane) to give the desired product as a white solid (5.8 g, 60%).

10

Example 102D3-Methyl-5-trimethylstannanyl-1*H*-indazole

A mixture of Example 102C (10.08 g, 47.8 mmol), hexamethyl-di-tin 2 (18 g, 55 mmol) and tetrakis(triphenylphosphine)palladium (5.5 g, 4.8 mmol) in toluene (100 mL) was stirred at 95 °C for 6 h. The mixture was then evaporated and the residue was taken into ethyl acetate (300 mL), washed with saturated sodium bicarbonate (100 mL), water (100 mL) and brine (100 mL). The ethyl acetate was evaporated off and the residue was purified by flash column chromatography on silica gel, eluting with 1:4 ethyl acetate/hexanes to give 11.2 g desired product (80%). MS: (ESI) m/z 409 (M + H)⁺.

20

Example 102E(1*S*)-{1-(1*H*-Indol-3-ylmethyl)-2-[5-(3-methyl-1*H*-indazol-5-yl)-pyridin-3-yloxy]-ethyl}-carbamic acid *tert*-butyl ester

The desired product was prepared by substituting Example 102D for Example 27A in Example 27B.

25

Example 102F(1*S*)-1-(1*H*-Indol-3-ylmethyl)-2-[5-(3-methyl-1*H*-indazol-5-yl)-pyridin-3-yloxy]-ethylamine

The desired product was prepared as the trifluoroacetate salt by substituting Example 102E for Example 27B in Example 27C. MS (ESI) m/e 398 (M+H)⁺; ¹H NMR (DMSO-d₆) 300 MHz) δ 2.55 (s, 3 H) 2.79 (dd, *J*=14.07, 7.29 Hz, 1 H) 2.99 (dd, *J*=14.07, 7.29 1 H) 3.32 (s, 2 H) 3.40 (m, 1 H) 4.03 (m, 2 H) 6.95 (t, *J*=7.46 Hz, 1 H) 7.05 (t, *J*=6.95 Hz, 1 H) 7.21 (d, *J*=2.37 Hz, 1 H) 7.34 (d, *J*=7.80 Hz, 1 H) 7.56 (m, 2 H) 7.67 (m, 2 H) 8.08 (s, 1 H) 8.26 (d, *J*=2.37 Hz, 1 H) 8.54 (d, *J*=2.03 Hz, 1 H) 10.85 (s, 1 H) 12.73 (s, 1 H); Anal. Calcd for C₂₄H₂₃N₅O•2.25 HCl: C, 59.62; H, 5.31; N, 14.60;. Found: C, 59.62; H, 5.31; N, 14.28.

Example 103(1*S*)-1-(1*H*-Indol-3-ylmethyl)-2-{5-[3-(1*H*-pyrrol-2-yl)-1*H*-indazol-5-yl]-pyridin-3-yloxy}-ethylamine

5

Example 103A5-Bromo-2-fluoro-benzoic acid

A mixture of 5-bromo-2-fluorobenzaldehyde (810 mg; 4.0 mmol), 15% NaOH (aq.) (3 mL), MeOH (5 mL), and 30% H₂O₂ (5 mL) was stirred at r.t. for 2 hrs., then acidified with 10% HCl (aq.). The resulting white solid was collected, rinsed with water, and dried to give the 10 desired product (670 mg; 77%).

Example 103B5-Bromo-2-fluoro-benzoyl chloride

Example 103A (665 mg; 3.0 mmol) in thionyl chloride (7 mL) was heated at reflux for 2 hrs., 15 concentrated, and azeotroped with toluene to give a colorless oil that was carried on with no further purification.

Example 103C(5-Bromo-2-fluoro-phenyl)-(1*H*-pyrrol-2-yl)-methanone

20 A solution of 103B (720 mg; 3.0 mmol), and pyrrole (203 mg; 3.0 mmol) in 1,2-dichloroethane (10 mL) at 0 °C was treated portionwise with AlCl₃, stirred overnight while gradually warming to r.t., treated with ice and 1 N HCl, stirred for 1.5 hrs., and extracted with CH₂Cl₂. The extracts were rinsed with water and saturated NaHCO₃ (aq.), dried over Na₂SO₄, concentrated, and isolated by flash chromatography (10% EtOAc/hexane) to give the desired 25 product as a purple solid (252 mg; 31%).

Example 103D5-Bromo-3-(1*H*-pyrrol-2-yl)-1*H*-indazole

The desired product was prepared by substituting Example 103C for Example 102B in 30 Example 102C.

Example 103E(1*S*)-1-(1*H*-Indol-3-ylmethyl)-2-{5-[3-(1*H*-pyrrol-2-yl)-1*H*-indazol-5-yl]-pyridin-3-yloxy}-ethylamine

35 The desired product was prepared as the trifluoroacetate salt by substituting Example 103D for 6-bromoisoquinoline in Example 27. MS (ESI) m/e 449 (M+H)⁺; ¹H NMR (DMSO-d₆, 300 MHz) δ 3.18 (m, 2 H) 3.87 (m, 1 H) 4.20 (dd, *J*=10.51, 5.76 Hz, 1 H) 4.38 (m, 1 H) 6.21

(m, 1 H) 6.86 (m, 2 H) 7.01 (t, $J=7.46$ Hz, 1 H) 7.10 (t, $J=7.46$ Hz, 1 H) 7.30 (d, $J=2.03$ Hz, 1 H) 7.38 (d, $J=8.14$ Hz, 1 H) 7.67 (m, 4 H) 8.15 (bs, 2 H) 8.26 (s, 1 H) 8.35 (d, $J=2.37$ Hz, 1 H) 8.68 (s, 1 H) 11.03 (s, 1 H) 11.38 (s, 1 H) 13.10 (bs, 1 H); Anal. Calcd for $C_{27}H_{24}N_6O \cdot 2.5$ TFA: C, 52.39; H, 3.64; N, 11.46;. Found: C, 52.26; H, 3.67; N, 11.39.

5

Example 104

(1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(3-phenyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine

The desired product was prepared as the trifluoroacetate salt by substituting phenyl 10 magnesium bromide for methyl magnesium bromide in Example 102. MS (ESI) m/e 460 ($M+H$)⁺; ¹H NMR (300 MHz, DMSO-D6) δ ppm 3.17 (m, 2 H) 3.87 (m, 1 H) 4.19 (dd, $J=10.51, 5.76$ Hz, 1 H) 4.38 (m, 1 H) 7.00 (t, $J=7.46$ Hz, 1 H) 7.09 (t, $J=7.46$ Hz, 1 H) 7.30 (d, $J=2.37$ Hz, 1 H) 7.39 (m, 1 H) 7.44 (d, $J=7.12$ Hz, 1 H) 7.54 (m, $J=7.46, 7.46$ Hz, 2 H) 7.62 (d, $J=7.46$ Hz, 1 H) 7.72 (s, 2 H) 7.76 (m, 1 H) 8.05 (s, 1 H) 8.08 (s, 1 H) 8.16 (m, 2 H) 15 8.30 (s, 1 H) 8.36 (d, $J=2.71$ Hz, 1 H) 8.68 (d, $J=1.70$ Hz, 1 H) 11.03 (s, 1 H) 13.45 (bs, 1 H); Anal. Calcd for $C_{27}H_{24}N_6O \cdot 3$ TFA \cdot 2 H₂O: C, 53.24; H, 4.08; N, 8.87;. Found: C, 52.91; H, 3.68; N, 8.80.

20

Example 105

(1S)-2-[5-(3-Cyclopropyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(1H-indol-3-ylmethyl)-ethylamine

The desired product was prepared as the trifluoroacetate salt by substituting cyclopropyl 25 magnesium bromide for methyl magnesium bromide in Example 102. MS (ESI) m/e 424 ($M+H$)⁺; ¹H NMR (300 MHz, DMSO-D6) δ ppm 1.02 (m, 4 H) 2.36 (m, 1 H) 3.15 (m, 2 H) 3.86 (m, 1 H) 4.19 (dd, $J=10.68, 5.93$ Hz, 1 H) 4.37 (dd, $J=10.68, 3.22$ Hz, 1 H) 7.01 (t, $J=7.46$ Hz, 1 H) 7.10 (t, $J=6.95$ Hz, 1 H) 7.30 (d, $J=2.37$ Hz, 1 H) 7.38 (d, $J=8.14$ Hz, 1 H) 7.56 (d, $J=8.48$ Hz, 1 H) 7.65 (m, 2 H) 7.73 (m, 1 H) 8.12 (s, 1 H) 8.19 (m, 2 H) 8.33 (d, $J=2.37$ Hz, 1 H) 8.63 (d, $J=1.36$ Hz, 1 H) 11.03 (d, $J=2.03$ Hz, 1 H) 12.73 (m, 1 H); Anal. 30 Calcd for $C_{26}H_{25}N_5O \cdot 2.6$ TFA: C, 52.05; H, 3.86; N, 9.73;. Found: C, 52.03; H, 3.89; N, 9.69.

Example 106

(1S)-2-[5-(3-Ethyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(1H-indol-3-ylmethyl)-ethylamine

The desired product was prepared as the trifluoroacetate salt by substituting ethyl magnesium 35 bromide for methyl magnesium bromide in Example 102. MS (ESI) m/e 412 ($M+H$)⁺; ¹H NMR (300 MHz, DMSO-D6) δ ppm 1.35 (t, $J=7.63$ Hz, 3 H) 2.99 (q, $J=7.57$ Hz, 2 H) 3.17

(m, 2 H) 3.86 (m, 1 H) 4.19 (dd, $J=10.85, 6.10$ Hz, 1 H) 4.37 (m, 1 H) 7.01 (t, $J=7.46$ Hz, 1 H) 7.11 (t, $J=7.46$ Hz, 1 H) 7.30 (d, $J=2.37$ Hz, 1 H) 7.38 (d, $J=7.80$ Hz, 1 H) 7.63 (m, 3 H) 7.72 (m, 1 H) 8.08 (s, 1 H) 8.16 (m, 2 H) 8.33 (d, $J=2.71$ Hz, 1 H) 8.63 (d, $J=1.70$ Hz, 1 H) 11.04 (d, $J=2.03$ Hz, 1 H) 12.80 (m, 1 H); Anal. Calcd for $C_{25}H_{25}N_5O\cdot 2.7$ TFA: C, 50.76; H, 3.88; N, 9.74;. Found: C, 51.09; H, 3.88; N, 9.66.

Example 107

(1S)-1-(1H-Indol-3-ylmethyl)-2-[5-[3-(1-methyl-1H-imidazol-2-yl)-1H-indazol-5-yl]-10 pyridin-3-yloxy]-ethylamine

The desired product was prepared as the trifluoroacetate salt by substituting *N*-methyl-2-imidazolyl lithium chloride for methyl magnesium bromide in Example 102. MS (ESI) m/e 464 (M+H)⁺; ¹H NMR (400 MHz, DMSO-D6) δ ppm 3.18 (m, 2 H) 3.84 (s, 1 H) 4.07 (s, 3 H) 4.20 (dd, $J=10.59, 5.98$ Hz, 1 H) 4.36 (m, 1 H) 7.00 (t, $J=7.36$ Hz, 1 H) 7.09 (t, $J=7.36$ Hz, 1 H) 7.18 (s, 1 H) 7.31 (d, $J=2.15$ Hz, 1 H) 7.37 (m, 2 H) 7.64 (m, 2 H) 7.72 (s, 2 H) 8.33 (m, 3 H) 8.56 (d, $J=1.53$ Hz, 1 H) 8.63 (s, 1 H) 11.06 (s, 1 H) 13.56 (s, 1 H).

Example 108

(1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(3-thiazol-2-yl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine

The desired product was prepared as the trifluoroacetate salt by substituting 2-thiazolyl lithium chloride for methyl magnesium bromide in Example 102. MS (ESI) m/e 467 (M+H)⁺; ¹H NMR (500 MHz, DMSO-D6) δ ppm 3.19 (d, $J=7.18$ Hz, 2 H) 3.86 (m, 1 H) 4.22 (dd, $J=10.29, 5.93$ Hz, 1 H) 4.38 (dd, $J=10.45, 2.65$ Hz, 1 H) 7.01 (t, $J=7.49$ Hz, 1 H) 7.09 (t, $J=7.49$ Hz, 1 H) 7.31 (d, $J=1.56$ Hz, 1 H) 7.38 (d, $J=8.11$ Hz, 1 H) 7.64 (d, $J=7.80$ Hz, 1 H) 7.73 (s, 1 H) 7.78 (s, 2 H) 7.79 (d, $J=3.12$ Hz, 1 H) 8.04 (d, $J=3.43$ Hz, 1 H) 8.28 (s, 2 H) 8.38 (d, $J=2.18$ Hz, 1 H) 8.60 (s, 2 H) 11.04 (s, 1 H) 13.74 (s, 1 H)

30

Example 109

(1S)-2-[5-[3-(1H-Imidazol-2-yl)-1H-indazol-5-yl]-pyridin-3-yloxy]-1-(1H-indol-3-ylmethyl)-ethylamine

Example 109A

(1S)-[1-(1H-Indol-3-ylmethyl)-2-(5-[3-[1-(2-trimethylsilyl-ethoxymethyl)-1H-imidazol-2-yl]-1H-indazol-5-yl]-pyridin-3-yloxy)-ethyl]-carbamic acid tert-butyl ester

The desired product was prepared as the trifluoroacetate salt by substituting *N*-[2-trimethylsilyl)ethoxy]methyl)-2-imidazolyl lithium chloride for methyl magnesium bromide in Example 102 without doing the last step.

5

Example 109B(1*S*)-2-{5-[3-(1*H*-Imidazol-2-yl)-1*H*-indazol-5-yl]-pyridin-3-yloxy}-1-(1*H*-indol-3-ylmethyl)-ethylamine

A solution of Example 109A (40 mg; 0.06 mmol) in MeOH (4 mL) was treated with conc. HCl (1 mL) and heated at reflux for 6 hrs., concentrated and purified by reverse phase HPLC on a C18 column with 0-100% CH₃CN/H₂O/0.1 % TFA to provide the desired product as the trifluoroacetate salt. MS (ESI) m/e 450 (M+H)⁺; ¹H NMR (500 MHz, DMSO-D6) δ ppm 3.19 (d, *J*=7.17 Hz, 2 H) 3.86 (s, 1 H) 4.22 (dd, *J*=10.45, 5.77 Hz, 1 H) 4.37 (dd, *J*=10.45, 2.96 Hz, 1 H) 7.00 (t, *J*=7.49 Hz, 1 H) 7.09 (t, *J*=7.49 Hz, 1 H) 7.30 (d, *J*=2.18 Hz, 1 H) 7.38 (d, *J*=8.11 Hz, 1 H) 7.63 (d, *J*=8.11 Hz, 1 H) 7.76 (s, 1 H) 7.83 (s, 1 H) 7.86 (s, 2 H) 8.26 (bs, 3 H) 8.39 (d, *J*=2.50 Hz, 1 H) 8.61 (s, 1 H) 8.72 (s, 1 H) 11.04 (s, 1 H) 14.36 (s, 1 H)

20

Example 110(1*S*)-1-(1*H*-Indol-3-ylmethyl)-2-[5-(3-thiophen-2-yl-1*H*-indazol-5-yl)-pyridin-3-yloxy]-ethylamine

25

The desired product was prepared by substituting 2-thiophenyl lithium chloride for methylmagnesium bromide in Example 102. MS (ESI) m/e 466 (M+H)⁺; ¹H NMR (400 MHz, DMSO-D6) δ ppm 3.21 (d, *J*=7.06 Hz, 2 H) 3.86 (bs, 1 H) 4.23 (dd, *J*=10.43, 5.83 Hz, 1 H) 4.38 (m, 1 H) 7.00 (t, *J*=7.52 Hz, 1 H) 7.10 (t, *J*=7.06 Hz, 1 H) 7.23 (dd, *J*=5.22, 3.68 Hz, 1 H) 7.31 (d, *J*=2.15 Hz, 1 H) 7.39 (d, *J*=7.98 Hz, 1 H) 7.59 (d, *J*=6.14 Hz, 1 H) 7.64 (d, *J*=7.98 Hz, 1 H) 7.73 (m, 3 H) 7.91 (d, *J*=2.76 Hz, 1 H) 8.34 (m, 4 H) 8.67 (s, 1 H) 11.06 (s, 1 H) 13.39 (s, 1 H)

30

Example 111(1*S*)-1-(1*H*-Indol-3-ylmethyl)-2-[5-(3-morpholin-4-yl-1*H*-indazol-5-yl)-pyridin-3-yloxy]-ethylamineExample 111A5-Bromo-3-morpholin-4-yl-1*H*-indazole

35

The reaction between Example 35A and morpholine was carried out according to the procedure described by U. Wrzeciono, K. Majewska, J. Dudzinska-Usarewicz, M. Bernas, *Pharmazie*, 1986, 41, 472-474.

Example 111B(1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(3-morpholin-4-yl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine

5 The desired product was prepared by substituting Example 111A for 6-bromoisoquinoline in Example 27. MS (ESI) m/e 469 (M+H)⁺; ¹H NMR (300 MHz, DMSO-D6) δ ppm 3.16 (d, *J*=7.12 Hz, 2 H) 3.35 (m, 4 H) 3.81 (m, 4 H) 3.88 (m, 1 H) 4.19 (dd, *J*=10.68, 5.93 Hz, 1 H) 4.35 (m, 1 H) 7.01 (t, *J*=7.46 Hz, 1 H) 7.10 (t, *J*=7.46 Hz, 1 H) 7.30 (d, *J*=2.37 Hz, 1 H) 7.38 (d, *J*=7.80 Hz, 1 H) 7.48 (d, *J*=8.82 Hz, 1 H) 7.62 (m, 2 H) 7.72 (m, 1 H) 8.09 (s, 1 H) 8.17 (m, 2 H) 8.33 (d, *J*=2.71 Hz, 1 H) 8.65 (d, *J*=1.70 Hz, 1 H) 11.03 (s, 1 H) 12.21 (s, 1 H); Anal. Calcd for C₂₇H₂₈N₆O₂•3.4 TFA: C, 47.41; H, 3.70; N, 9.82; Found: C, 47.10; H, 3.86; N, 9.95.

10

Example 112(1S)-2-[5-(1,3-Dimethyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(1H-indol-3-ylmethyl)-ethylamineExample 112A5-Bromo-1,3-dimethyl-1H-indazole

20 Example 102C (500 mg; 2.37 mmol) was added to a mixture of 60% NaH (115 mg; 2.84 mmol) in DMF (10 mL). After 15 min. at r.t. iodomethane (456 mg; 3.21 mmol) was added, the reaction was stirred for 2 hrs then diluted with water and extracted with EtOAc. The extracts were rinsed with water and brine, dried (MgSO₄), evaporated, and isolated by flash chromatography (1:1 Et₂O:hexane) to give the desired product (360 mg; 67%).

25

Example 112B

The desired product was prepared as the trifluoroacetate salt by substituting Example 112A for Example 6-bromoisoquinoline in Example 27. MS (ESI) m/e 412 (M+H)⁺; ¹H NMR (300 MHz, DMSO-D6) δ ppm 2.54 (s, 3 H) 3.18 (m, 2 H) 3.86 (s, 1 H) 4.00 (s, 3 H) 4.20 (dd, *J*=10.51, 6.10 Hz, 1 H) 4.37 (m, 1 H) 7.01 (t, *J*=7.46 Hz, 1 H) 7.10 (t, *J*=7.12 Hz, 1 H) 7.30 (d, *J*=2.37 Hz, 1 H) 7.39 (d, *J*=7.80 Hz, 1 H) 7.63 (d, *J*=7.80 Hz, 1 H) 7.73 (m, 2 H) 8.08 (s, 1 H) 8.18 (m, 3 H) 8.34 (d, *J*=2.71 Hz, 1 H) 8.66 (d, *J*=1.70 Hz, 1 H) 11.04 (s, 1 H); Anal. Calcd for C₂₅H₂₅N₅O•2.8 TFA: C, 50.29; H, 3.83; N, 9.58; Found: C, 50.36; H, 3.84, N, 9.60.

35

Example 113(1S)-1-(1H-Indol-3-ylmethyl)-2-[3-(3-methyl-1H-indazol-5-yl)-phenoxy]-ethylamine

The desired product was prepared as the trifluoroacetate salt by substituting 3-bromophenol for 3-bromo-5-hydroxypyridine in Example 102. MS (ESI) m/e 397 (M+H)⁺; ¹H NMR (300 MHz, DMSO-D6) δ ppm 2.54 (s, 3 H) 3.17 (m, 2 H) 3.81 (m, 1 H) 4.09 (dd, *J*=10.51, 5.76 Hz, 1 H) 4.25 (dd, *J*=10.51, 3.05 Hz, 1 H) 6.93 (m, 1 H) 7.01 (t, *J*=7.46 Hz, 1 H) 7.10 (t, *J*=7.46 Hz, 1 H) 7.28 (m, 2 H) 7.37 (m, 3 H) 7.52 (d, *J*=8.48 Hz, 1 H) 7.61 (m, 2 H) 7.93 (s, 1 H) 8.15 (bs, 2 H) 11.03 (s, 1 H) 12.62 (bs, 1 H)

Example 114

10 (1S)-1-(1H-Indol-3-ylmethyl)-2-{5-[3-(4-methyl-piperazin-1-yl)-1H-indazol-5-yl]-pyridin-3-
yloxy}-ethylamine

Example 114A

5-Bromo-3-(4-methyl-piperazin-1-yl)-1H-indazole

15 The reaction between Example 35A and *N*-methyl piperazine was carried out according to the procedure described by U. Wrzeciono, K. Majewska, J. Dudzinska-Usarewicz, M. Bernas, *Pharmzie*, 1986, 41, 472-474.

Example 114B

20 (1S)-1-(1H-Indol-3-ylmethyl)-2-{5-[3-(4-methyl-piperazin-1-yl)-1H-indazol-5-yl]-pyridin-3-
yloxy}-ethylamine

The desired product was prepared by substituting Example 114A for 6-bromoisoquinoline in Example 27. MS (ESI) m/e 482 (M+H)⁺; ¹H NMR (300 MHz, DMSO-D6) δ ppm 2.54 (s, 3 H) 2.90 (m, 2 H) 3.21 (m, 4 H) 3.54 (m, 2 H) 3.83 (m, 1 H) 4.06 (m, 2 H) 4.19 (dd, *J*=10.68, 5.93 Hz, 1 H) 4.35 (dd, *J*=10.51, 2.71 Hz, 1 H) 7.01 (t, *J*=6.95 Hz, 1 H) 7.10 (t, *J*=7.12 Hz, 1 H) 7.30 (d, *J*=2.03 Hz, 1 H) 7.38 (d, *J*=8.14 Hz, 1 H) 7.51 (d, *J*=8.82 Hz, 1 H) 7.65 (m, 3 H) 8.15 (s, 1 H) 8.21 (m, 2 H) 8.33 (d, *J*=2.71 Hz, 1 H) 8.66 (d, *J*=1.70 Hz, 1 H) 11.04 (s, 1 H) 12.36 (s, 1 H); Anal. Calcd for C₂₈H₃₁N₇O•4.45 TFA: C, 44.81; H, 3.61; N, 9.91;. Found: C, 44.83; H, 3.53, N, 9.97.

Example 115

35 (1S)-(5-{5-[2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-1H-indazol-3-yl)-dimethyl-
amine

Example 115A

(5-Bromo-1H-indazol-3-yl)-dimethyl-amine

The reaction between Example 35A and dimethylamine was carried out according to the procedure described by U. Wrzeciono, K. Majewska, J. Dudzinska-Usarewicz, M. Bernas, *Pharmazie*, 1986, 41, 472-474.

5

Example 115B(1S)-(5-{5-[2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-1H-indazol-3-yl)-dimethyl-amine

The desired product was prepared by substituting Example 115A for 6-bromoisoquinoline in Example 27. MS (ESI) m/e 427 (M+H)⁺; ¹H NMR (300 MHz, DMSO-D6)δ ppm 3.04 (s, 6 H) 3.16 (m, 2 H) 3.86 (s, 1 H) 4.19 (m, 1 H) 4.36 (m, 1 H) 7.01 (t, *J*=6.95 Hz, 1 H) 7.10 (t, *J*=7.12 Hz, 1 H) 7.30 (d, *J*=2.37 Hz, 1 H) 7.38 (d, *J*=8.14 Hz, 1 H) 7.45 (d, *J*=8.82 Hz, 1 H) 7.61 (m, 2 H) 7.73 (s, 1 H) 8.07 (s, 1 H) 8.17 (m, 2 H) 8.33 (d, *J*=2.37 Hz, 1 H) 8.62 (d, *J*=1.36 Hz, 1 H) 11.03 (s, 1 H) 12.04 (s, 1 H); Anal. Calcd for C₂₅H₂₆N₈O•3.5 TFA: C, 46.55; H, 3.60; N, 10.18;. Found: C, 46.71; H, 3.65, N, 10.02.

Example 116(1S)-(4-(5-(2-Amino-3-(1H-indol-3-yl)-propoxy)-pyridin-3-yl)-benzyl)-phenyl-amine

20

Example 116A(1S)-[2-[5-(4-Formyl-phenyl)-pyridin-3-yloxy]-1-(1H-indol-3-ylmethyl)-ethyl]-carbamic acid
tert-butyl ester

The desired product was prepared by substituting 4-formylphenylboronic acid for 4-cyanophenylboronice acid in Example 22. MS: (ESI) m/z 472 (M + H)⁺.

25

Example 116B(1S)-{1-(1H-Indol-3-ylmethyl)-2-[5-(4-phenylaminomethyl-phenyl)-pyridin-3-yloxy]-ethyl}-
carbamic acid tert-butyl ester

A solution of Example 116A (0.03 g, 0.06 mmol) in 2 mL of MeOH was cooled to 0°C then treated with aniline (0.018 g 0.2 mmol), NaBH₃CN (0.004 g, 0.06 mmol) and AcOH (1 ml). The mixture was allowed to warm to room temperature overnight. The mixture was diluted with ethyl acetate (20 ml), washed with water (10 ml) and brine (10 ml). The ethyl acetate was evaporated off and the residue was used without further purification.

35

Example 116C(1S)-(4-(5-(2-Amino-3-(1H-indol-3-yl)-propoxy)-pyridin-3-yl)-benzyl)-phenyl-amine

The desired product was prepared by substituting Example 116B for Example 27B in Example 27C. MS: (ESI) (M + H)⁺ m/z = 449. ¹H NMR (500 MHz, DMSO-D6) δ ppm 3.82 (m, 7 H) 4.18 (m, 1 H) 4.32 (d, J=4.06 Hz, 2 H) 6.55 (d, J=32.76 Hz, 1 H) 6.59 (d, J=7.49 Hz, 1 H) 6.89 (d, J=7.49 Hz, 1 H) 7.04 (m, 3 H) 7.18 (m, 1 H) 7.29 (d, J=2.50 Hz, 1 H) 7.37 (d, J=7.80 Hz, 1 H) 7.48 (d, J=8.11 Hz, 1 H) 7.62 (m, 3 H) 8.31 (bs, 3 H) 8.52 (d, J=1.56 Hz, 1 H) 11.04 (d, J=1.87 Hz, 1 H)

Example 117

10 (1S)-(4-(5-(2-Amino-3-(1H-indol-3-yl)-propoxy)-pyridin-3-yl)-phenyl)-methanol

Example 117A

15 (1S)-{2-[5-(4-Hydroxymethyl-phenyl)-pyridin-3-yloxy]-1-phenyl-ethyl}-carbamic acid *tert*-butyl ester

Example 116A (0.03 g, 0.06 mmol) was dissolved in 2 mL of MeOH and cooled to 0 °C, then treated with NaBH₄ (0.003 g, 0.08 mmol). The mixture was allowed to warm to room temperature over 2 h. The mixture was diluted with ethyl acetate (20 ml), washed with water (10 ml) and brine (10 ml). The ethyl acetate was evaporated off and the residue was used without further purification.

Example 117B

(1S)-(4-(5-(2-Amino-3-(1H-indol-3-yl)-propoxy)-pyridin-3-yl)-phenyl)-methanol

25 The desired product was prepared by substituting Example 117A for Example 27B in Example 27C. MS: (ESI) m/z 374 (M + H)⁺; ¹H NMR (500 MHz, DMSO-D6) δ ppm 3.15 (m, 4 H) 3.72 (m, 1 H) 4.16 (dd, J=10.29, 5.93 Hz, 1 H) 4.29 (m, 1 H) 4.55 (s, 2 H) 5.29 (s, 1 H) 6.99 (t, J=7.02 Hz, 1 H) 7.09 (t, J=7.02 Hz, 1 H) 7.28 (d, J=2.18 Hz, 1 H) 7.37 (d, J=8.11 Hz, 1 H) 7.43 (d, J=8.42 Hz, 2 H) 7.59 (m, 1 H) 7.64 (dd, J=10.61, 8.42 Hz, 3 H) 8.30 (d, J=2.81 Hz, 1 H) 8.51 (d, J=1.56 Hz, 1 H) 11.03 (s, 1 H)

30

Example 118

(1S)-2-(5-(4-Fluoro-phenyl)- pyridin-3-yloxy)-1-(1H-indol-3-ylmethyl)-ethylamine

35 The desired product was prepared by substituting 4-fluorophenylboronic acid for 4-cyanophenylboronic acid in Example 22. MS: (ESI) m/z 362 (M + H)⁺; ¹H NMR (500 MHz, DMSO-D6) δ ppm 3.09 (m, 2 H) 3.17 (d, J=4.68 Hz, 1 H) 3.71 (s, 1 H) 4.12 (dd, J=10.29, 6.24 Hz, 1 H) 4.26 (dd, J=10.29, 3.43 Hz, 1 H) 6.99 (t, J=7.49 Hz, 1 H) 7.09 (m, 1 H) 7.26 (d,

5 $J=2.18$ Hz, 1 H) 7.34 (m, 3 H) 7.59 (m, 2 H) 7.74 (m, 2 H) 8.32 (d, $J=2.50$ Hz, 1 H) 8.50 (d, $J=1.87$ Hz, 1 H) 10.97 (s, 1 H).

Example 119

5 (1S)-4-(5-(2-Amino-3-(1*H*-indol-3-yl)-propoxy)-pyridin-3-yl)-benzoic acid

The desired product was prepared by substituting 4-hydroxycarbonylphenylboronic acid for 4-cyanophenylboronic acid in Example 22. MS (ESI) m/z 388 (M + H)⁺; 1H NMR (500 MHz, DMSO-D6) δ ppm 3.17 (m, 1 H) 3.84 (m, 1 H) 4.20 (m, 1 H) 4.35 (m, 1 H) 7.00 (t, $J=6.86$ Hz, 1 H) 7.10 (t, $J=7.02$ Hz, 1 H) 7.30 (d, $J=2.18$ Hz, 1 H) 7.38 (d, $J=8.11$ Hz, 1 H) 10 7.63 (d, $J=7.49$ Hz, 1 H) 7.68 (m, 1 H) 7.83 (d, $J=8.42$ Hz, 1 H) 8.04 (m, 2 H) 8.26 (s, 3 H) 8.38 (d, $J=2.50$ Hz, 1 H) 8.59 (d, $J=1.87$ Hz, 1 H) 11.02 (d, $J=1.87$ Hz, 1 H)

Example 120

15 (1*S*)-2-(3-Bromo-5-isoquinolin-6-yl-phenoxyoxy)-1-(1*H*-indol-3-ylmethyl)-ethylamine

Step 1.

Example 120A

20 (2*S*)-[1-(3,5-Dibromo-phenoxyethyl)-2-(1*H*-indol-3-yl)-ethyl]-carbamic acid tert-butyl ester

A solution of 3,5-dibromo-phenol (1 g, 4.1 mmol), (2-hydroxy-1-phenyl-ethyl)- carbamic acid tert-butyl ester (1.2 g, 4.1 mmol), and triphenylphosphine (1.6 g, 2 mmol) in THF (30 mL) was stirred at 0 °C for 30 min. To the mixture was added a solution of di*t*-butyl azidodicarboxylate (1.45 g, 9.2 mmol) in 5 ml of THF. The mixture was allowed to warm to room temperature then stirred at room temperature for 20h. The THF was evaporated off and the residue was taken into ethyl acetate (75 ml), washed with saturated sodium bicarbonate (50 ml) water (50 ml) and brine (50 ml). The ethyl acetate was evaporated of and the residue was purified by flash column chromatography on silica gel, eluting with a solvent gradient of 1:4 to 1:1 ethyl acetate/hexane. Recovered 1.33 g of product (64 %).

30

Example 120B

(2*S*)-[1-(3-Bromo-5-isoquinolin-6-yl-phenoxyethyl)-2-(1*H*-indol-3-yl)-ethyl]-carbamic acid tert-butyl ester

A solution of Example 120A above (0.6 g, 01.1 mmol) and 6-trimethylstannanyl-isoquinoline (0.26 g, 1 mmol) in 5 mL of DMF was treated with Pd₂(dba)₃ (0.1 g, 0.1 mmol), P(o-tol)₃ (0.07 g, 0.2 mmol), and TEA (0.3 mL, 2.3 mmol). The reaction was heated to 95°C for 6.5 h, then cooled and diluted with ethyl acetate (75 ml), washed with saturated sodium bicarbonate

(50 ml) water (50 ml) and brine (50 ml). The ethyl acetate was evaporated off and the residue was purified by flash column chromatography on silica gel, eluting with a solvent gradient of 1:4 to 1:1 ethyl acetate/hexane.

0.2 g of product (30 %). MS (ESI) m/z 572 (M + H)⁺.

5

Example 120C

(1S)-2-(3-Bromo-5-isoquinolin-6-yl-phenoxyoxy)-1-(1H-indol-3-ylmethyl)-ethylamine

The desired product was prepared by substituting Example 120B for Example 27B in Example 27C. MS (ESI) m/z 472 (M + H)⁺; ¹H NMR (500 MHz, DMSO-D6) δ ppm 2.87 (d, J=6.55 Hz, 1 H) 3.00 (d, J=6.55 Hz, 1 H) 3.47 (m, 2 H) 3.99 (dd, J=9.67, 6.24 Hz, 1 H) 4.07 (d, J=4.37 Hz, 1 H) 6.96 (t, J=7.02 Hz, 1 H) 7.06 (t, J=7.02 Hz, 1 H) 7.22 (d, J=2.18 Hz, 1 H) 7.24 (m, 1 H) 7.35 (d, J=8.11 Hz, 1 H) 7.41 (m, 1 H) 7.58 (d, J=7.80 Hz, 1 H) 7.62 (s, 1 H) 7.89 (d, J=5.93 Hz, 1 H) 8.00 (dd, J=8.42, 1.87 Hz, 1 H) 8.21 (d, J=8.73 Hz, 1 H) 8.32 (s, 1 H) 8.54 (d, J=5.62 Hz, 1 H) 9.35 (s, 1 H) 10.87 (s, 1 H)

15

Example 121

N4-(3-(5-(2-Amino-3-(1H-indol-3-yl)-propoxy)-pyridin-3-yl)-phenyl)-pyrimidine-2,4-diamine

20

Example 121A

(1S)-[2-[5-(3-Amino-phenyl)-pyridin-3-yloxy]-1-(1H-indol-3-ylmethyl)-ethyl]-carbamic acid *tert*-butyl ester

The desired product was prepared by substituting 3-aminophenylboronic acid for 4-cyanophenylboronic acid in Example 22.

25

Example 121B

(1S)-[2-[5-[3-(2-Amino-pyrimidin-4-ylamino)-phenyl]-pyridin-3-yloxy]-1-(1H-indol-3-ylmethyl)-ethyl]-carbamic acid *tert*-butyl ester

A mixture of Example 121A (0.07 g, 0.153 mmol) and 4-chloro-2-pyrimidinylamine (0.021 g, 0.163 mmol) was dissolved in EtOH (1mL). The mixture was heated to 80°C overnight then cooled and evaporated. The product was used without further purification.

Example 121C

(1S)-[2-[5-(3-Amino-phenyl)-pyridin-3-yloxy]-1-(1H-indol-3-ylmethyl)-ethyl]-carbamic acid *tert*-butyl ester

The desired product was prepared by substituting Example 121B for Example 27B in Example 27C. MS (ESI) m/z 452 (M + H)⁺. ¹H NMR (500 MHz, DMSO-D6) δ ppm 3.17 (m,

2 H) 3.85 (m, 1 H) 3.97 (s, 1 H) 4.19 (m, 1 H) 4.35 (m, 1 H) 6.35 (d, $J=6.86$ Hz, 1 H) 7.00 (t, $J=7.49$ Hz, 1 H) 7.10 (m, 1 H) 7.29 (d, $J=2.18$ Hz, 1 H) 7.38 (d, $J=8.11$ Hz, 1 H) 7.52 (m, $J=7.80$ Hz, 2 H) 7.62 (d, $J=7.80$ Hz, 1 H) 7.66 (m, 1 H) 7.88 (d, $J=7.18$ Hz, 1 H) 8.25 (d, $J=4.37$ Hz, 2 H) 8.38 (d, $J=2.50$ Hz, 1 H) 8.58 (d, $J=1.56$ Hz, 1 H) 10.73 (s, 1 H) 11.02 (d, $J=1.87$ Hz, 1 H).

Example 122

(1S)-3-(2-Amino-3-(1H-indol-3-yl)-propoxy)-5-isoquinolin-6-yl-phenylamine

10

Example 122A

(1S)-[2-[3-(Benzhydrylidene-amino)-5-isoquinolin-6-yl-phenoxy]-1-(1H-indol-3-ylmethyl)-ethyl]-carbamic acid *tert*-butyl ester

A solution of Example 120B (0.165 g, 0.29 mmol) and benzophenone imine (0.1 mL, 0.6 mmol) in 5 mL of toluene was treated with Pd_2dba_3 (0.026 g, 0.028 mmol), BINAP (0.036 g, 0.058 mmol) and sodium *t*butoxide (0.042 g, 0.44 mmol). The reaction was heated to 80°C overnight then to 95 °C for 24 h. The mixture was cooled and filtered through celite. The residue was purified by flash column chromatography on silica gel, eluting with 1:1 ethyl acetate/hexane. Recovered 0.175 g of product (90 %). MS (ESI) m/z 673 (M + H)⁺.

20

Example 122B

(1S)-3-(2-Amino-3-(1H-indol-3-yl)-propoxy)-5-isoquinolin-6-yl-phenylamine

A solution of Example 122A (0.175 g, 0.26 mmol) in 2 mL of THF was cooled to 0°C then treated with 1 mL of 3N HCl. The mixture was stirred at 0 °C for 15 minutes then at room temperature for 4 h. The mixture was evaporated and the residue was purified by flash column chromatography on silica gel, eluting with 10 % methanol in methylene chloride. Recovered 0.029 g of product (23 %). MS (ESI) m/z 408 (M + H)⁺; ¹H NMR (500 MHz, DMSO-D6) δ ppm 3.20 (m, 2 H) 3.77 (m, 1 H) 4.12 (d, $J=5.62$ Hz, 1 H) 4.21 (d, $J=3.43$ Hz, 1 H) 6.58 (s, 1 H) 6.86 (m, 1 H) 6.95 (s, 1 H) 7.01 (m, 1 H) 7.08 (d, $J=7.18$ Hz, 1 H) 7.29 (d, $J=2.18$ Hz, 1 H) 7.37 (d, $J=8.11$ Hz, 1 H) 7.66 (d, $J=7.80$ Hz, 1 H) 8.13 (d, $J=8.73$ Hz, 1 H) 8.38 (d, $J=6.24$ Hz, 1 H) 8.43 (s, 1 H) 8.52 (m, 3 H) 8.65 (d, $J=6.24$ Hz, 1 H) 9.78 (s, 1 H) 11.06 (d, $J=1.87$ Hz, 1 H)

35

Example 123

4-(5-Isoquinolin-6-yl-pyridin-3-yl)-piperazine-1-carboxylic acid *tert*-butyl ester

Example 123A4-(5-Bromo-pyridin-3-yl)-piperazine-1-carboxylic acid *tert*-butyl ester

A solution of the 3,5-dibromo-pyridine (12.8 g, 68.8 mmol) and piperazine-1-carboxylic acid *tert* butyl ester (10 g, 42.4 mmol) in 200 mL of dioxane was treated with $\text{Pd}(\text{dba})_3$ (5 g, 5.5 mmol), 2-(di-*t*butyl-phosphino)biphenyl (4 g, 13.4 mmol), and sodium *t*-butoxide (7.2 g, 75 mmol). The reaction was heated to 95 °C for 8 h then cooled and filtered through celite. The mixture was evaporated and the residue was purified by flash column chromatography on silica gel, eluting with a solvent gradient of 1:4 ethyl acetate/hexane to 100 % ethyl acetate. Recovered 2.9 g of product (20 %). MS (ESI) m/z 344 (M + H)⁺.

10

Example 123B4-(5-Isoquinolin-6-yl-pyridin-3-yl)-piperazine-1-carboxylic acid *tert*-butyl ester

The desired product was prepared by substituting Example 123A for Example 27A in Example 123B. MS (ESI) m/z 408 (M + H)⁺; ¹H NMR (500 MHz, CHLOROFORM-D) δ ppm 1.50 (m, 9 H) 3.29 (m, 4 H) 3.65 (m, 4 H) 7.46 (m, 1 H) 7.72 (d, *J*=5.62 Hz, 1 H) 7.83 (d, *J*=1.87 Hz, 1 H) 7.99 (s, 1 H) 8.09 (d, *J*=8.74 Hz, 1 H) 8.37 (d, *J*=2.81 Hz, 1 H) 8.46 (d, *J*=1.87 Hz, 1 H) 8.59 (d, *J*=5.93 Hz, 1 H) 9.31 (s, 1 H).

20

Example 1246-(5-Piperazin-1-yl-pyridin-3-yl)-isoquinoline

The desired product was prepared by substituting Example 123 for Example 27B in Example 27C. MS (ESI) m/z 291 (M + H)⁺; ¹H NMR (500 MHz, Solvent) δ ppm 3.47 (m, 4 H) 3.79 (m, 4 H) 8.30 (m, 1 H) 8.39 (dd, *J*=8.58, 1.72 Hz, 1 H) 8.49 (d, *J*=6.55 Hz, 1 H) 8.57 (d, *J*=2.50 Hz, 1 H) 8.63 (m, 2 H) 8.70 (m, 2 H) 9.78 (s, 1 H).

30

Example 125((2*S*)-2-Amino-5-(5-(2-amino-3-(1*H*-indol-3-yl)-propoxy)-pyridin-3-yl)-phenyl-(3-chlorophenyl-methanone

The title compound was prepared by substituting 2-amino-5-iodo-3'-chloro benzophenone for Example 32A in Example 32. MS (ESI) m/z 291 (M + H)⁺; ¹H NMR (500 MHz, DMSO-D6) δ ppm 3.15 (m, 2 H) 3.81 (m, 1 H) 4.11 (m, 1 H) 4.26 (m, 1 H) 7.00 (m, 2 H) 7.09 (m, 1 H) 7.27 (m, 1 H) 7.39 (m, 2 H) 7.60 (m, 4 H) 8.21 (m, 1 H) 8.32 (m, 3 H) 11.07 (m, 1 H).

35

Example 126(1*S*)-N6-(3-(5-(2-Amino-3-(1*H*-indol-3-yl)-propoxy)-pyridin-3-yl)-phenyl)-9*H*-purine-2,6-diamine

The title compound was prepared by substituting 6-Chloro-9*H*-purin-2-ylamine for 4-chloro-2-pyrimidinylamine in Example 121. MS (ESI) m/z 492 (M + H)⁺; ¹H NMR (400 MHz, DMSO-D6) δ ppm 3.18 (d, *J*=8.29 Hz, 2 H) 3.83 (m, 1 H) 4.01 (m, 1 H) 4.19 (m, 1 H) 4.36 (m, 1 H) 7.01 (m, 2 H) 7.09 (t, *J*=7.06 Hz, 1 H) 7.16 (s, 1 H) 7.30 (m, 2 H) 7.38 (d, *J*=8.29 Hz, 1 H) 7.63 (m, 2 H) 8.18 (s, 2 H) 8.30 (m, 2 H) 8.35 (d, *J*=2.45 Hz, 1 H) 8.56 (d, *J*=1.84 Hz, 1 H) 11.02 (s, 1 H).

10

Example 127(3-(5-((2*S*)-2-Amino-3-(1*H*-indol-3-yl)-propoxy)-pyridin-3-yl)-phenyl)-pyrimidin-2-yl-amine

The title compound was prepared by substituting 2-chloropyrimidine for 4-chloro-2-pyrimidinylamine in Example 121. MS (ESI) m/z 437 (M + H)⁺; ¹H NMR (500 MHz, DMSO-D6) δ ppm 3.17 (d, *J*=5.30 Hz, 1 H) 4.06 (q, *J*=5.30 Hz, 5 H) 6.86 (t, *J*=4.84 Hz, 2 H) 6.96 (d, *J*=7.18 Hz, 1 H) 7.05 (s, 1 H) 7.26 (m, 1 H) 7.34 (d, *J*=8.11 Hz, 1 H) 7.40 (t, *J*=7.96 Hz, 1 H) 7.54 (m, 1 H) 7.55 (s, 1 H) 7.85 (m, 2 H) 8.07 (t, *J*=1.72 Hz, 1 H) 8.30 (d, *J*=2.50 Hz, 1 H) 8.44 (d, *J*=1.87 Hz, 1 H) 8.50 (d, *J*=4.68 Hz, 2 H) 9.68 (s, 1 H) 10.85 (s, 1 H).

20

Example 128(3-(5-((2*S*)-2-Amino-3-(1*H*-indol-3-yl)-propoxy)-pyridin-3-yl)-phenyl)-thiazol-2-yl-amine

The title compound was prepared by substituting 2-chlorothiazole for 4-chloro-2-pyrimidinylamine in Example 121. MS (ESI) m/z 442 (M + H)⁺; ¹H NMR (500 MHz, DMSO-D6) δ ppm 3.16 (m, 3 H) 4.16 (m, 1 H) 4.34 (m, 1 H) 6.94 (d, *J*=3.74 Hz, 1 H) 7.01 (m, 1 H) 7.10 (m, 1 H) 7.22 (m, 1 H) 7.28 (dd, *J*=7.96, 2.96 Hz, 2 H) 7.38 (d, *J*=8.42 Hz, 1 H) 7.42 (d, *J*=7.80 Hz, 1 H) 7.57 (m, 1 H) 7.62 (d, *J*=8.11 Hz, 1 H) 8.02 (s, 1 H) 8.14 (s, 2 H) 8.35 (d, *J*=2.50 Hz, 1 H) 8.48 (d, *J*=1.87 Hz, 1 H) 10.31 (s, 1 H) 11.01 (s, 1 H).

30

Example 129*N*-(3-(5-((2*S*)-2-Amino-3-(1*H*-indol-3-yl)-propoxy)-pyridin-3-yl)-phenyl)-acetamide

35

Example 129A(1*S*)-[2-[5-(3-Acetylamino-phenyl)-pyridin-3-yloxy]-1-(1*H*-indol-3-ylmethyl)-ethyl]-carbamic acid *tert*-butyl ester

Example 121A (0.05 g, 0.11 mmol) was taken in methylene chloride (1.5 mL) and treated with acetic anhydride (0.2 mL, 2.1 mmol) and triethylamine (0.1 mL, 0.77 mmol). The mixture was stirred overnight at room temperature then diluted with methylene chloride (25 mL) and washed with water (15 mL) and brine (15 mL). The mixture was evaporated and used without further purification.

5 Example 129B

N-(3-((2S)-2-Amino-3-(1H-indol-3-yl)-propoxy)-pyridin-3-yl)-phenyl)-acetamide

The desired product was prepared by substituting Example 129A for Example 27B in Example 27C. MS (ESI) m/z 401 (M + H)⁺; ¹H NMR (400 MHz, DMSO-D6) δ ppm 2.07 (m, 3 H) 3.16 (m, 3 H) 4.16 (m, 1 H) 4.33 (m, 1 H) 7.01 (m, 1 H) 7.10 (m, 1 H) 7.29 (m, 1 H) 7.38 (m, 3 H) 7.55 (m, 2 H) 7.62 (m, 1 H) 7.99 (m, 1 H) 8.14 (m, 2 H) 8.35 (m, 1 H) 8.48 (m, 1 H) 10.06 (m, 1 H) 11.01 (m, 1 H).

10 Example 130

6-(5-(4-(1H-Indol-3-ylmethyl)-piperazin-1-yl)-pyridin-3-yl)-isoquinoline

The title compound was prepared by substituting Example 124 for aniline, and 3-formylindole for Example 116A in example 116B. MS (ESI) (m/z 420M + H)⁺; ¹H NMR (400 MHz, DMSO-D6) δ ppm 1.89 (s, 2 H) 2.50 (m, 4 H) 2.60 (m, 4 H) 7.02 (m, 2 H) 7.27 (d, J=2.46 Hz, 1 H) 7.36 (d, J=7.98 Hz, 1 H) 7.68 (m, 2 H) 7.87 (d, J=5.83 Hz, 1 H) 8.05 (dd, J=8.59, 1.53 Hz, 1 H) 8.22 (d, J=8.90 Hz, 1 H) 8.34 (m, 2 H) 8.44 (d, J=1.84 Hz, 1 H) 8.54 (d, J=5.83 Hz, 1 H) 9.35 (s, 1 H) 10.93 (s, 1 H).

25 Example 131

3-((2S)-2-Amino-3-(1H-indol-3-yl)-propoxy)-5-isoquinolin-6-yl-benzoic acid


Example 131A

3-[(2S)-2-*tert*-Butoxycarbonylamino-3-(1H-indol-3-yl)-propoxy]-5-isoquinolin-6-yl-benzoic acid

A solution of Example 120 (0.2 g, 0.3 mmol) 6 mL of DMF was treated with Pd(dppf)₂Cl₂ (0.039 g, 0.07 mmol), Pd(OAc)₂ (0.016 g, 0.07 mmol), ammonium hydroxide (0.15 mL), and triethylamine (0.5 mL, 3.9 mmol). The reaction was heated to 80 °C after which CO was bubbled through for 30 minutes. The mixture was heated to 80 °C overnight then cooled, neutralized with HCl and washed with ethyl acetate. The water was evaporated off to yield the product. MS (ESI) m/z 538 (M + H)⁺.

Example 131B3-((2S)-2-Amino-3-(1H-indol-3-yl)-propoxy)-5-isoquinolin-6-yl-benzoic acid

The desired product was prepared by substituting Example 131A for Example 27B in Example 27C. MS (ESI) m/z 438 (M + H)⁺; ¹H NMR (500 MHz, DMSO-D6) δ ppm 3.14 (m, 3 H) 4.20 (m, 1 H) 4.35 (d, *J*=2.81 Hz, 1 H) 7.02 (m, 1 H) 7.09 (d, *J*=8.11 Hz, 1 H) 7.30 (d, *J*=2.50 Hz, 1 H) 7.38 (d, *J*=8.11 Hz, 1 H) 7.63 (m, 2 H) 7.68 (s, 1 H) 8.04 (s, 1 H) 8.11 (m, 2 H) 8.18 (s, 3 H) 8.36 (d, *J*=8.73 Hz, 1 H) 8.42 (s, 1 H) 8.61 (d, *J*=5.93 Hz, 1 H) 9.53 (s, 1 H) 11.02 (d, *J*=1.56 Hz, 1 H).

Example 1324-(5-((2S)-2-Amino-3-(1H-indol-3-yl)-propoxy)-pyridin-3-yl)-phenylamine

The desired product was prepared by substituting 4-aminophenylboronic acid for 4-cyanophenylboronic acid in Example 22. MS (ESI) m/z 359 (M + H)⁺; ¹H NMR (500 MHz, DMSO-D6) δ ppm 3.16 (m, 2 H) 3.90 (d, *J*=63.33 Hz, 3 H) 4.16 (dd, *J*=10.61, 6.24 Hz, 1 H) 4.33 (m, 1 H) 6.77 (d, *J*=8.42 Hz, 1 H) 7.01 (m, 1 H) 7.11 (s, 1 H) 7.29 (d, *J*=2.18 Hz, 1 H) 7.38 (d, *J*=8.11 Hz, 1 H) 7.47 (d, *J*=8.42 Hz, 1 H) 7.61 (m, 2 H) 8.17 (s, 2 H) 8.24 (d, *J*=2.50 Hz, 1 H) 8.50 (d, *J*=1.56 Hz, 1 H) 11.02 (s, 1 H).

Example 133*N*-(4-(5-((2S)-2-Amino-3-(1H-indol-3-yl)-propoxy)-pyridin-3-yl)-phenyl)-acetamide

The desired product was prepared by substituting Example 132 for Example 121A in Example 129. MS (ESI) m/z 401 (M + H)⁺; ¹H NMR (500 MHz, DMSO-D6) δ ppm 3.17 (d, *J*=6.86 Hz, 5 H) 4.18 (d, *J*=5.93 Hz, 1 H) 4.32 (d, *J*=3.12 Hz, 1 H) 7.01 (m, 1 H) 7.09 (d, *J*=7.18 Hz, 1 H) 7.29 (d, *J*=2.18 Hz, 1 H) 7.38 (d, *J*=8.11 Hz, 1 H) 7.58 (d, *J*=2.18 Hz, 1 H) 7.65 (m, 4 H) 8.28 (m, 4 H) 8.51 (d, *J*=1.25 Hz, 1 H) 10.10 (s, 1 H) 11.03 (d, *J*=1.25 Hz, 1 H).

Example 134*N*6-(4-(5-((2S)-2-Amino-3-(1H-indol-3-yl)-propoxy)-pyridin-3-yl)-phenyl)-9*H*-purine-2,6-diamine

The title compound was prepared by substituting Example 132 for Example 121A in Example 126. MS (ESI) m/z 492 (M + H)⁺; ¹H NMR (500 MHz, DMSO-D6) δ ppm 2.51 (m,

3 H) 3.16 (t, $J=7.49$ Hz, 1 H) 3.91 (d, $J=53.97$ Hz, 2 H) 4.19 (dd, $J=10.76, 6.08$ Hz, 1 H) 4.35 (dd, $J=10.76, 2.96$ Hz, 1 H) 7.01 (t, $J=7.18$ Hz, 1 H) 7.11 (t, $J=7.02$ Hz, 1 H) 7.30 (d, $J=2.18$ Hz, 1 H) 7.39 (d, $J=8.11$ Hz, 1 H) 7.64 (m, 2 H) 7.74 (d, $J=8.73$ Hz, 1 H) 8.02 (d, $J=8.42$ Hz, 1 H) 8.20 (d, $J=3.74$ Hz, 2 H) 8.26 (s, 1 H) 8.34 (d, $J=2.50$ Hz, 1 H) 8.58 (d, $J=1.56$ Hz, 1 H) 10.52 (s, 1 H) 11.03 (d, $J=1.87$ Hz, 1 H).

5
10
15
20
25
30

Example 135

N4-(4-((2S)-2-Amino-3-(1H-indol-3-yl)-propoxy)-pyridin-3-yl)-phenyl)-pyrimidine-2,4-diamine

The title compound was prepared by substituting Example 132 for Example 121A in Example 121. MS (ESI) m/z 452 (M + H)⁺; ¹H NMR (500 MHz, DMSO-D6) δ ppm 3.16 (d, $J=7.18$ Hz, 2 H) 3.86 (m, 2 H) 4.18 (m, 1 H) 4.33 (d, $J=3.12$ Hz, 1 H) 6.35 (d, $J=7.18$ Hz, 1 H) 7.01 (t, $J=7.33$ Hz, 1 H) 7.10 (t, $J=7.02$ Hz, 1 H) 7.29 (d, $J=2.18$ Hz, 1 H) 7.39 (d, $J=8.11$ Hz, 1 H) 7.62 (dd, $J=4.52, 2.03$ Hz, 2 H) 7.73 (d, $J=8.73$ Hz, 2 H) 7.88 (d, $J=7.49$ Hz, 2 H) 8.20 (s, 3 H) 8.34 (d, $J=2.81$ Hz, 1 H) 8.56 (d, $J=1.87$ Hz, 1 H) 10.69 (s, 1 H) 11.02 (d, $J=1.87$ Hz, 1 H).


Example 136

(4-((2S)-2-Amino-3-(1H-indol-3-yl)-propoxy)-pyridin-3-yl)-phenyl)-pyrimidin-2-yl-amine

The title compound was prepared by substituting Example 132 for Example 121A in Example 127. MS (ESI) m/z 437 (M + H)⁺; ¹H NMR (500 MHz, DMSO-D6) δ ppm 2.94 (d, $J=6.55$ Hz, 1 H) 3.04 (m, 1 H) 3.17 (d, $J=3.74$ Hz, 1 H) 3.55 (m, 1 H) 4.04 (dd, $J=9.83, 6.40$ Hz, 1 H) 4.16 (dd, $J=9.98, 4.06$ Hz, 1 H) 6.88 (t, $J=4.84$ Hz, 1 H) 6.98 (t, $J=7.49$ Hz, 1 H) 7.08 (t, $J=7.64$ Hz, 1 H) 7.24 (d, $J=2.18$ Hz, 1 H) 7.36 (d, $J=8.11$ Hz, 1 H) 7.55 (m, 1 H) 7.59 (d, $J=7.80$ Hz, 1 H) 7.64 (d, $J=8.73$ Hz, 2 H) 7.90 (d, $J=9.05$ Hz, 2 H) 8.25 (d, $J=2.81$ Hz, 1 H) 8.49 (d, $J=1.56$ Hz, 1 H) 8.52 (d, $J=4.99$ Hz, 2 H) 9.78 (s, 1 H).

Example 137

3-((2S)-2-Amino-3-(1H-indol-3-yl)-propoxy)-5-isoquinolin-6-yl-benzonitrile



Example 137A(1*S*)-[2-(3-Cyano-5-isoquinolin-6-yl-phenoxy)-1-(1*H*-indol-3-ylmethyl)-ethyl]-carbamic acid
tert-butyl ester

A solution of Example 120 (0.15 g, 0.3 mmol) 3 mL of dioxane and 1 mL of DMF was
 5 treated with $\text{Pd}(\text{PPh}_3)_4$ (0.030 g, 0.026 mmol), and zinc cyanide (0.037 g, 0.3 mmol). The reaction was heated to 95 °C for 3 days. The mixture was diluted with ethyl acetate (25 mL) and washed with water (15 mL) and brine (15 mL). The mixture was evaporated and the residue was purified by flash column chromatography on silica gel, eluting 1:1 ethyl acetate/hexane. Recovered 0.108 g of product (79 %). MS (ESI) m/z 519 ($\text{M} + \text{H}$)⁺.

10

Example 137B3-((2*S*)-2-Amino-3-(1*H*-indol-3-yl)-propoxy)-5-isoquinolin-6-yl-benzonitrile

The desired product was prepared by substituting Example 137A for Example 27B in Example 27C. MS (ESI) m/z 419 ($\text{M} + \text{H}$)⁺; ¹H NMR (500 MHz, DMSO-D6) δ ppm 2.95 (d, $J=6.55$ Hz, 1 H) 3.05 (dd, $J=14.35$, 7.18 Hz, 1 H) 3.57 (m, 1 H) 4.07 (m, 1 H) 4.16 (d, $J=4.06$ Hz, 1 H) 6.96 (t, $J=7.18$ Hz, 1 H) 7.06 (t, $J=7.18$ Hz, 1 H) 7.23 (d, $J=2.18$ Hz, 1 H) 7.34 (d, $J=8.11$ Hz, 1 H) 7.50 (s, 1 H) 7.58 (d, $J=7.80$ Hz, 1 H) 7.73 (s, 1 H) 7.87 (d, $J=5.93$ Hz, 1 H) 7.93 (s, 1 H) 8.04 (dd, $J=8.58$, 1.72 Hz, 1 H) 8.23 (d, $J=8.42$ Hz, 1 H) 8.36 (s, 1 H) 8.55 (d, $J=5.62$ Hz, 1 H) 9.36 (s, 1 H) 10.91 (s, 1 H).

20

Example 1385'-Benzylxy-5-isoquinolin-6-yl-(3,3')bipyridinylExample 138A6-(5-Bromo-pyridin-3-yl)-isoquinoline

The title compound was prepared by substituting 3,5-dibromopyridine for Example 2A in Example 27B.

Example 138B3-Benzylxy-5-trimethylstannanyl-pyridine

The title compound was prepared by substituting 3-benzylxy-5-bromopyridine for 6-bromoisoquinoline in Example 27A.

Example 138C5'-Benzylxy-5-isoquinolin-6-yl-(3,3')bipyridinyl

35 The title compound was prepared by substituting Example 138A for Example 2A, Example 138B for Example 27A in Example 27B. MS (ESI) m/z 390 ($\text{M} + \text{H}$)⁺; ¹H NMR (400 MHz, DMSO-D6) δ ppm 5.35 (s, 2 H) 7.38 (d, $J=7.36$ Hz, 1 H) 7.44 (t, $J=7.21$ Hz, 2 H) 7.53 (d,

5 $J=6.75$ Hz, 2 H) 8.11 (m, 1 H) 8.32 (d, $J=6.14$ Hz, 1 H) 8.50 (m, 2 H) 8.57 (m, 1 H) 8.70 (d, $J=6.14$ Hz, 1 H) 8.74 (t, $J=2.15$ Hz, 1 H) 8.79 (m, 2 H) 9.14 (d, $J=2.15$ Hz, 1 H) 9.22 (d, $J=1.84$ Hz, 1 H) 9.76 (s, 1 H).

10 Example 140

(7-((2S)-2-Amino-3-(1H-indol-3-yl)-propoxy)-pyridin-3-yl)-pyrido(2,3-d)pyrimidin-4-yl)-phenyl-amine

15 Example 140A


2-Amino-6-chloro-nicotinic acid

A mixture of 2,6-dichloro-nicotinic acid (17.77 g, 92.6 mmol) in concentrated aqueous ammonia (173 mL) at 200 psi, was heated to 130°C for 24 h. The mixture evaporated and the residue was taken into water (200 mL) and neutralized with conc HCl then extracted into ether (200 mL). The ether was evaporated off to yield 12 g of product (75 %). MS (DCI/NH3) m/z 173 (M + 1)⁺.

20 Example 140B

2-Amino-6-chloro-nicotinamide


To a mixture of Example 140A (11.9 g, 69.2 mmol) in 1,2-dichloroethane (100 mL) was added thionyl chloride (30 mL, 411 mmol) and DMF (catalytic). The mixture was refluxed for 4 h then evaporated. The residue was taken in ether (200 mL) and ammonia was bubbled through for 15 min. The mixture was stirred overnight at rt then washed with water (100 mL) and brine (100 mL). The ether was evaporated off to yield 9.2 g of product (78 %). MS (DCI/NH3) m/z 172 (M + 1)⁺.



Example 140C

7-Chloro-pyrido[2,3-d]pyrimidin-4-ol


A mixture of Example 140B (1 g, 5.8 mmol) in triethylorthoformate (30 mL) was refluxed for 6 h then cooled. Hexane (150 mL) was added and the solid formed was filtered and washed with water and hexane to yield 0.27 g of product (26 %). MS: (DCI/NH3) m/z = 182 (M + 1)



Example 140D

4,7-Dichloro-pyrido[2,3-d]pyrimidine

A mixture of Example 140C (1 g, 5.5 mmol) in phosphorus oxychloride (40 mL) was refluxed for 2 h then cooled and evaporated. The residue was taken into ethyl acetate (75 ml), washed with saturated sodium bicarbonate (50 ml) water (50 ml) and brine (50 ml). The ethyl acetate was evaporated to yield 0.8 g of product (73 %).




5

Example 140E

(7-Chloro-pyrido[2,3-d]pyrimidin-4-yl)-phenyl-amine

A solution of Example 140D (0.5 g, 2.5 mmol), and aniline (0.23 mL, 2.5 mmol) in THF (25 mL) and 2-propanol (2.5 mL) was stirred at 0 °C for 1 h then at room temperature for 2 days.

10 The THF was evaporated off and the residue was taken into ethyl acetate (75 ml), washed with water (50 ml) and brine (50 ml). The ethyl acetate was evaporated off and the residue was purified by flash column chromatography on silica gel, eluting with 1:1 ethyl acetate/hexane. Recovered 0.15 g of product (23 %). MS (ESI) m/z 390 (M + H)⁺.




15

Example 140F

(7-((2S)-2-Amino-3-(1H-indol-3-yl)-propoxy)-pyridin-3-yl)-pyrido(2,3-d)pyrimidin-4-yl)-phenyl-amine

The title compound was prepared by substituting Example 140E for 6-bromoisoquinoline in Example 27. MS (ESI) m/z 257 (M + H)⁺; ¹H NMR (500 MHz, DMSO-D6) δ ppm 3.15 (m, 3 H) 3.38 (s, 4 H) 4.06 (dd, J=10.29, 5.93 Hz, 4 H) 4.21 (dd, J=10.45, 2.96 Hz, 1 H) 6.99 (t, J=7.18 Hz, 1 H) 7.09 (t, J=7.18 Hz, 1 H) 7.26 (d, J=2.18 Hz, 1 H) 7.35 (m, 4 H) 8.21 (d, J=4.37 Hz, 3 H) 11.02 (s, 1 H)




A-565462.6

Example 141

(7-(5-((2S)-2-Amino-3-(1H-indol-3-yl)-propoxy)-pyridin-3-yl)-pyrido(2,3-d)pyrimidin-4-yl)-
5 ethyl-amine

The title compound was prepared by substituting ethylamine for aniline in Example 140. MS (ESI) m/z 440 (M + H)⁺; ¹H NMR (500 MHz, DMSO-D6) δ ppm 1.30 (m, 3 H) 3.19 (m, 2 H) 3.78 (m, 2 H) 4.05 (s, 2 H) 4.21 (dd, J=10.45, 5.77 Hz, 1 H) 4.38 (dd, J=10.45, 2.96 Hz, 1 H) 7.00 (t, J=7.49 Hz, 1 H) 7.09 (t, J=7.49 Hz, 1 H) 7.30 (d, J=2.18 Hz, 1 H) 7.38 (d, J=7.80 Hz, 10 1 H) 7.61 (d, J=7.80 Hz, 1 H) 8.15 (s, 1 H) 8.24 (d, J=4.06 Hz, 2 H) 8.51 (d, J=8.42 Hz, 1 H) 8.56 (d, J=1.56 Hz, 1 H) 8.96 (s, 1 H) 9.01 (d, J=8.74 Hz, 1 H) 9.12 (s, 1 H) 11.03 (d, J=1.56 Hz, 1 H).



A-622026.6


Example 142

(7-(5-((2S)-2-Amino-3-(1H-indol-3-yl)-propoxy)-pyridin-3-yl)-pyrido(2,3-d)pyrimidin-4-yl)-
15 benzyl-amine

The title compound was prepared by substituting benzylamine for aniline in Example 140.

MS (ESI) m/z 502 (M + H)⁺; ¹H NMR (400 MHz, DMSO-D6) δ ppm 3.19 (m, J=6.60, 6.60

20 Hz, 2 H) 3.89 (m, 1 H) 4.22 (dd, J=10.43, 5.52 Hz, 1 H) 4.38 (m, 1 H) 5.00 (d, J=5.52 Hz, 2 H) 7.00 (m, 1 H) 7.09 (m, 1 H) 7.34 (m, 5 H) 7.45 (m, 1 H) 7.62 (d, J=7.98 Hz, 1 H) 8.17 (m, 1 H) 8.31 (d, J=3.68 Hz, 2 H) 8.54 (m, 2 H) 8.97 (s, 1 H) 9.07 (d, J=8.90 Hz, 1 H) 9.12 (d, J=1.84 Hz, 1 H) 10.81 (s, 1 H) 11.05 (d, J=2.15 Hz, 1 H).




A-640684.7

Example 143

(1S)-1-(1H-Indol-3-ylmethyl)-2-(6-isoquinolin-6-yl-pyrazin-2-yloxy)-ethylamine

5 The title compound was prepared by substituting 6-chloro-pyrazin-2-ol for 3-bromo-5-hydroxypyridine in Example 27. MS (ESI) m/z 396 (M + H)⁺; ¹H NMR (400 MHz, DMSO-D₆) δ ppm 3.20 (m, 1 H) 3.95 (m, 1 H) 4.52 (m, J=7.36 Hz, 1 H) 4.76 (m, 1 H) 7.02 (m, J=7.06 Hz, 1 H) 7.11 (m, J=7.98 Hz, 1 H) 7.34 (d, J=2.15 Hz, 1 H) 7.41 (d, J=8.29 Hz, 1 H) 7.65 (d, J=7.98 Hz, 1 H) 7.99 (d, J=5.83 Hz, 1 H) 8.17 (s, 3 H) 8.28 (m, 2 H) 8.41 (s, 1 H) 8.62 (m, 1 H) 8.72 (s, 1 H) 9.10 (s, 1 H) 11.05 (s, 1 H).


10



A-646435.2

Example 144

(1S)-2-(5-isoquinolin-6-yl-pyridin-3-yloxy)-1-phenyl-ethylamine



Example 144A


(1S)-[2-(5-Bromo-pyridin-3-yloxy)-1-phenyl-ethyl]-carbamic acid tert-butyl ester

15 A solution of 5-bromo-pyridin-3-ol (0.3 g, 1.7 mmol), (2-hydroxy-1-phenyl-ethyl)-carbamic acid tert-butyl ester (0.41 g 1.7 mmol), and triphenylphosphine (0.52 g, 2 mmol) in THF (15 mL) was stirred at 0 °C for 30 min. To the mixture was added a solution of di-*t*-butyl azidodicarboxylate (0.46 g, 2 mmol) in 5 ml of THF. The mixture was allowed to warm to room temperature then stirred at room temperature for 20h. The THF was evaporated off and the residue was taken into ethyl acetate (75 ml), washed with saturated sodium bicarbonate (50 ml) water (50 ml) and brine (50 ml). The ethyl acetate was evaporated off and the residue was purified by flash column chromatography on silica gel, eluting with a solvent gradient of

20

25


1:4 to 1:2 ethyl acetate/hexane. Recovered 0.82 g of a mixture of product and di-tert-butyl azidodicarboxylate. MS (ESI) m/z 395 (M + H)⁺.



Example 144B

(1S)-2-(5-isoquinolin-6-yl-pyridin-3-yloxy)-1-phenyl-ethylamine

The title compound was prepared by substituting Example 144A for Example 2A in Example 27. MS (ESI) m/z 342 (M + H)⁺; ¹H NMR (500 MHz, DMSO-D6) δ ppm 4.51 (m, J=8.74 Hz, 1 H) 4.57 (m, 1 H) 4.87 (m, 1 H) 7.49 (m, 3 H) 7.63 (d, J=7.18 Hz, 2 H) 7.90 (d, J=5.62 Hz, 1 H) 7.93 (m, 1 H) 8.10 (dd, J=8.73, 1.56 Hz, 1 H) 8.26 (d, J=8.73 Hz, 1 H) 8.39 (s, 1 H) 8.45 (d, J=2.50 Hz, 1 H) 8.56 (d, J=5.62 Hz, 1 H) 8.69 (m, 2 H) 8.74 (d, J=1.56 Hz, 1 H) 9.39 (s, 1 H).




A-656339.6

Example 145

(1S)-1-(1H-Indol-3-ylmethyl)-2-(6-(3-methyl-1H-indazol-5-yl)-pyrazin-2-yloxy)-ethylamine

The title compound was prepared by substituting 102C for 6-bromoisoquinoline in Example 143. MS (ESI) m/z 399 (M + H)⁺; ¹H NMR (400 MHz, DMSO-D6) δ ppm 2.54 (s, 3 H) 3.18 (m, 2 H) 3.92 (m, 1 H) 4.47 (d, J=7.06 Hz, 1 H) 4.70 (m, 1 H) 7.02 (d, J=7.06 Hz, 1 H) 7.10 (m, 1 H) 7.32 (d, J=2.15 Hz, 1 H) 7.39 (d, J=8.29 Hz, 1 H) 7.49 (d, J=8.59 Hz, 1 H) 7.64 (d, J=8.29 Hz, 1 H) 7.92 (dd, J=8.75, 1.69 Hz, 1 H) 8.15 (m, 2 H) 8.24 (s, 1 H) 8.46 (s, 1 H) 8.95 (s, 1 H) 11.04 (d, J=1.53 Hz, 1 H).

The following compounds were made according the procedures used in Example 27 or 102, using the appropriate Boc protected N-Boc-aminoethanols.




A-659228.2

Example 146

(1S)-1-Cyclohexylmethyl-2-(5-isoquinolin-6-yl-pyridin-3-yloxy)-ethylamine

5 MS (ESI) m/z 362 (M + H)⁺; ¹H NMR (500 MHz, DMSO-D6) δ ppm 0.92 (s, 2 H) 1.24 (m, 3 H) 1.64 (m, 6 H) 3.52 (s, 2 H) 4.23 (dd, J=10.61, 6.55 Hz, 1 H) 4.40 (dd, J=10.61, 3.12 Hz, 1 H) 7.91 (m, 1 H) 7.96 (d, J=5.93 Hz, 1 H) 8.13 (dd, J=8.58, 1.72 Hz, 4 H) 8.32 (d, J=8.73 Hz, 1 H) 8.43 (m, 2 H) 8.59 (m, J=5.62 Hz, 1 H) 8.74 (d, J=1.56 Hz, 1 H) 9.44 (s, 1 H).




A-674563.7

Example 147

(1S)-1-Benzyl-2-(5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy)-ethylamine

10 MS (ESI) m/z 359 (M + H)⁺; ¹H NMR (500 MHz, DMSO-D6) δ ppm 2.55 (m, 3 H) 3.05 (m, 1 H) 3.38 (m, 1 H) 3.87 (m, 1 H) 4.12 (dd, J=10.76, 5.77 Hz, 1 H) 4.28 (dd, J=10.76, 2.96 Hz, 1 H) 7.33 (m, 4 H) 7.57 (d, J=8.73 Hz, 1 H) 7.67 (m, 2 H) 8.06 (s, 1 H) 8.21 (s, 2 H) 8.31 (d, J=1.56 Hz, 1 H) 8.61 (s, 1 H) 12.74 (s, 1 H).




A-679219.7

Example 148

(1S)-2-(5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy)-1-phenyl-ethylamine

15 MS (ESI) m/z 345 (M + H)⁺; ¹H NMR (400 MHz, DMSO-D6) δ ppm 2.55 (m, 3 H) 4.01 (s, 1 H) 4.31 (m, 1 H) 4.39 (m, 1 H) 4.57 (m, 1 H) 7.36 (m, 1 H) 7.43 (t, J=7.36 Hz, 2 H) 7.55 (t,

J=7.67 Hz, 4 H) 7.70 (m, 1 H) 8.08 (s, 1 H) 8.29 (d, J=2.76 Hz, 1 H) 8.57 (d, J=1.84 Hz, 1 H) 12.72 (s, 1 H).



5


A-682487.7

Example 149

(1S)-2-(5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy)-1-phenyl-ethylamine

MS (ESI) m/z 365 (M + H)⁺; ¹H NMR (400 MHz, DMSO-D6) δ ppm 0.90 (d, J=14.12 Hz, 2 H) 1.16 (m, 3 H) 1.44 (m, 3 H) 1.69 (m, 3 H) 2.55 (d, J=5.22 Hz, 3 H) 3.37 (m, 3 H) 4.03 (m, 1 H) 4.17 (dd, J=9.97, 4.14 Hz, 1 H) 7.56 (d, J=8.59 Hz, 1 H) 7.71 (m, 2 H) 8.08 (s, 1 H) 8.28 (d, J=2.76 Hz, 1 H) 8.57 (d, J=1.53 Hz, 1 H) 12.73 (s, 1 H).

10



A-697376.7


15

Example 150

4-((2S)-2-Amino-3-(5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy)propyl)-benzonitrile

MS (ESI) m/z 384 (M + H)⁺; ¹H NMR (400 MHz, DMSO-D6) δ ppm 2.55 (s, 3 H) 3.14 (d, J=7.06 Hz, 2 H) 3.94 (m, 1 H) 4.15 (dd, J=10.74, 5.52 Hz, 1 H) 4.32 (dd, J=10.74, 3.07 Hz, 1 H) 7.57 (t, J=8.13 Hz, 2 H) 7.69 (m, 1 H) 7.73 (t, J=1.99 Hz, 1 H) 7.85 (d, J=7.98 Hz, 2 H) 8.07 (s, 1 H) 8.24 (m, 2 H) 8.32 (d, J=2.45 Hz, 1 H) 8.64 (d, J=1.53 Hz, 1 H).

20




A-697379.7

Example 151

25 (1S)-2-(5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy)-1-naphthalen-2-ylmethyl-ethylamine

MS: (ESI) m/z 409 (M + H)⁺; ¹H NMR (400 MHz, DMSO-D6) δ ppm 2.54 (s, 3 H) 3.23 (d, J=7.06 Hz, 2 H) 4.00 (s, 1 H) 4.21 (dd, J=10.74, 5.52 Hz, 1 H) 4.37 (dd, J=10.74, 3.07 Hz, 1 H) 7.51 (m, 3 H) 7.56 (d, J=8.29 Hz, 1 H) 7.67 (dd, J=8.59, 1.84 Hz, 1 H) 7.78 (m, 1 H) 7.86 (m, 2 H) 7.91 (m, 2 H) 8.07 (s, 1 H) 8.26 (m, 2 H) 8.36 (d, J=2.76 Hz, 1 H) 8.65 (d, J=1.84 Hz, 1 H).

5




A-697738.2

Example 152

10 4-((2S)-2-Amino-3-(5-isoquinolin-6-yl-pyridin-3-yloxy-propyl)-benzonitrile

MS (ESI) m/z 381 (M + H)⁺; ¹H NMR (400 MHz, DMSO-D6) δ ppm 3.16 (m, 2 H) 3.97 (s, 1 H) 4.26 (m, 2 H) 7.56 (d, J=8.29 Hz, 2 H) 7.84 (d, J=8.29 Hz, 2 H) 7.90 (m, 1 H) 8.24 (m, 2 H) 8.33 (m, 2 H) 8.48 (m, 2 H) 8.55 (s, 1 H) 8.67 (d, J=6.14 Hz, 1 H) 8.79 (d, J=1.84 Hz, 1 H) 9.67 (s, 1 H).

15




A-697741.2

Example 153

(1S)-2-(5-Isoquinolin-6-yl-pyridin-3-yloxy)-1-naphthalen-2-ylmethyl)-ethylamine

MS: (ESI) m/z 406 (M + H)⁺; ¹H NMR (400 MHz, DMSO-D6) δ ppm 3.24 (m, 2 H) 4.03 (s, 1 H) 4.31 (m, 2 H) 7.50 (m, 3 H) 7.89 (m, 5 H) 8.22 (m, 2 H) 8.33 (s, 3 H) 8.48 (m, 2 H) 8.54 (s, 1 H) 8.66 (m, J=6.14 Hz, 1 H) 8.78 (d, J=1.84 Hz, 1 H).

25




A-703291.2

Example 154

(1S)-1-Benzyl-2-(5-isoquinolin-6-yl-pyridin-3-yloxy)-ethylamine

MS (ESI) m/z 356 (M + H)⁺; ¹H NMR (500 MHz, DMSO-D6) δ ppm 3.05 (m, 2 H) 3.88 (s, 1 H) 4.16 (dd, J=10.61, 5.62 Hz, 1 H) 4.32 (dd, J=10.76, 2.96 Hz, 1 H) 7.29 (m, 1 H) 7.35 (m, 3 H) 7.85 (m, 1 H) 7.99 (d, J=5.62 Hz, 1 H) 8.12 (dd, J=8.58, 1.72 Hz, 1 H) 8.27 (m, 3 H) 8.33 (d, J=8.74 Hz, 1 H) 8.43 (m, 2 H) 8.60 (d, J=5.93 Hz, 1 H) 8.75 (d, J=1.87 Hz, 1 H) 9.47 (s, 1 H).

5




A-726437.7

Example 155

10 (1S)-1-(4-Fluoro-benzyl)-2-(5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy)-ethylamine

MS (ESI) m/z 377 (M + H)⁺; ¹H NMR (500 MHz, DMSO-D6) δ ppm 2.55 (s, 3 H) 3.04 (d, J=7.18 Hz, 2 H) 3.85 (m, 1 H) 4.14 (dd, J=10.76, 5.77 Hz, 1 H) 4.30 (m, 1 H) 7.19 (m, J=8.89, 8.89 Hz, 2 H) 7.37 (dd, J=8.58, 5.46 Hz, 2 H) 7.58 (d, J=8.73 Hz, 1 H) 7.69 (dd, J=8.74, 1.56 Hz, 1 H) 7.75 (s, 1 H) 8.08 (s, 1 H) 8.23 (s, 3 H) 8.34 (s, 1 H) 8.65 (s, 1 H)

15




A-703291.2

Example 156

(1S)-1-(4-Fluoro-benzyl)-2-(5-isoquinolin-6-yl-pyridin-3-yloxy)-ethylamine

20 MS (ESI) m/z 374 (M + H)⁺; ¹H NMR (500 MHz, DMSO-D6) δ ppm 3.05 (m, 2 H) 3.88 (s, 1 H) 4.17 (dd, J=10.92, 5.62 Hz, 1 H) 4.34 (dd, J=10.76, 2.96 Hz, 1 H) 7.18 (m, 2 H) 7.38 (dd, J=8.58, 5.46 Hz, 2 H) 7.90 (m, 1 H) 8.24 (m, 5 H) 8.47 (d, J=8.73 Hz, 2 H) 8.53 (d, J=9.98 Hz, 1 H) 8.79 (s, 1 H) 9.67 (s, 1 H).

25




A-733910.7

Example 157

2-((2S)-2-Amino-3-(5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy)-propyl)-benzonitrile

MS (ESI) m/z 384 (M + H)⁺; ¹H NMR (500 MHz, DMSO-D6) δ ppm 2.54 (d, J=4.06 Hz, 3 H) 3.34 (m, 2 H) 4.03 (m, 1 H) 4.11 (dd, J=10.61, 4.99 Hz, 1 H) 4.33 (dd, J=10.92, 3.12 Hz, 1 H) 7.50 (t, J=7.64 Hz, 1 H) 7.65 (m, 7 H) 7.85 (d, J=7.80 Hz, 1 H) 8.06 (s, 1 H) 8.37 (s, 2 H) 8.65 (s, 1 H).




A-734322.2

Example 158

2-((2S)-2-Amino-3-(5-isoquinolin-6-yl)-pyridin-3-yloxy)-propyl)-benzonitrile

MS (ESI) m/z 381 (M + H)⁺; ¹H NMR (500 MHz, DMSO-D6) δ ppm 3.32 (m, 2 H) 4.04 (m, 1 H) 4.16 (m, 1 H) 4.37 (dd, J=10.76, 3.28 Hz, 1 H) 7.50 (t, J=7.64 Hz, 1 H) 7.64 (d, J=7.49 Hz, 1 H) 7.71 (d, J=7.49 Hz, 1 H) 7.84 (m, 2 H) 8.00 (d, J=5.62 Hz, 1 H) 8.12 (dd, J=8.73, 1.87 Hz, 1 H) 8.34 (d, J=8.73 Hz, 1 H) 8.40 (m, 2 H) 8.54 (s, 2 H) 8.60 (d, J=5.61 Hz, 1 H) 8.74 (d, J=1.56 Hz, 1 H) 9.48 (s, 1 H).




A-738508.7

Example 159

(1S)-2-5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy)-1-pyridin-4-ylmethyl-ethylamine

MS (ESI) m/z 360 (M + H)⁺; ¹H NMR (500 MHz, DMSO-D6) δ ppm 2.50 (s, 3 H) 3.24 (d, J=6.86 Hz, 2 H) 4.05 (m, 1 H) 4.12 (m, 1 H) 4.25 (m, J=3.43 Hz, 1 H) 7.49 (m, J=4.68 Hz, 2 H) 7.53 (d, J=1.87 Hz, 1 H) 7.59 (m, 1 H) 7.71 (m, 1 H) 7.80 (m, 3 H) 8.09 (s, 1 H) 8.30 (d, J=4.06 Hz, 1 H) 8.40 (s, 2 H) 8.78 (m, J=499 Hz, 1 H).




A-738511.2

Example 160

(1S)-2-(5-Isoquinolin-6-yl-pyridin-3-yloxy)-1-pyridin-4-ylmethyl-ethylamine

5 MS (ESI) m/z 357 (M + H)⁺; ¹H NMR (500 MHz, DMSO-D6) δ ppm 3.24 (d, J=7.17 Hz, 1 H) 3.28 (d, J=7.18 Hz, 1 H) 4.04 (m, 1 H) 4.26 (m, 1 H) 4.40 (d, J=3.43 Hz, 1 H) 7.83 (dd, J=14.66, 6.24 Hz, 3 H) 7.93 (m, 1 H) 8.26 (m, 2 H) 8.38 (m, 1 H) 8.47 (d, J=2.81 Hz, 2 H) 8.51 (d, J=8.42 Hz, 1 H) 8.58 (s, 1 H) 8.68 (d, J=6.24 Hz, 1 H) 8.80 (m, 2 H) 9.71 (s, 1 H).




A-740051.7

Example 161

(1S)-1-(4-Methyl-benzyl)-2-(5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy)-ethylamine

10 MS (ESI) m/z 373 (M + H)⁺; ¹H NMR (500 MHz, DMSO-D6) δ ppm 2.28 (m, 3 H) 2.55 (s, 3 H) 2.98 (m, 2 H) 3.81 (s, 1 H) 4.11 (dd, J=10.45, 6.08 Hz, 1 H) 4.27 (dd, J=10.76, 2.96 Hz, 1 H) 7.16 (m, 3 H) 7.21 (m, 1 H) 7.57 (d, J=8.73 Hz, 1 H) 7.69 (m, 2 H) 8.07 (s, 1 H) 8.21 (m, 3 H) 8.31 (d, J=2.18 Hz, 1 H) 8.62 (s, 1 H).




A-741300.2

Example 162

(1S)-2-(5-Isoquinolin-6-yl-pyridin-3-yloxy)-1-(4-methyl-benzyl)-ethylamine


20 MS (ESI) m/z 370 (M + H)⁺; ¹H NMR (500 MHz, DMSO-D6) δ ppm 2.28 (m, 3 H) 3.01 (m, 2 H) 3.83 (s, 1 H) 4.14 (dd, J=10.76, 5.77 Hz, 1 H) 4.30 (m, 1 H) 7.18 (m, 6 H) 7.84 (m, 1 H) 7.97 (d, J=5.93 Hz, 1 H) 8.10 (dd, J=8.58, 1.72 Hz, 1 H) 8.24 (m, 2 H) 8.31 (d, J=8.74 Hz, 1 H) 8.59 (d, J=5.93 Hz, 1 H) 8.74 (d, J=1.87 Hz, 1 H) 9.45 (s, 1 H)



A-741302.7

Example 163


5 (1S)-2-(5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy)-1-quinolin-3-ylmethyl-ethylamine
 MS (ESI) m/z 410 (M + H)⁺; ¹H NMR (500 MHz, DMSO-D6) δ ppm 2.56 (m, 3 H) 3.29 (m, 2 H) 4.12 (m, 1 H) 4.29 (m, 1 H) 4.42 (dd, J=10.76, 3.28 Hz, 1 H) 7.56 (d, J=8.73 Hz, 1 H) 7.66 (m, 2 H) 7.78 (m, 2 H) 7.97 (t, J=7.18 Hz, 2 H) 8.05 (m, 2 H) 8.36 (m, 4 H) 8.91 (m, 2 H)



A-741305.2

Example 164

10 (1S)-2-(5-Isoquinolin-6-yl-pyridin-3-yloxy)-1-quinolin-3-ylmethyl-ethylamine
 MS (ESI) m/z 407 (M + H)⁺; ¹H NMR (500 MHz, DMSO-D6) δ ppm 3.27 (m, 2 H) 4.09 (d, J=5.62 Hz, 1 H) 4.27 (dd, J=10.92, 5.62 Hz, 1 H) 4.43 (dd, J=10.61, 3.43 Hz, 1 H) 5.75 (s, 1 H) 7.62 (m, 1 H) 7.76 (m, 1 H) 7.86 (m, 1 H) 7.94 (m, 2 H) 8.06 (m, 1 H) 8.30 (m, 5 H) 8.46 (d, J=2.81 Hz, 1 H) 8.59 (d, J=5.93 Hz, 1 H) 8.74 (m, J=1.87 Hz, 1 H) 8.89 (dd, J=20.28, 2.18 Hz, 1 H) 9.43 (s, 1 H).




A-742710.7

Example 165

20 (1R)-1-Benzyl-2-(5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy)-ethylamine
 MS (ESI) m/z 358 (M + H)⁺; ¹H NMR (500 MHz, DMSO-D6) δ ppm 2.49 (s, 3 H) 2.99 (m, 2 H) 3.79 (s, 1 H) 4.07 (dd, J=10.61, 5.93 Hz, 1 H) 4.23 (dd, J=10.76, 2.96 Hz, 1 H) 7.22 (m, 2

H) 7.29 (m, 3 H) 7.51 (d, $J=8.73$ Hz, 1 H) 7.62 (dd, $J=8.73$, 1.56 Hz, 1 H) 7.64 (m, 1 H) 8.00 (s, 1 H) 8.19 (s, 3 H) 8.26 (m, 1 H) 8.56 (s, 1 H).



5


A-746444.2

Example 166

(1R)-1-Benzyl-2-(5-isoquinolin-6-yl-pyridin-3-yloxy)-ethylamine

MS (ESI m/z 356) ($M + H$)⁺; ¹H NMR (500 MHz, DMSO-D6) δ ppm 2.86 (m, 1 H) 2.95 (m, 1 H) 3.58 (m, 1 H) 4.08 (m, 1 H) 4.18 (m, 1 H) 7.28 (m, 5 H) 7.81 (m, 1 H) 7.88 (m, 1 H) 8.06 (m, 1 H) 8.25 (m, 1 H) 8.36 (m, 1 H) 8.39 (m, 1 H) 8.55 (m, 1 H) 8.69 (m, 1 H) 9.37 (m, 1 H)

10




A-748632.7

Example 167

4-((2S)-2-Amino-3-(5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy)-propyl)-phenol

MS (ESI) m/z 374 ($M + H$)⁺; ¹H NMR (400 MHz, DMSO-D6) δ ppm 2.55 (s, 3 H) 3.50 (m, 8 H) 6.73 (dd, $J=8.44$, 2.92 Hz, 1 H) 7.09 (m, 1 H) 7.59 (m, 2 H) 7.69 (m, 2 H) 7.87 (s, 1 H) 8.14 (m, 2 H) 8.23 (d, $J=1.84$ Hz, 1 H) 8.62 (s, 1 H).

20



A-748633.7


Example 168

(1S)-1-(4-Benzyl-1-oxobutyl)-2-(5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy)-ethylamine

MS m/z 465 (ESI) ($M + H$)⁺; ¹H NMR (400 MHz, DMSO-D6) δ ppm 2.55 (s, 3 H) 2.97 (m, 2 H) 3.82 (m, 1 H) 4.13 (m, 1 H) 4.28 (m, 1 H) 5.07 (s, 2 H) 6.99 (d, $J=8.59$ Hz, 3 H) 7.24 (d,

25

J=8.59 Hz, 2 H) 7.32 (m, J=7.06 Hz, 1 H) 7.40 (m, 4 H) 7.69 (dd, J=8.75, 1.69 Hz, 1 H) 7.73 (m, 1 H) 8.08 (s, 1 H) 8.19 (m, 3 H) 8.33 (m, J=2.46 Hz, 1 H) 8.64 (d, J=1.53 Hz, 1 H).




5

A-751256.7

Example 169

(1S)-1-(3-Methyl-benzyl)-2-(5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy)-ethylamine
 MS (ESI) m/z 373 (M + H)⁺; ¹H NMR (500 MHz, DMSO-D6) δ ppm 2.28 (s, 3 H) 2.56 (s, 3 H) 3.01 (m, 2 H) 4.15 (dd, J=10.92, 5.62 Hz, 1 H) 4.30 (m, J=2.81 Hz, 1 H) 7.11 (m, J=17.00, 10 H) 7.64 Hz, 3 H) 7.23 (m, J=7.49 Hz, 1 H) 7.58 (d, J=8.73 Hz, 1 H) 7.70 (dd, J=8.73, 1.56 Hz, 1 H) 7.80 (m, 1 H) 8.10 (s, 1 H) 8.26 (s, 3 H) 8.35 (d, J=2.81 Hz, 1 H) 8.67 (d, J=1.56 Hz, 1 H).

10




A-751278.7

Example 170

15

(1S)-1-(2-Methyl-benzyl)-2-(5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy)-ethylamine
 MS (ESI) m/z 373 (M + H)⁺; ¹H NMR (500 MHz, DMSO-D6) δ ppm 2.30 (d, J=7.80 Hz, 1 H) 2.33 (s, 3 H) 2.56 (m, 3 H) 3.07 (d, J=7.80 Hz, 1 H) 3.80 (s, 1 H) 4.12 (dd, J=10.76, 4.84 Hz, 1 H) 4.26 (dd, J=10.61, 2.81 Hz, 1 H) 7.19 (m, 4 H) 7.57 (d, J=8.73 Hz, 1 H) 7.68 (dd, J=11.07, 20 H) 2.03 Hz, 2 H) 8.06 (s, 1 H) 8.31 (s, 3 H) 8.62 (s, 1 H).




A-751282.7

Example 171

(1S)-2-(5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy)-1-(4-nitro-benzyl)-ethylamine

MS (ESI) m/z 404 (M + H)⁺; ¹H NMR (500 MHz, DMSO-D6) δ ppm 2.55 (s, 3 H) 3.19 (m, 2 H) 3.97 (s, 1 H) 4.18 (dd, J=10.92, 5.62 Hz, 1 H) 4.34 (dd, J=10.76, 3.28 Hz, 1 H) 7.57 (d, J=8.74 Hz, 1 H) 7.64 (m, J=8.73 Hz, 2 H) 7.69 (dd, J=8.58, 1.72 Hz, 1 H) 7.77 (m, 1 H) 8.08 (s, 1 H) 8.23 (d, J=8.73 Hz, 2 H) 8.29 (m, 2 H) 8.34 (d, J=2.50 Hz, 1 H) 8.66 (d, J=1.25 Hz, 1 H).




A-755097.7

Example 172

(1S)-1-(4-Methoxy-benzyl)-2-(5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy)-ethylamine

MS (ESI) m/z 389 (M + H)⁺; ¹H NMR (500 MHz, DMSO-D6) δ ppm 2.56 (s, 3 H) 2.98 (dd, J=15.13, 6.08 Hz, 2 H) 3.73 (m, 3 H) 3.80 (m, 1 H) 4.16 (dd, J=10.76, 5.77 Hz, 1 H) 4.32 (dd, J=10.61, 3.12 Hz, 1 H) 6.91 (m, 2 H) 7.21 (dd, J=8.58, 2.65 Hz, 1 H) 7.25 (d, J=8.73 Hz, 2 H) 7.59 (d, J=8.73 Hz, 1 H) 7.71 (dd, J=8.73, 1.87 Hz, 1 H) 7.84 (m, 1 H) 8.11 (s, 1 H) 8.28 (m, 2 H) 8.37 (d, J=2.81 Hz, 1 H) 8.69 (d, J=1.56 Hz, 1 H).




A-757584.7

Example 173

(1S)-1-Biphenyl-4-ylmethyl-2-(5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy)-ethylamine

MS (ESI) m/z 435 (M + H)⁺; ¹H NMR (500 MHz, DMSO-D6) δ ppm 2.55 (s, 3 H) 3.10 (m, 2 H) 3.92 (s, 1 H) 4.21 (dd, J=10.92, 5.62 Hz, 1 H) 4.36 (dd, J=10.76, 2.96 Hz, 1 H) 7.36 (t, J=7.49 Hz, 1 H) 7.44 (m, 4 H) 7.57 (d, J=8.73 Hz, 1 H) 7.65 (dd, J=10.29, 7.80 Hz, 4 H) 7.70 (dd, J=8.73, 1.56 Hz, 1 H) 7.82 (s, 1 H) 8.10 (s, 1 H) 8.30 (d, J=2.81 Hz, 3 H) 8.37 (d, J=2.50 Hz, 1 H) 8.67 (d, J=1.25 Hz, 1 H).




A-757602.7

Example 174

(1S)-2-(5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy)-1-naphthalen-1-ylmethyl-ethylamine

5 MS (ESI) m/z 409 (M + H)⁺; ¹H NMR (500 MHz, DMSO-D6) δ ppm 2.55 (s, 3 H) 3.44 (dd, J=14.04, 6.86 Hz, 2 H) 3.93 (s, 1 H) 4.17 (dd, J=10.61, 4.99 Hz, 1 H) 4.32 (m, 1 H) 7.48 (m, 2 H) 7.59 (m, 3 H) 7.66 (dd, J=8.58, 1.72 Hz, 1 H) 7.69 (m, 1 H) 7.89 (dd, J=6.24, 3.12 Hz, 1 H) 7.98 (d, J=8.11 Hz, 1 H) 8.05 (s, 1 H) 8.21 (d, J=8.42 Hz, 1 H) 8.29 (m, 2 H) 8.32 (d, J=2.81 Hz, 1 H) 8.63 (d, J=1.56 Hz, 1 H).

10




A-763516.7

Example 175

(1S)-1-(3-Chloro-benzyl)-2-(5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy)-ethylamine

15 MS (ESI) m/z 393 (M + H)⁺; ¹H NMR (500 MHz, DMSO-D6) δ ppm 2.55 (s, 3 H) 3.06 (d, J=7.49 Hz, 2 H) 3.92 (m, 1 H) 4.16 (m, 1 H) 4.33 (dd, J=10.92, 3.12 Hz, 1 H) 7.31 (d, J=7.49 Hz, 1 H) 7.37 (m, J=14.51, 7.02 Hz, 2 H) 7.45 (s, 1 H) 7.58 (d, J=8.73 Hz, 1 H) 7.70 (dd, J=8.73, 1.56 Hz, 1 H) 7.77 (s, 1 H) 8.08 (s, 1 H) 8.23 (s, 3 H) 8.34 (d, J=2.50 Hz, 1 H) 8.65 (s, 1 H).


20



A-763977.7

Example 176


3-((2S)-2-Amino-3-(5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy)-propyl)-benzonitrile
 MS (ESI) m/z 384 (M + H)⁺; ¹H NMR (500 MHz, DMSO-D6) δ ppm 2.55 (s, 3 H) 3.12 (d, J=7.49 Hz, 2 H) 3.96 (s, 1 H) 4.17 (dd, J=10.76, 5.77 Hz, 1 H) 4.33 (m, 1 H) 7.57 (dd, J=8.11, 6.55 Hz, 2 H) 7.69 (dd, J=8.42, 1.56 Hz, 2 H) 7.76 (m, 2 H) 7.84 (s, 1 H) 8.08 (s, 1 H) 8.23 (s, 3 H) 8.33 (d, J=2.81 Hz, 1 H) 8.64 (d, J=1.56 Hz, 1 H).



A-764024.7

Example 177

10 (1S)-1-(3,4-Difluoro-benzyl)-2-(5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy)-ethylamine
 MS (ESI) m/z 395 (M + H)⁺; ¹H NMR (500 MHz, DMSO-D6) δ ppm 2.56 (s, 3 H) 3.05 (d, J=7.18 Hz, 2 H) 3.90 (m, 1 H) 4.17 (dd, J=10.92, 5.93 Hz, 1 H) 4.34 (dd, J=10.61, 3.12 Hz, 1 H) 7.19 (m, J=2.18 Hz, 1 H) 7.44 (m, 2 H) 7.58 (d, J=8.73 Hz, 1 H) 7.70 (dd, J=8.73, 1.56 Hz, 1 H) 7.77 (d, J=2.50 Hz, 1 H) 8.08 (s, 1 H) 8.23 (s, 3 H) 8.34 (d, J=2.50 Hz, 1 H) 8.65 (d, J=1.56 Hz, 1 H).




A-768008.7

Example 178

20 (1S)-1-(3,4-Dimethoxy-benzyl)-2-(5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy)-ethylamine

MS (ESI) m/z 419 (M + H)⁺; ¹H NMR (500 MHz, DMSO-D6) δ ppm 2.55 (s, 3 H) 2.98 (m, 2 H) 3.70 (s, 3 H) 3.71 (s, 3 H) 3.82 (s, 1 H) 4.14 (dd, J=10.61, 5.62 Hz, 1 H) 4.31 (dd, J=10.76, 2.96 Hz, 1 H) 6.82 (d, J=8.11 Hz, 1 H) 6.91 (m, 2 H) 7.57 (d, J=8.42 Hz, 1 H) 7.68 (m, 1 H) 7.71 (s, 1 H) 8.07 (s, 1 H) 8.28 (s, 3 H) 8.32 (s, 1 H) 8.62 (s, 1 H).




A-768009.7

Example 179

(1S)-1-(3-Fluoro-benzyl)-2-(5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy)-ethylamine

5 MS (ESI) m/z 377 (M + H)⁺; ¹H NMR (500 MHz, DMSO-D6) δ ppm 2.55 (s, 3 H) 3.08 (m, 2 H) 3.91 (s, 1 H) 4.15 (dd, J=10.61, 5.93 Hz, 1 H) 4.32 (dd, J=10.61, 3.12 Hz, 1 H) 7.12 (m, 1 H) 7.20 (m, 2 H) 7.40 (m, 1 H) 7.57 (d, J=8.73 Hz, 1 H) 7.69 (dd, J=8.42, 1.56 Hz, 1 H) 7.71 (d, J=1.87 Hz, 1 H) 8.07 (s, 1 H) 8.29 (s, 3 H) 8.31 (d, J=2.81 Hz, 1 H) 8.62 (s, 1 H).




A-770247.7

Example 180

(1S)-2-(5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy)-1-(3-trifluoromethyl-benzyl)-ethylamine

15 MS (ESI) m/z 427. (M + H)⁺; ¹H NMR (500 MHz, DMSO-D6) δ ppm 2.55 (s, 3 H) 3.16 (dd, J=7.33, 2.34 Hz, 2 H) 3.97 (s, 1 H) 4.16 (dd, J=10.61, 5.62 Hz, 1 H) 4.34 (dd, J=10.76, 3.28 Hz, 1 H) 7.58 (d, J=8.42 Hz, 1 H) 7.61 (d, J=7.49 Hz, 1 H) 7.65 (s, 1 H) 7.66 (s, 1 H) 7.69 (dd, J=8.74, 1.56 Hz, 1 H) 7.73 (s, 1 H) 7.75 (m, 1 H) 8.07 (s, 1 H) 8.22 (s, 3 H) 8.33 (d, J=2.50 Hz, 1 H) 8.64 (d, J=1.56 Hz, 1 H).




A-770248.7

Example 181

(1S)-1-(4-Ethoxy-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine

MS (ESI) m/z 403 (M + H)⁺; ¹H NMR (500 MHz, DMSO-D6) δ ppm 1.30 (t, J=7.02 Hz, 3 H) 2.55 (s, 3 H) 2.97 (m, 2 H) 3.79 (s, 1 H) 3.98 (q, J=6.86 Hz, 2 H) 4.13 (dd, J=10.76, 5.77 Hz, 1 H) 4.29 (dd, J=10.76, 2.96 Hz, 1 H) 6.89 (d, J=8.42 Hz, 1 H) 7.22 (d, J=8.42 Hz, 1 H) 7.57 (d, J=8.42 Hz, 2 H) 7.61 (m, J=11.85 Hz, 1 H) 7.69 (dd, J=8.73, 1.56 Hz, 1 H) 7.75 (s, 1 H) 8.08 (s, 1 H) 8.18 (s, 3 H) 8.33 (d, J=2.50 Hz, 1 H) 8.65 (d, J=1.56 Hz, 1 H).

5




A-771648.7

Example 182

10 (1S)-1-(4-tert-Butyl-benzyl)-2-(5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy)-ethylamine
 MS (ESI) m/z 415 (M + H)⁺; ¹H NMR (500 MHz, DMSO-D6) δ ppm 1.26 (m, 9 H) 2.55 (s, 3 H) 2.80 (dd, J=13.73, 6.86 Hz, 1 H) 2.92 (m, 1 H) 3.55 (m, 1 H) 4.06 (dd, J=9.98, 5.93 Hz, 1 H) 4.15 (m, 1 H) 7.21 (d, J=8.11 Hz, 2 H) 7.34 (d, J=8.42 Hz, 2 H) 7.56 (d, J=8.42 Hz, 1 H) 7.69 (m, 2 H) 8.08 (s, 1 H) 8.28 (d, J=2.50 Hz, 1 H) 8.57 (d, J=1.56 Hz, 1 H) 12.73 (s, 1 H).

15




A-772078.7

Example 183

20 (1S)-1-(4-Methoxy-3-methyl-benzyl)-2-(5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy)-ethylamine
 MS (ESI) m/z 403 (M + H)⁺; ¹H NMR (500 MHz, DMSO-D6) δ ppm 2.11 (s, 3 H) 2.55 (s, 3 H) 2.71 (m, 1 H) 2.83 (dd, J=13.73, 6.86 Hz, 1 H) 3.17 (d, J=3.74 Hz, 2 H) 3.47 (m, 1 H) 3.74 (m, 3 H) 4.07 (m, 2 H) 6.86 (d, J=8.11 Hz, 1 H) 7.05 (m, 2 H) 7.56 (m, J=8.73 Hz, 1 H) 7.67 (m, 2 H) 8.07 (s, 1 H) 8.27 (d, J=2.81 Hz, 1 H) 8.57 (d, J=1.56 Hz, 1 H) 12.72 (s, 1 H).

25




A-772635.7

Example 184

2-((2S)-2-Amino-3-(5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy)-propyl)-4-methyl-phenol

5 MS (ESI) m/z 403 (M + H)⁺; ¹H NMR (500 MHz, DMSO-D6) δ ppm 2.18 (s, 3 H) 2.55 (s, 3 H) 2.98 (d, J=7.49 Hz, 2 H) 3.73 (d, J=3.74 Hz, 3 H) 3.79 (m, 1 H) 4.12 (dd, J=10.61, 5.62 Hz, 1 H) 4.27 (dd, J=10.61, 3.12 Hz, 1 H) 6.90 (d, J=8.11 Hz, 1 H) 7.02 (s, 1 H) 7.07 (d, J=8.42 Hz, 1 H) 7.57 (d, J=8.73 Hz, 1 H) 7.68 (dd, J=8.73, 1.56 Hz, 1 H) 7.71 (s, 1 H) 8.07 (s, 1 H) 8.17 (s, 3 H) 8.31 (d, J=2.50 Hz, 1 H) 8.64 (d, J=1.56 Hz, 1 H).

10




(A-755387)

Example 185

(1S)-1-Methyl-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine

15 MS (ESI) m/e 283 (M+H)⁺; ¹H NMR (300 MHz, DMSO-D6) δ ppm 1.32 (d, J=6.78 Hz 3 H) 2.56 (s, 3 H) 3.66 (m, 1 H) 4.16 (dd, J=10.51, 7.12 Hz, 1 H) 4.35 (dd, J=10.51, 3.73 Hz, 1 H) 7.57 (d, J=8.81 Hz, 1 H) 7.72 (m, 1 H) 7.78 (m, 1 H) 8.01 (m, 2 H) 8.10 (m, 1 H) 8.33 (d, J=2.71 Hz, 1 H) 8.63 (d, J=1.70 Hz, 1 H) 12.70 (bs, 1 H); Anal. Calcd for C₁₆H₁₈N₂O•2.2 TFA: C, 45.95; H, 3.82; N, 10.51;. Found: C, 46.11; H, 3.76; N, 10.55.

20




(A-444277)

Example 186

(±)-1-(1H-Benzimidazol-2-ylmethyl)-2-(5-isoquinolin-6-yl-pyridin-3-yloxy)-ethylamine

MS (ESI) m/e 396 (M+H)⁺; ¹H NMR (500 MHz, DMSO-D6) δ ppm 3.51 (m, 2 H) 4.32 (m, 1 H) 4.44 (m, 1 H) 4.55 (m, 1 H) 7.36 (dd, J=6.24, 3.12 Hz, 2 H) 7.68 (dd, J=5.93, 3.12 Hz, 2 H) 7.88 (d, J=2.18 Hz, 1 H) 8.12 (d, J=6.24 Hz, 1 H) 8.19 (dd, J=8.58, 1.40 Hz, 1 H) 8.42 (m, 2 H) 8.49 (s, 1 H) 8.64 (d, J=5.93 Hz, 1 H) 8.77 (d, J=1.56 Hz, 1 H) 9.60 (s, 1 H).

5




(A-475104)

Example 187

(±)-1-(1H-Indazol-3-ylmethyl)-2-(5-isoquinolin-6-yl-pyridin-3-ylxy)-ethylamine

10 MS (ESI) m/e 396 (M+H)⁺; ¹H NMR (400 MHz, DMSO-D6) δ ppm 3.21 (m, 2 H) 3.84 (m, 1 H) 4.21 (dd, J=9.97, 5.98 Hz, 1 H) 4.31 (dd, J=9.97, 5.98 Hz, 1 H) 7.08 (t, J=7.21 Hz, 1 H) 7.33 (t, J=7.21 Hz, 1 H) 7.49 (d, J=8.59 Hz, 1 H) 7.80 (m, 2 H) 7.89 (d, J=5.83 Hz, 1 H) 8.06 (dd, J=8.59, 1.84 Hz, 1 H) 8.25 (d, J=8.59 Hz, 1 H) 8.36 (s, 1 H) 8.39 (d, J=2.76 Hz, 1 H) 8.56 (d, J=5.83 Hz, 1 H) 8.69 (d, J=1.84 Hz, 1 H) 9.37 (s, 1 H) 12.87 (s, 1 H).

15




(A-757590)

Example 188

(1S)-1-(2-Fluoro-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-ylxy]-ethylamine

20 MS (ESI) m/e 377 (M+H)⁺; ¹H NMR (300 MHz, DMSO-D6) δ ppm 2.55 (s, 3 H) 3.11 (d, J=7.12 Hz, 2 H) 3.86 (m, 1 H) 4.15 (m, 1 H) 4.31 (dd, J=10.85, 3.39 Hz, 1 H) 7.20 (m, 2 H) 7.37 (m, 2 H) 7.57 (d, J=9.49 Hz, 1 H) 7.71 (m, 2 H) 8.08 (s, 1 H) 8.29 (s, 2 H) 8.31 (d, J=2.71 Hz, 1 H) 8.64 (d, J=1.69 Hz, 1 H) 12.74 (bs, 1 H).

25




(A-760116)

Example 189

(1S)-1-(2-Chloro-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine

MS (ESI) m/e 393 (M+H)⁺; ¹H NMR (300 MHz, DMSO-D6) δ ppm 2.55 (s, 3 H) 3.22 (m, 2 H) 3.89 (m, 1 H) 4.15 (m, 1 H) 4.31 (m, 1 H) 7.35 (m, 2 H) 7.48 (m, 3 H) 7.58 (d, J=8.82 Hz, 1 H) 7.70 (m, 2 H) 8.08 (s, 1 H) 8.31 (d, J=2.71 Hz, 2 H) 8.64 (d, J=1.70 Hz, 1 H) 12.84 (bs, 1 H).




(A-760117)

Example 190

(1S)-2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-thiophen-2-ylmethyl-ethylamine

MS (ESI) m/e 365 (M+H)⁺; ¹H NMR (300 MHz, DMSO-D6) δ ppm 2.55 (s, 3 H) 3.28 (m, 2 H) 3.90 (m, 1 H) 4.20 (m, 1 H) 4.35 (m, 1 H) 7.03 (m, 2 H) 7.46 (m, 1 H) 7.58 (d, J=8.82 Hz, 1 H) 7.70 (m, 1 H) 7.75 (m, 1 H) 8.09 (s, 1 H) 8.26 (m, 2 H) 8.33 (d, J=2.71 Hz, 1 H) 8.64 (d, J=1.70 Hz, 1 H) 12.53 (bs, 1 H).




(A-751365)

Example 191

(1R)-1-(1H-Indol-3-ylmethyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine

MS (ESI) m/e 398 (M+H)⁺; ¹H NMR (300 MHz, DMSO-D6) δ ppm 2.55 (s, 3 H) 3.16 (m, 2 H) 3.86 (d, J=1.70 Hz, 1 H) 4.19 (dd, J=10.51, 6.10 Hz, 1 H) 4.36 (dd, J=10.85, 3.39 Hz, 1 H) 7.01 (t, J=7.46 Hz, 1 H) 7.10 (t, J=6.95 Hz, 1 H) 7.30 (d, J=2.37 Hz, 1 H) 7.38 (d, J=8.14 Hz, 1 H) 7.65 (m, 5 H) 8.07 (s, 1 H) 8.16 (s, 2 H) 8.33 (d, J=2.71 Hz, 1 H) 8.63 (d, J=1.70 Hz, 1 H) 11.04 (bs, 1 H); Anal. Calcd for C₂₄H₂₃N₅O•2.9 TFA: C, 49.16; H, 3.59; N, 9.62; Found: C, 49.36; H, 3.66; N, 9.78.




A-752674.7

Example 192

1-(4-Chloro-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine

5 MS (ESI) m/e 393 (M+1)⁺; ¹H NMR (300 MHz, Solvent) δ ppm 2.63 (s, 3 H) 3.16 (m, 2 H) 3.98 (m, 1 H) 4.29 (m, 1 H) 4.44 (m, 1 H) 7.34 (m, 2 H) 7.39 (m, 2 H) 7.63 (d, J=8.82 Hz, 1 H) 7.74 (dd, J=8.82, 1.70 Hz, 1 H) 8.09 (m, 1 H) 8.11 (m, 1 H) 8.42 (br. s., 1 H) 8.73 (br. s., 1 H).




A-768094.0

Example 193.

(1S)-2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(4-pyrrol-1-yl-benzyl)-ethylamine

MS (ESI) m/e 424 (M+1)⁺; ¹H NMR (300 MHz, Solvent) δ ppm 2.61 (m, 3 H) 3.19 (m, 2 H) 4.10 (m, 1 H) 4.30 (m, 1 H) 4.44 (m, 1 H) 6.27 (t, J=2.03 Hz, 2 H) 7.16 (t, J=2.03 Hz, 2 H) 7.41 (d, J=8.48 Hz, 1 H) 7.49 (d, J=8.48 Hz, 2 H) 7.59 (d, J=8.48 Hz, 1 H) 7.70 (m, 1 H) 7.94 (m, 1 H) 8.07 (m, 1 H) 8.38 (br. s., 1 H) 8.66 (br. s., 1 H).




A-770737.7

Example 194

(1S)-1-(4-Methyl-benzylsulfanyl)methyl-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine

MS (ESI) m/e 419 (M+1)⁺; ¹H NMR (300 MHz, MeOH) δ ppm 2.26 (s, 3 H) 2.62 (s, 3 H) 2.88 (m, 2 H) 3.67 (m, 1 H) 3.82 (s, 2 H) 4.38 (m, 2 H) 7.18 (m, 6 H) 7.62 (d, J=8.81 Hz, 1 H) 7.72 (dd, J=8.81, 1.70 Hz, 1 H) 7.85 (dd, J=2.71, 1.70 Hz, 1 H) 8.06 (m, 1 H) 8.30 (d, J=2.71 Hz, 1 H) 8.62 (d, J=1.70 Hz, 1 H).




A-750982.3

Example 195

5 (1S)-2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(2-trifluoromethyl-benzyl)-ethylamine

MS m/z 427 (M + H)⁺; ¹H NMR (300 MHz, DMSO-D6) δ ppm 2.57 (s, 3 H) 3.30 (m, 2 H) 3.93 (s, 1 H) 4.32 (dd, J=10.85, 5.42 Hz, 1 H) 4.45 (m, 1 H) 7.53 (td, J=8.22, 3.90 Hz, 1 H) 7.61 (dd, J=8.82, 0.68 Hz, 1 H) 7.68 (m, 2 H) 7.77 (m, 2 H) 8.14 (s, 1 H) 8.23 (d, J=0.68 Hz, 1 H) 8.46 (d, J=2.03 Hz, 1 H) 8.65 (s, 3 H) 8.83 (s, 1 H).




A-754683.3

Example 196

15 (1R)-1-Benzyl-3-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-propylamine

MS m/z 373 (M + H)⁺; ¹H NMR (300 MHz, DMSO-D6) δ ppm 2.05 (m, 2 H) 2.57 (s, 3 H) 2.91 (dd, J=13.73, 8.65 Hz, 1 H) 3.11 (m, 1 H) 3.63 (m, 1 H) 4.41 (m, 2 H) 7.25 (m, 1 H) 7.33 (m, 4 H) 7.61 (dd, J=8.81, 0.68 Hz, 1 H) 7.81 (dd, J=8.81, 1.70 Hz, 1 H) 8.21 (s, 1 H) 8.28 (s, 2 H) 8.47 (d, J=2.37 Hz, 1 H) 8.82 (s, 1 H).

20




A-761612.3

Example 197

(1R)-1-Benzyl-4-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-butylamine

25 MS m/z 387 (M + H)⁺; ¹H NMR (300 MHz, DMSO-D6) δ ppm 1.70 (q, J=7.23 Hz, 2 H) 1.91 (m, 2 H) 2.57 (s, 3 H) 2.82 (dd, J=13.56, 8.48 Hz, 1 H) 3.06 (dd, J=13.73, 5.26 Hz, 1 H) 3.47 (s, 1 H) 4.27 (m, 2 H) 7.27 (m, 5 H) 7.61 (d, J=8.48 Hz, 1 H) 7.84 (dd, J=8.81, 1.70 Hz, 1 H) 8.29 (s, 2 H) 8.33 (s, 1 H) 8.49 (d, J=2.37 Hz, 1 H) 8.87 (s, 1 H).




A-761613.3

Example 198

(1S)-1-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxyethyl]-3-phenyl-propylamine

5 MS m/z 373 (M + H)⁺; ¹H NMR (300 MHz, DMSO-D6) δ ppm 2.04 (m, 2 H) 2.57 (s, 3 H) 2.80 (m, 2 H) 3.57 (m, 1 H) 4.44 (dd, J=10.68, 6.61 Hz, 1 H) 4.59 (m, 1 H) 7.24 (m, 5 H) 7.62 (d, J=8.82 Hz, 1 H) 7.82 (dd, J=8.65, 1.53 Hz, 1 H) 8.27 (s, 2 H) 8.50 (s, 2 H) 8.54 (d, J=2.71 Hz, 1 H) 8.86 (s, 1 H).




A-431070.6

Example 199

(1S)-2-(5-Isoquinolin-6-yl-pyridin-3-yloxy)-1-(1-methyl-1H-indol-3-ylmethyl)-ethylamine trifluoroacetic acid salt


15 MS (DCI/NH₃) m/z 409(M+1)⁺; ¹H NMR (500 MHz, MeOD) δ ppm 3.28 (m, 1 H) 3.33 (m, 1 H) 3.77 (s, 3 H) 4.00 (m, 1 H) 4.33 (dd, J=10.61, 5.93 Hz, 1 H) 4.46 (dd, J=10.61, 3.12 Hz, 1 H) 7.04 (m, 1 H) 7.17 (m, 1 H) 7.17 (s, 1 H) 7.36 (d, J=8.42 Hz, 1 H) 7.59 (d, J=7.80 Hz, 1 H) 7.93 (m, 1 H) 8.28 (dd, J=8.73, 1.87 Hz, 1 H) 8.49 (m, 2 H) 8.59 (m, 3 H) 8.76 (s, 1 H) 9.77 (s, 1 H).



A-437689.6

Example 199

(1S)-[1-(1H-Indol-3-ylmethyl)-2-(5-isoquinolin-6-yl-pyridin-3-yloxy)-ethyl]-dimethyl-amine
25 ¹H NMR (400 MHz, MeOD) δ ppm 3.16 (s, 6 H) 3.44 (m, 2 H) 4.11 (m, 1 H) 4.46 (m, 1 H) 4.55 (m, 1 H) 7.00 (m, 1 H) 7.09 (m, 1 H) 7.26 (m, 1 H) 7.35 (d, J=8.29 Hz, 1 H) 7.60 (d, J=7.98 Hz, 1 H) 7.81 (m, 1 H) 8.22 (dd, J=8.59, 1.53 Hz, 1 H) 8.42 (m, 2 H) 8.50 (m, 1 H) 8.55 (d, J=8.90 Hz, 1 H) 8.61 (m, 1 H) 8.72 (m, 1 H) 9.73 (s, 1 H)




A-750069.7

Example 200

5 (1S)-1-Benzo[b]thiophen-3-ylmethyl-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine

MS (DCI/NH₃) m/z 415 (M+1); ¹HNMR (400 MHz, MeOD) δ ppm 2.62 (s, 3 H) 3.41 (dd, J=14.73, 6.75 Hz, 1 H) 3.50 (dd, J=14.42, 8.59 Hz, 1 H) 4.12 (m, 1 H) 4.32 (dd, J=10.43, 5.22 Hz, 1 H) 4.45 (dd, J=10.74, 3.07 Hz, 1 H) 7.40 (m, 2 H) 7.55 (m, 1 H) 7.61 (d, J=8.90 Hz, 1 H) 7.68 (dd, J=8.59, 1.53 Hz, 1 H) 7.91 (m, 3 H) 8.03 (s, 1 H) 8.35 (s, 1 H) 8.64 (s, 1 H).

10




A-759277.2

Example 201

15 (1S)-2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-thiophen-3-ylmethyl-ethylamine

MS (DCI/NH₃) m/z 365 (M+1)⁺; ¹HNMR (500 MHz, MeOD) δ ppm 2.63 (s, 3H) 3.43 (m, 2 H) 3.98 (m, 1 H) 4.40 (dd, J=10.61, 5.62 Hz, 3 H) 4.52 (dd, J=10.61, 3.12 Hz, 1 H) 7.03 (dd, J=8.42, 3.43 Hz, 1 H) 7.06 (m, 1 H) 7.36 (dd, J=4.99, 1.25 Hz, 1 H) 7.64 (d, J=8.73 Hz, 1 H) 7.75 (dd, J=8.73, 1.87 Hz, 1 H) 8.14 (s, 1 H) 8.21 (m, 1 H) 8.47 (brs, 1 H) 8.77 (s, 1 H).

20




A-713679.21

Example 202


(1S)-1-Benzyloxymethyl-2-(5-isoquinolin-6-yl-pyridin-3-yloxy)-ethylamine

25



Example 202A


(1S)-[1-Benzylloxymethyl-2-(5-bromo-pyridin-3-yloxy)-ethyl]-carbamic acid tert-butyl ester
 The product was prepared by substituting Boc-serinol(Bn) for Boc-tryptophanol in Example 2A. MS m/z 437, 439 (M + H)⁺; ¹H NMR (300 MHz, DMSO-D6) δ ppm 1.37 (s, 9 H) 3.50 (d, J=6.10 Hz, 2 H) 3.97 (m, 1 H) 4.11 (m, 2 H) 4.50 (s, 2 H) 6.99 (d, J=7.80 Hz, 1 H) 7.29 (m, 5 H) 7.70 (m, 1 H) 8.28 (dd, J=4.75, 2.37 Hz, 2 H).



Example 202B

(1S)-[1-Benzylloxymethyl-2-(5-isoquinolin-6-yl-pyridin-3-yloxy)-ethyl]-carbamic acid tert-butyl ester


10 The desired product was prepared by substituting 202A for Example 2A in Example 27B. ¹H NMR (300 MHz, DMSO-D6) δ ppm 1.38 (s, 9 H) 3.56 (d, J=6.10 Hz, 2 H) 4.04 (m, 1 H) 4.22 (d, J=5.43 Hz, 2 H) 4.52 (s, 2 H) 7.05 (d, J=8.14 Hz, 1 H) 7.28 (m, 5 H) 7.87 (m, 2 H) 8.10 (dd, J=8.65, 1.53 Hz, 1 H) 8.25 (d, J=8.82 Hz, 1 H) 8.35 (d, J=2.71 Hz, 1 H) 8.40 (s, 1 H) 8.56 (d, J=5.76 Hz, 1 H) 8.68 (d, J=1.70 Hz, 1 H) 9.37 (s, 1 H).



Example 202C

(1S)-1-Benzylloxymethyl-2-(5-isoquinolin-6-yl-pyridin-3-yloxy)-ethylamine


15 The desired product was prepared by substituting Example 202B for Example 27A in Example 202. in Example 27C. MS m/z 386 (M + 1)⁺; ¹H NMR (300 MHz, DMSO-D6) δ ppm 3.76 (m, 3 H) 3.97 (s, 2 H) 4.44 (m, 2 H) 4.60 (s, 2 H) 7.35 (m, 5 H) 8.00 (m, 1 H) 8.33 (m, 2 H) 8.48 (d, J=2.71 Hz, 1 H) 8.54 (d, J=8.81 Hz, 1 H) 8.66 (s, 1 H) 8.68 (d, J=6.10 Hz, 1 H) 8.81 (d, J=1.70 Hz, 1 H) 9.75 (s, 1 H).



A-750983.3

Example 203


(1S)-1-Benzylloxymethyl-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine



Example 203A

5-Bromo-3-methyl-indazole-1-carboxylic acid tert-butyl ester


A solution of Example 102C (1.0 g; 4.7 mmol), TEA (526 mg; 5.2 mmol), DMAP (200 mg; 1.6 mmol) and di-tert-butyldicarbonate (1.1 g; 5.0 mmol) in CH₃CN (15 mL) was stirred at r.t. for 3 hrs, evaporated, and isolated by flash chromatography (30% Et₂O/hexane) to give the desired product as a white solid (1.4 g; 95%).



Example 203B

3-Methyl-5-trimethylstannanyl-indazole-1-carboxylic acid tert-butyl ester

A solution of Example 203A (1.35 g; 4.3 mmol), hexamethylditin (1.56 g; 4.8 mmol), and Pd(PPh₃)₄ (250 mg, 0.22 mmol) in toluene (15 mL) was stirred overnight at 85 °C, evaporated and purified by flash chromatography (20% Et₂O/hexane) to provide the desired product (1.32 g; 77%).




Example 203C

(2S)-5-[5-(3-Benzyl-2-tert-butoxycarbonylamino-propoxy)-pyridin-3-yl]-3-methyl-indazole-1-carboxylic acid tert-butyl ester

The desired product was prepared by substituting 203B for Example 27A in Example 202B.

MS m/z 589 (M + H)⁺; ¹H NMR (300 MHz, DMSO-D6) δ ppm 1.38 (s, 9 H) 1.66 (s, 9 H) 2.59 (s, 3 H) 3.32 (m, 1 H) 3.56 (d, J=6.10 Hz, 2 H) 4.20 (d, J=5.76 Hz, 2 H) 4.52 (s, 2 H) 7.03 (d, J=8.14 Hz, 1 H) 7.27 (m, 1 H) 7.32 (m, 4 H) 7.78 (s, 1 H) 8.00 (dd, J=8.82, 1.70 Hz, 1 H) 8.12 (m, 1 H) 8.26 (d, J=1.02 Hz, 1 H) 8.29 (d, J=2.71 Hz, 1 H) 8.61 (d, J=1.70 Hz, 1 H).




Example 203D

(1S)-1-Benzyl-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine

The desired product was prepared by substituting 203C for Example 27B in Example 27C.

MS m/z 389 (M + H)⁺; ¹H NMR (300 MHz, DMSO-D6) δ ppm 2.57 (s, 3 H) 3.79 (m, 3 H)

4.51 (m, 2 H) 4.60 (s, 2 H) 4.90 (br s, 2 H) 7.34 (m, 5 H) 7.61 (d, $J=8.81$ Hz, 1 H) 7.80 (dd, $J=8.81$, 1.70 Hz, 1 H) 8.23 (s, 1 H) 8.27 (s, 1 H) 8.52 (m, 2 H) 8.85 (d, $J=1.70$ Hz, 1 H).




5

A-682707.0

Example 204


(1S)-2-(5-Isoquinolin-6-yl-pyridin-3-yloxy)-1-(naphthalen-2-yloxymethyl)-ethylamine



Example 204A

10 (1S)-[1-Hydroxymethyl-2-(5-isoquinolin-6-yl-pyridin-3-yloxy)-ethyl]-carbamic acid tert-butyl ester

To Example 202B (290 mg, 0.60 mmol) was added sequentially: ammonium formate (377 mg, 5.97 mmol), MeOH (wet) (15 mL), and 10% Pd/C (320 mg). The resulting black reaction mixture was warmed to 70 °C for 6 d and then cooled to room temperature and 15 filtered through Celite. K_2CO_3 (50 mg) and silica gel were added and the volatiles removed on a rotary evaporator. Flash chromatography (2-3-5-7% MeOH/CH₂Cl₂) gave 40 mg (14%) recovered starting material and 89 mg (38%) of as a colorless waxy solid. R_f = 0.32 (10% MeOH/CH₂Cl₂); ¹H NMR (300 MHz, DMSO-D6) δ ppm 1.38 (s, 9 H) 3.51 (td, $J=5.76$, 2.71 Hz, 2 H) 3.84 (m, 1 H) 4.19 (m, 2 H) 4.84 (t, $J=5.76$ Hz, 1 H) 6.82 (d, $J=8.14$ Hz, 1 H) 7.89 (m, 2 H) 8.11 (dd, $J=8.65$, 1.53 Hz, 1 H) 8.25 (d, $J=8.82$ Hz, 1 H) 8.36 (d, $J=2.71$ Hz, 1 H) 8.41 (s, 1 H) 8.56 (d, $J=5.76$ Hz, 1 H) 8.68 (d, $J=1.70$ Hz, 1 H) 9.37 (s, 1 H).




Example 204B

25 (1S)-[2-(5-Isoquinolin-6-yl-pyridin-3-yloxy)-1-(naphthalen-2-yloxymethyl)-ethyl]-carbamic acid tert-butyl ester

2-Naphthol (15 mg, 101 μ mol), Example 204A (20 mg, 51 μ mol), DBAD (17 mg, 76 μ mol), and PPh₃-polymer (3 mmol/g) (34 mg, 101 μ mol) were combined in a 10 mL round

bottom flask. THF (2 mL) was added and the reaction mixture stirred 2 d at 23 °C and then rotavapped with silica gel. Flash chromatography (2-3-5-10% MeOH/CH₂Cl₂) gave 19 mg (73%) of as a colorless waxy solid. R_f = 0.47 (10% MeOH/CH₂Cl₂); ¹H NMR (300 MHz, DMSO-D6) δ ppm 1.41 (s, 9 H) 4.24 (m, 3 H) 4.37 (m, 2 H) 7.19 (dd, J=8.82, 2.71 Hz, 1 H) 7.34 (m, 3 H) 7.45 (td, J=7.54, 1.19 Hz, 1 H) 7.78 (s, 1 H) 7.81 (s, 1 H) 7.84 (s, 1 H) 7.88 (d, J=5.76 Hz, 1 H) 7.92 (s, 1 H) 8.10 (dd, J=8.48, 1.70 Hz, 1 H) 8.24 (d, J=8.48 Hz, 1 H) 8.40 (m, 2 H) 8.56 (d, J=5.76 Hz, 1 H) 8.69 (d, J=1.70 Hz, 1 H) 9.37 (s, 1 H).



Example 204C

(1S)-2-(5-Isoquinolin-6-yl-pyridin-3-yloxy)-1-(naphthalen-2-yloxymethyl)-ethylamine
The desired product was prepared by substituting Example 204B for Example 27B in Example 27C. LCMS m/z 422 (M+1)⁺; ¹H NMR (300 MHz, DMSO-D6) δ ppm 3.54 (dt, J=11.44, 5.64 Hz, 1 H) 4.23 (m, 4 H) 7.20 (dd, J=8.98, 2.54 Hz, 1 H) 7.34 (m, 2 H) 7.45 (ddd, J=8.05, 6.87, 1.36 Hz, 1 H) 7.81 (m, 3 H) 7.88 (m, 2 H) 8.09 (m, 1 H) 8.24 (d, J=8.48 Hz, 1 H) 8.38 (s, 1 H) 8.42 (d, J=2.71 Hz, 1 H) 8.55 (d, J=5.76 Hz, 1 H) 8.67 (d, J=1.70 Hz, 1 H) 9.37 (s, 1 H).

Example 205

(1S)-2-(5-Isoquinolin-6-yl-pyridin-3-yloxy)-1-(pyridin-3-yloxymethyl)-ethylamine
The desired product was prepared as tri-TFA salt by substituting 3-hydroxypyridine for 2-naphthol in Example 204. MS m/z 373 (M + 1)⁺; ¹H NMR (300 MHz, DMSO-D6) δ ppm 4.10 (m, 1 H) 4.48 (m, 4 H) 7.44 (dd, J=8.65, 4.92 Hz, 1 H) 7.54 (m, 1 H) 7.96 (t, J=2.03 Hz, 1 H) 8.09 (d, J=6.78 Hz, 1 H) 8.21 (dd, J=8.65, 1.53 Hz, 1 H) 8.27 (d, J=4.75 Hz, 1 H) 8.41 (m, 2 H) 8.49 (m, 4 H) 8.63 (d, J=5.76 Hz, 1 H) 8.79 (d, J=1.70 Hz, 1 H) 9.56 (s, 1 H).

Example 206

(1S)-2-(5-Isoquinolin-6-yl-pyridin-3-yloxy)-1-(quinolin-7-yloxymethyl)-ethylamine
The desired product was prepared as trifluoroacetic acid salt by substituting 7-hydroxyquinoline for 2-naphthol in Example 204. ¹H NMR (300 MHz, DMSO-D6) δ ppm 4.24 (m, 4 H) 7.45 (m, 3 H) 7.90 (m, 3 H) 8.09 (dd, J=8.48, 1.70 Hz, 1 H) 8.23 (s, 1 H) 8.25 (s, 1 H) 8.39 (s, 1 H) 8.42 (d, J=2.71 Hz, 1 H) 8.56 (d, J=5.43 Hz, 1 H) 8.67 (d, J=1.70 Hz, 1 H) 8.73 (dd, J=4.41, 1.70 Hz, 1 H) 9.37 (s, 1 H).

Example 207(2S)-4-[2-Amino-3-(5-isoquinolin-6-yl-pyridin-3-yloxy)-propoxy]-benzonitrile

The desired product was prepared as trifluoroacetic acid salt by substituting 4-cyanophenol for 2-naphthol in Example 204. ^1H NMR (300 MHz, DMSO-D6) δ ppm 2.27 (br s, 2 H) 3.49 (m, 1 H) 4.18 (m, 4 H) 7.16 (m, 2 H) 7.76 (m, 2 H) 7.86 (dd, J =2.71, 2.03 Hz, 1 H) 7.89 (d, J =5.76 Hz, 1 H) 8.09 (dd, J =8.65, 1.86 Hz, 1 H) 8.25 (d, J =8.82 Hz, 1 H) 8.39 (m, 2 H) 8.56 (d, J =5.76 Hz, 1 H) 8.68 (d, J =1.69 Hz, 1 H) 9.37 (s, 1 H).

10

Example 208(2S)-N'-(5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yl)-3-phenyl-propane-1,2-diamineExample 208A15 (2S)-{1-[(5-Bromo-pyridin-3-ylamino)-methyl]-2-phenyl-ethyl}-carbamic acid *tert*-butyl ester

A solution of Example 23B (0.4 g, 2.3 mmol), (1-formyl-2-phenyl-ethyl)-carbamic acid *tert*-butyl ester (0.7 g, 2.8 mmol), and $\text{Ti}(\text{iPrO})_4$ (10 ml) in CH_2Cl_2 (15 mL) was stirred at room temperature for 2 h. The solvent was evaporated off and the residue was dissolved in 15 ml of EtOH. The solution was treated with NaBH_3CN (0.5 g, 4.9 mmol) then stirred overnight at room temperature. The mixture was diluted with ethyl acetate (50 ml), washed with water (25 ml) and brine (25 ml). The ethyl acetate was evaporated off and the residue was purified by flash column chromatography on silica gel, eluting with a solvent gradient of 1:4 to 1:1 ethyl acetate/hexane to give 0.28 g of product (30 %). MS: (ESI) m/z 408 ($\text{M} + \text{H}$) $^+$.

25

Example 208B(2S)-5-[5-(2-*tert*-Butoxycarbonylamino-3-phenyl-propylamino)-pyridin-3-yl]-3-methyl-indazole-1-carboxylic acid *tert*-butyl ester

The desired product was prepared by substituting Example 208A for Example 202A in Example 203C.

Example 208C(2S)-N'-(5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yl)-3-phenyl-propane-1,2-diamine

The desired product was prepared by substituting Example 208B for Example 27B in Example 27C. MS: (ESI) m/z 358 ($\text{M} + \text{H}$) $^+$; ^1H NMR (500 MHz, DMSO-D6) δ ppm 2.56 (d, J =3.74 Hz, 3 H) 3.00 (m, 2 H) 3.42 (d, J =5.30 Hz, 3 H) 6.89 (m, 1 H) 7.27 (m, 2 H) 7.35 (m, 3

H) 7.57 (s, 1 H) 7.62 (d, J =4.06 Hz, 2 H) 8.01 (s, 1 H) 8.07 (m, 1 H) 8.13 (s, 2 H) 8.38 (s, 1 H).

5

Example 209(2S)-N-(2-Amino-3-phenyl-propyl)-N-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yl]-methanesulfonamide

Example 208B (500mg, 0.90mmol) in pyridine (8ml) was added dropwise with methyl sulfonyl chloride (308mg, 2.7mmol) in an ice-bath. The reaction mixture was allowed to 10 warm up to rt and stirred for 12hrs. The solvent was removed by bubbling nitrogen to the reaction flask. The residue was chromatographed on silica gel eluting with EtOAc to give the Boc protected product, which was deprotected according to the procedure described in Example 27C to give the title compound as trifluoroacetic acid salt (21.2mg, 4%). MS (DCI/NH₃) m/z 436 (M+1)⁺; ¹HNMR (500 MHz, MeOD) δ ppm 2.62 (s, 3 H) 2.89 (dd, 15 J =14.35, 9.36 Hz, 1 H) 3.03 (s, 3 H) 3.05 (dd, J =14.35, 5.62 Hz, 1 H) 3.59 (m, 1 H) 4.06 (d, J =5.93 Hz, 2 H) 7.07 (s, 1 H) 7.09 (s, 1 H) 7.18 (d, J =7.18 Hz, 1 H) 7.24 (m, 2 H) 7.60 (s, 1 H) 7.60 (s, 1 H) 7.95 (s, 1 H) 8.10 (t, J =1.87 Hz, 1 H) 8.59 (s, 1 H) 8.87 (s, 1 H).

20

Example 210(2S)-N-(2-Amino-3-phenyl-propyl)-N-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yl]-benzenesulfonamide

The desired product was prepared as trifluoroacetic acid salt by substituting benzenesulfonyl chloride for methanesulfonyl chloride in Example 209. MS (DCI/NH₃) m/z 498 (M+1)⁺; ¹H NMR (500 MHz, DMSO-D6) δ ppm 2.55 (s, 3 H) 2.84 (dd, J =14.04, 8.42 Hz, 1 H) 2.97 (dd, 25 J =14.04, 5.62 Hz, 1 H) 3.45 (m, 1H) 3.78 (m, 2 H) 7.17 (s, 1 H) 7.19 (s, 1 H) 7.24 (d, J =7.18 Hz, 1 H) 7.30 (m, 2 H) 7.43 (s, 1 H) 7.44 (d, J =0.62 Hz, 1 H) 7.50 (dd, J =8.73, 1.56 Hz, 1 H) 7.57 (d, J =8.42 Hz, 1 H) 7.62 (m, 3 H) 7.78 (t, J =7.49 Hz, 1 H) 7.82 (s, 1 H) 8.11 (s, 3 H) 8.25 (d, J =2.18 Hz, 1 H) 8.92 (d, J =1.87 Hz, 1 H).

30

Example 211(2S)-N-(2-Amino-3-phenyl-propyl)-N-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yl]-benzamide

35 The desired product was prepared as trifluoroacetic acid salt by substituting benzoyl chloride for methanesulfonyl chloride in Example 209. MS (DCI/NH₃) m/z 462 (M+1)⁺; ¹H NMR (500 MHz, DMSO-D6) δ ppm 2.54 (s, 3 H) 2.90 (dd, J =14.04, 9.05 Hz, 1 H) 3.03 (dd,

$J=14.04, 5.30$ Hz, 1 H) 3.65 (m, 1 H) 4.09 (dd, $J=14.97, 4.06$ Hz, 1 H) 4.28 (dd, $J=14.97, 8.42$ Hz, 1 H) 7.19 (m, 3 H) 7.27 (m, 4 H) 7.33 (m, 2 H) 7.44 (dd, $J=8.73, 1.56$ Hz, 1 H) 7.54 (d, $J=8.73$ Hz, 1 H) 7.75 (s, 1 H) 7.86 (m, 1 H) 8.09 (s, 3 H) 8.22 (d, $J=2.18$ Hz, 1 H) 8.69 (d, $J=1.87$ Hz, 1 H).

5

Example 212

(2S)-N-(2-Amino-3-phenyl-propyl)-N-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yl]-acetamide

The desired product was prepared as trifluoroacetic acid salt by substituting acetyl chloride for methanesulfonyl chloride in Example 209. MS (DCI/NH₃) m/z 400 (M+1)⁺; ¹H NMR (400 MHz, MeOD) δ ppm 1.98 (s, 3 H) 2.63 (s, 3 H) 2.90 (dd, $J=14.12, 8.90$ Hz, 1 H) 3.02 (dd, $J=13.81, 5.83$ Hz, 1 H) 3.68 (m, 1 H) 3.76 (dd, $J=15.04, 2.46$ Hz, 1 H) 4.31 (dd, $J=15.04, 7.98$ Hz, 1 H) 7.25-7.11 (m, 6H) 7.64 (m, 2 H) 8.00 (s, 1 H) 8.03 (s, 1 H) 8.46 (s, 1 H) 8.93 s, 1 H)

15

Example 213

(2S)-3-[2-Amino-3-(1H-indol-3-yl)-propylidene]-5-isoquinolin-6-yl-1,3-dihydro-indol-2-one

The desired product was prepared as trifluoroacetic acid salt by substituting 5-bromooxindole for 5-bromo-7 aza-oxindole in Example 44. MS (DCI/NH₃) m/z 431 (M+1)⁺; ¹H NMR (500 MHz, MeOD) δ ppm 3.26 (dd, $J=14.35, 9.67$ Hz, 1 H) 3.57 (dd, $J=14.66, 4.06$ Hz, 1 H) 5.05 (dt, $J=19.34, 4.06$ Hz, 1 H) 6.71 (m, 1 H) 6.83 (d, $J=9.98$ Hz, 1 H) 6.85 (m, 1 H) 6.98 (d, $J=8.42$ Hz, 1 H) 7.03 (m, 1 H) 7.06 (d, $J=8.11$ Hz, 1 H) 7.14 (d, $J=1.56$ Hz, 1 H) 7.55 (dd, $J=8.73, 1.87$ Hz, 1 H) 7.64 (dd, $J=8.11, 1.56$ Hz, 1 H) 7.69 (d, $J=8.11$ Hz, 1 H) 7.94 (s, 1 H) 8.18 (d, $J=6.24$ Hz, 1 H) 8.31 (d, $J=8.73$ Hz, 1 H) 8.52 (s, 1 H) 9.55 (s, 1 H).

Example 214

(1S)-2-(5-Isoquinolin-6-yl-pyridin-3-yloxy)-1-(1-methyl-1H-indol-3-ylmethyl)-ethylamine

The title compound was prepared as trifluoroacetic acid salt by substituting 5-bromo-7-azaindole (D. Mazeas, et al., *Heterocycles* **1990**, *50*, 1065) for 6-bromophthalimide in Example 32. MS (DCI/NH₃) m/z 384 (M+1)⁺; ¹H NMR (500 MHz, MeOD) δ ppm 3.29 (m, 1 H) 3.33 (dd, $J=8.11, 2.81$ Hz, 1 H) 4.03 (m, 1 H) 4.36 (dd, $J=10.61, 5.62$ Hz, 1 H) 4.49 (dd, $J=10.61, 3.12$ Hz, 1 H) 6.69 (d, $J=3.12$ Hz, 1 H) 7.02 (m, 1 H) 7.10 (t, $J=7.49$ Hz, 1 H) 7.25 (s, 1 H) 7.36 (d, $J=8.11$ Hz, 1 H) 7.57 (m, 2 H) 8.08 (s, 1 H) 8.45 (s, 2 H) 8.58 (s, 1 H) 8.80 (s, 1 H).

Example 215(1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(1H-pyrrolo[2,3-*b*]pyridin-5-yl)-pyridin-3-yloxy]-ethylamine

5

Example 215A(1S)-N-[1-(1H-Indol-3-ylmethyl)-2-(5-isoquinolin-6-yl-pyridin-3-yloxy)-ethyl]-2-nitro-benzenesulfonamide

10 To a solution of Example 27 (400mg, 1.01mmol) and DIEA (1.06mL, 6.06mmol) in THF (30mL) in ice-bath cooling was added 2-nitrobenzylsulfonyl chloride (896mg, 4.04mmol). The reaction was allowed to warm up to rt for 12hrs. The reaction mixture was concentrated and the resulting crude oil was purified by flash column chromatography eluting with EtOAc/Hex (1:1), EtOAc, and EtOAc/MeOH (20:1) to give the title compound (267mg, 46%). MS (DCI/NH₃) m/z 580(M+1)⁺.

15

Example 215B(1S)-N-[1-(1H-Indol-3-ylmethyl)-2-(5-isoquinolin-6-yl-pyridin-3-yloxy)-ethyl]-N-methyl-2-nitro-benzenesulfonamide

20 To a solution of Example 215A (260mg, 0.45mmol), MeOH (16uL, 4.5mmol), and Ph₃P (591mg, 2.25mmol) in THF (10mL) in an ice-bath was added dropwise DEAD (392mg, 2.25mmol). The reaction was allowed to ward up to rt for 12hrs. The reaction mixture was concentrated and the resulting crude oil was purified by flash column chromatography eluting with EtOAc, and EtOAc/MeOH (40:3) to give the title compound (47mg, 18%). MS (DCI/NH₃) m/z 594(M+1)⁺.

25

Example 215C(1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(1H-pyrrolo[2,3-*b*]pyridin-5-yl)-pyridin-3-yloxy]-ethylamine

30 A mixture of Example 215B (47mg, 0.08mmol), PhSH (9.7uL, 0.095mmol), and K₂CO₃ (33mg, 0.237mmol) in DMF (5mL) was stirred at rt for 2hrs. The reaction was Concentrated to dryness. The resulting residue was purified on C18 HPLC to afford the title compound (34.2mg, 58%). MS (DCI/NH₃) m/z 409(M+1)⁺; ¹H NMR (500 MHz, MeOD) δ ppm 2.91 (s, 3 H) 2.99 (brs, 1 H) 3.37 (dd, *J*=14.66, 9.36 Hz, 1 H) 3.43 (dd, *J*=14.66, 5.93 Hz, 1 H) 3.96 (m, 1 H) 4.38 (dd, *J*=10.92, 4.37 Hz, 1 H) 4.52 (dd, *J*=10.92, 2.81 Hz, 1 H) 6.99 (dt, *J*=8.11, 0.94 Hz, 1 H) 7.10 (dt, *J*=8.11, 0.94 Hz, 1 H) 7.25 (s, 1 H) 7.36 (d, *J*=8.11 Hz, 1 H) 7.58 (d, *J*=8.11 Hz, 1 H) 7.92 (m, 1 H) 8.29 (dd, *J*=8.73, 1.87 Hz, 1 H) 8.49 (d, *J*=6.55 Hz, 1 H) 8.50

(s, 1 H) 8.56 (s, 1 H) 8.60 (d, $J=8.73$ Hz, 1 H) 8.63 (d, $J=6.55$ Hz, 1 H) 8.77 (s, 1 H) 9.78 (s, 1 H).

5

Example 216


(1S)-2-{5-[2-(2-Fluoro-pyridin-4-yl)-vinyl]-pyridin-3-yloxy}-1-(1H-indol-3-ylmethyl)-ethylamine

10

Example 216A2-Fluoro-4-vinylpyridine

A mixture of 2-fluoro-4-iodopyridine (2.23g, 10.0mmol), tributyl vinyl tin (3.8g, 12mmol), and $Pd_2Cl_2(PPh_3)_2$ (703mg, 1.0mmol) in dioxane (20mL) was heated under nitrogen at 80 °C overnight. After cooled, ethyl acetate (40 ml) and saturated KF aqueous solution were added to the reaction mixture. The mixture was stirred for 30 min. The organic layer was separated and washed with water, dried ($MgSO_4$), and concentrated. The resulting residue was purified by flash column chromatography eluting with hexane/ethyl acetate (20:1) to provide the title compound (463mg, 38%). 1H NMR (500 MHz, $CDCl_3$) δ ppm 5.55 (d, $J=10.92$ Hz, 1 H) 5.99 (d, $J=17.47$ Hz, 1 H) 6.67 (dd, $J=17.47, 10.61$ Hz, 1 H) 6.88 (m, 1 H) 7.17 (dt, $J=5.30, 1.56$ Hz, 1 H) 8.16 (d, $J=5.30$ Hz, 1 H).

15



20

Example 216B

(1S)-[2-{5-[2-(2-Fluoro-pyridin-4-yl)-vinyl]-pyridin-3-yloxy}-1-(1H-indol-3-ylmethyl)-ethyl]-carbamic acid *tert*-butyl ester

The desired product was prepared as a trifluoroacetic acid salt by substituting Example 216A for 4-vinylpyridine in Example 2 (1.067g, 84%). MS (DCI/NH₃) m/z 489 (M+1)⁺; 1H NMR (400 MHz, MeOD) δ ppm 1.42 (m, 9 H) 2.98 (m, 1 H) 3.04 (m, 1 H) 3.14 (m, 1 H) 4.09 (m, 2 H) 4.25 (m, 1 H) 6.96 (t, $J=7.36$ Hz, 1 H) 7.07 (t, $J=7.07$ Hz, 1 H) 7.09 (m, 1 H) 7.20 (m, 1 H) 7.29 (m, 2 H) 7.45 (m, 2 H) 7.59 (m, 2 H) 8.16 (d, $J=5.52$ Hz, 1 H) 8.19 (s, 1 H) 8.32 (s, 1 H).

30

Example 217

(1S)-1-(1H-Indol-3-ylmethyl)-2-{5-[2-(2-methoxy-pyridin-4-yl)-vinyl]-pyridin-3-yloxy}-ethylamine

Example 217A

(1S)-(1-(1H-Indol-3-ylmethyl)-2-{5-[2-(2-methoxy-pyridin-4-yl)-vinyl]-pyridin-3-yloxy}-ethyl)-carbamic acid *tert*-butyl ester

A mixture of Example 216B (100mg, 0.2mmol), NaOMe (25% in MeOH) (1mL) in MeOH (10mL) was refluxed for 8 hrs. The mixture was concentrated to give the crude product.

5

Example 217B

(1S)-1-(1H-Indol-3-ylmethyl)-2-{5-[2-(2-methoxy-pyridin-4-yl)-vinyl]-pyridin-3-yloxy}-ethylamine

Example 217A was treated with TFA (1mL) at rt for 10 min. Upon Removal of the TFA, the crude product was purified on C18 HPLC to give the title compound (101.8mg, 69%). MS (DCI/NH₃) m/z 401 (M+1)⁺; ¹HNMR (400 MHz, MeOD) δ ppm 3.31 (m, 2 H) 3.99 (s, 3 H) 4.00 (m, 1H) 4.29 (dd, *J*=10.43, 5.52 Hz, 1 H) 4.41 (dd, *J*=10.43, 3.07 Hz, 1 H) 7.03 (m, 1 H) 7.06 (s, 1 H) 7.13 (m, 1 H) 7.24 (s, 1 H) 7.27 (dd, *J*=5.52, 1.23 Hz, 1 H) 7.34 (d, *J*=16.26 Hz, 1 H) 7.39 (d, *J*=8.29 Hz, 1 H) 7.48 (d, *J*=16.57 Hz, 1 H) 7.59 (d, *J*=7.98 Hz, 1 H) 7.87 (s, 1 H) 8.16 (d, *J*=5.22 Hz, 1 H) 8.40 (brs, 1 H) 8.57 (brs, 1 H).

15

Example 218

(1S)-1-(1H-Indol-3-ylmethyl)-2-{5-[2-(2-phenoxy-pyridin-4-yl)-vinyl]-pyridin-3-yloxy}-ethylamine

20 A mixture of Example 216B (50 mg, 0.1 mmol), phenol (94mg, 1.0mmol) and KOH (11.2mg, 0.2mmol) was heated at 140 C in a sealed bottle for 2 hrs. The mixture was concentrated to dryness. The residue was then treated with TFA (1mL) at rt for 10 min. Upon Removal of TFA, the crude product was purified on C18 HPLC to give the title compound (4.3mg, 5.3%). MS (DCI/NH₃) m/z 463 (M+1)⁺; ¹HNMR (400 MHz, MeOD) δ ppm 3.30 (m, 1 H) 3.48 (dd, *J*=13.81, 7.06 Hz, 1 H) 4.00 (m, 1 H) 4.27 (dd, *J*=10.43, 5.83 Hz, 1 H) 4.40 (dd, *J*=10.43, 3.07 Hz, 1 H) 7.15-7.01 (m, 5H) 7.26-7.23 (m, 2H) 7.48-7.32 (m, 6H) 7.59 (d, *J*=7.98 Hz, 1 H) 7.87 (m, 1 H) 8.16 (d, *J*=5.52 Hz, 1 H) 8.35 (s, 1 H) 8.53 (s, 1 H).

25

Example 219

(1S)-2-{5-[2-(2-Benzylsulfanyl-pyridin-4-yl)-vinyl]-pyridin-3-yloxy}-1-(1H-indol-3-ylmethyl)-ethylamine

30 The title compound was prepared as trifluoroacetic acid salt by substituting benzylthiol for phenol in Example 218. MS (DCI/NH₃) m/z 493(M+1)⁺; ¹HNMR (500 MHz, MeOD) δ ppm 3.31 (m, 1 H) 3.35 (m, 1 H) 4.00 (m, 1 H) 4.26 (dd, *J*=10.61, 5.62 Hz, 1 H) 4.39 (dd, *J*=10.61, 3.43 Hz, 1 H) 4.48 (m, 2 H) 7.03 (m, 1 H) 7.13 (m, 1 H) 7.27 (m, 6 H) 7.40 (m, 4 H) 7.47 (d,

J=16.53 Hz, 1 H) 7.52 (m, 1 H) 7.59 (d, J=7.80 Hz, 1 H) 7.78 (s, 1 H) 8.43 (d, J=5.30 Hz, 1 H) 8.56 (s, 1 H).

5

Example 220[4-(2-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-vinyl)-pyridin-2-yl]-cyclopropyl-amine

A mixture of Example 216 (100 mg, 0.2 mmol) and cyclopropyl amine (1.5mL) was heated at 125 °C for 36 hrs. The mixture was concentrated to dryness. The residue was then treated 10 with TFA (1mL) at rt for 10 min. Upon removal of TFA, the crude product was purified on C18 HPLC to give the title compound (4.1mg, 3%). MS (DCI/NH₃) m/z 426(M+1)⁺; ¹HNMR (500 MHz, MeOD) δ ppm 0.74 (m, 2 H) 1.03 (m, 2 H) 2.71 (m, 1 H) 3.29 (m, 1 H) 3.34 (m, 1 H) 4.00 (m, 1 H) 4.27 (dd, J=10.61, 5.62 Hz, 1 H) 4.39 (dd, J=10.61, 3.43 Hz, 1 H) 7.03 (m, J=15.91 Hz, 1 H) 7.10 (s, 1 H) 7.13 (m, 1 H) 7.23 (s, 1 H) 7.26 (dd, J=6.86, 1.56 Hz, 1 H) 15 7.39-7.34 (m, 2H) 7.58 (d, J=5.30 Hz, 1 H) 7.60 (d, J=3.12 Hz, 1 H) 7.83 (m, 1 H) 7.87 (d, J=6.86 Hz, 1 H) 8.37 (s, 1 H) 8.52 (s, 1 H).

20

Example 221[4-(2-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-vinyl)-pyridin-2-yl]-benzyl-amine

The title compound was prepared as trifluoroacetic acid salt by substituting benzylamine for cyclopropylamine in Example 220 (38.2mg, 23%). MS (DCI/NH₃) m/z 476 (M+1)⁺; ¹HNMR 1H NMR (500 MHz, MeOD) δ ppm 3.30 (m, 1 H) 3.34 (m, 1 H) 3.99 (m, 1 H) 4.24 (dd, J=10.61, 5.62 Hz, 1 H) 4.37 (dd, J=10.61, 3.12 Hz, 1 H) 4.63 (s, 2 H) 7.02 (m, 1 H) 7.10 (m, 1 H) 7.12 (m, 1 H) 7.22 (m, 2 H) 7.41 (m, 3 H) 7.39-7.29 (m, 4H) 7.57 (d, J=9.05 Hz, 1 H) 7.59 (m, 1 H) 7.73 (s, 1 H) 7.82 (d, J=6.86 Hz, 1 H) 8.37 (s, 1 H) 8.52 (s, 1 H).

30

Example 222[4-(2-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-vinyl)-pyridin-2-yl]-ethyl-amine

The title compound was prepared as trifluoroacetic acid salt by substituting ethylamine for cyclopropylamine in Example 220 (16mg, 15%). MS (DCI/NH₃) m/z 414(M+1)⁺; ¹HNMR (400 MHz, MeOD) δ ppm 1.36 (t, J=7.06 Hz, 3 H) 3.98 (m, 4 H) 4.24 (dd, J=10.43, 5.52 Hz, 1 H) 4.37 (dd, J=10.74, 3.38 Hz, 1 H) 7.02 (m, 2 H) 7.12 (d, J=8.29 Hz, 1 H) 7.18 (d, J=8.29 Hz, 1 H) 7.23 (s, 1 H) 7.30 (d, J=16.26 Hz, 1 H) 7.38 (d, J=8.90 Hz, 1 H) 7.56 (d, J=11.97 Hz,

1 H) 7.59 (d, $J=3.68$ Hz, 1 H) 7.72 (s, 1 H) 7.77 (d, $J=7.06$ Hz, 1 H) 7.87 (m, 2 H) 8.33 (s, 1 H) 8.48 (s, 1 H).

5

Example 223[4-(2-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-vinyl)-pyridin-2-yl]-methyl-amine

The title compound was prepared as trifluoroacetic acid salt by substituting methylamine for cyclopropylamine in Example 220 (11.9mg, 8%). MS (DCI/NH₃): m/z 400 (M+1)⁺; ¹HNMR (400 MHz, MeOD) δ ppm 3.05 (s, 3 H) 3.32 (m, 2 H) 3.99 (m, 1 H) 4.24 (dd, $J=10.43$, 5.52 Hz, 1 H) 4.37 (dd, $J=10.74$, 3.38 Hz, 1 H) 7.03 (m, 1 H) 7.05 (m, 1 H) 7.13 (m, 1 H) 7.19 (d, $J=7.06$ Hz, 1 H) 7.23 (m, 1 H) 7.31 (d, $J=16.57$ Hz, 1 H) 7.39 (d, $J=7.36$ Hz, 1 H) 7.57 (d, $J=7.06$ Hz, 1 H) 7.60 (m, 1 H) 7.74 (s, 1 H) 7.80 (d, $J=7.06$ Hz, 1 H) 8.41 (brs, 1 H) 8.57 (brs, 1 H).

15

Example 224(1S)-1-(1H-Indol-3-ylmethyl)-2-{5-[2-(2-indol-1-yl-pyridin-4-yl)-vinyl]-pyridin-3-yloxy}-ethylamine

20 A mixture of Example 216 (100 mg, 0.2 mmol), indole (48mg, 0.4mmol), and NaH (60%) (29mg, 0.72mmol) in DMF (5mL) was heated at 125 °C for 1.5 hrs. The mixture was concentrated to dryness. The residue was then treated with TFA (1mL) at rt for 10 min. Upon removal of TFA, the crude product was purified on C18 HPLC to give the title compound (8.1mg, 5%). MS (DCI/NH₃) m/z 486(M+1)⁺; ¹HNMR (500 MHz, MeOD) δ ppm 3.29 (m, 1 H) 3.35 (m, 1 H) 4.00 (m, 1 H) 4.26 (dd, $J=10.61$, 5.93 Hz, 1 H) 4.39 (dd, $J=10.29$, 3.12 Hz, 1 H) 6.73 (d, $J=3.43$ Hz, 1 H) 7.05 (m, 1 H) 7.11-7.18 (m, 2H) 7.24 (s, 1H) 7.26 (m, 1H) 7.63-7.38 (m, 6H) 7.75 (m, 1.H) 7.80 (m, 1 H) 7.84 (d, $J=3.43$ Hz, 1 H) 8.22 (dd, $J=8.42$, 0.62 Hz, 1 H) 8.32 (s, 1 H) 8.52 (s, 1 H) 8.53 (s, 1 H).

30

Example 225(±)-2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(2-methyl-1H-indol-3-ylmethyl)-ethylamine

35

Example 225A3-Bromo-2-hydroxyimino-propionic acid ethyl ester

Ethyl bromopyruvate (5.0 mL, 39.8 mmol) was added to hydroxylamine hydrochloride (2.52 g, 36.2 mmol) in H₂O (10 mL) and CHCl₃ (10 mL). The reaction mixture was capped and stirred overnight at 23 °C at which time CH₂Cl₂ and H₂O were added, the layers separated, the organics dried over Na₂SO₄, and the volatiles removed on a rotary evaporator to yield 7.58 g (100%) of as a white solid. ¹H NMR (300 MHz, DMSO-D6) δ ppm 1.26 (t, *J*=7.12 Hz, 3 H) 4.20 (s, 2 H) 4.24 (m, 2 H) 13.19 (s, 1 H).

5
10
15
20
25
30
35
Example 225B

2-Hydroxyimino-3-(2-methyl-1*H*-indol-3-yl)-propionic acid ethyl ester

The desired compound was prepared by a reference method (*J. Chem. Soc. Chem. Comm* 1979, 1089). To 2-methylindole (1.28 g, 9.76 mmol) and Na₂CO₃ (1.24 g, 11.7 mmol) in CH₂Cl₂ was added Example 225A (2.05 g, 9.76 mmol). The resulting reaction mixture was stirred overnight at 23 °C at which time H₂O was added, the layers separated, and the organics dried over Na₂SO₄. Flash chromatography (20-30-50-70% EtOAc/hexanes) gave 1.41 g (56%) of as a green solid. *R_f* = 0.30 (50% EtOAc/hexanes); MS *m/z* 261 (M + H)⁺; ¹H NMR (300 MHz, DMSO-D6) δ ppm 1.13 (t, *J*=7.12 Hz, 3 H) 2.35 (s, 3 H) 3.84 (s, 2 H) 4.08 (q, *J*=7.12 Hz, 2 H) 6.92 (m, 2 H) 7.19 (d, *J*=7.80 Hz, 1 H) 7.44 (d, *J*=7.46 Hz, 1 H) 10.74 (s, 1 H) 12.34 (s, 1 H).

Example 225C

(±)-2-*tert*-Butoxycarbonylamino-3-(2-methyl-1*H*-indol-3-yl)-propionic acid ethyl ester

The desired compound was prepared by a reference method (*Angew. Chem. Int. Ed. Engl* 1979, 78, and *Tet. Lett.* 1988, p447). Aluminum foil (1.18 g, 43.8 mmol) was cut into long, thin (1 cm) strips then dipped into a 2% aqueous HgCl₂ solution (30 sec each strip). Each strip was immediately washed successively with H₂O, MeOH, then Et₂O. Each strip was then immediately cut into small pieces (~1 X 0.5 cm) into a solution of Example 225B (1.14 g, 4.38 mmol) in THF (60 mL) and H₂O (6 mL) which was kept at room temperature with a water bath. The mixture was stirred vigorously at 23 °C. After a short time fine black solids began to form and much bubbling was observed. The reaction mixture was stirred 3 h then filtered through Celite, and the filter cake washed with Et₂O. All volatiles were removed on a rotary evaporator. MeOH (50 mL) was added followed by Na₂CO₃ (0.51 g, 4.82 mmol) and Boc₂O (1.00 g, 4.60 mmol). The resulting reaction mixture was stirred 30 min at 23 °C and then silica gel was added and the volatiles removed on a rotary evaporator. Flash chromatography (10-30-40-50% EtOAc/hexanes) gave 1.33 g (88%) of as an off-white solid. *R_f* = 0.68 (70% EtOAc/hexanes); MS *m/z* 345 (M - H)⁺; ¹H NMR (300 MHz, DMSO-D6) δ ppm 1.02 (t, *J*=7.12 Hz, 3 H) 1.33 (s, 9 H) 2.28 (s, 3 H) 3.00 (m, 2 H) 3.97 (q, *J*=7.12 Hz, 2 H)

4.10 (m, 1 H) 6.94 (m, 2 H) 7.14 (d, $J=8.14$ Hz, 1 H) 7.21 (d, $J=7.12$ Hz, 1 H) 7.38 (d, $J=7.12$ Hz, 1 H) 10.73 (s, 1 H).

Example 225D

(\pm)-[2-Hydroxy-1-(2-methyl-1*H*-indol-3-ylmethyl)-ethyl]-carbamic acid *tert*-butyl ester

To Example 225C (1.30 g, 3.75 mmol) and CaCl_2 (anhydrous) (0.83 g, 7.51 mmol) in a 500 mL round bottom flask equipped with a stirbar was added sequentially: EtOH (wet) (30 mL), THF (20 mL) and NaBH_4 (0.57 g, 15.0 mmol). The resulting cloudy reaction mixture was stirred 1 h at 23 °C and then poured onto 1 M citric acid and extracted with EtOAc. The 10 organic extracts were washed with brine and dried over MgSO_4 . Silica gel and NaHCO_3 (100 mg) were added and the volatiles removed on a rotary evaporator. Flash chromatography (35-50-60% EtOAc/hexanes) gave 1.08 g (95%) of as a white solid. $R_f = 0.51$ (70% EtOAc/hexanes); MS m/z 303 ($M - H$) $^+$; ^1H NMR (300 MHz, DMSO-D6) δ ppm 1.35 (s, 9 H) 2.31 (s, 3 H) 2.71 (m, 2 H) 3.29 (t, $J=5.42$ Hz, 2 H) 3.57 (m, 1 H) 4.54 (t, $J=5.42$ Hz, 1 H) 6.45 (d, $J=8.48$ Hz, 1 H) 6.92 (m, 2 H) 7.19 (dd, $J=6.78, 1.02$ Hz, 1 H) 7.48 (d, $J=7.12$ Hz, 1 H) 10.64 (s, 1 H).

Example 225E

(\pm)-[2-(5-Bromo-pyridin-3-yloxy)-1-(2-methyl-1*H*-indol-3-ylmethyl)-ethyl]-carbamic acid *tert*-butyl ester

The desired product was prepared by substituting Example 225D for Boc-tryptophanol in Example 2A. $R_f = 0.41$ (50% EtOAc/hexanes); MS m/z 460, 462 ($M + H$) $^+$; ^1H NMR (300 MHz, DMSO-D6) δ ppm 1.35 (s, 9 H) 2.30 (s, 3 H) 2.86 (m, 2 H) 3.97 (s, 2 H) 6.93 (m, 3 H) 7.21 (d, $J=7.80$ Hz, 1 H) 7.46 (d, $J=7.46$ Hz, 1 H) 7.59 (s, 1 H) 8.13 (dd, $J=3.56, 2.20$ Hz, 1 H) 8.25 (dd, $J=5.09, 2.03$ Hz, 2 H) 10.72 (s, 1 H).

Example 225F

(\pm)-[1-(2-Methyl-1*H*-indol-3-ylmethyl)-2-(5-trimethylstannanyl-pyridin-3-yloxy)-ethyl]-carbamic acid *tert*-butyl ester

Example 225D (350 mg, 0.76 mmol), $\text{Pd}(\text{PPh}_3)_4$ (88 mg, 0.08 mmol) and hexamethylditin (300 mg, 0.92 mmol) were combined in a 25 mL round bottom flask with a stirbar. The atmosphere of the flask was evacuated and replaced with argon. Toluene (4 mL) was added and the resulting reaction mixture warmed to 100 °C for 2 h and then cooled to room temperature. EtOAc and silica gel were added and the volatiles removed on a rotary evaporator. Flash chromatography (30-40-50-60% EtOAc/hexanes) gave 294 mg (71%) of as a yellow solid. $R_f = 0.43$ (70% EtOAc/hexanes); MS m/z 546 ($M + H$) $^+$; ^1H NMR (300 MHz, DMSO-D6) δ ppm 0.28 (s, 9 H) 1.36 (s, 9 H) 2.30 (s, 3 H) 2.86 (m, 2 H) 3.95 (s, 3 H) 6.93 (m,

3 H) 7.21 (d, $J=7.80$ Hz, 1 H) 7.33 (d, $J=2.03$ Hz, 1 H) 7.44 (d, $J=7.46$ Hz, 1 H) 8.14 (s, 2 H) 10.72 (s, 1 H).

Example 225G

(\pm)-[2-[5-(3-Methyl-1*H*-indazol-5-yl)-pyridin-3-yl]oxy]-1-(2-methyl-1*H*-indol-3-ylmethyl)-5-ethyl]-carbamic acid *tert*-butyl ester

Bromo-methylindazole (71 mg, 0.33 mmol), Example 225F (200 mg, 367 mmol), Pd_2dba_3 (61 mg, 0.7 mmol), and $P(o-tol)_3$ (41 mg, 0.14 mmol) were combined in a 10 mL round bottom flask with a stirbar. DMF (2 mL) was added and the atmosphere of the flask evacuated and replaced with argon twice. Et_3N (0.09 mL, 0.67 mmol) was added and the reaction mixture warmed to 80 °C for 5 h and then cooled to room temperature. $EtOAc$ was added and the resulting mixture filtered through Celite. The filtrate was washed twice with H_2O and once with brine. Silica gel was added and the volatiles removed on a rotary evaporator. Flash chromatography (70-85-100% $EtOAc$ /hexanes) gave 48 mg (28%) of as a yellow solid. $R_f=0.30$ ($EtOAc$); MS m/z 512 ($M + H$)⁺; ¹H NMR (300 MHz, DMSO-D6) δ ppm 1.36 (s, 9 H) 2.31 (s, 3 H) 2.54 (s, 3 H) 2.90 (m, 2 H) 4.05 (m, 3 H) 6.93 (m, 3 H) 7.20 (m, 2 H) 7.58 (m, 3 H) 8.06 (s, 1 H) 8.20 (d, $J=2.71$ Hz, 1 H) 8.53 (d, $J=1.70$ Hz, 1 H) 10.72 (s, 1 H) 12.72 (s, 1 H).

Example 225H

(\pm)-2-[5-(3-Methyl-1*H*-indazol-5-yl)-pyridin-3-yl]oxy]-1-(2-methyl-1*H*-indol-3-ylmethyl)-ethylamine

The title compound was prepared as trifluoroacetic acid salt by substituting Example 225G for Example 27B in Example 27C (31.9 mg, 84%). MS m/z 412 ($M + H$)⁺; ¹H NMR (300 MHz, DMSO-D6) δ ppm 2.33 (s, 3 H) 2.55 (s, 3 H) 2.75 (dd, $J=14.41, 6.61$ Hz, 1 H) 2.92 (m, 1 H) 3.18 (s, 2 H) 3.99 (m, 2 H) 4.09 (q, $J=5.43$ Hz, 1 H) 6.89 (m, 1 H) 6.96 (td, $J=7.46, 1.02$ Hz, 1 H) 7.22 (d, $J=7.80$ Hz, 1 H) 7.46 (d, $J=7.46$ Hz, 1 H) 7.54 (d, $J=8.82$ Hz, 1 H) 7.63 (m, 1 H) 7.67 (m, 1 H) 8.08 (s, 1 H) 8.25 (d, $J=2.37$ Hz, 1 H) 8.54 (d, $J=1.70$ Hz, 1 H) 10.75 (s, 1 H) 12.73 (s, 1 H).

30

Example 226

7-[5-[(2*S*)-2-Amino-3-(1*H*-indol-3-yl)-propoxy]pyridin-3-yl]-quinazolin-2-ylamine

35

Example 226A

7-Bromo-quinazolin-2-ylamine

The 4-Bromo-2-fluoro-benzaldehyde (0.61g, 3 mmol), guanidine (1.05g, 5.83 mmol) and DMF were heated at 140°C for 2.5 hours. 50 ml water was added to the mixture. The orange precipitate was filtered and washed with water. The solid was dissolved in 2N HCl and filtered. The HCl solution was neutralized by ammonia hydroxyl. The off white solid was filtered and dried under vacuum to afforded the desired product (91 mg, 14%). MS (ESI) m/e 224 (M+1)⁺; ¹H NMR (300 MHz, DMSO-D6) δ ppm 7.00 (br. s., 2 H) 7.36 (d, *J*=8.82 Hz, 1 H) 7.77 (dd, *J*=9.16, 2.37 Hz, 1 H) 8.05 (d, *J*=2.37 Hz, 1 H) 9.09 (br. s., 1 H).

Example 226B

10 7-{5-[(2*S*)-2-Amino-3-(1*H*-indol-3-yl)-propoxy]-pyridin-3-yl}-quinazolin-2-ylamine

The desired product was prepared by substituting Example 226A for 6-bromophthalimide in Example 32 as the tri-TFA salt. MS *m/z* 11 (M + H)⁺, (M - H)⁺; ¹H NMR (300 MHz, DMSO-D6) δ ppm 2.85 (m, 1 H) 3.01 (m, 1 H) 3.32 (m, 1 H) 4.06 (m, 2 H) 6.96 (m, 3 H) 7.05 (m, 1 H) 7.22 (d, *J*=2.03 Hz, 1 H) 7.34 (d, *J*=8.14 Hz, 1 H) 7.54 (m, 1 H) 7.68 (m, 1 H) 8.05 (dd, *J*=8.99, 2.20 Hz, 1 H) 8.19 (d, *J*=2.03 Hz, 1 H) 8.30 (d, *J*=2.71 Hz, 1 H) 8.57 (d, *J*=2.03 Hz, 1 H) 9.16 (s, 1 H) 10.88 (s, 1 H).

Example 227

20 2-Phenyl-2-(3-pyridin-4-yl-1*H*-pyrazolo[3,4-b]pyridin-6-yl)-ethylamine

Example 227A

(2,6-Difluoro-pyridin-3-yl)-pyridin-4-yl-methanol

To diisopropylamine (9.3 mL, 66.1 mmol) in THF (100 mL) at -78 °C was added *n*-BuLi (23.1 mL of a 2.5 M solution in hexanes, 57.8 mmol) dropwise via syringe. 2,6-difluoropyridine (5.0 mL, 55.1 mmol) in THF (100 mL) at -78°C was added to the above prepared LDA solution dropwise via canula to give a clear yellow-green solution. isonicotinaldehyde (6.3 mL, 66.1 mmol) was added causing a white precipitate to form. The reaction mixture was warmed to room temperature and then glacial acetic acid (3.3 mL, 57.8 mmol) was added. Silica gel was added and the volatiles removed on a rotary evaporator. Flash chromatography (80-100% EtOAc/hexanes-3-5-7% MeOH/EtOAc) gave 8.48 g (69%) of as an off white solid. *R*_f = 0.38 (5% MeOH/EtOAc); MS *m/z* 223 (M + H)⁺; ¹H NMR (300 MHz, DMSO-D6) δ ppm 5.91 (d, *J*=4.41 Hz, 1 H) 6.49 (d, *J*=4.41 Hz, 1 H) 7.20 (dd, *J*=8.31, 2.54 Hz, 1 H) 7.36 (m, 2 H) 8.19 (m, 1 H) 8.53 (m, 2 H); Found: 223, 221; Anal calcd for C₁₁H₈F₂N₂O: C, 59.46; H, 3.63; N, 12.61. Found: C: 59.45, H: 3.66, N: 12.62.

Example 227B

(2,6-Difluoro-pyridin-3-yl)-pyridin-4-yl-methanone

Example 227A (7.36 g, 33.1 mmol) and MnO₂ (8.64 g, 99.4 mmol) were combined in a 500 mL round bottom flask with a stirbar. 1,4-dioxane (120 mL) was added and the resulting black mixture warmed to 110 °C. MnO₂ (~22 g) was added in 2 g amounts every couple of hours over the next 2 days. The reaction mixture was cooled to room temperature and filtered through Celite. The filter cake was washed with EtOAc and then all volatiles were removed on a rotary evaporator. Flash chromatography (50-70-80% EtOAc/hexanes) gave 4.61 g (63%) of as a green solid. R_f = 0.58 (5% MeOH/EtOAc); MS *m/z* 221. (M + H)⁺; ¹H NMR (300 MHz, DMSO-D6) δ ppm 7.41 (ddd, *J*=8.14, 2.37, 0.68 Hz, 1 H) 7.72 (m, 2 H) 8.47 (dt, *J*=9.41, 8.01 Hz, 1 H) 8.85 (m, 2 H); Anal calcd for C₁₁H₆F₂N₂O: C, 60.01; H, 2.75; N, 12.72. Found: C: 60.05, H: 2.87, N: 12.97.

Example 227C6-Fluoro-3-pyridin-4-yl-1*H*-pyrazolo[3,4-*b*]pyridine

To Example 227B (4.20 g, 19.1 mmol) in 1,4-dioxane (100 mL) was added hydrazine hydrate (0.93 mL, 19.1 mmol). The resulting yellow reaction mixture was stirred 20 min at 23 °C and then silica gel was added and the volatiles removed on a rotary evaporator. Flash chromatography (60-80-100% EtOAc/hexanes-1-5% MeOH/EtOAc) gave 2.49 g (61%) of as a white solid. R_f = 0.40 (5% MeOH/EtOAc); MS *m/z* 215 (M + H)⁺; ¹H NMR (300 MHz, DMSO-D6) δ ppm 7.14 (dd, *J*=8.65, 0.85 Hz, 1 H) 8.02 (m, 2 H) 8.71 (m, 2 H) 8.87 (dd, *J*=8.48, 7.80 Hz, 1 H) 14.25 (s, 1 H); Anal calcd for C₁₁H₇FN₄: C, 61.68; H, 3.29; N, 26.16. Found: C: 61.35, H: 3.35, N: 25.81.

Example 227DPhenyl-(3-pyridin-4-yl-1*H*-pyrazolo[3,4-*b*]pyridin-6-yl)-acetonitrile

To a stirred mixture of Example 227C (0.96 g, 4.48 mmol) in DMF (20 mL) at -35°C was added benzyl cyanide (1.55 mL, 13.4 mmol) and then NaH (0.57 g of 95% NaH, 22.4 mmol). The resulting dark red mixture was stirred 15 min while being slowly warmed to ~-20 °C. At this time most of the bubbling had stopped and the reaction mixture was then quickly warmed to room temperature and then to 100 °C overnight. The reaction mixture was cooled to room temperature and saturated aqueous NH₄Cl was added. The mixture was extracted with EtOAc and the organic extracts washed twice with H₂O and once with brine. Silica gel was added and the volatiles removed on a rotary evaporator. Flash chromatography (60-80-100% EtOAc-3% MeOH/EtOAc) gave 1.14 g (82%) of as an orange solid. R_f = 0.40 (5% MeOH/EtOAc); MS *m/z* 312 (M + H)⁺; ¹H NMR (300 MHz, DMSO-D6) δ ppm 6.17 (s, 1 H) 7.40 (m, 4 H) 7.52 (m, 2 H) 8.00 (m, 2 H) 8.70 (m, 2 H) 8.74 (d, *J*=8.48 Hz, 1 H) 14.36 (s, 1 H); Anal Calcd for C₁₉H₁₃N₅: C, 73.30; H, 4.21; N, 22.49. Found: C: 73.09, H: 4.10, N: 22.58.

Example 227E2-Phenyl-2-(3-pyridin-4-yl-1H-pyrazolo[3,4-b]pyridin-6-yl)-ethylamine

The desire product was prepared by substituting Example 227D for Example 41C in Example 41D (84 mg, 27%). $R_f = 0.33$ (20% MeOH/CH₂Cl₂); MS *m/z* 316 (M + H)⁺; ¹H NMR (300 MHz, DMSO-D6) δ ppm 3.23 (m, 1 H) 3.34 (br s, 3 H) 3.52 (m, 1 H) 4.34 (m, 1 H) 7.27 (m, 6 H) 7.99 (d, *J*=6.10 Hz, 2 H) 8.57 (d, *J*=8.48 Hz, 1 H) 8.68 (d, *J*=6.10 Hz, 2 H).

Example 228Naphthalen-2-yl-(3-pyridin-4-yl-1H-pyrazolo[3,4-b]pyridin-6-yl)-acetonitrile

The desired product was obtained by substituting 2-naphthyl acetonitrile for benzyl nitrile in Example 227D (244 mg, 42%). $R_f = 0.46$ (EtOAc); MS *m/z* 362 (M + H)⁺; ¹H NMR (300 MHz, DMSO-D6) δ ppm 6.36 (s, 1 H) 7.44 (d, *J*=8.48 Hz, 1 H) 7.57 (m, 3 H) 7.98 (m, 6 H) 8.09 (d, *J*=1.36 Hz, 1 H) 8.69 (m, 2 H) 8.75 (d, *J*=8.48 Hz, 1 H).

Example 2292-Naphthalen-2-yl-2-(3-pyridin-4-yl-1H-pyrazolo[3,4-b]pyridin-6-yl)-ethylamine

The desire product was prepared by substituting Example 228 for Example 41C in Example 41D. MS *m/z* 366 (M + H)⁺; ¹H NMR (300 MHz, DMSO-D6) δ ppm 3.96 (m, 2 H) 4.82 (t, *J*=7.46 Hz, 1 H) 7.39 (d, *J*=8.48 Hz, 1 H) 7.52 (m, 3 H) 7.89 (m, 4 H) 8.20 (d, *J*=6.10 Hz, 2 H) 8.68 (d, *J*=8.48 Hz, 1 H) 8.80 (m, 3 H).

25

Example 230(3-Isoquinolin-6-yl-1H-pyrazolo[3,4-b]pyridin-6-yl)-phenyl-acetonitrileExample 230AIsoquinoline-6-carbaldehyde

A solution of 6-bromoisoquinoline (19.9 g, 95.6 mmol), PdCl₂(dpff).CH₂Cl₂ (1.8 g), and triethylamine (30 mL) in toluene (50 mL) was heated to 130 °C under 850 psi of H₂/CO (1:1) for 4 h. After cooling to rt, the reaction mixture was filtered. The filtrate was concentrated and the residue was purified by flash chromatography eluting with 70-80-90-100% EtOAc/hexanes to give 6.11 g (41%) of the aldehyde as a yellow solid. $R_f = 0.55$ (EtOAc); ¹H NMR (300 MHz, DMSO-D6) δ ppm 8.07 (m, 2 H) 8.30 (dd, *J*=8.48, 0.68 Hz, 1 H) 8.64 (s, 1 H) 8.67 (d, *J*=5.76 Hz, 1 H) 9.47 (s, 1 H) 10.23 (s, 1 H).

Example 230B(3-Isoquinolin-6-yl-1*H*-pyrazolo[3,4-*b*]pyridin-6-yl)-phenyl-acetonitrile

The desired product (244 mg, 42%) was obtained by substituting Example 230A for 5 isonicotinaldehyde in Example 227. $R_f = 0.46$ (EtOAc); MS m/z 362 ($M + H$) $^+$; 1H NMR (300 MHz, DMSO-D6) δ ppm 6.18 (s, 1 H) 7.40 (m, 4 H) 7.54 (m, 2 H) 7.99 (d, $J = 5.76$ Hz, 1 H) 8.25 (d, $J = 8.48$ Hz, 1 H) 8.36 (m, 1 H) 8.56 (d, $J = 5.42$ Hz, 1 H) 8.63 (s, 1 H) 8.87 (d, $J = 8.48$ Hz, 1 H) 9.35 (s, 1 H) 14.27 (s, 1 H).

10

Example 2312-(3-Isoquinolin-6-yl-1*H*-pyrazolo[3,4-*b*]pyridin-6-yl)-2-phenyl-ethylamine

The desire product was prepared by substituting Example 230 for Example 41C in Example 15 41D. MS m/z 366 ($M + H$) $^+$; 1H NMR (300 MHz, DMSO-D6) δ ppm 3.11 (m, 1 H) 3.90 (m, 1 H) 4.66 (dd, $J = 9.16, 6.10$ Hz, 1 H) 7.31 (m, 8 H) 8.28 (d, $J = 6.10$ Hz, 1 H) 8.42 (d, $J = 8.82$ Hz, 1 H) 8.54 (d, $J = 8.48$ Hz, 1 H) 8.63 (d, $J = 6.44$ Hz, 1 H) 8.78 (s, 1 H) 8.82 (d, $J = 8.48$ Hz, 1 H) 9.59 (s, 1 H) 14.26 (s, 1 H).

20

Example 232(1*S*)-1-Benzyl-2-(3-pyridin-4-yl-1*H*-pyrazolo[3,4-*b*]pyridin-5-yloxy)-ethylamineExample 232B5-(*tert*-Butyl-dimethyl-silanyloxy)-2-fluoro-pyridine

25 A mixture of 2-fluoro-5-hydroxypyridine (1.00 g, 8.84 mmol) and BDCS reagent (0.5M TBSCl, 1.0M imidazole in DMF) (35.4 mL, 17.7 mmol) was stirred at rt for 1h. The reaction was poured into satd. aqueous $NaHCO_3$ solution. The aqueous layer was extracted with ether. The combined extracts were washed with water, brine, dried over $MgSO_4$, and concentrated. The residue was purified by flash column chromatography on silica gel eluting 30 with 10% ethyl acetate /hexanes to give the title compound (1.96 g, 98%).

Example 232B5-(*tert*-Butyl-dimethyl-silanyloxy)-3-pyridin-4-yl-1*H*-pyrazolo[3,4-*b*]pyridine

35 The desired product was prepared according to the procedures used for Example 227C by substituting Example 232A for 2,6-difluoropyridine in Example 227A.

Example 232C

5-(*tert*-Butyl-dimethyl-silanyloxy)-3-pyridin-4-yl-pyrazolo[3,4-*b*]pyridine-1-carboxylic acid
tert-butyl ester

The desired product was prepared by substituting Example 232B for Example 102C in Example 203A (75%).

Example 232D

5-Hydroxy-3-pyridin-4-yl-pyrazolo[3,4-*b*]pyridine-1-carboxylic acid *tert*-butyl ester

A mixture of Example 232C (91 mg, 0.213 mmol) and TBAF (1M in THF, 213 μ L, 0.213 mmol) in THF (10 mL) was stirred at rt for 5 min. Reaction was concentrated. Flash column chromatography eluting with 5% methanol/CH₂Cl₂ to give the dedired product purified the residue (75%).

Example 232E

5-((2*S*)-2-*tert*-Butoxycarbonylamino-3-phenyl-propoxy)-3-pyridin-4-yl-pyrazolo[3,4-*b*]pyridine-1-carboxylic acid *tert*-butyl ester

15 The title compound was prepared by substituting Example 232D for Example 238A and Boc-phenylalaninol for Boc-4'-bromophenylalaninol in Example 238B.

Example 232F

(1*S*)-1-Benzyl-2-(3-pyridin-4-yl-1*H*-pyrazolo[3,4-*b*]pyridin-5-yloxy)-ethylamine

To Example 232E (39 mg, 71 μ mol) in CH_2Cl_2 (4 mL) was added 4-methoxybenzyl mercaptan (30 μ L, 214 μ mol) and then TFA (1 mL). The resulting yellow reaction mixture was stirred 50 min at 23 °C at which time all volatiles were removed on a rotary evaporator. K_2CO_3 (excess) and MeOH (5 mL) were added and the resulting mixture stirred 1 h at 23 °C at which time silica gel was added and the volatiles removed on a rotary evaporator. Flash chromatography (EtOAc-5-10-12% MeOH/ CH_2Cl_2) gave a light yellow waxy product which was dissolved in 20% MeOH/ CH_2Cl_2 and stirred for 1 h with 1 N HCl (1 mL of a 1 N solution in Et_2O , 1 mmol). The volatiles were removed to give 11 mg (17%, two steps) of a yellow solid which was the bis-HCl salt. MS m/z 346 ($\text{M} + \text{H}$)⁺; ¹H NMR (300 MHz, DMSO-D6) δ ppm 2.92 (dd, J =13.73, 8.98 Hz, 1 H) 3.12 (dd, J =14.24, 5.09 Hz, 1 H) 4.14 (dd, J =5.59, 1.86 Hz, 1 H) 4.74 (t, J =5.93 Hz, 2 H) 7.20 (m, 5 H) 7.97 (d, J =2.37 Hz, 1 H) 8.38 (m, 5 H) 8.90 (d, J =6.78 Hz, 2 H) 10.31 (s, 1 H).

Example 233

2-Benzyl-3-[5-(3-methyl-1*H*-indazol-5-yl)-pyridin-3-yloxy]-propylamine

The desired product was prepared as trifluoroacetic acid by substituting (2-Benzyl-3-hydroxy-propyl)-carbamic acid *tert*-butyl ester (Khumtaveeporn, K.; Ullmann, A.; Matsumoto, K.; Davis, B. G.; Jones, J. B. *Tetrahedron: Asymmetry* **2001**, *12*, 249) for Example Boc-tryptophanol in Example 102. MS *m/z* 373 (M + H)⁺, (M - H)⁺; ¹H NMR (300

MHz, DMSO-D₆) δ ppm 2.55 (s, 3 H) 2.81 (dd, *J*=7.29, 3.56 Hz, 2 H) 2.92 (m, 1 H) 3.05 (m, 1 H) 4.09 (dd, *J*=10.17, 5.76 Hz, 2 H) 4.16 (m, 2 H) 7.28 (m, 5 H) 7.57 (dd, *J*=8.48, 0.68 Hz, 1 H) 7.69 (m, 1 H) 7.74 (m, 1 H) 7.82 (s, 2 H) 8.09 (m, 1 H) 8.30 (d, *J*=2.71 Hz, 1 H) 8.62 (d, *J*=1.70 Hz, 1 H).

5

Example 234(1*S*)-1-(1*H*-Indol-3-ylmethyl)-2-(2-pyridin-4-yl-[1,7]naphthyridin-5-yloxy)-ethylamine

10

Example 234A3-Bromo-5-(4-methoxy-benzyloxy)-pyridine

3-Bromo-5-hydroxypyridine (14.7 g, 84.3 mmol), tetrabutylammonium iodide (0.3 g, 0.8 mmol), and K₂CO₃ (14.0 g, 101 mmol) were combined in a dry 500 mL round bottom flask with a stirbar. DMF (170 mL) was added followed by PMBCl (12.0 mL, 88.5 mmol). The resulting brown colored mixture was stirred 3.5 days at 23 °C and then silica gel was added and the volatiles removed on a rotary evaporator. Flash chromatography (10-20-40% EtOAc/hexanes) gave 14.1 g (57%) of as an orange solid. R_f = 0.52 (50% EtOAc/hexanes)¹H NMR (300 MHz, DMSO-D₆) δ ppm 3.32 (s, 3 H) 5.12 (s, 2 H) 6.96 (m, 2 H) 7.39 (m, 2 H) 7.79 (m, 1 H) 8.28 (d, *J*=2.03 Hz, 1 H) 8.34 (d, *J*=2.71 Hz, 1 H). ¹³C NMR (100 MHz, DMSO-D₆) δ ppm 55.0, 69.8, 113.8, 119.9, 124.0, 127.8, 129.8, 137.1, 142.1, 155.1, 159.2; Anal Calcd for C₁₂H₁₀BrNO: C, 53.08; H, 4.11; N, 4.76. Found: C: 53.00, H: 3.98, N: 4.66.

Example 234B3-Amino-5-(4-methoxy-benzyloxy)-pyridine

25 Example 234A (16.15 g, 54.9 mmol), Pd₂dba₃ (0.50 g, 0.55 mmol), *rac*-BINAP (1.03 g, 1.65 mmol), and sodium *tert*-butoxide (7.39 g, 76.9 mmol) were combined in a 500 mL round bottom flask with a stirbar. Benzophenone imine (11.1 mL, 65.9 mmol) was added followed by toluene (180 mL). The resulting reaction mixture was warmed to 80 °C for 3 h and then allowed to cool to room temperature, diluted with Et₂O, and filtered through Celite. The volatiles were removed on a rotary evaporator. Flash chromatography (30-40-50% EtOAc/hexanes) yielded an impure orange oil which was dissolved in THF (180 mL) and 1 N HCl (60 mL). The resulting orange mixture was stirred 15 min and then partitioned between 30% EtOAc/hexanes and 0.5 M HCl. The layers were separated and the organic layer washed once with 0.5 M HCl. The combined HCl layers were washed once with 30% EtOAc/hexanes and then cooled to 0 °C. 50% aqueous NaOH was added until the mixture was basic on litmus paper and then the mixture was extracted twice with CH₂Cl₂. The combined organic extracts were dried over Na₂SO₄ and the volatiles removed on a rotary

evaporator to yield 8.92 g (71%, two steps) of as a yellow solid. ^1H NMR (300 MHz, DMSO-D6) δ ppm 3.75 (s, 3 H) 4.97 (s, 2 H) 4.97 (s, 2 H) 5.29 (s, 2 H) 6.54 (t, J =2.37 Hz, 1 H) 7.35 (m, 2 H) 7.50 (d, J =2.37 Hz, 1 H) 7.54 (d, J =2.37 Hz, 1 H), ^{13}C NMR (100 MHz, DMSO-D6) δ ppm 55.0, 68.9, 105.6, 113.8, 125.3, 128.7, 129.3, 129.4, 145.7, 155.1, 159.0.

5

Example 234C

[5-(4-Methoxy-benzyloxy)-pyridin-3-yl]-carbamic acid *tert*-butyl ester

To a stirred solution of Example 234B (8.92 g, 38.7 mmol) in THF (240 mL) at 23 °C was added NaHMDS (129 mL of a 0.6 M solution in toluene, 77.5 mmol) dropwise via syringe.

10 The resulting cloudy yellow-brown mixture was stirred 5 min and then Boc_2O (8.45 g, 38.7 mmol) was added all at once. The cloudiness of the mixture disappeared leaving a clear yellow-brown solution. 0.1 M HCl was added and the resulting aqueous and organic layers separated. The pH of the aqueous layer was ~8. The organic layer was washed with brine and then combined with silica gel before the volatiles were removed on a rotary evaporator.

15 Flash chromatography (30-40-50-70% EtOAc/hexanes-5-10% MeOH/CH₂Cl₂) gave 1.69 (10%) of bis-Boc protected as an orange solid, 7.04 g (55%) of the desired mono-Boc protected as a yellow solid, and 1.51 g (17%) of starting amine as an orange solid. Data for bis-Boc: R_f = 0.38 (50% EtOAc/hexanes) ^1H NMR (300 MHz, DMSO-D6) δ ppm 1.35 (s, 18 H) 3.75 (s, 3 H) 5.11 (s, 2 H) 6.94 (m, 2 H) 7.39 (m, 2 H) 7.43 (dd, J =2.71, 2.03 Hz, 1 H) 8.02 (d, J =2.03 Hz, 1 H) 8.28 (d, J =2.37 Hz, 1 H). Data for mono-Boc: R_f = 0.30 (50% EtOAc/hexanes) ^1H NMR (300 MHz, DMSO-D6) δ ppm 1.48 (s, 9 H) 3.76 (s, 3 H) 5.04 (s, 2 H) 6.95 (m, 2 H) 7.39 (m, 2 H) 7.60 (t, J =2.20 Hz, 1 H) 7.96 (d, J =2.71 Hz, 1 H) 8.22 (d, J =2.03 Hz, 1 H) 9.57 (s, 1 H). ^{13}C NMR (100 MHz, DMSO-D6) δ ppm 28.0, 55.0, 69.3, 79.6, 110.8, 113.8, 128.3, 129.6, 131.1, 132.3, 136.9, 152.7, 154.4, 159.1, Anal Calcd for

20 $\text{C}_{18}\text{H}_{22}\text{N}_2\text{O}_4$: C, 65.44; H, 6.71; N, 8.48. Found: C: 65.40, H: 6.66, N: 8.40.

25

Example 234D

[4-Formyl-5-(4-methoxy-benzyloxy)-pyridin-3-yl]-carbamic acid *tert*-butyl ester

To Example 234C (2.50 g, 7.54 mmol) in THF (125 mL) at -78 °C was added dropwise via syringe *n*-BuLi (6.64 mL of a 2.5 M solution in hexanes, 16.6 mmol). The resulting dark orange reaction mixture was slowly warmed to ~-10 °C over 45 min and then recooled to -78 °C. Methyl formate (1.40 mL, 22.6 mmol) was added dropwise via syringe and the reaction was stirred an additional 10 min at -78 °C. Saturated aqueous NH₄Cl was added and the quenched reaction mixture warmed to room temperature. H₂O and Et₂O were added and the layers separated. The organics were washed with brine and dried over MgSO₄. Flash chromatography (20-40-60-80% EtOAc/hexanes gave 0.3 g (12%) of recovered starting material, and 1.7 g (63%) of as a yellow solid. (^1H NMR (400 MHz, DMSO-D6) δ ppm 1.47

(s, 9 H) 3.75 (s, 3 H) 5.28 (s, 2 H) 6.95 (d, $J=8.59$ Hz, 2 H) 7.43 (d, $J=8.59$ Hz, 2 H) 8.38 (s, 1 H) 9.07 (s, 1 H) 10.17 (s, 1 H) 10.35 (s, 1 H), ^{13}C NMR (100 MHz, DMSO-D6) δ ppm 27.7, 55.0, 70.8, 81.1, 113.9, 114.6, 127.7, 129.6, 130.0, 133.3, 134.6, 151.7, 154.7, 159.2, 192.8, Anal Calcd for $\text{C}_{19}\text{H}_{22}\text{N}_2\text{O}_5$: C, 63.67; H, 6.19; N, 7.82. Found: C: 63.59, H: 6.21, N: 7.64.

5

Example 234E

5-(4-Methoxy-benzyl)-[1,7]naphthyridin-2-ol

To Bis(2,2,2-trifluoroethyl) (methoxycarbonylmethyl)phosphonate (1.27 mL, 5.99 mmol) in THF (45 mL) at -78 °C was added KHMDS (11.1 mL of a 0.5 M solution in toluene, 5.53 mmol) dropwise via syringe. The resulting clear, light yellow solution was added dropwise via canula to Example 234D (1.65 g, 4.60 mmol) in THF (60 mL) at -78 °C. The resulting cloudy yellow reaction mixture was stirred 20 min at -78 °C at which time saturated aqueous NH_4Cl was added and the quenched reaction mixture warmed to room temperature. H_2O and Et_2O were added and the layers separated. The organics were washed with brine and dried over MgSO_4 . Flash chromatography (40-50-60-70% EtOAc/hexanes) gave 1.98 g of impure product which was a 5 : 1 mixture of Z : E olefin isomers. To the crude product in THF (150 mL) was added NaHMDS (11.6 mL of a 0.6 M solution in toluene, 6.95 mmol). The resulting reaction mixture was stirred 30 min at 23 °C at which time silica gel was added and the volatiles removed on a rotary evaporator. Flash chromatography (60-100% EtOAc/hexanes-5-10% MeOH/CH₂Cl₂) gave 0.23 g (12%) of E-olefin as a yellow solid and the desired product 0.98 g (75%, two steps) of as a white solid. R_f = 0.32 (10% MeOH/CH₂Cl₂), ^1H NMR (400 MHz, DMSO-D6) δ ppm 3.77 (s, 3 H) 5.27 (s, 2 H) 6.68 (d, $J=9.51$ Hz, 1 H) 6.98 (m, 2 H) 7.46 (m, 2 H) 8.00 (d, $J=9.82$ Hz, 1 H) 8.18 (s, 1 H) 8.31 (s, 1 H) 11.98 (s, 1 H), ^{13}C NMR (100 MHz, DMSO-D6) δ ppm 55.0, 70.2, 113.7, 113.9, 125.7, 125.8, 128.1, 129.5, 131.0, 132.7, 134.9, 149.3, 159.2, 161.2, Anal Calcd for $\text{C}_{16}\text{H}_{14}\text{N}_2\text{O}_3$: C, 68.07; H, 5.00; N, 9.92. Found: C: 67.75, H: 4.89, N: 9.88.

Example 234F

2-Chloro-5-(4-methoxy-benzyl)-[1,7]naphthyridine

To a suspension of Example 234D (2.21 g, 7.83 mmol) in DMF (50 mL) at 23 °C was added POCl_3 (2.2 mL, 23.5 mmol). All the solid starting material dissolved and the resulting yellow reaction mixture was warmed to 45 °C for 6 h. The color of the reaction changed from yellow to dark red-brown. The reaction was poured onto NaHCO_3 (13.2 g 157 mmol) in ice water (250 mL) in a 1 L Ehrlemeyer flask with vigorous stirring. The product was extracted with EtOAc and Et_2O and the organic extracts washed twice with H_2O and once with brine. Silica gel was added and the volatiles removed on a rotary evaporator. Flash chromatography (20-30-45-50% EtOAc/hexanes) gave 1.86 g (79%) of as an off-white solid. R_f = 0.65 (10%

MeOH/CH₂Cl₂), ¹H NMR (400 MHz, DMSO-D6) δ ppm 3.79 (s, 3 H) 5.35 (s, 2 H) 6.99 (d, J=8.59 Hz, 2 H) 7.51 (d, J=8.90 Hz, 2 H) 7.77 (d, J=8.90 Hz, 1 H) 8.47 (s, 1 H) 8.52 (dd, J=8.90, 0.61 Hz, 1 H) 8.96 (s, 1 H), ¹³C NMR (100 MHz, DMSO-D6) δ ppm 55.0, 70.4, 113.9, 121.8, 125.9, 126.5, 127.9, 129.6, 133.7, 142.4, 144.0, 148.5, 151.7, 159.2; Anal Calcd for C₁₆H₁₃CIN₂O₂: C, 63.90; H, 4.36; N, 9.31. Found: C: 63.54, H: 4.17, N: 9.14.

Example 234G

5-(4-Methoxy-benzyloxy)-2-pyridin-4-yl-[1,7]naphthyridine

Example 234F (164 mg, 0.55 mmol), 4-tributylstannylpyridine (401 mg, 1.09 mmol), Pd₂dba₃ (50 mg, 0.06 mmol), and 2-dicyclohexylphosphino-2'-(N,N-dimethylamino)biphenyl (43 mg, 0.11 mmol) were combined in a 10 mL round bottom flask with a stirbar. The atmosphere of the flask was evacuated and replaced with argon twice. DMF (2 mL) and Et₃N (0.5 mL, 3.27 mmol) were added and the reaction mixture warmed to 100 °C for 5 h. The reaction mixture was cooled to room temperature, diluted with EtOAc and Et₂O, and filtered through Celite. The filtrate was washed twice with H₂O and once with brine. Silica gel was added and the volatiles removed by rotary evaporation. Flash chromatography (70-100% EtOAc/hexanes-2-5% MeOH/CH₂Cl₂) gave 92 mg (49%) of as a yellow solid. R_f = 0.39 (10% MeOH/CH₂Cl₂), ¹H NMR (400 MHz, DMSO-D6) δ ppm 3.79 (s, 3 H) 5.37 (s, 2 H) 7.01 (m, 2 H) 7.53 (m, 2 H) 8.21 (d, J=5.83 Hz, 2 H) 8.43 (m, 2 H) 8.64 (d, J=8.59 Hz, 1 H) 8.80 (d, J=4.30 Hz, 2 H) 9.13 (s, 1 H), ¹³C NMR (100 MHz, DMSO-D6) δ ppm 55.1, 70.3, 113.9, 121.3, 122.1, 122.6, 126.0, 128.1, 129.6, 131.3, 142.7, 144.6, 145.8, 148.4, 150.5, 155.5, 159.2; Anal Calcd for C₂₁H₁₇N₃O₂: C, 73.45; H, 4.99; N, 12.24. Found: C: 73.32, H: 5.10, N: 12.17.

25

Example 234I

2-Pyridin-4-yl-[1,7]naphthyridin-5-ol

To Example 234H (108 mg, 0.32 mmol) in a 50 mL round bottom flask with a stirbar was added a mixture of 1 N HCl (1.6 mL, 1.57 mmol) in EtOH (8 mL). The resulting reaction mixture was warmed to 90 °C for 2 h, cooled to room temperature, and then poured onto K₂CO₃ (120 mg, 0.87 mmol) in a 100 mL round bottom flask. MeOH (10 mL) was added and the mixture was stirred vigorously for 1 h at which time silica gel was added and the volatiles removed on a rotary evaporator. Flash chromatography (3-5-7-12% MeOH/CH₂Cl₂) gave 52 mg (74%) of as an off-white solid. R_f = 0.24 (10% MeOH/CH₂Cl₂); MS m/z 224 (M + H)⁺; ¹H NMR (300 MHz, DMSO-D6) δ ppm 8.20 (s, 1 H) 8.24 (m, 2 H) 8.44 (d, J=8.82 Hz, 1 H) 8.69 (d, J=8.82 Hz, 1 H) 8.80 (m, 2 H) 9.01 (s, 1 H) 10.91 (Br S, 1 H).

Example 234J(1S)-[1-(1H-Indol-3-ylmethyl)-2-(2-pyridin-4-yl-[1,7]naphthyridin-5-yloxy)-ethyl]-carbamic acid *tert*-butyl ester

The desired product was prepared by substituting Example 232I for 3-bromo-5-hydroxypyridine in Example 27A. $R_f = 0.41$ (10% MeOH/CH₂Cl₂); ¹H NMR (300 MHz, DMSO-D6) δ ppm 1.37 (s, 9 H) 3.07 (m, 1 H) 3.38 (m, 1 H) 4.25 (m, 3 H) 6.93 (m, 1 H) 7.05 (td, $J=7.54, 1.19$ Hz, 1 H) 7.15 (d, $J=2.03$ Hz, 1 H) 7.21 (d, $J=7.80$ Hz, 1 H) 7.33 (d, $J=7.80$ Hz, 1 H) 7.56 (d, $J=7.80$ Hz, 1 H) 8.27 (m, 3 H) 8.51 (d, $J=8.82$ Hz, 1 H) 8.82 (m, 3 H) 9.13 (s, 1 H) 10.82 (s, 1 H).

10

Example 234K(1S)-1-(1H-Indol-3-ylmethyl)-2-(2-pyridin-4-yl-[1,7]naphthyridin-5-yloxy)-ethylamine

The desire product was prepared as trifluoroacetic acid salt by substituting Example 234K for Example 232D in Example 232E. MS *m/z* 396 (M + H)⁺; ¹H NMR (300 MHz, DMSO-D6) (of the free base) δ ppm 2.96 (m, 1 H) 3.11 (m, 1 H) 3.24 (m, 1 H) 3.61 (s, 1 H) 4.09 (q, $J=5.09$ Hz, 1 H) 4.16 (dd, $J=9.49, 6.10$ Hz, 1 H) 4.26 (m, 1 H) 6.93 (m, 1 H) 7.06 (td, $J=7.46, 1.02$ Hz, 1 H) 7.22 (d, $J=2.37$ Hz, 1 H) 7.34 (d, $J=8.14$ Hz, 1 H) 7.58 (d, $J=8.14$ Hz, 1 H) 8.27 (m, 3 H) 8.51 (d, $J=8.82$ Hz, 1 H) 8.82 (m, 2 H) 8.89 (d, $J=8.82$ Hz, 1 H) 9.14 (s, 1 H) 10.88 (s, 1 H).

20

Example 235(1R)-1-(1H-Indol-3-ylmethyl)-2-(2-pyridin-4-yl-[1,7]naphthyridin-5-yloxy)-ethylamine

The desired product was prepared by substituting Boc-*R*-Tryptophanol for Boc-*L*-tryptophanol in Example 234. MS *m/z* 396 (M + H)⁺; ¹H NMR (300 MHz, DMSO-D6) δ ppm 3.31 (m, 2 H) 4.34 (dd, $J=10.51, 5.42$ Hz, 1 H) 4.50 (dd, $J=10.68, 2.54$ Hz, 1 H) 6.95 (m, 1 H) 7.08 (m, 1 H) 7.29 (d, $J=2.03$ Hz, 1 H) 7.37 (d, $J=8.14$ Hz, 1 H) 7.63 (d, $J=7.80$ Hz, 1 H) 8.30 (s, 1 H) 8.65 (m, 6 H) 8.99 (d, $J=5.76$ Hz, 2 H) 9.23 (s, 1 H) 9.29 (m, 1 H) 11.04 (d, $J=1.70$ Hz, 1 H).

30

Example 236(1S)-1-(1H-Indol-3-ylmethyl)-2-(5-isoquinolin-6-yl-pyridin-3-ylsulfanyl)-ethylamine

35

Example 236A3-Bromo-5-(4-methoxy-benzylsulfanyl)-pyridine

To a suspension of sodium hydride (370 mg, 60% in mineral oil, 9.25 mmol) in DMF (30 ml) (4-Methoxy-phenyl)-methanethiol (1.25ml, 9 mmol) was added. The resulting solution was stirred at room temperature for 1 hour and added to 3.5-dibromopyridine (2.13 g, 8.99 mmol) in DMF (30ml). The mixture was stirred at room temperature for 48 hours. The reaction 5 solution was partitioned between ether and water. The organic layer was washed (brine), dried (Na_2SO_4), filtered and concentrated under vacuum. Purification on silica gel eluting with 5% ethyl acetate/hexane provides the title compound (1.75 g, 63%). MS (DCI/NH₃) m/e 310 (M+1)⁺; ¹H NMR (300 MHz, DMSO-D6) δ ppm 3.72 (s, 3 H) 4.30 (s, 2 H) 6.85 (d, J =2.03 Hz, 1 H) 6.89 (d, J =2.37 Hz, 1 H) 7.26 (d, J =2.37 Hz, 1 H) 7.29 (d, J =2.03 Hz, 1 H) 10 8.04 (dd, J =2.03 Hz, 1 H) 8.45 (d, J =2.03 Hz, 1 H) 8.48 (d, J =2.03 Hz, 1 H).

Example 236B

5-Bromo-pyridine-3-thiol

A mixture of Example 236A (1.43 g, 4.6mmol), m-cresol (4.9ml, 47mmol) and TFA (4ml) 15 was refluxed for 24hours. After cooled to room temperature, the solution was dried by vacuum. Purification on silica gel eluted with 5% ethyl acetate in hexanes to provide the crude title compound (contaminated with disulfide).

Example 236C

20 (1*S*)-[2-(5-Bromo-pyridin-3-ylsulfanyl)-1-(1*H*-indol-3-ylmethyl)-ethyl]-carbamic acid *tert*-butyl ester

A 100 ml RBF was charged with Example 236B (0.620 mg, 3.26 mmol), 2-Hydroxy-1-(1*H*-indol-3-ylmethyl)-ethyl]-carbamic acid *tert*-butyl ester (1.077g, 3.71 mmol), Ph_3P (1.23 g, 4.69 mmol) and DBAD (1.0968g, 4.763 mmol). THF (10 ml) was added at 0 °C. The reaction 25 mixture was stirred at 0°C for 1 h and at room temperature for 22 hours. The reaction mixture was concentrated and the residue was separated by flash chromatography (30% EtOAc in hexane) to provide 0.614g product with DBAD.

Example 236D

30 (1*S*)-1-(1*H*-Indol-3-ylmethyl)-2-(5-isoquinolin-6-yl-pyridin-3-ylsulfanyl)-ethylamine

The desired compound was prepared by substituting Example 236C for Example 2A in Example 27. MS (ESI) m/e 411 (M+1)⁺; ¹H NMR (300 MHz, DMSO-D6) δ ppm 3.13 (m, 2 H) 3.37 (m, 2 H) 3.57 (m, 1 H) 6.90 (t, J =8.14 Hz, 1 H) 7.02 (t, J =8.14 Hz, 1 H) 7.25 (d, J =2.37 Hz, 1 H) 7.31 (d, J =8.14 Hz, 1 H) 7.47 (m, 1 H) 8.06 (br. s., 2 H) 8.18 (m, 2 H) 8.28 (t, J =2.03 Hz, 1 H) 8.46 (m, 1 H) 8.52 (br. s., 1 H) 8.67 (d, J =6.10 Hz, 1 H) 8.69 (d, J =2.03 Hz, 1 H) 8.97 (d, J =2.03 Hz, 1 H) 9.66 (br. s., 1 H) 11.03 (br. s., 1 H).

Example 237.(1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-ylsulfanyl]-ethylamine

5 The title compound was prepared by substituting Example 102C for 6-bromoisoquinoline in Example 236. MS (ESI) m/e 414 (M+1)⁺; ¹H NMR (300 MHz, MeOH) δ ppm 3.20 (d, *J*=6.78 Hz, 2 H) 3.25 (m, 1 H) 3.50 (m, 1 H) 3.69 (m, 1 H) 6.91 (td, *J*=8.14, 6.10, 1.02 Hz, 1 H) 7.02 (td, *J*=8.14, 6.10, 1.02 Hz, 1 H) 7.15 (br. s., 1 H) 7.26 (d, *J*=8.14 Hz, 1 H) 7.40 (d, *J*=8.14 Hz, 1 H) 7.53 (t, *J*=8.82 Hz, 1 H) 7.60 (d, *J*=8.82 Hz, 1 H) 7.93 (m, 1 H) 8.12 (t, *J*=2.03 Hz, 1 H) 8.51 (br. s., 1 H) 8.74 (br. s., 1 H).

10

Example 238(1S)-1-(4-Bromo-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine

15

Example 238A5-(5-Hydroxy-pyridin-3-yl)-3-methyl-indazole-1-carboxylic acid *tert*-butyl ester

The desired product was prepared by substituting 3-bromo-5-hydroxypyridine for Example 203B in Example 203C.

20

Example 238B(1S)-{1-(4-Bromo-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethyl}-carbamic acid *tert*-butyl ester

The desired product was prepared according to the procedures described for Example 2A, substituting Example 238A for 3-bromo-5-hydroxypyridine, and 3'-bromo-Boc-phenylalaninol for Boc-tryptophanol in Example 2A.

25

Example 238C(1S)-1-(4-Bromo-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine

The desired product was prepared as trifluoroacetic acid salt by substituting Example 238B for Example 27B in Example 27. MS (ESI) m/e 437 (M+1); ¹H NMR (300 MHz, TRIFLUOROACETIC ACID-D) δ ppm 3.16 (s, 3 H) 3.46 (m, 2 H) 4.48 (m, 1 H) 4.86 (m, 2 H) 7.34 (m, 2 H) 7.70 (m, 2 H) 8.24 (m, 2 H) 8.57 (m, 2 H) 8.86 (m, 1 H) 9.07 (m, 1 H).

30

35

Example 239(1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(2-methyl-quinazolin-7-yl)-pyridin-3-yloxy]-ethylamine

Example 239A7-Bromo-2-methyl-quinazoline

The 4-Bromo-2-fluoro-benzaldehyde (1g, 4.9 mmol), acetamidine and DMA were mixed and heated to 140°C for 5 hours. The mixture was cooled to room temperature and dried under 5 vacuum. The mixture was purified by flash column afforded 47mg product in 4% yield. MS (ESI) m/e 223 (M+1)⁺.

Example 239B(1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(2-methyl-quinazolin-7-yl)-pyridin-3-yloxy]-ethylamine

10 The desired product was prepared by substituting Example 239A for 6-bromophthalimide in Example 32. MS (ESI) m/e 410 (M+1)⁺; ¹H NMR (300 MHz, DMSO-D6) δ ppm 2.57 (s, 3 H) 3.10 (m, 2 H) 3.85 (m, 1 H) 4.29 (m, 1 H) 4.46 (m, 1 H) 7.39 (m, 5 H) 7.62 (dd, *J*=8.81, 0.68 Hz, 1 H) 7.80 (dd, *J*=8.81, 1.70 Hz, 1 H) 8.28 (d, *J*=0.68 Hz, 2 H) 8.56 (m, 5 H) 8.89 (d, *J*=1.70 Hz, 1 H).

15

Example 240(1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(1H-indol-5-yl)-pyridin-3-yloxy]-ethylamine

20 The desired product was prepared by substituting 5-bromoindole for 6-bromophthalimide in Example 32. MS (ESI) m/e 383 (M+1)⁺; ¹H NMR (300 MHz, DMSO-D6) δ ppm 3.58 (m, 1 H) 4.09 (m, 3 H) 4.18 (m, 1 H) 6.67 (br. s., 2 H) 6.98 (m, 1 H) 7.08 (m, 1 H) 7.27 (m, 3 H) 7.38 (m, 4 H) 7.50 (m, 1 H) 7.60 (m, 2 H) 7.88 (br. s., 1 H) 8.23 (br. s., 1 H) 8.51 (br. s., 1 H).

25

Example 241(1S)-1-(1H-Indol-3-ylmethyl)-2-[5-[4-(1H-tetrazol-5-yl)-phenyl]-pyridin-3-yloxy]-ethylamine

30 The desired product was prepared by substituting 5-(4-bromo-phenyl)-1*H*-tetrazole for 6-bromophthalimide in Example 32. MS (ESI) m/e 412 (M+1)⁺; ¹H NMR (300 MHz, Solvent) δ ppm 3.24 (m, 2 H) 3.99 (m, 1 H) 4.29 (m, 1 H) 4.44 (m, 1 H) 7.04 (m, 1 H) 7.14 (m, 1 H) 7.24 (m, 1 H) 7.39 (m, 1 H) 7.61 (m, 1 H) 7.79 (m, 1 H) 7.86 (m, 2 H) 8.17 (br. s., 1 H) 8.20 (br. s., 1 H) 8.39 (br. s., 1 H) 8.61 (br. s., 1 H).

35

Example 242(1S)-1-(1H-Indol-3-ylmethyl)-2-(5-isoquinolin-6-yl-pyrimidin-4-yloxy)-ethylamine

Example 242A5-Bromo-pyrimidin-4-ol

The Pyrimidin-4-ol (366mg, 3.8 mmol) and AcOH were cooled to 0°C. Br₂ (0.27ml) was added slowly *via* syringe. The mixture was stirred at room temperature for 3 hours. The 5 AcOH was removed under pressure. The residue was dissolved in CH₂Cl₂, washed with saturated NaHCO₃, brine, and dried over MgSO₄. The solvent was removed and the product was purified by flash column chromatography to afforded the desired product (605 mg, 91%). MS (ESI) m/e 175 (M+1)⁺; ¹H NMR (300 MHz, DMSO-D6) δ ppm 8.23 (br. s., 1 H) 8.33 (br. s., 1 H) 13.08 (br. s., 1 H).

Example 242B(1S)-1-(1H-Indol-3-ylmethyl)-2-(5-isoquinolin-6-yl-pyrimidin-4-yloxy)-ethylamine

The title compound was prepared by substituting Example 242A for 3-bromo-5-hydroxypyridine in Example 27. MS (ESI) m/e 396 (M+1)⁺; ¹H NMR (300 MHz, DMSO-D6) δ ppm 3.10 (m, 2 H) 4.35 (m, 1 H) 4.48 (m, 1 H) 4.72 (m, 1 H) 6.96 (m, 2 H) 7.31 (m, 3 H) 8.26 (m, 3 H) 8.50 (m, 3 H) 8.68 (m, 1 H) 8.88 (s, 2 H) 9.74 (br. s., 1 H) 10.99 (br. s., 1 H)

Example 243(1S)-1-Benzyl-2-[3-(3-methyl-1H-indazol-5-yl)-phenoxy]-ethylamineExample 243A[1-Benzyl-2-(3-bromo-phenoxy)-ethyl]-carbamic acid *tert*-butyl ester

The desired product was prepared by substituting 3-bromophenol for 3-bromo-5-hydroxypyridine and L-Boc-phenylalaninol for L-Boc-tryptophanol in Example 2A.

Example 243B5-[3-((2S)-2-*tert*-Butoxycarbonylamino-3-phenyl-propoxy)-phenyl]-3-methyl-indazole-1-carboxylic acid *tert*-butyl ester

The desired product was prepared by substituting Example 243A for Example 2A in Example 30 102E.

Example 243C(1S)-1-Benzyl-2-[3-(3-methyl-1H-indazol-5-yl)-phenoxy]-ethylamine

The desired product was prepared as the trifluoroacetate salt by substituting Example 243B for Example 27B in Example 27C. MS (ESI) m/e 358 (M+H)⁺; ¹H NMR (500 MHz, DMSO-D6) δ ppm 2.54 (s, 3 H) 3.06 (m, 2 H) 3.82 (m, 1 H) 4.02 (dd, *J*=10.61, 5.62 Hz, 1 H) 4.18 (dd, *J*=10.61, 3.12 Hz, 1 H) 6.93 (dd, *J*=7.80, 1.56 Hz, 1 H) 7.28 (d, *J*=2.18 Hz, 1 H) 7.36 (m,

7 H) 7.53 (d, $J=8.42$ Hz, 1 H) 7.62 (m, 1 H) 7.94 (s, 1 H) 8.27 (s, 2 H) 12.68 (bs, 1 H); Anal. Calcd for $C_{23}H_{23}N_3O \cdot 1.45$ TFA: C, 59.50; H, 4.71; N, 8.04;. Found: C, 59.46; H, 4.69, N, 8.25.

5

Example 244(1S)-1-Benzyl-2-[6-(3-methyl-1H-indazol-5-yl)-pyridin-2-yloxy]-ethylamine

The desired product was prepared as the trifluoroacetate salt by substituting Example 3-bromo-6-hydroypyridine for 3-bromophenol in Example 243. MS (ESI) m/e 359 ($M+H$)⁺; ¹H NMR (300 MHz, DMSO-D6) δ ppm 2.54 (s, 3 H) 3.05 (m, 2 H) 3.90 (m, 1 H) 4.33 (dd, $J=11.70, 6.27$ Hz, 1 H) 4.60 (dd, $J=11.87, 3.39$ Hz, 1 H) 6.80 (d, $J=8.14$ Hz, 1 H) 7.33 (m, 5 H) 7.49 (d, $J=7.80$ Hz, 1 H) 7.68 (d, $J=7.12$ Hz, 1 H) 7.83 (m, 1 H) 7.96 (dd, $J=8.81, 1.70$ Hz, 1 H) 8.20 (s, 2 H) 8.35 (s, 1 H) 12.69 (bs, 1 H); Anal. Calcd for $C_{22}H_{22}N_4O \cdot 1.4$ TFA \cdot 1 H₂O: C, 55.56; H, 4.78; N, 10.45;. Found: C, 55.45; H, 4.51, N, 10.50.

15

Example 245(1S)-2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(4-thiophen-3-yl-benzyl)-ethylamine

20

Example 245A(1S)-[2-Hydroxy-1-(4-iodo-benzyl)-ethyl]-carbamic acid *tert*-butyl ester

The material was prepared from L-Boc-(4-iodophenyl)alanine according to the procedure described by M. Rodriguez, M. Llinares, S. Doulut, A. Heitz, J. Martinez *Tetrahedron Letters* 1991, 32 (7), 923-926.

25

Example 245B(1S)-[2-(5-Bromo-pyridin-3-yloxy)-1-(4-iodo-benzyl)-ethyl]-carbamic acid *tert*-butyl ester

The desired product was prepared by substituting Example 245A for L-Boc-tryptophanol in Example 2A.

30

Example 245C(1S)-[2-(5-Bromo-pyridin-3-yloxy)-1-(4-thiophen-3-yl-benzyl)-ethyl]-carbamic acid *tert*-butyl ester

35

A solution of Example 245B (200 mg; 0.37 mmol), 3-thiopheneboronic acid (50 mg; 0.39 mmol), Pd(PPh₃)₄ (25 mg; 0.02 mmol) and CsF (115 mg; 0.76 mmol) in 1:2 MeOH:DME (5 mL) was heated at reflux for 4 hrs, cooled, diluted with water, and extracted with EtOAc.

The extracts were rinsed with brine, dried (MgSO_4), evaporated, and purified by flash chromatography (30% Et_2O /hexane) to provide the desired product (145 mg, 79%).

5 Example 245D

(1S)-[2-[5-(3-Methyl-1*H*-indazol-5-yl)-pyridin-3-yloxy]-1-(4-thiophen-3-yl-benzyl)-ethyl]-carbamic acid *tert*-butyl ester

The desired product was prepared by substituting Example 245C for Example 2A in Example 102E.

10 Example 245E

(1S)-2-[5-(3-Methyl-1*H*-indazol-5-yl)-pyridin-3-yloxy]-1-(4-thiophen-3-yl-benzyl)-ethylamine

The desired product was prepared as the trifluoroacetate salt by substituting Example 245D for Example 27B in Example 27C. MS (ESI) m/e 441 ($\text{M}+\text{H}$)⁺; ¹H NMR (300 MHz, DMSO-D6) δ ppm 2.54 (s, 3 H) 3.06 (d, $J=7.12$ Hz, 2 H) 3.89 (m, 1 H) 4.16 (dd, $J=10.68, 5.59$ Hz, 1 H) 4.33 (dd, $J=10.68, 2.88$ Hz, 1 H) 7.37 (d, $J=8.48$ Hz, 2 H) 7.55 (m, 2 H) 7.63 (m, 1 H) 7.70 (m, 3 H) 7.76 (m, 1 H) 7.85 (dd, $J=3.05, 1.36$ Hz, 1 H) 8.08 (s, 1 H) 8.22 (m, 2 H) 8.35 (d, $J=2.71$ Hz, 1 H) 8.64 (d, $J=1.70$ Hz, 1 H) 12.47 (bs, 1 H).

20

Example 246

(1S)-1-(4-Iodo-benzyl)-2-[5-(3-methyl-1*H*-indazol-5-yl)-pyridin-3-yloxy]-ethylamine

The desired product was prepared as the trifluoroacetate salt by substituting Boc-3'-bromophenylalaninol for Example 245A in Example 238. MS (ESI) m/e 485 ($\text{M}+\text{H}$)⁺; ¹H NMR (300 MHz, DMSO-D6) δ ppm 2.55 (s, 3 H) 3.00 (d, $J=7.12$ Hz, 2 H) 3.85 (m, 1 H) 4.13 (m, 1 H) 4.30 (m, 1 H) 7.16 (d, $J=8.14$ Hz, 2 H) 7.58 (d, $J=8.82$ Hz, 1 H) 7.70 (m, 3 H) 8.08 (s, 1 H) 8.19 (d, $J=3.05$ Hz, 2 H) 8.32 (d, $J=2.71$ Hz, 1 H) 8.63 (d, $J=1.70$ Hz, 1 H) 8.97 (s, 1 H) 12.72 (bs, 1 H).

30

Example 247

[4-((2*S*)-2-Amino-3-phenyl-propoxy)-2-(3-methyl-1*H*-indazol-5-yl)-phenyl]-methanol

35 Example 247A

(1*S*)-[1-Benzyl-2-(3-chloro-4-formyl-phenoxy)-ethyl]-carbamic acid *tert*-butyl ester

The desired product was prepared by substituting 2-chloro-4-hydroxybenzaldehyde for 3-bromo-5-hydroxypyridine and L-Boc-phenylalaninol for L-Boc-tryptophanol in Example 2A.

Example 247B(1S)-{1-Benzyl-2-[4-formyl-3-(3-methyl-1H-indazol-5-yl)-phenoxy]-ethyl}-carbamic acid
tert-butyl ester

5 A solution of Example 102D (230 mg; 0.78 mmol) and Example 247A (300 mg; 0.77 mmol) in DMF (4 mL) was treated with Pd2(dba)3 (73 mg; 0.008 mmol), 2-dicyclohexylphosphino-2'-(N,N-dimethylamino)biphenyl (61 mg; 0.15 mmol), and triethylamine (97 mg; 0.96 mmol), heated at 110 °C for 4 hrs., partitioned between brine and EtOAc, filtered through Celite®, and extracted with EtOAc. The extracts were rinsed with brine, dried (MgSO₄), 10 concentrated, and purified by flash chromatography (40% EtOAc/hexane) to provide the desired product (235 mg; 63%).

Example 247C(1S)-{1-Benzyl-2-[4-hydroxymethyl-3-(3-methyl-1H-indazol-5-yl)-phenoxy]-ethyl}-
carbamic acid tert-butyl ester

15 A solution of Example 247B (225 mg; 0.46 mmol) in EtOH (4 mL) was treated portionwise with NaBH₄ (26 mg; 0.70 mmol) and stirred for 30 min., diluted with water, and extracted into EtOAc. The extracts were rinsed with brine, dried (MgSO₄), concentrated, and purified by flash chromatography (60% EtOAc/hexane) to provide the desired product (150 mg; 20 66%).

Example 247D[4-((2S)-2-Amino-3-phenyl-propoxy)-2-(3-methyl-1H-indazol-5-yl)-phenyl]-methanol

Example 247C (115 mg; 0.23 mmol) was heated neat at 190 °C for 45 min. then purified by 25 flash chromatography on silica gel eluting with 10% MeOH/CH₂Cl₂ to provide the desired product (17 mg; 19%). MS (ESI) m/e 388 (M+H)⁺; ¹H NMR (300 MHz, DMSO-D6) δ ppm 2.50 (s, 3 H) 2.60 (dd, *J*=13.22, 7.80 Hz, 1 H) 2.83 (dd, *J*=13.22, 5.76 Hz, 1 H) 3.25 (m, 1 H) 3.82 (t, *J*=5.59 Hz, 2 H) 4.33 (d, *J*=5.09 Hz, 2 H) 4.99 (t, *J*=5.26 Hz, 1 H) 6.81 (d, *J*=2.37 Hz, 1 H) 6.93 (dd, *J*=8.48, 2.37 Hz, 1 H) 7.23 (m, 5 H) 7.36 (d, *J*=8.48 Hz, 1 H) 7.46 (m, 3 H) 30 7.69 (s, 2 H) 12.66 (s, 1 H).

Example 248(1S)-2-[5-(1H-Benzotriazol-5-yl)-pyridin-3-yloxy]-1-(1H-indol-3-ylmethyl)-ethylamine

35

Example 248A4-Bromo-benzene-1,2-diamine

A mixture of 4-bromo-2-nitroaniline (1 g; 4.6 mmol) and $\text{SnCl}_2 \cdot 2 \text{H}_2\text{O}$ (6.2 g; 27.6 mmol) in MeOH (30 mL) with 5-6 drops of conc. HCl was heated at reflux for 5 hrs., concentrated, suspended in sat'd NaHCO_3 (aq.) and extracted with EtOAc. The extracts were rinsed with brine, dried (MgSO_4), and concentrated to provide the product of sufficient purity to carry on.

5

Example 248B

5-Bromo-1*H*-benzotriazole

A mixture of Example 248A (262 mg; 1.4 mmol) in 10% H_2SO_4 (4 mL) was treated with NaNO_2 (120 mg; 1.7 mmol) in water (1 mL), stirred for 30 min., diluted with water, and 10 extracted with EtOAc. The extracts were rinsed with brine, dried (Na_2SO_4), concentrated and purified by flash chromatography (5% MeOH/CH₂Cl₂) to provide the desired product.

Example 248C

5-Bromo-benzotriazole-1-carboxylic acid *tert*-butyl ester

15 A solution of Example 248B (770 mg; 5 mmol) in THF (5 mL) was added to a solution of 20% phosgene in toluene (10 mL) at -20 °C, stirred for 1 hr. at -20 °C then 2 hrs. at r.t., evaporated and dissolved in THF (4 mL). This solution was added to a solution of *t*BuOH (1 mL), and pyridine (426 mg; 5.4 mmol) in THF (3 mL) at -20 °C then stirred overnight at r.t. The solids were removed by filtration and rinsed with EtOAc. The filtrate was rinsed with 20 water and brine, dried (MgSO_4), concentrated, and isolated by flash chromatography (1:1 Et₂O:hexane) to provide the desired product (970 mg; 76%).

Example 248D

(1*S*)-2-[5-(1*H*-Benzotriazol-5-yl)-pyridin-3-yloxy]-1-(1*H*-indol-3-ylmethyl)-ethylamine

25 The desired product was prepared as the trifluoroacetate salt by substituting Example 248C for 6-bromophthalimide in Example 32. MS (ESI) m/e 385 (M+H)⁺; ¹H NMR (300 MHz, DMSO-D6) δ ppm 3.17 (d, *J*=7.12 Hz, 2 H) 3.86 (m, 1 H) 4.21 (dd, *J*=10.68, 6.27 Hz, 1 H) 4.38 (dd, *J*=10.68, 2.88 Hz, 1 H) 7.01 (t, *J*=6.95 Hz, 1 H) 7.10 (t, *J*=7.12 Hz, 1 H) 7.30 (d, *J*=2.37 Hz, 1 H) 7.38 (d, *J*=8.14 Hz, 1 H) 7.63 (d, *J*=7.80 Hz, 1 H) 7.78 (m, 1 H) 8.01 (m, 1 H) 8.18 (m, 3 H) 8.27 (m, 1 H) 8.38 (d, *J*=2.71 Hz, 1 H) 8.66 (d, *J*=1.36 Hz, 1 H) 11.03 (s, 1 H).

Example 249

(1*S*)-2-[5-(1*H*-Benzotriazol-5-yl)-pyridin-3-yloxy]-1-benzyl-ethylamine

35

Example 249A

(1*S*)-[1-Benzyl-2-(5-bromo-pyridin-3-yloxy)-ethyl]-carbamic acid *tert*-butyl ester

The desired product was prepared by substituting L-Boc-phenylalaninol for L-Boc-tryptophanol in Example 2A.

Example 249B

5 (1S)-[1-Benzyl-2-(5-trimethylstannanyl-pyridin-3-yloxy)-ethyl]-carbamic acid *tert*-butyl ester

The desired product was prepared by substituting Example 249A for Example 2A in Example 32A.

10 Example 249C

5-[5-((2S)-2-*tert*-Butoxycarbonylamino-3-phenyl-propoxy)-pyridin-3-yl]-benzotriazole-1-carboxylic acid *tert*-butyl ester

A solution of Example 249B (400 mg; 0.81 mmol) and Example 73C (255 mg; 0.85 mmol) in DMF (6 mL) was treated with $Pd_2(dba)_3$ (111 mg; 0.12 mmol), tri-*o*-tolylphosphine (74 mg; 0.24 mmol), and triethylamine (102 mg; 1.0 mmol), heated at 110 °C for 4 hrs., partitioned between brine and EtOAc, filtered through Celite®, and extracted with EtOAc. The extracts were rinsed with brine, dried ($MgSO_4$), concentrated, and purified by flash chromatography (80% EtOAc/CH₂Cl₂) to provide the desired product (110 mg; 25%).

20 Example 249D

(1S)-2-[5-(1*H*-Benzotriazol-5-yl)-pyridin-3-yloxy]-1-benzyl-ethylamine

The desired product was prepared as the trifluoroacetate salt by substituting Example 249C for Example 27B in Example 27C. MS (ESI) m/e 346 ($M+H$)⁺; ¹H NMR (300 MHz, DMSO-D6) δ ppm 3.04 (m, 2 H) 3.86 (m, 1 H) 4.14 (m, 1 H) 4.30 (m, 1 H) 7.32 (m, 5 H) 7.78 (m, 2 H) 8.02 (m, 1 H) 8.22 (m, 3 H) 8.38 (d, *J*=2.37 Hz, 1 H) 8.66 (d, *J*=2.03 Hz, 1 H); Anal. Calcd for C₂₀H₁₉N₅O•2.6 TFA: C, 47.16; H, 3.39; N, 10.91; Found: C, 46.90; H, 3.26; N, 11.01.

Example 250

30 (1S)-1-Benzyl-2-[5-(3-morpholin-4-yl-1*H*-indazol-5-yl)-pyridin-3-yloxy]-ethylamine

The desired product was prepared as the trifluoroacetate salt by substituting Example 111A for Example 249A in Example 249. MS (ESI) m/e 430 ($M+H$)⁺; ¹H NMR (400 MHz, DMSO-D6) δ ppm 3.04 (m, 2 H) 3.36 (m, 4 H) 3.81 (m, 4 H) 3.87 (m, 1 H) 4.13 (dd, *J*=10.74, 5.83 Hz, 1 H) 4.29 (dd, *J*=10.74, 2.76 Hz, 1 H) 7.30 (m, 5 H) 7.49 (d, *J*=8.90 Hz, 1 H) 7.64 (d, *J*=8.59 Hz, 1 H) 7.71 (s, 1 H) 8.09 (s, 1 H) 8.26 (bs, 2 H) 8.32 (d, *J*=2.15 Hz, 1 H) 8.64 (s, 1 H) 12.20 (bs, 1 H).

Example 251(1S)-1-Benzyl-2-{5-[3-(4-methyl-piperazin-1-yl)-1H-indazol-5-yl]-pyridin-3-yloxy}-ethylamine

5 The desired product was prepared as the trifluoroacetate salt by substituting Example 114A for Example 249A in Example 249. MS (ESI) m/e 443 (M+H)⁺; ¹H NMR (300 MHz, DMSO-D6) δ ppm 2.53 (s, 3 H) 2.90 (m, 4 H) 3.04 (m, 2 H) 3.17 (m, 2 H) 3.53 (m, 2 H) 3.84 (m, 1 H) 4.10 (m, 1 H) 4.27 (dd, *J*=11.02, 3.22 Hz, 1 H) 7.32 (m, 5 H) 7.52 (d, *J*=8.82 Hz, 1 H) 7.66 (m, 2 H) 8.15 (s, 1 H) 8.24 (m, 2 H) 8.32 (d, *J*=2.71 Hz, 1 H) 8.66 (d, *J*=1.70 Hz, 1 H) 12.36 (s, 1 H); Anal. Calcd for C₂₆H₃₀N₆O•3 TFA: C, 48.98; H, 4.21; N, 10.71;. Found: C, 48.60; H, 4.39; N, 11.05.

10

Example 252

15 (1S)-{5-[5-(2-Amino-3-phenyl-propoxy)-pyridin-3-yl]-1H-indazol-3-yl}-dimethyl-amine
The desired product was prepared as the trifluoroacetate salt by substituting Example 115A for Example 249A in Example 249. MS (ESI) m/e 388 (M+H)⁺; ¹H NMR (300 MHz, DMSO-D6) δ ppm 3.03 (m, 8 H) 3.83 (m, 1 H) 4.13 (m, 1 H) 4.29 (m, 1 H) 7.34 (m, 5 H) 7.46 (d, *J*=8.81 Hz, 1 H) 7.63 (dd, *J*=8.65, 1.53 Hz, 1 H) 7.75 (m, 1 H) 8.08 (s, 1 H) 8.21 (m, 2 H) 8.33 (d, *J*=2.71 Hz, 1 H) 8.64 (d, *J*=1.70 Hz, 1 H) 12.01 (bs, 1 H); Anal. Calcd for C₂₃H₂₅N₅O•3 TFA: C, 47.74; H, 3.87; N, 9.60;. Found: C, 47.76; H, 3.76; N, 9.52.

20

Example 253

25 (1S)-{5-[5-(2-Amino-3-phenyl-propoxy)-pyridin-3-yl]-1H-indazol-3-yl}-(2-methoxy-ethyl)-amine

Example 253A(5-Bromo-1H-indazol-3-yl)-(2-methoxy-ethyl)-amine

30 The reaction between Example 35A and *O*-methyl ethanolamine was carried out according to the procedure described by U. Wrzeciono, K. Majewska, J. Dudzinska-Usarewicz, M. Bernas, *Pharmzie*, 1986, 41, 472-474.

Example 253A

35 (1S)-{5-[5-(2-Amino-3-phenyl-propoxy)-pyridin-3-yl]-1H-indazol-3-yl}-(2-methoxy-ethyl)-amine

The desired product was prepared as the trifluoroacetate salt by substituting Example 253A for Example 249A in Example 249. MS (ESI) m/e 418 (M+H)⁺; ¹H NMR (300 MHz, DMSO-

D6) δ ppm 3.04 (m, 2 H) 3.30 (s, 3 H) 3.46 (m, 2 H) 3.57 (m, 2 H) 3.83 (m, 1 H) 4.11 (dd, $J=10.68, 5.60$ Hz, 1 H) 4.28 (m, 1 H) 7.34 (m, 5 H) 7.64 (dd, $J=10.68, 1.87$ Hz, 3 H) 8.21 (s, 3 H) 8.30 (d, $J=2.37$ Hz, 1 H) 8.58 (d, $J=1.70$ Hz, 1 H) 11.67 bs, 1 H); Anal. Calcd for $C_{24}H_{27}N_5O_2 \cdot 3$ TFA: C, 46.34; H, 4.15; N, 9.01; Found: C, 46.54; H, 4.34; N, 8.79.

5

Example 254

{5-[5-((2S)-2-Amino-3-phenyl-propoxy)-pyridin-3-yl]-1H-indazol-3-yl}-(2-morpholin-4-yl-ethyl)-amine

10

Example 254A

(5-Bromo-1H-indazol-3-yl)-(2-morpholin-4-yl-ethyl)-amine

The reaction between Example 35A and 4-(2-aminoethyl)morpholine was carried out according to the procedure described by U. Wrzeciono, K. Majewska, J. Dudzinska-

15

Usarewicz, M. Bernas, *Pharmazie*, 1986, 41, 472-474.

Example 254B

{5-[5-((2S)-2-Amino-3-phenyl-propoxy)-pyridin-3-yl]-1H-indazol-3-yl}-(2-morpholin-4-yl-ethyl)-amine

20

The desired product was prepared as the trifluoroacetate salt by substituting Example 254A for Example 249A in Example 249. MS (ESI) m/e 473 (M+H)⁺; ¹H NMR (300 MHz, DMSO-D6) δ ppm 2.50 (m, 8 H) 3.04 (m, 2 H) 3.43 (m, 2 H) 3.68 (m, 2 H) 3.87 (m, 1 H) 4.10 (m, 1 H) 4.28 (m, 1 H) 7.36 (m, 7 H) 7.65 (m, 2 H) 8.07 (s, 1 H) 8.21 (m, 2 H) 8.31 (d, $J=2.71$ Hz, 1 H) 8.55 (d, $J=1.70$ Hz, 1 H) 11.83 (bs, 1 H)

25

Example 255

5-[5-((2S)-2-Amino-3-phenyl-propoxy)-pyridin-3-yl]-1H-indazol-3-ylamine

30

The desired product was prepared as the trifluoroacetate salt by substituting Example 249A for Example 2A in Example 97. MS (ESI) m/e 360 (M+H)⁺; ¹H NMR (300 MHz, DMSO-D6) δ ppm 3.04 (m, 2 H) 3.85 (m, 1 H) 4.11 (dd, $J=10.68, 5.59$ Hz, 1 H) 4.28 (dd, $J=10.68, 2.88$ Hz, 1 H) 7.35 (m, 6 H) 7.65 (m, 2 H) 8.14 (s, 1 H) 8.21 (m, 4 H) 8.31 (d, $J=2.71$ Hz, 1 H) 8.56 (d, $J=2.03$ Hz, 1 H) 11.87 (bs, 1 H); Anal. Calcd for $C_{21}H_{21}N_5O \cdot 3.1$ TFA: C, 45.83; H, 3.41; N, 9.82; Found: C, 45.58; H, 3.34; N, 9.57.

35

Example 256*N*-(5-[(2*S*)-2-Amino-3-phenyl-propoxy]-pyridin-3-yl)-1*H*-indazol-3-yl}-2,2,2-trifluoro-acetamide

5

Example 256A5-Bromo-1*H*-indazol-3-ylamine

The desired product was prepared by substituting 5-bromo-2-fluorobenzonitrile for 5-bromo-2-fluorobenzaldehyde in Example 35A.

10

Example 256B*N*-(5-Bromo-1*H*-indazol-3-yl)-2,2,2-trifluoro-acetamide

A solution of 256A (2.5 g; 12 mmol) and trifluoroacetic anhydride (3.4 mL; 24 mmol) in pyridine (50 mL) was stirred at r.t. for 2 days, acidified with 10% HCl (aq), and extracted with EtOAc. The extracts were rinsed with water and brine, dried (MgSO_4), concentrated and purified by flash chromatography (1:1 EtOAc:hexane) to provide the desired product (3.0 g; 84%).

20

Example 256C*N*-(5-[(2*S*)-2-Amino-3-phenyl-propoxy]-pyridin-3-yl)-1*H*-indazol-3-yl}-2,2,2-trifluoro-acetamide

25

The desired product was prepared as the trifluoroacetate salt by substituting Example 256B for Example 249A in Example 249. MS (ESI) m/e 454 ($\text{M}+\text{H}$)⁺; ¹H NMR (300 MHz, DMSO-D₆) δ ppm 3.04 (m, 2 H) 3.84 (m, 1 H) 4.11 (dd, *J*=10.85, 5.76 Hz, 1 H) 4.28 (dd, *J*=10.68, 2.88 Hz, 1 H) 7.35 (m, 6 H) 7.68 (m, 2 H) 8.16 (s, 1 H) 8.22 (m, 3 H) 8.32 (d, *J*=2.71 Hz, 1 H) 8.57 (d, *J*=1.70 Hz, 1 H) 11.87 (bs, 1 H).

30

Example 257(2*S*)-2-Amino-*N*-(5-(3-methyl-1*H*-indazol-5-yl)-pyridin-3-yl)-3-phenyl-propionamide

35

Example 257A5-(5-Amino-pyridin-3-yl)-3-methyl-indazole-1-carboxylic acid *tert*-butyl ester

The desired product was prepared by substituting Example 203B for Example 27A and Example 23B for Example 2A in Example 27B.

Example 257B

5-[5-((2*S*)-2-*tert*-Butoxycarbonylamino-3-phenyl-propionylamino)-pyridin-3-yl]-3-methyl-indazole-1-carboxylic acid *tert*-butyl ester

The desired product was prepared by substituting Example 257A for Example 25E and L-Boc-phenylalanine for Boc-tryptophane in Example 25G.

5

Example 257C

(2*S*)-2-Amino-N-[5-(3-methyl-1*H*-indazol-5-yl)-pyridin-3-yl]-3-phenyl-propionamide

The desired product was prepared as the trifluoroacetate salt by substituting Example 257B for Example 27B in Example 27C. MS (ESI) m/e 372 (M+H)⁺; ¹H NMR (300 MHz, DMSO-D6) δ ppm 2.55 (s, 3 H) 3.19 (m, 2 H) 4.23 (m, 1 H) 7.32 (m, 6 H) 7.62 (s, 1 H) 8.01 (s, 1 H) 8.19 m, 1 H) 8.36 (s, 2 H) 8.68 (d, *J*=2.03 Hz, 1 H) 8.74 (d, *J*=2.03 Hz, 1 H) 10.70 (s, 1 H) 12.85 (bs, 1 H); Anal. Calcd for C₂₂H₂₁N₅O•2.6 TFA: C, 48.91; H, 3.56; N, 10.49; Found: C, 48.96; H, 3.71; N, 10.64.

15

Example 258

(1*S*)-2-[5-(3-Benzyl-1*H*-indazol-5-yl)-pyridin-3-yloxy]-1-(1*H*-indol-3-ylmethyl)-ethylamine

The desired product was prepared as the trifluoroacetate salt by substituting benzyl magnesium chloride for methyl magnesium bromide in Example 102. MS (ESI) m/e 474 (M+H)⁺; ¹H NMR (300 MHz, DMSO-D6) δ ppm 3.17 (m, 2 H) 3.86 (m, 1 H) 4.17 (dd, *J*=10.68, 5.93 Hz, 1 H) 4.35 (s, 2 H) 4.42 (dd, *J*=10.68, 5.93 Hz, 1 H) 7.02 (t, *J*=7.12 Hz, 1 H) 7.08 (m, 1 H) 7.29 (m, 7 H) 7.61 (m, 4 H) 7.98 (s, 1 H) 8.15 (m, 3 H) 8.32 (d, *J*=2.71 Hz, 1 H) 8.55 (d, *J*=1.70 Hz, 1 H) 11.03 (s, 1 H); Anal. Calcd for C₃₀H₂₁N₅O•3.9 TFA: C, 49.44; H, 3.39; N, 7.63; Found: C, 49.07; H, 3.75; N, 7.42.

25

Example 259

(1*S*)-1-Benzyl-2-[5-(3-benzyl-1*H*-indazol-5-yl)-pyridin-3-yloxy]-ethylamine

The desired product was prepared as the trifluoroacetate salt by substituting 249B for Example 2A in Example 258. MS (ESI) m/e 435 (M+H)⁺; ¹H NMR (300 MHz, DMSO-D6) δ ppm 3.03 (m, 2 H) 3.86 (m, 1 H) 4.11 (dd, *J*=10.85, 5.76 Hz, 1 H) 4.28 (dd, *J*=10.68, 2.88 Hz, 1 H) 5.72 (s, 2 H) 7.30 (m, 8 H) 7.72 (m, 3 H) 7.84 (m, 1 H) 8.13 (s, 1 H) 8.21 (m, 3 H) 8.33 (d, *J*=2.71 Hz, 1 H) 8.60 (d, *J*=1.70 Hz, 1 H)

35

Example 260

(1*S*)-2-[5-(3-Benzyl-1*H*-indazol-5-yl)-pyridin-3-yloxy]-1-methyl-ethylamine

Example 260A(1S)-[2-(5-Bromo-pyridin-3-yloxy)-1-methyl-ethyl]-carbamic acid *tert*-butyl ester

The desired product was prepared by substituting Boc-alaninol for Boc-tryprophanol in Example 2A.

Example 260B(1S)-[1-Methyl-2-(5-trimethylstannanyl-pyridin-3-yloxy)-ethyl]-carbamic acid *tert*-butyl ester

The desire product was prepared by substituting Example 260A for Example 249A in Example 249B.

Example 260C(1S)-2-[5-(3-Benzyl-1*H*-indazol-5-yl)-pyridin-3-yloxy]-1-methyl-ethylamine

The desired product was prepared as the trifluoroacetate salt by subsituting 260B for Example 32A in Example 258. MS (ESI) m/e 359 (M+H)⁺; ¹H NMR (300 MHz, DMSO-D6) δ ppm 1.31 (m, 3 H) 4.10 (m, 1 H) 4.30 (m, 1 H) 4.35 (s, 2 H) 4.41 (m, 1 H) 7.17 (m, 1 H) 7.29 (m, 2 H) 7.36 (m, 2 H) 7.61 (s, 2 H) 7.69 (s, 2 H) 8.02 (bs, 2 H) 8.33 (d, *J*=2.37 Hz, 1 H) 8.56 (s, 1 H) 12.71 (bs, 1 H); Anal. Calcd for C₂₂H₂₂N₄O•3.2 TFA: C, 47.16; H, 3.51; N, 7.75; Found: C, 47.27; H, 3.60; N, 7.60.

Example 261(6-{5-[(2*S*)-2-Amino-3-(1*H*-indol-3-yl)-propoxy]-pyridin-3-yl}-cinnolin-4-yl)-phenyl-amine

A solution of Example 34D (500 mg; 2.5 mmol) and aniline (1.5 mL) in MeOH (11 mL) was stirred at r.t. for 2.5 hrs, the resulting precipitate was collected, rinsed with water and dried under vacuum to provide the desired product (400 mg; 62%).

Example 261B(6-{5-[(2*S*)-2-Amino-3-(1*H*-indol-3-yl)-propoxy]-pyridin-3-yl}-cinnolin-4-yl)-phenyl-amine

The desired product was prepared as the trifluoroacetate salt by substituting Example 261A for Example 27A in Example 27. MS (ESI) m/e 487 (M+H)⁺; ¹H NMR (500 MHz, DMSO-D6) δ ppm 3.18 (m, 2 H) 3.86 (m, 1 H) 4.25 (dd, *J*=10.61, 5.93 Hz, 1 H) 4.39 (m, 1 H) 6.99 (t,

$J=7.49$ Hz, 1 H) 7.09 (t, $J=7.02$ Hz, 1 H) 7.31 (d, $J=2.50$ Hz, 1 H) 7.38 (d, $J=8.11$ Hz, 1 H) 7.45 (t, $J=7.33$ Hz, 1 H) 7.60 (m, 6 H) 7.90 (m, 1 H) 8.19 (d, $J=9.05$ Hz, 1 H) 8.35 (bs, 2 H) 8.44 (m, 2 H) 8.64 (s, 1 H) 8.81 (d, $J=1.56$ Hz, 1 H) 9.08 (s, 1 H) 11.04 (d, $J=1.87$ Hz, 1 H).

5

Example 262(1S)-2-[5-(1H-Indazol-6-yl)-pyridin-3-yloxy]-1-(1H-indol-3-ylmethyl)-ethylamine

The desired product was prepared as the trifluoroacetate salt by substituting 4-bromo-2-fluorobenzaldehyde for 5-bromo-2-fluorobenzaldehyde in Example 35. MS (ESI) m/e 384 (M+H)⁺; ¹H NMR (500 MHz, DMSO-D6) δ ppm 2.97 (m, 2 H) 3.60 (m, 1 H) 4.13 (m, 2 H) 6.99 (m, 2 H) 7.24 (m, 1 H) 7.38 (m, 2 H) 7.61 (m, 3 H) 7.84 (m, 3 H) 8.11 (m, 1 H) 8.31 (m, 1 H) 8.55 (m, 1 H) 11.03 (m, 1 H) 12.98 (m, 1 H)

15

Example 2635-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-2,3-dihydro-isoindol-1-oneExample 263A4-Bromo-2-methyl-benzoic acid methyl ester

20 A solution of 4-bromo-2-methyl benzoic acid (1.0 g; 4.7 mmol) in MeOH (24 mL) with 20 drops conc. HCl was heated at reflux for 6 hrs. the concentrated to provide the desired product (1.1 g; 100%).

Example 263B4-Bromo-2-bromomethyl-benzoic acid methyl ester

25 A solution of Example 263A (1.02 g; 4.5 mmol) in CCl₄ (22 mL) was treated with AIBN (65 mg; 0.4 mmol), heated at reflux for 4 hrs., washed with water, dried (Na₂SO₄) and concentrated to provide the desired product (1.1 g; 79%).

30

Example 263C5-Bromo-2,3-dihydro-isoindol-1-oneExample 263D5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-2,3-dihydro-isoindol-1-one

35 The desired product was prepared as the trifluoroacetate salt by substituting Example 263C for 5-bromooxindole in Example 36. MS (ESI) m/e 399 (M+H)⁺; ¹H NMR (d₆-DMSO, 300 MHz) δ : 11.03 (bs, 1H), 8.63 (s, 1H), 8.57 (s, 1H), 8.35 (bs, 3H), 7.90 (s, 1H), 7.78 (s, 2H),

7.67 (s, 1H), 7.61 (d, $J=8$ Hz, 1H), 7.37 (d, $J=8$ Hz, 1H), 7.79 (d, $J=2$ Hz, 1H), 7.03-7.10 (m, 1H), 6.96-7.01 (m, 1H), 4.32-4.36 (m, 1H), 4.17-4.22 (m, 1H), 3.80-3.83 (m, 1H), 3.18 (d, $J=8$ Hz, 2H), 2.50 (s, 2H).

5

Example 2646-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-1H-cinnolin-4-one

The desired product was prepared as the trifluoroacetate salt by substituting Example 34A for 6-bromophthalimide in Example 32. MS (ESI) m/e 412 (M+H)⁺; ¹H NMR (500 MHz, DMSO-D6) δ ppm 3.19 (d, $J=7.18$ Hz, 2 H) 3.84 (m, 1 H) 4.24 (dd, $J=10.61, 5.93$ Hz, 1 H) 4.39 (dd, $J=10.61, 3.12$ Hz, 1 H) 7.01 (t, $J=7.02$ Hz, 1 H) 7.10 (t, $J=7.18$ Hz, 1 H) 7.31 (d, $J=2.50$ Hz, 1 H) 7.38 (d, $J=8.11$ Hz, 1 H) 7.64 (d, $J=7.80$ Hz, 1 H) 7.76 (d, $J=8.73$ Hz, 1 H) 7.80 (m, 2 H) 7.96 (s, 1 H) 8.17 (dd, $J=8.73, 2.18$ Hz, 1 H) 8.32 (d, $J=2.18$ Hz, 2 H) 8.40 (d, $J=2.81$ Hz, 1 H) 8.65 (d, $J=1.87$ Hz, 1 H) 11.05 (d, $J=1.56$ Hz, 1 H) 13.72 (bs, 1 H); Anal. Calcd for C₂₄H₂₁N₅O₂•3 TFA: C, 47.82; H, 3.21; N, 9.29;. Found: C, 47.88; H, 3.41; N, 9.35.

Example 265(1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(4-phenyl-cinnolin-6-yl)-pyridin-3-yloxy]-ethylamine

20

Example 265A1-(1H-Indol-3-ylmethyl)-2-[5-(4-phenyl-cinnolin-6-yl)-pyridin-3-yloxy]-ethylamine

A solution of Example 34C (200 mg; 0.8 mmol) in THF (10 mL) was treated with 3.0 M phenylmagnesium bromide in Et₂O (1.6 mL; 4.8 mmol), stirred at r.t. for 4 hrs., sat'd NH₄Cl (aq) was added, and extracted with EtOAc. The extracts were rinsed with brine, dried (MgSO₄), concentrated and purified by flash chromatography (30% EtOAc/hexane) to provide the desired product (67 mg; 29%).

Example 265B(1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(4-phenyl-cinnolin-6-yl)-pyridin-3-yloxy]-ethylamine

The desired product was prepared as the trifluoroacetate salt by substituting Example 265A for 6-bromophthalimide in Example 32. MS (ESI) m/e 472 (M+H)⁺; ¹H NMR (500 MHz, DMSO-D6) δ ppm 3.15 (d, $J=7.18$ Hz, 2 H) 3.84 (m, 1 H) 4.17 (dd, $J=10.61, 5.93$ Hz, 1 H) 4.33 (dd, $J=10.61, 3.12$ Hz, 1 H) 6.98 (t, $J=7.49$ Hz, 1 H) 7.08 (t, $J=7.49$ Hz, 1 H) 7.28 (d, $J=2.18$ Hz, 1 H) 7.37 (d, $J=8.11$ Hz, 1 H) 7.64 (m, 5 H) 7.70 (d, $J=1.87$ Hz, 1 H) 7.78 (d, $J=6.55$ Hz, 2 H) 8.16 (bs, 2 H) 8.30 (dd, $J=8.89, 1.72$ Hz, 1 H) 8.42 (d, $J=2.50$ Hz, 1 H) 8.61

(d, $J=1.56$ Hz, 1 H) 8.69 (d, $J=9.05$ Hz, 1 H) 9.41 (s, 1 H) 11.01 (s, 1 H); Anal. Calcd for $C_{30}H_{25}N_5O \cdot 1.9$ TFA: C, 58.99; H, 3.94; N, 10.18; Found: C, 58.87; H, 3.85; N, 10.08.

5

Example 266(6-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-cinnolin-4-yl)-benzyl-amineExample 266ABenzyl-(6-bromo-cinnolin-4-yl)-amine

10 A solution of 34D (100 mg; 0.41 mmol) and benzylamine (0.5 mL) in MeOH (3 mL) was stirred at r.t. for 24 hrs., concentrated, suspended in Et_2O , and the precipitate was collected to provide the desired product (100 mg; 78%).

Example 266B(6-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-cinnolin-4-yl)-benzyl-amine

The desired product was prepared as the trifluoroacetate salt by substituting Example 266A for 6-bromophthalimide in Example 32. MS (ESI) m/e 501 ($M+H$)⁺; ¹H NMR (500 MHz, DMSO-D6) δ ppm 3.18 (d, $J=7.18$ Hz, 2 H) 3.87 (m, 1 H) 4.23 (dd, $J=10.61$, 5.62 Hz, 1 H) 4.38 (dd, $J=10.45$, 2.96 Hz, 1 H) 5.00 (d, $J=5.62$ Hz, 2 H) 7.00 (t, $J=7.49$ Hz, 1 H) 7.09 (t, $J=7.18$ Hz, 1 H) 7.30 (d, $J=2.50$ Hz, 1 H) 7.37 (m, 4 H) 7.50 (d, $J=7.49$ Hz, 2 H) 7.62 (d, $J=8.11$ Hz, 1 H) 7.83 (d, $J=2.18$ Hz, 1 H) 8.10 (d, $J=9.05$ Hz, 1 H) 8.29 (bs, 2 H) 8.40 (dd, $J=8.89$, 1.40 Hz, 1 H) 8.45 (d, $J=2.50$ Hz, 1 H) 8.78 (d, $J=1.56$ Hz, 1 H) 8.80 (s, 1 H) 8.98 (s, 1 H) 10.35 (bs, 1 H) 11.03 (s, 1 H); Anal. Calcd for $C_{31}H_{28}N_6O \cdot 3.1$ TFA: C, 52.31; H, 3.67; N, 9.84; Found: C, 52.36; H, 3.47; N, 9.67.

25

Example 267(6-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-cinnolin-4-yl)-methyl-amine

The desired product was prepared as the trifluoroacetate salt by substituting methylamine for benzylamine in Example 266. MS (ESI) m/e 425 ($M+H$)⁺; ¹H NMR (500 MHz, DMSO-D6) δ ppm 2.50 (d, $J=1.87$ Hz, 3 H) 3.19 (m, 2 H) 3.85 (m, 1 H) 4.26 (dd, $J=10.92$, 5.93 Hz, 1 H) 4.40 (dd, $J=10.61$, 3.12 Hz, 1 H) 6.99 (t, $J=7.49$ Hz, 1 H) 7.09 (t, $J=7.33$ Hz, 1 H) 7.32 (d, $J=1.87$ Hz, 1 H) 7.37 (d, $J=8.11$ Hz, 1 H) 7.63 (d, $J=8.11$ Hz, 1 H) 7.87 (s, 1 H) 8.10 (d, $J=9.05$ Hz, 1 H) 8.37 (m, 3 H) 8.43 (d, $J=2.81$ Hz, 1 H) 8.72 (s, 1 H) 8.76 (d, $J=1.56$ Hz, 1 H) 8.93 (s, 1 H) 10.00 (bs, 1 H) 11.04 (d, $J=1.25$ Hz, 1 H)

Example 2686-{5-[(2S)-2-Amino-3-(1*H*-indol-3-yl)-propoxy]-pyridin-3-yl}-cinnolin-4-ylamine

The desired product was prepared as the trifluoroacetate salt by substituting ammonia for benzylamine in Example 266. MS (ESI) m/e 411 (M+H)⁺; ¹H NMR (500 MHz, DMSO-D6) δ 5 ppm 3.18 m, 2 H) 3.86 (m, 1 H) 4.27 (m, 1 H) 4.41 (m, 1 H) 6.99 (m, 1 H) 7.08 (m, 1 H) 7.36 (m, 2 H) 7.64 (d, *J*=6.55 Hz, 1 H) 7.89 (s, 1 H) 8.10 (d, *J*=8.42 Hz, 1 H) 8.46 (m, 4 H) 8.59 (s, 1 H) 8.76 (s, 1 H) 9.00 (s, 1 H) 10.06 (s, 2 H) 11.08 (s, 1 H)

Example 269[(3*S*)-3-(5-Isoquinolin-6-yl-pyridin-3-yloxymethyl)-1,2,3,4-tetrahydro-*b*-carbolin-9-yl]-methanol

A solution of Example 27 (100 mg; 0.19 mmol) and 37% formaldehyde (aq) (18 μL) in water (1 mL) with 2 drops conc. H₂SO₄ was heated at reflux for 3 hrs., evaporated and purified by 10 reverse phase HPLC on a C18 column with 0-100% CH₃CN/H₂O/0.1 % TFA to provide the desired product as the trifluoroacetate salt. MS (ESI) m/e 412 (M+H)⁺; ¹H NMR (400 MHz, DMSO-D6) δ ppm 3.04 (m, 1 H) 3.20 (m, 3 H) 4.19 (bs, 1 H) 4.53 (m, 6.75 Hz, 1 H) 4.64 (m, 1 H) 4.70 (m, 1 H) 5.52 (m, 2 H) 7.12 ((t, *J*=7.67 Hz, 1 H) 7.22 (t, *J*=7.67 Hz, 1 H) 7.52 (d, *J*=7.98 Hz, 1 H) 7.58 (d, *J*=8.29 Hz, 1 H) 8.05 (s, 1 H) 8.26 (d, *J*=6.44 Hz, 1 H) 8.33 (d, *J*=8.59 Hz, 1 H) 8.53 (m, 2 H) 8.63 (s, 1 H) 8.68 (d, *J*=5.83 Hz, 1 H) 8.83 (s, 1 H) 9.71 (s, 1 H) 9.94 (bs, 1 H)

Example 2703-(5-Isoquinolin-6-yl-pyridin-3-yloxymethyl)-2,3,4,9-tetrahydro-1*H*-*β*-carboline

A solution of Example 27 (100 mg; 0.19 mmol) and 37% formaldehyde (aq) (17 μL) in water (1 mL) with conc. H₂SO₄ (6 μL) was stirred overnight at r.t., neutralized with NH₃/MeOH, concentrated and purified by flash chromatography (10% MeOH/CH₂Cl₂) to provide the desired product. MS (ESI) m/e 407 (M+H)⁺; ¹H NMR (500 MHz, DMSO-D6) δ ppm 2.58 (dd, *J*=14.66, 9.98 Hz, 1 H) 2.85 (dd, *J*=14.97, 3.74 Hz, 1 H) 3.38 (m, 2 H) 4.02 (d, *J*=4.99 Hz, 1 H) 4.33 (m, 2 H) 6.95 (t, *J*=7.02 Hz, 1 H) 7.02 (t, *J*=7.49 Hz, 1 H) 7.29 (d, *J*=8.11 Hz, 1 H) 7.39 (d, *J*=8.11 Hz, 1 H) 7.91 (m, 2 H) 8.12 (dd, *J*=8.42, 1.56 Hz, 1 H) 8.25 (d, *J*=8.42 Hz, 1 H) 8.41 (s, 1 H) 8.45 (t, *J*=2.65 Hz, 1 H) 8.56 (d, *J*=5.62 Hz, 1 H) 8.69 (d, *J*=1.56 Hz, 1 H) 9.37 (s, 1 H) 10.72 (s, 1 H).

35

Example 271

5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-1H-indazole-3-carboxylic acid

Example 271A

5

1H-Indazole-3-carboxylic acid methyl ester

A solution of 3-carboxyindazole (2.0 g; 12.3 mmol) and conc.HCl (2 mL) in MeOH (50 mL) was heated at reflux overnight, concentrated, diluted with 2N NaOH (aq), and extracted with EtOAc. The extracts were rinsed with brine, dried (MgSO_4), and concentrated to provide the desired product.

10

Example 271B

5-Iodo-1H-indazole-3-carboxylic acid methyl ester

A solution of Example 271A (300 mg; 1.7 mmol), bis(trifluoroacetoxy)iodobenzene (800 mg; 1.9 mmol), and iodine (253 mg; 1.0 mmol) in CH_2Cl_2 (10 mL) was stirred overnight at r.t., 15 and treated with sodium bisulfite (aq). The precipitate was collected, rinsed with water and hexane, and dried under vacuum to provide the desired product (180 mg; 36%).

Example 271C

5-{5-[(2S)-2-*tert*-Butoxycarbonylamino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-1H-indazole-3-carboxylic acid methyl ester

20

The desired product was prepared by substituting Example 271B for 6-bromophthalimide in Example 32B.

Example 271D

5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-1H-indazole-3-carboxylic acid methyl ester

The desired product was prepared by substituting Example 271C for Example 27B in Example 27C.

30

Example 271E

5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-1H-indazole-3-carboxylic acid

A solution of Example 271D (150 mg; 0.34 mmol) and 1N NaOH (5 mL) in MeOH (1 mL) was heated at reflux for 6 hrs., concentrated, and purified by reverse phase HPLC on a C18 column with 0-100% $\text{CH}_3\text{CN}/\text{H}_2\text{O}/0.1\%$ TFA to provide the desired product as the trifluoroacetate salt. MS (ESI) m/e 428 ($\text{M}+\text{H}^+$); ^1H NMR (500 MHz, DMSO-D6) δ ppm 3.18 (d, $J=7.49$ Hz, 2 H) 3.86 (m, 1 H) 4.21 (dd, $J=10.29$, 5.93 Hz, 1 H) 4.37 (dd, $J=10.29$, 2.50

Hz, 1 H) 7.01 (t, J =7.33 Hz, 1 H) 7.10 (t, J =7.33 Hz, 1 H) 7.30 (d, J =1.87 Hz, 1 H) 7.38 (d, J =8.11 Hz, 1 H) 7.63 (d, J =7.80 Hz, 1 H) 7.71 (s, 1 H) 7.77 (m, 2 H) 8.26 (s, 3 H) 8.32 (s, 1 H) 8.37 (s, 1 H) 8.59 (s, 1 H) 11.03 (s, 1 H) 13.64 (m, 1 H).

5

Example 2725-[5-((2S)-2-*tert*-Butoxycarbonylamino-3-hydroxy-propoxy)-pyridin-3-yl]-3-methyl-indazole-1-carboxylic acid *tert*-butyl ester

Example 203 (719 mg, 1.22 mmol) was dissolved in 30 mL EtOAc in a 100 mL round bottom flask with a stirbar. A combination vacuum/Ar/H₂ manifold was attached and the flask evacuated and filled with Ar twice. Pd/C (800 mg, 10 wt. % (dry basis)) was added and the flask evacuated and filled with H₂ twice. The resultant black mixture was stirred vigorously and warmed to 50 °C for 20 h at which time TLC indicated ~70% consumption of starting material. Another 480 mg of the Pd/C was added and a fresh H₂ balloon attached. The reaction was stirred another 26 h at 50 °C at which time it was cooled to room temperature and the flask evacuated and filled with Ar. The cooled reaction mixture was filtered through Celite and the filter cake washed with EtOAc. The filtrate was subjected to rotary evaporation and then dried with house vacuum to yield the desired product (540 mg, 89%) as a colorless foam/solid. R_f = 0.26 (EtOAc); MS *m/z* 499 (M + H)⁺; ¹H NMR (300 MHz, DMSO-D6) δ ppm 1.39 (s, 9 H) 1.66 (s, 9 H) 2.60 (s, 3 H) 3.50 (m, 2 H) 3.82 (m, 1 H) 4.17 (m, 2 H) 4.83 (t, J =5.59 Hz, 1 H) 6.82 (d, J =8.14 Hz, 1 H) 7.79 (s, 1 H) 8.02 (dd, J =8.65, 1.53 Hz, 1 H) 8.12 (m, 1 H) 8.27 (d, J =1.02 Hz, 1 H) 8.29 (d, J =2.71 Hz, 1 H) 8.61 (d, J =2.03 Hz, 1 H).

25

Example 2735-[5-((2S)-Aziridin-2-ylmethoxy)-pyridin-3-yl]-3-methyl-1*H*-indazoleExample 273A(1*R*)-[2-(5-Bromo-pyridin-3-yloxy)-1-(*tert*-butyl-dimethyl-silanyloxymethyl)-ethyl]-carbamic acid *tert*-butyl ester

A 100 mL RBF was charged with 3-bromo-5-hydroxypyridine (1.20 g, 6.87 mmol), (*R*)-[1-(*tert*-butyl-dimethyl-silanyloxymethyl)-2-hydroxy-ethyl]-carbamic acid *tert*-butyl ester (2.1 g, 6.87 mmol) and Ph₃P (2.34 g, 8.93 mmol), and was purged with nitrogen. THF (30 mL) was added at 0 °C. After stirring at 0°C for 10 min, DEAD (1.41 mL, 8.93 mmol) was added via syringe. The reaction mixture was stirred at 0°C for 0.5 h and at rt for 2 h. The reaction mixture was concentrated and the residue was separated by flash chromatography (5-25%

EtOAc in hexane) to provide the desired product (3.14 g, 99%). MS (DCI) m/z 461, 463 (M+1)⁺.

Example 273B

5 (1S)-[2-(5-Bromo-pyridin-3-yloxy)-1-hydroxymethyl-ethyl]-carbamic acid *tert*-butyl ester

To a solution of Example 273A (3.14 g, 6.8 mmol) in THF (40 mL) was added TBAF (7.14 mL, 7.14 mmol) at rt. The solution was stirred at rt for 1 h and was concentrated. The residual oil was purified by flash chromatography (40-80% EtOAc in hexane) to give the desired product (2.19 g, 93%). MS (DCI) m/z 347, 349 (M+1)⁺.

10

Example 273C

(2S)-2-(5-Bromo-pyridin-3-yloxyethyl)-aziridine-1-carboxylic acid *tert*-butyl ester

Ph₃P (1.13 g, 4.32 mmol) was dissolved in 9:1 THF/CH₃CN (30 mL) and cooled to 4 °C with an ice/water bath. DIAD (850 µL, 4.32 mmol) was added slowly. After stirring 15 min, a 15 solution of Example 273B (1.0 g, 2.88 mmol) in THF (4 mL) was added slowly. The solution was allowed to warm to rt and stirred for over night. The solution was concentrated and the residual oil was purified by flash chromatography (20-40% EtOAc in hexane) to give the desired product (1.0 g, 75%). MS (DCI) m/z 329, 331 (M+1)⁺.

20

Example 273D

5-[5-((2S)-1-*tert*-Butoxycarbonyl-aziridin-2-ylmethoxy)-pyridin-3-yl]-3-methyl-indazole-1-carboxylic acid *tert*-butyl ester

Method 1. A 100 mL RBF was charged with Example 273C (950 mg, 2.88 mmol), Example 203B (1.14 g, 2.88 mmol), Pd₂(dba)₃ (263 mg, 0.288 mmol), and tri-*o*-tolylphosphine (263 mg), and was purged with N₂. Anhydrous DMF (35 mL) and Et₃N (1.2 mL) were added via syringe. The solution was purged with N₂ again and was heated at 72 °C for 4 h. After cooled, ethyl acetate (150 mL) was added. The mixture was washed with brine (200 mL) and water (200 mL). The ethyl acetate solution was concentrated and the residual oil was separated by flash chromatography (50-80% EtOAc in hexane) to give the desired product (634 mg, 65%). MS (APCI) m/z 481 (M+1)⁺.

30

Method 2. To a stirred solution of PPh₃ (2.16 g, 8.24 mmol) in THF (130 mL) and CH₃CN (20 mL) at 0°C was added DIAD (1.62 mL, 8.24 mmol) slowly via syringe. After 20 min the resulting light yellow solution was canulated onto Example 272 (2.74 g, 5.50 mmol) in THF (150 mL). The reaction mixture was stirred 6 h at 23 °C and then silica gel was added and the volatiles removed on a rotary evaporator. Flash chromatography (50-60-70-80% EtOAc/hexanes) gave 3.72 g of a white solid which was a 1.33 : 1 mixture of

35

triphenylphosphine oxide : aziridine. $R_f = 0.50$ (EtOAc). This was used without further purification.

Example 273E

5-[5-((2S)-Aziridin-2-ylmethoxy)-pyridin-3-yl]-3-methyl-1*H*-indazole

The desired product was prepared as the trifluoroacetate by substituting Example 273D for Example 27B in Examples 27C. MS (APCI) m/z 281 (M+1)⁺; ¹H NMR (300 MHz, CD₃OD) δ 2.63 (s, 3 H), 3.31 (dd, $J=3.30$, 1.83 Hz, 2 H), 3.62 (dd, $J=6.23$, 1.83 Hz, 2 H), 3.89 (m, 1 H), 4.60 (m, 2 H), 7.64 (d, $J=8.79$ Hz, 1 H), 7.77 (d, $J=8.79$ Hz, 1 H), 8.15 (s, 1 H), 8.22 (s, 1 H).

Example 274

(1*S*)-2-[5-(3-Methyl-1*H*-indazol-5-yl)-pyridin-3-yloxy]-1-(3-trifluoromethoxy-benzyl)-ethylamine

Example 274A

5-{5-[(2*S*)-2-tert-Butoxycarbonylamino-3-(3-trifluoromethoxy-phenyl)-propoxy]-pyridin-3-yl}-3-methyl-indazole-1-carboxylic acid *tert*-butyl ester

To a suspension of CuBr-SMe₂ (25 mg, 0.12 mmol) and Example 273D (100 mg, 0.21 mmol) in THF (6 mL) was added 3-trifluoromethoxyphenylmagnesium bromide (0.5 M solution in THF, 1.6 mL, 0.8 mmol) at approximately -35 °C. The formed clear solution was allowed to warm up to -20 °C within 40 min and was partitioned between ether and water. The organic layer was concentrated and the residue was separated by flash chromatography (40-65% EtOAc in hexane) to give the desired product (88 mg, 66%). MS (APCI) m/z 643 (M+1)⁺.

Example 274B

(1*S*)-2-[5-(3-Methyl-1*H*-indazol-5-yl)-pyridin-3-yloxy]-1-(3-trifluoromethoxy-benzyl)-ethylamine

The desired product was prepared as the trifluoroacetate by substituting Example 274A for Example 27B in Examples 27C. MS (APCI) m/z 444 (M+1)⁺; ¹H NMR (300 MHz, CD₃OD) δ 2.62 (s, 3 H), 3.22 (dd, $J=7.29$, 5.26 Hz, 2 H), 4.00 (m, 1 H), 4.26 (dd, $J=10.51$, 5.09 Hz, 1 H), 4.43 (dd, $J=10.85$, 3.05 Hz, 1 H), 7.25 (d, $J=8.48$ Hz, 1 H), 7.30 (s, 1 H), 7.36 (d, $J=7.46$ Hz, 1 H), 7.49 (t, $J=7.97$ Hz, 1 H), 7.62 (d, $J=8.48$ Hz, 1 H), 7.72 (dd, $J=8.82$, 1.70 Hz, 1 H), 8.00 (s, 1 H), 8.08 (s, 1 H), 8.40 (d, $J=2.03$ Hz, 1 H), 8.68 (s, 1 H). Anal. Calcd for C₂₃H₂₁F₃N₄O₂•2.6 TFA: C, 45.84; H, 3.22; N, 7.58. Found: C, 45.87; H, 3.17; N, 7.28.

The following compounds were prepared by substituting the appropriate Grignard reagents for 3-trifluoromethoxyphenylmagnesium bromide in Example 274.

5

Example 275(1*S*)-1-(3,5-Dichloro-benzyl)-2-[5-(3-methyl-1*H*-indazol-5-yl)-pyridin-3-yloxy]-ethylamine

MS (APCI) m/z 427 (M+1)⁺; ¹H NMR (300 MHz, CD₃OD) δ 2.63 (s, 3 H), 3.18 (dd, *J*=7.32, 3.30 Hz, 2 H), 4.02 (m, 1 H), 4.32 (dd, *J*=10.44, 5.31 Hz, 1 H), 4.47 (dd, *J*=10.62, 2.93 Hz, 1 H), 7.37 (s, 1 H), 7.39 (d, *J*=8.06 Hz, 1 H), 7.63 (d, *J*=8.79 Hz, 1 H), 7.74 (d, *J*=8.06 Hz, 1 H), 8.10 (s, 3 H), 8.44 (s, 1 H), 8.73 (s, 1 H); Anal. Calcd for C₂₂H₂₀Cl₂N₄O•3.2 TFA: C, 43.38; H, 2.98; N, 7.18. Found: C, 43.49; H, 3.18; N, 6.92.

10

Example 276(1*S*)-1-(2,3-Dichloro-benzyl)-2-[5-(3-methyl-1*H*-indazol-5-yl)-pyridin-3-yloxy]-ethylamine

15

MS (APCI) m/z 427 (M+1)⁺; ¹H NMR (300 MHz, CD₃OD) δ 2.63 (s, 3 H), 3.40 (dd, *J*=7.32, 5.13 Hz, 2 H), 4.10 (m, 1 H), 4.33 (dd, *J*=10.62, 4.76 Hz, 1 H), 4.47 (dd, *J*=10.99, 2.93 Hz, 1 H), 7.30 (t, *J*=7.69 Hz, 1 H), 7.39 (d, *J*=7.32 Hz, 1 H), 7.52 (d, *J*=7.69 Hz, 1 H), 7.63 (d, *J*=8.79 Hz, 1 H), 7.74 (d, *J*=8.79 Hz, 1 H), 8.11 (s, 2 H), 8.45 (s, 1 H), 8.75 (s, 1 H); Anal. Calcd for C₂₂H₂₀Cl₂N₄O•3.5TFA: C, 42.15; H, 2.87; N, 6.78. Found: C, 41.86; H, 3.05; N, 6.60.

20

Example 277(1*S*)-1-Biphenyl-3-ylmethyl-2-[5-(3-methyl-1*H*-indazol-5-yl)-pyridin-3-yloxy]-ethylamine

MS (APCI) m/z 435 (M+1)⁺; ¹H NMR (300 MHz, CD₃OD) δ 2.61 (s, 3 H), 3.25 (d, *J*=7.69 Hz, 2 H), 4.05 (m, 1 H), 4.33 (dd, *J*=10.62, 5.13 Hz, 1 H), 4.46 (d, *J*=10.25 Hz, 1 H), 7.36 (m, 4 H), 7.46 (t, *J*=7.14 Hz, 1 H), 7.57 (m, 6 H), 8.06 (s, 2 H), 8.42 (s, 1 H), 8.69 (s, 1 H); Anal. Calcd for C₂₈H₂₆N₄O•3.2 TFA: C, 51.68; H, 3.68; N, 7.01. Found: C, 51.94; H, 3.66; N, 6.85.

30

Example 278(1*S*)-1-(3-Chloro-4-fluoro-benzyl)-2-[5-(3-methyl-1*H*-indazol-5-yl)-pyridin-3-yloxy]-ethylamine

MS (APCI) m/z 411 (M+1)⁺; ¹H NMR (300 MHz, CD₃OD) δ 2.62 (s, 3 H) 3.15 (t, *J*=7.12 Hz, 2 H) 3.98 (m, 1 H) 4.28 (dd, *J*=10.51, 5.42 Hz, 1 H) 4.44 (dd, *J*=10.51, 3.05 Hz, 1 H) 7.23 (d, *J*=8.48 Hz, 1 H) 7.30 (m, 1 H) 7.51 (dd, *J*=7.12, 2.03 Hz, 1 H) 7.62 (d, *J*=8.81 Hz, 1 H) 7.72 (dd, *J*=8.48, 1.36 Hz, 1 H) 7.99 (s, 1 H) 8.08 (s, 1 H) 8.39 (s, 1 H) 8.68 (s, 1 H); Anal. Calcd for C₂₂H₂₀ClFN₄O•2.7 TFA: C, 45.79; H, 3.18; N, 7.80. Found: C, 45.86; H, 3.44; N, 7.66.

Example 279(1S)-1-(4-Chloro-3-fluoro-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine

5 MS (APCI) m/z 411 (M+1)⁺; ¹H NMR (300 MHz, CD₃OD) δ 2.63 (s, 3 H), 3.17 (t, *J*=6.95 Hz, 2 H), 4.00 (m, 1 H), 4.28 (dd, *J*=10.51, 5.43 Hz, 1 H), 4.44 (dd, *J*=10.51, 3.05 Hz, 1 H), 7.17 (dd, *J*=8.14, 1.70 Hz, 1 H), 7.29 (dd, *J*=10.00, 1.87 Hz, 1 H), 7.49 (t, *J*=7.97 Hz, 1 H), 7.62 (d, *J*=8.82 Hz, 1 H), 7.73 (d, *J*=7.12 Hz, 1 H), 8.01 (m, 1 H), 8.09 (s, 1 H), 8.40 (d, *J*=2.37 Hz, 1 H), 8.68 (d, *J*=1.70 Hz, 1 H); Anal. Calcd for C₂₂H₂₀ClFN₄O•2.7 TFA: C, 45.79; H, 3.18; N, 7.80. Found: C, 45.86; H, 3.44; N, 7.66.

Example 280(1S)-2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(4-trifluoromethoxy-benzyl)-ethylamine

15 MS (APCI) m/z 443 (M+1)⁺; ¹H NMR (300 MHz, CD₃OD) δ 2.62 (s, 3 H) 3.20 (t, *J*=6.95 Hz, 2 H) 3.98 (m, 1 H) 4.28 (dd, *J*=10.51, 5.42 Hz, 1 H) 4.43 (dd, *J*=10.51, 2.71 Hz, 1 H) 7.30 (d, *J*=7.80 Hz, 2 H) 7.45 (d, *J*=8.48 Hz, 2 H) 7.62 (d, *J*=8.48 Hz, 1 H) 7.73 (d, *J*=8.81 Hz, 1 H) 8.00 (s, 1 H) 8.08 (s, 1 H) 8.40 (s, 1 H) 8.68 (s, 1 H). Anal. Calcd for C₂₃H₂₁F₃N₂O₂•2.4 TFA: C, 46.63; H, 3.29; N, 7.82. Found: C, 46.57; H, 3.30; N, 7.80.

20

Example 281(1S)-1-(2-Fluoro-4-trifluoromethyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine

25 MS (APCI) m/z 445 (M+1)⁺; ¹H NMR (300 MHz, CD₃OD) δ 2.62 (s, 3 H), 3.31 (m, 2 H), 4.04 (m, 1 H), 4.29 (dd, *J*=10.85, 5.09 Hz, 1 H), 4.45 (dd, *J*=10.85, 3.39 Hz, 1 H), 7.54 (d, *J*=8.81 Hz, 1 H), 7.55 (s, 1 H), 7.60 (dd, *J*=4.07, 3.39 Hz, 1 H), 7.63 (s, 1 H), 7.72 (dd, *J*=8.81, 1.70 Hz, 1 H), 7.96 (s, 1 H), 8.07 (s, 1 H), 8.39 (s, 1 H), 8.67 (s, 1 H).

30

Example 282(1S)-1-(3-Fluoro-5-trifluoromethyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine

MS (APCI) m/z 445 (M+1)⁺; ¹H NMR (300 MHz, CD₃OD) δ 2.62 (s, 3 H), 3.30 (m, 2 H), 4.06 (m, 1 H), 4.29 (dd, *J*=10.51, 5.09 Hz, 1 H), 4.45 (dd, *J*=10.85, 3.05 Hz, 1 H), 7.45 (dd, *J*=7.80, 5.76 Hz, 2 H), 7.55 (s, 1 H), 7.62 (d, *J*=8.81 Hz, 1 H), 7.73 (d, *J*=8.48 Hz, 1 H), 7.98 (s, 1 H), 8.07 (s, 1 H), 8.42 (br s, 1H), 8.73 (br s, 1H).

Example 283(1S)-1-(2-Methoxy-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine

MS (APCI) m/z 389 (M+1)⁺; ¹H NMR (300 MHz, CD₃OD) δ 2.62 (s, 3 H), 3.16 (d, *J*=7.46 Hz, 2 H), 3.85 (s, 3 H), 3.99 (m, 1H), 4.23 (dd, *J*=10.51, 5.76 Hz, 1 H), 4.39 (dd, *J*=10.85, 3.39 Hz, 1 H), 6.94 (t, *J*=7.46 Hz, 1 H), 7.03 (d, *J*=8.14 Hz, 1 H), 7.23 (d, *J*=7.46 Hz, 1 H), 7.32 (dd, *J*=8.14, 7.46 Hz, 1 H), 7.62 (d, *J*=8.48 Hz, 1 H), 7.71 (d, *J*=8.82 Hz, 1 H), 7.91 (d, *J*=2.03 Hz, 1 H), 8.06 (s, 1 H), 8.34 (d, *J*=2.71 Hz, 1 H), 8.65 (s, 1 H).

Example 284(3-{(2S)-2-Amino-3-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-propyl}-phenyl)-dimethyl-amine

MS (DCI/NH₃) m/e 402 (M+1)⁺; ¹H NMR (300 MHz, CD₃OD) δ = 8.73 (s; 1H), 8.43 (s; 1H), 8.10 (m; 2H), 7.74 (d; 1H; *J*=7.5 Hz), 7.63 (d; 1H; *J*=7.5 Hz), 7.38(t; 1H; *J*=7.5Hz), 7.09 (s; 1H), 7.08 (d; 1H; *J*=7.5 Hz), 7.04 (d; 1H; *J*=7.5 Hz), 4.45 (dd; 1H; *J*=10.8 Hz; *J*=3.0Hz), 4.31 (dd; 1H; *J*=10.8Hz; *J*=6.0Hz), 4.00 (m; 1H), 3.17 (m; 2H), 3.05 (s; 6H), 2.64 (s; 3H).

Example 285(1S)-1-(4-Chloro-2-methyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine

MS (DCI/NH₃) m/e 407 (M+1)⁺; ¹H NMR (300 MHz, CD₃OD) δ = 8.71 (s; 1H), 8.41 (s; 1H), 8.10 (s; 1H), 8.04 (s; 1H), 7.73 (d; 1H; *J*=8.1 Hz), 7.62 (d; 1H; *J*=8.1 Hz), 7.28 (s; 1H), 7.22 (m; 2H), 4.40 (dd; 1H; *J*=10.8 Hz; *J*=3.0Hz), 4.26 (dd; 1H; *J*=10.8Hz; *J*=4.5Hz), 3.94 (m; 1H), 3.17 (m; 2H), 2.62 (s; 3H), 2.39 (s; 3H).

Example 286(1S)-1-(3-Iodo-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine

MS (DCI/NH₃) m/e 485 (M+1)⁺; ¹H NMR (300 MHz, CD₃OD) δ = 8.65 (s; 1H), 8.36 (s; 1H), 8.07 (s; 1H), 7.92 (s; 1H), 7.75 (s; 1H), 7.72 (d; 1H; *J*=8.1 Hz), 7.68 (d; 1H; *J*=7.8 Hz), 7.62 (d; 1H; *J*=8.1 Hz), 7.35 (d; 1H; *J*=7.8 Hz), 7.16 (d; 1H; *J*=7.8 Hz), 4.40 (dd; 1H; *J*=10.8 Hz; *J*=3.0Hz), 4.24 (dd; 1H; *J*=10.8Hz; *J*=4.5Hz), 3.96 (m; 1H), 3.12 (m; 2H), 2.62 (s; 3H).

35

Example 287

(1S)- (1S)-1-(3-Fluoro-4-methyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine

5 MS (DCI/NH₃) m/e 391 (M+1)⁺; ¹H NMR (300 MHz, CD₃OD) δ = 8.73 (s; 1H), 8.42 (s; 1H), 8.12 (s; 1H), 8.10 (s; 1H), 7.74 (d; 1H; J=8.1 Hz), 7.63 (d; 1H; J=8.1 Hz), 7.24 (t; 1H; J=8.4 Hz), 7.05 (m; 2H), 4.44 (dd; 1H; J=10.8 Hz; J=3.0Hz), 4.28 (dd; 1H; J=10.8Hz; J=4.5Hz), 3.97 (m; 1H), 3.13 (m; 2H), 2.62 (s; 3H), 2.23 (s; 3H).

Example 288

10 (1S)-1-(3-Fluoro-4-methoxy-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine

15 MS (DCI/NH₃) m/e 407 (M+1)⁺; ¹H NMR (300 MHz, CD₃OD) δ = 8.73 (s; 1H), 8.42 (s; 1H), 8.12 (s; 1H), 8.10 (s; 1H), 7.74 (d; 1H; J=8.1 Hz), 7.63 (d; 1H; J=8.1 Hz), 7.24 (t; 1H; J=8.4 Hz), 7.05 (m; 2H), 4.44 (dd; 1H; J=10.8 Hz; J=3.0Hz), 4.28 (dd; 1H; J=10.8Hz; J=4.5Hz), 3.97 (m; 1H), 3.13 (m; 2H), 2.62 (s; 3H), 2.23 (s; 3H).

Example 289

20 (1S)-2-[6-Chloro-5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(3,4-dichloro-benzyl)-ethylamine

25 MS (DCI/NH₃) m/e 462 (M+1)⁺; ¹H NMR (300 MHz, CD₃OD) δ = 8.16 (s; 1H), 7.78 (s; 1H), 7.54 (m; 4H), 7.48 (d; 1H; J=8.1 Hz), 7.25 (d; 1H; J=8.1 Hz), 4.32 (dd; 1H; J=10.8 Hz; J=3.0Hz), 4.15 (dd; 1H; J=10.8Hz; J=4.5Hz), 3.93 (m; 1H), 3.12 (m; 2H), 2.58 (s; 3H).

25

Example 290

(1S)-1-(2-Fluoro-6-trifluoromethyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine

30 MS (DCI/NH₃) m/e 445 (M+1)⁺; ¹H NMR (300 MHz, CD₃OD) δ = 8.69 (s; 1H), 8.36 (s; 1H), 8.08 (s; 1H), 7.96 (s; 1H), 7.73 (d; 1H; J=8.1 Hz), 7.63 (m; 3H), 7.50 (t; 1H; J=9.0 Hz), 4.44 (dd; 1H; J=10.8 Hz; J=3.0Hz), 4.32 (dd; 1H; J=10.8Hz; J=4.5Hz), 4.08 (m; 1H), 3.48 (m; 1H), 3.35 (m; 1H), 2.62 (s; 3H).

35

Example 291

(1S)-1-(4-Fluoro-3-trifluoromethyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine

MS (DCI/NH₃) m/e 445 (M+1)⁺; ¹H NMR (300 MHz, CD₃OD) δ = 8.70 (s; 1H), 8.09 (s; 1H), 8.04 (s; 1H), 7.74 (d; 1H; J=8.1 Hz), 7.68 (m; 1H), 7.62 (d; 1H; J=8.1 Hz), 7.36 (t; 1H; J=9.0 Hz), 4.44 (dd; 1H; J=10.8 Hz; J=3.0Hz), 4.28 (dd; 1H; J=10.8Hz; J=4.5Hz), 4.02 (m; 1H), 3.23 (m; 2H), 2.62 (s; 3H).

5

Example 292

(1S)-1-Furan-2-ylmethyl-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine

MS (DCI/NH₃) m/e 349 (M+1)⁺; ¹H NMR (300 MHz, CD₃OD) δ = 8.68 (s; 1H), 8.39 (s; 1H), 8.09 (m; 1H), 8.00 (s; 1H), 7.73 (d; 1H; J=9.0 Hz), 7.62 (d; 1H; J=9.0 Hz), 7.50 (s; 1H), 6.42 (m; 1H), 6.33 (m; 1H), 4.49 (dd; 1H; J=10.8 Hz; J=3.0Hz), 4.31 (dd; 1H; J=10.8Hz; J=4.5Hz), 4.02 (m; 1H), 3.24 (m; 2H), 2.62 (s; 3H).

15

Example 293

(1S)-1-Benzofuran-2-ylmethyl-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine

MS (DCI/NH₃) m/e 398 (M+1)⁺; ¹H NMR (300 MHz, CD₃OD) δ = 8.72 (s; 1H), 8.42 (s; 1H), 8.09 (m; 2H), 7.72 (d; 1H; J=9.0 Hz), 7.62 (d; 1H; J=9.0 Hz), 7.55 (d; 1H; J=8.4 Hz), 7.45 (d; 1H; J=8.4 Hz), 7.44 (m; 2H), 6.78 (s; 1H), 4.58 (dd; 1H; J=10.8 Hz; J=3.0Hz), 4.44 (dd; 1H; J=10.8Hz; J=4.5Hz), 4.18 (m; 1H), 3.41 (m; 2H), 2.62 (s; 3H).

20

Example 294

(1S)-1-(3-Fluoro-4-trifluoromethyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine

MS (DCI/NH₃) m/e 445 (M+1)⁺; ¹H NMR (300 MHz, CD₃OD) δ = 8.74 (s; 1H), 8.44 (s; 1H), 8.13 (m; 2H), 7.75 (d; 1H; J=8.1 Hz), 7.70 (t; 1H; J=8.4 Hz), 7.43 (d; 1H; J=8.4 Hz), 7.40 (d; 1H; J=12.0 Hz), 7.38 (d; 1H; J=8.1 Hz), 4.48 (dd; 1H; J=10.8 Hz; J=3.0Hz), 4.32 (dd; 1H; J=10.8Hz; J=4.5Hz), 4.08 (m; 1H), 3.28 (m; 2H), 2.62 (s; 3H).

30

Example 295

(1S)-1-(4-Chloro-3-methyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine

MS (DCI/NH₃) m/e 407 (M+1)⁺; ¹H NMR (300 MHz, CD₃OD) δ = 8.71 (s; 1H), 8.41 (s; 1H), 8.10 (s; 1H), 8.05 (s; 1H), 7.73 (d; 1H; J=8.4 Hz), 7.63 (d; 1H; J=8.4 Hz), 7.36 (d; 1H; J=8.4

Hz), 7.27 (s; 1H), 7.15 (d; 1H; J=8.4 Hz), 4.44 (dd; 1H; J=10.8 Hz; J=3.0Hz), 4.28 (dd; 1H; J=10.8Hz; J=4.5Hz), 3.96 (m; 1H), 3.11 (m;2H), 2.62 (s; 3H), 2.34 (s; 3H).

5

Example 296

(1S)-1-Furan-3-ylmethyl-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine
MS (DCI/NH₃) m/e 349 (M+1)⁺; ¹H NMR (300 MHz, CD₃OD) δ = 8.73 (s; 1H), 8.43 (s; 1H), 8.12 (m; 2H), 7.74 (d; 1H; J=8.4 Hz), 7.63 (d; 1H; J=8.4 Hz), 7.53 (m; 2H), 6.47 (m; 1H), 4.49 (dd; 1H; J=10.8 Hz; J=3.0Hz), 4.33 (dd; 1H; J=10.8Hz; J=4.5Hz), 3.91 (m; 1H), 3.00 (m;2H), 2.62 (s; 3H).

10

Example 297

(1S)-1-(2-Fluoro-5-methyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine

MS (DCI/NH₃) m/e 391 (M+1)⁺; ¹H NMR (300 MHz, CD₃OD) δ = 8.65 (s; 1H), 8.36 (s; 1H), 8.05 (s; 1H), 7.90 (s; 1H), 7.70 (d; 1H; J=8.4 Hz), 7.62 (d; 1H; J=8.4 Hz), 7.09 (s; 1H), 7.27 (d; 1H; J=8.1Hz) 7.18 (t; 1H; J=8.1 Hz), 4.39 (dd; 1H; J=10.8 Hz; J=3.0Hz), 4.25 (dd; 1H; J=10.8Hz; J=4.5Hz), 4.04 (m; 1H), 3.28 (m; 2H), 2.62 (s; 3H), 2.30 (s; 3H).

20

Example 298

(1S)-1-(3-Chloro-5-fluoro-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine

MS (DCI/NH₃) m/e 411 (M+1)⁺; ¹H NMR (300 MHz, CD₃OD) δ = 8.71 (s; 1H), 8.41 (s; 1H), 8.10 (s; 1H), 8.06 (s; 1H), 7.73 (d; 1H; J=8.4 Hz), 7.63 (d; 1H; J=8.4 Hz), 7.26 (s; 1H), 7.18 (d; 1H; J=8.4 Hz), 7.12 (d; 1H; J=8.4 Hz), 4.46 (dd; 1H; J=10.8 Hz; J=3.0Hz), 4.30 (dd; 1H; J=10.8Hz; J=4.5Hz), 4.02 (m; 1H), 3.18 (m; 2H), 2.62 (s; 3H).

30

Example 299

(1S)-2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(3,4,5-trifluoro-benzyl)-ethylamine
MS (DCI/NH₃) m/e 413 (M+1)⁺; ¹H NMR (300 MHz, CD₃OD) δ = 8.73 (s; 1H), 8.44 (s; 1H), 8.10 (m; 2H), 7.74 (d; 1H; J=8.4 Hz), 7.63 (d; 1H; J=8.4 Hz), 7.17 (t; 2H; J=9.0 Hz), 4.47 (dd; 1H; J=10.8 Hz; J=3.0Hz), 4.32 (dd; 1H; J=10.8Hz; J=4.5Hz), 4.00 (m; 1H), 3.15 (m;2H), 2.62 (s; 3H).

Example 300(1S)-1-(4-Fluoro-3-methyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine

5 MS (DCI/NH₃) m/e 391 (M+1)⁺; ¹H NMR (300 MHz, CD₃OD) δ = 8.73 (s; 1H), 8.42 (s; 1H), 8.12 (s; 1H), 8.08 (s; 1H), 7.73 (d; 1H; J=8.4 Hz), 7.62 (d; 1H; J=8.4 Hz), 7.18 (m; 2H), 7.03 (t; 1H; J=9.0 Hz), 4.44 (dd; 1H; J=10.8 Hz; J=3.0Hz), 4.28 (dd; 1H; J=10.8Hz; J=4.5Hz), 3.94 (m; 1H), 3.10 (m; 2H), 2.62 (s; 3H), 2.24 (s; 3H).


10

Example 301(1S)-1-(2,4-Dichloro-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine

15 MS (DCI/NH₃) m/e 428 (M+1)⁺; ¹H NMR (300 MHz, CD₃OD) δ = 8.69 (s; 1H), 8.40 (s; 1H), 8.10 (s; 1H), 8.00 (s; 1H), 7.73 (d; 1H; J=8.4 Hz), 7.62 (d; 1H; J=8.4 Hz), 7.56 (s; 1H), 7.41 (d; 1H; J=8.1 Hz), 7.36 (d; 1H; J=8.1), 4.43 (dd; 1H; J=10.8 Hz; J=3.0Hz), 4.28 (dd; 1H; J=10.8Hz; J=4.5Hz), 4.05 (m; 1H), 3.31 (m; 2H), 2.62 (s; 3H).

Example 302(1S)-1-(4-Chloro-3-trifluoromethyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine

20 MS (DCI/NH₃) m/e 461 (M+1)⁺; ¹H NMR (300 MHz, CD₃OD) δ = 8.69 (s; 1H), 8.39 (s; 1H), 8.08 (s; 1H), 8.00 (s; 1H), 7.79 (s; 1H), 7.72 (d; 1H; J=8.4 Hz), 7.62 (m; 3H), 4.44 (dd; 1H; J=10.8 Hz; J=3.0Hz), 4.28 (dd; 1H; J=10.8Hz; J=4.5Hz), 4.02 (m; 1H), 3.26 (m; 2H), 2.62 (s; 3H).



A-766820.6

Example 303(1S)-2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(2-trifluoromethoxy-benzyl)-ethylamine

30 MS (DCI/NH₃) m/e 443 (M+1)⁺; ¹H NMR (300 MHz, CD₃OD) δ = 8.70 (s; 1H), 8.39 (s; 1H), 8.09 (s; 1H), 8.01 (s; 1H), 7.73 (d; 1H; J=8.4 Hz), 7.63 (d; 1H; J=8.4 Hz), 7.42 (m; 4H), 4.40 (dd; 1H; J=10.8 Hz; J=3.0Hz), 4.24 (dd; 1H; J=10.8Hz; J=4.5Hz), 4.00 (m; 1H), 3.28 (m; 2H), 2.62 (s; 3H).

Example 304(1S)-1-(2,5-Dimethoxy-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine

5

MS (DCI/NH₃) m/e 419 (M+1)⁺; ¹H NMR (300 MHz, CD₃OD) δ = 8.71 (s; 1H), 8.40 (s; 1H), 8.10 (s; 1H), 8.04 (s; 1H), 7.73 (d; 1H; J=8.4 Hz), 7.63 (d; 1H; J=8.4 Hz), 6.95 (d; 1H; J=9.0 Hz), 6.85 (m; 2H), 4.43 (dd; 1H; J=10.8 Hz; J=3.0Hz), 4.27 (dd; 1H; J=10.8Hz; J=4.5Hz), 4.00 (m; 1H), 3.80 (s; 3H), 3.69 (s; 3H), 3.13 (m; 2H), 2.62 (s; 3H).

10

Example 305(1S)-2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(4-methylsulfanyl-benzyl)-ethylamine

15

MS (DCI/NH₃) m/e 405 (M+1)⁺; ¹H NMR (300 MHz, CD₃OD) δ = 8.73 (s; 1H), 8.62 (s; 1H), 8.12 (s; 1H), 8.08 (s; 1H), 7.73 (d; 1H; J=8.4 Hz), 7.63 (d; 1H; J=8.4 Hz), 7.28 (s; 4H), 4.44 (dd; 1H; J=10.8 Hz; J=3.0Hz), 4.29 (dd; 1H; J=10.8Hz; J=4.5Hz), 3.95 (m; 1H), 3.12 (m; 2H), 2.62 (s; 3H), 2.44 (s; 3H).

20

Example 306(1S)-1-(2-Cyclohexyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine

MS (DCI/NH₃) m/e 441 (M+1)⁺; ¹H NMR (300 MHz, CD₃OD) δ = 8.70 (s; 1H), 8.40 (s; 1H), 8.07 (s; 1H), 8.01 (s; 1H), 7.71 (d; 1H; J=8.4 Hz), 7.62 (d; 1H; J=8.4 Hz), 7.34 (d; 1H; J=7.8 Hz), 7.25 (m; 2H), 7.16 (t; 1H; J=7.8 Hz), 4.37 (dd; 1H; J=10.8 Hz; J=3.0Hz), 4.23 (dd; 1H; J=10.8Hz; J=4.5Hz), 3.38 (m; 1H), 3.27 (m; 2H), 2.77 (m; 1H), 2.62 (s; 3H), 1.85 (m; 1H), 1.74 (m; 4H), 1.48 (m; 3H), 1.29 (m, 2H).

25

Example 307

30

(1S)-1-(2,5-Dichloro-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine

MS (DCI/NH₃) m/e 428 (M+1)⁺; ¹H NMR (300 MHz, CD₃OD) δ = 8.71 (s; 1H), 8.41 (s; 1H), 8.10 (s; 1H), 8.04 (s; 1H), 7.73 (d; 1H; J=8.4 Hz), 7.63 (d; 1H; J=8.4 Hz), 7.48 (m; 2H), 7.36 (d; 1H; J=8.4 Hz), 4.44 (dd; 1H; J=10.8 Hz; J=3.0Hz), 4.28 (dd; 1H; J=10.8Hz; J=4.5Hz), 4.07 (m; 1H), 3.36 (m; 2H), 2.62 (s; 3H).

35

Example 308

(1S)-1-(2,5-Dimethyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine

MS (DCI/NH₃) m/e 387 (M+1)⁺; ¹H NMR (300 MHz, CD₃OD) δ = 8.74 (s; 1H), 8.2 (s; 1H), 8.11 (s; 1H), 8.08 (s; 1H), 7.73 (d; 1H; J=8.4 Hz), 7.63 (d; 1H; J=8.4 Hz), 7.11 (d; 1H; J=8.1 Hz), 7.03 (m; 2H), 4.41 (dd; 1H; J=10.8 Hz; J=3.0Hz), 4.28 (dd; 1H; J=10.8Hz; J=4.5Hz), 3.94 (m; 1H), 3.14 (m; 2H), 2.62 (s; 3H), 2.34 (s; 3H), 2.23 (s; 3H).

5

Example 309(1S)-1-(2,3-Dimethyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine

MS (DCI/NH₃) m/e 387 (M+1)⁺; ¹H NMR (300 MHz, CD₃OD) δ = 8.65 (s; 1H), 8.35 (s; 1H), 8.05 (s; 1H), 7.90 (s; 1H), 7.70 (d; 1H; J=8.4 Hz), 7.60 (d; 1H; J=8.4 Hz), 7.07 (m; 3H), 4.35 (dd; 1H; J=10.8 Hz; J=3.0Hz), 4.22 (dd; 1H; J=10.8Hz; J=4.5Hz), 3.88 (m; 1H), 3.21 (m; 2H), 2.62 (s; 3H), 2.31 (s; 3H), 2.28 (s; 3H).

15

Example 310(1S)-1-(3,4-Dichloro-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine

MS (DCI/NH₃) m/e 428 (M+1)⁺; ¹H NMR (300 MHz, CD₃OD) δ = 8.68 (s; 1H), 8.39 (s; 1H), 8.08 (s; 1H), 7.98 (s; 1H), 7.72 (d; 1H; J=8.4 Hz), 7.62 (d; 1H; J=8.4 Hz), 7.56 (s; 1H), 7.54 (d; 1H; J=8.4 Hz), 7.28 (d; 1H; J=8.4 Hz), 4.43 (dd; 1H; J=10.8 Hz; J=3.0Hz), 4.27 (dd; 1H; J=10.8Hz; J=4.5Hz), 3.99 (m; 1H), 3.16 (m; 2H), 2.62 (s; 3H).

20

Example 311(1S)-1-(2,4-Dimethyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine

MS (DCI/NH₃) m/e 387 (M+1)⁺; ¹H NMR (300 MHz, CD₃OD) δ = 8.68 (s; 1H), 8.37 (s; 1H), 8.08 (s; 1H), 7.96 (s; 1H), 7.71 (d; 1H; J=8.4 Hz), 7.61 (d; 1H; J=8.4 Hz), 7.10 (d; 1H; J=7.5 Hz), 7.06 (s; 1H), 6.98 (d; 1H; J=7.5 Hz), 4.37 (dd; 1H; J=10.8 Hz; J=3.0Hz), 4.24 (dd; 1H; J=10.8Hz; J=4.5Hz), 3.90 (m; 1H), 3.14 (m; 2H), 2.62 (s; 3H), 2.35 (s; 3H), 2.26 (s; 3H).

30

Example 312(1S)-1-(3-Fluoro-4-trifluoromethyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine

MS (DCI/NH₃) m/e 445 (M+1)⁺; ¹H NMR (300 MHz, CD₃OD) δ = 8.68 (s; 1H), 8.39 (s; 1H), 8.08 (s; 1H), 7.98 (s; 1H), 7.72 (d; 1H; J=8.4 Hz), 7.70 (d; 1H; J=8.4 Hz), 7.62 (d; 1H; J=8.4

Hz), 7.39 (d; 1H; J=12.0 Hz), 7.35 (d; 1H; J=8.4 Hz), 4.44 (dd; 1H; J=10.8 Hz; J=3.0Hz), 4.28 (dd; 1H; J=10.8Hz; J=4.5Hz), 4.05 (m; 1H), 3.28 (m;2H), 2.62 (s; 3H).

5

Example 313

(1S)-1-(3,5-Dimethyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine
MS (DCI/NH₃) m/e 387 (M+1)⁺; ¹H NMR (300 MHz, CD₃OD) δ = 8.68 (s; 1H), 8.38 (s; 1H), 8.08 (s; 1H), 7.97 (s; 1H), 7.71 (d; 1H; J=8.4 Hz), 6.94 (m; 3H), 4.41 (dd; 1H; J=10.8 Hz; J=3.0Hz), 4.25 (dd; 1H; J=10.8Hz; J=4.5Hz), 3.92 (m; 1H), 3.07 (m; 2H), 2.62 (s; 3H), 2.26 (s; 6H).

10

Example 314

(1S)-1-Biphenyl-2-ylmethyl-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine
MS (DCI/NH₃) m/e 435 (M+1)⁺; ¹H NMR (300 MHz, CD₃OD) δ = 8.64 (s; 1H), 8.11 (s; 1H), 8.05 (s; 1H), 7.70 (d; 1H; J=8.4 Hz), 7.68 (s; 1H), 7.63 (d; 1H; J=8.4 Hz), 7.34 (m; 9H), 4.12 (dd; 1H; J=10.8 Hz; J=3.0Hz), 3.89 (dd; 1H; J=10.8Hz; J=4.5Hz), 3.64 (m; 1H), 3.39 (dd; 1H; J=14.4 Hz; J=9.3 Hz), 3.16 (dd; 1H; J=14.4 Hz, J=4.5 Hz), 2.62 (s; 3H).

20

Example 315

(1S)-1-(3,4-Dimethyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine
MS (DCI/NH₃) m/e 387 (M+1)⁺; ¹H NMR (300 MHz, CD₃OD) δ = 8.69 (s; 1H), 8.38 (s; 1H), 8.08 (s; 1H), 7.99 (s; 1H), 7.72 (d; 1H; J=8.4 Hz), 7.62 (d; 1H; J=8.4 Hz), 7.08 (m; 3H), 4.41 (dd; 1H; J=10.8 Hz; J=3.0Hz), 4.26 (dd; 1H; J=10.8Hz; J=4.5Hz), 3.91 (m; 1H), 3.08 (m; 2H), 2.62 (s; 3H), 2.29 (s; 3H), 2.23 (s; 3H).

25

Example 316

(1S)-1-(2,3-Difluoro-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine
MS (DCI/NH₃) m/e 395 (M+1)⁺; ¹H NMR (300 MHz, CD₃OD) δ = 8.74(s; 1H), 8.44 (s; 1H), 8.12 (s; 2H), 7.74 (d; 1H; J=8.4 Hz), 7.62 (d; 1H; J=8.4 Hz), 7.19 (m; 3H), 4.48 (dd; 1H; J=10.8 Hz; J=3.0Hz), 4.32 (dd; 1H; J=10.8Hz; J=4.5Hz), 4.03 (m; 1H), 3.30 (m; 2H), 2.62 (s; 3H).

35

Example 317

(1S)-1-(2,5-Difluoro-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine
MS (DCI/NH₃) m/e 395 (M+1)⁺; ¹H NMR (300 MHz, CD₃OD) δ = 8.77 (s; 1H), 8.46 (s; 1H),
8.18 (s; 1H), 8.13 (s; 1H), 7.75 (d; 1H; J=8.4 Hz), 7.63 (d; 1H; J=8.4 Hz), 7.17 (m; 3H), 4.49
(dd; 1H; J=10.8 Hz; J=3.0Hz), 4.33 (dd; 1H; J=10.8Hz; J=4.5Hz), 4.02 (m; 1H), 3.12 (m;2H),
5 2.62 (s; 3H).

Example 318

(1S)-1-(2,6-Dichloro-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine
MS (DCI/NH₃) m/e 428 (M+1)⁺; ¹H NMR (300 MHz, CD₃OD) δ = 8.64 (s; 1H), 8.33 (s; 1H),
10 8.05 (s; 1H), 7.88 (s; 1H), 7.70 (d; 1H; J=8.4 Hz), 7.61 (d; 1H; J=8.4 Hz), 7.48 (d; 2H; J=7.2
Hz), 7.33 (t; 1H; J=7.2 Hz), 4.40 (dd; 1H; J=10.8 Hz; J=3.0Hz), 4.29 (dd; 1H; J=10.8Hz;
J=4.5Hz), 4.10 (m; 1H), 3.67 (dd; 1H; J=15.0 Hz; J=9.6 Hz), 3.43 (dd; 1H; J=15.0 Hz; J=5.4
Hz), 2.62 (s; 3H).

15

Example 319

(1S)-1-(2,4-Difluoro-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine
MS (DCI/NH₃) m/e 395 (M+1)⁺; ¹H NMR (300 MHz, CD₃OD) δ = 8.67 (s; 1H), 8.37 (s; 1H),
8.08 (s; 1H), 7.94 (s; 1H), 7.71 (d; 1H; J=8.4 Hz), 7.61 (d; 1H; J=8.4 Hz), 7.40(m; 1H), 7.01
20 (m; 2H), 4.43 (dd; 1H; J=10.8 Hz; J=3.0Hz), 4.27 (dd; 1H; J=10.8Hz; J=4.5Hz), 3.96 (m; 1H),
3.10 (m; 2H), 2.62 (s; 3H).

Example 320

(1S)-1-(2,6-Dimethyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine
MS (DCI/NH₃) m/e 387 (M+1)⁺; ¹H NMR (300 MHz, CD₃OD) δ = 8.62 (s; 1H), 8.32 (s; 1H),
8.03 (s; 1H), 7.83 (s; 1H), 7.69 (d; 1H; J=8.4 Hz), 7.60 (d; 1H; J=8.4 Hz), 7.70 (m; 3H), 4.29
(dd; 1H; J=10.8 Hz; J=3.0Hz), 4.16 (dd; 1H; J=10.8Hz; J=4.5Hz), 3.92 (m; 1H), 3.37 (dd;1H;
J=15.0 Hz; J=10.5 Hz), 3.15 (dd; 1H; J=15.0 Hz; J=5.4 Hz), 2.62 (s; 3H), 2.38 (s; 6H).

30

Example 321

(1S)-1-(2,3-Dihydro-benzo[1,4]dioxin-6-ylmethyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine

35 MS (DCI/NH₃) m/e 417 (M+1)⁺; ¹H NMR (300 MHz, CD₃OD) δ = 8.64 (s; 1H), 8.36 (s; 1H),
8.07 (s; 1H), 7.91 (s; 1H), 7.71 (d; 1H; J=8.4 Hz), 7.61 (d; 1H; J=8.4 Hz), 6.80(m; 3H), 4.40

(dd; 1H; $J=10.8$ Hz; $J=3.0$ Hz), 4.23 (dd; 1H; $J=10.8$ Hz; $J=4.5$ Hz), 4.20 (s; 4H), 3.88 (m; 1H), 3.03 (m; 2H), 2.62 (s; 3H).


5

Example 322

(1S)-1-(3,5-Difluoro-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine
 MS (DCI/NH₃) m/e 395 (M+1)⁺; ¹H NMR (300 MHz, CD₃OD) δ = 8.67 (s; 1H), 8.39 (s; 1H), 8.08 (s; 1H), 7.98 (s; 1H), 7.73 (d; 1H; $J=8.4$ Hz), 7.61 (d; 1H; $J=8.4$ Hz), 6.97 (m; 3H), 4.44 (dd; 1H; $J=10.8$ Hz; $J=3.0$ Hz), 4.29 (dd; 1H; $J=10.8$ Hz; $J=4.5$ Hz), 4.01 (m; 1H), 3.19 (m; 2H), 10 2.62 (s; 3H).

Example 323

(1S)-1-(2,6-Difluoro-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine
 MS (DCI/NH₃) m/e 395 (M+1)⁺; ¹H NMR (300 MHz, CD₃OD) δ = 8.41 (s; 1H), 8.31 (s; 1H), 8.04 (s; 1H), 7.84 (s; 1H), 7.70 (d; 1H; $J=8.4$ Hz), 7.60 (d; 1H; $J=8.4$ Hz), 7.40 (m; 1H), 7.06 (m; 2H), 4.42 (dd; 1H; $J=10.8$ Hz; $J=3.0$ Hz), 4.24 (dd; 1H; $J=10.8$ Hz; $J=4.5$ Hz), 3.97 (m; 1H), 3.31 (m; 2H), 2.62 (s; 3H).



20

Example 324

(1S)-1-Benzo[1,3]dioxol-5-ylmethyl-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine

MS (APCI) m/z 404 (M+1)⁺; ¹H NMR (500 MHz, CD₃OD) δ ppm 2.63 (s, 3H), 3.08 (dd, $J=7.64, 2.65$ Hz, 2H), 3.92 (m, 1H), 4.32 (dd, $J=10.45, 5.77$ Hz, 1H), 4.46 (dd, $J=10.61, 2.81$ Hz, 1H), 5.92 (d, $J=1.87$ Hz, 2H), 6.80 (d, $J=1.87$ Hz, 2H), 6.85 (s, 1H), 7.64 (d, $J=8.73$ Hz, 1H), 7.74 (dd, $J=8.73, 1.56$ Hz, 1H), 8.12 (s, 1H), 8.14 (d, $J=1.87$ Hz, 1H), 8.45 (d, $J=1.87$ Hz, 1H), 8.74 (s, 1H); Anal. Calcd for C₂₃H₂₂N₄O₃: C, 48.46; H, 3.55; N, 8.02. Found: C, 48.59; H, 3.65; N, 8.13.

30

Example 325

(1S)-1-(4-Fluoro-3-methyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine

MS (APCI) m/z 392 (M+1)⁺; ¹H NMR (500 MHz, CD₃OD) δ ppm 2.24 (s, 3H), 2.63 (s, 3H), 3.11 (dd, *J*=7.64, 3.90 Hz, 2H), 3.94 (m, 1H), 4.29 (dd, *J*=10.61, 5.62 Hz, 1H), 4.44 (dd, *J*=10.61, 2.81 Hz, 1H), 7.03 (m, 1H), 7.16 (m, 1H), 7.21 (d, *J*=7.18 Hz, 1H), 7.63 (d, *J*=8.73 Hz, 1H), 7.74 (d, *J*=1.87 Hz, 1H), 8.06 (s, 1H), 8.10 (s, 1H), 8.42 (s, 1H), 8.71 (s, 1H); Anal. Calcd for C₂₃H₂₃FN₄O: C, 50.79; H, 3.91; N, 8.58. Found: C, 51.10; H, 4.02; N, 8.43.

Example 326

10 (1S)-2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(2,4,6-trimethyl-benzyl)-ethylamine

MS (APCI) m/z 402 (M+1)⁺; ¹H NMR (500 MHz, CD₃OD) δ ppm 2.21 (s, 3H), 2.34 (s, 6H), 2.62 (s, 3H), 3.14 (dd, *J*=14.19, 5.46 Hz, 2H), 3.92 (m, *J*=8.73, 4.99 Hz, 1H), 4.26 (dd, *J*=10.45, 4.84 Hz, 1H), 4.36 (m, 1H), 6.89 (s, 2H), 7.63 (d, *J*=8.74 Hz, 1H), 7.72 (dd, *J*=8.73, 1.56 Hz, 1H), 8.11 (s, 2H), 8.42 (s, 1H), 8.75 (s, 1H); Anal. Calcd for C₂₅H₂₈N₄O: C, 52.56; H, 4.48; N, 8.17. Found: C, 52.49; H, 4.41; N, 8.06.

Example 327

20 (1S)-1-(2,4-Dimethoxy-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine

MS (APCI) m/z 419 (M+1)⁺; ¹H NMR (500 MHz, CD₃OD) δ ppm 2.63 (s, 3H), 3.08 (dd, *J*=7.33, 2.96 Hz, 2H), 3.77 (s, 3H), 3.83 (s, 3H), 3.94 (m, 1H), 4.26 (dd, *J*=10.45, 5.77 Hz, 1H), 4.41 (dd, *J*=10.61, 3.12 Hz, 1H), 6.50 (dd, *J*=8.27, 2.34 Hz, 1H), 6.59 (d, *J*=2.50 Hz, 1H), 7.12 (d, *J*=8.42 Hz, 1H), 7.63 (d, *J*=8.73 Hz, 1H), 7.72 (m, 1H), 8.00 (s, 1H), 8.09 (s, 1H), 8.40 (s, 1H), 8.71 (s, 1H).

Example 328

(1S)-2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(4-trifluoromethyl-benzyl)-ethylamine

30 MS (APCI) m/z 428 (M+1)⁺; ¹H NMR (500 MHz, CD₃OD) δ ppm 2.63 (s, 3H), 3.28 (m, 2H), 4.05 (m, 1H), 4.32 (dd, *J*=10.61, 5.30 Hz, 1H), 4.47 (dd, *J*=10.61, 2.81 Hz, 1H), 7.56 (d, *J*=7.80 Hz, 2H), 7.63 (d, *J*=8.74 Hz, 1H), 7.69 (d, *J*=8.11 Hz, 2H), 7.74 (dd, *J*=8.74, 1.56 Hz, 1H), 8.12 (d, *J*=6.55 Hz, 2H), 8.45 (br s, 1H), 8.74 (br s, 1H); Anal. Calcd for C₂₃H₂₁F₃N₄O: C, 46.45; H, 3.25; N, 7.63. Found: C, 46.55; H, 3.30; N, 7.64.

35

Example 329

(1S)-1-(5-Fluoro-2-methyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine

MS (APCI) m/z 391 (M+1)⁺; ¹H NMR (500 MHz, CD₃OD) δ ppm 2.36 (s, 3H), 2.62 (s, 3H), 3.16 (dd, *J*=14.19, 6.71 Hz, 1H), 3.23 (m, 1H), 3.97 (m, 1H), 4.29 (dd, *J*=10.45, 4.84 Hz, 1H), 4.42 (dd, *J*=10.61, 3.12 Hz, 1H), 6.95 (td, *J*=8.42, 2.81 Hz, 1H), 7.04 (dd, *J*=9.67, 2.81 Hz, 1H), 7.25 (dd, *J*=8.42, 5.93 Hz, 1H), 7.63 (d, *J*=8.74 Hz, 1H), 7.73 (dd, *J*=8.73, 1.56 Hz, 1H), 8.05 (s, 1H), 8.09 (s, 1H), 8.42 (s, 1H), 8.71 (s, 1H); Anal. Calcd for C₂₃H₂₃FNO: C, 49.31; H, 3.76; N, 8.16. Found: C, 49.28; H, 3.61; N, 8.10.

10 Example 330

(1S)-1-(3,5-Bis-trifluoromethyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine

MS (APCI) m/z 495 (M+1)⁺; ¹H NMR (500 MHz, CD₃OD) δ ppm 2.62 (s, 3H), 3.35 (m, 1H), 3.42 (m, 1H), 4.12 (m, 1H), 4.31 (dd, *J*=10.61, 5.30 Hz, 1H), 4.49 (dd, *J*=10.61, 3.12 Hz, 1H), 7.63 (d, *J*=8.73 Hz, 1H), 7.73 (dd, *J*=8.74, 1.87 Hz, 1H), 7.94 (s, 1H), 8.01 (s, 2H), 8.05 (s, 1H), 8.08 (s, 1H), 8.43 (s, 1H), 8.72 (s, 1H); Anal. Calcd for C₂₄H₂₀F₆N₂O: C, 43.69; H, 2.82; N, 6.89. Found: C, 43.70; H, 2.65; N, 6.82.

20 Example 331

(1S)-1-(4-Fluoro-2-methyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine

MS (APCI) m/z 392 (M+1)⁺; ¹H NMR (500 MHz, CD₃OD) δ ppm 2.40 (s, 3H), 2.62 (s, 3H), 3.15 (dd, *J*=14.19, 6.40 Hz, 1H), 3.22 (m, 1H), 3.94 (m, 1H), 4.29 (dd, *J*=10.61, 4.99 Hz, 1H), 4.42 (dd, *J*=10.61, 2.81 Hz, 1H), 6.91 (td, *J*=8.42, 2.50 Hz, 1H), 7.00 (dd, *J*=9.83, 2.34 Hz, 1H), 7.26 (dd, *J*=8.42, 5.93 Hz, 1H), 7.63 (d, *J*=8.74 Hz, 1H), 7.73 (dd, *J*=8.74, 1.25 Hz, 1H), 8.08 (s, 1H), 8.10 (s, 1H), 8.43 (s, 1H), 8.72 (s, 1H); Anal. Calcd for C₂₃H₂₃FNO: C, 48.40; H, 3.66; N, 7.89. Found: C, 48.59; H, 3.85; N, 7.90.

25 Example 332

(1S)-1-(5-Fluoro-2-methoxy-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine

MS (APCI) m/z 408 (M+1)⁺; ¹H NMR (500 MHz, CD₃OD) δ ppm 2.63 (s, 3H), 3.16 (d, *J*=7.18 Hz, 2H), 3.84 (s, 3H), 4.02 (m, 1H), 4.30 (dd, *J*=10.61, 5.93 Hz, 1H), 4.45 (dd, *J*=10.45, 2.96 Hz, 1H), 7.04 (m, 3H), 7.64 (d, *J*=8.73 Hz, 1H), 7.74 (d, *J*=8.74 Hz, 1H), 8.12 (s, 2H), 8.43 (s, 1H), 8.74 (s, 1H); Anal. Calcd for C₂₃H₂₃FN₄O₂: C, 44.73; H, 3.32; N, 6.96. Found: C, 44.77; H, 3.46; N, 6.83.

Example 333(1S)-2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(2-methyl-naphthalen-1-ylmethyl)-ethylamine

MS (APCI) m/z 424 (M+1)⁺; ¹H NMR (500 MHz, CD₃OD) δ ppm 2.58 (s, 3H), 2.61 (s, 3H), 3.61 (dd, *J*=14.19, 4.84 Hz, 1H), 3.84 (dd, *J*=14.19, 10.76 Hz, 1H), 4.06 (m, *J*=9.20, 4.21 Hz, 1H), 4.14 (dd, *J*=10.29, 3.74 Hz, 1H), 4.28 (dd, *J*=10.45, 2.65 Hz, 1H), 7.41 (m, 3H), 7.60 (d, *J*=8.42 Hz, 1H), 7.65 (m, 1H), 7.75 (d, *J*=8.42 Hz, 1H), 7.84 (m, 2H), 8.01 (s, 1H), 8.12 (d, *J*=8.11 Hz, 1H), 8.33 (s, 1H), 8.66 (s, 1H); Anal. Calcd for C₂₇H₂₈N₄O: C, 52.30; H, 3.87; N, 7.44. Found: C, 52.56; H, 4.00; N, 7.38.

10

Example 334(1S)-1-(2,2-Difluoro-benzo[1,3]dioxol-4-ylmethyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine

MS (APCI) m/z 437 (M-1)⁺; ¹H NMR (500 MHz, CD₃OD) δ ppm 2.63 (s, 3H), 3.28 (m, 2H), 4.07 (m, 1H), 4.34 (dd, *J*=10.61, 4.99 Hz, 1H), 4.51 (dd, *J*=10.61, 2.81 Hz, 1H), 7.17 (m, 3H), 7.64 (d, *J*=8.73 Hz, 1H), 7.75 (d, *J*=8.73 Hz, 1H), 8.12 (s, 1H), 8.16 (s, 1H), 8.46 (s, 1H), 8.76 (s, 1H); Anal. Calcd for C₂₃H₂₀F₂N₄O₃: C, 44.63; H, 2.97; N, 7.18. Found: C, 44.74; H, 3.08; N, 7.23.

20

Example 335(1S)-1-(4-Fluoro-naphthalen-1-ylmethyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine

MS (APCI) m/z 428 (M+1)⁺; ¹H NMR (500 MHz, CD₃OD) δ ppm 2.62 (s, 3H), 3.60 (dd, *J*=14.04, 6.55 Hz, 1H), 3.66 (m, 1H), 4.09 (m, 1H), 4.29 (dd, *J*=10.61, 4.99 Hz, 1H), 4.42 (dd, *J*=10.61, 3.12 Hz, 1H), 7.19 (dd, *J*=10.29, 7.80 Hz, 1H), 7.47 (dd, *J*=7.80, 5.30 Hz, 1H), 7.61 (d, *J*=8.73 Hz, 2H), 7.64 (d, *J*=7.18 Hz, 1H), 7.68 (t, *J*=8.11 Hz, 1H), 7.96 (s, 1H), 8.05 (s, 1H), 8.15 (d, *J*=8.11 Hz, 1H), 8.18 (d, *J*=8.42 Hz, 1H), 8.38 (s, 1H), 8.68 (s, 1H).

Example 336(1S)-2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(2,2,3,3-tetrafluoro-2,3-dihydro-benzo[1,4]dioxin-6-ylmethyl)-ethylamine

MS (APCI) m/z 487 (M-1)⁺; ¹H NMR (500 MHz, CD₃OD) δ ppm 2.63 (s, 3H), 3.18 (dd, *J*=14.19, 7.02 Hz, 1H), 3.24 (m, 1H), 4.02 (m, *J*=5.15, 2.65 Hz, 1H), 4.33 (dd, *J*=10.45, 5.46 Hz, 1H), 4.47 (dd, *J*=10.61, 3.12 Hz, 1H), 7.29 (m, 2H), 7.34 (s, 1H), 7.63 (d, *J*=8.73 Hz, 1H), 7.74 (dd, *J*=8.74, 1.25 Hz, 1H), 8.11 (s, 2H), 8.44 (s, 1H), 8.72 (s, 1H); Anal. Calcd for C₂₃H₂₀F₂N₄O₃: C, 43.08; H, 2.77; N, 6.65. Found: C, 42.94; H, 2.79; N, 6.64.

Example 337(1S)-2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(4-methyl-naphthalen-1-ylmethyl)-ethylamine

MS (APCI) m/z 421 (M-1)⁺; ¹H NMR (500 MHz, CD₃OD) δ ppm 2.61 (d, *J*=8.11 Hz, 3H), 2.67 (s, 3H), 3.62 (m, 2H), 4.09 (m, 1H), 4.28 (dd, *J*=10.61, 4.99 Hz, 1H), 4.40 (dd, *J*=10.61, 3.12 Hz, 1H), 7.32 (d, *J*=7.49 Hz, 1H), 7.38 (m, 1H), 7.58 (m, 2H), 7.62 (d, *J*=8.73 Hz, 1H), 7.68 (m, 1H), 7.97 (s, 1H), 8.06 (s, 1H), 8.10 (m, 1H), 8.15 (m, 1H), 8.37 (d, *J*=2.50 Hz, 1H), 8.68 (s, 1H); Anal. Calcd for C₂₇H₂₆N₄O: C, 52.79; H, 3.91; N, 7.55. Found: C, 52.64; H, 3.85; N, 7.53.

10

Example 338(1S)-2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(2,4,6-trifluoro-benzyl)-ethylamine

MS (APCI) m/z 411 (M-1)⁺; ¹H NMR (500 MHz, CD₃OD) δ ppm 2.63 (s, 3H), 3.19 (m, 2H), 3.97 (m, 1H), 4.32 (dd, *J*=10.61, 4.99 Hz, 1H), 4.49 (dd, *J*=10.61, 3.12 Hz, 1H), 6.95 (t, *J*=8.27 Hz, 2H), 7.63 (d, *J*=8.73 Hz, 1H), 7.74 (dd, *J*=8.74, 1.56 Hz, 1H), 8.08 (d, *J*=2.18 Hz, 1H), 8.10 (s, 1H), 8.41 (s, 1H), 8.72 (s, 1H); Anal. Calcd for C₂₂H₁₉F₃N₄O: C, 44.57; H, 2.94; N, 7.43. Found: C, 44.47; H, 2.78; N, 7.46.

Example 339(1S)-2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(2,3,4-trifluoro-benzyl)-ethylamine

¹H NMR (500 MHz, CD₃OD) δ ppm 2.62 (s, 3H), 3.23 (m, 2H), 4.00 (m, 1H), 4.31 (dd, *J*=10.61, 5.30 Hz, 1H), 4.46 (dd, *J*=10.61, 3.12 Hz, 1H), 7.17 (m, 2H), 7.62 (d, *J*=8.73 Hz, 1H), 7.73 (dd, *J*=8.74, 1.56 Hz, 1H), 8.02 (s, 1H), 8.08 (s, 1H), 8.40 (s, 1H), 8.69 (s, 1H); Anal. Calcd for C₂₂H₁₉F₃N₄O: C, 45.31; H, 3.00; N, 7.66. Found: C, 45.59; H, 2.73; N,

25 7.84.

Example 340(1S)-1-(4-Bromo-2-fluoro-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine

¹H NMR (500 MHz, CD₃OD) δ ppm 2.63 (s, 3H), 3.22 (m, 2H), 4.00 (m, 1H), 4.34 (dd, *J*=10.61, 5.30 Hz, 1H), 4.49 (dd, *J*=10.61, 3.12 Hz, 1H), 7.33 (t, *J*=8.11 Hz, 1H), 7.37 (d, *J*=1.56 Hz, 1H), 7.41 (m, 1H), 7.64 (d, *J*=8.73 Hz, 1H), 7.75 (dd, *J*=8.74, 1.56 Hz, 1H), 8.13 (s, 1H), 8.19 (s, 1H), 8.46 (s, 1H), 8.77 (s, 1H); Anal. Calcd for C₂₂H₂₀BrFN₄O: C, 42.80; H, 2.97; N, 7.23. Found: C, 42.73; H, 3.17; N, 7.02.

35

Example 341

(1S)-1-(4-Bromo-3-fluoro-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine

MS (ESI) m/z 456 (M+1)[†]; ¹H NMR (500 MHz, CD₃OD) δ ppm 2.63 (s, 3H), 3.18 (m, 2H), 4.01 (m, 1H), 4.32 (dd, *J*=10.61, 5.62 Hz, 1H), 4.46 (dd, *J*=10.61, 2.81 Hz, 1H), 7.11 (dd, *J*=8.11, 1.56 Hz, 1H), 7.26 (dd, *J*=9.36, 1.87 Hz, 1H), 7.62 (d, *J*=7.18 Hz, 1H), 7.63 (d, *J*=8.42 Hz, 1H), 7.74 (dd, *J*=8.73, 1.56 Hz, 1H), 8.10 (d, *J*=4.06 Hz, 2H), 8.43 (s, 1H), 8.72 (s, 1H); Anal. Calcd for C₂₂H₂₀BrFN₄O: C, 43.46; H, 3.03; N, 7.45. Found: C, 43.52; H, 3.07; N, 7.43.

10 Example 342

(1S)-1-(2-Bromo-4,6-difluoro-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine

¹H NMR (500 MHz, CD₃OD) δ ppm 2.63 (s, 3H), 3.32 (m, 1H), 3.48 (m, 1H), 4.03 (m, 1H), 4.34 (dd, *J*=10.45, 4.84 Hz, 1H), 4.48 (dd, *J*=10.61, 3.43 Hz, 1H), 7.13 (t, *J*=8.11 Hz, 1H), 7.40 (d, *J*=8.11 Hz, 1H), 7.63 (d, *J*=8.73 Hz, 1H), 7.74 (dd, *J*=8.73, 1.56 Hz, 1H), 8.09 (s, 1H), 8.11 (s, 1H), 8.42 (s, 1H), 8.73 (s, 1H); Anal. Calcd for C₂₂H₁₉BrF₂N₄O: C, 41.24; H, 2.72; N, 6.87. Found: C, 41.35; H, 2.68; N, 6.76.

20 Example 343

(1S)-1-(4-Bromo-3-methyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine

MS (ESI) m/z 452 (M+1)[†]; ¹H NMR (500 MHz, CD₃OD) δ ppm 2.37 (s, 3H), 2.63 (s, 3H), 3.11 (m, 2H), 3.97 (m, 1H), 4.29 (dd, *J*=10.61, 5.62 Hz, 1H), 4.44 (dd, *J*=10.61, 3.12 Hz, 1H), 7.07 (dd, *J*=8.11, 1.87 Hz, 1H), 7.27 (s, 1H), 7.54 (d, *J*=8.11 Hz, 1H), 7.63 (d, *J*=8.73 Hz, 1H), 7.73 (d, *J*=8.73 Hz, 1H), 8.06 (s, 1H), 8.10 (s, 1H), 8.41 (s, 1H), 8.71 (s, 1H); Anal. Calcd for C₂₃H₂₃BrN₄O: C, 44.93; H, 3.41; N, 7.38. Found: C, 45.11; H, 3.36; N, 7.28.

30 Example 344

(1S)-Bromo-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine

¹H NMR (500 MHz, CD₃OD) δ ppm 2.62 (s, 3H), 3.37 (m, 2H), 4.10 (m, 1H), 4.30 (dd, *J*=10.61, 4.99 Hz, 1H), 4.43 (dd, *J*=10.61, 3.12 Hz, 1H), 7.25 (t, *J*=6.71 Hz, 1H), 7.37 (t, *J*=6.86 Hz, 1H), 7.42 (m, 1H), 7.63 (d, *J*=8.74 Hz, 1H), 7.66 (d, *J*=8.11 Hz, 1H), 7.73 (dd, *J*=8.73, 1.56 Hz, 1H), 8.03 (d, *J*=1.87 Hz, 1H), 8.09 (s, 1H), 8.40 (s, 1H), 8.70 (s, 1H); Anal. Calcd for C₂₂H₂₁BrN₄O: C, 43.48; H, 3.14; N, 7.30. Found: C, 43.67; H, 3.06; N, 7.10.

Example 345(1S)-1-(3-Methoxy-benzyl)-2-[5-(3-methyl-1*H*-indazol-5-yl)-pyridin-3-yloxy]-ethylamine

MS *m/z* 389 (M + H)⁺; ¹H NMR (300 MHz, DMSO-D6) δ ppm 2.57 (s, 3 H) 3.00 (dd, *J*=13.56, 9.16 Hz, 1 H) 3.12 (m, 1 H) 3.73 (s, 3 H) 4.28 (dd, *J*=10.85, 5.43 Hz, 1 H) 4.44 (m, 2 H) 6.85 (dd, *J*=8.48, 2.37 Hz, 1 H) 6.91 (m, 2 H) 7.27 (t, *J*=7.80 Hz, 1 H) 7.61 (d, *J*=8.82 Hz, 1 H) 7.79 (dd, *J*=8.82, 1.70 Hz, 1 H) 8.23 (s, 1 H) 8.26 (s, 1 H) 8.53 (d, *J*=2.37 Hz, 4 H) 8.86 (s, 1 H).

10

Example 346(1S)-1-(3-Bromo-benzyl)-2-[5-(3-methyl-1*H*-indazol-5-yl)-pyridin-3-yloxy]-ethylamine

MS *m/z* 437, 439 (M + H)⁺; ¹H NMR (300 MHz, DMSO-D6) δ ppm 2.57 (s, 3 H) 3.08 (m, 2 H) 4.27 (dd, *J*=10.85, 5.43 Hz, 1 H) 4.43 (m, 1 H) 7.34 (m, 2 H) 7.49 (dt, *J*=7.54, 1.65 Hz, 1 H) 7.61 (m, 2 H) 7.77 (dd, *J*=8.65, 1.53 Hz, 1 H) 8.14 (s, 1 H) 8.22 (s, 1 H) 8.49 (s, 2 H) 8.82 (s, 1 H).

15

Example 347(1S)-1-(2-Methoxy-naphthalen-1-ylmethyl)-2-[5-(3-methyl-1*H*-indazol-5-yl)-pyridin-3-yloxy]-ethylamine

MS (ESI) m/e 439 (M+1)⁺; ¹H NMR (300 MHz, Solvent) δ ppm 2.62 (s, 3 H) 3.55 (m, 1 H) 3.74 (m, 1 H) 3.97 (s, 3 H) 4.03 (m, 1 H) 4.23 (m, 1 H) 4.39 (m, 1 H) 7.33 (m, 1 H) 7.46 (m, 2 H) 7.64 (m, 2 H) 7.84 (m, 1 H) 7.92 (m, 2 H) 8.03 (m, 2 H) 8.34 (br. s., 1 H) 8.67 (br. s., 1 H).

25

Example 348(1R)-1-(4-Chloro-benzyl)-2-[5-(3-methyl-1*H*-indazol-5-yl)-pyridin-3-yloxy]-ethylamine

30

Example 348A5-[5-((2*R*)-1-*tert*-Butoxycarbonyl-aziridin-2-ylmethoxy)-pyridin-3-yl]-3-methyl-indazole-1-carboxylic acid *tert*-butyl ester

35

The desired product was prepared by substituting (*S*)-[1-(*tert*-Butyl-dimethyl-silanyloxymethyl)-2-hydroxy-ethyl]-carbamic acid *tert*-butyl ester for (*R*)-[1-(*tert*-Butyl-dimethyl-silanyloxymethyl)-2-hydroxy-ethyl]-carbamic acid *tert*-butyl ester in Example 273D. MS (APCI) *m/z* 481 (M+1)⁺.

Example 348B

(1R)-1-(4-Chloro-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine

The desired product was prepared as the trifluoroacetate by substituting Example 348A for Example 273D and 4-chlorophenylmagnesium bromide for 3-trifluoromethoxyphenylmangnesium bromide in Example 274. MS (APCI) m/z 393 (M+1)⁺; ¹H NMR (300 MHz,

5 CD₃OD) δ 2.63 (s, 3 H), 3.16 (dd, *J*=7.63, 2.54 Hz, 2 H), 3.98 (m, 1 H), 4.30 (dd, *J*=10.51, 5.42 Hz, 1 H), 4.45 (dd, *J*=10.51, 3.05 Hz, 1 H), 7.34 (d, *J*=8.81 Hz, 2 H), 7.39 (d, *J*=8.81 Hz, 2 H), 7.63 (d, *J*=8.81 Hz, 1 H), 7.74 (dd, *J*=8.81, 1.70 Hz, 1 H), 8.11 (m, 2 H), 8.43 (d, *J*=2.03 Hz, 1 H), 8.73 (s, 1 H); Anal. Calcd for C₂₂H₂₁ClN₄O•3 TFA: C, 45.76; H, 3.29; N, 7.62. Found: C, 45.86; H, 3.28; N, 7.72.

10

The following compounds were prepared by substituting appropriate Girgnard reagents for 3-trifluoromethoxyphenyl-mangnesium bromide in Example 348.

) Example 349(1R)-1-Benzo[1,3]dioxol-5-ylmethyl-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine

MS (APCI) m/z 403 (M+1)⁺; ¹H NMR (300 MHz, CD₃OD) δ 2.63 (s, 3 H), 3.08 (dd, *J*=8.14, 2.03 Hz, 2 H), 3.92 (m, 1 H), 4.31 (dd, *J*=10.51, 5.76 Hz, 1 H), 4.46 (dd, *J*=10.51, 3.05 Hz, 1 H), 5.92 (s, 2 H), 6.79 (d, *J*=8.14 Hz, 1 H), 6.81 (d, *J*=8.14 Hz, 1 H), 6.85 (s, 1 H), 7.64 (d, *J*=8.81 Hz, 1 H), 7.75 (d, *J*=8.81 Hz, 1 H), 8.14 (m, 2 H), 8.44 (d, *J*=2.37 Hz, 1 H), 8.75 (d, *J*=1.70 Hz, 1 H); Anal. Calcd for C₂₃H₂₂N₄O₃•3.3 TFA: C, 45.65; H, 3.27; N, 7.19. Found: C, 45.71; H, 3.15; N, 7.21.

Example 350(1R)-1-(3-Fluoro-4-methyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine

MS (APCI) m/z 391 (M+1)⁺; ¹H NMR (300 MHz, CD₃OD) δ 2.24 (d, *J*=1.70 Hz, 3 H), 2.63 (s, 3 H), 3.11 (d, *J*=8.14 Hz, 2 H), 3.96 (m, 1 H), 4.31 (dd, *J*=10.51, 5.76 Hz, 1 H), 4.46 (dd, *J*=10.85, 3.05 Hz, 1 H), 7.03 (t, *J*=8.48 Hz, 1 H), 7.15 (m, 1 H), 7.21 (d, *J*=7.46 Hz, 1 H), 7.64 (d, *J*=8.48 Hz, 1 H), 7.74 (dd, *J*=8.81, 1.70 Hz, 1 H), 8.14 (m, 2 H), 8.45 (d, *J*=2.37 Hz, 1 H), 8.75 (d, *J*=1.36 Hz, 1 H); Anal. Calcd for C₂₃H₂₃FN₄O•2.9 TFA: C, 47.97; H, 3.62; N, 7.77. Found: C, 48.09; H, 3.75; N, 7.87.

Example 351(1S)-1-Benzyl-2-[6-chloro-5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamineExample 351A

5-(2-Chloro-5-hydroxy-pyridin-3-yl)-3-methyl-indazole-1-carboxylic acid tert-butyl ester

A 250 mL RBF was charged with Example 12B (1.58 g, 7.59 mmol), Example 203B (3.0 g, 7.59 mmol), $\text{Pd}_2(\text{dba})_3$ (696 mg, 0.76 mmol), and tri-*o*-tolylphosphine (696 mg), and was purged with N_2 . Anhydrous DMF (60 mL) and Et_3N (3.17 mL) were added via syringe. The 5 solution was purged with N_2 again and was heated at 70 °C for 15 h. After cooled, ethyl acetate (300 mL) was added. The mixture was washed with brine (500 mL) and water (500 mL). The ethyl acetate solution was concentrated and the residual oil was separated by flash chromatography (40-65% EtOAc in hexane) to give the desired product. (1.86 g, 68%). MS (APCI) m/z 360 (M+1)⁺.

10

Example 351B5-[5-((2*S*)-2-tert-Butoxycarbonylamino-3-phenyl-propoxy)-2-chloro-pyridin-3-yl]-3-methyl-indazole-1-carboxylic acid tert-butyl ester

A 25 mL RBF was charged with Example 351A (150 mg, 0.417 mmol), Boc-phenylalaninol 15 (157 mg, 0.625 mmol), DBAD (144 mg, 0.625 mmol) and Ph_3P (163 mg, 0.625 mmol), and was purged with nitrogen. THF (8 mL) was added at 0 °C. After stirring at 0 °C for 30 min the ice-H₂O bath was removed and the reaction mixture was stirred at rt overnight. The reaction mixture was concentrated and the residue was separated by flash chromatography (20-40% EtOAc in hexane) to provide the desired product (215.0 mg, 87%). MS (APCI) m/z 20 593 (M+1)⁺.

Example 351C(1*S*)-1-Benzyl-2-[6-chloro-5-(3-methyl-1*H*-indazol-5-yl)-pyridin-3-yloxy]-ethylamine

The desired product was prepared as the trifluoroacetate by substituting Example 351B for Example 27B in Examples 27C. MS (APCI) m/z 393 (M+1)⁺; ¹H NMR (300 MHz, CD₃OD) δ 2.58 (s, 3 H), 3.12 (d, *J*=7.46 Hz, 2 H), 3.91 (m, 1 H), 4.14 (dd, *J*=10.51, 5.43 Hz, 1 H), 4.30 (dd, *J*=10.51, 3.05 Hz, 1 H), 7.34 (m, 5 H), 7.47 (dd, *J*=8.65, 1.53 Hz, 1 H), 7.52 (d, *J*=3.05 Hz, 1 H), 7.56 (d, *J*=8.82 Hz, 1 H), 7.78 (s, 1 H), 8.14 (d, *J*=2.71 Hz, 1 H); Anal. Calcd for C₂₂H₂₁ClN₄O•1.6 TFA: C, 52.61; H, 3.96; N, 9.74. Found: C, 52.87; H, 3.90; N, 30 9.81.

The following compounds were prepared by substituting the appropriate Boc-aminoalcohol for Boc-phenylalaninol in Example 351.

Example 352(1*S*)-1-(4-Bromo-benzyl)-2-[6-chloro-5-(3-methyl-1*H*-indazol-5-yl)-pyridin-3-yloxy]-ethylamine

MS (APCI) m/z 471, 473 (M+1)⁺; ¹H NMR (300 MHz, CD₃OD) δ 2.59 (s, 3 H), 3.10 (dd, J=7.63, 2.88 Hz, 2 H), 3.90 (m, 1 H), 4.15 (dd, J=10.85, 5.43 Hz, 1 H), 4.30 (dd, J=10.51, 3.05 Hz, 1 H), 7.24 (d, J=8.48 Hz, 2 H), 7.47 (dd, J=8.65, 1.53 Hz, 1 H), 7.51 (s, 1 H), 7.54 (s, 1 H), 7.56 (d, J=8.48 Hz, 2 H), 7.79 (s, 1 H), 8.15 (d, J=3.05 Hz, 1 H); Anal. Calcd for C₂₂H₂₀BrClN₄O•1.5 TFA: C, 46.71; H, 3.37; N, 8.72. Found: C, 46.62; H, 3.29; N, 8.64.

Example 353

(1S)-1-(4-Chloro-benzyl)-2-[6-chloro-5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine

MS (APCI) m/z 427 (M+1)⁺; ¹H NMR (300 MHz, CD₃OD) δ 2.59 (s, 3 H), 3.12 (dd, J=7.63, 2.54 Hz, 2 H), 3.91 (m, 1 H), 4.15 (dd, J=10.51, 5.43 Hz, 1 H), 4.30 (dd, J=10.51, 3.05 Hz, 1 H), 7.30 (d, J=8.48 Hz, 2 H), 7.37 (d, J=8.82 Hz, 2 H), 7.47 (dd, J=8.65, 1.53 Hz, 1 H), 7.53 (d, J=3.05 Hz, 1 H), 7.56 (d, J=8.48 Hz, 1 H), 7.79 (s, 1 H), 8.15 (d, J=3.05 Hz, 1 H); Anal. Calcd for C₂₂H₂₀Cl₂N₄O•1.6 TFA: C, 49.64; H, 3.57; N, 9.19. Found: C, 49.99; H, 3.56; N, 9.22.

Example 354

(1S)-2-[6-Chloro-5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-cyclohexylmethyl-ethylamine

MS (APCI) m/z 399 (M+1)⁺; ¹H NMR (300 MHz, CD₃OD) δ 1.01 (m, 2 H), 1.31 (m, 4 H), 1.49 (m, 1 H), 1.65 (q, J=6.89 Hz, 2 H), 1.78 (m, 4 H), 2.59 (s, 3 H), 3.74 (m, 1 H), 4.18 (dd, J=10.51, 6.44 Hz, 1 H), 4.37 (dd, J=10.51, 3.39 Hz, 1 H), 7.49 (dd, J=8.82, 1.70 Hz, 1 H), 7.56 (dd, J=8.48, 0.68 Hz, 1 H), 7.59 (d, J=3.05 Hz, 1 H), 7.80 (s, 1 H), 8.17 (d, J=3.05 Hz, 1 H); Anal. Calcd for C₂₂H₂₇ClN₄O•1.75 TFA: C, 51.18; H, 4.84; N, 9.36. Found: C, 51.13; H, 4.75; N, 9.20.

Example 355

(1S)-2-[6-Chloro-5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(2,6-dimethyl-benzyl)-ethylamine

MS (DCI/NH₃) m/e 421 (M+1)⁺; ¹H NMR (300 MHz, CD₃OD) δ = 8.10 (d; 1H; J=8.4 Hz), 7.75 (d; 1H; J=8.4 Hz), 7.55 (s; 1H), 7.53 (s; 1H), 7.44 (m; 3H), 7.04 (s; 1H), 4.30 (dd; 1H; J=10.8 Hz; J=3.0Hz), 4.09 (dd; 1H; J=10.8Hz; J=4.5Hz), 4.87 (m; 1H), 3.30 (m;2H), 2.62 (s; 3H), 2.36 (s; 6H).

35

Example 356

(1S)-1-[6-Chloro-5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxyethyl]-2-phenyl-propylamine

The desired product was prepared by substituting Example 12B for 3-bromo-5-hydroxypyridine and Boc-3-methyl-phenylalaninol for Boc-tryptophanol in Example 102.

5 MS (DCI/NH₃) m/e 407 (M+1)⁺; ¹H NMR (300 MHz, CD₃OD) δ = 8.20 (d; 1H; J=3.0 Hz), 7.81 (s; 1H), 7.61 (d; 1H; J=3.0 Hz), 7.57 (d; 1H; J=8.4 Hz), 7.40 (m; 6H), 4.44 (d; 2H; J=4.5 Hz), 3.88 (m; 1H), 3.28 (m; 1H), 2.59 (s; 3H), 1.42 (d; 3H; J=7.5 Hz).

10

Example 357

(1S)-1-[6-Chloro-5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxyethyl]-2,2-diphenyl-ethylamine

The desired product was prepared by substituting Example 12B for 3-bromo-5-hydroxypyridine and Boc-3,3-diphenylalaninol for Boc-tryptophanol in Example 102. MS (DCI/NH₃) m/e 469 (M+1)⁺; ¹H NMR (300 MHz, CD₃OD) δ = 8.08 (d; 1H; J=3.0 Hz), 7.74 (s; 1H), 7.55 (m; 3H), 7.43 (m; 5H), 7.31 (m; 3H), 7.21 (m; 2H), 4.65 (d; 1H; J=11.1 Hz), 4.44 (d; 1H; J=11.1 Hz), 4.31 (d; 1H; J=11.1 Hz), 4.09 (d; 1H; J=11.1 Hz), 2.59 (s; 3H).

20

Example 358

(1S)-1-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxyethyl]-2-phenyl-propylamine

The desired product was prepared by substituting Boc-3-methyl-phenylalaninol for Boc-tryptophanol in Example 102. MS (DCI/NH₃) m/e 373 (M+1)⁺; ¹H NMR (300 MHz, CD₃OD) δ = 8.11 (s; 2H), 8.05 (s; 2H), 7.74 (d; 1H; J=8.4 Hz), 7.62 (d; 1H; J=8.4 Hz), 7.40(m; 1H), 7.39 (m; 5H), 4.56 (m; 2H), 3.92 (m; 2H), 2.62 (s; 3H), 1.6 (d; 3H; J=7.5 Hz).

25

Example 359

(1S)-1-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxyethyl]-2,2-diphenyl-ethylamine

30 The desired product was prepared by substituting Boc-3,3-diphenylalaninol for Boc-tryptophanol in Example 102. MS (DCI/NH₃) m/e 435 (M+1)⁺; ¹H NMR (300 MHz, CD₃OD) δ = 8.62 (s; 1H), 8.31 (s; 1H), 8.02 (s; 1H), 7.82 (s; 1H), 7.67 (d; 1H; J=8.4 Hz), 7.60 (d; 1H; J=8.4 Hz), 7.58 (d; 1H; J=6.9 Hz), 7.43(m; 4H), 7.30 (m; 5H), 4.61 (d; 1H; J=12.0 Hz), 4.48 (d; 1H; J=12 Hz), 4.40 (dd; 1H; J=11.4 Hz; J=3.0 Hz), 4.00 (dd; 1H; J=11.4 Hz), 2.62 (s; 3H).

35

Example 360

(1S)-3-Methyl-1-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxyethyl]-butylamine

The desired product was prepared by substituting Example 12B for 3-bromo-5-hydroxypyridine and Boc-leucinol for Boc-tryptophanol in Example 102. MS (APCI) m/z 357 (M-1)⁺; ¹H NMR (500 MHz, CD₃OD) δ ppm 1.02 (m, *J*=6.40, 3.90 Hz, 6H), 1.67 (m, 2H), 1.80 (dd, *J*=13.57, 6.71 Hz, 1H), 2.59 (s, 3H), 3.71 (m, *J*=6.86, 3.12 Hz, 1H), 4.20 (dd, *J*=10.61, 6.55 Hz, 1H), 4.38 (dd, *J*=10.45, 3.28 Hz, 1H), 7.49 (dd, *J*=8.58, 1.72 Hz, 1H), 7.56 (d, *J*=8.11 Hz, 1H), 7.59 (d, *J*=3.12 Hz, 1H), 7.80 (s, 1H), 8.17 (d, *J*=3.12 Hz, 1H); Anal. Calcd for C₁₉H₂₃ClN₄O: C, 49.56; H, 5.21; N, 10.88. Found: C, 49.86; H, 4.83; N, 10.49.

Example 361

10 (1*S*)-2-[6-Chloro-5-(3-methyl-1*H*-indazol-5-yl)-pyridin-3-yloxy]-1-(1*H*-indol-3-ylmethyl)-ethylamine

The desired product was prepared by substituting Example 12B for 3-bromo-5-hydroxypyridine in Example 102. MS (APCI) m/z 533 (M+1)⁺; ¹H NMR (500 MHz, CD₃OD) δ ppm 2.58 (s, 3H), 3.28 (m, 2H), 3.96 (m, 1H), 4.20 (dd, *J*=10.45, 5.77 Hz, 1H), 4.34 (dd, *J*=10.61, 3.12 Hz, 1H), 7.02 (t, *J*=7.49 Hz, 1H), 7.12 (t, *J*=7.64 Hz, 1H), 7.22 (s, 1H), 7.37 (d, *J*=8.42 Hz, 1H), 7.44 (dd, *J*=8.42, 1.56 Hz, 1H), 7.47 (d, *J*=3.12 Hz, 1H), 7.54 (d, *J*=8.42 Hz, 1H), 7.57 (d, *J*=8.11 Hz, 1H), 7.74 (s, 1H), 8.12 (d, *J*=2.81 Hz, 1H); Anal. Calcd for C₂₄H₂₂ClN₅O: C, 52.08; H, 4.12; N, 11.61. Found: C, 52.45; H, 4.08; N, 11.24.

20

Example 362

(1*S*)-2-(6-Chloro-5-thieno[2,3-*c*]pyridin-2-yl-pyridin-3-yloxy)-1-(1*H*-indol-3-ylmethyl)-ethylamine

Example 362A

25 (1*S*)-[2-(6-Chloro-5-thieno[2,3-*c*]pyridin-2-yl-pyridin-3-yloxy)-1-(1*H*-indol-3-ylmethyl)-ethyl]-carbamic acid *tert*-butyl ester

The title compound was prepared by substituting Example 13A for Example 2A and Example 38A for Example 27A in Example 27B.

Example 362B

30 (1*S*)-2-(6-Chloro-5-thieno[2,3-*c*]pyridin-2-yl-pyridin-3-yloxy)-1-(1*H*-indol-3-ylmethyl)-ethylamine

The title compound was prepared by substituting Example 362A for Example 27B in Example 27C. MS (APCI) m/z 436 (M+1)⁺; ¹H NMR (300 MHz, CD₃OD) δ 3.29 (m, 2 H), 4.00 (m, 1 H), 4.26 (dd, *J*=10.51, 5.76 Hz, 1 H), 4.40 (dd, *J*=10.51, 3.05 Hz, 1 H), 7.02 (t, *J*=7.63 Hz, 1 H), 7.10 (t, *J*=6.95 Hz, 1 H), 7.23 (s, 1 H), 7.36 (d, *J*=8.14 Hz, 1 H), 7.58 (d, *J*=7.80 Hz, 1 H), 7.74 (d, *J*=3.05 Hz, 1 H), 8.05 (s, 1 H), 8.29 (d, *J*=3.05 Hz, 1 H), 8.35 (d,

J=6.10 Hz, 1 H), 8.64 (d, *J*=6.10 Hz, 1 H), 9.57 (s, 1 H); Anal. Calcd for C₂₃H₁₉ClN₄OS₂ 2.6 TFA: C, 46.31; H, 2.98; N, 7.66. Found: C, 46.22; H, 2.94; N, 7.52.

5

Example 3635-[(2*S*)-2-Amino-3-(1*H*-indol-3-yl)-propoxy]-3-isoquinolin-6-yl-pyridine-2-carbonitrile

Example 363A

(1*S*)-[2-(6-Chloro-5-isoquinolin-6-yl-pyridin-3-yloxy)-1-(1*H*-indol-3-ylmethyl)-ethyl]-carbamic acid *tert*-butyl ester

The title compound was prepared by substituting Example 13A for Example 2A in Example 27B. MS (APCI) m/z 529 (M+1)⁺.

15

Example 363B

(1*S*)-[2-(6-Cyano-5-isoquinolin-6-yl-pyridin-3-yloxy)-1-(1*H*-indol-3-ylmethyl)-ethyl]-carbamic acid *tert*-butyl ester

20

A 10 mL RBF was charged with Example 363A (100mg, 0.189 mmol), zinc cyanide (56 mg, 0.47 mmol) and Pd(PPh₃)₄ (44 mg, 0.0378 mmol), and was purged with nitrogen. Anhydrous DMF (3 mL) was added and the solution was purged with nitrogen again. The reaction mixture was stirred at 90 °C for 70 h. After cooled, the mixture was partitioned between ethyl acetate and brine, and the organic phase was washed with water. The Organic layer was concentrated and the residue was separated by flash chromatography (40-100% EtOAc in hexane) to give the desired product (87.4 mg, 89%). MS (APCI) m/z 520 (M+1)⁺.

Example 363C

5-[(2*S*)-2-Amino-3-(1*H*-indol-3-yl)-propoxy]-3-isoquinolin-6-yl-pyridine-2-carbonitrile

30 The desired product was prepared as the trifluoroacetate by substituting Example 363B for Example 27B in Examples 27C. MS (APCI) m/z 421 (M+1)⁺; ¹H NMR (300 MHz, CD₃OD) δ 3.31 (m, 2 H), 4.03 (m, 1 H), 4.34 (dd, *J*=10.85, 5.76 Hz, 1 H), 4.48 (dd, *J*=10.85, 3.39 Hz, 1 H), 7.00 (t, *J*=7.46 Hz, 1 H), 7.10 (t, *J*=6.95 Hz, 1 H), 7.23 (s, 1 H), 7.35 (d, *J*=8.14 Hz, 1 H), 7.57 (d, *J*=7.80 Hz, 1 H), 7.64 (d, *J*=2.71 Hz, 1 H), 8.08 (dd, *J*=8.48, 1.69 Hz, 1 H), 8.39 (d, *J*=7.46 Hz, 1 H), 8.37 (d, *J*=6.44 Hz, 1 H), 8.55 (d, *J*=7.12 Hz, 1 H), 8.56 (m, 1 H), 8.65 (d, *J*=6.10 Hz, 1 H), 9.72 (s, 1 H); Anal. Calcd for C₂₆H₂₁N₅O₂ 2.9 TFA: C, 50.92; H, 3.21; N, 9.34. Found: C, 50.98; H, 3.23; N, 9.48.

Example 364(1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(3-phenyl-isoquinolin-6-yl)-pyridin-3-yloxy]-ethylamine

5

Example 364A(1S)-{1-(1H-Indol-3-ylmethyl)-2-[5-(3-phenyl-isoquinolin-6-yl)-pyridin-3-yloxy]-ethyl}-carbamic acid *tert*-butyl ester

To a solution of Example 80E (150 mg, 0.28 mmol), (1,1,1-tributylstannyl)benzene (137 mg, 0.57 mmol), tris(dibenzylideneacetone)-dipalladium (27 mg, 0.028 mmol) and 2-

10 dicyclohexylphosphino-2'-dimethylamino-1,1'-biphenyl (22 mg, 0.057 mmol) in dry DMF (10 ml) triethyl amine was added under N₂. The resulting solution was stirred 3 hours at 100 °C. The reaction solution was partitioned between ethylacetate and water. The organic layer was washed (brine), dried (Na₂SO₄), filtered and concentrated under vacumm. Purification on silica gel with 60% ethyl acetate/ hexane to provide the title compound (70 mg, 47 %).

15 MS (DCI/NH₃) m/e 571 (M+1)⁺.

Example 364B(1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(3-phenyl-isoquinolin-6-yl)-pyridin-3-yloxy]-ethylamine

The title compound was prepared as trifluoroacetic acid salt by substituting Example 354A

20 for Example 27B in Example 27C. MS (DCI/NH₃) m/e 471 (M+1)⁺; ¹H NMR (300 MHz, D₆-DMSO) δ 11.04 (s; 1H), 9.49 (s; 1H), 8.74 (s; 1H), 8.45 (s; 1H), 8.44 (s; 1H), 8.39 (s; 1H), 8.28 (d; 1H; J=8.4 Hz), 8.23 (d; 1H; J=7.5 Hz), 8.08 (s; 2H), 8.02 (d; 1H; J=8.4 Hz), 7.83 (s; 1H), 7.63 (d; 1H; J=8.4 Hz), 7.55 (t; 3H; J=7.5 Hz), 7.47 (d; 1H; J=7.5 Hz), 7.37 (d; 1H; J=8.4 Hz), 7.31 (s; 1H), 7.10 (t; 1H; J=7.2 Hz), 7.00 (t; 1H; J=7.2 Hz), 4.40 (m; 1H), 4.23 (m; 1H), 3.88 (m; 1H), 3.18 (m; 2H)

25 The following compounds were prepared by substituting the appropriate tributylsannyl reagents for (1,1,1-tributylstannyl)benzene in Example 364.

Example 365(1S)-2-[5-(3-Ethyl-isoquinolin-6-yl)-pyridin-3-yloxy]-1-(1H-indol-3-ylmethyl)-ethylamine

30 MS (DCI/NH₃) m/e 423 (M+1)⁺; ¹H NMR (300 MHz, D₆-DMSO) δ = 11.04 (s; 1H), 9.61 (s; 1H), 8.77 (s; 1H), 8.47 (s; 1H), 8.45 (s; 1H), 8.42 (d; 1H; J=9.0 Hz), 8.20 (s; 2H), 8.14 (d; 2H; J=9.0 Hz), 8.03 (s; 2H), 7.85 (s; 1H), 7.63 (d; 1H; J=7.5 Hz), 7.38 (d; 1H; J=7.5 Hz), 7.30 (s; 1H), 7.10 (t; 1H; J=7.5 Hz), 7.00 (t; 1H; J=7.5 Hz), 4.40 (m; 1H), 4.22 (m; 1H), 3.88 (m; 1H), 3.18 (m; 2H), 3.04 (q; 2H; J=7.5 Hz), 1.37 (t; 3H; J=7.5 Hz).

Example 366

(1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(3-pyridin-4-yl-isoquinolin-6-yl)-pyridin-3-yloxy]-ethylamine

MS (DCI/NH₃) m/e 472 (M+1)⁺; ¹H NMR (300 MHz, D₆-DMSO) δ = 11.04 (s; 1H), 9.54 (s; 1H), 8.93 (d; 2H; J=7.5 Hz), 8.87 (d; 2H; J=7.5 Hz), 8.83 (s; 1H), 8.70 (s; 1H), 8.43 (s; 2H), 5 8.35 (d; 1H; J=8.4 Hz), 8.09 (d; 2H; J=8.4 Hz), 7.84 (s; 1H), 7.61 (d; 1H; J=8.4 Hz), 7.38 (d; 1H; J=8.4 Hz), 7.25 (s; 1H), 7.12 (t; 1H; J=8.4 Hz), 7.03 (t; 1H; J=8.4 Hz), 4.45 (m; 1H), 4.30 (m; 1H), 4.00 (m; 1H), 3.30 (m; 2H)

Example 367

10 (1S)-2-[5-(3-Furan-2-yl-isoquinolin-6-yl)-pyridin-3-yloxy]-1-(1H-indol-3-ylmethyl)-ethylamine

MS (DCI/NH₃) m/e 461 (M+1)⁺; ¹H NMR (300 MHz, D₆-DMSO) δ = 11.04 (s; 1H), 9.39 (s; 1H), 8.74 (s; 1H), 8.44 (s; 1H), 8.41 (s; 1H), 8.25 (d; 1H; J=8.4 Hz), 8.18 (m; 3H), 8.00 (d; 2H; J=8.4 Hz), 7.89 (s; 1H), 7.83 (s; 1H), 7.63 (d; 1H; J=8.4 Hz), 7.39 (d; 1H; J=8.4 Hz), 7.31 (s; 1H), 15 7.18 (s; 1H), 7.11 (t; 1H; J=8.4 Hz), 7.01 (t; 1H; J=8.4 Hz), 6.71 (s; 1H), 4.40 (m; 1H), 4.21 (m; 1H), 3.88 (m; 1H), 3.18 (m; 2H)

Example 368

20 (1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(3-phenylethynyl-isoquinolin-6-yl)-pyridin-3-yloxy]-ethylamine

MS (DCI/NH₃) m/e 495 (M+1)⁺; ¹H NMR (300 MHz, D₆-DMSO) δ = 11.04 (s; 1H), 9.41 (s; 1H), 8.73 (s; 1H), 8.45 (s; 1H), 8.35 (s; 1H), 8.31 (d; 1H; J=5.4 Hz), 8.24 (s; 2H), 8.21 (s; 1H), 8.07 (d; 1H; J=5.4 Hz), 7.82 (s; 1H), 7.65 m; 4H), 7.48 (m; 2H), 7.39 (d; 1H; J=5.4 Hz), 7.30 (s; 1H), 7.10 (t; 1H; J=5.4 Hz), 7.00 (t; 1H; J=5.4 Hz), 4.40 (m; 1H), 4.22 (m; 1H), 4.13 (m; 1H), 25 3.18 (m; 2H).

Example 369

30 (1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(3-prop-1-ynyl-isoquinolin-6-yl)-pyridin-3-yloxy]-ethylamine

MS (DCI/NH₃) m/e 433 (M+1)⁺; ¹H NMR (300 MHz, D₆-DMSO) δ = 11.04 (s; 1H), 9.32 (s; 1H), 8.71 (s; 1H), 8.43 (s; 1H), 8.28 (s; 1H), 8.25 (d; 1H; J=8.4 Hz), 8.18 (s; 2H), 8.02 (d; 1H; J=8.4 Hz), 7.99 (s; 1H), 7.80 (s; 1H), 7.62 (d; 1H; J=8.4 Hz), 7.38 (d; 1H; J=8.4 Hz), 7.30 (s; 1H), 7.10 (t; 1H; J=8.4 Hz), 7.00 (t; 1H; J=8.4 Hz), 4.40 (m; 1H), 4.21 (m; 1H), 3.88 (m; 1H), 3.18 (m; 2H), 2.13 (s; 3H).

35

Example 370

(1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(3-vinyl-isoquinolin-6-yl)-pyridin-3-yloxy]-ethylamine

MS (DCI/NH₃) m/e 421 (M+1)⁺; ¹H NMR (300 MHz, D₆-DMSO) δ = 11.04 (s; 1H), 9.36 (s; 1H), 8.71 (s; 1H), 8.42 (s; 1H), 8.28 (s; 1H), 8.25 (d; 1H; J=9.0 Hz), 8.18 (s; 2H), 8.00 (d; 1H; J=9.0 Hz), 7.85 (s; 1H), 7.81 (s; 1H), 7.63 (d; 1H; J=8.4 Hz), 7.38 (d; 1H; J=8.4 Hz), 7.29 (s; 1H), 7.10 (t; 1H; J=8.4 Hz), 7.01 (t; 1H; J=8.4 Hz), 6.98 (dd; 1H; J=17.4 Hz; J=12.0 Hz), 6.40 (d; 1H; J=17.4 Hz), 5.50 (d; 1H; J=12.0 Hz), 4.40 (m; 1H), 4.21 (m; 1H), 3.88 (m; 1H), 3.18 (m; 2H).

Example 371

(1S)-6-{5-[2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-isoquinoline-3-carbonitrile

10

Example 371A

(1S)-[2-[5-(3-Cyano-isoquinolin-6-yl)-pyridin-3-yloxy]-1-(1H-indol-3-ylmethyl)-ethyl]-carbamic acid *tert*-butyl ester

The desired product was obtained by substituting Example 80E for example 363A in

15 Example 363B.

Example 371B

(1S)-6-{5-[2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-isoquinoline-3-carbonitrile

The desired product was obtained as trifluoroacetic acid salt by substituting Example 371A for Example 27B in Example 27C. MS (DCI/NH₃) m/e 420 (M+1)⁺; ¹H NMR (300 MHz, D₆-DMSO) δ = 11.04 (s; 1H), 9.52 (s; 1H), 8.75 (s; 1H), 8.64 (s; 1H), 8.47 (s; 2H), 8.42 (d; 1H; J=6.0 Hz), 8.26 (m; 3H), 7.84 (s; 1H), 7.62 (d; 1H; J=6.0 Hz), 7.38 (d; 1H; J=6.0 Hz), 7.31 (s; 1H), 7.10 (t; 1H; J=6.0 Hz), 7.00 (t; 1H; J=6.0 Hz), 4.40 (m; 1H), 4.22 (m; 1H), 3.88 (m; 1H), 3.18 (m; 2H).

25

Example 372

(1S)-1-(1H-Indol-3-ylmethyl)-2-(5-isoquinolin-6-yl-6-vinyl-pyridin-3-yloxy)-ethylamine

The desired product was prepared as the trifluoroacetate by substituting tributylvinyltin for tributylphenyltin and Example 363A for Example 80E in Example 364. MS (APCI) m/z 420 (M+1)⁺; ¹H NMR (300 MHz, CD₃OD) δ 3.30 (m, 2 H), 3.98 (m, 1 H), 4.24 (dd, J=10.51, 5.76 Hz, 1 H), 4.38 (dd, J=10.51, 3.05 Hz, 1 H), 5.39 (dd, J=10.85, 1.70 Hz, 1 H), 6.24 (dd, J=16.95, 1.70 Hz, 1 H), 6.66 (dd, J=17.12, 10.68 Hz, 1 H), 7.00 (dd, J=6.78, 6.10 Hz, 1 H), 7.09 (t, J=7.63 Hz, 1 H), 7.22 (s, 1 H), 7.35 (d, J=8.14 Hz, 1 H), 7.40 (d, J=2.71 Hz, 1 H), 7.57 (d, J=7.80 Hz, 1 H), 7.95 (dd, J=8.48, 1.70 Hz, 1 H), 8.22 (s, 1 H), 8.45 (d, J=7.46 Hz, 1 H), 8.45 (s, 1 H), 8.56 (d, J=8.81 Hz, 1 H), 8.64 (d, J=6.44 Hz, 1 H), 9.79 (s, 1 H); Anal. Calcd for C₂₇H₂₄N₄O•4 TFA: C, 47.96, 3.22; N, 6.39. Found: C, 48.02; H, 3.00; N, 6.07.

Example 373

(1S)-2-(6-Ethynyl-5-isoquinolin-6-yl-pyridin-3-yloxy)-1-(1H-indol-3-ylmethyl)-ethylamine

The desired product was prepared as the trifluoroacetate by substituting tributylethynyltin for tributylphenyltin and Example 363A for Example 80E in Example 364. MS (APCI) m/z 419 (M+1)⁺; ¹H NMR (300 MHz, CD₃OD) δ 3.31 (m, 2 H), 3.67 (s, 1 H), 3.99 (m, 1 H), 4.28 (dd, J=10.74, 5.83 Hz, 1 H), 4.42 (dd, J=10.74, 3.07 Hz, 1 H), 7.00 (t, J=7.06 Hz, 1 H), 7.09 t, J=7.21 Hz, 1 H), 7.23 (s, 1 H), 7.35 (d, J=8.29 Hz, 1 H), 7.55 (m, 1 H), 7.56 (d, J=7.98 Hz, 1 H), 8.19 (dd, J=8.59, 1.53 Hz, 1 H), 8.42 (s, 2 H), 8.47 (d, J=6.44 Hz, 1 H), 8.56 (d, J=8.59 Hz, 1 H), 8.63 (d, J=6.44 Hz, 1 H), 9.79 (s, 1 H); Anal. Calcd for C₂₇H₂₂N₄O•2.9 TFA: C, 52.59; H, 3.35; N, 7.48. Found: C, 52.52; H, 3.44; N, 7.01.

5 Example 374

10 (1S)-2-(6-Furan-2-yl-5-isoquinolin-6-yl-pyridin-3-yloxy)-1-(1H-indol-3-ylmethyl)-ethylamine

The desired product was prepared as the trifluoroacetate by substituting tributylethynyltin for tributylstannylfuran and Example 363A for Example 80E in Example 364. MS (APCI) m/z 461 (M+1)⁺; ¹H NMR (300 MHz, CD₃OD) δ 3.30 (m, 2 H), 3.98 (m, 1 H), 4.25 (dd, J=10.51, 5.76 Hz, 1 H), 4.40 (dd, J=10.51, 3.05 Hz, 1 H), 6.39 (dd, J=3.39, 1.70 Hz, 1 H), 6.44 (d, J=4.41 Hz, 1 H), 7.00 (dd, J=7.80, 7.12 Hz, 1 H), 7.09 (t, J=6.78 Hz, 1 H), 7.21 (s, 1 H), 7.28 (d, J=1.70 Hz, 1 H), 7.37 (d, J=8.14 Hz, 1 H), 7.47 (d, J=2.71 Hz, 1 H), 7.57 (d, J=7.80 Hz, 1 H), 7.80 (dd, J=8.65, 1.53 Hz, 1 H), 8.21 (s, 1 H), 8.42 (d, J=6.78 Hz, 1 H), 8.46 (d, J=7.12 Hz, 1 H), 8.48 (s, 1 H), 8.62 (d, J=6.44 Hz, 1 H), 9.77 (s, 1 H); Anal. Calcd for C₂₉H₂₄N₄O₂•3.9 TFA: C, 48.83; H, 3.11; N, 6.19. Found: C, 48.86; H, 3.31; N, 6.18.

15 Example 375

20 (1S)-1-(1H-Indol-3-ylmethyl)-2-(5-isoquinolin-6-yl-6-phenylethynyl-pyridin-3-yloxy)-ethylamine

The desired product was prepared as the trifluoroacetate by substituting 25 tributyl(phenylethynyl)tin tributylphenyltin and Example 363A for Example 80E in Example 364. MS (APCI) m/z 495 (M+1)⁺; ¹H NMR (300 MHz, CD₃OD) δ 3.30 (m, 2 H), 4.02 (m, 1 H), 4.30 (dd, J=10.51, 5.76 Hz, 1 H), 4.44 (dd, J=10.51, 3.05 Hz, 1 H), 7.01 (t, J=7.46 Hz, 1 H), 7.11 (t, J=7.46 Hz, 1 H), 7.24 (s, 1 H), 7.29 (m, 5 H), 7.36 (d, J=8.14 Hz, 1 H), 7.61 (d, J=2.71 Hz, 1 H), 7.59 (d, J=7.80 Hz, 1 H), 8.24 (dd, J=8.65, 1.53 Hz, 1 H), 8.38 (d, J=6.44 Hz, 1 H), 8.46 (d, J=2.71 Hz, 1 H), 8.46 (s, 1 H), 8.55 (d, J=8.81 Hz, 1 H), 8.62 (d, J=6.44 Hz, 1 H), 9.72 (s, 1 H); Anal. Calcd for C₃₃H₂₆N₄O•2.3 TFA: C, 59.67; H, 3.77; N, 7.40. Found: C, 59.61; H, 4.04; N, 7.36.

30 Example 376

35 6-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-isoquinolin-5-ylamine

The desired product was prepared as the trifluoroacetate by substituting 5-amino-6-bromoisoquinoline for 6-bromophthalimide in Example 32. MS (APCI) m/z 410 (M+1)⁺; ¹H NMR (300 MHz, CD₃OD) δ 3.32 (m, 2 H), 4.00 (m, 1 H), 4.27 (dd, J=10.51, 5.76 Hz, 1 H),

4.44 (dd, $J=10.51$, 3.39 Hz, 1 H), 7.01 (t, $J=7.46$ Hz, 1 H), 7.10 (t, $J=7.46$ Hz, 1 H), 7.24 (s, 1 H), 7.36 (d, $J=7.80$ Hz, 1 H), 7.59 (d, $J=7.80$ Hz, 1 H), 7.67 (d, $J=8.14$ Hz, 1 H), 7.73 (s, 1 H), 7.80 (d, $J=8.48$ Hz, 1 H) 8.45 (s, 2 H), 8.50 (d, $J=6.78$ Hz, 1 H), 8.66 (d, $J=6.78$ Hz, 1 H), 9.60 (s, 1 H); Anal. Calcd for $C_{25}H_{23}N_5O\bullet 3.3$ TFA: C, 48.30; H, 3.37; N, 8.91. Found: C, 48.35; H, 3.44; N, 8.91.

Example 377

(1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(8-methyl-isoquinolin-6-yl)-pyridin-3-yloxy]-ethylamine

The desired product was prepared as the trifluoroacetate by substituting 6-bromo-8-methyl-isoquinoline for 6-bromophthalimide in Example 32. MS (APCI) m/z 409 (M+1) $^+$; 1 H NMR (300 MHz, CD_3OD) δ 2.91 (s, 3 H), 3.32 (m, 2 H), 4.02 (m, 1 H), 4.32 (dd, $J=10.51$, 5.76 Hz, 1 H), 4.47 (dd, $J=10.51$, 3.39 Hz, 1 H), 7.02 (t, $J=7.46$ Hz, 1 H), 7.11 (t, $J=7.63$ Hz, 1 H), 7.25 (s, 1 H), 7.37 (d, $J=8.14$ Hz, 1 H), 7.60 (d, $J=8.14$ Hz, 1 H), 7.91 (dd, $J=8.31$, 4.92 Hz, 1 H), 7.96 (d, $J=1.70$ Hz, 1 H), 8.15 (s, 1 H), 8.31 (d, $J=2.03$ Hz, 1 H), 8.46 (s, 1 H), 8.74 (s, 1 H), 8.87 (dd, $J=8.48$, 1.70 Hz, 1 H), 9.08 (dd, $J=4.92$, 1.53 Hz, 1 H); Anal. Calcd for $C_{26}H_{24}N_4O\bullet 3.5$ TFA: C, 49.08; H, 3.43; N, 6.94. Found: C, 49.23; H, 3.24; N, 6.87.

Example 378

(1S)-2-[5-(4-Chloro-thieno[2,3-c]pyridin-2-yl)-pyridin-3-yloxy]-1-(1H-indol-3-ylmethyl)-ethylamine

The title compound was prepared by substituting 4-chlorothieno[2,3-c]pyridine for thieno[2,3-c]pyridine in Example 38. MS (APCI) m/z 435 (M+1) $^+$; 1 H NMR (300 MHz, CD_3OD) δ 3.31 (m, 2 H), 4.01 (m, 1 H), 4.29 (dd, $J=10.51$, 5.76 Hz, 1 H), 4.44 (dd, $J=10.51$, 3.05 Hz, 1 H), 7.04 (t, $J=8.14$ Hz, 1 H), 7.12 (t, $J=6.95$ Hz, 1 H), 7.25 (s, 1 H), 7.39 (d, $J=8.14$ Hz, 1 H), 7.61 (d, $J=7.80$ Hz, 1 H), 7.84 (t, $J=2.71$ Hz, 1 H), 8.04 (s, 1 H), 8.42 (d, $J=2.03$ Hz, 1 H), 8.51 (s, 1 H), 8.72 (s, 1 H), 9.13 (s, 1 H); Anal. Calcd for $C_{23}H_{19}ClN_4OS\bullet 2.8$ TFA: C, 45.55; H, 2.91; N, 7.43. Found: C, 45.42; H, 2.70; N, 7.28.

Example 379

(1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(4-phenyl-thieno[2,3-c]pyridin-2-yl)-pyridin-3-yloxy]-ethylamine

The title compound was prepared by substituting 4-phenylthieno[2,3-c]pyridine for thieno[2,3-c]pyridine in Example 38. MS (APCI) m/z 477 (M+1) $^+$; 1 H NMR (300 MHz, CD_3OD) δ 3.31 (m, 2 H), 4.00 (m, 1 H), 4.26 (dd, $J=10.51$, 5.76 Hz, 1 H), 4.41 (dd, $J=10.51$, 3.39 Hz, 1 H), 6.99 (t, $J=6.95$ Hz, 1 H), 7.10 (t, $J=7.12$ Hz, 1 H), 7.22 (s, 1 H), 7.36 (d, $J=7.80$ Hz, 1 H), 7.57 (d, $J=7.80$ Hz, 1 H), 7.65 (m, 3 H), 7.73 (t, $J=2.03$ Hz, 1 H), 7.76 (d, $J=1.70$ Hz, 1 H), 7.84 (m, 1 H), 8.11 (s, 1 H), 8.46 (s, 1 H), 8.62 (s, 1 H), 8.74 (s, 1 H) 9.52 (s, 1 H); Anal. Calcd for $C_{29}H_{24}N_4OS\bullet 2.8$ TFA: C, 52.22; H, 3.39; N, 7.04. Found: C, 52.11; H, 3.13; N, 6.91.

Example 380

(1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(4-phenoxy-thieno[2,3-c]pyridin-2-yl)-pyridin-3-yloxy]-ethylamine

The title compound was prepared by substituting 4-phenoxythieno[2,3-c]pyridine for thieno[2,3-c]pyridine in Example 38. MS (APCI) m/z 493 (M+1)⁺; ¹H NMR (300 MHz, CD₃OD) δ 3.30 (m, 2 H), 4.01 (m, 1 H), 4.27 (dd, *J*=10.51, 5.76 Hz, 1 H), 4.42 (dd, *J*=10.51, 3.05 Hz, 1 H), 7.03 (t, *J*=7.46 Hz, 1 H), 7.11 (t, *J*=7.46 Hz, 1 H), 7.24 (s, 1 H), 7.25 (d, *J*=8.82 Hz, 1 H), 7.33 (t, *J*=7.46 Hz, 2 H), 7.38 (d, *J*=7.80 Hz, 1 H), 7.52 (t, *J*=7.97 Hz, 2 H), 7.60 (d, *J*=7.80 Hz, 1 H), 7.85 (s, 1 H), 8.00 (s, 1 H), 8.16 (s, 1 H), 8.44 (d, *J*=2.03 Hz, 1 H), 8.72 (s, 1 H), 9.17 (s, 1 H).

10

Example 381

(1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(4-vinyl-thieno[2,3-c]pyridin-2-yl)-pyridin-3-yloxy]-ethylamine

15

Example 381A

(1S)-[2-[5-(4-Chloro-thieno[2,3-c]pyridin-2-yl)-pyridin-3-yloxy]-1-(1H-indol-3-ylmethyl)-ethyl]-carbamic acid *tert*-butyl ester

The title compound was prepared by substituting 4-chlorothieno[2,3-c]pyridine for thieno[2,3-c]pyridine in Example 38. MS (APCI) m/z 535 (M+1)⁺.

20

Example 381B

(1S)-{1-(1H-Indol-3-ylmethyl)-2-[5-(4-vinyl-thieno[2,3-c]pyridin-2-yl)-pyridin-3-yloxy]-ethyl}-carbamic acid *tert*-butyl ester

A 25 mL RBF was charged with Example 381A (102 mg, 0.19 mmol), Pd₂(dba)₃ (18 mg, 0.019 mmol), and 2-dicyclohexylphosphino-2'-(N,N-dimethylamino)biphenyl (15 mg, 0.038 mmol), and was purged with N₂. Anhydrous DMF (5 mL), tributylvinyltin (111 μL, 0.38 mmol) and Et₃N (80 μL) were added via syringe. The solution was purged with N₂ again and was heated at 70 °C for 20 h. After cooled, ethyl acetate (50 mL) was added. The mixture was washed with brine (50 mL) and water (50 mL). The ethyl acetate solution was concentrated, and the residual oil was separated by flash chromatography (A: 2:1 EtOAc/hexane, 0-15% CH₃OH in A) to give the desired product (72 mg, 72%). MS (APCI) m/z 527 (M+1)⁺.

Example 381C

(1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(4-vinyl-thieno[2,3-c]pyridin-2-yl)-pyridin-3-yloxy]-ethylamine

35 The desired product was prepared as the trifluoroacetate by substituting Example 381B for Example 27B in Examples 27C. MS (APCI) m/z 427 (M+1)⁺; ¹H NMR (300 MHz, CD₃OD) δ 3.32 (m, 2 H), 4.03 (m, 1 H), 4.30 (dd, *J*=10.51, 5.76 Hz, 1 H), 4.46 (dd, *J*=10.51, 3.39 Hz,

1 H), 5.84 (d, $J=11.19$ Hz, 1 H), 6.26 (d, $J=17.29$ Hz, 1 H), 7.03 (t, $J=7.46$ Hz, 1 H), 7.12 (t, $J=7.63$ Hz, 1 H), 7.25 (s, 1 H), 7.35 (d, $J=10.85$ Hz, 1 H), 7.41 (d, $J=10.85$ Hz, 1 H), 7.60 (d, $J=7.80$ Hz, 1 H), 7.90 (m, 1 H), 8.44 (s, 1 H), 8.49 (d, $J=2.37$ Hz, 1 H), 8.79 (s, 2 H), 9.42 (s, 1 H); Anal. Calcd for $C_{25}H_{22}N_4OS\cdot 3.2$ TFA: C, 47.65; H, 3.21; N, 7.08. Found: C, 47.74; H, 3.13; N, 6.96.

5 Example 382

(1S)-2-[5-(4-Ethyl-thieno[2,3-*c*]pyridin-2-yl)-pyridin-3-yloxy]-1-(1*H*-indol-3-ylmethyl)-ethylamine

To a solution of Example 381A (50 mg, 0.063 mmol) in methanol (4 mL) was added triethylamine (56 μ L) and 10% Pd/C (20 mg) under nitrogen. The suspension was purged with H_2 (balloon) and was stirred at rt for 6 h. The solid material was filtered off. The filtrate was concentrated and the residue was purified by HPLC (Zorbax, C-18, 250x2.54 column, Mobile phase A: 0.1% TFA in H_2O ; B: 0.1% TFA in CH_3CN ; 0-100% gradient) to provide the title compound (37.2 mg, 74%). MS (APCI) m/z 429 ($M+1$) $^+$; 1H NMR (300 MHz, CD_3OD) δ 1.46 (t, $J=7.46$ Hz, 3 H), 3.23 (q, $J=7.46$ Hz, 2 H), 3.36 (m, 2 H), 4.03 (m, 1 H), 4.31 (dd, $J=10.51$, 5.76 Hz, 1 H), 4.47 (dd, $J=10.51$, 3.39 Hz, 1 H), 7.02 (t, $J=7.46$ Hz, 1 H), 7.12 (t, $J=7.46$ Hz, 1 H), 7.25 (s, 1 H), 7.38 (d, $J=8.14$ Hz, 1 H), 7.60 (d, $J=7.80$ Hz, 1 H), 7.92 (t, $J=2.03$ Hz, 1 H), 8.39 (s, 1 H), 8.49 (s, 1 H), 8.49 (d, $J=3.05$ Hz, 1 H), 8.81 (d, $J=1.70$ Hz, 1 H), 9.45 (s, 1 H); Anal. Calcd for $C_{25}H_{24}N_4OS\cdot 3.3$ TFA: C, 47.16; H, 3.42; N, 6.96. Found: C, 47.03; H, 3.34; N, 6.96.

20 Example 383

(1S)-(2-[5-[2-Amino-3-(1*H*-indol-3-yl)-propoxy]-pyridin-3-yl]-thieno[2,3-*c*]pyridin-4-yl)-phenyl-amine

25 Example 383A

(1S)-{1-(1*H*-Indol-3-ylmethyl)-2-[5-(4-phenylamino-thieno[2,3-*c*]pyridin-2-yl)-pyridin-3-yloxy]-ethyl}-carbamic acid *tert*-butyl ester

A 25 mL RBF was charged with Example 381A (100 mg, 0.186 mmol), $Pd_2(dbu)_3$ (17 mg, 0.0186 mmol), and 1,3-bis(2,6-di-i-propylphenyl)imidazolium chloride (Nolan ligand) (16 mg, 0.0372 mmol), and was purged with N_2 . Anhydrous dioxane (3 mL), aniline (21 mg, 0.224 mmol) and potassium *tert*-butoxide (1.0 M solution in THF, 0.279 mL) were added via syringe. The solution was purged with N_2 again, and was heated at 100°C for 20 h. After cooled, ethyl acetate (50 mL) was added, and the mixture was washed with brine (50 mL) and water. The EtOAc solution was concentrated, and the residue was separated by flash chromatography (30-80% EtOAc in hexane) to provide the desire product (34 mg, 31%). MS (APCI) m/z 592 ($M+1$) $^+$.

35 Example 383B

(1*S*)-(2-{5-[2-Amino-3-(1*H*-indol-3-yl)-propoxy]-pyridin-3-yl}-thieno[2,3-*c*]pyridin-4-yl)-phenyl-amine

The desired product was prepared as the trifluoroacetate by substituting Example 383A for Example 27B in Examples 27C. MS (APCI) m/z 492 (M+1)⁺; ¹H NMR (300 MHz, DMSO-d₆) δ 3.19 (d, J=7.12 Hz, 2 H), 3.88 (m, 1 H), 4.20 (dd, J=10.51, 5.42 Hz, 1 H), 4.38 (d, J=10.51 Hz, 1 H), 7.01 (t, J=7.46 Hz, 1 H), 7.11 (m, 3 H), 7.38 (m, 6 H), 7.62 (d, J=8.14 Hz, 1 H), 7.78 (s, 1 H), 8.22 (s, 2 H), 8.29 (s, 1 H), 8.47 (s, 1 H), 8.74 (s, 1 H), 8.98 (s, 1 H), 9.06 (s, 1 H), 11.04 (s, 1 H); Anal. Calcd for C₂₉H₂₅N₅OS•3 TFA: C, 50.42; H, 3.39; N, 8.40. Found: C, 50.40; H, 3.58; N, 8.23.

10 Example 384

5-{5-[2*S*]-2-Amino-3-(1*H*-indol-3-yl)-propoxy]-pyridin-3-yl}-3,3-difluoro-1,3-dihydro-indol-2-one

The desired product was prepared as the trifluoroacetate by substituting 5-Bromo-3,3-difluoro-1,3-dihydro-indol-2-one for 6-bromophthalimide in Example 32. MS (APCI) m/z 435 (M+1)⁺; ¹H NMR (300 MHz, CD₃OD) δ 3.36 (m, 2 H), 4.01 (m, 1 H), 4.26 (dd, J=10.51, 5.76 Hz, 1 H), 4.43 (dd, J=10.51, 3.05 Hz, 1 H), 7.03 (t, J=7.46 Hz, 1 H), 7.13 (t, J=7.46 Hz, 2 H), 7.24 (s, 1 H), 7.39 (d, J=8.14 Hz, 1 H), 7.60 (d, J=8.14 Hz, 1 H), 7.79 (m, 2 H), 7.90 (d, J=1.70 Hz, 1 H), 8.36 (d, J=2.03 Hz, 1 H), 8.56 (s, 1 H); Anal. Calcd for C₂₄H₂₀F₂N₄O₂•2.5 TFA: C, 48.41; H, 3.15; N, 7.79. Found: C, 48.66; H, 3.20; N, 7.82.

20 Example 385

6-{5-[2*S*]-2-Amino-3-(1*H*-indol-3-yl)-propoxy]-pyridin-3-yl}-3*H*-oxazolo[4,5-*b*]pyridin-2-one

The desired product was prepared as the trifluoroacetate by substituting 6-Bromo-3*H*-oxazolo[4,5-*b*]pyridin-2-one for 6-bromophthalimide in Example 32. MS (APCI) m/z 402 (M+1)⁺; ¹H NMR (300 MHz, CD₃OD) δ 3.34 (m, 2 H), 4.00 (m, 1 H), 4.28 (dd, J=10.51, 5.76 Hz, 1 H), 4.42 (dd, J=10.51, 3.05 Hz, 1 H), 7.02 (t, J=7.46 Hz, 1 H), 7.12 (t, J=7.63 Hz, 1 H), 7.23 (s, 1 H), 7.38 (d, J=8.14 Hz, 1 H), 7.59 (d, J=7.80 Hz, 1 H), 7.74 (d, J=1.70 Hz, 1 H), 7.83 (d, J=1.70 Hz, 1 H), 8.33 (d, J=2.03 Hz, 1 H), 8.38 (d, J=2.37 Hz, 1 H), 8.55 (s, 1 H); Anal. Calcd for C₂₂H₁₉N₅O₃•2.6 TFA: C, 46.81; H, 3.12; N, 10.04. Found: C, 46.67; H, 2.98; N, 9.89.

30 Example 386

N1-(5-Isoquinolin-6-yl-pyridin-3-yl)-ethane-1,2-diamine

Example 386A

[2-(5-Bromo-pyridin-3-ylamino)-ethyl]-carbamic acid *tert*-butyl ester

A 50 mL RBF was charged with 3,5-dibromopyridine (3.70 g, 15.6 mmol), *t*-butyl N-(2-aminoethyl)carbamate (2.50 g, 15.6 mmol), Pd₂(dba)₃ (714 mg, 0.78 mmol), (R)-BINAP

(1.46 g, 2.34 mol) and Cs_2CO_3 (7.62 g, 23.4 mmol), and was purged with N_2 . Anhydrous toluene (120 mL) was added via syringe. The solution was purged with N_2 again, and was heated at 100 °C overnight. After cooled, ethyl acetate (500 mL) was added and the mixture was washed with water. The EtOAc solution was concentrated and the residue was separated by flash chromatography (20-80% EtOAc in hexane) to provide the desired product (2.1 g, 43%). MS (DCI) m/z 316, 318 ($\text{M}+1$)⁺.

Example 386B

[2-(5-Isoquinolin-6-yl-pyridin-3-ylamino)-ethyl]-carbamic acid *tert*-butyl ester

10 The desired product was prepared by substituting Example 386A for Example 2A in Example 27B. MS (APCI) m/z 365 ($\text{M}+1$)⁺.

Example 386C

N1-(5-Isoquinolin-6-yl-pyridin-3-yl)-ethane-1,2-diamine

15 The desired product was prepared as the trifluoroacetate by substituting Example 386B for Example 27B in Examples 27C. MS (APCI) m/z 265 ($\text{M}+1$)⁺; ¹H NMR (300 MHz, CD_3OD) δ 3.26 (t, $J=5.76$ Hz, 2 H), 3.70 (t, $J=5.76$ Hz, 2 H), 8.10 (s, 1 H), 8.25 (s, 1 H), 8.33 (d, $J=8.82$ Hz, 1 H), 8.45 (d, $J=6.44$ Hz, 1 H), 8.56 (s, 1 H), 8.63 (m, 3 H), 9.76 (s, 1 H).

Example 387

Naphthalene-2-sulfonic acid (2-amino-ethyl)-(5-isoquinolin-6-yl-pyridin-3-yl)-amide

20

Example 387A

{2-[5-Isoquinolin-6-yl-pyridin-3-yl)-(naphthalene-2-sulfonyl)-amino]-ethyl}-carbamic acid *tert*-butyl ester

25 To a solution of Example 386B (70 mg, 0.192 mmol) in pyridine (3 mL) was added 2-naphthalenesulfonyl chloride (87 mg, 0.384 mmol) at rt. The formed yellow solution was stirred at rt for 15 h. Pyridine was removed under reduced pressure and the residual oil was purified by flash chromatography (0-15% CH_3OH in 2:1 EtOAc/hexane) to provide the desired product (69 mg, 65%). MS (APCI) m/z 555 ($\text{M}+1$)⁺.

Example 387B

Naphthalene-2-sulfonic acid (2-amino-ethyl)-(5-isoquinolin-6-yl-pyridin-3-yl)-amide

30 The desired product was prepared as the trifluoroacetate by substituting Example 387B for Example 27B in Examples 27C. MS (APCI) m/z 455 ($\text{M}+1$)⁺; ¹H NMR (300 MHz, CD_3OD) δ 3.17 (t, $J=5.76$ Hz, 2 H), 4.09 (t, $J=5.43$ Hz, 2 H), 7.66 (t, $J=6.78$ Hz, 1 H), 7.75 (t, $J=7.46$ Hz, 1 H), 7.99 (m, 2 H), 8.06 (m, 3 H), 8.13 (d, $J=8.82$ Hz, 1 H), 8.26 (m, 2 H), 8.31 (s, 1 H), 35 8.47 (d, $J=8.48$ Hz, 1 H), 8.59 (m, 2 H), 9.08 (d, $J=2.03$ Hz, 1 H), 9.69 (s, 1 H).

Example 388

Naphthalene-1-sulfonic acid (2-amino-ethyl)-(5-isoquinolin-6-yl-pyridin-3-yl)-amide

The desired product was prepared as the trifluoroacetate by substituting 1-naphthalenesulfonyl chloride for 2-naphthalenesulfonyl chloride in Examples 387. MS (APCI) m/z 455 (M+1)⁺; ¹H NMR (300 MHz, CD₃OD) δ 3.14 (t, J=5.76 Hz, 2 H), 4.04 (t, J=5.76 Hz, 2 H), 7.33 (t, J=7.46 Hz, 1 H), 7.51 (t, J=7.12 Hz, 1 H), 7.70 (t, J=8.14 Hz, 1 H), 7.85 (t, J=2.20 Hz, 1 H), 7.92 (dd, J=8.48, 1.70 Hz, 1 H), 8.04 (dd, J=8.31, 3.56 Hz, 2 H), 8.15 (s, 1 H), 8.29 (d, J=4.75 Hz, 1 H), 8.31 (d, J=5.42 Hz, 2 H), 8.47 (d, J=8.48 Hz, 1 H), 8.60 (d, J=6.44 Hz, 1 H), 8.63 (d, J=2.37 Hz, 1 H), 9.03 (d, J=2.03 Hz, 1 H), 9.67 (s, 1 H).

Example 389

5-Dimethylamino-naphthalene-1-sulfonic acid (2-amino-ethyl)-(5-isoquinolin-6-yl-pyridin-3-yl)-amide

The desired product was prepared as the trifluoroacetate by substituting dansyl chloride for 2-naphthalenesulfonyl chloride in Example 387. MS (APCI) m/z 498 (M+1)⁺; ¹H NMR (300 MHz, CD₃OD) δ 2.81 (s, 6 H), 3.16 (d, J=5.76 Hz, 2 H), 4.06 (d, J=5.76 Hz, 2 H), 7.16 (d, J=7.12 Hz, 1 H), 7.25 (t, J=7.80 Hz, 1 H), 7.67 (dd, J=8.48, 7.80 Hz, 1 H), 7.75 (d, J=8.48 Hz, 1 H), 7.85 (t, J=2.20 Hz, 1 H), 7.98 (dd, J=8.48, 1.70 Hz, 1 H), 8.29 (d, J=7.12 Hz, 1 H), 8.30 (s, 1 H), 8.43 (d, J=6.44 Hz, 1 H), 8.53 (d, J=8.82 Hz, 1 H), 8.64 (m, 3 H), 9.03 (d, J=2.03 Hz, 1 H), 9.76 (s, 1 H); Anal. Calcd for C₂₈H₂₇N₅O₂S•4 TFA: C, 45.34; H, 3.28; N, 7.34. Found: C, 45.28; H, 3.11; N, 7.23.

Example 390

Quinoline-5-sulfonic acid (2-amino-ethyl)-(5-isoquinolin-6-yl-pyridin-3-yl)-amide

The desired product was prepared as the trifluoroacetate by substituting 8-quinolinesulfonyl chloride for 2-naphthalenesulfonyl chloride in Example 387. MS (APCI) m/z 456 (M+1)⁺; ¹H NMR (300 MHz, CD₃OD) δ 3.29 (t, J=5.43 Hz, 2 H), 4.57 (t, J=5.43 Hz, 2 H), 7.65 (t, J=7.46 Hz, 1 H), 7.76 (dd, J=8.48, 4.41 Hz, 1 H), 8.12 (dd, J=8.48, 1.70 Hz, 1 H), 8.18 (t, J=2.03 Hz, 1 H), 8.29 (s, 1 H), 8.31 (d, J=7.12 Hz, 1 H), 8.33 (dd, J=7.46, 1.36 Hz, 1 H), 8.41 (s, 1 H), 8.42 (d, J=7.80 Hz, 1 H), 8.55 (d, J=8.82 Hz, 1 H), 8.56 (dd, J=8.31, 1.87 Hz, 1 H), 8.62 (d, J=6.44 Hz, 1 H), 8.95 (d, J=1.70 Hz, 1 H), 9.08 (dd, J=4.41, 1.70 Hz, 1 H), 9.74 (s, 1 H); Anal. Calcd for C₂₅H₂₁N₅O₂S•3.3 TFA: C, 45.63; H, 2.94; N, 8.42. Found: C, 45.70; H, 2.64; N, 8.18.

Example 391

Biphenyl-4-sulfonic acid (2-amino-ethyl)-(5-isoquinolin-6-yl-pyridin-3-yl)-amide

The desired product was prepared as the trifluoroacetate by substituting biphenyl-4-sulfonyl chloride for 2-naphthalenesulfonyl chloride in Example 387. MS (APCI) m/z 481 (M+1)⁺; ¹H NMR (300 MHz, CD₃OD) δ 3.16 (t, J=5.76 Hz, 2 H), 4.10 (t, J=5.76 Hz, 2 H), 7.49 (m, 3 H), 7.68 (d, J=8.14 Hz, 2 H), 7.72 (d, J=8.82 Hz, 2 H), 7.89 (d, J=8.48 Hz, 2 H), 8.07 (t, J=2.03 Hz, 1 H), 8.22 (dd, J=8.48, 1.70 Hz, 1 H), 8.29 (d, J=6.44 Hz, 1 H), 8.45 (s, 1 H), 8.53 (d, J=8.82 Hz, 1 H), 8.57 (d, J=6.44 Hz, 1 H), 8.63 (d, J=2.03 Hz, 1 H), 9.10 (d, J=1.70

Hz, 1 H), 9.72 (s, 1 H); Anal. Calcd for $C_{28}H_{24}N_4O_2S$ •3.1 TFA: C, 49.25; H, 3.27; N, 6.72.

Found: C, 49.20; H, 3.24; N, 6.62.

Example 392

1-Methyl-1*H*-imidazole-4-sulfonic acid (2-amino-ethyl)-(5-isoquinolin-6-yl-pyridin-3-yl)-amide

5

The desired product was prepared as the trifluoroacetate by substituting 1-methylimidazole-4-sulfonyl chloride for 2-naphthalenesulfonyl chloride in Example 387. MS (APCI) m/z 409 (M+1)⁺; ¹H NMR (300 MHz, CD₃OD) δ 3.19 (t, *J*=5.59 Hz, 2 H), 3.77 (s, 3 H), 4.18 (t, *J*=5.59 Hz, 2 H), 7.71 (s, 1 H), 7.89 (s, 1 H), 8.31 (m, 2 H), 8.50 (d, *J*=6.44 Hz, 1 H), 8.57 (d, *J*=8.14 Hz, 1 H), 8.59 (s, 1 H), 8.62 (d, *J*=8.48 Hz, 1 H), 8.64 (d, *J*=6.44 Hz, 1 H), 9.07 (d, *J*=2.03 Hz, 1 H), 9.78 (s, 1 H); Anal. Calcd for $C_{26}H_{20}N_6O_2S$ •3.8 TFA: C, 39.38; H, 2.85; N, 9.98. Found: C, 39.35; H, 2.73; N, 9.79.

Example 393

3-Amino-2-[5-(3-methyl-1*H*-indazol-5-yl)-pyridin-3-yloxy]-propan-1-ol

15

Example 393A

[3-(*tert*-Butyl-dimethyl-silanyloxy)-2-hydroxy-propyl]-carbamic acid *tert*-butyl ester

To a solution of *t*-butyl *N*-(2,3-dihydroxypropyl)carbamate (9.0 g, 47 mmol) in CH₂Cl₂ (75 mL) was added *t*-butyldimethylsilyl chloride (7.80 g, 51.7 mmol), triethylamine (7.86 mL, 56.4 mmol) and DMAP (230 mg). The solution was stirred at rt overnight. After diluting with CH₂Cl₂ (50 mL), the solution was washed with water (2x100 mL), dried over MgSO₄ and concentrated. The residual oil was distilled by Kugelrohr under vacuum to give the desired product (13.6 g, 95%). MS (DCI) m/z 306 (M+1)⁺.

25

Example 393B

[2-(5-Bromo-pyridin-3-yloxy)-3-(*tert*-butyl-dimethyl-silanyloxy)-propyl]-carbamic acid *tert*-butyl ester

A 100 mL RBF was charged with 3-bromo-5-hydroxypyridine (949 mg, 5.45 mmol), Example 393A (2.0 g, 6.45 mmol) and Ph₃P (1.72 g, 6.54 mmol), and was purged with nitrogen. THF (22 mL) was added at 0 °C. After stirring at 0 °C for 10 min, DEAD (1.03 mL, 6.54 mmol) was added via syringe. The reaction mixture was stirred at 0 °C for 1 h and at rt overnight. The reaction mixture was concentrated and the residue was separated by flash chromatography (5-30% EtOAc in hexane) to provide the desired product (1.76 g, 70%). MS (DCI) m/z 461, 463 (M+1)⁺.

35

Example 393C

5-[5-[2-*tert*-Butoxycarbonylamino-1-(*tert*-butyl-dimethyl-silyloxyethyl)-ethoxy]-pyridin-3-yl]-3-methyl-indazole-1-carboxylic acid *tert*-butyl ester

A 100 mL RBF was charged with Example 393B (1.60 g, 3.47 mmol), Example 203B (1.37 g, 3.47 mmol), $\text{Pd}_2(\text{dba})_3$ (318 mg, 0.347 mmol), and tri-*o*-tolylphosphine (318 mg), and was purged with N_2 . Anhydrous DMF (50 mL) and Et_3N (1.45 mL) were added via syringe. The solution was purged with N_2 again and was heated at 75 °C for 5 h. After cooled, ethyl acetate (200 mL) was added. The mixture was washed with brine (250 mL) and water (250 mL). The ethyl acetate solution was concentrated and the residual oil was separated by flash chromatography (20-60% EtOAc in hexane) to give the desired product (1.51 g, 71%). MS (DCI) m/z 613 (M+1)⁺.

Example 393D

5-[5-(2-*tert*-Butoxycarbonylamino-1-hydroxymethyl-ethoxy)-pyridin-3-yl]-3-methyl-indazole-1-carboxylic acid *tert*-butyl ester

To a solution of Example 393C (1.122 g, 1.83 mmol) in THF (20 mL) was added TBAF (1.92 mL) at rt. The solution was stirred at rt for 1 h and was concentrated. The residual oil was separated by flash chromatography (0-15% CH_3OH in 2:1 EtOAc/hexane) to give the title compound (0.82 g, 90%). MS (DCI) m/z 499 (M+1)⁺.

Example 393E

3-Amino-2-[5-(3-methyl-1*H*-indazol-5-yl)-pyridin-3-yl]propan-1-ol

The desired product was prepared as HCl salt by substituting Example 393D for Example 27B in Examples 27C. MS (APCI) m/z 299 (M+1)⁺; ¹H NMR (300 MHz, DMSO-d_6) δ 2.58 (s, 3 H), 3.26 (m, 2 H), 3.68 (dd, $J=12.21, 5.09$ Hz, 1 H), 3.75 (dd, $J=12.54, 4.75$ Hz, 1 H), 5.05 (m, $J=4.07$ Hz, 1 H), 7.62 (d, $J=8.81$ Hz, 1 H), 7.85 (dd, $J=8.81, 1.70$ Hz, 1 H), 8.35 (s, 4 H), 8.52 (s, 1 H), 8.64 (d, $J=2.37$ Hz, 1 H), 8.90 (s, 1 H); Anal. Calcd for $\text{C}_{16}\text{H}_{18}\text{N}_4\text{O}_2 \cdot 3.2 \text{ HCl}$: C, 46.31; H, 5.15; N, 13.50. Found: C, 46.46; H, 5.12; N, 13.42.

Example 394

2-[5-(3-Methyl-1*H*-indazol-5-yl)-pyridin-3-yl]phenoxy-propylamine

Example 394A

5-[5-(2-*tert*-Butoxycarbonylamino-1-phenoxyethyl-ethoxy)-pyridin-3-yl]-3-methyl-indazole-1-carboxylic acid *tert*-butyl ester

A 25 mL RBF was charged with phenol (42 mg, 0.45 mmol), Example 393D (150 mg, 0.3 mmol) and Ph_3P (142 mg, 0.54 mmol), and was purged with nitrogen. THF (4 mL) was added at 0 °C. After stirring at 0 °C for 10 min, DEAD (85 μL , 0.54 mmol) was added via syringe. The reaction mixture was stirred at 0 °C for 1 h and at rt overnight. The reaction

mixture was concentrated and the residue was separated by flash chromatography (20-60% EtOAc in hexane) to provide the desire product (163 mg, 95%). MS (DCI) m/z 575 (M+1)⁺.

Example 394B

2-[5-(3-Methyl-1*H*-indazol-5-yl)-pyridin-3-yloxy]-3-phenoxy-propylamine

5 The desired product was prepared as the trifluoroacetate by substituting Example 394A for Example 27B in Examples 27C. MS (APCI) m/z 375 (M+1)⁺; ¹H NMR (300 MHz, CD₃OD) δ 2.62 (s, 3 H), 3.58 (d, *J*=5.76 Hz, 2 H), 4.34 (dd, *J*=11.19, 5.09 Hz, 1 H), 4.42 (dd, *J*=11.19, 3.73 Hz, 1 H), 5.33 (m, 1 H), 6.94 (m, 3 H), 7.26 (dd, *J*=8.81, 7.46 Hz, 2 H), 7.62 (d, *J*=7.80 Hz, 1 H), 7.72 (dd, *J*=8.81, 1.70 Hz, 1 H), 8.09 (s, 1 H), 8.27 (s, 1 H), 8.52 (d, *J*=2.37 Hz, 1 H), 8.75 (d, *J*=1.36 Hz, 1 H); Anal. Calcd for C₂₂H₂₂N₄O₂•2 TFA: C, 51.83; H, 4.02; N, 9.30. Found: C, 51.97; H, 3.97; N, 9.41.

10

Example 395

2-[5-(3-Methyl-1*H*-indazol-5-yl)-pyridin-3-yloxy]-3-(naphthalen-2-yloxy)-propylamine

The desired product was prepared as the trifluoroacetate by substituting 2-naphthol for phenol in Examples 394. MS (APCI) m/z 425 (M+1)⁺; ¹H NMR (300 MHz, CD₃OD) δ 2.56 (s, 3 H), 3.62 (d, *J*=5.76 Hz, 2 H), 4.47 (dd, *J*=11.19, 5.09 Hz, 1 H), 4.56 (dd, *J*=11.19, 3.73 Hz, 1 H), 5.36 (m, 1 H), 7.08 (dd, *J*=8.98, 2.54 Hz, 1 H), 7.28 (m, 1 H), 7.33 (d, *J*=8.14 Hz, 1 H), 7.40 (t, *J*=8.14 Hz, 1 H), 7.54 (d, *J*=8.48 Hz, 1 H), 7.62 (dd, *J*=10.17, 1.70 Hz, 1 H), 7.71 (d, *J*=8.14 Hz, 1 H), 7.72 (d, *J*=2.03 Hz, 1 H), 7.74 (s, 1 H), 8.00 (s, 1 H), 8.11 (m, 1 H), 8.50 (d, *J*=2.37 Hz, 1 H), 8.68 (d, *J*=1.36 Hz, 1 H); Anal. Calcd for C₂₆H₂₄N₄O₂•2.8 TFA: C, 51.03; H, 3.63; N, 7.53. Found: C, 51.18; H, 3.47; N, 7.55.

20

Example 396

3-(Biphenyl-4-yloxy)-2-[5-(3-methyl-1*H*-indazol-5-yl)-pyridin-3-yloxy]-propylamine

The desired product was prepared as the trifluoroacetate by substituting 4-phenylphenol for phenol in Examples 394. MS (APCI) m/z 452 (M+1)⁺; ¹H NMR (300 MHz, CD₃OD) δ 2.57 (s, 3 H), 3.58 (d, *J*=6.10 Hz, 2 H), 4.39 (dd, *J*=11.19, 5.09 Hz, 1 H), 4.47 (dd, *J*=11.53, 3.73 Hz, 1 H), 5.30 (m, 1 H), 6.99 (d, *J*=8.81 Hz, 2 H), 7.27 (d, *J*=7.12 Hz, 1 H), 7.36 (t, *J*=7.46 Hz, 2 H), 7.51 (m, 4 H), 7.57 (d, *J*=8.48 Hz, 1 H), 7.67 (dd, *J*=8.81, 1.70 Hz, 1 H), 8.03 (s, 1 H), 8.09 (dd, *J*=4.41, 2.37 Hz, 1 H), 8.49 (d, *J*=2.37 Hz, 1 H), 8.69 (s, 1 H); Anal. Calcd for C₂₈H₂₆N₄O₂•3.2 TFA: C, 50.67; H, 3.61; N, 6.87. Found: C, 50.77; H, 3.51; N, 6.64.

30

Example 397

2-[5-(3-Methyl-1*H*-indazol-5-yl)-pyridin-3-yloxy]-3-(quinolin-7-yloxy)-propylamine

The desired product was prepared as the trifluoroacetate by substituting 7-hydroxyquinoline for phenol in Examples 394. MS (APCI) m/z 426 (M+1)⁺; ¹H NMR (300 MHz, CD₃OD) δ 2.59 (s, 3 H), 3.64 (d, *J*=5.76 Hz, 2 H), 4.62 (dd, *J*=10.85, 5.09 Hz, 1 H), 4.70 (d, *J*=11.19 Hz, 1 H), 5.42 (m, 1 H), 7.50 (dd, *J*=9.32, 2.20 Hz, 1 H), 7.58 (dd, *J*=5.26, 3.22 Hz, 2 H), 7.69 (d, *J*=8.48 Hz, 1 H), 7.78 (dd, *J*=8.14, 5.43 Hz, 1 H), 8.03 (s, 1 H), 8.07 (s, 1 H), 8.16 (d,

35

J=9.16 Hz, 1 H), 8.47 (s, 1 H), 8.67 (s, 1 H), 8.88 (d, *J*=8.14 Hz, 1 H), 8.98 (d, *J*=4.41 Hz, 1 H); Anal. Calcd for C₂₅H₂₃N₅O₂•3.9 TFA: C, 45.27; H, 3.12; N, 8.05. Found: C, 45.26; H, 3.05; N, 7.92.

Example 398

5 2-[5-(3-Methyl-1*H*-indazol-5-yl)-pyridin-3-yloxy]-3-(pyridin-4-yloxy)-propylamine

The desired product was prepared as HCl salt by substituting 4-hydroxypyridine for phenol in Examples 394. MS (APCI) m/z 376 (M+1)⁺; ¹H NMR (300 MHz, DMSO-d₆) δ 2.58 (s, 3 H), 3.40 (br s, 2 H), 4.75 (d, *J*=11.87 Hz, 1 H), 4.85 (d, *J*=11.49 Hz, 1 H), 5.61 (m, 1 H), 7.59 (m, 2 H), 7.86 (d, *J*=8.82 Hz, 1 H), 8.37 (s, 1 H), 8.56 (s, 1 H), 8.66 (s, 1 H), 8.73 (s, 2 H), 8.79 (s, 1 H), 8.81 (s, 1 H), 8.92 (s, 1 H); Anal. Calcd for C₂₁H₂₁N₅O₂•4.5 HCl: C, 46.75; H, 4.76; N, 12.98. Found: C, 46.77; H, 4.41; N, 12.83.

10 Example 399

2-[5-(3-Methyl-1*H*-indazol-5-yl)-pyridin-3-yloxy]-3-(naphthalen-1-yloxy)-propylamine

The desired product was prepared as the trifluoroacetate by substituting 1-naphthol for phenol in Examples 394. MS (APCI) m/z 426 (M+1)⁺; ¹H NMR (300 MHz, CD₃OD) δ 3.34 (s, 3 H), 3.65 (d, *J*=5.76 Hz, 2 H), 4.57 (m, 2 H), 5.49 (m, 1 H), 6.97 (d, *J*=7.46 Hz, 1 H), 7.23 (t, *J*=7.63 Hz, 1 H), 7.37 (d, *J*=7.46 Hz, 1 H), 7.41 (d, *J*=8.82 Hz, 1 H), 7.44 (d, *J*=8.48 Hz, 1 H), 7.56 (s, 2 H), 7.74 (d, *J*=8.48 Hz, 1 H), 7.84 (d, *J*=7.80 Hz, 1 H), 7.92 (s, 1 H), 8.15 (s, 1 H), 8.50 (d, *J*=2.03 Hz, 1 H), 8.65 (s, 1 H); Anal. Calcd for C₂₆H₂₄N₄O₂•3.1 TFA: C, 49.71; H, 3.51; N, 7.20. Found: C, 49.70; H, 3.47; N, 7.07.

20 Example 400

3-[(2*S*)-2-Amino-3-[5-(3-methyl-1*H*-indazol-5-yl)-pyridin-3-yloxy]-propyl]-1*H*-indol-5-ol

25 Example 400A

(2*S*)-2-*tert*-Butoxycarbonylamino-3-(5-hydroxy-1*H*-indol-3-yl)-propionic acid methyl ester

To a solution of BOC-5-hydroxy-tryptophan (5.9 g, 18.4 mmol) and iodomethane (3.43 mL) in DMF (80 mL) was added powdered KHCO₃ (3.68 g). The reaction mixture was stirred at rt for 4 hours. EtOAc (500 mL) was added and the mixture was washed with brine (500 mL) and water (500 mL). The organic phase was concentrated and the residual oil was triturated with CH₂Cl₂ (20 mL). The formed white solid was collected by filtration, washed with CH₂Cl₂ (20 mL) and dried to give the desired product (4.48 g, 73%). MS (DCI) m/z 335 (M+1)⁺.

35 Example 400B

(2*S*)-2-*tert*-Butoxycarbonylamino-3-[5-(*tert*-butyl-dimethyl-silyloxy)-1*H*-indol-3-yl]-propionic acid methyl ester

To a solution of Example 400A (1.20 g, 3.59 mmol) in DMF (20 mL) was added *t*-butyldimethylsilyl chloride (649 mg, 4.3 mmol), imidazole (293 mg, 4.3 mmol) and DMAP (50 mg) at rt. The reaction mixture was stirred at rt for 16 hours. EtOAc (100 mL) was added and the mixture was washed with brine (100 mL) and water (100 mL). The organic phase was concentrated and the residual oil was purified by flash chromatography (10-40% EtOAc in hexane) to give the desire product (1.6 g, 100%). MS (DCI) m/z 466 (M+18)⁺.

5
10
15
20
25
30

Example 400C

(1*S*)-{2-[5-(*tert*-Butyl-dimethyl-silyloxy)-1*H*-indol-3-yl]-1-hydroxymethyl-ethyl}-carbamic acid *tert*-butyl ester

To a solution of Example 400B (1.50 g, 3.3 mmol) in THF (15 mL) was slowly added LiAlH₄ powder (127 mg, 3.3 mmol) in several portion at rt. After the addition, the reaction mixture was becoming sticky and the stirring stopped. The temperature of the mixture arises to ~50 °C. Ether (30 mL) was added and the mixture was stirred for 20 min. Methanol (2 mL) and diluted HCl was added slowly and the mixture was extracted with ether. The organic phase was washed with water and concentrated. The residue was separated by flash chromatography (20-60% EtOAc in hexane) to give the desired product (982 mg, 70%). MS (DCI) m/z 421 (M+1)⁺.

Example 400D

(1*S*)-{2-(5-Bromo-pyridin-3-yloxy)-1-[5-(*tert*-butyl-dimethyl-silyloxy)-1*H*-indol-3-ylmethyl]-ethyl}-carbamic acid *tert*-butyl ester

A 100 mL RBF was charged with 3-bromo-5-hydroxypyridine (432 mg, 2.48 mmol), Example 400C (950 mg, 2.26 mmol) and Ph₃P (711 mg, 2.71 mmol), and was purged with nitrogen. THF (15 mL) was added at 0 °C. After stirring at 0 °C for 10 min, DEAD (427 μL, 2.71 mmol) was added via syringe. The reaction mixture was stirred at 0 °C for 1 h and at rt overnight. The reaction mixture was concentrated and the residue was separated by flash chromatography (10-50% EtOAc in hexane) to provide the desired product (1.05 g, 80%). MS (APCI) m/z 576, 578 (M+1)⁺.

Example 400E

5-(5-{(2*S*)-2-*tert*-Butoxycarbonylamino-3-[5-(*tert*-butyl-dimethyl-silyloxy)-1*H*-indol-3-yl]-propoxy}-pyridin-3-yl)-3-methyl-indazole-1-carboxylic acid *tert*-butyl ester

The desire product was prepared by substituting Example 400D for Example 202A in Example 203C. MS (DCI) m/z 728 (M+1)⁺.

Example 400F

5-[(2S)-2-*tert*-Butoxycarbonylamino-3-(5-hydroxy-1*H*-indol-3-yl)-propoxy]-pyridin-3-yl}-3-methyl-indazole-1-carboxylic acid *tert*-butyl ester

To a solution of Example 400E (850 mg, 1.17 mmol) in THF (10 mL) was added TBAF (1.28 mL, 1.28 mmol) at rt. The solution was stirred at rt for 2 h and was concentrated. The residual oil was purified by flash chromatography (0-15% CH₃OH in 2:1 EtOAc/hexane) to give the desired product (530 mg, 74%). MS (DCI) m/z 614 (M+1)[†].

Example 400G

3-[(2S)-2-Amino-3-[5-(3-methyl-1*H*-indazol-5-yl)-pyridin-3-yloxy]-propyl]-1*H*-indol-5-ol

The desired product was prepared as the trifluoroacetate by substituting Example 400F for Example 27B in Examples 27C. MS (APCI) m/z 414 (M+1)[†]; ¹H NMR (300 MHz, CD₃OD) δ 2.63 (s, 3 H), 3.25 (dd, *J*=7.12, 2.37 Hz, 2 H), 3.98 (m, 1 H), 4.35 (dd, *J*=10.51, 5.76 Hz, 1 H), 4.48 (dd, *J*=10.51, 3.39 Hz, 1 H), 6.70 (dd, *J*=8.48, 2.37 Hz, 1 H), 6.93 (d, *J*=2.03 Hz, 1 H), 7.18 (s, 1 H), 7.20 (d, *J*=8.48 Hz, 1 H), 7.63 (d, *J*=8.81 Hz, 1 H), 7.71 (dd, *J*=8.81, 2.03 Hz, 1 H), 8.11 (m, 2 H), 8.41 (d, *J*=2.37 Hz, 1 H), 8.74 (d, *J*=1.70 Hz, 1 H); Anal. Calcd for C₂₄H₂₃N₅O₂•3.7 TFA: C, 45.15; H, 3.22; N, 8.38. Found: C, 45.15; H, 3.45; N, 8.43.

Example 401

(1*S*)-1-(5-Methoxy-1*H*-indol-3-ylmethyl)-2-[5-(3-methyl-1*H*-indazol-5-yl)-pyridin-3-yloxy]-ethylamine

Example 401A

5-[(2S)-2-*tert*-Butoxycarbonylamino-3-(5-methoxy-1*H*-indol-3-yl)-propoxy]-pyridin-3-yl}-3-methyl-indazole-1-carboxylic acid *tert*-butyl ester

A 25 mL RBF was charged with Example 400F (100 mg, 0.163 mmol) and Ph₃P (85 mg, 0.325 mmol), and was purged with nitrogen. THF (4 mL) and methanol (14 μ L) were added at 0 °C. After stirring at 0°C for 10 min, DEAD (51 μ L, 0.325 mmol) was added via syringe. The reaction mixture was stirred at 0°C for 1 h and at rt over weekend. The reaction mixture was concentrated and the residue was separated by flash chromatography (50-80% EtOAc in hexane) to provide the desired product (33 mg, 32%). MS (APCI) m/z 628 (M+1)[†].

Example 401B

(1*S*)-1-(5-Methoxy-1*H*-indol-3-ylmethyl)-2-[5-(3-methyl-1*H*-indazol-5-yl)-pyridin-3-yloxy]-ethylamine

The desired product was prepared as the trifluoroacetate by substituting Example 401A for Example 27B in Examples 27C. MS (APCI) m/z 428 (M+1)[†]; ¹H NMR (300 MHz, CD₃OD) δ 2.62 (s, 3 H), 3.33 (m, 2 H), 3.70 (s, 3 H), 3.98 (m, 1 H), 4.32 (dd, *J*=10.51, 5.42 Hz, 1 H), 4.45 (dd, *J*=10.51, 3.05 Hz, 1 H), 6.78 (dd, *J*=8.81, 2.37 Hz, 1 H), 7.05 (d, *J*=2.03 Hz, 1 H), 7.21 (s, 1 H), 7.27 (d, *J*=8.81 Hz, 1 H), 7.60 (d, *J*=7.80 Hz, 1 H), 7.67 (dd, *J*=8.81, 1.70 Hz, 1 H), 7.91 (m, 1 H), 8.03 (s, 1 H), 8.35 (d, *J*=2.03 Hz, 1 H), 8.65 (s, 1 H).

Example 402(1S)-1-(5-Ethoxy-1H-indol-3-ylmethyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine

The desired product was prepared as the trifluoroacetate by substituting ethanol for methanol in Example 401. MS (APCI) m/z 442 (M+1)⁺; ¹H NMR (300 MHz, CD₃OD) δ 1.26 (t, *J*=6.95 Hz, 3 H), 2.62 (s, 3 H), 3.35 (m, 2 H), 3.86 (q, *J*=7.12 Hz, 2 H), 3.95 (m, 1 H), 4.32 (dd, *J*=10.51, 5.42 Hz, 1 H), 4.45 (dd, *J*=10.51, 3.39 Hz, 1 H), 6.78 (dd, *J*=8.82, 2.37 Hz, 1 H), 7.02 (d, *J*=2.37 Hz, 1 H), 7.21 (s, 1 H), 7.26 (d, *J*=8.81 Hz, 1 H), 7.61 (d, *J*=9.49 Hz, 1 H), 7.68 (d, *J*=8.81 Hz, 1 H), 7.97 (s, 1 H), 8.05 (s, 1 H), 8.37 (d, *J*=2.37 Hz, 1 H), 8.68 (d, *J*=1.36 Hz, 1 H); Anal. Calcd for C₂₆H₂₇N₅O₂•3.2 TFA: C, 48.26; H, 3.77; N, 8.68. Found: C, 48.14; H, 3.60; N, 8.45.

Example 403(1S)-1-(5-Butoxy-1H-indol-3-ylmethyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine

The desired product was prepared as the trifluoroacetate by substituting *n*-butanol for methanol in Example 401. MS (APCI) m/z 470 (M+1)⁺; ¹H NMR (300 MHz, CD₃OD) δ 0.87 (t, *J*=7.36 Hz, 3 H), 1.37 (m, 2 H), 1.59 (m, 2 H), 2.61 (s, 3 H), 3.29 (m, 2 H), 3.81 (m, 2 H), 3.97 (s, 1 H), 4.35 (dd, *J*=10.13, 4.91 Hz, 1 H), 4.46 (d, *J*=7.98 Hz, 1 H), 6.76 (d, *J*=8.59 Hz, 1 H), 7.01 (s, 1 H), 7.21 (s, 1 H), 7.25 (d, *J*=8.59 Hz, 1 H), 7.61 (d, *J*=8.59 Hz, 1 H), 7.68 (d, *J*=8.59 Hz, 1 H), 8.06 (s, 2 H), 8.38 (s, 1 H), 8.71 (s, 1 H); Anal. Calcd for C₂₈H₃₁N₅O₂•2.8 TFA: C, 51.16; H, 4.32; N, 8.88. Found: C, 51.36; H, 4.51; N, 8.99.

Example 404(1S)-1-(5-Isopropoxy-1H-indol-3-ylmethyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine

The desired product was prepared as the trifluoroacetate by substituting isopropanol for methanol in Example 401. MS (APCI) m/z 456 (M+1)⁺; ¹H NMR (400 MHz, CD₃OD) δ 1.18 (m, 6 H), 2.61 (s, 3 H), 3.30 (m, 2 H), 3.97 (s, 1 H), 4.38 (m, 2 H), 4.48 (d, *J*=8.29 Hz, 1 H), 6.77 (d, *J*=7.98 Hz, 1 H), 7.07 (s, 1 H), 7.23 (s, 1 H), 7.26 (d, *J*=8.90 Hz, 1 H), 7.61 (d, *J*=8.90 Hz, 1 H), 7.69 (d, *J*=8.59 Hz, 1 H), 8.08 (s, 1 H), 8.12 (s, 1 H), 8.42 (s, 1 H), 8.74 (s, 1 H); Anal. Calcd for C₂₇H₂₉N₅O₂•3.2 TFA: C, 48.90; H, 3.96; N, 8.54. Found: C, 48.93; H, 3.88; N, 8.55.

Example 4053-(1H-Indol-3-yl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-propan-1-olExample 405A2-(5-Bromo-pyridin-3-yloxy)-3-(1H-indol-3-yl)-propionic acid methyl ester

A 100 mL RBF was charged with 3-bromo-5-hydroxypyridine (1.67 g, 9.58 mmol), 2-hydroxy-3-(1*H*-indol-3-yl)-propionic acid methyl ester (2.1 g, 9.58 mmol) which was synthesized according to literature method (M. E. Jung *et al* *J. Org. Chem.* 1999, 64, 2976) and Ph₃P (3.01 g, 11.5 mmol), and was purged with nitrogen. THF (40 mL) was added at 0 °C. After stirring at 0°C for 10 min, DEAD (1.81 mL, 11.5 mmol) was added via syringe. The reaction mixture was stirred at 0°C for 1 h and at rt overnight. The reaction mixture was concentrated and the residue was separated by flash chromatography (20-60% EtOAc in hexane) to provide the desired product (3.4 g, 94%). MS (DCI) m/z 375, 377 (M+1)⁺.

10

Example 405B2-(5-Bromo-pyridin-3-yloxy)-3-(1*H*-indol-3-yl)-propan-1-ol

To a solution of Example 405A (3.2 g, 8.5 mmol) in THF (20 mL) and ether (30 mL) was slowly added LiAlH₄ powder (323 mg, 8.5 mmol) in several portion at rt. While LAH was added a lot of solid material precipitated from the solution and the temperature arises to about 40 °C. Water (2 mL) and diluted HCl was added slowly and the mixture was neutralized with NaHCO₃ and extracted with ethyl acetate. The organic phase was washed with water and concentrated. The residue was separated by flash chromatography (20-80% EtOAc in hexane) to give the desired product (1.24 g, 42%). MS (DCI) m/z 347, 349 (M+1)⁺.

20

Example 405C5-{5-[1-Hydroxymethyl-2-(1*H*-indol-3-yl)-ethoxy]-pyridin-3-yl}-3-methyl-indazole-1-carboxylic acid *tert*-butyl ester

A 50 mL RBF was charged with Example 405B (580 mg, 1.67 mmol), Example 203B (660 mg, 1.67 mmol), Pd₂(dba)₃ (153 mg, 0.167 mmol), and tri-*o*-tolylphosphine (153 mg), and was purged with N₂. Anhydrous DMF (22 mL) and Et₃N (0.698 mL) were added via syringe. The solution was purged with N₂ again and was heated at 70 °C for 15 h. After cooled, ethyl acetate (100 mL) was added. The mixture was washed with brine (100 mL) and water (100 mL). The ethyl acetate solution was concentrated and the residual oil was separated by flash chromatography (0-15% CH₃OH in 2:1 EtOAc/hexane) to give the desired product (656 mg, 79%). MS (APCI) m/z 499 (M+1)⁺.

Example 405D3-(1*H*-Indol-3-yl)-2-[5-(3-methyl-1*H*-indazol-5-yl)-pyridin-3-yloxy]-propan-1-ol

The desired product was prepared as the trifluoroacetate by substituting Example 405C for Example 27B in Examples 27C. MS (APCI) m/z 399 (M+1)⁺; ¹H NMR (400 MHz, CD₃OD) δ 2.56 (s, 3 H), 3.09 (dd, *J*=14.73, 8.90 Hz, 1 H), 3.19 (dd, *J*=15.04, 3.99 Hz, 1 H), 3.85 (dd, *J*=12.12, 6.60 Hz, 1 H), 3.92 (m, 1 H), 4.99 (m, 1 H), 6.97 (dd, *J*=6.14, 3.07 Hz, 2 H), 7.07 (s, 1 H), 7.16 (m, 1 H), 7.25 (dd, *J*=8.75, 1.38 Hz, 1 H), 7.49 (d, *J*=8.90 Hz, 1 H), 7.57 (dd,

J=6.14, 2.76 Hz, 1 H), 7.84 (d, *J*=10.43 Hz, 2 H), 8.14 (s, 1 H), 8.38 (s, 1 H); Anal. Calcd for C₂₄H₂₂N₄O₂•1.7 TFA: C, 55.56; H, 4.03; N, 9.46. Found: C, 55.69; H, 4.02; N, 9.58.

Example 406

3-(1*H*-Indol-3-yl)-2-[5-(3-methyl-1*H*-indazol-5-yl)-pyridin-3-yloxy]-propylamine

5

Example 406A

5-[5-[1-Azidomethyl-2-(1*H*-indol-3-yl)-ethoxy]-pyridin-3-yl]-3-methyl-indazole-1-carboxylic acid *tert*-butyl ester

A 50 mL RBF was charged with Example 405C (580 mg, 1.16 mmol) and Ph₃P (456 mg, 1.74 mmol), and was purged with nitrogen. THF (14 mL) was added at 0°C, followed by addition of DPPA (375 μ L, 1.74 mmol). After stirring at 0°C for 1 min, DEAD (274 μ L, 1.74 mmol) was added via syringe. The reaction mixture was stirred at 0°C for 0.5 h and at rt overnight.

The reaction mixture was concentrated and the residue was separated by flash chromatography (20-80% EtOAc in hexane) to provide the desired product (534 mg, 87%).

15 MS (APCI) m/z 524 (M+1)⁺.

Example 406B

5-[5-[1-Aminomethyl-2-(1*H*-indol-3-yl)-ethoxy]-pyridin-3-yl]-3-methyl-indazole-1-carboxylic acid *tert*-butyl ester

20 To a solution of Example 406A (480 mg) in ethanol was added 10% Pd/C (160 mg) under nitrogen. This suspension was purged with hydrogen (3 circles) and was stirred under hydrogen (balloon) for 4 h. The solid material was filtered off and the filtrate was concentrated to give the desired product (443 mg, 97%). MS (APCI) m/z 498 (M+1)⁺.

Example 406C

3-(1*H*-Indol-3-yl)-2-[5-(3-methyl-1*H*-indazol-5-yl)-pyridin-3-yloxy]-propylamine

The desired product was prepared as the trifluoroacetate by substituting Example 406B for Example 27B in Examples 27C. MS (APCI) m/z 398 (M+1)⁺; ¹H NMR (300 MHz, CD₃OD) δ 2.62 (s, 3 H), 3.29 (m, 2 H), 3.40 (dd, *J*=13.56, 9.15 Hz, 1 H), 3.53 (dd, *J*=13.90, 2.71 Hz, 1 H), 5.32 (m, 1 H), 7.03 (m, 2 H), 7.14 (s, 1 H), 7.20 (dd, *J*=6.27, 2.54 Hz, 1 H), 7.28 (dd, *J*=8.81, 1.70 Hz, 1 H), 7.55 (d, *J*=8.48 Hz, 1 H), 7.59 (dd, *J*=6.10, 2.37 Hz, 1 H), 7.80 (s, 1 H), 7.85 (s, 1 H), 8.22 (d, *J*=2.37 Hz, 1 H), 8.47 (s, 1 H); Anal. Calcd for C₂₄H₂₃N₅O•3.3 TFA: C, 47.50; H, 3.43; N, 9.05. Found: C, 47.41; H, 3.71; N, 9.11.

Example 407

Naphthalene-2-sulfonic acid (2-amino-ethyl)-[5-(3-methyl-1*H*-indazol-5-yl)-pyridin-3-yl]-amide

35

Example 407A

{2-[(5-Bromo-pyridin-3-yl)-(naphthalene-2-sulfonyl)-amino]-ethyl}-carbamic acid *tert*-butyl ester

To a solution of Example 386A (50 mg, 0.158 mmol) in pyridine (2 mL) was added 2-naphthalenesulfonyl chloride (72 mg, 0.316 mmol) at rt. The formed yellow solution was 5 stirred at rt for 15 h. Pyridine was removed by blowing with nitrogen and the residual yellow solid was purified by flash chromatography (30-60% EtOAc in hexane) to the desired product (81 mg, 100%). MS (DCI) m/z 506, 508 (M+1)⁺.

Example 407B

10 {2-[(5-(3-Methyl-1*H*-indazol-5-yl)-pyridin-3-yl)-(naphthalene-2-sulfonyl)-amino]-ethyl}-carbamic acid *tert*-butyl ester

A 25 mL RBF was charged with Example 407A (78 mg, 0.154 mmol), Example 203B (45 mg, 0.154 mmol), Pd₂(dba)₃ (14 mg, 0.0154 mmol), and tri-*o*-tolylphosphine (14 mg), and was purged with N₂. Anhydrous DMF (4 mL) and Et₃N (64 μ L) were added via syringe. The 15 solution was purged with N₂ again and was heated at 70°C for 15 h. After cooled, ethyl acetate (50 mL) was added. The mixture was washed with brine (50 mL) and water (50 mL). The ethyl acetate solution was concentrated and the residual oil was separated by flash chromatography (A: 2:1 EtOAc/hexane, 0-15% CH₃OH/A) to give the desired product (54 mg, 63%). MS (APCI) m/z 558 (M+1)⁺.

20 Example 407C

Naphthalene-2-sulfonic acid (2-amino-ethyl)-[5-(3-methyl-1*H*-indazol-5-yl)-pyridin-3-yl]-amide

The desired product was prepared as the trifluoroacetate by substituting Example 407B for Example 27B in Examples 27C. MS (APCI) m/z 458 (M+1)⁺; ¹H NMR (300 MHz, CD₃OD) δ 2.50 (s, 3 H), 3.14 (t, *J*=5.59 Hz, 2 H), 4.06 (t, *J*=5.59 Hz, 2 H), 7.48 (m, 2 H), 7.66 (m, 2 H), 7.74 (d, *J*=8.14 Hz, 1 H), 7.77 (d, *J*=8.14 Hz, 1 H), 7.80 (t, *J*=2.03 Hz, 1 H), 8.02 (d, *J*=8.14 Hz, 1 H), 8.06 (d, *J*=8.48 Hz, 1 H), 8.14 (d, *J*=8.48 Hz, 1 H), 8.28 (s, 1 H), 8.47 (d, *J*=2.37 Hz, 1 H), 8.92 (d, *J*=1.70 Hz, 1 H); Anal. Calcd for C₂₅H₂₃N₅O₂S•3.3 TFA: C, 45.52; H, 3.18; N, 8.40. Found: C, 45.42; H, 3.13; N, 8.43.

30) Example 408

Biphenyl-4-sulfonic acid (2-amino-ethyl)-[5-(3-methyl-1*H*-indazol-5-yl)-pyridin-3-yl]-amide

The desired product was prepared as the trifluoroacetate by substituting 4-biphenylsulfonyl chloride for 2-naphthalenesulfonyl chloride in Examples 407. MS (APCI) m/z 484 (M+1)⁺; ¹H NMR (300 MHz, DMSO-d₆) δ 2.42 (s, 3 H), 2.96 (m, 2 H), 3.95 (m, 2 H), 7.54 (m, 4 H), 7.69 (d, *J*=8.48 Hz, 2 H), 7.77 (d, *J*=7.12 Hz, 2 H), 7.95 (m, 5 H), 8.45 (s, 1 H), 8.98 (s, 1 H); Anal. Calcd for C₂₇H₂₅N₅O₂S•1.3 TFA: C, 56.27; H, 4.20; N, 11.08. Found: C, 56.00; H, 4.21; N, 10.87.

Example 4095-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3-isopropylidene-1,3-dihydro-indol-2-one

The desired compound was prepared by as the trifluoroacetate salt substituting 5-Bromo-3-isopropylidene-1,3-dihydro-indol-2-one (L. Sun, et al., *J. Med. Chem.*, **1998**, *41*, 2588.) for 6-bromophthalimide in Example 32. ^1H NMR (400 MHz, CD_3OD) δ ppm 2.47 (s, 3H), 2.60 (s, 3H), 3.31 (m, 2H), 4.01 (m, 1H), 4.34 (dd, $J=10.43, 5.83$ Hz, 1H), 4.47 (dd, $J=10.43, 3.38$ Hz, 1H), 7.01 (t, $J=7.06$ Hz, 1H), 7.04 (d, $J=7.98$ Hz, 1H), 7.12 (t, $J=7.06$ Hz, 1H), 7.24 (s, 1H), 7.38 (d, $J=8.29$ Hz, 1H), 7.50 (dd, $J=7.98, 1.84$ Hz, 1H), 7.58 (d, $J=7.98$ Hz, 1H), 7.79 (d, $J=1.53$ Hz, 1H), 7.97 (d, $J=1.84$ Hz, 1H), 8.37 (s, 1H), 8.63 (s, 1H); Anal. Calcd for $\text{C}_{27}\text{H}_{26}\text{N}_4\text{O}_2$: C, 52.14; H, 3.88; N, 7.51. Found: C, 52.19; H, 3.67; N, 7.42.

Example 4105-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3-(1H-imidazol-2-ylmethylene)-1,3-dihydro-indol-2-one

The desired compound was prepared by as the trifluoroacetate salt substituting 5-Bromo-3-(1H-imidazol-2-ylmethylene)-1,3-dihydro-indol-2-one (L. Sun, et al., *J. Med. Chem.*, **1998**, *41*, 2588.) for 6-bromophthalimide in Example 32. MS (DCI/ NH_3) m/z 477 ($\text{M}+1$) $^+$; ^1H NMR (500 MHz, CD_3OD) δ ppm 3.31 (m, 2H), 4.04 (m, 1H), 4.37 (dd, $J=10.45, 5.77$ Hz, 1H), 4.50 (dd, $J=10.29, 3.12$ Hz, 1H), 7.02 (t, $J=7.49$ Hz, 1H), 7.11 (d, $J=7.49$ Hz, 1H), 7.13 (m, 1H), 7.25 (s, 1H), 7.38 (d, $J=8.11$ Hz, 1H), 7.60 (d, $J=7.80$ Hz, 1H), 7.72 (d, $J=8.11$ Hz, 1H), 7.77 (s, 2H), 7.85 (s, 1H), 8.02 (s, 1H), 8.13 (s, 1H), 8.42 (s, 1H), 8.67 (s, 1H).

Example 4115-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3-pyridin-2-ylmethylene-1,3-dihydro-indol-2-one

The desired compound was prepared by as the trifluoroacetate salt substituting 5-Bromo-3-pyridin-2-ylmethylene-1,3-dihydro-indol-2-one (L. Sun, et al., *J. Med. Chem.*, **1998**, *41*, 2588.) for 6-bromophthalimide in Example 32. MS (DCI/ NH_3) m/z 488 ($\text{M}+1$) $^+$; ^1H NMR (500 MHz, CD_3OD) δ ppm 3.32 (m, 2H), 4.02 (m, 1H), 4.34 (dd, $J=10.61, 5.62$ Hz, 1H), 4.47 (dd, $J=10.45, 3.28$ Hz, 1H), 7.03 (t, $J=7.02$ Hz, 1H), 7.13 (m, 1H), 7.19 (d, $J=8.11$ Hz, 1H), 7.25 (s, 1H), 7.38 (d, $J=8.42$ Hz, 1H), 7.60 (d, $J=7.80$ Hz, 1H), 7.76 (dd, $J=8.11, 1.87$ Hz, 1H), 7.94 (dd, $J=2.50, 1.87$ Hz, 1H), 8.14 (m, 1H), 8.17 (s, 1H), 8.26 (d, $J=1.56$ Hz, 1H), 8.38 (d, $J=7.80$ Hz, 1H), 8.41 (s, 1H), 8.66 (s, 1H), 8.72 (m, 1H), 9.08 (dd, $J=5.62, 1.56$ Hz, 1H); Anal. Calcd for $\text{C}_{30}\text{H}_{25}\text{N}_5\text{O}_2$: C, 47.41; H, 3.02; N, 7.16. Found: C, 47.40; H, 2.93; N, 6.98.

Example 4125-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3-furan-2-ylmethylene-1,3-dihydro-indol-2-one

The desired compound was prepared by as the trifluoroacetate salt substituting 5-Bromo-3-furan-2-ylmethylene-1,3-dihydro-indol-2-one (L. Sun, et al., *J. Med. Chem.*, 1998, 41, 2588.) for 6-bromophthalimide in Example 32. MS (DCI/NH₃) m/z 477 (M+1)⁺; ¹H NMR (500 MHz, CD₃OD) δ ppm 3.34 (m, 4H), 4.06 (m, 2H), 4.37 (dd, *J*=10.45, 5.77 Hz, 2H), 4.51 (dd, *J*=10.45, 3.28 Hz, 2H), 6.68 (dd, *J*=3.28, 1.40 Hz, 1H), 6.72 (dd, *J*=3.59, 1.72 Hz, 1H), 7.02 (t, *J*=7.64 Hz, 2H), 7.05 (d, *J*=8.11 Hz, 2H), 7.12 (m, 3H), 7.26 (s, 1H), 7.27 (s, 1H), 7.38 (d, *J*=8.11 Hz, 2H), 7.43 (s, 1H), 7.55 (d, *J*=1.87 Hz, 1H), 7.58 (dd, *J*=8.11, 1.87 Hz, 1H), 7.61 (d, *J*=7.80 Hz, 2H), 7.73 (s, 1H), 7.77 (d, *J*=1.56 Hz, 1H), 7.85 (d, *J*=1.87 Hz, 1H), 7.97 (d, *J*=1.56 Hz, 1H), 8.06 (d, *J*=4.37 Hz, 1H), 8.15 (d, *J*=1.87 Hz, 1H), 8.30 (d, *J*=3.43 Hz, 1H), 8.44 (m, 2H), 8.69 (s, 1H), 8.73 (d, *J*=1.87 Hz, 2H); Anal. Calcd for C₂₉H₂₄N₄O₃: C, 50.33; H, 3.24; N, 6.61. Found: C, 50.30; H, 3.12; N, 6.65.

Example 413

5-[5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxyl]pyridin-3-yl]-3-(5-methyl-furan-2-ylmethylene)-1,3-dihydro-indol-2-one

The desired compound was prepared by as the trifluoroacetate salt substituting 5-Bromo-3-(5-methyl-furan-2-ylmethylene)-1,3-dihydro-indol-2-one (L. Sun, et al., *J. Med. Chem.*, 1998, 41, 2588.) 6-bromophthalimide in Example 32. MS (DCI/NH₃) m/z 477 (M+1)⁺; ¹H NMR (500 MHz, CD₃OD) δ ppm 2.41 (s, 3H), 3.32 (m, 2H), (4.02 (m, 1H), 4.31 (dd, *J*=10.45, 5.77 Hz, 1H), 4.45 (dd, *J*=10.45, 3.28 Hz, 1H), 6.38 (dd, *J*=3.43, 0.94 Hz, 1H), 7.03 (m, 3H), 7.12 (t, *J*=7.18 Hz, 1H), 7.24 (s, 1H), 7.37 (s, 1H), 7.38 (d, *J*=8.11 Hz, 1H), 7.54 (dd, *J*=8.11, 1.87 Hz, 1H), 7.60 (d, *J*=8.11 Hz, 1H), 7.90 (dd, *J*=2.50, 1.87 Hz, 1H), 8.38 (s, 1H), 8.64 (s, 1H), 8.73 (s, 1H); Anal. Calcd for C₃₀H₂₆N₄O₃: C, 49.59; H, 3.31; N, 6.22. Found: C, 4990; H, 3.18; N, 6.10.

Example 414

5-[5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxyl]pyridin-3-yl]-3-(4,5-dimethyl-furan-2-ylmethylene)-1,3-dihydro-indol-2-one

The desired compound was prepared by as the trifluoroacetate salt substituting 5-Bromo-3-(4,5-dimethyl-furan-2-ylmethylene)-1,3-dihydro-indol-2-one (L. Sun, et al., *J. Med. Chem.*, 1998, 41, 2588.) for 6-bromophthalimide in Example 32. MS (DCI/NH₃) m/z 505 (M+1)⁺; ¹H NMR (500 MHz, CD₃OD) δ ppm 1.99 (s, 3H), 2.27 (s, 3H), 3.34 (m, 2H), 4.06 (m, 1H), 4.37 (dd, *J*=10.45, 5.77 Hz, 1H), 4.51 (dd, *J*=10.45, 3.28 Hz, 1H), 6.82 (s, 1H), 6.99 (d, *J*=8.42 Hz, 1H), 7.03 (t, *J*=7.02 Hz, 1H), 7.13 (t, *J*=7.02 Hz, 1H), 7.21 (s, 1H), 7.27 (s, 1H), 7.39 (d, *J*=8.11 Hz, 1H), 7.52 (dd, *J*=8.11, 1.87 Hz, 1H), 7.61 (d, *J*=8.11 Hz, 1H), 8.05 (s, 1H), 8.45 (s, 1H), 8.62 (d, *J*=1.56 Hz, 1H), 8.66 (s, 1H); Anal. Calcd for C₃₁H₂₈N₄O₃: C, 52.92; H, 3.73; N, 6.71. Found: C, 52.90; H, 3.45; N, 6.97.

Example 415

5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3-thiophen-2-ylmethylene-1,3-dihydro-indol-2-one

The desired compound was prepared by as the trifluoroacetate salt substituting 5-Bromo-3-thiophen-2-ylmethylene-1,3-dihydro-indol-2-one (L. Sun, et al., *J. Med. Chem.*, 1998, 41, 2588.) for 6-bromophthalimide in Example 32. MS (APCI) m/z 493 (M+1)⁺; ¹H NMR (500 MHz, CD₃OD) δ ppm 3.32 (m, 4H), 4.03 (m, 2H), 4.30 (dd, *J*=10.45, 5.77 Hz, 1H), 4.35 (dd, *J*=10.61, 5.93 Hz, 1H), 4.44 (dd, *J*=10.29, 3.12 Hz, 1H), 4.48 (dd, *J*=10.61, 3.12 Hz, 1H), 7.02 (m, 2H), 7.04 (s, 1H), 7.06 (d, *J*=0.94 Hz, 1H), 7.08 (d, *J*=8.11 Hz, 1H), 7.14 (t, *J*=7.49 Hz, 2H), 7.20 (dd, *J*=4.99, 3.74 Hz, 1H), 7.23 (d, *J*=1.25 Hz, 1H), 7.24 (s, 1H), 7.26 (m, 1H), 7.37 (s, 1H), 7.39 (d, *J*=8.11 Hz, 1H), 7.53 (dd, *J*=8.11, 1.87 Hz, 1H), 7.56 (dd, *J*=8.11, 1.56 Hz, 1H), 7.59 (s, 1H), 7.61 (d, *J*=7.80 Hz, 1H), 7.71 (d, *J*=2.50 Hz, 1H), 7.74 (d, *J*=5.30 Hz, 1H), 7.79 (d, *J*=4.99 Hz, 1H), 7.92 (s, 1H), 7.93 (s, 1H), 7.96 (s, 1H), 7.98 (d, *J*=1.56 Hz, 1H), 8.09 (s, 1H), 8.37 (s, 2H), 8.48 (d, *J*=1.56 Hz, 1H), 8.56 (s, 1H), 8.65 (s, 1H); Anal. Calcd for C₂₉H₂₄N₄O₂S: C, 50.37; H, 3.26; N, 6.71. Found: C, 50.52; H, 3.45; N, 6.84.

15

(A-441246) Example 416

5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3-(1-methyl-1H-pyrrol-2-ylmethylene)-1,3-dihydro-indol-2-one

The desired compound was prepared by as the trifluoroacetate salt substituting 5-Bromo-3-(1-methyl-1H-pyrrol-2-ylmethylene)-1,3-dihydro-indol-2-one (L. Sun, et al., *J. Med. Chem.*, 1998, 41, 2588.) for 6-bromophthalimide in Example 32. MS (APCI) m/z 490 (M+1)⁺; ¹H NMR (500 MHz, CD₃OD) δ ppm 3.32 (m, 4H), 3.81 (s, 3H), 3.89 (s, 3H), 4.03 (m, 2H), 4.30 (dd, *J*=10.61, 5.93 Hz, 1H), 4.37 (dd, *J*=10.61, 5.93 Hz, 1H), 4.44 (dd, *J*=10.45, 3.28 Hz, 1H), 4.50 (dd, *J*=10.29, 3.12 Hz, 1H), 6.28 (m, 2H), 7.02 (m, 3H), 7.07 (m, 3H), 7.12 (m, 2H), 7.19 (d, *J*=3.74 Hz, 1H), 7.24 (s, 1H), 7.26 (s, 1H), 7.38 (d, *J*=8.11 Hz, 1H), 7.39 (d, *J*=8.11 Hz, 1H), 7.46 (dd, *J*=8.11, 1.87 Hz, 1H), 7.50 (dd, *J*=8.27, 1.72 Hz, 1H), 7.59 (d, *J*=7.80 Hz, 1H), 7.61 (d, *J*=8.11 Hz, 1H), 7.70 (s, 1H), 7.74 (s, 1H), 7.86 (s, 1H), 7.98 (d, *J*=1.87 Hz, 1H), 8.08 (s, 1H), 8.30 (dd, *J*=4.37, 1.56 Hz, 1H), 8.34 (d, *J*=1.56 Hz, 1H), 8.38 (s, 2H), 8.57 (s, 1H), 8.73 (s, 1H); Anal. Calcd for C₃₀H₂₇N₅O₂: C, 55.28; H, 3.93; N, 9.32. Found: C, 55.32; H, 3.57; N, 9.08

Example 417

5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3-(1H-indol-3-ylmethylene)-1,3-dihydro-indol-2-one

The desired compound was prepared by as the trifluoroacetate salt substituting 5-Bromo-3-(1H-indol-3-ylmethylene)-1,3-dihydro-indol-2-one (L. Sun, et al., *J. Med. Chem.*, 1998, 41, 2588.) 6-bromophthalimide in Example 32. MS (APCI) m/z 526 (M+1)⁺; ¹H NMR (500 MHz, CD₃OD) δ ppm 3.32 (m, 4H), 4.05 (m, 2H), 4.15 (m, 1H), 4.25 (m, 1H), 4.38 (d, *J*=5.93

Hz, 1H), 4.49 (dd, $J=10.29$, 3.12 Hz, 1H), 7.02 (m, 2H), 7.06 (m, 1H), 7.09 (m, 2H), 7.14 (t, $J=7.64$ Hz, 2H), 7.23 (m, 4H), 7.28 (s, 1H), 7.39 (m, 2H), 7.43 (d, $J=4.99$ Hz, 1H), 7.47 (m, 4H), 7.56 (d, $J=8.11$ Hz, 1H), 7.59 (s, 1H), 7.63 (d, $J=8.11$ Hz, 2H), 8.01 (m, 2H), 8.06 (d, $J=1.56$ Hz, 1H), 8.12 (s, 2H), 8.24 (s, 1H), 8.28 (s, 1H), 8.35 (s, 2H), 8.72 (s, 1H), 9.40 (s, 1H); Anal. Calcd for $C_{33}H_{27}N_5O_2$: C, 53.99; H, 3.48; N, 8.07. Found: C, 54.27; H, 3.64; N, 7.84

5 Example 418

5-[5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl]-3-(1-phenyl-1H-pyrrol-3-ylmethylene)-1,3-dihydro-indol-2-one

The desired compound was prepared by as the trifluoroacetate salt substituting 5-Bromo-3-(2,5-dimethyl-1-phenyl-1H-pyrrol-3-ylmethylene)-1,3-dihydro-indol-2-one (L. Sun, et al., *J. Med. Chem.*, 1998, 41, 2588.) 6-bromophthalimide in Example 32. MS (APCI) m/z 580 (M+1)⁺; ¹H NMR (500 MHz, CD₃OD) δ ppm 1.98 (s, 3 H) 2.01 (s, 3 H) 2.18 (s, 3 H) 2.28 (s, 3 H) 3.32 (m, 4H), 4.02 (m, 2 H) 4.32 (dd, $J=10.45$, 5.46 Hz, 1 H) 4.37 (dd, $J=10.61$, 5.93 Hz, 1 H) 4.49 (m, 2 H) 6.68 (m, 1 H) 7.01 (m, 3 H) 7.10 (m, 3 H) 7.25 (m, 6 H) 7.36 (t, $J=8.73$ Hz, 2 H) 7.47 (m, 3 H) 7.57 (m, 8 H) 7.84 (d, $J=2.18$ Hz, 2 H) 7.93 (s, 2 H) 8.13 (s, 1 H) 8.32 (s, 1 H) 8.38 (s, 2 H) 8.60 (s, 1 H) 8.73 (s, 1 H); Anal. Calcd for $C_{33}H_{33}N_5O_2$: C, 54.38; H, 3.79; N, 7.24. Found: C, 54.45; H, 3.92; N, 6.97.

10 Example 419

5-[5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl]-3-pyridin-3-ylmethylene-1,3-dihydro-indol-2-one

The desired compound was prepared by as the trifluoroacetate salt substituting 5-Bromo-3-pyridin-3-ylmethylene-1,3-dihydro-indol-2-one (L. Sun, et al., *J. Med. Chem.*, 1998, 41, 2588.) 6-bromophthalimide in Example 32. MS (APCI) m/z 488 (M+1)⁺; ¹H NMR (500 MHz, CD₃OD) δ ppm 3.32 (m, 4H), 4.03 (m, 2H), 4.26 (dd, $J=10.45$, 5.46 Hz, 1H), 4.36 (dd, $J=10.45$, 5.77 Hz, 1H), 4.40 (dd, $J=10.29$, 3.12 Hz, 1H), 4.49 (dd, $J=10.29$, 3.12 Hz, 1H), 7.01 (m, 1H), 7.05 (m, 3H), 7.08 (d, $J=8.11$ Hz, 1H), 7.12 (t, $J=7.64$ Hz, 2H), 7.23 (s, 1H), 7.25 (s, 1H), 7.38 (d, $J=8.11$ Hz, 1H), 7.57 (m, 1H), 7.59 (m, 1H), 7.61 (s, 1H), 7.64 (dd, $J=8.11$, 1.87 Hz, 1H), 7.66 (m, 1H), 7.71 (m, 1H), 7.78 (s, 1H), 7.93 (s, 1H), 7.99 (m, $J=8.27$, 5.77 Hz, 3H), 8.09 (d, $J=1.56$ Hz, 1H), 8.34 (d, $J=8.11$ Hz, 2H), 8.41 (m, 2H), 8.56 (d, $J=4.68$ Hz, 1H), 8.67 (s, 1H), 8.77 (d, $J=5.30$ Hz, 1H), 9.01 (s, 1H), 9.11 (d, $J=8.11$ Hz, 1H), 9.69 (s, 1H); Anal. Calcd for $C_{30}H_{25}N_5O_2$: C, 49.22; H, 3.17; N, 7.65. Found: C, 49.23; H, 3.15; N, 7.38.

20 Example 420

5-[5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl]-3-(1H-pyrrol-3-ylmethylene)-1,3-dihydro-indol-2-one

25 The desired compound was prepared by as the trifluoroacetate salt substituting 5-Bromo-3-(1H-pyrrol-3-ylmethylene)-1,3-dihydro-indol-2-one (L. Sun, et al., *J. Med. Chem.*, 1998, 41, 2588.) for 6-bromophthalimide in Example 32. MS (APCI) m/z 476 (M+1)⁺; ¹H NMR (500

MHz, CD₃OD) δ ppm 3.32 (m, 4H), 4.04 (m, 2H), 4.32 (dd, *J*=10.45, 5.77 Hz, 1H), 4.38 (dd, *J*=10.61, 5.93 Hz, 1H), 4.46 (dd, *J*=10.45, 3.28 Hz, 1H), 4.50 (dd, *J*=10.29, 3.12 Hz, 1H), 6.77 (dd, *J*=2.81, 1.56 Hz, 1H), 6.85 (dd, *J*=2.65, 2.03 Hz, 1H), 6.91 (m, 1H), 7.04 (m, 5H), 7.13 (m, 2H), 7.24 (s, 1H), 7.26 (s, 1H), 7.39 (t, *J*=7.49 Hz, 2H), 7.43 (s, 1H), 7.48 (m, 2H), 7.60 (m, *J*=8.73, 8.73 Hz, 2H), 7.80 (s, 1H), 7.84 (s, 1H), 7.90 (m, 2H), 8.09 (s, 1H), 8.16 (s, 1H), 8.28 (d, *J*=1.56 Hz, 1H), 8.39 (s, 2H), 8.59 (s, 1H), 8.70 (s, 1H); Anal. Calcd for C₂₅H₂₅N₅O₂: C, 51.42; H, 3.45; N, 8.57. Found: C, 51.73; H, 3.41; N, 8.58.

5

Example 421

10

5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3-(tetrahydro-pyran-4-ylidene)-1,3-dihydro-indol-2-one


The desired compound was prepared by as the trifluoroacetate salt substituting 5-Bromo-3-(tetrahydro-pyran-4-ylidene)-1,3-dihydro-indol-2-one (L. Sun, et al., *J. Med. Chem.*, 1998, 41, 2588.) 6-bromophthalimide in Example 32. MS (APCI) m/z 481 (M+1)⁺; ¹H NMR (400 MHz, DMSO-d₆) δ ppm 3.02 (t, *J*=5.52 Hz, 2H), 3.19 (m, 2H) 3.44 (t, *J*=5.52 Hz, 2H), 3.80 (m, 5H), 4.18 (dd, *J*=10.74, 5.83 Hz, 1H), 4.34 (m, 1H), 7.00 (m, 1H), 7.10 (t, *J*=7.06 Hz, 1H), 7.29 (d, *J*=2.15 Hz, 1H), 7.38 (d, *J*=7.98 Hz, 1H), 7.49 (dd, *J*=8.13, 1.69 Hz, 1H), 7.62 (m, 2H), 7.85 (s, 1H), 8.23 (s, 2H), 8.24 (s, 1H), 8.32 (d, *J*=2.76 Hz, 1H), 8.55 (d, *J*=1.53 Hz, 1H), 10.67 (s, 1H), 11.03 (d, *J*=1.84 Hz, 1H); Anal. Calcd for C₂₉H₂₈N₄O₃: C, 55.38; H, 4.21; N, 7.78. Found: C, 55.29; H, 4.12; N, 7.70.

20

Example 422

5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3-(4-ethyl-3,5-dimethyl-1H-pyrrol-2-ylmethylene)-1,3-dihydro-indol-2-one

The desired compound was prepared by as the trifluoroacetate salt substituting 5-Bromo-3-(4-ethyl-3,5-dimethyl-1H-pyrrol-2-ylmethylene)-1,3-dihydro-indol-2-one (L. Sun, et al., *J. Med. Chem.*, 1998, 41, 2588.) 6-bromophthalimide in Example 32. MS (APCI) m/z 530 (M-1)⁺; ¹H NMR (500 MHz, CD₃OD) δ ppm 1.10 (t, *J*=7.52 Hz, 3H), 2.31 (s, 3H), 2.34 (s, 3H), 2.49 (q, *J*=7.57 Hz, 2H), 3.32 (m, 2H), 4.03 (m, 1H), 4.36 (dd, *J*=10.59, 5.68 Hz, 1H), 4.49 (m, 1H), 7.05 (m, 2H), 7.13 (t, *J*=7.06 Hz, 1H), 7.25 (s, 1H), 7.41 (m, 2H), 7.61 (d, *J*=7.67 Hz, 1H), 7.66 (s, 1H), 7.93 (d, *J*=1.53 Hz, 1H), 8.07 (m, 1H), 8.37 (s, 1H), 8.72 (s, 1H); Anal. Calcd for C₃₃H₃₃N₅O₂: C, 54.94; H, 4.29; N, 8.34. Found: C, 55.03; H, 4.09; N, 8.20.



(A-485149) Example 423

5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3-cyclopropylmethylen-1,3-dihydro-indol-2-one

The desired compound was prepared by as the trifluoroacetate salt substituting 5-Bromo-3-cyclopropylmethylen-1,3-dihydro-indol-2-one (L. Sun, et al., *J. Med. Chem.*, 1998, 41, 2588.) 6-bromophthalimide in Example 32. MS (APCI) m/z 451 (M+1)⁺; ¹H NMR (400 MHz, DMSO-d₆) δ ppm 0.79 (m, *J*=4.30, 2.45 Hz, 2H), 0.93 (m, 3H), 1.19 (m, 5H), 2.52 (m, 4H), 3.84 (s, 2H), 4.19 (m, 2H), 4.35 (m, 2H), 6.33 (d, *J*=11.66 Hz, 1H), 6.59 (d, *J*=11.05 Hz, 1H), 6.92 (d, *J*=7.98 Hz, 1H), 7.00 (m, 1H), 7.10 (t, *J*=7.06 Hz, 2H), 7.29 (d, *J*=2.15 Hz, 2H), 7.38 (d, *J*=8.29 Hz, 2H), 7.51 (m, 2H), 7.62 (d, *J*=7.67 Hz, 2H), 7.69 (m, *J*=5.06, 3.22 Hz, 2H), 7.86 (d, *J*=1.84 Hz, 1H), 8.03 (d, *J*=1.53 Hz, 1H), 8.23 (br s, 3H), 8.24 (br s, 3H), 8.32 (d, *J*=2.76 Hz, 1H), 8.33 (d, *J*=2.76 Hz, 1H), 8.57 (d, *J*=1.53 Hz, 1H), 8.60 (d, *J*=1.84 Hz, 1H), 10.54 (s, 1H), 10.58 (s, 1H), 11.03 (d, *J*=1.84 Hz, 2H); Anal. Calcd for C₂₈H₂₆N₄O₂: C, 55.48; H, 4.05; N, 7.99. Found: C, 55.63; H, 3.98; N, 7.90.

Example 424

15 5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3-pyrrolidin-2-ylmethylen-1,3-dihydro-indol-2-one

The desired compound was prepared by as the trifluoroacetate salt substituting 5-Bromo-3-pyrrolidin-2-ylmethylen-1,3-dihydro-indol-2-one (L. Sun, et al., *J. Med. Chem.*, 1998, 41, 2588.) 6-bromophthalimide in Example 32. MS (APCI) m/z 480 (M+1)⁺; ¹H NMR (400 MHz, CD₃OD) δ ppm 1.53 (m, 1H), 1.60 (m, 1H), 1.70 (m, 1H), 2.01 (m, 1H), 2.20 (m, 2H), 2.49 (m, 1H), 3.44 (m, 2H), 4.01 (m, 1H), 4.32 (dd, *J*=10.43, 5.83 Hz, 1H), 4.46 (m, 1H), 7.05 (m, 3H), 7.13 (t, *J*=7.67 Hz, 1H), 7.24 (s, 1H), 7.38 (d, *J*=8.29 Hz, 1H), 7.61 (m, 2H), 7.92 (m, 2H), 8.36 (s, 1H), 8.59 (s, 1H); Anal. Calcd for C₂₉H₂₉N₅O₂: C, 52.24; H, 4.03; N, 8.83. Found: C, 52.32; H, 4.24; N, 8.63.

Example 425

5-(5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl)-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-furan-2-carboxylic acid

The desired compound was prepared by as the trifluoroacetate salt substituting 5-(5-Bromo-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-furan-2-carboxylic acid (L. Sun, et al., *J. Med. Chem.*, 1998, 41, 2588.) for 6-bromophthalimide in Example 32. MS (APCI) m/z 521 (M+1)⁺; ¹H NMR (400 MHz, DMSO-d₆) δ ppm 3.16 (d, *J*=6.75 Hz, 2H), 3.86 (m, 1H), 4.21 (dd, *J*=10.74, 6.44 Hz, 1H), 4.41 (m, 1H), 6.97 (t, *J*=6.90 Hz, 1H), 7.03 (d, *J*=7.98 Hz, 1H), 7.08 (t, *J*=7.06 Hz, 1H), 7.29 (d, *J*=2.46 Hz, 1H), 7.37 (d, *J*=8.29 Hz, 1H), 7.40 (d, *J*=3.99 Hz, 1H), 7.44 (m, 1H), 7.47 (s, 1H), 7.62 (m, 2H), 7.71 (m, 1H), 8.17 (br s, 2H), 8.33 (d, *J*=2.45 Hz, 1H), 8.71 (d, *J*=1.84 Hz, 1H), 8.98 (d, *J*=1.84 Hz, 1H), 10.84 (s, 1H), 11.01 (d, *J*=2.15 Hz, 1H); Anal. Calcd for C₃₀H₂₄N₄O₅: C, 51.75; H, 3.28; N, 6.86. Found: C, 51.69; H, 3.16; N, 6.71.

Example 4265-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3-benzylidene-1,3-dihydro-indol-2-one

The desired compound was prepared by as the trifluoroacetate salt substituting 3-Benzylidene-5-bromo-1,3-dihydro-indol-2-one (L. Sun, et al., *J. Med. Chem.*, **1998**, *41*, 2588.) for 6-bromophthalimide in Example 32. MS (APCI) m/z 485 (M-1)⁺; ¹H NMR (500 MHz, CD₃OD) δ ppm 3.32 (m, 2H), 4.01 (m, 1H), 4.23 (dd, *J*=10.61, 5.62 Hz, 1H), 4.37 (m, 1H), 7.03 (m, 2H), 7.13 (t, *J*=7.64 Hz, 1H), 7.22 (s, 1H), 7.34 (t, *J*=7.49 Hz, 1H), 7.39 (d, *J*=8.42 Hz, 1H), 7.44 (m, 2H), 7.53 (dd, *J*=8.27, 1.72 Hz, 1H), 7.58 (d, *J*=8.11 Hz, 1H), 7.62 (s, 1H), 7.69 (d, *J*=7.80 Hz, 1H), 7.78 (d, *J*=1.87 Hz, 1H), 7.83 (s, 1H), 8.00 (d, *J*=1.56 Hz, 1H), 8.31 (m, *J*=6.40, 2.96 Hz, 1H), 8.37 (s, 1H); Anal. Calcd for C₃₁H₂₆N₄O₂: C, 55.53; H, 3.68; N, 7.16. Found: C, 55.74; H, 3.50; N, 7.05.

Example 4275-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-1H-indole-2,3-dione 3-oxime

The desired compound was prepared by as the trifluoroacetate salt substituting 5-Bromo-1H-indole-2,3-dione 3-oxime (L. Sun, et al., *J. Med. Chem.*, **1998**, *41*, 2588.) 6-bromophthalimide in Example 32. MS (ESI) m/z 428 (M+1)⁺; ¹H NMR (500 MHz, CD₃OD) δ ppm 3.32 (m, 2H), 4.00 (m, 1H), 4.29 (dd, *J*=10.45, 5.77 Hz, 1H), 4.44 (dd, *J*=10.61, 3.12 Hz, 1H), 7.05 (m, 2H), 7.13 (t, *J*=7.17 Hz, 1H), 7.24 (s, 1H), 7.38 (d, *J*=8.11 Hz, 1H), 7.60 (d, *J*=8.11 Hz, 1H), 7.65 (dd, *J*=8.27, 2.03 Hz, 1H), 7.78 (m, 1H), 8.32 (d, *J*=1.87 Hz, 1H), 8.34 (s, 1H), 8.52 (s, 1H); Anal. Calcd for C₂₄H₂₄N₂O₃: C, 51.30; H, 3.54; N, 10.68. Found: C, 50.99; H, 3.33; N, 10.47.

The following compounds were prepared by substituting the appropriate tributylsannyl reagents for (1,1,1-tributylstannyl)benzene and Example 362A for 80E in Example 364.

Example 428(1*S*)-2-(5-Benzo[*b*]thiophen-2-yl-6-furan-2-yl-pyridin-3-yloxy)-1-(1*H*-indol-3-ylmethyl)-ethylamine

MS (APCI) m/z 465 (M-1)⁺; ¹H NMR (500 MHz, CD₃OD) δ ppm 3.32 (m, 2H), 3.99 (m, 1H), 4.27 (dd, *J*=10.61, 5.62 Hz, 1H), 4.41 (m, 1H), 6.47 (dd, *J*=3.43, 1.87 Hz, 1H), 6.66 (d, *J*=3.43 Hz, 1H), 7.01 (t, *J*=7.02 Hz, 1H), 7.10 (t, *J*=8.11 Hz, 1H), 7.23 (s, 1H), 7.35 (d, *J*=8.11 Hz, 1H), 7.39 (d, *J*=1.25 Hz, 1H), 7.56 (d, *J*=2.81 Hz, 1H), 7.58 (d, *J*=7.80 Hz, 1H), 7.72 (s, 1H), 8.31 (d, *J*=6.24 Hz, 1H), 8.50 (d, *J*=2.81 Hz, 1H), 8.61 (d, *J*=6.24 Hz, 1H), 9.51 (s, 1H); Anal. Calcd for C₂₇H₂₂N₄O₂S: C, 52.57; H, 3.40; N, 7.81. Found: C, 52.35; H, 3.20; N, 7.73.

Example 429(1*S*)-2-(5-Benzo[*b*]thiophen-2-yl-6-vinyl-pyridin-3-yloxy)-1-(1*H*-indol-3-ylmethyl)-ethylamine

MS (APCI) m/z 427 (M+1)⁺; ¹H NMR (400 MHz, DMSO-d₆) δ ppm 3.15 (m, 2H), 3.85 (m, 1H), 4.17 (dd, *J*=10.76, 6.08 Hz, 1H), 4.33 (dd, *J*=10.76, 2.96 Hz, 1H), 5.44 (m, 1H), 6.30 (dd, *J*=16.85, 2.18 Hz, 1H), 6.93 (dd, *J*=16.69, 10.76 Hz, 1H), 7.00 (t, *J*=7.33 Hz, 1H), 7.08 (t, *J*=7.49 Hz, 1H), 7.29 (d, *J*=2.18 Hz, 1H), 7.36 (d, *J*=8.11 Hz, 1H), 7.51 (d, *J*=2.81 Hz, 1H), 5 7.60 (d, *J*=8.11 Hz, 1H), 7.77 (s, 1H), 8.18 (d, *J*=5.93 Hz, 1H), 8.25 (m, 2H), 8.51 (d, *J*=2.81 Hz, 1H), 8.67 (d, *J*=5.93 Hz, 1H), 9.56 (s, 1H), 11.02 (s, 1H); Anal. Calcd for C₂₅H₂₂N₄OS: C, 48.44; H, 3.28; N, 7.29. Found: C, 48.38; H, 3.32; N, 7.02.

Example 430

(1*S*)-2-(5-Benzo[*b*]thiophen-2-yl-6-thiophen-2-yl-pyridin-3-yloxy)-1-(1*H*-indol-3-ylmethyl)-10 ethylamine

MS (APCI) m/z 481 (M-1)⁺; ¹H NMR (500 MHz, DMSO-d₆) δ ppm 3.15 (m, 2H), 3.85 (m, 1H), 4.18 (dd, *J*=10.76, 6.08 Hz, 1H), 4.34 (dd, *J*=10.61, 3.12 Hz, 1H), 6.71 (dd, *J*=3.59, 1.09 Hz, 1H), 6.90 (dd, *J*=4.99, 3.74 Hz, 1H), 7.00 (t, *J*=7.02 Hz, 1H), 7.08 (t, *J*=7.18 Hz, 1H), 7.29 (d, *J*=2.18 Hz, 1H), 7.36 (d, *J*=7.80 Hz, 1H), 7.55 (dd, *J*=5.15, 1.09 Hz, 1H), 7.57 (d, 15 *J*=2.81 Hz, 1H), 7.60 (d, *J*=7.80 Hz, 1H), 7.78 (s, 1H), 8.13 (d, *J*=5.93 Hz, 1H), 8.23 (br s, 2H), 8.50 (d, *J*=2.81 Hz, 1H), 8.64 (d, *J*=5.93 Hz, 1H), 9.50 (s, 1H), 11.02 (d, *J*=1.56 Hz, 1H); Anal. Calcd for C₂₇H₂₂N₄OS₂: C, 48.83; H, 3.12; N, 6.99. Found: C, 48.74; H, 3.07; N, 6.88.

Example 431

(1*S*)-2-(5-Benzo[*b*]thiophen-2-yl-6-thiazol-2-yl-pyridin-3-yloxy)-1-(1*H*-indol-3-ylmethyl)-20 ethylamine

MS (APCI) m/z 484 (M+1)⁺; ¹H NMR (500 MHz, DMSO-d₆) δ ppm 3.15 (m, 2H), 3.84 (m, *J*=14.12 Hz, 1H), 4.22 (dd, *J*=10.89, 5.98 Hz, 1H), 4.38 (dd, *J*=10.74, 3.07 Hz, 1H), 6.98 (t, *J*=7.06 Hz, 1H), 7.07 (t, *J*=7.52 Hz, 1H), 7.29 (d, *J*=2.15 Hz, 1H), 7.35 (d, *J*=7.98 Hz, 1H), 7.60 (d, *J*=7.98 Hz, 1H), 7.63 (d, *J*=2.76 Hz, 2H), 7.73 (s, 1H), 7.77 (d, *J*=3.38 Hz, 1H), 8.16 25 (d, *J*=5.83 Hz, 1H), 8.29 (br s, 2H), 8.56 (d, *J*=2.76 Hz, 1H), 8.63 (d, *J*=5.83 Hz, 1H), 9.52 (s, 1H), 11.02 (d, *J*=1.84 Hz, 1H); Anal. Calcd for C₂₆H₂₁N₅OS: C, 46.55; H, 2.93; N, 8.48. Found: C, 46.87; H, 2.97; N, 8.46.

Example 432

(1*S*)-2-(5-Benzo[*b*]thiophen-2-yl-6-pyrazin-2-yl-pyridin-3-yloxy)-1-(1*H*-indol-3-ylmethyl)-30 ethylamine

MS (APCI) m/z 479 (M-1)⁺; ¹H NMR (500 MHz, CD₃OD) δ ppm 3.32 (m, 2H), 4.02 (m, 1H), 4.33 (dd, *J*=10.61, 5.62 Hz, 1H), 4.47 (dd, *J*=10.61, 3.12 Hz, 1H), 7.02 (t, *J*=7.02 Hz, 1H), 7.10 (t, *J*=7.18 Hz, 1H), 7.25 (s, 1H), 7.36 (d, *J*=8.11 Hz, 1H), 7.60 (d, *J*=7.80 Hz, 1H), 7.63 35 (s, 1H), 7.67 (d, *J*=2.50 Hz, 1H), 8.25 (d, *J*=5.93 Hz, 1H), 8.32 (s, 1H), 8.52 (d, *J*=1.87 Hz, 1H), 8.58 (d, *J*=6.24 Hz, 1H), 8.63 (d, *J*=2.18 Hz, 1H), 9.09 (s, 1H), 9.46 (s, 1H).

Example 433

{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-3-benzo[b]thiophen-2-yl-pyridin-2-yl}-phenyl-amine

The title compound was prepared by substituting Example 362A for Example 381A in Example 318. MS (APCI) m/z 492 (M+1)⁺; ¹H NMR (500 MHz, DMSO-d₆) δ ppm 3.16 (m, 2H), 3.83 (m, J=2.50 Hz, 1H), 4.13 (dd, J=10.61, 5.93 Hz, 1H), 4.29 (dd, J=10.45, 2.96 Hz, 1H), 6.86 (t, J=7.18 Hz, 1H), 7.01 (t, J=7.49 Hz, 1H), 7.09 (t, J=7.33 Hz, 1H), 7.20 (t, J=7.80 Hz, 2H), 7.25 (m, 2H), 7.30 (d, J=2.18 Hz, 1H), 7.38 (d, J=8.11 Hz, 1H), 7.62 (d, J=7.80 Hz, 1H), 7.72 (d, J=3.12 Hz, 1H), 8.11 (s, 1H), 8.16 (d, J=3.12 Hz, 1H), 8.20 (d, J=6.24 Hz, 1H), 8.25 (br s, 2H), 8.38 (s, 1H), 8.64 (d, J=6.24 Hz, 1H), 9.55 (s, 1H), 11.03 (d, J=1.56 Hz, 1H); Anal. Calcd for C₂₉H₂₅N₅OS: C, 48.90; H, 3.26; N, 7.96. Found: C, 48.88; H, 3.13; N, 7.90.

Example 434

{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-3-benzo[b]thiophen-2-yl-pyridin-2-yl}-pyridin-3-yl-amine

The title compound was prepared by substituting 3-aminopyridine for aniline in Example 433. MS (APCI) m/z 491 (M-1)⁺; ¹H NMR (500 MHz, CD₃OD) δ ppm 3.32 (m, 2H), 3.97 (m, 1H), 4.24 (dd, J=10.29, 5.93 Hz, 1H), 4.37 (dd, J=10.45, 3.28 Hz, 1H), 7.03 (t, J=7.18 Hz, 1H), 7.11 (t, J=7.18 Hz, 1H), 7.24 (s, 1H), 7.37 (d, J=8.42 Hz, 1H), 7.59 (d, J=8.11 Hz, 1H), 7.68 (d, J=3.12 Hz, 1H), 7.87 (dd, J=8.74, 5.62 Hz, 1H), 8.05 (s, 1H), 8.24 (d, J=3.12 Hz, 1H), 8.30 (d, J=5.30 Hz, 1H), 8.32 (d, J=6.24 Hz, 1H), 8.42 (dd, J=8.73, 1.56 Hz, 1H), 8.63 (d, J=6.24 Hz, 1H), 9.15 (d, J=2.18 Hz, 1H), 9.53 (s, 1H); Anal. Calcd for C₂₈H₂₄N₆OS: C, 48.93; H, 3.26; N, 10.07. Found: C, 48.82; H, 3.35; N, 9.92.

Example 435

6-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3H-benzooxazol-2-one

The desired compound was prepared by substituting 6-Bromo-3H-benzooxazol-2-one (C. Flouzat, et al, *J. Med. Chem.*, 1993, 36, 497) for 6-bromophthalimide in Example 32. MS (APCI) m/z 401 (M+1)⁺; ¹H NMR (500 MHz, DMSO-d₆) δ ppm 3.16 (d, J=9.67 Hz, 2H), 3.85 (m, 1H), 4.18 (dd, J=10.61, 5.93 Hz, 1H), 4.34 (dd, J=10.76, 2.96 Hz, 1H), 7.01 (t, J=7.49 Hz, 1H), 7.10 (t, J=7.49 Hz, 1H), 7.20 (d, J=8.11 Hz, 1H), 7.29 (d, J=2.18 Hz, 1H), 7.38 (d, J=8.11 Hz, 1H), 7.50 (dd, J=8.11, 1.56 Hz, 1H), 7.62 (d, J=7.80 Hz, 1H), 7.65 (s, 1H), 7.70 (s, 1H), 8.18 (s, 2H), 8.33 (d, J=2.81 Hz, 1H), 8.55 (d, J=1.56 Hz, 1H); 11.02 (s, 1H), 11.81 (s, 1H); Anal. Calcd for C₂₃H₂₀N₄O₃: C, 50.53; H, 3.44; N, 8.60. Found: C, 50.71; H, 3.46; N, 8.42.

Example 436

1-Benzimidazol-1-ylmethyl-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine

35

Example 436A

3-Bromo-5-oxiranylmethoxy-pyridine

To a solution of 5-Bromo-pyridin-3-ol (0.50 g, 2.87 mmol), oxiranyl-methanol (0.38 mL, 5.74 mmol) and triphenylphosphine (1.50 g, 5.74 mmol) in anhydrous THF (20 mL) was added di-*tert*-butyl azodicarboxylate (DBAD) (1.32 g, 5.74 mmol) and the reaction mixture stirred at room temperature for 18 hrs and concentrated. The residue was purified by flash 5 column chromatography on silica gel eluting with 10%-35% ethyl acetate/hexanes to provide the desire product (0.48g, 73%).

Example 436B

1-Benzimidazol-1-yl-3-(5-bromo-pyridin-3-yloxy)-propan-2-ol

10 A solution of Example 436A (500 mg, 2.17 mmol) and 1*H*-Benzimidazole (28 mg, 2.39 mmol) in 2-propanol (10 mL) was refluxed under N₂ for 2 hrs. The reaction mixture was cooled, diluted with ethyl acetate(50 mL) and washed with brine (2 X 25 mL). The residue was concentrated and purified by flash column chromatography on silica gel eluting with 100% ethyl acetate to 5% methanol/ethyl acetate to provide the desire product (1.08 mmol, 15 50%).

Example 436C

5-[5-(3-Benzimidazol-1-yl-2-hydroxy-propoxy)-pyridin-3-yl]-3-methyl-indazole-1-carboxylic acid *tert*-butyl ester

20 The product was prepared by substituting Example 436B for Example 202A in Example 203B.

Example 436D

1-Benzimidazol-1-ylmethyl-2-[5-(3-methyl-1*H*-indazol-5-yl)-pyridin-3-yloxy]-ethylamine

25 The desired compound was prepared by as trifluoroacetic acid salt by substituting Example 436C for Example 27B in Example 27C. MS (APCI) m/z 400 (M+1)⁺; ¹H NMR (400 MHz, CD₃OD) δ ppm 2.53 (m, 3H), 4.31 (dd, *J*=13.81, 4.91 Hz, 2H), 4.42 (m, *J*=7.98, 3.38 Hz, 1H), 4.54 (m, 2H), 7.56 (m, 3H), 7.67 (dd, *J*=8.75, 1.07 Hz, 1H), 7.78 (dd, *J*=5.83, 3.38 Hz, 1H), 7.94 (dd, *J*=6.14, 3.07 Hz, 1H), 8.05 (s, 1H), 8.12 (s, 1H), 8.35 (s, 1H), 8.64 (s, 1H), 9.36 (s, 30 1H).

Example 437

2-[5-(3-Methyl-1*H*-indazol-5-yl)-pyridin-3-yloxy]-1-morpholin-4-ylmethyl-ethylamine

Example 437A

1-(5-Bromo-pyridin-3-yloxy)-3-morpholin-4-yl-propan-2-ol

The desired compound was prepared by substituting morpholine for 1*H*-Benzoimidazole in Example 437B

Example 437B

5 [2-(5-Bromo-pyridin-3-yloxy)-1-morpholin-4-ylmethyl-ethyl]-carbamic acid *tert*-butyl ester

To a solution of the Example 437A (250 mg, 0.79 mmol), isoindole-1,3-dione (121 mg, 0.82 mmol) and triphenylphosphine (240 mg, 0.92 mmol) in anhydrous THF (10 mL) was added DIAD (0.16 mL, 0.83 mmol) and stirred at room temperature for 45 mins. The concentrated residue was then purified by flash column chromatography eluting with 60% ethyl acetate/hexanes to give the desired intermediate which was dissolved in absolute ethanol (10 mL). Hydrazine monohydrate (40 μ L) was added and the reaction mixture refluxed for 3 hrs. The cloudy solution was cooled, concentrated and dissolved in DMF (10 mL). Di*tert*-butyl-dicarbonate (271 mg, 1.25 mmol) and triethyl amine (0.18 mL, 1.25 mmol) were added and the clear solution stirred at room temperature for 15 hrs. The clear solution was diluted with ethyl acetate (25 mL) and washed with brine (25 mL) and water (25 mL). The concentrated residue was further purified by flash column chromatography eluting with 15% ethyl acetate/hexanes to give the desired product.

Example 437C

20 5-[5-(2-*tert*-Butoxycarbonylamino-3-morpholin-4-yl-propoxy)-pyridin-3-yl]-3-methyl-indazole-1-carboxylic acid *tert*-butyl ester

The product was prepared by substituting Example 437B for Example 202A in Example 203B.

Example 437D

2-[5-(3-Methyl-1*H*-indazol-5-yl)-pyridin-3-yloxy]-1-morpholin-4-ylmethyl-ethylamine

The desired compound was prepared as trifluoroacetic acid salt by substituting Example 437C for Example 27B in Example 27C. MS (APCI) m/z 369 (M+1)⁺; ¹H NMR (400 MHz, CD₃OD) δ ppm 2.62 (s, 3H), 2.73 (dd, *J*=11.51, 4.76 Hz, 2H), 2.86 (m, 2H), 2.98 (m, 2H), 3.79 (t, *J*=4.45 Hz, 4H), 4.04 (m, *J*=8.59, 3.38 Hz, 1H), 4.47 (dd, *J*=10.43, 5.52 Hz, 1H), 4.59 (m, 1H), 7.64 (d, *J*=8.59 Hz, 1H), 7.76 (dd, *J*=8.90, 1.23 Hz, 1H), 8.15 (s, 1H), 8.24 (s, 1H), 8.48 (s, 1H), 8.78 (s, 1H); Anal. Calcd for C₂₀H₂₅N₅O₂: C, 44.01; H, 3.98; N, 9.87. Found: C, 43.92; H, 3.92; N, 9.73.

Example 438

35 5-[5-((2*S*)-2-Amino-3-phenyl-propoxy)-pyridin-3-yl]-1,3-dihydro-indol-2-one

The desired product was prepared by substituting Boc-phenylalaninol for Boc-tryptophanol in Example 36. MS (APCI) m/z 360 (M+1)⁺; ¹H NMR (500 MHz, CD₃OD) δ ppm 3.15 (d,

J=7.49 Hz, 2H), 3.61 (s, 2H), 3.95 (m, 1H), 4.26 (dd, *J*=10.61, 5.62 Hz, 1H), 4.40 (dd, *J*=10.61, 3.12 Hz, 1H), 7.04 (d, *J*=8.11 Hz, 1H), 7.33 (m, 5H), 7.58 (d, *J*=8.11 Hz, 1H), 7.62 (s, 1H), 7.96 (s, 1H), 8.38 (d, *J*=2.50 Hz, 1H), 8.60 (s, 1H); Anal. Calcd for C₂₂H₂₄N₃O₂: C, 51.39; H, 3.78; N, 6.76. Found: C, 51.48; H, 3.63; N, 6.75.

-5

Example 4395-[5-((2*S*)-2-Amino-3-phenyl-propoxy)-pyridin-3-yl]-3-(1*H*-pyrrol-2-ylmethylene)-1,3-dihydro-indol-2-one

The desired product was prepared by substituting Boc-phenylalaninol for Boc-tryptophanol in Example 39. MS (APCI) m/z 437 (M+1)⁺; ¹H NMR (500 MHz, CD₃OD) δ ppm 3.17 (d, *J*=7.80 Hz, 2H), 3.97 (m, 1H), 4.28 (dd, *J*=10.61, 5.62 Hz, 1H), 4.43 (dd, *J*=10.45, 2.96 Hz, 1H), 6.38 (m, 1H), 6.85 (d, *J*=3.74 Hz, 1H), 7.06 (d, *J*=8.11 Hz, 1H), 7.25 (s, 1H), 7.34 (m, 5H), 7.51 (dd, *J*=8.11, 1.87 Hz, 1H), 7.73 (s, 1H), 7.94 (s, 1H), 8.03 (s, 1H), 8.38 (d, *J*=1.87 Hz, 1H), 8.67 (s, 1H), 13.32 (s, 1H); Anal. Calcd for C₂₇H₂₄N₄O₂: C, 53.27; H, 3.70; N, 7.76. Found: C, 53.46; H, 3.69; N, 7.77.

15

Example 4405-[5-((2*S*)-2-Amino-3-phenyl-propoxy)-pyridin-3-yl]-3-furan-2-ylmethylene-1,3-dihydro-indol-2-one

The desired product was prepared by substituting Boc-phenylalaninol for Boc-tryptophanol in Example 412. MS (APCI) m/z 438 (M+1)⁺; ¹H NMR (500 MHz, CD₃OD) δ ppm 3.85 (m, 4H), 4.75 (m, 2H), 4.93 (m, 2H), 5.10 (dd, *J*=10.61, 3.12 Hz, 2H), 7.64 (dd, *J*=3.43, 1.56 Hz, 1H), 7.77 (d, *J*=8.11 Hz, 1H), 7.82 (d, *J*=8.11 Hz, 1H), 8.08 (m, 2H), 8.14 (m, 8H), 8.22 (s, 1H), 8.39 (d, *J*=1.87 Hz, 1H), 8.42 (dd, *J*=8.11, 1.87 Hz, 1H), 8.45 (s, 1H), 8.53 (s, 1H), 8.68 (s, 1H), 8.80 (d, *J*=1.56 Hz, 1H), 8.90 (d, *J*=1.87 Hz, 1H), 9.00 (d, *J*=1.56 Hz, 1H), 9.07 (s, 2H), 9.11 (d, *J*=3.43 Hz, 1H), 9.16 (br s, 2H), 9.44 (d, *J*=1.56 Hz, 1H), 11.54 (s, 1H), 11.57 (s, 1H); Anal. Calcd for C₂₇H₂₃N₃O₃: C, 55.36; H, 3.74; N, 6.21. Found: C, 55.09; H, 3.74; N, 6.07.

30

Example 441(1*S*)-1-Benzimidazol-1-ylmethyl-2-[5-(3-methyl-1*H*-indazol-5-yl)-pyridin-3-yloxy]-ethylamineExample 441A(2*R*)-1-Benzimidazol-1-yl-3-benzyloxy-propan-2-ol

A solution of 2-(3-phenyl-propyl)-oxirane (3.0 g, 18.27 mmol) and benzimidazole (2.37 g, 20.1 mmol) in anhydrous 2-propanol (50 mL) was purged with nitrogen and refluxed for 2.5 hrs. The reaction mixture was cooled, concentrated and purified by flash column chromatography on silica gel [0(1 min)-15% (16 min) methanol in 2:1 ethyl acetate/hexanes to provide the desired product (4.72 g, 91%).

Example 441B(2S)-1-(2-Azido-3-benzyloxy-propyl)-1*H*-benzoimidazole

To a solution of Example 441A (1.0 g, 3.54 mmol) and triphenylphosphine (1.39 g, 5.31 mmol) in anhydrous THF (30 mL) was added diphenylphosphoryl azide (1.14 mL, 5.31 mmol) at 0 °C followed by the addition of DEAD (836 µL). The reaction mixture was stirred at 0 °C for 30 mins and at room temperature for 15 hrs. The concentrated residue was then purified by flash column chromatography on silica gel eluting with 60%-80% ethyl acetate/hexanes to provide the desired product.


10

Example 441C(2-Benzimidazol-1-yl-1-benzyloxymethyl-ethyl)-carbamic acid *tert*-butyl ester

To a solution of the Example 441B (~ 1 g, ~3.54 mmol) in ethanol (25 mL) was added 10% Pd/C (230 mg) under nitrogen. This suspension was purged with hydrogen and was stirred under hydrogen (balloon) for 1 h. The solid material was filtered off and the filtrate was concentrated. The residual foam was dissolved in anhydrous DMF (20 mL). Triethylamine (1.08 mL, 7.78 mmol) and di-*tert*-butyl dicarbonate (0.85 g, 3.89 mmol) were then added at room temperature and the solution stirred under nitrogen for 2h. EtOAc (200 mL) was added and the mixture was washed with brine (200 mL), and water (100 mL). The organic phase was concentrated and the residue was purified by flash chromatography [60-80%(5 min) EtOAc in hexane] to give desired product.

Example 441D(1*S*)-(2-Benzimidazol-1-yl-1-hydroxymethyl-ethyl)-carbamic acid *tert*-butyl ester

25 To a solution of the Example (0.78 g) in methanol (20 mL) was added 10% Pd-C (450 mg) under nitrogen. This reaction mixture was purged with hydrogen and was stirred under hydrogen at 86 °C for 3.5 days (balloon). The filtrate was concentrated and the residual oil was separated by flash chromatography (0-15% CH₃OH in 2:1 EtOAc/hexane) to give the desired product (199.7 mg, 33%).



30

Example 441E(1*S*)-[1-Benzimidazol-1-ylmethyl-2-(5-bromo-pyridin-3-yloxy)-ethyl]-carbamic acid *tert*-butyl ester

To a solution of 5-bromo-pyridin-3-ol (102 mg, 0.58 mmol), Example 441D (154 mg, 0.53 mmol) and triphenylphosphine (208 mg, 0.793 mmol) in anhydrous THF (20 mL) was added DEAD (125 μ L, 0.79 mmol) and the reaction mixture stirred at room temperature for 2 hrs and concentrated. The residue was purified by flash column chromatography on silica gel (0-5 15% CH₃OH in 2:1 EtOAc/hexane) to give the desired product (100 mg, 43%).

Example 441F

5-[5-(3-Benzimidazol-1-yl-2-tert-butoxycarbonylamino-propoxy)-pyridin-3-yl]-3-methyl-indazole-1-carboxylic acid *tert*-butyl ester

10 The product was prepared by substituting Example 447E for Example 202A in Example 203B.

Example 441G

(1*S*)-1-Benzimidazol-1-ylmethyl-2-[5-(3-methyl-1*H*-indazol-5-yl)-pyridin-3-yloxy]-ethylamine

15 The desired compound was prepared by as trifluoroacetic acid salt by substituting Example 441F for Example 27B in Example 27C. ¹H NMR (300 MHz, CD₃OD) δ ppm 2.63 (m, 3H), 4.53 (m, 2H), 4.65 (m, 1H), 5.09 (d, $J=6.78$ Hz, 2H), 7.66 (m, 2H), 7.74 (d, $J=1.70$ Hz, 1H), 7.77 (d, $J=1.70$ Hz, 1H), 7.90 (m, 1H), 8.02 (m, 1H), 8.12 (m, 1H), 8.15 (d, $J=2.37$ Hz, 1H), 20 8.46 (d, $J=2.71$ Hz, 1H), 8.77 (d, $J=1.70$ Hz, 1H), 9.40 (s, 1H); Anal. Calcd for C₂₃H₂₂N₆O: C, 42.16; H, 2.93; N, 9.22. Found: C, 42.08; H, 3.24; N, 9.13.

Example 442

3-{3-[(2*S*)-2-Amino-3-(1*H*-indol-3-yl)-propoxy]-5-isoquinolin-6-yl-pyridin-4-yl}-acrylonitrile

Example 442A

3-Chloro-5-(4-methoxy-benzylxy)-pyridine

To a solution of 3-chloro-5-hydroxypyridine (2.0 g, 17.0 mmol), 4-methoxybenzyl alcohol (2.85 g, 25.5 mmol) and triphenylphosphine (6.68 g, 25.5 mmol) in dry THF (100 ml) DEAD (4.44 g, 25.5 mmol) was added dropwise. The resulting solution was stirred 3 hours at room temperature. The reaction solution was partitioned between ethyl acetate and water. The organic layer was washed (brine), dried (Na₂SO₄), filtered and concentrated under vacuum. Purification on silica gel with 20% ethyl acetate/ hexane to provide the title compound (1.9 g, 35 53 %). MS (DCI/NH₃) m/e 250 (M+1)⁺.

Example 442B

3-Chloro-5-(4-methoxy-benzyloxy)-pyridine-4-carbaldehyde

A solution of DIPA (1.73 g, 17.16 mmol) in THF (100 ml) was treated dropwise with n-BuLi (6.86 ml, 17.16 mmol) at 0 °C, stirred for 30 min. at 0 °C. To the reaction Example 442A (3.56 g, 14.3 mmol) in THF (10 ml) was added dropwise at -78 °C. The resulting solution 5 was stirred 1 hours at -78 °C. The mixture was quenched with methyl formate (2.0 ml). The reaction solution was partitioned between ethylacetate and water. The organic layer was washed (brine), dried (Na_2SO_4), filtered and concentrated under vacumm. Purification on silica gel with 20% ethyl acetate/ hexane to provide the title compound (2.2 g, 56 %). MS (DCI/NH₃) m/e 278 (M+1)⁺.

10


Example 442C3-[3-Chloro-5-(4-methoxy-benzyloxy)-pyridin-4-yl]-acrylonitrile

A solution of diethylmethylcyanophosponate (212 mg, 1.2 mmol) in THF (4 ml) was treated dropwise with LiHMDS (1.2 ml, 1.2 mmol) at 0 °C, stirred for 30 min. at 0 °C. treated with 15 Example 442B (277 mg, 1 mmol) in THF (1 ml). The resulting solution was stirred 1 hours. The mixture was quenched with water. The reaction solution was partitioned between ethylacetate and water. The organic layer was washed (brine), dried (Na_2SO_4), filtered and concentrated under vacumm. Purification on silica gel with 20% ethyl acetate/ hexane to provide the title compound (210 mg, 70 %). MS (DCI/NH₃) m/e 301 (M+1)⁺.

20

Example 442D3-(3-Chloro-5-hydroxy-pyridin-4-yl)-acrylonitrile

To a solution of Example 442C (1.02 g, 3.4 mmol) in dichloromethane (10 ml) THA (1 ml) was added. The resulting solution was stirred for two hours. The reaction solution was 25 partitioned between ethylacetate and water. The organic layer was washed (brine), dried (Na_2SO_4), filtered and concentrated under vacumm. Purification on silica gel with 40% ethyl acetate/ hexane to provide the title compound (600 mg, 98 %). MS (DCI/NH₃) m/e 181 (M+1)⁺.




30

Example 442E(1*S*)-[2-[5-Chloro-4-(2-cyano-vinyl)-pyridin-3-yloxy]-1-(1*H*-indol-3-ylmethyl)-ethyl]-carbamic acid *tert*-butyl ester

To a solution of Example 442D (430 mg, 2.39 mmol), *N*-alpha-(*tert*-butoxycarbonyl)-*L*-tryptophanol (762 mg, 2.6 mmol) and triphenylphosphine (1.38 g, 5.26 mmol) in dry THF (40 ml) DBAD (880 mg, 3.82 mmol) was added. The resulting solution was stirred 3 hours at 35

room temperature. The reaction solution was partitioned between ethylacetate and water. The organic layer was washed (brine), dried (Na_2SO_4), filtered and concentrated under vacumm. Purification on silica gel with 20% ethyl acetate/ hexane to provide the title compound (340 g, 32 %). MS (DCI/NH₃) m/e 453 ($M+1$)⁺.

5



Example 442F

(1S)-[2-[4-(2-Cyano-vinyl)-5-isoquinolin-6-yl-pyridin-3-yloxy]-1-(1H-indol-3-ylmethyl)-ethyl]-carbamic acid *tert*-butyl ester

To a solution of Example 442E (330 mg, 0.73 mmol), 6-(1,1,1-trimethylstannyl)-isoquinoline(276 mg, 0.95 mmol), tris(dibenzylideneacetone)-dipalladium (66.8 mg, 0.073 mmol) and 2-dicyclohexylphosphino-2'-dimethylamino-1,1'-biphenyl (57.3 mg, 0.146 mmol) in dry DMF (10 ml) triethyl amine was added under N_2 . The resulting solution was stirred 3 hours at 100 °C. The reaction solution was partitioned between ethylacetate and water. The organic layer was washed (brine), dried (Na_2SO_4), filtered and concentrated under vacumm. Purification on silica gel with 60% ethyl acetate/ hexane to provide the title compound (61 mg, 17 %).MS (DCI/NH₃) m/e 546 ($M+1$)⁺.

10

15

Example 442G

3-{3-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-5-isoquinolin-6-yl-pyridin-4-yl}-acrylonitrile

MS (DCI/NH₃) m/e 446 ($M+1$)⁺; ¹H NMR (300 MHz, D₆-DMSO) δ 11.06 (s; 1H), 9.68 (s; 1H), 8.68 (d; 1H; J =6.0 Hz), 8.58 (s; 1H), 8.44 (d; 1H; J =8.4 Hz), 8.40 (s; 1H), 8.23 (d; 1H; J =6.0 Hz), 8.20 (s; 3H), 7.80 (d; 1H; J =8.4 Hz), 7.60 (d; 1H; J =8.4 Hz), 7.44 (d; 1H; J =17.1 Hz), 7.40 (d; 1H; J =8.4 Hz), 7.30 (s; 1H), 7.11 (t; 1H; J =8.4 Hz), 7.01 (t; 1H; J =8.4 Hz), 6.24 (d; 1H; J =17.1 Hz), 4.48 (m; 1H), 4.31 (m; 1H), 3.97 (m; 1H), 3.17 (m; 2H)

20

25

Example 443

(1S)-1-(1H-Indol-3-ylmethyl)-2-(5-isoquinolin-6-yl-4-methyl-pyridin-3-yloxy)-ethylamine

The desire product was prepared by substituting methyl iodide for ethyl acetate in Example 442, omitting the step of Example 442C. MS (DCI/NH₃) m/e 409 ($M+1$)⁺; ¹H NMR (300 MHz, D₆-DMSO) δ 11.06 (s; 1H), 9.72 (s; 1H), 8.68 (d; 1H; J =6.0 Hz), 8.47 (d; 1H; J =8.4 Hz), 8.37 (s; 1H), 8.32 (s; 1H), 8.22 (m; 4H), 7.91 (d; 1H; J =8.4 Hz), 7.61 (d; 1H; J =8.4 Hz), 7.40 (d; 1H; J =8.4 Hz), 7.30 (s; 1H), 7.12 (t; 1H; J =8.4 Hz), 7.02 (t; 1H; J =8.4 Hz), 4.37 (m; 1H), 4.22 (m; 1H), 3.89 (m; 1H), 3.20 (m; 2H), 2.29 (s; 3H).

30

35

Example 4445-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3-methyl-1,3-dihydro-indol-2-one

5

Example 444A3-Methyl-1,3-dihydro-indol-2-one

A solution of oxindole (665 mg, 5.0mmol) in THF (10 ml) was treated dropwise with n-BuLi (4.4 ml, 11.0 mmol) at -78 °C, stirred for 30 min. at -78 °C. To the reaction methyliodine (2 ml) was added dropwise at -78 °C. The resulting solution was warmed up to room 10 temperature. The mixture was quenched with water. The reaction solution was partitioned between ethylacetate and water. The organic layer was washed (brine), dried (Na_2SO_4), filtered and concentrated under vacumm. Purification on silica gel with 30% ethyl acetate/ hexane to provide the title compound (630 mg, 86 %). MS (DCI/NH₃) m/e 148 (M+1)⁺.

15

Example 444B5-Bromo-3-methyl-1,3-dihydro-indol-2-one

To a solution of Example 444B (625 mg, 4.25 mmol) in acetonitrile (10 ml) NBS (757 mg, 4.25 mmol) was added at -10 °C. The mixture was stirred at -10 °C for 1 hours and 0 °C for 20 2 hours. The reaction solution was partitioned between ethylacetate and water. The organic layer was washed (brine), dried (Na_2SO_4), filtered and concentrated under vacumm. Purification on silica gel with 30% ethyl acetate/ hexane to provide the title compound (640 mg, 66 %). MS (DCI/NH₃) m/e 227 (M+1)⁺.

Example 444C25 5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3-methyl-1,3-dihydro-indol-2-one

The desired product was prepared by substituting Example 444B for 6-bromophthalimide in Example 32. ¹H NMR (300 MHz, D₆-DMSO) δ 11.04 (s; 1H), 10.49 (s 1H), 8.53 (s; 1H), 8.30 (s; 1H), 8.16 (s; 2H), 7.64 (s; 1H), 7.62 (d; 1H; J=7.5 Hz), 7.53 (d; 1H; J=7.5 Hz), 7.38 (d; 1H; J=8.7 Hz), 7.30 (s; 1H), 7.10 (t; 1H; J=8.7 Hz), 7.01 (t; 1H; J=8.7 Hz), 6.93 (d; 1H; J=8.7 Hz), 4.33 (m; 1H), 4.14 (m; 1H), 3.84 (m; 1H), 3.49 (q; 1H; J=7.5), 3.14 (m; 2H), 1.39 (d; 3H; J=7.5 Hz); MS (DCI/NH₃) m/e 413 (M+1)⁺.

Example 44535 5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3,3-dimethyl-1,3-dihydro-indol-2-one

Example 445A3,3-Dimethyl-1,3-dihydro-indol-2-one

A solution of Example 444A (500 mg, 3.4mmol) in THF (10 ml) was treated dropwise with n-BuLi (2.7 ml, 6.8 mmol) at -78 °C, stirred for 30 min. at -78 °C. To the reaction 5 methyl iodide (2 ml) was added dropwise at -78 °C. The resulting solution was warmed up to room temperature. The mixture was quenched with water. The reaction solution was partitioned between ethyl acetate and water. The organic layer was washed (brine), dried (Na₂SO₄), filtered and concentrated under vacuum. Purification on silica gel with 30% ethyl acetate/ hexane to provide the title compound (410 mg, 75 %). MS (DCI/NH₃) m/e 162 10 (M+)⁺.

Example 445B5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3,3-dimethyl-1,3-dihydro-indol-2-one

15 The title compound was prepared by substituting Example 445A for Example 444A in Example 444. ¹H NMR (300 MHz, D₆-DMSO) δ 11.03 (s; 1H), 10.49 (s; 1H), 8.56 (s; 1H), 8.31 (s; 1H), 8.18 (s; 2H), 7.70 (s; 1H), 7.64 (s; 1H), 7.61 (d; 1H; J=7.5 Hz), 7.57 (d; 1H; J=7.5 Hz), 7.38 (d; 1H; J=8.7 Hz), 7.27 (s; 1H), 7.10 (t; 1H; J=8.7 Hz), 7.01 (t; 1H; J=8.7 Hz), 6.96 (d; 1H; J=8.7 Hz), 4.33 (m; 1H), 4.17 (m; 1H), 3.84 (m; 1H), 3.17 (m; 2H), 1.31 (s; 6H); 20 MS (DCI/NH₃) m/e 427 (M+1)⁺.

Example 4465-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-1,3,3-trimethyl-1,3-dihydro-indol-2-one

25

Example 446A1,3,3-Trimethyl-1,3-dihydro-indol-2-one

The title compound was prepared by substituting Example 445A for Example 102A in Example 112. MS (DCI/NH₃) m/e 176 (M+1)⁺.

30

Example 446B5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-1,3,3-trimethyl-1,3-dihydro-indol-2-one

35 The title compound was prepared by substituting Example 446A for Example 444A in Example 444. ¹H NMR (300 MHz, D₆-DMSO) δ 11.03 (s; 1H), 8.60 (s; 1H), 8.32 (s; 1H), 8.20 (s; 2H), 7.78 (s; 1H), 7.67 (d; 1H; J=7.5 Hz), 7.62 (d; 1H; J=7.5 Hz), 7.39 (d; 1H; J=8.7 Hz), 7.29 (s; 1H), 7.14 (d; 1H; J=8.7 Hz), 7.10 (t; 1H; J=8.7 Hz), 7.01 (t; 1H; J=8.7 Hz), 4.35

(m; 1H), 4.28 (m; 1H), 3.83 (m; 1H), 3.19 (s; 3H), 3.17 (m; 2H), 1.33 (s; 6H); MS (DCI/NH₃) m/e 441 (M+1)⁺.

Example 447

5 5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3-ethyl-1,3-dihydro-indol-2-one

The title compound was prepared by substituting iodoethane for iodomethane in Example 444. ¹H NMR (300 MHz, D₆-DMSO) δ 11.04 (s; 1H), 10.51 (s; 1H), 8.53 (s; 1H), 8.30 (s; 1H), 8.16 (s; 2H), 7.64 (s; 1H), 7.62 (d; 1H; J=7.5 Hz), 7.53 (d; 1H; J=7.5 Hz), 7.38 (d; 1H; J=8.7 Hz), 7.28 (s; 1H), 7.10 (t; 1H; J=8.7 Hz), 7.01 (t; 1H; J=8.7 Hz), 6.93 (d; 1H; J=8.7 Hz), 4.33 (m; 1H), 4.16 (m; 1H), 3.84 (m; 1H), 3.49 (t; 1H; J=7.5), 3.14 (m; 2H), 1.85 (m; 2H), 1.09 (d; 3H; J=7.5 Hz); MS (DCI/NH₃) m/e 427 (M+1)⁺.

Example 448


15 5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3-benzyl-1,3-dihydro-indol-2-one

The title compound was prepared by substituting benzyl chloride for iodomethane in Example 444. ¹H NMR (300 MHz, D₆-DMSO) δ 11.04 (s; 1H), 10.48 (s; 1H), 8.38 (s; 1H), 8.27 (s; 1H), 8.15 (s; 2H), 7.62 (d; 1H; J=7.5 Hz), 7.44 (d; 1H; J=7.5 Hz), 7.40 (s; 1H), 7.39 (d; 1H; J=8.7 Hz), 7.29 (s; 1H), 7.17 (m; 5H), 7.10 (t; 1H; J=8.7 Hz), 7.01 (t; 1H; J=8.7 Hz), 6.82 (d; 1H; J=8.7 Hz), 4.30 (m; 1H), 4.12 (m; 1H), 3.86 (m; 1H), 3.40 (m; 1H), 3.17 (m; 2H), 3.01 (m; 1H); MS (DCI/NH₃) m/e 489 (M+1)⁺.

It will be evident to one skilled in the art that the present invention is not limited to the foregoing illustrative examples, and that it can be embodied in other specific forms without departing from the essential attributes thereof. It is therefore desired that the examples be considered in all respects as illustrative and not restrictive, reference being made to the appended claims, rather than to the foregoing examples, and all changes which come within the meaning and range of equivalency of the claims are therefore intended to be embraced therein.

WHAT IS CLAIMED IS

1. A compound of formula (I)



5 or a therapeutically acceptable salt thereof, wherein

X is selected from the group consisting of C(R⁸) and N; wherein R⁸ is selected from the group consisting of hydrogen, alkyl, amino, carboxy, cyano, halo, hydroxy, and amido;

X' is selected from the group consisting of C and N;

Y is selected from the group consisting of C and N;

10 Y' is selected from the group consisting of C(R⁹) and N; wherein R⁹ is selected from the group consisting of hydrogen and -L²-L³(R³)(R⁶);

Z is selected from the group consisting of C and N;

provided that 0, 1, or 2 of X, X', Y, Y', and Z are N;

15 L¹ is selected from the group consisting of a bond, -O-, -NR⁵-, alkenyl, alkynyl, -C(O)-, -S-, -S(O)-, -S(O)₂-, -S(O)₂N(R⁵)-, -N(R⁵)S(O)₂-, -C(R¹²)₂-, -C(R¹²)₂N(R⁵)-, -N(R⁵)C(O)-, and -C(O)N(R⁵)-; wherein each group is drawn with its left end attached to R¹ and its right end attached to the aromatic ring;

L² is selected from the group consisting of a bond, -O-, -C(R¹²)₂-, -S-, -N(R⁵)-, -N(R⁵)C(O)-, and -C(O)N(R⁵)-;

20 L³ is selected from the group consisting of a bond, alkylidene and alkylene, wherein the alkylidene and the alkylene are optionally substituted with one or two substituents independently selected from the group consisting of alkoxy, amino, cyano, and hydroxy;

R¹ is selected from the group consisting of aryl, heteroaryl, and heterocycle;

25 R² and R⁴ are independently absent or selected from the group consisting of hydrogen, alkenyl, alkyl, alkynyl, amino, aryl, arylalkynyl, cyano, cyanoalkenyl, halo, heteroaryl, heterocycle, hydroxyalkyl, and nitro; or

R² and L¹, together with the carbon atoms to which they are attached, form a ring selected from the group consisting of aryl, heteroaryl, and heterocycle; or

30 R⁴ and L², together with the carbon atoms to which they are attached, form a ring selected from the group consisting of aryl, heteroaryl, and heterocycle; provided that when L³ is alkylidene, R⁴ and L², together with the carbon atoms to which they are attached, form a ring selected from the group consisting of aryl, heteroaryl, and heterocycle;

35 R^3 is absent or selected from the group consisting of hydrogen, aryl, arylalkoxy, arylalkylamino, arylalkylthio, aryloxy, arylthio, cycloalkyl, heteroaryl, heteroarylalkoxy, heteroaryloxy, and heterocycle;

R^6 is selected from the group consisting of hydrogen, aryl, arylalkoxy, arylalkylamino, arylalkylthio, aryloxy, arylthio, cycloalkyl, heteroaryl, heteroarylalkoxy, heteroaryloxy, and heterocycle;

40 provided that when L^1 and L^2 are bonds, at least one of R^3 and R^6 is other than hydrogen;


R^5 is selected from the group consisting of hydrogen, alkyl, alkylcarbonyl, alkylsulfonyl, arylcarbonyl, arylsulfonyl, and heteroarylsulfonyl;

45 R^7 is absent or selected from the group consisting of hydrogen, alkyl, cyanoalkenyl, and $-L^2-L^3(R^3)(R^6)$; or

R^7 and L^1 , together with the carbon atoms to which they are attached, form a ring selected from the group consisting of aryl, heteroaryl, and heterocycle; and

each R^{12} is selected from the group consisting of hydrogen, alkenyl, alkyl, alkynyl, amino, aryl, cyano, halo, heteroaryl, heterocycle, and nitro.

2. A compound of formula (II)



or a therapeutically acceptable salt thereof, wherein

5 L^1 is selected from the group consisting of a bond, $-O-$, $-N(R^5)-$, alkenyl, alkynyl, $-N(R^5)C(O)-$, and $-C(O)N(R^5)-$;

L^2 is selected from the group consisting of a bond, $-O-$, $-N(R^5)-$, $-N(R^5)C(O)-$, and $-C(O)N(R^5)-$;

10 L^3 is selected from the group consisting of a bond, alkylidene, and alkylene, wherein the alkylidene and the alkylene are optionally substituted with one or two substituents independently selected from the group consisting of amino, cyano, and hydroxy;

R^1 is selected from the group consisting of aryl, heteroaryl, and heterocycle;

R^2 and R^4 are independently selected from the group consisting of hydrogen, alkenyl, alkynyl, arylalkynyl, amino, cyano, cyanoalkenyl, halo, hydroxyalkyl, and heteroaryl; 15 wherein the heteroaryl is selected from the group consisting of furyl, pyrazinyl, thiazolyl, and thienyl; or

R^2 and L^1 , together with the carbon atoms to which they are attached, form a ring selected from the group consisting of dihydropyrrolyl, pyrazolyl, and phenyl; or

20 R^4 and L^2 , together with the carbon atoms to which they are attached, form a ring selected from the group consisting of dihydropyrrolyl, phenyl, pyridinyl, and pyrrolyl; wherein the ring can be optionally substituted with oxo; provided that when L^3 is alkylidene, R^4 and L^2 , together with the carbon atoms to which they are attached, form a ring selected from the group consisting of dihydropyrrolyl, phenyl, pyridinyl, and pyrrolyl; wherein the ring can be optionally substituted with oxo;

25 R^3 is absent or selected from the group consisting of hydrogen, aryl, arylalkoxy, arylalkylthio, aryloxy, arylthio, cycloalkyl, heteroaryl, heteroarylalkoxy, heteroaryloxy, and heterocycle;


30 R^6 are independently selected from the group consisting of hydrogen, aryl, arylalkoxy, arylalkylthio, aryloxy, arylthio, cycloalkyl, heteroaryl, and heteroarylalkoxy, heteroaryloxy, and heterocycle;

provided that when L^1 and L^2 are bonds, at least one of R^3 and R^6 is other than hydrogen;

R^5 is selected from the group consisting of hydrogen, alkyl, alkylcarbonyl, alkylsulfonyl, arylcarbonyl, arylsulfonyl, and heteroarylalkoxy; and

35 X is selected from the group consisting of $C(R^8)$ and N ; wherein R^8 is selected from the group consisting of hydrogen, amino, carboxy, cyano, and halo.

3. A compound of formula (III)



or a therapeutically acceptable salt thereof, wherein

5 L^1 is selected from the group consisting of a bond, -O-, -N(R^5)-, alkenyl, alkynyl, and -N(R^5)C(O)-;

L^2 is selected from the group consisting of a bond, -O-, -N(R^5)-, -N(R^5)C(O)-, and -C(O)N(R^5)-;

10 L^3 is alkylene, wherein the alkylene is substituted with one or two substituents independently selected from the group consisting of amino and hydroxy;

R^1 is selected from the group consisting of aryl, heteroaryl, and heterocycle;

R^2 and R^4 are independently selected from the group consisting of hydrogen and halo;

15 R^3 and R^6 are independently selected from the group consisting of hydrogen, aryl, arylalkoxy, and heteroaryl; provided that when L^1 and L^2 are bonds, at least one of R^3 and R^6 is other than hydrogen; and

R^5 is selected from the group consisting of hydrogen and alkyl.

4. The compound according to Claim 1 wherein L^1 is alkenyl.

5. The compound according to Claim 4 wherein Y' is C(R⁹) wherein R⁹ is -L²-L³(R³)(R⁶) and wherein L² is -O-.

6. The compound according to Claim 5 selected from the group consisting of N,N-dimethyl-N-[2-({5-[{E}-2-pyridin-4-ylvinyl]pyridin-3-yl}oxy)ethyl]amine; (1S)-2-(1H-indol-3-yl)-1-[({5-[{E}-2-pyridin-4-ylvinyl]pyridin-3-yl}oxy)methyl]ethylamine; (1R)-2-(1H-indol-3-yl)-1-[({5-[{E}-2-pyridin-4-ylvinyl]pyridin-3-yl}oxy)methyl]ethylamine; 5 1-(1H-indol-3-yl)-3-({5-[{E}-2-pyridin-4-ylvinyl]pyridin-3-yl}oxy)propan-2-ol; (1S)-2-(1-benzothien-3-yl)-1-[({5-[{E}-2-pyridin-4-ylvinyl]pyridin-3-yl}oxy)methyl]ethylamine; 10 (1S)-2,2-diphenyl-1-[({5-[{E}-2-pyridin-4-ylvinyl]pyridin-3-yl}oxy)methyl]ethylamine; (1S)-1-{4-[{2,6-dichlorobenzyl}oxy]benzyl}-2-({5-[{E}-2-pyridin-4-ylvinyl]pyridin-3-yl}oxy)ethylamine; 15 (1S)-2-(benzyloxy)-1-[({5-[{E}-2-pyridin-4-ylvinyl]pyridin-3-yl}oxy)methyl]ethylamine; N,N-dimethyl-N-[(1S,2S)-1-methyl-2-phenyl-2-({5-[{E}-2-pyridin-4-ylvinyl]pyridin-3-yl}oxy)ethyl]amine; (1S)-2-(2-naphthyl)-1-[({5-[{E}-2-pyridin-4-ylvinyl]pyridin-3-yl}oxy)methyl]ethylamine; 20 (1S)-2-({2-chloro-5-[{E}-2-pyridin-4-ylvinyl]pyridin-3-yl}oxy)-1-(1H-indol-3-ylmethyl)ethylamine; (1S)-2-({6-chloro-5-[{E}-2-pyridin-4-ylvinyl]pyridin-3-yl}oxy)-1-(1H-indol-3-ylmethyl)ethylamine; (1S)-2-(1H-indol-3-yl)-1-[({5-[{Z}-2-pyridin-4-ylvinyl]pyridin-3-yl}oxy)methyl]ethylamine; 25 and N-[(2E)-3-(4-bromophenyl)prop-2-enyl]-N-[2-({5-[{E}-2-pyridin-4-ylvinyl]pyridin-3-yl}oxy)ethyl]amine.

7. The compound according to Claim 4 wherein Y' is C(R⁹) wherein R⁹ is -L²-L³(R³)(R⁶) and whereein L² is selected from the group consisting of a bond, -N(R⁵)-, -N(R⁵)C(O)-, and -C(O)N(R⁵)-.

8. The compound according to Claim 7 selected from the group consisting of N-[(2S)-2-amino-3-(1H-indol-3-yl)propyl]-N-{5-[{E}-2-pyridin-4-ylvinyl]pyridin-3-yl}amine; (2S)-2-amino-4-phenyl-N-{5-[{E}-2-pyridin-4-ylvinyl]pyridin-3-yl}butanamide; 5 N-(aminomethyl)-5-[{E}-2-pyridin-4-ylvinyl]nicotinamide; and

(1R)-3-{6-chloro-5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-yl}-1-(1H-indol-3-ylmethyl)propylamine.

9. The compound according to Claim 1 wherein L¹ is a bond.

10. The compound according to Claim 9 wherein Y' is C(R⁹) wherein R⁹ is -L²-L³(R³)(R⁶) and wherein L² is -O-.

11. The compound according to Claim 10 selected from the group consisting of 4-(5-{[(2S)-2-amino-3-(1H-indol-3-yl)propyl]oxy}pyridin-3-yl)benzonitrile; (1S)-2-(1H-indol-3-yl)-1-{[(5-isoquinolin-6-ylpyridin-3-yl)oxy]methyl}ethylamine; (1R)-2-(1H-indol-3-yl)-1-{[(5-quinolin-6-ylpyridin-3-yl)oxy]methyl}ethylamine;

5 (1S)-2-[(6-chloro-5-isoquinolin-6-ylpyridin-3-yl)oxy]-1-(1H-indol-3-ylmethyl)ethylamine;

(1S)-2-[(2-chloro-5-isoquinolin-6-ylpyridin-3-yl)oxy]-1-(1H-indol-3-ylmethyl)ethylamine;

10 5-(5-{[(2S)-2-amino-3-(1H-indol-3-yl)propyl]oxy}pyridin-3-yl)-1H-isoindole-1,3(2H)-dione;

5-(5-{[(2S)-2-amino-3-(1H-indol-3-yl)propyl]oxy}pyridin-3-yl)isoindolin-1-one;

(1S)-2-[(5-cinnolin-6-ylpyridin-3-yl)oxy]-1-(1H-indol-3-ylmethyl)ethylamine;

(1S)-2-{[5-(1H-indazol-5-yl)pyridin-3-yl]oxy}-1-(1H-indol-3-ylmethyl)ethylamine;

15 5-(5-{[(2S)-2-amino-3-(1H-indol-3-yl)propyl]oxy}pyridin-3-yl)-1,3-dihydro-2H-indol-2-one;

(1S)-2-[(5-(2,1,3-benzoxadiazol-5-yl)pyridin-3-yl)oxy]-1-(1H-indol-3-ylmethyl)ethylamine;

(1S)-2-(1H-indol-3-yl)-1-{[(5-thieno[2,3-c]pyridin-2-ylpyridin-3-yl)oxy]methyl}ethylamine;

20 (3Z)-5-(5-{[(2S)-2-amino-3-(1H-indol-3-yl)propyl]oxy}pyridin-3-yl)-3-(1H-pyrrol-2-ylmethylene)-1,3-dihydro-2H-indol-2-one; and

6-(5-{[(2R)-2-amino-3-(1H-indol-3-yl)propyl]oxy}pyridin-3-yl)-1,3-benzothiazol-2(3H)-one.

12. The compound according to Claim 9 wherein Y' is C(R⁹) wherein R⁹ is -L²-L³(R³)(R⁶) and wherein L² is selected from the group consisting of a bond, -N(R⁵)C(O)-, and -N(R⁵)-.

13. The compound according to Claim 12 selected from the group consisting of

(2S)-2-amino-3-(1H-indol-3-yl)-N-[5-(1,6-naphthyridin-2-yl)pyridin-3-yl]propanamide;

5 N-[(2S)-2-amino-3-(1H-indol-3-yl)propyl]-N-[5-(1,6-naphthyridin-2-yl)pyridin-3-yl]amine;

(1R)-1-(1H-indol-3-ylmethyl)-3-(5-isoquinolin-6-ylpyridin-3-yl)propylamine;

2-(1H-indol-3-yl)-2-(5-isoquinolin-6-ylpyridin-3-yl)ethanamine; and

2-(1H-indol-3-yl)-3-(5-isoquinolin-6-ylpyridin-3-yl)propan-1-amine.

14. The compound according to Claim 9 wherein Y' is C(R⁹) wherein R⁹ is -L²-L³(R³)(R⁶) and wherein L² and R⁴, together with the atoms to which they are attached, form a heterocycle ring.

15. The compound according to Claim 14 which is

(3Z)-3-[(2S)-2-amino-3-(1H-indol-3-yl)propylidene]-5-isoquinolin-6-yl-1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one.

16. The compound according to Claim 1 wherein L¹ is selected from the group consisting of alkynyl, -N(R⁵)C(O)-, -N(R⁵)-, and -O-.

17. The compound according to Claim 16 selected from the group consisting of

(1S)-2-(1H-indol-3-yl)-1-{{[5-(pyridin-4-ylethynyl)pyridin-3-yl]oxy}methyl}ethylamine;

5 5-{{[2(S)-2-amino-3-(1H-indol-3-yl)propyl]oxy}-N-pyridin-4-yl}nicotinamide;

N⁴-{(3-{{[2(S)-2-amino-3-(1H-indol-3-yl)propyl]oxy}phenyl)pyrimidine-2,4-diamine;

N-{{[2(S)-2-amino-3-(1H-indol-3-yl)propyl]-N'-isoquinolin-5-yl}pyridine-3,5-diamine;

and

N-{{[2(S)-2-amino-3-(1H-indol-3-yl)propyl]-N-[5-(isoquinolin-5-yloxy)pyridin-3-yl]amine.

18. The compound according to Claim 1 wherein L¹ and R², together with the atoms to which they are attached, form an aryl ring.

19. The compound according to Claim 18 which is

(1S)-2-(1H-indol-3-yl)-1-{{[(6-pyridin-4-ylquinolin-3-yl)oxy]methyl}ethylamine.

20. The compound according to Claim 1 selected from the group consisting of

3-Butoxyl-5-[2-(4-pyridinyl)vinyl]pyridine;

3-Methoxyl-5-[2-(4-pyridinyl)vinyl]pyridine;

S-3-[2-Amino-3-phenyl-propyloxy]-5-[2-(4-pyridinyl)vinyl]pyridine hydrochloride;

5 3-[2-(1H-3-Indolyl)-ethoxy]-5-[2-(4-pyridinyl)vinyl]pyridine hydrochloride;

3-[2-(1H-3-Indolyl)-propyloxy]-5-[2-(4-pyridinyl)vinyl]pyridine;

S-3-[2-Amino-3-(4-benzyloxyphenyl)-propyloxy]-5-[2-(4-pyridinyl)vinyl]pyridine hydrochloride;

3-(Piperidin-4-yl)-5-[2-(4-pyridinyl)vinyl]pyridine;

10 R-3-{{2-Amino-3-benzyloxypropyloxy}-5-[2-(4-pyridinyl)vinyl]pyridine hydrochloride;

3-(1-Methyl-imidazole-4-methoxyl)-5-[2-(4-pyridinyl)vinyl]pyridine;

S-3-{{2-Amino-3-[3-hydroxylphenyl]-propyloxy}-5-[2-(4-pyridinyl)vinyl]pyridine trifluoroacetic acid salt;

15 S-3-{2-Amino-3-[3-cyanophenyl]-propyloxy]-5-[2-(4-pyridinyl)vinyl]pyridine hydrochloride salt;
3-[1-(4-Cyanobenzyl)-imidazole-4-methoxy]-5-[2-(4-pyridinyl)vinyl]pyridine;
S-3-[2-Amino-3-(1-methyl-1H-3-indolyl)-propyloxy]-5-[2-(4-pyridinyl)vinyl]pyridine hydrochloride salt;

20 S-3-[2-Dimethylamino-3-(1H-3-indolyl)-propyloxy]-5-[2-(4-pyridinyl)vinyl]pyridine hydrochloride salt;
S-3-[2-Amino-3-(1-naphthyl)-propyloxy]-5-[2-(4-pyridinyl)vinyl]pyridine hydrochloride salt;
3-(2-Aminoethoxy)-5-[2-(4-pyridinyl)vinyl]pyridine hydrochloride salt;

25 3-(3-Aminopropyl)-5-[2-(4-pyridinyl)vinyl]pyridine hydrochloride salt;
S-3-(2-Amino-3-methylbutyloxy)-5-[2-(4-pyridinyl)vinyl]pyridine hydrochloride salt;
3-(1-Methyl-3-piperidinyloxy)-5-[2-(4-pyridinyl)vinyl]pyridine trifluoroacetic acid salt;

30 3-(2-Chlorobenzyl)-5-[2-(4-pyridinyl)vinyl]pyridine trifluoroacetic acid salt;
3-(N-Benzyl-N-methylaminoethoxy)-5-[2-(4-pyridinyl)vinyl]pyridine trifluoroacetic acid salt;
3-(6-(N,N-Dimethylamino)hexyloxy)-5-[2-(4-pyridinyl)vinyl]pyridine trifluoroacetic acid salt;

35 3-(2-Thiophenoxy-ethoxy)-5-[2-(4-pyridinyl)vinyl]pyridine trifluoroacetic acid salt;
3-(1-Methyl-3-pyrrolidinyloxy)-5-[2-(4-pyridinyl)vinyl]pyridine trifluoroacetic acid salt;

40 3-[(1-Methyl-2-piperidinyl)methoxy]-5-[2-(4-pyridinyl)vinyl]pyridine trifluoroacetic acid salt;
3-(1-Pyridinyl-ethoxy)-5-[2-(4-pyridinyl)vinyl]pyridine trifluoroacetic acid salt;
4-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-N-hydroxyl-benzamidine trifluoroacetic acid salt;

45 4-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-benzamidine trifluoroacetic acid salt;
3-[(2S)-2-Amino-3-(1H-3-indolyl)-propyloxy]-6-(3-pyridinyl)-quinoline;

50 3-[(2S)-2-Amino-3-(1H-3-indolyl)-propyloxy]-6-(3-quinolinyl)-quinoline;
3-[(2S)-2-Amino-3-(1H-3-indolyl)-propyloxy]-5-[2-(2-amino-4-pyridinyl)vinyl]pyridine trifluoroacetic acid salt;
5-[(2S)-2-(Amino-3-(1H-3-indolyl)-propyloxy)-3-[2-(2-amino-4-pyridinyl)vinyl]-2-chloro-pyridine trifluoroacetic acid salt;

(1S)-1-(1H-Indol-3-ylmethyl)-2-(5-naphthalen-2-yl-pyridin-3-yloxy)-ethylamine;
(1S)-1-(1H-Indol-3-ylmethyl)-2-(5-isoquinolin-5-yl-pyridin-3-yloxy)-ethylamine;

6-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-2H-isoquinolin-1-one;
(1S)-2-[5-(3-Chloro-isoquinolin-6-yl)-pyridin-3-yloxy]-1-(1H-indol-3-ylmethyl)-ethylamine;
55 (1S)-2-([3,4']Bipyridinyl-5-yloxy)-1-(1H-indol-3-ylmethyl)-ethylamine trifluoroacetic acid;
(1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(2-pyridin-2-yl-vinyl)-pyridin-3-yloxy]-ethylamine;
60 (1S)-1-(1H-Indol-3-ylmethyl)-2-(5-pyridin-3-ylethynyl-pyridin-3-yloxy)-ethylamine trifluoroacetic acid salt;
(1S)-2-[5-(2-Fluoro-pyridin-4-ylethynyl)-pyridin-3-yloxy]-1-(1H-indol-3-ylmethyl)-ethylamine trifluoroacetic acid salt;
65 (1S)-4-{5-[2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-ylethynyl}-pyridin-2-ol trifluoroacetic acid salt;
(1S)-2-[6-Chloro-5-(1-chloro-isoquinolin-6-yl)-pyridin-3-yloxy]-1-(1H-indol-3-ylmethyl)-ethylamine trifluoroacetic acid salt;
70 Bis-[3-(4-Bromo-phenyl)-allyl]-{2-[5-(2-pyridin-4-yl-vinyl)-pyridin-3-yloxy]-ethyl}-amine hydrochloride;
N⁴-[3-(2-Amino-ethoxy)-phenyl]-pyrimidine-2,4-diamine hydrochloride;
trans-[4-(2-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propylamino]-pyridin-3-yl}-vinyl)-pyrimidin-2-yl]-carbamic acid ethyl ester trifluoroacetic acid salt;
75 1-Amino-6-{5-[(2S)-2-amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-isoquinoline trifluoroacetic acid salt;
6-{5-[(2S)-2-amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-1-chloro-isoquinoline trifluoroacetic acid salt;
80 (2S)-2-Amino-3-(1H-indol-3-yl)-N-[5-(2-pyridin-4-yl-vinyl)-pyridin-3-yl]-propionamide;
(2S)-2-Amino-3-(naphtha-1-yl)-N-[5-(2-pyridin-4-yl-vinyl)-pyridin-3-yl]-propionamide hydrochloride;
85 (2S)-2-Amino-3-phenyl-N-[5-(2-pyridin-4-yl-vinyl)-pyridin-3-yl]-propionamide hydrochloride;
S-2-Amino-3-(imidazol-4-yl)-N-[5-(2-pyridin-4-yl-vinyl)-pyridin-3-yl]-propionamide hydrochloride;
(1R)-2-(1H-indol-3-yl)-1-{{[5-isoquinolin-6-ylpyridin-3-yl]oxy]methyl}ethylamine;
85 (1S)-5-{5-[2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-1H-indazol-3-ylamine;
(1S)-6-{5-[2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-1H-indazol-3-ylamine;

90 2-Amino-N-[(1S)-1-(1H-indol-3-ylmethyl)-2-(5-isoquinolin-6-yl-pyridin-3-yloxy)-ethyl]-acetamide;

90 (2S)-2-Amino-N-[(1S)-1-(1H-indol-3-ylmethyl)-2-(5-isoquinolin-6-yl-pyridin-3-yloxy)-ethyl]-propionamide;

95 2-Dimethylamino-N-[(1S)-1-(1H-indol-3-ylmethyl)-2-(5-isoquinolin-6-yl-pyridin-3-yloxy)-ethyl]-acetamide;

95 (1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;

100 (1S)-1-(1H-Indol-3-ylmethyl)-2-{5-[3-(1H-pyrrol-2-yl)-1H-indazol-5-yl]-pyridin-3-yloxy}-ethylamine;

100 (1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(3-phenyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;

105 (1S)-2-[5-(3-Cyclopropyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(1H-indol-3-ylmethyl)-ethylamine;

105 (1S)-1-(1H-Indol-3-ylmethyl)-2-{5-[3-(1-methyl-1H-imidazol-2-yl)-1H-indazol-5-yl]-pyridin-3-yloxy}-ethylamine;

110 (1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(3-thiazol-2-yl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;

110 (1S)-2-{5-[3-(1H-Imidazol-2-yl)-1H-indazol-5-yl]-pyridin-3-yloxy}-1-(1H-indol-3-ylmethyl)-ethylamine;

115 (1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(3-thiophen-2-yl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;

115 (1S)-2-[5-(1,3-Dimethyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(1H-indol-3-ylmethyl)-ethylamine;

120 (1S)-1-(1H-Indol-3-ylmethyl)-2-[3-(3-methyl-1H-indazol-5-yl)-phenoxy]-ethylamine;

120 (1S)-1-(1H-Indol-3-ylmethyl)-2-{5-[3-(4-methyl-piperazin-1-yl)-1H-indazol-5-yl]-pyridin-3-yloxy}-ethylamine;

125 (1S)-(5-{5-[2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-1H-indazol-3-yl)-dimethyl-amine;

125 (1S)-(4-(5-(2-Amino-3-(1H-indol-3-yl)-propoxy)-pyridin-3-yl)-benzyl)-phenyl-amine;

125 (1S)-(4-(5-(2-Amino-3-(1H-indol-3-yl)-propoxy)-pyridin-3-yl)-phenyl)-methanol;

125 (1S)-2-(5-(4-Fluoro-phenyl)-pyridin-3-yloxy)-1-(1H-indol-3-ylmethyl)-ethylamine;

(1S)-4-(5-(2-Amino-3-(1H-indol-3-yl)-propoxy)-pyridin-3-yl)-benzoic acid;

(1S)-2-(3-Bromo-5-isoquinolin-6-yl-phenoxyoxy)-1-(1H-indol-3-ylmethyl)-ethylamine;

130 N4-(3-(5-(2-Amino-3-(1H-indol-3-yl)-propoxy)-pyridin-3-yl)-phenyl)-pyrimidine-2,4-diamine;

(1S)-3-(2-Amino-3-(1H-indol-3-yl)-propoxy)-5-isoquinolin-6-yl-phenylamine;

4-(5-Isoquinolin-6-yl-pyridin-3-yl)-piperazine-1-carboxylic acid tert-butyl ester;

6-(5-Piperazin-1-yl-pyridin-3-yl)-isoquinoline;

135 (2S)-2-Amino-5-(5-(2-amino-3-(1H-indol-3-yl)-propoxy)-pyridin-3-yl)-phenyl-(3-chloro-phenyl-methanone;

(1S)-N6-(3-(5-(2-Amino-3-(1H-indol-3-yl)-propoxy)-pyridin-3-yl)-phenyl)-9H-purine-2,6-diamine;

(3-(5-((2S)-2-Amino-3-(1H-indol-3-yl)-propoxy)-pyridin-3-yl)-phenyl)-pyrimidin-2-yl-amine;

140 (3-(5-((2S)-2-Amino-3-(1H-indol-3-yl)-propoxy)-pyridin-3-yl)-phenyl)-thiazol-2-yl-amine;

N-(3-(5-((2S)-2-Amino-3-(1H-indol-3-yl)-propoxy)-pyridin-3-yl)-phenyl)-acetamide;

6-(5-(4-(1H-Indol-3-ylmethyl)-piperazin-1-yl)-pyridin-3-yl)-isoquinoline;

3-((2S)-2-Amino-3-(1H-indol-3-yl)-propoxy)-5-isoquinolin-6-yl-benzoic acid;

145 4-(5-((2S)-2-Amino-3-(1H-indol-3-yl)-propoxy)-pyridin-3-yl)-phenylamine;

N-(4-(5-((2S)-2-Amino-3-(1H-indol-3-yl)-propoxy)-pyridin-3-yl)-phenyl)-acetamide;

N6-(4-(5-((2S)-2-Amino-3-(1H-indol-3-yl)-propoxy)-pyridin-3-yl)-phenyl)-9H-purine-2,6-diamine;

150 N4-(4-(5-((2S)-2-Amino-3-(1H-indol-3-yl)-propoxy)-pyridin-3-yl)-phenyl)-pyrimidine-2,4-diamine;

(4-(5-((2S)-2-Amino-3-(1H-indol-3-yl)-propoxy)-pyridin-3-yl)-phenyl)-pyrimidin-2-yl-amine;

3-((2S)-2-Amino-3-(1H-indol-3-yl)-propoxy)-5-isoquinolin-6-yl-benzonitrile;

5'-Benzylxy-5-isoquinolin-6-yl-(3,3')bipyridinyl;

155 (7-(5-((2S)-2-Amino-3-(1H-indol-3-yl)-propoxy)-pyridin-3-yl)-pyrido(2,3-d)pyrimidin-4-yl)-phenyl-amine;

(7-(5-((2S)-2-Amino-3-(1H-indol-3-yl)-propoxy)-pyridin-3-yl)-pyrido(2,3-d)pyrimidin-4-yl)-ethyl-amine;

160 (7-(5-((2S)-2-Amino-3-(1H-indol-3-yl)-propoxy)-pyridin-3-yl)-pyrido(2,3-d)pyrimidin-4-yl)-benzyl-amine;

(1S)-1-(1H-Indol-3-ylmethyl)-2-(6-isoquinolin-6-yl-pyrazin-2-yloxy)-ethylamine;

(1S)-2-(5-isoquinolin-6-yl-pyridin-3-yloxy)-1-phenyl-ethylamine;

(1*S*)-1-(1*H*-Indol-3-ylmethyl)-2-(6-(3-methyl-1*H*-indazol-5-yl)-pyrazin-2-yloxy)-ethylamine;

165 (1*S*)-1-Cyclohexylmethyl-2-(5-isoquinolin-6-yl-pyridin-3-yloxy)-ethylamine;
(1*S*)-1-Benzyl-2-(5-(3-methyl-1*H*-indazol-5-yl)-pyridin-3-yloxy)-ethylamine;
(1*S*)-2-(5-(3-Methyl-1*H*-indazol-5-yl)-pyridin-3-yloxy)-1-phenyl-ethylamine;
(1*S*)-2-(5-(3-Methyl-1*H*-indazol-5-yl)-pyridin-3-yloxy)-1-phenyl-ethylamine;
4-((2*S*)-2-Amino-3-(5-(3-methyl-1*H*-indazol-5-yl)-pyridin-3-yloxy)propyl)-
170 benzonitrile;
(1*S*)-2-(5-(3-Methyl-1*H*-indazol-5-yl)-pyridin-3-yloxy)-1-naphthalen-2-ylmethyl-ethylamine;
4-((2*S*)-2-Amino-3-(5-isoquinolin-6-yl-pyridin-3-yloxy-propyl)-benzonitrile;
(1*S*)-2-(5-Isoquinolin-6-yl-pyridin-3-yloxy)-1-naphthalen-2-ylmethyl-ethylamine;
175 (1*S*)-1-Benzyl-2-(5-isoquinolin-6-yl-pyridin-3-yloxy)-ethylamine;
(1*S*)-1-(4-Fluoro-benzyl)-2-(5-(3-methyl-1*H*-indazol-5-yl)-pyridin-3-yloxy)-ethylamine;
(1*S*)-1-(4-Fluoro-benzyl)-2-(5-isoquinolin-6-yl-pyridin-3-yloxy)-ethylamine;
2-((2*S*)-2-Amino-3-(5-(3-methyl-1*H*-indazol-5-yl)-pyridin-3-yloxy)-propyl)-
180 benzonitrile;
2-((2*S*)-2-Amino-3-(5-isoquinolin-6-yl)-pyridin-3-yloxy)-propyl)-benzonitrile;
(1*S*)-2-5-(3-methyl-1*H*-indazol-5-yl)-pyridin-3-yloxy)-1-pyridin-4-ylmethyl-ethylamine;
(1*S*)-2-(5-Isoquinolin-6-yl-pyridin-3-yloxy)-1-pyridin-4-ylmethyl-ethylamine;
185 (1*S*)-1-(4-Methyl-benzyl)-2-(5-(3-methyl-1*H*-indazol-5-yl)-pyridin-3-yloxy)-ethylamine;
(1*S*)-2-(5-Isoquinolin-6-yl-pyridin-3-yloxy)-1-(4-methyl-benzyl)-ethylamine;
(1*S*)-2-(5-(3-methyl-1*H*-indazol-5-yl)-pyridin-3-yloxy)-1-quinolin-3-ylmethyl-ethylamine;
190 (1*S*)-2-(5-Isoquinolin-6-yl-pyridin-3-yloxy)-1-quinolin-3-ylmethyl-ethylamine;
(1*R*)-1-Benzyl-2-(5-(3-methyl-1*H*-indazol-5-yl)-pyridin-3-yloxy)-ethylamine;
(1*R*)-1-Benzyl-2-(5-isoquinolin-6-yl-pyridin-3-yloxy)-ethylamine;
4-((2*S*)-2-Amino-3-(5-(3-methyl-1*H*-indazol-5-yl)-pyridin-3-yloxy)-propyl)-phenol;
(1*S*)-1-(4-Benzyloxy-benzyl)-2-(5-(3-methyl-1*H*-indazol-5-yl)-pyridin-3-yloxy)-
195 ethylamine;
(1*S*)-1-(3-Methyl-benzyl)-2-(5-(3-methyl-1*H*-indazol-5-yl)-pyridin-3-yloxy)-ethylamine;
(1*S*)-1-(2-Methyl-benzyl)-2-(5-(3-methyl-1*H*-indazol-5-yl)-pyridin-3-yloxy)-ethylamine;

200 (1*S*)-2-(5-(3-methyl-1*H*-indazol-5-yl)-pyridin-3-yloxy)-1-(4-nitro-benzyl)-ethylamine;
(1*S*)-1-(4-Methoxy-benzyl)-2-(5-(3-methyl-1*H*-indazol-5-yl)-pyridin-3-yloxy)-ethylamine;
(1*S*)-1-Biphenyl-4-ylmethyl-2-(5-(3-methyl-1*H*-indazol-5-yl)-pyridin-3-yloxy)-ethylamine;
205 (1*S*)-2-(5-(3-Methyl-1*H*-indazol-5-yl)-pyridin-3-yloxy)-1-naphthalen-1-ylmethyl-ethylamine;
(1*S*)-1-(3-Chloro-benzyl)-2-(5-(3-methyl-1*H*-indazol-5-yl)-pyridin-3-yloxy)-ethylamine;
210 3-((2*S*)-2-Amino-3-(5-(3-methyl-1*H*-indazol-5-yl)-pyridin-3-yloxy)-propyl)-benzonitrile;
(1*S*)-1-(3,4-Difluoro-benzyl)-2-(5-(3-methyl-1*H*-indazol-5-yl)-pyridin-3-yloxy)-ethylamine;
215 (1*S*)-1-(3,4-Dimethoxy-benzyl)-2-(5-(3-methyl-1*H*-indazol-5-yl)-pyridin-3-yloxy)-ethylamine;
(1*S*)-1-(3-Fluoro-benzyl)-2-(5-(3-methyl-1*H*-indazol-5-yl)-pyridin-3-yloxy)-ethylamine;
220 (1*S*)-2-(5-(3-methyl-1*H*-indazol-5-yl)-pyridin-3-yloxy)-1-(3-trifluoromethyl-benzyl)-ethylamine;
(1*S*)-1-(4-Ethoxy-benzyl)-2-[5-(3-methyl-1*H*-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
225 (1*S*)-1-(4-*tert*-Butyl-benzyl)-2-(5-(3-methyl-1*H*-indazol-5-yl)-pyridin-3-yloxy)-ethylamine;
(1*S*)-1-(4-Methoxy-3-methyl-benzyl)-2-(5-(3-methyl-1*H*-indazol-5-yl)-pyridin-3-yloxy)-ethylamine;
230 2-((2*S*)-2-Amino-3-(5-(3-methyl-1*H*-indazol-5-yl)-pyridin-3-yloxy)-propyl)-4-methyl-phenol;
(1*S*)-1-Methyl-2-[5-(3-methyl-1*H*-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(\pm)-1-(1*H*-Benzimidazol-2-ylmethyl)-2-(5-isoquinolin-6-yl-pyridin-3-yloxy)-ethylamine;
235 (1*S*)-1-(1*H*-Indazol-3-ylmethyl)-2-(5-isoquinolin-6-yl-pyridin-3-yloxy)-ethylamine;
(1*S*)-1-(2-Fluoro-benzyl)-2-[5-(3-methyl-1*H*-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1*S*)-1-(2-Chloro-benzyl)-2-[5-(3-methyl-1*H*-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;

(1*S*)-2-[5-(3-Methyl-1*H*-indazol-5-yl)-pyridin-3-yloxy]-1-thiophen-2-ylmethyl-ethylamine;

(1*R*)-1-(1*H*-Indol-3-ylmethyl)-2-[5-(3-methyl-1*H*-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;

240 1-(4-Chloro-benzyl)-2-[5-(3-methyl-1*H*-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;

(1*S*)-2-[5-(3-Methyl-1*H*-indazol-5-yl)-pyridin-3-yloxy]-1-(4-pyrrol-1-yl-benzyl)-ethylamine;

(1*S*)-1-(4-Methyl-benzylsulfanyl-methyl)-2-[5-(3-methyl-1*H*-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;

245 (1*S*)-2-[5-(3-Methyl-1*H*-indazol-5-yl)-pyridin-3-yloxy]-1-(2-trifluoromethyl-benzyl)-ethylamine;

(1*R*)-1-Benzyl-3-[5-(3-methyl-1*H*-indazol-5-yl)-pyridin-3-yloxy]-propylamine;

(1*R*)-1-Benzyl-4-[5-(3-methyl-1*H*-indazol-5-yl)-pyridin-3-yloxy]-butylamine;

(1*S*)-1-[5-(3-Methyl-1*H*-indazol-5-yl)-pyridin-3-yloxy-methyl]-3-phenyl-propylamine;

250 (1*S*)-2-(5-Isoquinolin-6-yl-pyridin-3-yloxy)-1-(1-methyl-1*H*-indol-3-ylmethyl)-ethylamine trifluoroacetic acid salt;

(1*S*)-[1-(1*H*-Indol-3-ylmethyl)-2-(5-isoquinolin-6-yl-pyridin-3-yloxy)-ethyl]-dimethyl-amine;

(1*S*)-1-Benzo[b]thiophen-3-ylmethyl-2-[5-(3-methyl-1*H*-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;

255 (1*S*)-2-[5-(3-Methyl-1*H*-indazol-5-yl)-pyridin-3-yloxy]-1-thiophen-3-ylmethyl-ethylamine;

(1*S*)-1-Benzyl-3-[5-(3-methyl-1*H*-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;

(1*S*)-1-Benzyl-4-[5-(3-methyl-1*H*-indazol-5-yl)-pyridin-3-yloxy]-butylamine;

260 (1*S*)-2-(5-Isoquinolin-6-yl-pyridin-3-yloxy)-1-(naphthalen-2-yloxy-methyl)-ethylamine;

(1*S*)-2-(5-Isoquinolin-6-yl-pyridin-3-yloxy)-1-(pyridin-3-yloxy-methyl)-ethylamine;

(1*S*)-2-(5-Isoquinolin-6-yl-pyridin-3-yloxy)-1-(quinolin-7-yloxy-methyl)-ethylamine;

265 (2*S*)-4-[2-Amino-3-(5-isoquinolin-6-yl-pyridin-3-yloxy)-propoxy]-benzonitrile;

(2*S*)-N'-(5-(3-methyl-1*H*-indazol-5-yl)-pyridin-3-yl)-3-phenyl-propane-1,2-diamine;

(2*S*)-N-(2-Amino-3-phenyl-propyl)-N-[5-(3-methyl-1*H*-indazol-5-yl)-pyridin-3-yl]-methanesulfonamide;

270 (2*S*)-N-(2-Amino-3-phenyl-propyl)-N-[5-(3-methyl-1*H*-indazol-5-yl)-pyridin-3-yl]-benzenesulfonamide;

(2*S*)-N-(2-Amino-3-phenyl-propyl)-N-[5-(3-methyl-1*H*-indazol-5-yl)-pyridin-3-yl]-benzamide;

(2S)-N-(2-Amino-3-phenyl-propyl)-N-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yl]-acetamide;

275 (2S)-3-[2-Amino-3-(1H-indol-3-yl)-propylidene]-5-isoquinolin-6-yl-1,3-dihydro-indol-2-one;

(1S)-2-(5-Isoquinolin-6-yl-pyridin-3-yloxy)-1-(1-methyl-1H-indol-3-ylmethyl)-ethylamine;

280 (1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(1H-pyrrolo[2,3-b]pyridin-5-yl)-pyridin-3-yloxy]-ethylamine;

(1S)-2-{5-[2-(2-Fluoro-pyridin-4-yl)-vinyl]-pyridin-3-yloxy}-1-(1H-indol-3-ylmethyl)-ethylamine;

(1S)-1-(1H-Indol-3-ylmethyl)-2-{5-[2-(2-methoxy-pyridin-4-yl)-vinyl]-pyridin-3-yloxy}-ethylamine;

285 (1S)-1-(1H-Indol-3-ylmethyl)-2-{5-[2-(2-phenoxy-pyridin-4-yl)-vinyl]-pyridin-3-yloxy}-ethylamine;

(1S)-2-{5-[2-(2-Benzylsulfanyl-pyridin-4-yl)-vinyl]-pyridin-3-yloxy}-1-(1H-indol-3-ylmethyl)-ethylamine;

290 [4-(2-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-vinyl)-pyridin-2-yl]-cyclopropyl-amine;

[4-(2-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-vinyl)-pyridin-2-yl]-benzyl-amine;

[4-(2-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-vinyl)-pyridin-2-yl]-ethyl-amine;

295 [4-(2-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-vinyl)-pyridin-2-yl]-methyl-amine;

(1S)-1-(1H-Indol-3-ylmethyl)-2-{5-[2-(2-indol-1-yl-pyridin-4-yl)-vinyl]-pyridin-3-yloxy}-ethylamine;

300 (±)-2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(2-methyl-1H-indol-3-ylmethyl)-ethylamine;

7-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-quinazolin-2-ylamine;

2-Phenyl-2-(3-pyridin-4-yl-1H-pyrazolo[3,4-b]pyridin-6-yl)-ethylamine;

Naphthalen-2-yl-(3-pyridin-4-yl-1H-pyrazolo[3,4-b]pyridin-6-yl)-acetonitrile;

2-Naphthalen-2-yl-2-(3-pyridin-4-yl-1H-pyrazolo[3,4-b]pyridin-6-yl)-ethylamine;

305 (3-Isoquinolin-6-yl-1H-pyrazolo[3,4-b]pyridin-6-yl)-phenyl-acetonitrile;

2-(3-Isoquinolin-6-yl-1H-pyrazolo[3,4-b]pyridin-6-yl)-2-phenyl-ethylamine;

(1S)-1-Benzyl-2-(3-pyridin-4-yl-1H-pyrazolo[3,4-b]pyridin-5-yloxy)-ethylamine;

2-Benzyl-3-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-propylamine;

310 (1S)-1-(1H-Indol-3-ylmethyl)-2-(2-pyridin-4-yl-[1,7]naphthyridin-5-yloxy)-ethylamine;

(1R)-1-(1H-Indol-3-ylmethyl)-2-(2-pyridin-4-yl-[1,7]naphthyridin-5-yloxy)-ethylamine;

(1S)-1-(1H-Indol-3-ylmethyl)-2-(5-isoquinolin-6-yl-pyridin-3-ylsulfanyl)-ethylamine;

(1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-ylsulfanyl]-ethylamine;

(1S)-1-(4-Bromo-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;

(1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(2-methyl-quinazolin-7-yl)-pyridin-3-yloxy]-ethylamine;

320 (1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(1H-indol-5-yl)-pyridin-3-yloxy]-ethylamine;

(1S)-1-(1H-Indol-3-ylmethyl)-2-[5-[4-(1H-tetrazol-5-yl)-phenyl]-pyridin-3-yloxy]-ethylamine;

(1S)-1-(1H-Indol-3-ylmethyl)-2-(5-isoquinolin-6-yl-pyrimidin-4-yloxy)-ethylamine;

(1S)-1-Benzyl-2-[3-(3-methyl-1H-indazol-5-yl)-phenoxy]-ethylamine;

325 (1S)-1-Benzyl-2-[6-(3-methyl-1H-indazol-5-yl)-pyridin-2-yloxy]-ethylamine;

(1S)-2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(4-thiophen-3-yl-benzyl)-ethylamine;

(1S)-1-(4-Iodo-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;

330 [4-((2S)-2-Amino-3-phenyl-propoxy)-2-(3-methyl-1H-indazol-5-yl)-phenyl]-methanol;

(1S)-2-[5-(1H-Benzotriazol-5-yl)-pyridin-3-yloxy]-1-(1H-indol-3-ylmethyl)-ethylamine;

(1S)-2-[5-(1H-Benzotriazol-5-yl)-pyridin-3-yloxy]-1-benzyl-ethylamine;

335 (1S)-1-Benzyl-2-[5-(3-morpholin-4-yl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;

(1S)-1-Benzyl-2-[5-[3-(4-methyl-piperazin-1-yl)-1H-indazol-5-yl]-pyridin-3-yloxy]-ethylamine;

(1S)-{5-[5-(2-Amino-3-phenyl-propoxy)-pyridin-3-yl]-1H-indazol-3-yl}-dimethyl-amine;

340 (1S)-{5-[5-(2-Amino-3-phenyl-propoxy)-pyridin-3-yl]-1H-indazol-3-yl}-(2-methoxyethyl)-amine;

{5-[5-((2S)-2-Amino-3-phenyl-propoxy)-pyridin-3-yl]-1H-indazol-3-yl}-(2-morpholin-4-yl-ethyl)-amine;

5-[5-((2S)-2-Amino-3-phenyl-propoxy)-pyridin-3-yl]-1H-indazol-3-ylamine;

345 N-{5-[5-((2S)-2-Amino-3-phenyl-propoxy)-pyridin-3-yl]-1H-indazol-3-yl}-2,2,2-trifluoro-acetamide;

(2S)-2-Amino-N-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yl]-3-phenyl-propionamide;

(1S)-2-[5-(3-Benzyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(1H-indol-3-ylmethyl)-ethylamine;

(1S)-1-Benzyl-2-[5-(3-benzyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;

(1S)-2-[5-(3-Benzyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-methyl-ethylamine;

(6-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-cinnolin-4-yl)-phenyl-amine;

355 (1S)-2-[5-(1H-Indazol-6-yl)-pyridin-3-yloxy]-1-(1H-indol-3-ylmethyl)-ethylamine;

5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-2,3-dihydro-isoindol-1-one;

6-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-1H-cinnolin-4-one;

(1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(4-phenyl-cinnolin-6-yl)-pyridin-3-yloxy]-ethylamine;

360 (6-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-cinnolin-4-yl)-benzyl-amine;

(6-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-cinnolin-4-yl)-methyl-amine;

365 6-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-cinnolin-4-ylamine;

[(3S)-3-(5-Isoquinolin-6-yl-pyridin-3-yloxymethyl)-1,2,3,4-tetrahydro-b-carolin-9-yl]-methanol;

3-(5-Isoquinolin-6-yl-pyridin-3-yloxymethyl)-2,3,4,9-tetrahydro-1H-□-carboline;

5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-1H-indazole-3-carboxylic acid;

370 5-[5-((2S)-2-tert-Butoxycarbonyl-amino-3-hydroxy-propoxy)-pyridin-3-yl]-3-methyl-indazole-1-carboxylic acid tert-butyl ester;

5-[5-((2S)-Aziridin-2-ylmethoxy)-pyridin-3-yl]-3-methyl-1H-indazole;

(1S)-2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(3-trifluoromethoxy-benzyl)-ethylamine;

375 (1S)-1-(3,5-Dichloro-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;

(1S)-1-(2,3-Dichloro-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;

380 (1S)-1-Biphenyl-3-ylmethyl-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;

(1S)-1-(3-Chloro-4-fluoro-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;

385 (1S)-1-(4-Chloro-3-fluoro-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;

(1S)-2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(4-trifluoromethoxy-benzyl)-ethylamine;

(1S)-1-(2-Fluoro-4-trifluoromethyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;

390 (1S)-1-(3-Fluoro-5-trifluoromethyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;

(1S)-1-(2-Methoxy-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;

395 (3-{(2S)-2-Amino-3-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-propyl}-phenyl)-dimethyl-amine;

(1S)-1-(4-Chloro-2-methyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;

(1S)-1-(3-Iodo-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;

400 (1S)- (1S)-1-(3-Fluoro-4-methyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;

(1S)-1-(3-Fluoro-4-methoxy-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;

405 (1S)-2-[6-Chloro-5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(3,4-dichloro-benzyl)-ethylamine;

(1S)-1-(2-Fluoro-6-trifluoromethyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;

(1S)-1-(4-Fluoro-3-trifluoromethyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;

410 (1S)-1-Furan-2-ylmethyl-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;

(1S)-1-Benzofuran-2-ylmethyl-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;

(1S)-1-(3-Fluoro-4-trifluoromethyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;

415 (1S)-1-(4-Chloro-3-methyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;

(1S)-1-Furan-3-ylmethyl-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;

420 (1S)-1-(2-Fluoro-5-methyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;

(1S)-1-(3-Chloro-5-fluoro-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;

425 (1S)-2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(3,4,5-trifluoro-benzyl)-ethylamine;

(1S)-1-(4-Fluoro-3-methyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;

(1S)-1-(2,4-Dichloro-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;

430 (1S)-1-(4-Chloro-3-trifluoromethyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;

(1S)-2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(2-trifluoromethoxy-benzyl)-ethylamine;

(1S)-1-(2,5-Dimethoxy-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;

435 (1S)-2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(4-methylsulfanyl-benzyl)-ethylamine;

(1S)-1-(2-Cyclohexyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;

440 (1S)-1-(2,5-Dichloro-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;

(1S)-1-(2,5-Dimethyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;

(1S)-1-(2,3-Dimethyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;

445 (1S)-1-(3,4-Dichloro-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;

(1S)-1-(2,4-Dimethyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;

450 (1S)-1-(3-Fluoro-4-trifluoromethyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;

(1S)-1-(3,5-Dimethyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;

(1S)-1-Biphenyl-2-ylmethyl-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;

(1S)-1-(3,4-Dimethyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;

(1S)-1-(2,3-Difluoro-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;

(1S)-1-(2,5-Difluoro-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;

(1S)-1-(2,6-Dichloro-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;

(1S)-1-(2,4-Difluoro-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;

(1S)-1-(2,6-Dimethyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;

(1S)-1-(2,3-Dihydro-benzo[1,4]dioxin-6-ylmethyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;

(1S)-1-(3,5-Difluoro-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;

(1S)-1-(2,6-Difluoro-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;

(1S)-1-Benzo[1,3]dioxol-5-ylmethyl-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;

(1S)-1-(4-Fluoro-3-methyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;

(1S)-2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(2,4,6-trimethyl-benzyl)-ethylamine;

(1S)-1-(2,4-Dimethoxy-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;

(1S)-2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(4-trifluoromethyl-benzyl)-ethylamine;

(1S)-1-(5-Fluoro-2-methyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;

(1S)-1-(3,5-Bis-trifluoromethyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;

(1S)-1-(4-Fluoro-2-methyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;

490 (1S)-1-(5-Fluoro-2-methoxy-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;

1 (1S)-2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(2-methyl-naphthalen-1-ylmethyl)-ethylamine;

495 (1S)-1-(2,2-Difluoro-benzo[1,3]dioxol-4-ylmethyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;

(1S)-1-(4-Fluoro-naphthalen-1-ylmethyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;

500 (1S)-2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(2,2,3,3-tetrafluoro-2,3-dihydro-benzo[1,4]dioxin-6-ylmethyl)-ethylamine;

(1S)-2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(4-methyl-naphthalen-1-ylmethyl)-ethylamine;

505 (1S)-2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(2,4,6-trifluoro-benzyl)-ethylamine;

(1S)-2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(2,3,4-trifluoro-benzyl)-ethylamine;

(1S)-1-(4-Bromo-2-fluoro-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;

(1S)-1-(4-Bromo-3-fluoro-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;

510 (1S)-1-(2-Bromo-4,6-difluoro-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;

(1S)-1-(4-Bromo-3-methyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;

(1S)-Bromo-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;

515 (1S)-1-(3-Methoxy-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;

(1S)-1-(3-Bromo-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;

(1S)-1-(2-Methoxy-naphthalen-1-ylmethyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;

520 (1R)-1-(4-Chloro-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;

(1R)-1-Benzo[1,3]dioxol-5-ylmethyl-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;

525 (1R)-1-(3-Fluoro-4-methyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;

(1S)-1-Benzyl-2-[6-chloro-5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;

530 (1S)-1-(4-Bromo-benzyl)-2-[6-chloro-5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;

(1S)-1-(4-Chloro-benzyl)-2-[6-chloro-5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;

(1S)-2-[6-Chloro-5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-cyclohexylmethyl-ethylamine;

535 (1S)-2-[6-Chloro-5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(2,6-dimethyl-benzyl)-ethylamine;

(1S)-1-[6-Chloro-5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy-methyl]-2-phenyl-propylamine;

540 (1S)-1-[6-Chloro-5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy-methyl]-2,2-diphenyl-ethylamine;

(1S)-1-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy-methyl]-2-phenyl-propylamine;

(1S)-1-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy-methyl]-2,2-diphenyl-ethylamine;

(1S)-3-Methyl-1-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy-methyl]-butylamine;

545 (1S)-2-[6-Chloro-5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(1H-indol-3-ylmethyl)-ethylamine;

(1S)-2-(6-Chloro-5-thieno[2,3-c]pyridin-2-yl-pyridin-3-yloxy)-1-(1H-indol-3-ylmethyl)-ethylamine;

550 5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-3-isoquinolin-6-yl-pyridine-2-carbonitrile;

(1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(3-phenyl-isoquinolin-6-yl)-pyridin-3-yloxy]-ethylamine;

(1S)-2-[5-(3-Ethyl-isoquinolin-6-yl)-pyridin-3-yloxy]-1-(1H-indol-3-ylmethyl)-ethylamine;

555 (1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(3-pyridin-4-yl-isoquinolin-6-yl)-pyridin-3-yloxy]-ethylamine;

(1S)-2-[5-(3-Furan-2-yl-isoquinolin-6-yl)-pyridin-3-yloxy]-1-(1H-indol-3-ylmethyl)-ethylamine;

560 (1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(3-phenylethynyl-isoquinolin-6-yl)-pyridin-3-yloxy]-ethylamine;

(1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(3-prop-1-ynyl-isoquinolin-6-yl)-pyridin-3-yloxy]-ethylamine;

(1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(3-vinyl-isoquinolin-6-yl)-pyridin-3-yloxy]-ethylamine;

565 (1S)-6-{5-[2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-isoquinoline-3-carbonitrile;

(1S)-1-(1H-Indol-3-ylmethyl)-2-(5-isoquinolin-6-yl-6-vinyl-pyridin-3-yloxy)-ethylamine;

570 (1S)-2-(6-Ethynyl-5-isoquinolin-6-yl-pyridin-3-yloxy)-1-(1H-indol-3-ylmethyl)-ethylamine;

(1S)-2-(6-Furan-2-yl-5-isoquinolin-6-yl-pyridin-3-yloxy)-1-(1H-indol-3-ylmethyl)-ethylamine;

(1S)-1-(1H-Indol-3-ylmethyl)-2-(5-isoquinolin-6-yl-6-phenylethynyl-pyridin-3-yloxy)-ethylamine;

575 6-{5-[2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-isoquinolin-5-ylamine;

(1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(8-methyl-isoquinolin-6-yl)-pyridin-3-yloxy]-ethylamine;

580 (1S)-2-[5-(4-Chloro-thieno[2,3-c]pyridin-2-yl)-pyridin-3-yloxy]-1-(1H-indol-3-ylmethyl)-ethylamine;

(1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(4-phenyl-thieno[2,3-c]pyridin-2-yl)-pyridin-3-yloxy]-ethylamine;

(1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(4-phenoxy-thieno[2,3-c]pyridin-2-yl)-pyridin-3-yloxy]-ethylamine;

585 (1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(4-vinyl-thieno[2,3-c]pyridin-2-yl)-pyridin-3-yloxy]-ethylamine;

(1S)-2-[5-(4-Ethyl-thieno[2,3-c]pyridin-2-yl)-pyridin-3-yloxy]-1-(1H-indol-3-ylmethyl)-ethylamine;

590 (1S)-(2-{5-[2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-thieno[2,3-c]pyridin-4-yl)-phenyl-amine;

5-{5-[2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3,3-difluoro-1,3-dihydro-indol-2-one;

6-{5-[2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3H-oxazolo[4,5-b]pyridin-2-one;

595 N1-(5-Isoquinolin-6-yl-pyridin-3-yl)-ethane-1,2-diamine;

Naphthalene-2-sulfonic acid (2-amino-ethyl)-(5-isoquinolin-6-yl-pyridin-3-yl)-amide;

Naphthalene-1-sulfonic acid (2-amino-ethyl)-(5-isoquinolin-6-yl-pyridin-3-yl)-amide;

5-Dimethylamino-naphthalene-1-sulfonic acid (2-amino-ethyl)-(5-isoquinolin-6-yl-pyridin-3-yl)-amide;

600 Quinoline-5-sulfonic acid (2-amino-ethyl)-(5-isoquinolin-6-yl-pyridin-3-yl)-amide;
 Biphenyl-4-sulfonic acid (2-amino-ethyl)-(5-isoquinolin-6-yl-pyridin-3-yl)-amide;
 1-Methyl-1H-imidazole-4-sulfonic acid (2-amino-ethyl)-(5-isoquinolin-6-yl-pyridin-3-yl)-amide;
 3-Amino-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-propan-1-ol;
605 2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-3-phenoxy-propylamine;
 2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-3-(naphthalen-2-yloxy)-
 propylamine;
 3-(Biphenyl-4-yloxy)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-
 propylamine;
610 2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-3-(quinolin-7-yloxy)-propylamine;
 2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-3-(pyridin-4-yloxy)-propylamine;
 2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-3-(naphthalen-1-yloxy)-
 propylamine;
 3-{(2S)-2-Amino-3-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-propyl}-1H-
615 indol-5-ol;
 (1S)-1-(5-Methoxy-1H-indol-3-ylmethyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-
 yloxy]-ethylamine;
 (1S)-1-(5-Ethoxy-1H-indol-3-ylmethyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-
 yloxy]-ethylamine;
620 (1S)-1-(5-Butoxy-1H-indol-3-ylmethyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-
 yloxy]-ethylamine;
 (1S)-1-(5-Isopropoxy-1H-indol-3-ylmethyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-
 yloxy]-ethylamine;
 3-(1H-Indol-3-yl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-propan-1-ol;
625 3-(1H-Indol-3-yl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-propylamine;
 Naphthalene-2-sulfonic acid (2-amino-ethyl)-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yl]-amide;
 Biphenyl-4-sulfonic acid (2-amino-ethyl)-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-
 yl]-amide;
630 5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3-isopropylidene-1,3-
 dihydro-indol-2-one;
 5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3-(1H-imidazol-2-
 ylmethylene)-1,3-dihydro-indol-2-one;
 5-{5-[2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3-pyridin-2-ylmethylene-
635 1,3-dihydro-indol-2-one;

5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3-furan-2-ylmethlene-1,3-dihydro-indol-2-one;

5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3-(5-methyl-furan-2-ylmethlene)-1,3-dihydro-indol-2-one;

5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3-(4,5-dimethyl-furan-2-ylmethlene)-1,3-dihydro-indol-2-one;

5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3-thiophen-2-ylmethlene-1,3-dihydro-indol-2-one;

5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3-(1-methyl-1H-pyrrol-2-ylmethlene)-1,3-dihydro-indol-2-one;

5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3-(1H-indol-3-ylmethlene)-1,3-dihydro-indol-2-one;

5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3-(1-phenyl-1H-pyrrol-3-ylmethlene)-1,3-dihydro-indol-2-one;

5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3-pyridin-3-ylmethlene-1,3-dihydro-indol-2-one;

5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3-(1H-pyrrol-3-ylmethlene)-1,3-dihydro-indol-2-one;

5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3-(tetrahydro-pyran-4-ylidene)-1,3-dihydro-indol-2-one;

5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3-(4-ethyl-3,5-dimethyl-1H-pyrrol-2-ylmethlene)-1,3-dihydro-indol-2-one;

5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3-cyclopropylmethlene-1,3-dihydro-indol-2-one;

5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3-pyrrolidin-2-ylmethlene-1,3-dihydro-indol-2-one;

5-(5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-furan-2-carboxylic acid;

5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3-benzylidene-1,3-dihydro-indol-2-one;

5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-1H-indole-2,3-dione 3-oxime;

(1S)-2-(5-Benzo[b]thiophen-2-yl-6-furan-2-yl-pyridin-3-yloxy)-1-(1H-indol-3-ylmethy)-ethylamine;

(1S)-2-(5-Benzo[b]thiophen-2-yl-6-vinyl-pyridin-3-yloxy)-1-(1H-indol-3-ylmethy)-ethylamine;

(1S)-2-(5-Benzothiophen-2-yl-6-thiophen-2-yl-pyridin-3-yloxy)-1-(1H-indol-3-ylmethyl)-ethylamine;

675 (1S)-2-(5-Benzothiophen-2-yl-6-thiazol-2-yl-pyridin-3-yloxy)-1-(1H-indol-3-ylmethyl)-ethylamine;

(1S)-2-(5-Benzothiophen-2-yl-6-pyrazin-2-yl-pyridin-3-yloxy)-1-(1H-indol-3-ylmethyl)-ethylamine;

680 {5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-3-benzothiophen-2-yl-pyridin-2-yl}-phenyl-amine;

685 {5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-3-benzothiophen-2-yl-pyridin-2-yl}-pyridin-3-yl-amine;

6-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3H-benzooxazol-2-one;

1-Benzimidazol-1-ylmethyl-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;

2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-morpholin-4-ylmethyl-ethylamine;

5-[(2S)-2-Amino-3-phenyl-propoxy)-pyridin-3-yl]-1,3-dihydro-indol-2-one;

5-[(2S)-2-Amino-3-phenyl-propoxy)-pyridin-3-yl]-3-(1H-pyrrol-2-ylmethylene)-690 1,3-dihydro-indol-2-one;

5-[(2S)-2-Amino-3-phenyl-propoxy)-pyridin-3-yl]-3-furan-2-ylmethylene-1,3-dihydro-indol-2-one;

(1S)-1-Benzimidazol-1-ylmethyl-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;

695 3-{3-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-5-isoquinolin-6-yl-pyridin-4-yl}-acrylonitrile;

(1S)-1-(1H-Indol-3-ylmethyl)-2-(5-isoquinolin-6-yl-4-methyl-pyridin-3-yloxy)-ethylamine;

700 5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl]-3-methyl-1,3-dihydro-indol-2-one;

5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl]-3,3-dimethyl-1,3-dihydro-indol-2-one;

5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl]-1,3,3-trimethyl-1,3-dihydro-indol-2-one;

705 5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl]-3-ethyl-1,3-dihydro-indol-2-one; and

5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl]-3-benzyl-1,3-dihydro-indol-2-one.

21. A pharmaceutical composition comprising a compound of Claim 1, or a therapeutically acceptable salt thereof, in combination with a pharmaceutically acceptable carrier.

22. A method of inhibiting protein kinases in a patient in recognized need of such treatment comprising administering to the patient a therapeutically acceptable amount of a compound of Claim 1, or a therapeutically acceptable salt thereof.